FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Evans, DE Turkevich, LA Roettgers, CT Deye, GJ Baron, PA AF Evans, Douglas E. Turkevich, Leonid A. Roettgers, Cynthia T. Deye, Gregory J. Baron, Paul A. TI Dustiness of Fine and Nanoscale Powders SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE aerosolization; dustiness; dust generation; emissions; exposure; handling; nanomaterial; nanoparticle; nanoscale; powders; ultrafine; workplace ID WALLED-CARBON-NANOTUBES; AFFECT DUST GENERATION; ROTATING DRUM; EXPOSURE; INHALATION; RISK; MASS; NANOPARTICLES; INSULATION; WORKPLACES AB Dustiness may be defined as the propensity of a powder to form airborne dust by a prescribed mechanical stimulus; dustiness testing is typically intended to replicate mechanisms of dust generation encountered in workplaces. A novel dustiness testing device, developed for pharmaceutical application, was evaluated in the dustiness investigation of 27 fine and nanoscale powders. The device efficiently dispersed small (mg) quantities of a wide variety of fine and nanoscale powders, into a small sampling chamber. Measurements consisted of gravimetrically determined total and respirable dustiness. The following materials were studied: single and multiwalled carbon nanotubes, carbon nanofibers, and carbon blacks; fumed oxides of titanium, aluminum, silicon, and cerium; metallic nanoparticles (nickel, cobalt, manganese, and silver) silicon carbide, Arizona road dust; nanoclays; and lithium titanate. Both the total and respirable dustiness spanned two orders of magnitude (0.337.9% and 0.131.8% of the predispersed test powders, respectively). For many powders, a significant respirable dustiness was observed. For most powders studied, the respirable dustiness accounted for approximately one-third of the total dustiness. It is believed that this relationship holds for many fine and nanoscale test powders (i.e. those primarily selected for this study), but may not hold for coarse powders. Neither total nor respirable dustiness was found to be correlated with BET surface area, therefore dustiness is not determined by primary particle size. For a subset of test powders, aerodynamic particle size distributions by number were measured (with an electrical low-pressure impactor and an aerodynamic particle sizer). Particle size modes ranged from approximately 300nm to several micrometers, but no modes below 100nm, were observed. It is therefore unlikely that these materials would exhibit a substantial sub-100nm particle contribution in a workplace. RP Evans, DE (reprint author), NIOSH, Chem Exposure & Monitoring Branch, Div Appl Res & Technol, 4676 Columbia Pkwy,MS R7, Cincinnati, OH 45226 USA. EM dje3@cdc.gov FU NIOSH Division of Applied Research and Technology; NIOSH Nanotechnology Research Center FX We thank M. Boundy and D. Leith (UNC, Chapel Hill) for the fabrication and commissioning of the tester and for valuable discussions and assistance. We thank D. Bard, D. Mark, A. D. Maynard, and M. D. Hoover for helpful discussions; M. Miller for dustiness measurements of the lactose control; B. Jones for assistance with video graphic documentation. We thank Professor G. Oberdorster for the donations of the Printex 90 and Sterling V carbon blacks; Southwest Nanotechnologies for the donation of the SWeNT SWCNT; T. Polton (Pfizer) for the donation of the Holland lactose; T. Maher (AltairNano) for the donations of the lithium titanate spinel and of the titania (Kemira). We also acknowledge the assistance of K. Ashley, M. E. Birch, K. H. Dunn, C. Geraci, B. K. Ku, and the reviewers at Annals, for their comments in reviewing this article. This research was supported through the NIOSH Division of Applied Research and Technology and the NIOSH Nanotechnology Research Center. NR 64 TC 20 Z9 20 U1 2 U2 61 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD MAR PY 2013 VL 57 IS 2 BP 261 EP 277 DI 10.1093/annhyg/mes060 PG 17 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA 092YJ UT WOS:000315158600010 PM 23065675 ER PT J AU Kersh, GJ Fitzpatrick, KA Self, JS Priestley, RA Kelly, AJ Lash, RR Marsden-Haug, N Nett, RJ Bjork, A Massung, RF Anderson, AD AF Kersh, Gilbert J. Fitzpatrick, Kelly A. Self, Joshua S. Priestley, Rachael A. Kelly, Aubree J. Lash, R. Ryan Marsden-Haug, Nicola Nett, Randall J. Bjork, Adam Massung, Robert F. Anderson, Alicia D. TI Presence and Persistence of Coxiella burnetii in the Environments of Goat Farms Associated with a Q Fever Outbreak SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID UNITED-STATES; DNA; WASHINGTON AB Q fever is a zoonotic disease caused by inhalation of the bacterium Coxiella burnetii. Ruminant livestock are common reservoirs for C. burnetii, and bacteria present in aerosols derived from the waste of infected animals can infect humans. The significance of infection from material deposited in the environment versus transmission directly from infected animals is not known. In 2011, an outbreak of Q fever cases on farms in Washington and Montana was associated with infected goats. A study was undertaken to investigate the quantity and spatial distribution of C. burnetii in the environment of these goat farms. Soil, vacuum, and sponge samples collected on seven farms epidemiologically linked to the outbreak were tested for the presence of C. burnetii DNA by quantitative PCR. Overall, 70.1% of the samples were positive for C. burnetii. All farms had positive samples, but the quantity of C. burnetii varied widely between samples and between farms. High quantities of C. burnetii DNA were in goat housing/birthing areas, and only small quantities were found in samples collected more than 50 m from these areas. Follow-up sampling at one of the farms 1 year after the outbreak found small quantities of C. burnetii DNA in air samples and large quantities of C. burnetii persisting in soil and vacuum samples. The results suggest that the highest concentrations of environmental C. burnetii are found in goat birthing areas and that contamination of other areas is mostly associated with human movement. C1 [Kersh, Gilbert J.; Fitzpatrick, Kelly A.; Self, Joshua S.; Priestley, Rachael A.; Kelly, Aubree J.; Lash, R. Ryan; Bjork, Adam; Massung, Robert F.; Anderson, Alicia D.] Ctr Dis Control & Prevent CDC, Rickettsial Zoonoses Branch, Atlanta, GA USA. [Marsden-Haug, Nicola] Washington State Dept Hlth, Shoreline, WA USA. [Nett, Randall J.] Ctr Dis Control & Prevent, Career Epidemiol Field Officer Program, Atlanta, GA USA. [Nett, Randall J.] Montana Dept Publ Hlth & Human Serv, Communicable Dis Control & Prevent Bur, Helena, MT USA. RP Kersh, GJ (reprint author), Ctr Dis Control & Prevent CDC, Rickettsial Zoonoses Branch, Atlanta, GA USA. EM gkersh@cdc.gov RI Lash, R. Ryan/E-4115-2013; OI Bjork, Adam/0000-0001-7544-2987 NR 19 TC 21 Z9 23 U1 0 U2 16 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD MAR PY 2013 VL 79 IS 5 BP 1697 EP 1703 DI 10.1128/AEM.03472-12 PG 7 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 089ES UT WOS:000314893300033 PM 23315737 ER PT J AU Chai, SJ Davies-Cole, J Cookson, ST AF Chai, Shua J. Davies-Cole, John Cookson, Susan T. TI Infectious Disease Burden and Vaccination Needs Among Asylees Versus Refugees, District of Columbia SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE asylees; refugees; infectious diseases; vaccinations; screening ID FOREIGN-BORN PERSONS; HEPATITIS-B-VIRUS; UNITED-STATES; ASYLUM SEEKERS; TUBERCULOSIS INFECTION; SEROPREVALENCE SURVEYS; INTESTINAL PARASITES; MENTAL-HEALTH; REFUSAL BIAS; PREVALENCE AB Background. Unlike US-bound refugees, asylum seekers (asylees) apply for asylum while residing in the United States and are not provided a medical screening. Infectious disease burden and vaccination needs have not been described among US asylees. Methods. We conducted a retrospective cohort study of 630 asylees and 151 refugees referred to the District of Columbia (DC) Department of Health screening program for an initial US medical screening during September 2003 August 2007. We assessed the prevalence of latent tuberculosis infection (tuberculin skin test reactivity >= 10 mm), human immunodeficiency virus (HIV) and hepatitis B seropositivity, intestinal parasite test positivity, need for vaccinations, and time from date of US arrival to receipt of screening. Results. Asylees in DC had a similar prevalence as refugees of latent tuberculosis infection (39% vs 38%, respectively, P = .83), pathogenic intestinal parasites (4% vs 2%, P = .36), and need for adult vaccinations (80% vs 80%, P = .95). Asylees were screened significantly later after US arrival compared with refugees (55 weeks vs 1 week, P < .001). Asylees had higher prevalence of latent tuberculosis infection, hepatitis B and HIV seropositivity, and child and adult vaccination needs than the US population (P < .001). Conclusions. This study of the infectious disease concerns of a US asylee population suggests that in DC, asylees have similar infectious disease burden and prevention needs as refugees and should be screened with the same urgency. Because applicants for US asylum are not linked to prompt medical screenings, DC asylees are typically screened much later, placing them and US communities at risk. C1 [Chai, Shua J.] US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Davies-Cole, John] Dist Columbia Dept Hlth, Washington, DC USA. [Cookson, Susan T.] Ctr Dis Control & Prevent, Int Emergency & Refugee Hlth Branch, Atlanta, GA 30333 USA. RP Chai, SJ (reprint author), Ctr Dis Control & Prevent, Field & Appl Epidemiol Training Programs Branch, 1600 Clifton Rd,MS E-93, Atlanta, GA 30333 USA. EM schai@cdc.gov NR 40 TC 6 Z9 6 U1 1 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 1 PY 2013 VL 56 IS 5 BP 652 EP 658 DI 10.1093/cid/cis927 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 091OR UT WOS:000315060200010 PM 23118270 ER PT J AU Munk, R Sasseville, D Siegel, PD Law, BF Moreau, L AF Munk, Roni Sasseville, Denis Siegel, Paul D. Law, Brandon F. Moreau, Linda TI Thiurams in shoe contact dermatitis - a case series SO CONTACT DERMATITIS LA English DT Editorial Material DE allergic contact dermatitis; high-performance liquid chromatography; mercaptobenzothiazole; rubber; shoes; thiurams C1 [Munk, Roni; Sasseville, Denis; Moreau, Linda] McGill Univ, Ctr Hlth, Div Dermatol, Montreal, PQ H3A 1A1, Canada. [Siegel, Paul D.; Law, Brandon F.] NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Munk, R (reprint author), 5721 Lockwood, Montreal, PQ H4Z 1W1, Canada. EM roni.munk@mail.mcgill.ca FU Intramural CDC HHS [CC999999] NR 3 TC 1 Z9 1 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0105-1873 EI 1600-0536 J9 CONTACT DERMATITIS JI Contact Dermatitis PD MAR PY 2013 VL 68 IS 3 BP 185 EP 187 DI 10.1111/cod.12018 PG 3 WC Allergy; Dermatology SC Allergy; Dermatology GA 093UE UT WOS:000315217200010 PM 23421462 ER PT J AU Rudolph, K Bruce, M Bruden, D Zulz, T Wenger, J Reasonover, A Harker-Jones, M Hurlburt, D Hennessy, T AF Rudolph, Karen Bruce, Michael Bruden, Dana Zulz, Tammy Wenger, Jay Reasonover, Alisa Harker-Jones, Marcella Hurlburt, Debby Hennessy, Thomas TI Epidemiology of pneumococcal serotype 6A and 6C among invasive and carriage isolates from Alaska, 1986-2009 SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE Pneumococci; Surveillance; Pneumococcal conjugate vaccine; Multilocus sequence typing ID STREPTOCOCCUS-PNEUMONIAE SEROTYPE; CONJUGATE VACCINE; NASOPHARYNGEAL CARRIAGE; UNITED-STATES; DISEASE; CHILDREN; IMPACT; PREVALENCE; REDUCTION; EMERGENCE AB We investigated serotype 6A/6C invasive pneumococcal disease (IPD) incidence, genetic diversity, and carriage before and after 7-valent pneumococcal conjugate vaccine (PCV7) introduction in Alaska. IPD cases (1986-2009) were identified through population-based laboratory surveillance. Isolates were initially serotyped by conventional methods, and 6C isolates were differentiated from 6A by polymerase chain reaction. Among invasive and carriage isolates initially typed as 6A, 35% and 50% were identified as 6C, respectively. IPD rates caused by serotype 6A or 6C among children <5 years did not change from the pre- to post-PCV7 period (P = 0.71 and P = 0.09, respectively). Multilocus sequence typing of IPD isolates revealed 28 sequence types. The proportion of serotype 6A carriage isolates decreased from 7.4% pre-PCV7 to 1.8% (P < 0.001) during 2008-2009; the proportion of serotype 6C carriage isolates increased from 3.0% to 8.4% (P = 0.004) among children <5 years. Continued surveillance is warranted to monitor changes in serotype distribution and prevalence. Published by Elsevier Inc. C1 [Rudolph, Karen; Bruce, Michael; Bruden, Dana; Zulz, Tammy; Wenger, Jay; Reasonover, Alisa; Harker-Jones, Marcella; Hurlburt, Debby; Hennessy, Thomas] Ctr Dis Control & Prevent, Arct Invest Program, Anchorage, AK 99508 USA. RP Rudolph, K (reprint author), Ctr Dis Control & Prevent, Arct Invest Program, Anchorage, AK 99508 USA. FU Intramural CDC HHS [CC999999] NR 33 TC 5 Z9 5 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD MAR PY 2013 VL 75 IS 3 BP 271 EP 276 DI 10.1016/j.diagmicrobio.2012.11.021 PG 6 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 095FC UT WOS:000315319100009 PM 23276772 ER PT J AU Kavanaugh, ML Jerman, J Ethier, K Moskosky, S AF Kavanaugh, Megan L. Jerman, Jenna Ethier, Kathleen Moskosky, Susan TI Meeting the Contraceptive Needs of Teens and Young Adults: Youth-Friendly and Long-Acting Reversible Contraceptive Services in U.S. Family Planning Facilities SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Long acting reversible contraception ( LARC); Youth friendly services; Young adults; Title X; Unplanned pregnancy; Teen pregnancy; Contraception ID UNITED-STATES; INTRAUTERINE-DEVICES; WOMENS KNOWLEDGE; HEALTH-CARE; ADOLESCENT; ATTITUDES; PROVISION; PROJECT AB Purpose: Increased use of contraceptive services, including long acting reversible contraceptives (LARCs), among sexually active teens and young adults could significantly reduce unintended pregnancy. Objectives were to describe youth friendly contraceptive services (including LARC) available to teens and young adults at U. S. publicly funded family planning facilities. Methods: Between April and September 2011, center directors at a nationally representative sample of 1,196 U. S. publicly funded family planning facilities were surveyed to assess accessibility and provision of contraceptive services for teens and young adults; 584 (52%) responded. Results: Facilities were accessible to young clients in sever always, including not requiring scheduled appointments for method refills (67%) and having flexible hours (64%). Most facilities provided outreach and/or education to young people (70%), and 27% used social network media to do this. Most facilities took steps to ensure confidentiality for young clients. These youth friendly practices were more common at Planned Parenthood, Title X, and reproductive health focused facilities than at other facilities. Long acting reversible contraceptive methods were regularly discussed with younger clients at less than half the facilities. Youth friendly sites had increased rates of LARC provision among younger clients. The most common challenges to providing contraceptive and LARC services to younger clients were the costs of LARC methods (60%), inconvenient clinic hours (51%), staff concerns about intrauterine device (IUD) use among teens (47%), and limited training on implant insertion(47%). Conclusions: Improving the ability of family planning facilities to provide youth friendly contra ceptive and LARC specific methods to younger clients may increase the use of highly effective contraception in this population. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved. C1 [Kavanaugh, Megan L.; Jerman, Jenna] Alan Guttmacher Inst, Div Res, New York, NY 10038 USA. [Ethier, Kathleen] Ctr Dis Control & Prevent, Off Director, Atlanta, GA USA. [Moskosky, Susan] Off Populat Affairs, Washington, DC USA. RP Kavanaugh, ML (reprint author), Alan Guttmacher Inst, 125 Maiden Lane,7th Floor, New York, NY 10038 USA. EM mkavanaugh@guttmacher.org FU Office of Population Affairs, U.S. Department of Health and Human Services; Guttmacher Institute FX The authors thank Amelia Bucek, Deva Cats Baril, Carolyn Cox, Michelle Eilers, Allison Grossman, Asha Mattai, Emily Nell, Jesse Philbin, and Alyssa Tartaglione for research support and Jennifer Frost, Rachel Benson Gold, Julie Edelson, and Lawrence Finer for reviewing the manuscript. The research on which this report was based was funded through a cooperative agreement between the Office of Population Affairs, U.S. Department of Health and Human Services, and the Guttmacher Institute. Authors have no conflicts of interest to disclose. Representatives from each organization participated in each phase of the study, from project development through manuscript submission. The Principal Investigator (and first author) wrote the first draft of this manuscript. NR 34 TC 43 Z9 43 U1 3 U2 31 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAR PY 2013 VL 52 IS 3 BP 284 EP 292 DI 10.1016/j.jadohealth.2012.10.276 PG 9 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 094UP UT WOS:000315289900006 PM 23298980 ER PT J AU Suda, KJ Hicks, LA Roberts, RM Hunkler, RJ Danziger, LH AF Suda, Katie J. Hicks, Lauri A. Roberts, Rebecca M. Hunkler, Robert J. Danziger, Larry H. TI A national evaluation of antibiotic expenditures by healthcare setting in the United States, 2009 SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE antibiotic; expenditures; outpatient; healthcare setting ID FUTURE DRUG EXPENDITURES; INFECTIONS; COMMUNITY AB Promoting appropriate antibiotic use has the potential to decrease healthcare costs by reducing unnecessary prescriptions and the incidence of resistant infections. However, little is known about where antibiotic costs are incurred in the US healthcare system. We evaluated antibiotic expenditures by healthcare setting and antibiotic class in the USA. Systemic antibiotic expenditures in 2009 were extracted from the IMS Health (c) National Sales Perspectives database. These data represent a statistically valid projection of all medication purchases in the USA from 1 January 2009 to 31 December 2009. Antibiotic expenditures totalled $10.7 billion. The majority (61.5) of expenditures were associated with the outpatient setting, especially from community pharmacies. Inpatient and long-term care settings accounted for 33.6 and 4.9 of expenditures, respectively. The class of antibiotics that accounted for the most antibiotic expenditure overall was the quinolones, followed by the penicillins. Over $10.7 billion was spent in 2009 on antibiotic therapy in the USA. Differences were observed in antibiotic expenditures by healthcare setting, with the majority in the outpatient setting, 87 of which was in community pharmacies. C1 [Suda, Katie J.] Univ Tennessee, Ctr Hlth Sci, Dept Clin Pharm, Memphis, TN 38163 USA. [Hicks, Lauri A.; Roberts, Rebecca M.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Hunkler, Robert J.] IMS Hlth, Dept External Affairs, Danbury, CT USA. [Danziger, Larry H.] Univ Illinois, Dept Pharm Practice, Chicago, IL USA. RP Suda, KJ (reprint author), Univ Tennessee, Ctr Hlth Sci, Dept Clin Pharm, Memphis, TN 38163 USA. EM ksuda@uthsc.edu NR 16 TC 23 Z9 23 U1 1 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD MAR PY 2013 VL 68 IS 3 BP 715 EP 718 DI 10.1093/jac/dks445 PG 4 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 089EU UT WOS:000314893700037 PM 23148204 ER PT J AU Buttke, DE Wolkin, A Stapleton, HM Miranda, ML AF Buttke, Danielle E. Wolkin, Amy Stapleton, Heather M. Miranda, Marie Lynn TI Associations between serum levels of polybrominated diphenyl ether (PBDE) flame retardants and environmental and behavioral factors in pregnant women SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE biomonitoring; personal exposure; flame retardants ID IN-HOUSE DUST; INDOOR AIR; POLYCHLORINATED-BIPHENYLS; HUMAN EXPOSURE; BREAST-MILK; DIETARY; POPULATION; SEDIMENTS; RATS AB Polybrominated diphenyl ethers (PBDE) are flame retardants that were previously used in upholstery, fabrics, and household appliances. PBDEs have been linked to adverse health outcomes, including neurotoxicity, thyroid hormone dysregulation, endocrine disruption, and poor semen quality. Because PBDEs pass into placental circulation, maternal exposures can approximate fetal exposures. Our objectives were to determine whether diet and specific human behaviors were significantly associated with PBDE exposures in a cohort of pregnant women. Women between the 34th and 38th week of pregnancy were given a questionnaire about behavioral, environmental, and dietary factors and asked to provide blood samples. Serum PBDE levels were measured using GS-MS and lipid adjusted. An adjusted ordinary least squares regression model was run to identify potential associations between behaviors and serum PBDE levels. Serum concentrations of BDEs 47, 99, 100, and 153 were found above the limit of detection in at least 50% of study participants and used in our models. Associations with serum PBDEs were observed with self-reported hand-to-mouth behaviors, including biting nails and licking fingers. Serum BDE levels of 47, 99, 153, and total PBDEs were also significantly higher in those individuals owning a large-screen TV compared with those who did not. Serum PBDE levels were comparable to levels reported in the general population. Hand-to-mouth behaviors may influence serum PBDE concentrations in adults. Household electronics such as large-screen TVs appear to serve as a significant source of PBDEs in pregnant women. Together, hand-to-mouth behaviors and TV ownership may serve as a route of exposure to PBDEs in adults. Journal of Exposure Science and Environmental Epidemiology (2013) 23, 176-182; doi:10.1038/jes.2012.67; published online 4 July 2012 C1 [Buttke, Danielle E.; Wolkin, Amy] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Stapleton, Heather M.] Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA. [Miranda, Marie Lynn] Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48109 USA. [Miranda, Marie Lynn] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA. RP Buttke, DE (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, 4770 Buford Highway NE, Chamblee, GA 30341 USA. EM dbuttke@cdc.gov FU National Center for Environmental Health, Centers for Disease Control and Prevention FX This work was supported by the National Center for Environmental Health, Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 48 TC 18 Z9 19 U1 8 U2 98 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD MAR-APR PY 2013 VL 23 IS 2 BP 176 EP 182 DI 10.1038/jes.2012.67 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 092MH UT WOS:000315126200010 PM 22760441 ER PT J AU St Helen, G Holland, NT Balmes, JR Hall, DB Bernert, JT Vena, JE Wang, JS Naeher, LP AF St Helen, Gideon Holland, Nina T. Balmes, John R. Hall, Daniel B. Bernert, J. Thomas Vena, John E. Wang, Jia-Sheng Naeher, Luke P. TI Utility of urinary Clara cell protein (CC16) to demonstrate increased lung epithelial permeability in non-smokers exposed to outdoor secondhand smoke SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE secondhand smoke; CC16; epithelial permeability; biomarkers; smoking bans; tobacco control ID ENVIRONMENTAL TOBACCO-SMOKE; MAINSTREAM CIGARETTE-SMOKE; SECRETORY PROTEIN; BIOMARKER; RESTAURANTS; COTININE; KINETICS; GEORGIA; ATHENS; ADULTS AB The objective of this study was to assess the utility of urinary Clara cell protein (CC16) as a biomarker of increased lung epithelial permeability in non-smokers exposed to outdoor secondhand smoke. Twenty-eight healthy non-smoking adults visited outdoor patios of a restaurant and a bar where non-participants srnoked and an open-air control with no smokers on three weekend days in a crossover study; subjects visited each site once for 3 h. Urine samples were collected at baseline, immediately post exposure and next morning, and analyzed for CC16. Changes in CC16 across location types or with cigarette count were analyzed using mixed-effect models, which included all subjects and stratified by gender. Urinary CC16 was higher in males (n = 9) compared with females (n = 18) at all measurement occasions (P<0.002), possibly reflecting prostatic contamination. Urinary CC16 from pre-exposure to post-exposure was higher following visits to restaurant and bar sites compared with the control among females but this increase did not reach statistical significance. Post-exposure to pre-exposure urinary CC16 ratios among females increased with cigarette count (P = 0.048). Exposure-related increases in urinary CC16 were not seen among males. In conclusion, urinary CC16 may be a useful biomarker of increased lung epithelial permeability among female non-smokers; further work will be required to evaluate its applicability to males. Journal of Exposure Science and Environrnental Epidemiology (2013) 23, 183-189; doi:10.1038/jes.2012.68; published online 18 July 2012 C1 [St Helen, Gideon; Wang, Jia-Sheng; Naeher, Luke P.] Univ Georgia, Coll Publ Hlth, Dept Environm Hlth Sci, Athens, GA 30602 USA. [Holland, Nina T.; Balmes, John R.] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA. [Balmes, John R.] Univ Calif San Francisco, Dept Med, Div Occupat & Environm Med, San Francisco, CA USA. [Hall, Daniel B.] Univ Georgia, Dept Stat, Athens, GA 30602 USA. [Bernert, J. Thomas] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Vena, John E.] Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA. RP Naeher, LP (reprint author), Univ Georgia, Coll Publ Hlth, Dept Environm Hlth Sci, 206 Environm Hlth Sci Bldg, Athens, GA 30602 USA. EM LNaeher@uga.edu FU National Institutes of Environmental Health Science [1R21ES017845-01A1]; Flight Attendant Medical Research Institute (FAMRI) FX We thank the 28 study participants as well as Anderson Morris who served as a technician and driver. Thanks also to Pam Olive, Cindy Phan and Veronica Dave for help with analysis of CC16 and urinary creatinine. We further acknowledge Connie Sosnoff and Yang Xia for salivary cotinine and urinary NNAL analyses. This study was funded by the National Institutes of Environmental Health Science, project number 1R21ES017845-01A1. Dr. John Balmes is funded in part by the Flight Attendant Medical Research Institute (FAMRI). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 34 TC 5 Z9 5 U1 1 U2 25 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD MAR-APR PY 2013 VL 23 IS 2 BP 183 EP 189 DI 10.1038/jes.2012.68 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 092MH UT WOS:000315126200011 PM 22805990 ER PT J AU Parlett, LE Calafat, AM Swan, SH AF Parlett, Lauren E. Calafat, Antonia M. Swan, Shanna H. TI Women's exposure to phthalates in relation to use of personal care products SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE phthalates; epidemiology; personal exposure ID COSMETIC PRODUCTS; URINARY CONCENTRATIONS; DI(2-ETHYLHEXYL) PHTHALATE; OXIDATIVE METABOLITES; ANOGENITAL DISTANCE; DIETHYL PHTHALATE; PREGNANT-WOMEN; MEXICAN WOMEN; MALE INFANTS; ESTERS AB Several phthalates, particularly diethyl phthalate (DEP) and di-n-butyl phthalate, can be used in personal care products (PCPs) to fix fragrance and hold color. We investigated associations between women's reported use of PCPs within the 24 h before urine collection and concentrations of several urinary phthalate metabolites. Between 2002 and 2005, 337 women provided spot urine samples and answered questions regarding their use of 13 PCPs at a follow-up visit 3-36 months after pregnancy. We examined associations between urinary concentrations of several phthalate metabolites and use of PCPs using linear regression. Use of individual PCPs ranged from 7% (nail polish) to 91% (deodorant). After adjusting for age, education, and urinary creatinine, women reporting use of perfume had 2.92 times higher (95% CI: 2.20-3.89) concentration of rnonoethyl phthalate (MEP; the primary metabolite of DEP) than other women. Other PCPs that were significantly associated with MEP concentrations included: hair spray, nail polish, and deodorant. MEP concentrations increased with the nurnber of PCPs used. PCP use was widespread in this group of recently pregnant women. Women's use of PCPs, particularly of perfumes and fragranced products, was positively associated with urinary concentration of multiple phthalate metabolites. Joumal of Exposure Science and Environmental Epidemiology (2013) 23, 197-206; doi:10.1038/jes.2012.105; published online 21 November 2012 C1 [Parlett, Lauren E.] Univ Rochester, Sch Med & Dent, Dept Publ Hlth Sci, Rochester, NY 14642 USA. [Parlett, Lauren E.; Swan, Shanna H.] Univ Rochester, Med Ctr, Dept Obstet & Gynecol, Rochester, NY 14642 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Swan, Shanna H.] Mt Sinai Sch Med, Dept Prevent Med, New York, NY USA. RP Parlett, LE (reprint author), Univ Rochester, Sch Med & Dent, Dept Obstet & Gynecol, Off Res Adm, 601 Elmwood Ave,Box 668, Rochester, NY 14642 USA. EM Lauren_Parlett@urmc.rochester.edu RI Parlett, Lauren/I-3309-2013 OI Parlett, Lauren/0000-0003-1240-4566 FU US Environmental Protection Agency; National Institutes of Health [R01-ES09916, MO1-RR00400, MO1-RR0425]; State of Iowa to the University of Iowa [18018278, 1RC2ES018736-02] FX This study was supported by grants from the US Environmental Protection Agency; National Institutes of Health Grants R01-ES09916 to the University of Missouri, MO1-RR00400 to the University of Minnesota, and MO1-RR0425 to Harbor-UCLA Medical Center; Grant 18018278 from the State of Iowa to the University of Iowa and 1RC2ES018736-02 to the University of Rochester. We gratefully acknowledge the technical assistance of Manori Silva, Jack Reidy, Ella Samandar, Tao Jia, and Jim Preau (Centers for Disease Control and Prevention, Atlanta, GA, USA) in measuring the urinary concentrations of phthalate metabolites. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC. NR 54 TC 36 Z9 37 U1 7 U2 78 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD MAR-APR PY 2013 VL 23 IS 2 BP 197 EP 206 DI 10.1038/jes.2012.105 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 092MH UT WOS:000315126200013 PM 23168567 ER PT J AU Lau, FK deCastro, BR Mills-Herring, L Tao, L Valentin-Blasini, L Alwis, KU Blount, BC AF Lau, Fiona K. deCastro, B. Rey Mills-Herring, Lavinia Tao, Lin Valentin-Blasini, Liza Alwis, K. Udeni Blount, Benjamin C. TI Urinary perchlorate as a measure of dietary and drinking water exposure in a representative sample of the United States population 2001-2008 SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE perchlorate; NHANES; urine; water; diet ID TANDEM MASS-SPECTROMETRY; COLORADO RIVER REGION; ION CHROMATOGRAPHY; ACTIVE-TRANSPORT; US POPULATION; NITRATE; IODIDE; DAIRY; MILK; THIOCYANATE AB Perchlorate (CIO4-) is ubiquitous in the environment and inhibits the thyroid's uptake of iodide. Food and tap water are likely sources of environmental exposure to perchlorate. The aim of this study was to identify significant dietary sources of perchlorate using perchlorate measured in urine as an exposure indicator. Sample-weighted, age-stratified linear regression models of National Health and Nutrition Examination Survey (NHANES) 2001-2008 data (n = 16,955 participants) characterized the association between urinary perchlorate and the mass consumed in USDA food groups, controlling for urinary creatinine and other potential confounders. Separate models of NHANES 2005-2006 data (n = 2841) evaluated the association between urinary perchlorate and perchlorate consumed via residential tap water. Consumption of milk products was associated with statistically significant contributions to urinary perchlorate across all age strata: 2.93 ng CIO4-/m1 per kg consumed for children (6-11 years-old (YO)); 1.54 ng CIO4-/ml per kg for adolescents (12-19 YO); and 0.69 ng CIO4-/m1 per kg for adults (20-84 YO). Vegetables were a significant contributor for adolescents and adults, whereas fruits and eggs contributed significantly only for adults. Dark-green leafy vegetables contributed the most among all age strata: 30.83 ng CIO4-/ml per kg for adults. Fats, oils, and salad dressings were significant contributors only for children. Three food groups were negatively associated with urinary perchlorate: grain products for children; sugars, sweets, and beverages for adolescents; and home tap water for adults. In a separate model, however, perchlorate consumed via home tap water contributed significantly to adult urinary perchlorate: 2.11E-4 ng CIO4-/ml per ng perchlorate in tap water consumed. In a nationally representative sample of the United States 6-84 YO, diet and tap water contributed significantly to urinary perchlorate, with diet contributing substantially more than tap water. Journal of Exposure Science and Environmental Epidemiology (2013) 23, 207-214; doi:10.1038/jes.2012.108; published online 28 November 2012 C1 [Lau, Fiona K.; deCastro, B. Rey; Mills-Herring, Lavinia; Tao, Lin; Valentin-Blasini, Liza; Alwis, K. Udeni; Blount, Benjamin C.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Blount, BC (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway NE,Mailstop F-47, Atlanta, GA 30341 USA. EM bblount@cdc.gov OI deCastro, Rey/0000-0002-1610-5849 NR 52 TC 14 Z9 14 U1 3 U2 41 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD MAR-APR PY 2013 VL 23 IS 2 BP 207 EP 214 DI 10.1038/jes.2012.108 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 092MH UT WOS:000315126200014 PM 23188482 ER PT J AU Smith, SS Keller, PA Kobinsky, KH Baker, TB Fraser, DL Bush, T Magnusson, B Zbikowski, SM McAfee, TA Fiore, MC AF Smith, Stevens S. Keller, Paula A. Kobinsky, Kate H. Baker, Timothy B. Fraser, David L. Bush, Terry Magnusson, Brooke Zbikowski, Susan M. McAfee, Timothy A. Fiore, Michael C. TI Enhancing Tobacco Quitline Effectiveness: Identifying a Superior Pharmacotherapy Adjuvant SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID NICOTINE REPLACEMENT THERAPY; SMOKING-CESSATION PHARMACOTHERAPIES; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED CLINICAL-TRIAL; MISSING DATA; TELEPHONE QUITLINE; SMOKERS; INTERVENTION; ADHERENCE; OUTCOMES AB : Telephone tobacco quitlines are effective and are widely used, with more than 500,000 U.S. callers in 2010. This study investigated the clinical effectiveness and cost-effectiveness of 3 different quitline enhancements: combination nicotine replacement therapy (NRT), longer duration of NRT, and counseling to increase NRT adherence. : In this study, 987 quitline callers were randomized to a combination of quitline treatments in a 22 2 factorial design: NRT duration (2 vs. 6 weeks), NRT type (nicotine patch only vs. patch plus nicotine gum), and standard 4-call counseling (SC) versus SC plus medication adherence counseling (MAC). The primary outcome was 7-day point-prevalence abstinence (PPA) at 6 months postquit in intention-to-treat (ITT) analyses. : Combination NRT for 6 weeks yielded the highest 6-month PPA rate (51.6%) compared with 2 weeks of nicotine patch (38.4%), odds ratios [OR] 1.71 (95% confidence interval [CI]:1.202.45). A similar result was found for 2 weeks of combination NRT (48.2%), OR 1.49 (95% CI: 1.042.14) but not for 6 weeks of nicotine patch alone (46.2%), OR 1.38 (95% CI: 0.961.97). The MAC intervention effect was nonsignificant. Cost analyses showed that the 2-week combination NRT group had the lowest cost per quit ($442 vs. $464 for 2-week patch only, $505 for 6-week patch only, and $675 for 6-week combination NRT). : Combination NRT for 2 or 6 weeks increased 6-month abstinence rates by 10% and 13%, respectively, over rates produced by 2 weeks of nicotine patch when offered with quitline counseling. A 10% improvement would potentially yield an additional 50,000 quitters annually, assuming 500,000 callers to U.S. quitlines per year. C1 [Smith, Stevens S.; Baker, Timothy B.; Fiore, Michael C.] UWSMPH, Dept Med, Madison, WI USA. [Smith, Stevens S.; Kobinsky, Kate H.; Baker, Timothy B.; Fraser, David L.; Fiore, Michael C.] UWSMPH, Ctr Tobacco Res & Intervent, Madison, WI USA. [Keller, Paula A.] ClearWay Minnesota, Cessat Program, Minneapolis, MN USA. [Bush, Terry; Magnusson, Brooke; Zbikowski, Susan M.] Alere Wellbeing, Seattle, WA USA. [McAfee, Timothy A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. RP Smith, SS (reprint author), UW Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. EM sss@ctri.medicine.wisc.edu FU National Cancer Institute (NCI) [1RC1CA144382]; NCI [K05CA139871]; GlaxoSmithKline; Pfizer; Nabi FX National Cancer Institute (NCI) grant 1RC1CA144382 to S.S.S.; T.B.B. was supported by NCI grant K05CA139871. Clinical Trial Registry: clinicaltrials.gov Identifier: NCT01087905; registered March 15, 2010 (prior to enrollment of study participants).; S. S. S. has served in the past 5 years as a coinvestigator on research studies at the University of Wisconsin-Madison that were funded wholly or in part by GlaxoSmithKline and Pfizer. T. B. B. has served as an investigator in the past 5 years on research studies at the University of Wisconsin-Madison that were funded in part by GlaxoSmithKline. T. B., B. M., and S.M.Z. are employees at Alere Wellbeing and also own stock in Alere Wellbeing (formerly Free & Clear, Inc.), an organization providing quitline services in Wisconsin. T. A. M. was employed by and owned stock in Free & Clear prior to being appointed Director of the Office on Smoking and Health, CDC, in September 2010. He was also an unpaid member of the Board of Directors of the nonprofit North American Quitline Consortium. T. A. M. has no current financial disclosures. M. C. F. has served in the past 5 years as an investigator on research studies at the University of Wisconsin-Madison that were funded wholly or in part by Pfizer, GlaxoSmithKline, and Nabi. From 1997 to 2010, M. C. F. held a University of Wisconsin named Chair for the Study of Tobacco Dependence, made possible by a gift to the university from GlaxoWellcome. P. A. K., K. H. K., and D. L. F. have no financial disclosures. NR 54 TC 15 Z9 16 U1 2 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAR PY 2013 VL 15 IS 3 BP 718 EP 728 DI 10.1093/ntr/nts186 PG 11 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 093UY UT WOS:000315219400014 PM 22992296 ER PT J AU Sharp, J Harrison, CJ Puckett, K Selvaraju, SB Penaranda, S Nix, WA Oberste, MS Selvarangan, R AF Sharp, Justin Harrison, Christopher J. Puckett, Kelley Selvaraju, Suresh B. Penaranda, Silvia Nix, W. Allan Oberste, M. Steven Selvarangan, Rangaraj TI Characteristics of Young Infants in Whom Human Parechovirus, Enterovirus or Neither Were Detected in Cerebrospinal Fluid During Sepsis Evaluations SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article; Proceedings Paper CT 48th Annual Meeting of the Infectious-Diseases-Society-of-America (IDSA) CY OCT 21-24, 2010 CL Vancouver, CANADA SP Infect Dis Soc Amer (IDSA) DE human parechovirus; enterovirus; sepsis-like illness; children; cerebrospinal fluid ID INFECTIONS; IDENTIFICATION; ASSOCIATION; CHILDREN; SAMPLES; TYPE-3; FEVER AB Background: Human parechovirus (HPeV) causes central nervous system (CNS) infection in infants. To further understand HPeV CNS infection, we describe its clinical, laboratory and epidemiologic characteristics from a Midwestern US tertiary care center. Because HPeV CNS infections have appeared clinically and seasonally similar to enterovirus (EV) infections, we retrospectively compared characteristics of young infants undergoing sepsis evaluations in whom HPeV, EV or neither were detected in cerebrospinal fluid (CSF). Methods: HPeV real-time reverse-transcription polymerase chain reaction (RT-PCR) assay was performed on frozen nucleic acid extracts of CSF specimens submitted for EV RT-PCR assay from children seen at our hospital in 2009. HPeV genotyping was performed by sequencing of the viral protein 1 region. Clinical data were abstracted from medical records retrospectively for EV-positive, HPeV-positive and age-matched controls in whom neither virus was detected from CSF testing. Results: HPeV was detected in 66 of the 388 (17%) CSF specimens whereas EV was detected in 54 of the 388 (14%) from June through October 2009. Genotyping identified HPeV3 in 51 of the 66 (77%) positive CSF specimens. Males predominated (61%) with the most common presenting symptoms (91%) being fever and irritability. All HPeV-positive patients were <5 months of age. Eight required admission to the pediatric intensive care unit. In multivariate analysis, lower peripheral white blood cell counts with lower absolute lymphocyte count values, higher maximum temperatures, longer fever duration, absence of pleocytosis and longer hospitalization were independently associated with HPeV patients compared with patients with EV or patients negative for both HPeV and EV. Conclusions: Our data indicate that HPeV3, an emerging CNS pathogen of infants in the United States, should be considered in sepsis-like presentation even without CSF pleocytosis. Addition of HPeV RT-PCR to EV RT-PCR assay for CSF specimens of patients <6 months of age could reduce hospital stay and costs while improving clinical management C1 [Sharp, Justin; Harrison, Christopher J.; Puckett, Kelley; Selvaraju, Suresh B.; Selvarangan, Rangaraj] Childrens Mercy Hosp & Clin, Kansas City, MO USA. [Harrison, Christopher J.; Selvaraju, Suresh B.; Selvarangan, Rangaraj] Univ Missouri, Sch Med, Kansas City, MO 64108 USA. [Penaranda, Silvia; Nix, W. Allan; Oberste, M. Steven] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Selvarangan, R (reprint author), UMKC SOM, Kansas City, MO 64108 USA. EM rselvarangan@cmh.edu FU Intramural CDC HHS [CC999999] NR 22 TC 34 Z9 34 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAR PY 2013 VL 32 IS 3 BP 213 EP 216 DI 10.1097/INF.0b013e318276b328 PG 4 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 089TK UT WOS:000314932700009 PM 23042051 ER PT J AU Scallan, E Mahon, BE Hoekstra, RM Griffin, PM AF Scallan, Elaine Mahon, Barbara E. Hoekstra, Robert M. Griffin, Patricia M. TI Estimates of Illnesses, Hospitalizations and Deaths Caused by Major Bacterial Enteric Pathogens in Young Children in the United States SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE children; enteric infections; Salmonella; Campylobacter; bacterial ID YERSINIA-ENTEROCOLITICA INFECTION; POPULATION-BASED ESTIMATE; ESCHERICHIA-COLI O157-H7; FOODBORNE ILLNESS; DIARRHEAL ILLNESS; FOODNET; BURDEN; SURVEILLANCE; ETIOLOGY; INFANTS AB Background: Many enteric pathogens disproportionately affect young children. However, higher incidences of laboratory-confirmed illness may be explained, at least in part, by higher rates of medical care-seeking and stool sample submission in this age group. We estimated the overall number of bacterial enteric illnesses among children <5 years old in the United States caused by Campylobacter, Escherichia coli O157, nontyphoidal Salmonella, Shigella and Yersinia enterocolitica. Materials and Methods: We used a statistical model that scaled counts of laboratory-confirmed illnesses from the Foodborne Diseases Active Surveillance Network up to an estimated number of illnesses in the United States, adjusting for the surveillance steps needed for an illness to be laboratory diagnosed (medical care sought, stool sample submitted, bacterial culture performed, laboratory tested for pathogen, laboratory test sensitivity). Results: We estimated that 5 bacterial enteric pathogens caused 291,162 illnesses each year among children <5 years old, resulting in 102,746 physician visits, 7830 hospitalizations and 64 deaths. Nontyphoidal Salmonella caused most illnesses (42%), followed by Campylobacter (28%), Shigella (21%), Y. enterocolitica (5%) and E. coli O157 (3%). The estimated annual number of physician visits ranged from 3763 for E. coli O157 to 44,369 for nontyphoidal Salmonella. Nontyphoidal Salmonella was estimated to cause most hospitalizations (4670) and deaths (38). Conclusions: Bacterial enteric infections cause many illnesses in US children. Compared with the general population, enteric illnesses among children <5 years old are more likely to be diagnosed. However, overall rates of illness remain higher in children after adjusting for underdiagnosis in both groups. C1 [Scallan, Elaine] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO 80045 USA. [Mahon, Barbara E.; Griffin, Patricia M.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA USA. [Hoekstra, Robert M.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Biostat & Informat Management Off, Atlanta, GA USA. RP Scallan, E (reprint author), Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, UCD AMC Bldg 500,Room W3146,13001 E 17th Pl, Aurora, CO 80045 USA. EM Elaine.Scallan@ucdenver.edu FU Association of Public Health Laboratories; Centers for Disease Control and Prevention (CDC) [1U60HM000803] FX Supported by the Association of Public Health Laboratories and Cooperative Agreement Number #1U60HM000803 from Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC. The authors have no other funding or conflicts of interest to disclose. NR 26 TC 22 Z9 24 U1 0 U2 19 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAR PY 2013 VL 32 IS 3 BP 217 EP 221 DI 10.1097/INF.0b013e31827ca763 PG 5 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 089TK UT WOS:000314932700010 PM 23249909 ER PT J AU Singleton, R Wenger, J Klejka, JA Bulkow, LR Thompson, A Sarkozy, D Emini, EA Gruber, WC Scott, DA AF Singleton, Rosalyn Wenger, Jay Klejka, Joseph A. Bulkow, Lisa R. Thompson, Allison Sarkozy, Denise Emini, Emilio A. Gruber, William C. Scott, Daniel A. TI The 13-Valent Pneumococcal Conjugate Vaccine for Invasive Pneumococcal Disease in Alaska Native Children: Results of a Clinical Trial SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE invasive pneumococcal disease; children; Alaska Native; pneumococcal conjugate vaccine ID ROUTINE PEDIATRIC VACCINATIONS; STREPTOCOCCUS-PNEUMONIAE; SEROTYPE REPLACEMENT; HEALTHY INFANTS; PHASE-1 TRIAL; UNITED-STATES; IMMUNOGENICITY; SAFETY; TODDLERS; PREVENTION AB Background: During 1996 to 2000, Alaska Native children aged <5 years from Yukon Kuskokwim Delta (YKD) had invasive pneumococcal disease (IPD) rates 10-fold higher than non-Alaska Native children (547/100,000/yr versus 56/100,000/yr). After 7-valent pneumococcal conjugate vaccine (PCV7) introduction, IPD rates decreased to 148 per 100,000 during 2001 to 2004, increasing to 426 per 100,000 during 2005 to 2007 due to non-vaccine serotype disease. In 2009, we evaluated safety, immunogenicity and impact of 13-valent PCV (PCV13) in YKD children. Methods: In a prelicensure open-label clinical trial, eligible YKD children aged <5 years were offered PCV13 as appropriate for age and prior PCV7 history. PCV13 impact was assessed using existing Alaska-wide IPD surveillance. Serotype-specific anti-pneumococcal IgG levels were measured postinfant series and posttoddler dose in a subset of subjects. Adverse events and serious adverse events were collected in all; local reactions and systemic events were collected in toddlers. All YKD children were offered licensed PCV13 when it became available. Results: Three hundred seventy-two subjects received PCV13 during the clinical trial and 3342 postlicensure (April 2010 to August 2011). Adverse events were typically mild, or generally consistent with common childhood illnesses. IgG levels following PCV13 were similar to other populations. In YKD children aged <5 years, 52 IPD cases (31 PCV13-serotype) occurred during 2005 to 2008 (399.0/100,000/yr) versus 9 (7 PCV13-serotype) during January 2009 to August 2011 (106.7/100,000/yr; P < 0.001). No PCV13-serotype cases occurred among PCV13 recipients (3680 person follow-up years). Conclusions: PCV13-serotype IPD incidence declined significantly after PCV13 introduction. Although non-PCV13-serotype IPD also declined significantly, absence of PCV13-serotype IPD in children who received PCV13 suggests a protective vaccine effect. C1 [Singleton, Rosalyn; Wenger, Jay; Bulkow, Lisa R.] Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. [Klejka, Joseph A.] Yukon Kuskokwim Hlth Corp, Bethel, AK USA. [Thompson, Allison; Gruber, William C.; Scott, Daniel A.] Pfizer Inc, Pearl River, NY USA. [Sarkozy, Denise; Emini, Emilio A.] Pfizer Inc, Collegeville, PA USA. RP Singleton, R (reprint author), CDC, Arctic Invest Program, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM Ris2@cdc.gov FU Pfizer Inc.; Wyeth FX Editorial support was provided by Vicki Schwartz, PhD, at Excerpta Medica and was funded by Pfizer Inc. AT, EAE, WCG and DAS are employees of Pfizer Inc, and DS was an employee of Pfizer Inc at the time of the study. This study was sponsored by Wyeth, which was acquired by Pfizer Inc in October 2009. No honorarium, grant or other form of payment was provided to authors, with the exception of funding needed for the conduct of the study, and travel funding for RS to present study results. The authors have no other funding or conflicts of interest to disclose. NR 31 TC 21 Z9 21 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAR PY 2013 VL 32 IS 3 BP 257 EP 263 DI 10.1097/INF.0b013e3182748ada PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 089TK UT WOS:000314932700019 PM 23001026 ER PT J AU Peeling, RW Mabey, D Ballard, RC AF Peeling, Rosanna W. Mabey, David Ballard, Ronald C. TI s Introducing new diagnostics into STI control programmes: the importance of programme science SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Article ID RESOURCE-LIMITED SETTINGS; DEMONSTRATION PROJECT; SYPHILIS; PREGNANCY; PREVENTION; NAIROBI; AFRICA; KENYA; FIELD; HIV AB Many innovative diagnostic technologies will become commercially available over the next 5-10 years. These tests can potentially transform the diagnosis of sexually transmitted infections but their introduction into control programmes can be hampered by health system constraints, and political, cultural, socioeconomic and behavioural factors. We used the introduction of syphilis rapid tests to illustrate the importance of programme science to address the gap between accruing evidence of acceptable test performance and the complexity of programme design, implementation and evaluation of test deployment to address public health needs and improve patient-important outcomes. C1 [Peeling, Rosanna W.; Mabey, David] Univ London London Sch Hyg & Trop Med, Dept Clin Res, London WC1E 7HT, England. [Ballard, Ronald C.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. RP Peeling, RW (reprint author), Univ London London Sch Hyg & Trop Med, Dept Clin Res, Keppel St, London WC1E 7HT, England. EM rosanna.peeling@lshtm.ac.uk FU Bill & Melinda Gates Foundation [47697] FX Funding for the multi-country syphilis implementation project came from the Bill & Melinda Gates Foundation, grant #47697. NR 24 TC 5 Z9 5 U1 0 U2 5 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD MAR PY 2013 VL 89 IS 2 BP 115 EP 119 DI 10.1136/sextrans-2012-050617 PG 5 WC Infectious Diseases SC Infectious Diseases GA 093QZ UT WOS:000315207800012 PM 23270931 ER PT J AU Bowen, A Agboatwalla, M Ayers, T Tobery, T Tariq, M Luby, SP AF Bowen, Anna Agboatwalla, Mubina Ayers, Tracy Tobery, Timothy Tariq, Maria Luby, Stephen P. TI Sustained improvements in handwashing indicators more than 5years after a cluster-randomised, community-based trial of handwashing promotion in Karachi, Pakistan SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE handwashing; behaviour; Pakistan; soaps ID HYGIENE BEHAVIOR; HAND; RISK; SOAP; INTERVENTIONS; PERFORMANCE; INFECTIONS; DIARRHEA; PROGRAM; HABITS AB Objective To evaluate handwashing behaviour 5years after a handwashing intervention in Karachi, Pakistan. Methods In 2003, we randomised neighbourhoods to control, handwashing promotion, or handwashing promotion and water treatment. Intervention households were given soap +/ water treatment product and weekly handwashing education for 9months. In 2009, we re-enrolled 461 households from the three study groups: control (160), handwashing (141), and handwashing+water treatment (160) and assessed hygiene-related outcomes, accounting for clustering. Results Intervention households were 3.4 times more likely than controls to have soap at their handwashing stations during the study visit [293/301 (97%) vs. 45/159 (28%), P<0.0001]. While nearly all households reported handwashing after toileting, intervention households more commonly reported handwashing before cooking [relative risk (RR) 1.2 (95% confidence interval (CI) 1.01.4)] and before meals [RR 1.7 (95% CI, 1.32.1)]. Control households cited a mean of 3.87 occasions for washing hands; handwashing households, 4.74 occasions; and handwashing+water treatment households, 4.78 occasions (P<0.0001). Households reported purchasing a mean of 0.65 (control), 0.91 (handwashing) and 1.1 (handwashing+water treatment) bars of soap/person/month (P<0.0001). Conclusions Five years after receiving handwashing promotion, intervention households were more likely to have soap at the household handwashing station, know key times to wash hands and report purchasing more soap than controls, suggesting habituation of improved handwashing practices in this population. Intensive handwashing promotion may be an effective strategy for habituating hygiene behaviours and improving health. C1 [Bowen, Anna; Ayers, Tracy; Luby, Stephen P.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Agboatwalla, Mubina; Tariq, Maria] Hlth Oriented Prevent Educ, Karachi, Pakistan. [Tobery, Timothy] Procter & Gamble Co, Mason, OH USA. RP Bowen, A (reprint author), US Ctr Dis Control & Prevent, Atlanta, GA USA. EM abowen@cdc.gov OI Ayers, Tracy/0000-0003-4140-3263 FU Intramural CDC HHS [CC999999] NR 31 TC 4 Z9 4 U1 2 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD MAR PY 2013 VL 18 IS 3 BP 259 EP 267 DI 10.1111/tmi.12046 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 092FC UT WOS:000315103700004 PM 23294343 ER PT J AU Speer, PW Peterson, NA Armstead, TL Allen, CT AF Speer, Paul W. Peterson, N. Andrew Armstead, Theresa L. Allen, Christopher T. TI The Influence of Participation, Gender and Organizational Sense of Community on Psychological Empowerment: The Moderating Effects of Income SO AMERICAN JOURNAL OF COMMUNITY PSYCHOLOGY LA English DT Article DE Sense of community; Empowerment; Income; Moderator effects; Intrapersonal empowerment; Interactional empowerment; Participation; Gender ID SOCIOPOLITICAL CONTROL SCALE; HEALTH-PROMOTION; SOCIAL COHESION; PSYCHOPOLITICAL VALIDITY; AFRICAN-AMERICANS; PERCEIVED CONTROL; TOBACCO CONTROL; PREVENTION; COALITIONS; POWER AB This study explored the influence of participation, gender and organizational sense of community (SOC) on both the intrapersonal and interactional components of psychological empowerment (PE). Participants were residents (n = 562) involved in community organizing efforts in five U.S. communities. Measures of participation and SOC were tailored to community organization contexts. SOC assessed three dimensions: (1) connection of members to the organization; (2) perceptions about the organization as a bridge to other groups and organizations in the broader community; and (3) bond or attachment to the community at large. Income (low, middle and high-income) was tested as a moderator of these relationships. Results showed significant moderating effects of income on the relationship between participation, gender and SOC on both components of PE. Participation was positively related with intrapersonal empowerment across income levels, but positively related with interactional empowerment only for low-income individuals. Gender was only associated with intrapersonal empowerment, and only for low-income individuals. SOC, as expressed through bridging to the broader community, was positively related with interactional PE for all income levels, but with intrapersonal PE for only low and middle-income individuals. In contrast, member connection to the organization was not related to interactional empowerment and significantly related to intrapersonal empowerment only for individuals with higher income. The importance of participation, gender and SOC for different types of empowerment and the impact of income on the SOC-empowerment relationship are discussed. C1 [Speer, Paul W.] Vanderbilt Univ, Peabody Coll, Nashville, TN 37203 USA. [Peterson, N. Andrew; Allen, Christopher T.] Rutgers State Univ, Sch Social Work, New Brunswick, NJ 08903 USA. [Armstead, Theresa L.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Speer, PW (reprint author), Vanderbilt Univ, Peabody Coll, 230 Appleton Pl, Nashville, TN 37203 USA. EM paul.w.speer@vanderbilt.edu NR 58 TC 15 Z9 16 U1 0 U2 41 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0091-0562 J9 AM J COMMUN PSYCHOL JI Am. J. Community Psychol. PD MAR PY 2013 VL 51 IS 1-2 BP 103 EP 113 DI 10.1007/s10464-012-9547-1 PG 11 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Social Work SC Public, Environmental & Occupational Health; Psychology; Social Work GA 088KV UT WOS:000314834100009 PM 22847224 ER PT J AU Fleischer, NL Tiesman, HM Sumitani, J Mize, T Amarnath, KK Bayakly, AR Murphy, MW AF Fleischer, Nancy L. Tiesman, Hope M. Sumitani, Jeri Mize, Terry Amarnath, Kumar Kartik Bayakly, A. Rana Murphy, Matthew W. TI Public Health Impact of Heat-Related Illness Among Migrant Farmworkers SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID NORTH-CAROLINA; WORKERS AB Background: Migrant farmworkers are at risk for heat-related illness (HRI) at work. Purpose: The purpose of this study was to determine which risk factors could potentially reduce the prevalence of HRI symptoms among migrant farmworkers in Georgia. Methods: Trained interviewers conducted in-person interviews of adults who attended the South Georgia Farmworker Health Project clinics in June 2011. The analysis was conducted in 2011-2012. Population intervention models were used to assess where the greatest potential impact could be made to reduce the prevalence of HRI symptoms. Results: In total, 405 farmworkers participated. One third of participants had experienced three or more HRI symptoms in the preceding week. Migrant farmworkers faced barriers to preventing HRI at work, including lack of prevention training (77%) and no access to regular breaks (34%); shade (27%); or medical attention (26%). The models showed that the prevalence of three or more HRI symptoms (n = 361, 34.3%) potentially could be reduced by increasing breaks in the shade (-9.2%); increasing access to medical attention (-7.3%); reducing soda intake (-6.7%); or increasing access to regular breaks (-6.0%). Conclusions: Migrant farmworkers experienced high levels of HRI symptoms and faced substantial barriers to preventing these symptoms. Although data are cross-sectional, results suggest that heat-related illness may be reduced through appropriate training of workers on HRI prevention, as well as regular breaks in shaded areas. (Am J Prev Med 2013;44(3):199-206) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Fleischer, Nancy L.] CDC, Epidem Intelligence Serv, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Murphy, Matthew W.] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Sumitani, Jeri; Mize, Terry] Emory Univ, Phys Assistant Program, Atlanta, GA 30322 USA. [Bayakly, A. Rana] Georgia Dept Publ Hlth, Chron Dis Hlth Behav & Injury Epidemiol Sect, Atlanta, GA USA. [Tiesman, Hope M.] CDC, Natl Ctr Occupat Safety & Hlth, Morgantown, WV USA. [Amarnath, Kumar Kartik] Depauw Univ, Dept Biol, Greencastle, IN 46135 USA. RP Fleischer, NL (reprint author), Univ S Carolina, Arnold Sch Publ Hlth, 800 Sumter St, Columbia, SC 29208 USA. EM nfleischer@sc.edu FU Division of Environmental Hazards and Health Effects, NCEH, CDC FX This work was supported by the Division of Environmental Hazards and Health Effects, NCEH, CDC. The study sponsor reviewed the study design. The authors thank the following individuals for assistance with data collection: Andres Espinosa-Bode, Federico Feldstein, Jane Horton, Mildred Maisonet, Natasha Prudent, Dorimar Rosado, Raquel Sabogal, and Germaine Vazquez, all from the CDC; Marissa Hall from SciMetrika; Chantel Nicolas from Clark Atlanta University; and Aaron Storms from the Epidemic Intelligence Service at the CDC. The authors thank Adrianne Holmes from the CDC and Elena Soler from SciMetrika for administrative support; Shelia Ramer and staff from the GA Farm Worker Health Program in Decatur County; Julissa Clapp and staff from the Lake Park Migrant Farmworker Clinic; and the student providers during the 2011 Emory University Physician Assistant Program's South Georgia Farmworker Health Project. The authors thank Thomas Arcury and Maria Weir from Wake Forest University for reviewing the questionnaire, and Alan Hubbard and Stephan Ritter from the University of California, Berkeley, for their helpful advice regarding the analysis. NR 23 TC 22 Z9 22 U1 1 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2013 VL 44 IS 3 BP 199 EP 206 DI 10.1016/j.amepre.2012.10.020 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 090FZ UT WOS:000314965900002 PM 23415115 ER PT J AU Song, M Carroll, DD Fulton, JE AF Song, MinKyoung Carroll, Dianna D. Fulton, Janet E. TI Meeting the 2008 Physical Activity Guidelines for Americans Among U.S. Youth SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID RISK BEHAVIOR SURVEILLANCE; UNITED-STATES; ADOLESCENTS; CHILDREN; ACCELEROMETER; WEATHER; SEASON; AGE AB Background: Participation in physical activity brings health benefits for adolescents. However, limited data are available on the percentage of U. S. adolescents who engage in levels of aerobic and muscle-strengthening activities recommended in the 2008 Physical Activity Guidelines for Americans (2008 Guidelines). Purpose: To examine the prevalence at which U. S. adolescents aged 12-17 years meet the 2008 Guidelines, and whether demographic and BMI variables influence that prevalence. Methods: Using data from an interviewer-administered self-report questionnaire in the 1999-2006 National Health and Nutrition Examination Survey (analyzed in 2011), estimates were made of the percentage of adolescents who engaged in recommended levels of aerobic and muscle-strengthening activities (>= 60 minutes of aerobic activity/day and participation in muscle-strengthening activities >= 3 days/week). Results: Among 6547 U. S. adolescents aged 12-17 years, 16.3% (95% CI=14.9%, 17.9%) met both aerobic and muscle-strengthening guidelines; 14.7% (13.3%, 16.2%) met the aerobic guideline only, 21.3% (19.4%, 23.3%) met the muscle-strengthening guideline only, and 47.8% (45.4%, 50.1%) met neither guideline. Adjusted for covariates, odds of meeting either the aerobic or muscle-strengthening guideline only or both guidelines versus meeting neither guideline were (p<0.05) higher among boys than girls. The odds of meeting the aerobic guideline only were higher among underweight/normal-weight adolescents than among obese adolescents. No clear pattern was observed by family groups according to poverty-to-income ratio. Conclusions: Less than 20% of adolescents reported engaging in recommended levels of both aerobic and muscle-strengthening activities. (Am J Prev Med 2013;44(3):216-222) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Song, MinKyoung] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Song, MinKyoung; Carroll, Dianna D.; Fulton, Janet E.] CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. [Carroll, Dianna D.] US PHS, Atlanta, GA USA. RP Song, M (reprint author), Univ Michigan, Sch Nursing, 400 N Ingalls Bldg, Ann Arbor, MI 48109 USA. EM songmin@umich.edu NR 28 TC 22 Z9 23 U1 3 U2 25 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2013 VL 44 IS 3 BP 216 EP 222 DI 10.1016/j.amepre.2012.11.016 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 090FZ UT WOS:000314965900004 PM 23415117 ER PT J AU Mack, KA Rudd, RA Mickalide, AD Ballesteros, MF AF Mack, Karin A. Rudd, Rose A. Mickalide, Angela D. Ballesteros, Michael F. TI Fatal Unintentional Injuries in the Home in the U.S., 2000-2008 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID UNITED-STATES AB Background: From 1992 to 1999, an average of more than 18,000 unintentional home injury deaths occurred in the U.S. annually. Purpose: The objective of this study was to provide current prevalence estimates of fatal unintentional injury in the home. Methods: Data from the 2000-2008 National Vital Statistics System were used in 2011 to calculate average annual rates for unintentional home injury deaths for the U.S. overall, and by mechanism of injury, gender, and age group. Results: From 2000 to 2008, there was an annual average of 30,569 unintentional injury deaths occurring in the home environment in the U.S. (10.3 deaths per 100,000). Poisonings (4.5 per 100,000) and falls (3.5 per 100,000) were the leading causes of home injury deaths. Men/boys had higher rates of home injury death than women/girls (12.7 vs 8.2 per 100,000), and older adults (>= 80 years) had higher rates than other age groups. Home injury deaths and rates increased significantly from 2000 to 2008. Conclusions: More than 30,000 people die annually in the U.S. from unintentional injuries at home, with the trend rising since the year 2000. The overall rise is due in large part to the dramatic increase in deaths due to poisonings, and to a lesser degree falls at home. Unintentional home injuries are both predictable and preventable. Through a multifaceted approach combining behavioral change, adequate supervision of children, installation and maintenance of safety devices, and adherence to building codes, safety regulations and legislation, home injuries can be reduced. (Am J Prev Med 2013;44(3):239-246) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Mack, Karin A.; Rudd, Rose A.; Ballesteros, Michael F.] CDC, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30341 USA. [Mickalide, Angela D.] Safe Kids Worldwide, Washington, DC USA. RP Mack, KA (reprint author), CDC, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE F62, Atlanta, GA 30341 USA. EM kmack@cdc.gov RI Mack, Karin/A-3263-2012 OI Mack, Karin/0000-0001-9274-3001 FU Intramural CDC HHS [CC999999] NR 17 TC 7 Z9 7 U1 0 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2013 VL 44 IS 3 BP 239 EP 246 DI 10.1016/j.amepre.2012.10.022 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 090FZ UT WOS:000314965900007 PM 23415120 ER PT J AU Hoehner, CM Ribeiro, IC Parra, DC Reis, RS Azevedo, MR Hino, AA Soares, J Hallal, PC Simoes, EJ Brownson, RC AF Hoehner, Christine M. Ribeiro, Isabela C. Parra, Diana C. Reis, Rodrigo S. Azevedo, Mario R. Hino, Adriano A. Soares, Jesus Hallal, Pedro C. Simoes, Eduardo J. Brownson, Ross C. TI Physical Activity Interventions in Latin America Expanding and Classifying the Evidence SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID COMMUNITY-PREVENTIVE-SERVICES; EFFECTIVE PUBLIC-HEALTH; OBESITY PREVENTION; SYSTEMATIC REVIEWS; COORDINATED APPROACH; CHILDHOOD OBESITY; EXTERNAL VALIDITY; PROMOTION PROGRAM; DEVELOPING-WORLD; SCHOOL-CHILDREN AB Context: Systematic reviews of public health interventions are useful for identifying effective strategies for informing policy and practice. The goals of this review were to (1) update a previous systematic review of physical activity interventions in Latin America which found that only school-based physical education had sufficient evidence to recommend widespread adoption; (2) assess the reporting of external validity elements; and (3) develop and apply an evidence typology for classifying interventions. Evidence acquisition: In 2010-2011, community-level, physical activity intervention studies from Latin America were identified, categorized, and screened based on the peer-reviewed literature or Brazilian theses published between 2006 and 2010. Articles meeting inclusion criteria were evaluated using U. S. Community Guide methods. External validity reporting was assessed among a subset of articles reviewed to date. An evidence rating typology was developed and applied to classify interventions along a continuum based on evidence about their effectiveness in the U. S. context, reach, adoption, implementation, institutionalization, and benefits and costs. Evidence synthesis: Thirteen articles published between 2006 and 2010 met inclusion criteria and were abstracted systematically, yet when combined with evidence from articles from the previous systematic review, no additional interventions could be recommended for practice. Moreover, the reporting of external validity elements was low among a subset of 19 studies published to date (median=21% of elements reported). By applying the expanded evidence rating typology, one intervention was classified as evidence-based, seven as promising, and one as emerging. Conclusions: Several physical activity interventions have been identified as promising for future research and implementation in Latin America. Enhanced reporting of external validity elements will inform the translation of research into practice. (Am J Prev Med 2013;44(3):e31-e40) (C) 2013 American Journal of Preventive Medicine C1 [Hoehner, Christine M.; Brownson, Ross C.] Washington Univ, Sch Med, Div Publ Hlth Sci, St Louis, MO 63110 USA. [Hoehner, Christine M.; Brownson, Ross C.] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA. [Parra, Diana C.; Brownson, Ross C.] Washington Univ, Brown Sch, Prevent Res Ctr St Louis, St Louis, MO 63110 USA. [Simoes, Eduardo J.] Univ Missouri, Sch Med, Dept Hlth Management & Informat, Columbia, MO USA. [Ribeiro, Isabela C.] CDC, Publ Hlth Div, ICF Int, Atlanta, GA 30333 USA. [Soares, Jesus] CDC, Phys Act & Hlth Branch, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. [Reis, Rodrigo S.; Hino, Adriano A.] Pontificia Univ Catolica Parana, Sch Hlth & Biosci, Curitiba, Parana, Brazil. [Reis, Rodrigo S.; Hino, Adriano A.] Univ Fed Parana, Postgrad Program Phys Educ, BR-80060000 Curitiba, Parana, Brazil. [Azevedo, Mario R.; Hallal, Pedro C.] Univ Fed Pelotas, Postgrad Program Phys Educ, Pelotas, Brazil. RP Hoehner, CM (reprint author), Washington Univ, Sch Med, Div Publ Hlth Sci, 660 S Euclid Ave,Campus Box 8100, St Louis, MO 63110 USA. EM christy.hoehner@gmail.com RI Parra, Diana/D-7633-2013; Hino, Adriano Akira/F-5532-2012; Epidemiologicas, Centro de pesquisas /D-4561-2013; Hallal, Pedro/A-3249-2011; Parra, Diana/B-7761-2015; Reis, Rodrigo/F-7447-2012; OI Parra, Diana/0000-0002-9797-6231; Hino, Adriano Akira/0000-0003-1649-9419; Hallal, Pedro/0000-0003-1470-6461; Parra, Diana/0000-0002-9797-6231; Reis, Rodrigo/0000-0002-9872-9865; Simoes, Eduardo/0000-0003-4371-4305 FU CDC's Prevention Research Centers Program [U48/DP001903] FX This study was funded through the CDC's Prevention Research Centers Program contract U48/DP001903 (Applying Evidence-Physical Activity Recommendations in Brazil). The authors thank all members of Project GUIA for their valuable contribution and input, and especially Carlos Arango and Grace Gomes for assisting with article abstractions and Drs. Michael Pratt and Luiz Ramos for their insightful feedback as members of the GUIA Science Committee. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the CDC. NR 75 TC 23 Z9 23 U1 1 U2 30 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2013 VL 44 IS 3 BP E31 EP E40 DI 10.1016/j.amepre.2012.10.026 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 090FZ UT WOS:000314965900001 PM 23415133 ER PT J AU Levine, DJ Riley, DJ Jorgensen, JH McClain, WD Tio, F Visvesvara, GS Abboud-Werner, SL AF Levine, Deborah J. Riley, Daniel J. Jorgensen, James H. McClain, William D. Tio, Fermin Visvesvara, Govinda S. Abboud-Werner, Sherry L. TI Key Diagnostic Features of Granulomatous Interstitial Nephritis Due to Encephalitozoon cuniculi in a Lung Transplant Recipient SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE microsporidia; lung; kidney; transplant; albendazole ID BONE-MARROW-TRANSPLANTATION; ENTEROCYTOZOON-BIENEUSI; MICROSPORIDIOSIS; AIDS; INFECTION; MYOSITIS; PATIENT; GENOTYPES AB Microsporidia are increasingly recognized as opportunistic pathogens in immunocompromised organ transplant recipients (OTR). Disseminated infection due to Encephalitozoon sp. is reported mainly in human immunodeficiency virus (HIV)-positive patients and rarely in HIV-negative OTR. The clinical spectrum ranges from keratoconjunctivitis, to pneumonitis, to acute kidney injury. The kidney is a common site for disseminated infection; however, specialized techniques are required for definitive diagnosis. We report the first case of disseminated Encephalitozoon cuniculi infection in an HIV-negative lung transplant recipient diagnosed on renal biopsy. Five months after transplant, he presented with fever and a lung infiltrate and developed acute kidney injury. Renal biopsy showed granulomatous interstitial nephritis with gram-positive rod-shaped organisms with a "belt-like stripe" in tubular epithelial cells. Electron microscopy, polymerase chain reaction, and mammalian cell cultures of the urine sediment confirmed E. cuniculi infection. Retrospective review of a previous lung biopsy showed similar organisms. On the basis of electron microscopy findings, the patient was treated with albendazole, and immunosuppressive therapy was reduced. However, the patient expired due to Aspergillus pneumonia and disseminated E. cuniculi infection. Microsporidia should be considered in cases of fever of unknown origin and/or multiorgan infection in HIV-negative OTR when other causes have been excluded, as successful treatment requires early detection. C1 [Levine, Deborah J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis, San Antonio, TX 78229 USA. [Riley, Daniel J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Jorgensen, James H.; McClain, William D.; Tio, Fermin; Abboud-Werner, Sherry L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Jorgensen, James H.; McClain, William D.; Tio, Fermin; Abboud-Werner, Sherry L.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Visvesvara, Govinda S.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Abboud-Werner, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM abboudwerner@uthscsa.edu NR 33 TC 4 Z9 4 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD MAR PY 2013 VL 37 IS 3 BP 447 EP 452 DI 10.1097/PAS.0b013e31827e1968 PG 6 WC Pathology; Surgery SC Pathology; Surgery GA 092BY UT WOS:000315095000017 PM 23388129 ER PT J AU Karlsson, MS Bowen, A Reporter, R Folster, JP Grass, JE Howie, RL Taylor, J Whichard, JM AF Karlsson, Maria Sjoelund Bowen, Anna Reporter, Roshan Folster, Jason P. Grass, Julian E. Howie, Rebecca L. Taylor, Julia Whichard, Jean M. TI Outbreak of Infections Caused by Shigella sonnei with Reduced Susceptibility to Azithromycin in the United States SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Letter ID MANAGEMENT C1 [Karlsson, Maria Sjoelund; Bowen, Anna; Folster, Jason P.; Grass, Julian E.; Whichard, Jean M.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Reporter, Roshan] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Howie, Rebecca L.; Taylor, Julia] IHRC Inc, Atlanta, GA USA. RP Karlsson, MS (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. EM fwt4@cdc.gov NR 10 TC 15 Z9 15 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAR PY 2013 VL 57 IS 3 BP 1559 EP 1560 DI 10.1128/AAC.02360-12 PG 2 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 090GU UT WOS:000314968100067 ER PT J AU Jemal, A Simard, EP Xu, JQ Ma, JM Anderson, RN AF Jemal, Ahmedin Simard, Edgar P. Xu, Jiaquan Ma, Jiemin Anderson, Robert N. TI Selected cancers with increasing mortality rates by educational attainment in 26 states in the United States, 1993-2007 SO CANCER CAUSES & CONTROL LA English DT Article DE Epidemiology; Mortality; Socioeconomic status; Surveillance ID SOCIOECONOMIC-STATUS; RACIAL DISPARITIES; HEPATOCELLULAR-CARCINOMA; RISK-FACTORS; US ADULTS; TRENDS; VIRUS; INFECTION AB Mortality rates continue to increase for liver, esophagus, and pancreatic cancers in non-Hispanic whites and for liver cancer in non-Hispanic blacks. However, the extent to which trends vary by socioeconomic status (SES) is unknown. We calculated age-standardized death rates for liver, esophagus, and pancreas cancers for non-Hispanic whites and non-Hispanic blacks aged 25-64 years by sex and level of education (a parts per thousand currency sign12, 13-15, and a parts per thousand yen16 years, as a SES proxy) during 1993-2007 using mortality data from 26 states with consistent education information on death certificates. Temporal trends were evaluated using log-linear regression, and rate ratios (RRs) with 95 % confidence intervals (CIs) compared death rates in persons with a parts per thousand currency sign12 versus a parts per thousand yen16 years of education. Generally, death rates increased for cancers of the liver, esophagus, and pancreas in non-Hispanic whites and non-Hispanic blacks (liver cancer only) with a parts per thousand currency sign12 and 13-15 years of education, with steeper increases in the least educated group. In contrast, rates remained stable in persons with a parts per thousand yen16 years of education. During 1993-2007, the RR (rates in a parts per thousand currency sign12 versus a parts per thousand yen16 years of education) increased for all three cancers, particularly for liver cancer among men which increased from 1.76 (95 % CI, 1.38-2.25) to 3.23 (95 % CI, 2.78-3.75) in non-Hispanic whites and from 1.28 (95 % CI, 0.71-2.30) to 3.64 (95 % CI, 2.44-5.44) in non-Hispanic blacks. The recent increase in mortality rates for liver, esophagus, and pancreatic cancers in non-Hispanic whites and for liver cancer in non-Hispanic blacks reflects increases among those with lower education levels. C1 [Jemal, Ahmedin; Simard, Edgar P.; Ma, Jiemin] Amer Canc Soc, Surveillance Res Program, Atlanta, GA 30303 USA. [Xu, Jiaquan; Anderson, Robert N.] Ctr Dis Control & Prevent, Mortal Stat Branch, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Jemal, A (reprint author), Amer Canc Soc, Surveillance Res Program, 250 Williams St NW, Atlanta, GA 30303 USA. EM ajemal@cancer.org FU Intramural Research Program of the American Cancer Society FX This work was supported by the Intramural Research Program of the American Cancer Society. NR 34 TC 9 Z9 9 U1 0 U2 7 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAR PY 2013 VL 24 IS 3 BP 559 EP 565 DI 10.1007/s10552-012-9993-y PG 7 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 090KC UT WOS:000314976900015 PM 22729932 ER PT J AU Coxson, PG Cook, NR Joffres, M Hong, YL Orenstein, D Schmidt, SM Bibbins-Domingo, K AF Coxson, Pamela G. Cook, Nancy R. Joffres, Michel Hong, Yuling Orenstein, Diane Schmidt, Steven M. Bibbins-Domingo, Kirsten TI Mortality Benefits From US Population-wide Reduction in Sodium Consumption Projections From 3 Modeling Approaches SO HYPERTENSION LA English DT Article DE cardiovascular diseases; computer simulation; dietary sodium; hypertension; mortality ID JOINT NATIONAL COMMITTEE; CORONARY-HEART-DISEASE; HIGH BLOOD-PRESSURE; UNITED-STATES; CARDIOVASCULAR-DISEASE; DIETARY-SODIUM; URINARY SODIUM; SECULAR TRENDS; HYPERTENSION; RISK AB Computer simulations have been used to estimate the mortality benefits from population-wide reductions in dietary sodium, although comparisons of these estimates have not been rigorously evaluated. We used 3 different approaches to model the effect of sodium reduction in the US population over the next 10 years, incorporating evidence for direct effects on cardiovascular disease mortality (method 1), indirect effects mediated by blood pressure changes as observed in randomized controlled trials of antihypertension medications (method 2), or epidemiological studies (method 3). The 3 different modeling approaches were used to model the same scenarios: scenario A, gradual uniform reduction totaling 40% over 10 years; scenario B, instantaneous 40% reduction in sodium consumption sustained for 10 years to achieve a population-wide mean of 2200 mg/d; and scenario C, instantaneous reduction to 1500 mg sodium per day sustained for 10 years. All 3 methods consistently show a substantial health benefit for reductions in dietary sodium under each of the 3 scenarios tested. A gradual reduction in dietary sodium over the next decade (scenario A) as might be achieved with a range of proposed public health interventions would yield considerable health benefits over the next decade, with mean effects across the 3 models ranging from 280 000 to 500 000 deaths averted. Projections of instantaneous reductions illustrate the maximum benefits that could be achieved (0.7-1.2 million deaths averted in 10 years). Under 3 different modeling assumptions, the projected health benefits from reductions in dietary sodium are substantial. (Hypertension. 2013;61:564-570.) circle Online Data Supplement C1 [Coxson, Pamela G.; Bibbins-Domingo, Kirsten] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Cook, Nancy R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02115 USA. [Joffres, Michel] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada. [Hong, Yuling; Orenstein, Diane; Schmidt, Steven M.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. RP Coxson, PG (reprint author), UCSF SFGH, San Francisco, CA 94143 USA. EM pam.coxson@ucsf.edu FU Centers for Disease Control and Prevention; American Heart Association, Western States Affiliates [09GRNT2060096]; National Heart, Lung, and Blood Institute (NHLBI) FX Funding for this project was provided by the Centers for Disease Control and Prevention and in part by the American Heart Association, Western States Affiliates, Grant-in-Aid 09GRNT2060096.; Additional Centers for Disease Control and Prevention Workshop participants: Vicki Burt, ScM, RN; L. Randy Curtin, PhD; Majid Ezzati, MEng, PhD; J. Marianne Geleijnse, MSc, PhD; Jack Homer, PhD; Malcolm Law, MSc, MBBS; Darwin Labarthe, MD, MPH, PhD; and Catherine Loria, PhD, MS, MA. The FHS and Framingham Offspring Study (FOS) are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the FHS and FOS Investigators. This article was prepared using a limited-access data set obtained by the NHLBI and does not necessarily reflect the opinions or views of the FHS, the FOS, or the NHLBI. NR 34 TC 32 Z9 34 U1 1 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD MAR PY 2013 VL 61 IS 3 BP 564 EP 570 DI 10.1161/HYPERTENSIONAHA.111.201293 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 089DC UT WOS:000314888600005 PM 23399718 ER PT J AU Thompson, ND Edwards, JR Bamberg, W Beldavs, ZG Dumyati, G Godine, D Maloney, M Kainer, M Ray, S Thompson, D Wilson, L Magill, SS AF Thompson, Nicola D. Edwards, Jonathan R. Bamberg, Wendy Beldavs, Zintars G. Dumyati, Ghinwa Godine, Deborah Maloney, Meghan Kainer, Marion Ray, Susan Thompson, Deborah Wilson, Lucy Magill, Shelley S. TI Evaluating the Accuracy of Sampling to Estimate Central Line-Days: Simplification of the National Healthcare Safety Network Surveillance Methods SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID STREAM INFECTION-RATES; PATIENT SAFETY; RECORDS AB OBJECTIVE. To evaluate the accuracy of weekly sampling of central line-associated bloodstream infection (CLABSI) denominator to estimate central line-days (CLDs). DESIGN. Obtained CLABSI denominator logs showing daily counts of patient-days and CLD for 6-12 consecutive months from and CLABSI numerators and facility and location characteristics from the National Healthcare Safety Network (NHSN). SETTING AND PARTICIPANTS. Convenience sample of 119 inpatient locations in 63 acute care facilities within 9 states participating the Emerging Infections Program. METHODS. Actual CLD and estimated CLD obtained from sampling denominator data on all single-day and 2-day (day-pair) were compared by assessing the distributions of the CLD percentage error. Facility and location characteristics associated with precision of estimated CLD were assessed. The impact of using estimated CLD to calculate CLABSI rates was evaluated by measuring change in CLABSI decile ranking. RESULTS. The distribution of CLD percentage error varied by the day and number of days sampled. On average, day-pair provided more accurate estimates than did single-day samples. For several day-pair samples, approximately 90% of locations had percentage error of less than or equal to +/- 5%. A lower number of CLD per month was most significantly associated with poor in estimated CLD. Most locations experienced no change in CLABSI decile ranking, and no location's CLABSI ranking changed by than 2 deciles. CONCLUSIONS. Sampling to obtain estimated CLD is a valid alternative to daily data collection for a large proportion of Development of a sampling guideline for NHSN users is underway. Infect Control Hosp Epidemiol 2013;34(3):221-228 C1 [Thompson, Nicola D.; Edwards, Jonathan R.; Magill, Shelley S.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Bamberg, Wendy] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Beldavs, Zintars G.] Oregon Hlth Author, Portland, OR USA. [Dumyati, Ghinwa] Univ Rochester, Rochester, NY USA. [Godine, Deborah] Calif Emerging Infect Program, Oakland, CA USA. [Maloney, Meghan] Connecticut Dept Publ Hlth, Hartford, CT USA. [Kainer, Marion] Tennessee Dept Hlth, Nashville, TN USA. [Ray, Susan] Georgia Emerging Infect Program, Atlanta, GA USA. [Thompson, Deborah] New Mexico Dept Hlth, Santa Fe, NM USA. [Wilson, Lucy] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. RP Thompson, ND (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-24, Atlanta, GA 30333 USA. EM ndthompson@cdc.gov FU Centers for Disease Control and Prevention Emerging Infections Program FX This evaluation was funded by the Centers for Disease Control and Prevention Emerging Infections Program Cooperative Agreement. NR 15 TC 9 Z9 9 U1 0 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAR PY 2013 VL 34 IS 3 BP 221 EP 228 DI 10.1086/669515 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 088CG UT WOS:000314810800001 PM 23388355 ER PT J AU Coleman, LA Waring, SC Irving, SA Vandermause, M Shay, DK Belongia, EA AF Coleman, Laura A. Waring, Stephen C. Irving, Stephanie A. Vandermause, Mary Shay, David K. Belongia, Edward A. TI Evaluation of obesity as an independent risk factor for medically attended laboratory-confirmed influenza SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Body mass index; influenza; obesity ID PANDEMIC H1N1 INFLUENZA; PERIPHERAL-BLOOD; A H1N1; VIRUS; VACCINE; MICE; HOSPITALIZATION; INFECTIONS; MORTALITY; OUTCOMES AB Please cite this paper as: Coleman etal. (2013) Evaluation of obesity as an independent risk factor for medically attended laboratory-confirmed influenza. Influenza and Other Respiratory Viruses 7(2) 160167. Background The relationship between obesity and susceptibility to influenza infection in humans is unclear. Morbidly obese people were at an increased risk of complications from 2009 pandemic H1N1 influenza [A(H1N1)pdm09]. Objective The goal of this study was to determine whether medically attended, laboratory-confirmed influenza is independently associated with obesity in adults with acute respiratory illness. Patients/Methods Adults 20years with a medical encounter for acute respiratory illness were recruited from a population cohort during the 20072008 (n=903), 20082009 (n=869), and 2009 pandemic (n=851) season. Nasopharyngeal swabs were tested for influenza by real-time reverse-transcription polymerase chain reaction. Body mass index (BMI) was calculated using data from the electronic medical record. Logistic regression evaluated the association between influenza and obesity, adjusting for gender, vaccination, age, and high-risk medical condition. Results Influenza was detected in 50% of patients in 20072008, 15% in 20082009, and 14% during the 2009 pandemic. Predominant seasonal viruses in this population were A/H3N2 in 20072008, and A/H1N1 and B in 20082009. Mean (+/- SD) BMI was 30 center dot 58 (+/- 7 center dot 31) in patients with influenza and 30 center dot 93 (+/- 7 center dot 55) in test-negative controls during all seasons. Mean BMI of patients with influenza did not vary by season. After adjusting for confounders, neither obesity nor extreme obesity were associated with influenza by season or for all years combined (OR 0 center dot 95: 95% CI 0 center dot 75, 1 center dot 20 and 1 center dot 10: 0 center dot 80, 1 center dot 52, respectively, for obesity and extreme obesity, all years). Conclusions Obesity was not associated with medically attended influenza among adults with acute respiratory illness in this population. C1 [Coleman, Laura A.; Waring, Stephen C.; Irving, Stephanie A.; Vandermause, Mary; Belongia, Edward A.] Marshfield Clin Res Fdn, Epidemiol Res Ctr, Marshfield, WI 54449 USA. [Waring, Stephen C.] Essentia Inst Rural Hlth, Duluth, MN USA. [Shay, David K.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Coleman, LA (reprint author), Marshfield Clin Res Fdn, Epidemiol Res Ctr, ML2, 1000 N Oak Ave, Marshfield, WI 54449 USA. EM lacoleman@charter.net OI Irving, Stephanie/0000-0001-7437-6797; Shay, David/0000-0001-9619-4820 FU CDC [1 UO1 C1000192-01] FX We thank the research coordinators, interviewers, programmer/analysts, Core Laboratory staff, and administrative support staff at the Marshfield Clinic Research Foundation for their contribution to this project. This work was funded by CDC grant 1 UO1 C1000192-01. NR 33 TC 8 Z9 8 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAR PY 2013 VL 7 IS 2 BP 160 EP 167 DI 10.1111/j.1750-2659.2012.00377.x PG 8 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 089PC UT WOS:000314921500007 PM 22583620 ER PT J AU Laurie, KL Huston, P Riley, S Katz, JM Willison, DJ Tam, JS Mounts, AW Hoschler, K Miller, E Vandemaele, K Broberg, E Van Kerkhove, MD Nicoll, A AF Laurie, Karen L. Huston, Patricia Riley, Steven Katz, Jacqueline M. Willison, Donald J. Tam, John S. Mounts, Anthony W. Hoschler, Katja Miller, Elizabeth Vandemaele, Kaat Broberg, Eeva Van Kerkhove, Maria D. Nicoll, Angus TI Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Antibodies; influenza; pandemic; public health response; serological studies ID A H1N1 VIRUS; NEW-YORK-CITY; RISK-FACTORS; ASYMPTOMATIC INFECTIONS; HOUSEHOLD TRANSMISSION; ANTIBODY-RESPONSE; UNITED-KINGDOM; HOSPITAL STAFF; PREGNANT-WOMEN; 1ST WAVE AB Please cite this paper as: Laurie etal. (2013) Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting. Influenza and Other Respiratory Viruses 7(2) 211224. Background Serological studies can detect infection with a novel influenza virus in the absence of symptoms or positive virology, providing useful information on infection that goes beyond the estimates from epidemiological, clinical and virological data. During the 2009 A(H1N1) pandemic, an impressive number of detailed serological studies were performed, yet the majority of serological data were available only after the first wave of infection. This limited the ability to estimate the transmissibility and severity of this novel infection, and the variability in methodology and reporting limited the ability to compare and combine the serological data. Objectives To identify best practices for conduct and standardisation of serological studies on outbreak and pandemic influenza to inform public policy. Methods/Setting An international meeting was held in February 2011 in Ottawa, Canada, to foster the consensus for greater standardisation of influenza serological studies. Results Best practices for serological investigations of influenza epidemiology include the following: classification of studies as pre-pandemic, outbreak, pandemic or inter-pandemic with a clearly identified objective; use of international serum standards for laboratory assays; cohort and cross-sectional study designs with common standards for data collection; use of serum banks to improve sampling capacity; and potential for linkage of serological, clinical and epidemiological data. Advance planning for outbreak studies would enable a rapid and coordinated response; inclusion of serological studies in pandemic plans should be considered. Conclusions Optimising the quality, comparability and combinability of influenza serological studies will provide important data upon emergence of a novel or variant influenza virus to inform public health action. C1 [Laurie, Karen L.] WHO Collaborating Ctr Reference & Res Influenza, VIDRL, Melbourne, Vic 3051, Australia. [Huston, Patricia] Publ Hlth Agcy Canada, Ctr Immunizat & Resp Infect Dis, Pandem Preparedness Div, Ottawa, ON, Canada. [Riley, Steven; Van Kerkhove, Maria D.] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, MRC Ctr Outbreak Anal & Modelling, Dept Infect Dis Epidemiol, London SW7 2AZ, England. [Katz, Jacqueline M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Willison, Donald J.] Publ Hlth Ontario, Surveillance & Epidemiol, Toronto, ON, Canada. [Tam, John S.] WHO, Initiat Vaccine Res, CH-1211 Geneva, Switzerland. [Mounts, Anthony W.; Vandemaele, Kaat] WHO, Global Influenza Programme, CH-1211 Geneva, Switzerland. [Hoschler, Katja] Hlth Protect Agcy, Virus Reference Dept, Resp Virus Unit, Microbiol Serv Div Colindale, London, England. [Miller, Elizabeth] Hlth Protect Agcy, Hlth Protect Serv Colindale, Immunisat Dept, London, England. [Broberg, Eeva; Nicoll, Angus] European Ctr Dis Prevent & Control ECDC, Stockholm, Sweden. RP Laurie, KL (reprint author), WHO Collaborating Ctr Reference & Res Influenza, VIDRL, 10 Wreckyn St, Melbourne, Vic 3051, Australia. EM karen.laurie@influenzacentre.org OI Laurie, Karen/0000-0001-5186-8342 FU Wellcome Trust; National Institute of Health Research (NIHR), UK; UK Medical Research Centre; Bill and Melinda Gates Foundation; Novartis; Sanofi Pasteur; Baxter; CSL Limited; Juvaris Inc; Nobilon-Merck Sharp and Dohme; GlaxoSmithKline; Public Health Agency of Canada; Australian Government Department of Health and Ageing FX All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf (available on request from KLL) and declare that (i) SR has support from Wellcome Trust; KH has support from National Institute of Health Research (NIHR), UK; MDVK has support from the UK Medical Research Centre and the Bill and Melinda Gates Foundation, for the submitted work; (ii) KH, on behalf of HPA, was involved in projects outside the scope of this article, which were supported by funding from Novartis, Sanofi Pasteur, Baxter and CSL Limited in the previous 3 years; JMK received support for work not submitted in this manuscript from Juvaris Inc, Nobilon-Merck Sharp and Dohme, and GlaxoSmithKline in the previous 3 years; KLL, PH, SR, DJW, JST, AWM, EM, KV, EB, MDVK and AN have no relationships that might have an interest in the submitted work in the previous 3 years; (iii) KLL, PH, SR, JMK, DJW, JST, AWM, KH, EM, KV, EB, MDVK and AN their spouses, partners, or children have no financial relationships that may be relevant to the submitted work, and (iv) KLL, PH, SR, JMK, DJW, JST, AWM, KH, EM, KV, EB, MDVK and AN have no non-financial interests that may be relevant to the submitted work.; The International Influenza Seroprevalence Meeting held on 9-10 February, 2011 in Ottawa, Canada, was funded and hosted by the Public Health Agency of Canada. Financial support did not impact the study design, collection, analysis or interpretation of the data, writing the report, nor the decision to submit the article for publication. The findings in this manuscript are independent of funding agreements. The manuscript underwent internal clearance as is customary for a number of the agencies involved. The opinions expressed in this article are those of the members of the Expert Committee and do not necessarily reflect those of the institutions or organisations with which they are affiliated.; (c) 2012 Blackwell Publishing Ltd. The World Health Organization retains copyright and all other rights in the manuscript of this article as submitted for publication. The authors thank all the conference participants of the International Influenza Seroprevalence Meeting as well as the conference manager, Terri Champagne and the conference coordinator, Corinne Paollilo-Lessard. The authors are grateful to Professor Anne Kelso, Dr Barbara Raymond, Dr Alicia Fry and Professor Noel Gill for critical reading of previous versions of the manuscript. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health and Ageing. NR 91 TC 14 Z9 14 U1 0 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAR PY 2013 VL 7 IS 2 BP 211 EP 224 DI 10.1111/j.1750-2659.2012.0370a.x PG 14 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 089PC UT WOS:000314921500013 PM 22548725 ER PT J AU Rebeiro, P Althoff, KN Buchacz, K Gill, J Horberg, M Krentz, H Moore, R Sterling, TR Brooks, JT Gebo, KA Hogg, R Klein, M Martin, J Mugavero, M Rourke, S Silverberg, MJ Thorne, J Gange, SJ AF Rebeiro, Peter Althoff, Keri N. Buchacz, Kate Gill, John Horberg, Michael Krentz, Hartmut Moore, Richard Sterling, Timothy R. Brooks, John T. Gebo, Kelly A. Hogg, Robert Klein, Marina Martin, Jeffrey Mugavero, Michael Rourke, Sean Silverberg, Michael J. Thorne, Jennifer Gange, Stephen J. CA N Amer AIDS Cohort Collaboration R TI Retention Among North American HIV-Infected Persons in Clinical Care, 2000-2008 SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT 19th International AIDS Conference CY JUL 22-27, 2012 CL Washington, DC SP Int AIDS Soc DE retention; churn; HIV clinical care; North America; HRSA HAB; National HIV/AIDS Strategy ID MISSED VISITS; CELL COUNTS; ENGAGEMENT; ISSUES; COHORT; RNA AB Background: Retention in care is key to improving HIV outcomes. The goal of this study was to describe "churn" in patterns of entry, exit, and retention in HIV care in the United States and Canada. Methods: Adults contributing >= 1 CD4 count or HIV-1 RNA (HIV-lab) from 2000 to 2008 in North American AIDS Cohort Collaboration on Research and Design clinical cohorts were included. Incomplete retention was defined as lack of 2 HIV-laboratories (>= 90 days apart) within 12 months, summarized by calendar year. Beta-binomial regression models were used to estimate adjusted odds ratios (OR) and 95% confidence intervals (CI) of factors associated with incomplete retention. Results: Among 61,438 participants, 15,360 (25%) with incomplete retention significantly differed in univariate analyses (P < 0.001) from 46,078 (75%) consistently retained by age, race/ethnicity, HIV risk, CD4, antiretroviral therapy use, and country of care (United States vs. Canada). From 2000 to 2004, females (OR = 0.82, CI: 0.70 to 0.95), older individuals (OR = 0.78, CI: 0.74 to 0.83 per 10 years), and antiretroviral therapy users (OR = 0.61, CI: 0.54 to 0.68 vs. all others) were less likely to have incomplete retention, whereas black individuals (OR = 1.31, CI: 1.16 to 1.49, vs. white), those with injection drug use HIV risk (OR = 1.68, CI: 1.49 to 1.89, vs. non-injection drug use), and those in care longer (OR = 1.09, CI: 1.07 to 1.11 per year) were more likely to have incomplete retention. Results from 2005 to 2008 were similar. Discussion: From 2000 to 2008, 75% of the North American AIDS Cohort Collaboration on Research and Design population was consistently retained in care with 25% experiencing some changes in status or churn. In addition to the programmatic and policy implications, the findings of this study identify patient groups who may benefit from focused retention efforts. C1 [Rebeiro, Peter; Althoff, Keri N.; Gange, Stephen J.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. [Buchacz, Kate; Brooks, John T.] Ctr Dis Control & Prevent, Epidemiol Branch, Atlanta, GA USA. [Gill, John] Univ Calgary, Dept Med, Calgary, AB, Canada. [Horberg, Michael] Kaiser Permanente Midatlantic, Midatlantic Permanente Res Inst, Div Res, Rockville, MD USA. [Krentz, Hartmut] Univ Calgary, Dept Anthropol, Calgary, AB, Canada. [Moore, Richard; Gebo, Kelly A.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Sterling, Timothy R.] Vanderbilt Univ, Dept Med, Nashville, TN USA. [Hogg, Robert] British Columbia Ctr Excellence & HIV AIDS, Dept Hlth Sci, Vancouver, BC, Canada. [Hogg, Robert] Simon Fraser Univ, Vancouver, BC, Canada. [Klein, Marina] McGill Univ, Dept Med, Montreal, PQ, Canada. [Martin, Jeffrey] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Mugavero, Michael] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Rourke, Sean] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Silverberg, Michael J.] Kaiser Permanent No Calif, Div Res, Oakland, CA USA. [Thorne, Jennifer] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA. RP Rebeiro, P (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, 615 N Wolfe St,Room E-7133, Baltimore, MD 21205 USA. EM prebeiro@jhsph.edu RI Gill, John/G-7083-2016; OI Gill, John/0000-0002-8546-8790; Gange, Stephen/0000-0001-7842-512X; Rebeiro, Peter/0000-0003-1951-9104; Hogg, Robert/0000-0003-3463-5488 FU NCI NIH HHS [N02CP55504, Z01 CP010176]; NCRR NIH HHS [M01 RR000071, M01 RR000079, M01 RR000083, M01 RR000722, M01-RR00071, M01-RR00079, M01-RR00083]; NIAAA NIH HHS [R01 AA016893, R01-AA16893, U01 AA020790, U10 AA013566, U10-AA013566]; NIAID NIH HHS [U01 AI069434, AI-69432, K01 AI071725, K01 AI071754, K01-AI071725, K01-AI071754, K23-AI610320, P30 AI027757, P30 AI027763, P30 AI027767, P30 AI036219, P30 AI050410, P30 AI054999, P30 AI094189, P30-AI27757, P30-AI27767, P30-AI50410, P30-AI54999, R01-AI069434, R24 AI067039, R24-AI067039, U01 AI031834, U01 AI034989, U01 AI034993, U01 AI034994, U01 AI035004, U01 AI035039, U01 AI035040, U01 AI035041, U01 AI035042, U01 AI035043, U01 AI037613, U01 AI037984, U01 AI038855, U01 AI038858, U01 AI042590, U01 AI068634, U01 AI068636, U01 AI069432, U01 AI069918, U01-AI069918, U01-AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043, U01-AI37613, U01-AI37984, U01-AI38855, U01-AI38858, U01-AI42590, U01-AI68634, U01-AI68636, UM1 AI069432]; NICHD NIH HHS [U01 HD032632, U01-HD32632]; NIDA NIH HHS [K24 DA000432, K24-DA00432, R01 DA004334, R01 DA011602, R01 DA012568, R01-DA04334, R01-DA11602, R01-DA12568]; NIMH NIH HHS [R01 MH054907, R01-MH54907]; PHS HHS [290-01-0012] NR 23 TC 48 Z9 48 U1 1 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAR 1 PY 2013 VL 62 IS 3 BP 356 EP 362 DI 10.1097/QAI.0b013e31827f578a PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 088WT UT WOS:000314869300026 PM 23242158 ER PT J AU Gupta, S Granich, R Suthar, AB Smyth, C Baggaley, R Sculier, D Date, A Desai, MA Lule, F Raizes, E Blanc, L Hirnschall, G AF Gupta, Somya Granich, Reuben Suthar, Amitabh B. Smyth, Caoimhe Baggaley, Rachel Sculier, Delphine Date, Anand Desai, Mitesh A. Lule, Frank Raizes, Elliot Blanc, Leopold Hirnschall, Gottfried TI Global Policy Review of Antiretroviral Therapy Eligibility Criteria for Treatment and Prevention of HIV and Tuberculosis in Adults, Pregnant Women, and Serodiscordant Couples SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT 19th International AIDS Conference CY JUL 22-27, 2012 CL Washington, DC SP Int AIDS Soc DE antiretroviral therapy; CD4; heterosexual transmission; opportunistic infections; prevention of sexual transmission; tuberculosis ID VIRAL LOAD; AIDS; TRANSMISSION; INFECTION; RISK AB Objective: This article reviews the antiretroviral therapy (ART) initiation criteria from national treatment guidelines for 70 countries and determines the extent of consistency with the current World Health Organization (WHO) recommendations. Methods: Published ART guidelines were collected from the Internet, databases, and WHO staff. ART eligibility criteria for asymptomatic people, pregnant women, people with HIV-associated tuberculosis, serodiscordant couples, injecting drug users, men who have sex with men, and sex workers were abstracted from them. Multiple regression analysis was used to determine the relation between ART eligibility criteria, ART coverage, and various population characteristics and policy interventions. Results: Of the 70 countries, 42 (60%) follow WHO's ART guidelines for asymptomatic people and 31 (44%) for pregnant women, recommending ART at CD4 count of <= 350 cells/mm(3). Twenty-three (33%) countries recommend ART for people with HIV-associated tuberculosis irrespective of CD4 count. Nineteen countries are also recommending or considering earlier ART above CD4 count <= 350 cell/mm(3) for asymptomatic people, pregnant women, and/or serodiscordant couples. Multiple linear regression analysis shows that HIV prevalence, year of publication of guidelines, and HIV expenditure are significantly associated with published ART eligibility criteria. On average, the ART coverage is similar irrespective of published guidelines being consistent with the WHO recommendation (P < 0.53). Conclusions: Published guidelines from a significant number of countries are not following WHO recommendations. Although published guidelines may not reflect practice, it is important to adapt recommendations and services quickly to reflect the emerging science on the health and prevention benefits of earlier access to ART. C1 [Gupta, Somya; Granich, Reuben; Suthar, Amitabh B.; Smyth, Caoimhe; Baggaley, Rachel; Hirnschall, Gottfried] World Hlth Org, Dept HIV AIDS, CH-1211 Geneva, Switzerland. [Sculier, Delphine; Blanc, Leopold] World Hlth Org, Stop TB Dept, CH-1211 Geneva, Switzerland. [Date, Anand; Desai, Mitesh A.; Raizes, Elliot] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. [Lule, Frank] World Hlth Org, HIV Treatment & Care, Brazzaville, Congo. RP Gupta, S (reprint author), World Hlth Org, Antiretroviral Treatment & HIV Care, Dept HIV AIDS, Bldg D,1st Floor,Room 1005,Ave Appia 20, CH-1211 Geneva, Switzerland. EM somyagupta17@gmail.com NR 27 TC 19 Z9 19 U1 0 U2 34 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAR 1 PY 2013 VL 62 IS 3 BP E87 EP E97 DI 10.1097/QAI.0b013e31827e4992 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 088WT UT WOS:000314869300004 PM 23187942 ER PT J AU Knust, B Patton, E Ribeiro-Lima, J Bohn, JJ Wells, SJ AF Knust, Barbara Patton, Elisabeth Ribeiro-Lima, Joao Bohn, Jeff J. Wells, Scott J. TI Evaluation of the effects of a killed whole-cell vaccine against Mycobacterium avium subsp paratuberculogis in 3 herds of dairy cattle with natural exposure to the organism SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Article ID POLYMERASE-CHAIN-REACTION; JOHNES-DISEASE; PREVALENCE; MINNESOTA; PROGRAM; RISK; USA AB Objective-To evaluate effects of vaccination with a killed whole-cell vaccine against Mycobacterium avium subsp paratuberculosis (MAP) on fecal shedding of the organism, development of clinical paratuberculosis (Johne's disease [JD]), milk production, measures of reproduction, and within-herd longevity of dairy cattle naturally exposed to MAR Design-Controlled clinical trial. Animals-200 vaccinated and 195 unvaccinated (control) dairy cows from 3 herds in Wisconsin. Procedures Every other heifer calf born in each herd received the MAP vaccine; 162 vaccinates and 145 controls that had >= 1 lactation were included in analyses. Bacteriologic culture of fecal samples for MAP was performed annually for 7 years; results were confirmed via histologic methods and PCR assay. Production records and culture results were evaluated to determine effects of vaccination on variables of interest in study cows. Annual whole-herd prevalence of MAP shedding in feces was also determined. Results-Vaccinates had a significantly lower hazard of testing positive for MAP via culture of fecal samples than did controls over time (hazard ratio, 0.57; 95% confidence interval, 0.34 to 0.97). Fewer vaccinates developed clinical JD than did controls (n = 6 and 12, respectively), but these differences were nonsignificant. Overall within-herd longevity, total milk production, and calving-to-conception intervals were similar between vaccinates and controls. In all herds, prevalence of MAP shedding in feces decreased over time. Conclusions and Clinical Relevance-Vaccination with a killed whole-cell MAP vaccine appeared to be an effective tool as part of a program to control the spread of JD in dairy cattle. (J Am Vet Med Assoc 2013;242:663-669) C1 [Patton, Elisabeth] Wisconsin Dept Agr Trade & Consumer Protect, Madison, WI 53708 USA. [Bohn, Jeff J.] NW Wisconsin Vet Serv, Amery, WI 54001 USA. [Knust, Barbara; Ribeiro-Lima, Joao; Wells, Scott J.] Univ Minnesota, Coll Vet Med, Ctr Anim Hlth & Food Safety, St Paul, MN 55108 USA. RP Knust, B (reprint author), Natl Ctr Emerging & Zoonot Infect Dis, CDC, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM bknust@cdc.gov FU USDA APHIS FX Supported, in part, by a Cooperative Agreement from USDA APHIS. NR 27 TC 13 Z9 13 U1 0 U2 14 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 EI 1943-569X J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD MAR 1 PY 2013 VL 242 IS 5 BP 663 EP 669 PG 7 WC Veterinary Sciences SC Veterinary Sciences GA 090WY UT WOS:000315011900015 PM 23402414 ER PT J AU Tuttle, L Meng, QY Moya, J Johns, DO AF Tuttle, Lauren Meng, Qingyu Moya, Jacqueline Johns, Douglas O. TI Consideration of Age-Related Changes in Behavior Trends in Older Adults in Assessing Risks of Environmental Exposures SO JOURNAL OF AGING AND HEALTH LA English DT Article DE activity patterns; behavior; exposure factors; older adults; risk assessment ID HUMAN HEALTH-RISK; BODY-MASS INDEX; FUNCTIONAL-CAPACITY; FACTORS-HANDBOOK; MOBILITY; DISABILITY; CONTAMINATION; CONSUMPTION; LIMITATIONS; NHANES AB Objectives: To explore age-related behavior differences between older and younger adults, and to review how older adult activity patterns are considered in evaluating the potential risk of exposure to environmental pollutants. Methods: Activity pattern data and their use in risk assessments were analyzed using the U. S. EPA Exposure Factors Handbook (EFH), U. S. EPA Consolidated Human Activity Pattern Database (CHAD), and peer-reviewed literature describing human health risk assessments. Results: The characterization by age of some factors likely to impact older adults' exposures remains limited. We demonstrate that age-related behavior trends vary between younger and older adults, and these differences are rarely explicitly considered in environmental health risk assessment for older adults. Discussion: Incorporating older adult exposure factors into risk assessments may be challenging because of data gaps and difficulty in defining and appropriately binning older adults. Additional data related to older adult exposure factors are warranted for evaluating risk among this susceptible population. C1 [Tuttle, Lauren] US EPA, Oak Ridge Inst Sci & Educ, Natl Ctr Environm Assessment, Off Res & Dev, Res Triangle Pk, NC 27711 USA. [Meng, Qingyu] Univ Med & Dent New Jersey, Sch Publ Hlth, Piscataway, NJ 08854 USA. [Moya, Jacqueline] US EPA, Natl Ctr Environm Assessment, Off Res & Dev, Washington, DC 20460 USA. [Johns, Douglas O.] US EPA, Natl Ctr Environm Assessment, Off Res & Dev, Res Triangle Pk, NC 27711 USA. RP Johns, DO (reprint author), NIOSH, Ctr Dis Control & Prevent, Div Resp Dis Studies, 1095 Willowdale Rd,Mailstop H2900, Morgantown, WV 26505 USA. EM mengqi@umdnj.edu; djohns@cdc.gov NR 49 TC 1 Z9 1 U1 2 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0898-2643 J9 J AGING HEALTH JI J. Aging Health PD MAR PY 2013 VL 25 IS 2 BP 243 EP 273 DI 10.1177/0898264312468032 PG 31 WC Gerontology; Health Policy & Services SC Geriatrics & Gerontology; Health Care Sciences & Services GA 087NV UT WOS:000314769500003 PM 23223208 ER PT J AU Sabatino, SA Thompson, TD Smith, JL Rowland, JH Forsythe, LP Pollack, L Hawkins, NA AF Sabatino, Susan A. Thompson, Trevor D. Smith, Judith Lee Rowland, Julia H. Forsythe, Laura P. Pollack, Loria Hawkins, Nikki A. TI Receipt of cancer treatment summaries and follow-up instructions among adult cancer survivors: results from a national survey SO JOURNAL OF CANCER SURVIVORSHIP-RESEARCH AND PRACTICE LA English DT Article DE Cancer survivors; Treatment summaries; Cancer follow-up care; Survivorship care plans ID PRIMARY-CARE PHYSICIANS; BREAST-CANCER; CHILDHOOD-CANCER; PERSPECTIVES; PREVALENCE; KNOWLEDGE; QUALITY AB The purpose of this study is to examine reporting of treatment summaries and follow-up instructions among cancer survivors. Using the 2010 National Health Interview Survey, we created logistic regression models among cancer survivors not in treatment (n = 1,345) to determine characteristics associated with reporting treatment summaries and written follow-up instructions, adjusting for sociodemographic, access, and cancer-related factors. Findings are presented for all survivors and those recently diagnosed (a parts per thousand currency sign4 years). We also examined unadjusted associations between written instructions and subsequent surveillance and screening. Among those recently diagnosed, 38 % reported receiving treatment summaries and 58 % reported written instructions. Among all survivors, approximately one third reported summaries and 44 % reported written instructions. After adjustment, lower reporting of summaries was associated with cancer site, race, and number of treatment modalities among those recently diagnosed, and white vs. black or Hispanic race/ethnicity, breast vs. colorectal cancer, > 10 vs. a parts per thousand currency sign5 years since diagnosis, no clinical trials participation, and better than fair health among all survivors. For instructions, lower reporting was associated with no trials participation and lower income among those recently diagnosed, and increasing age, white vs. black race, lower income, > 10 vs. a parts per thousand currency sign5 years since diagnosis, 1 vs. a parts per thousand yen2 treatment modalities, no trials participation, and at least good vs. fair/poor health among all survivors. Written instructions were associated with reporting provider recommendations for breast and cervical cancer surveillance, and recent screening mammograms. Many recently diagnosed cancer survivors did not report receiving treatment summaries and written follow-up instructions. Opportunities exist to examine associations between use of these documents and recommended care and outcomes, and to facilitate their adoption. Cancer survivors who have completed therapy should ask their providers for treatment summaries and written follow-up instructions, and discuss with them how their cancer and therapy impact their future health care. C1 [Sabatino, Susan A.; Thompson, Trevor D.; Smith, Judith Lee; Hawkins, Nikki A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Rowland, Julia H.; Forsythe, Laura P.] NCI, Off Canc Survivorship, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Forsythe, Laura P.] NCI, Canc Prevent Fellowship Program, Ctr Canc Training, Bethesda, MD 20892 USA. [Pollack, Loria] Ctr Dis Control & Prevent, Div Appl Sci, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30341 USA. RP Sabatino, SA (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, MS K55,4770 Buford Highway, Atlanta, GA 30341 USA. EM SSabatino@cdc.gov NR 35 TC 22 Z9 22 U1 1 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1932-2259 J9 J CANCER SURVIV JI J. Cancer Surviv.-Res. Pract. PD MAR PY 2013 VL 7 IS 1 BP 32 EP 43 DI 10.1007/s11764-012-0242-x PG 12 WC Oncology; Social Sciences, Biomedical SC Oncology; Biomedical Social Sciences GA 087GL UT WOS:000314749200003 PM 23179495 ER PT J AU White, A Pollack, LA Smith, JL Thompson, T Underwood, JM Fairley, T AF White, Arica Pollack, Lori A. Smith, Judith Lee Thompson, Trevor Underwood, J. Michael Fairley, Temeika TI Racial and ethnic differences in health status and health behavior among breast cancer survivors-Behavioral Risk Factor Surveillance System, 2009 SO JOURNAL OF CANCER SURVIVORSHIP-RESEARCH AND PRACTICE LA English DT Article DE Breast cancer; Health behaviors; Health status; Disparity; Race/ethnicity ID QUALITY-OF-LIFE; PHYSICAL-ACTIVITY LEVELS; RETEST RELIABILITY; NONCANCER CONTROLS; DIAGNOSIS; WOMEN; RECURRENCE; QUESTIONS; VALIDITY; BRFSS AB Differences in health status and behavioral risk factors may explain racial/ethnic breast cancer disparities. We examined racial/ethnic differences in health status and behaviors among female breast cancer survivors compared to females without breast cancer. Using cross-sectional data from the 2009 Behavioral Risk Factor Surveillance System, a national state-based, random sample telephone survey, we explored differences in self-rated health, obesity and selected behaviors (physical activity, smoking, alcohol use, fruit, and vegetable consumption) among females aged 18 years and older, who reported a previous breast cancer diagnosis (survivors, n = 10,035) and those who reported no breast cancer history (n = 234,375) by race/ethnicity. Adjusted prevalences of health status and behaviors, accounting for sociodemographics, comorbidities and health care access, were estimated by race/ethnicity. Compared to all other racial/ethnic groups, more white females reported heavy alcohol consumption and more black females reported obesity regardless of their breast cancer status. Among breast cancer survivors, more whites (33.7 %) were former smokers compared to blacks (24.5 %), "others" (20.5 %), and Hispanics (16.2 %) (p = 0.001). Racial/ethnic differences in obesity also varied by reported time since diagnosis (p value = 0.018). Among long-term survivors (diagnosed > 5 years before interview), more black survivors (34.8 %) reported obesity compared to white survivors (23.0 %). Also, among "other" race survivors, long-term survivors (22.0 %) reported more obesity than survivors diagnosed less than 5 years before interview (7.8 %). These findings suggest opportunities to increase health behaviors and reduce racial disparities among breast cancer survivors. Engaging in healthy behaviors can play a significant role in enhancing health outcomes and quality of life of breast cancer survivors. More research is needed to better understand racial differences in obesity, smoking and alcohol consumption in order to develop effective, culturally appropriate interventions to promote a healthy lifestyle after a breast cancer diagnosis. C1 [White, Arica; Pollack, Lori A.; Smith, Judith Lee] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA 30341 USA. [Thompson, Trevor] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Canc Surveillance Branch, Atlanta, GA 30341 USA. [Underwood, J. Michael] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Comprehens Canc Control Branch, Atlanta, GA 30341 USA. [Fairley, Temeika] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Off Director, Atlanta, GA 30341 USA. RP White, A (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, 4770 Buford Hwy NE,Mailstop K-55, Atlanta, GA 30341 USA. EM awhite5@cdc.gov FU Intramural CDC HHS [CC999999] NR 41 TC 15 Z9 15 U1 1 U2 16 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1932-2259 J9 J CANCER SURVIV JI J. Cancer Surviv.-Res. Pract. PD MAR PY 2013 VL 7 IS 1 BP 93 EP 103 DI 10.1007/s11764-012-0248-4 PG 11 WC Oncology; Social Sciences, Biomedical SC Oncology; Biomedical Social Sciences GA 087GL UT WOS:000314749200009 PM 23212604 ER PT J AU Zhao, GX Li, CY Li, J Balluz, LS AF Zhao, Guixiang Li, Chaoyang Li, Jun Balluz, Lina S. TI Physical activity, psychological distress, and receipt of mental healthcare services among cancer survivors SO JOURNAL OF CANCER SURVIVORSHIP-RESEARCH AND PRACTICE LA English DT Article DE Cancer survivor; Physical activity; Serious psychological distress; Mental healthcare services; BRFSS ID QUALITY-OF-LIFE; FACTOR SURVEILLANCE SYSTEM; LONG-TERM SURVIVORS; RANDOMIZED CONTROLLED-TRIAL; POPULATION-BASED SAMPLE; DWELLING OLDER-ADULTS; COLORECTAL-CANCER; EXERCISE INTERVENTION; LEISURE-TIME; DEPRESSION AB Physical activity confers multiple health benefits in the general population. This study examined the associations of physical activity with serious psychological distress (SPD) and receipt of mental healthcare services among U.S. adult cancer survivors. We analyzed data from 4,797 cancer survivors (aged a parts per thousand yen18 years) and 38,571 adults without cancer who participated in the 2009 Behavioral Risk Factor Surveillance System. SPD was assessed using the Kessler-6 questionnaire. Adjusted prevalence and prevalence ratios were estimated by conducting log-linear regression analysis while controlling for potential confounders. Overall, 6.6 % of cancer survivors (vs. 3.7 % of adults without cancer, P < 0.001) reported having SPD, and 14.0 % of cancer survivors (vs. 10.0 % of adults without cancer, P < 0.001) reported receiving mental healthcare services; the percentages decreased with increasing physical activity levels. After multivariate adjustment, compared to cancer survivors who were physically inactive, cancer survivors who engaged in physical activity > 0 to < 150 min/week and a parts per thousand yen150 min/week were 62 % and 61 % (P < 0.001 for both) less likely to report SPD, respectively; cancer survivors who engaged in physical activity a parts per thousand yen150 min/week were 33 % (P < 0.05) less likely to report receiving mental healthcare services. Additionally, the inverse association between physical activity and receiving mental healthcare services persisted among women with breast or reproductive cancers and among men and women with gastrointestinal cancers. The inverse associations between physical activity and SPD or receiving mental healthcare services suggest that physical activity may play a role in improving mental health among cancer survivors. Healthcare clinicians may consider routinely monitoring and assessing the psychological well-being of cancer survivors and educate them about the potential benefits of physical activity in improving their mental health. C1 [Zhao, Guixiang; Li, Chaoyang; Balluz, Lina S.] Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance & Informat Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30329 USA. [Li, Jun] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Zhao, GX (reprint author), Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance & Informat Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30329 USA. EM fwj4@cdc.gov NR 48 TC 6 Z9 6 U1 1 U2 17 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1932-2259 J9 J CANCER SURVIV JI J. Cancer Surviv.-Res. Pract. PD MAR PY 2013 VL 7 IS 1 BP 131 EP 139 DI 10.1007/s11764-012-0254-6 PG 9 WC Oncology; Social Sciences, Biomedical SC Oncology; Biomedical Social Sciences GA 087GL UT WOS:000314749200013 PM 23184465 ER PT J AU Chen, CY Chi, KH Pillay, A Nachamkin, E Su, JR Ballard, RC AF Chen, Cheng-Yen Chi, Kai-Hua Pillay, Allan Nachamkin, Eli Su, John R. Ballard, Ronald C. TI Detection of the A2058G and A2059G 23S rRNA Gene Point Mutations Associated with Azithromycin Resistance in Treponema pallidum by Use of a TaqMan Real-Time Multiplex PCR Assay SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID PENICILLIN-G BENZATHINE; MACROLIDE RESISTANCE; EARLY SYPHILIS; SAN-FRANCISCO; UNITED-STATES; PREVALENCE; IRELAND; STRAINS AB Macrolide treatment failure in syphilis patients is associated with a single point mutation (either A2058G or A2059G) in both copies of the 23S rRNA gene in Treponema pallidum strains. The conventional method for the detection of both point mutations uses nested PCR combined with restriction enzyme digestions, which is laborious and time-consuming. We initially developed a TaqMan-based real-time duplex PCR assay for detection of the A2058G mutation, and upon discovery of the A2059G mutation, we modified the assay into a triplex format to simultaneously detect both mutations. The point mutations detected by the real-time triplex PCR were confirmed by pyrosequencing. A total of 129 specimens PCR positive for T. pallidum that were obtained from an azithromycin resistance surveillance study conducted in the United States were analyzed. Sixty-six (51.2%) of the 129 samples with the A2058G mutation were identified by both real-time PCR assays. Of the remaining 63 samples that were identified as having a macrolide-susceptible genotype by the duplex PCR assay, 17 (27%) were found to contain the A2059G mutation by the triplex PCR. The proportions of macrolide-susceptible versus -resistant genotypes harboring either the A2058G or the A2059G mutation among the T. pallidum strains were 35.6, 51.2, and 13.2%, respectively. None of the T. pallidum strains examined had both point mutations. The TaqMan-based real-time triplex PCR assay offers an alternative to conventional nested PCR and restriction fragment length polymorphism analyses for the rapid detection of both point mutations associated with macrolide resistance in T. pallidum. C1 [Chen, Cheng-Yen; Chi, Kai-Hua; Pillay, Allan; Nachamkin, Eli; Ballard, Ronald C.] Ctr Dis Control & Prevent, Lab Reference & Res Branch, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Su, John R.] Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Chen, CY (reprint author), Ctr Dis Control & Prevent, Lab Reference & Res Branch, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM cychen@cdc.gov NR 27 TC 20 Z9 22 U1 0 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 2013 VL 51 IS 3 BP 908 EP 913 DI 10.1128/JCM.02770-12 PG 6 WC Microbiology SC Microbiology GA 092LA UT WOS:000315121700026 PM 23284026 ER PT J AU Zeng, H Goldsmith, CS Maines, TR Belser, JA Gustin, KM Pekosz, A Zaki, SR Katz, JM Tumpey, TM AF Zeng, Hui Goldsmith, Cynthia S. Maines, Taronna R. Belser, Jessica A. Gustin, Kortney M. Pekosz, Andrew Zaki, Sherif R. Katz, Jacqueline M. Tumpey, Terrence M. TI Tropism and Infectivity of Influenza Virus, Including Highly Pathogenic Avian H5N1 Virus, in Ferret Tracheal Differentiated Primary Epithelial Cell Cultures SO JOURNAL OF VIROLOGY LA English DT Article ID LOWER RESPIRATORY-TRACT; INNATE IMMUNE-RESPONSES; HUMAN AIRWAY EPITHELIUM; A H5N1; RECEPTOR SPECIFICITY; SIALIC ACIDS; HUMANS; TRANSMISSION; REPLICATION; ATTACHMENT AB Tropism and adaptation of influenza viruses to new hosts is partly dependent on the distribution of the sialic acid (SA) receptors to which the viral hemagglutinin (HA) binds. Ferrets have been established as a valuable in vivo model of influenza virus pathogenesis and transmission because of similarities to humans in the distribution of HA receptors and in clinical signs of infection. In this study, we developed a ferret tracheal differentiated primary epithelial cell culture model that consisted of a layered epithelium structure with ciliated and nonciliated cells on its apical surface. We found that human-like (alpha 2,6-linked) receptors predominated on ciliated cells, whereas avian-like (alpha 2,3-linked) receptors, which were less abundant, were presented on nonciliated cells. When we compared the tropism and infectivity of three human (H1 and H3) and two avian (H1 and H5) influenza viruses, we observed that the human influenza viruses primarily infected ciliated cells and replicated efficiently, whereas a highly pathogenic avian H5N1 virus (A/Vietnam/1203/2004) replicated efficiently within nonciliated cells despite a low initial infection rate. Furthermore, compared to other influenza viruses tested, VN/1203 virus replicated more efficiently in cells isolated from the lower trachea and at a higher temperature (37 degrees C) compared to a lower temperature (33 degrees C). VN/1203 virus infection also induced higher levels of immune mediator genes and cell death, and virus was recovered from the basolateral side of the cell monolayer. This ferret tracheal differentiated primary epithelial cell culture system provides a valuable in vitro model for studying cellular tropism, infectivity, and the pathogenesis of influenza viruses. C1 [Zeng, Hui; Maines, Taronna R.; Belser, Jessica A.; Gustin, Kortney M.; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. [Goldsmith, Cynthia S.; Zaki, Sherif R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Pekosz, Andrew] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD USA. RP Tumpey, TM (reprint author), Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. EM tft9@cdc.gov NR 54 TC 18 Z9 20 U1 1 U2 18 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAR PY 2013 VL 87 IS 5 BP 2597 EP 2607 DI 10.1128/JVI.02885-12 PG 11 WC Virology SC Virology GA 088ZL UT WOS:000314876900021 PM 23255802 ER PT J AU Carroll, SA Towner, JS Sealy, TK McMullan, LK Khristova, ML Burt, FJ Swanepoel, R Rollin, PE Nichol, ST AF Carroll, Serena A. Towner, Jonathan S. Sealy, Tara K. McMullan, Laura K. Khristova, Marina L. Burt, Felicity J. Swanepoel, Robert Rollin, Pierre E. Nichol, Stuart T. TI Molecular Evolution of Viruses of the Family Filoviridae Based on 97 Whole-Genome Sequences SO JOURNAL OF VIROLOGY LA English DT Article ID EBOLA-VIRUS; HEMORRHAGIC-FEVER; MARBURG VIRUSES; INFECTION; OUTBREAK; ALIGNMENT; MURIDAE; AFRICA; CONGO; BAT AB Viruses in the Ebolavirus and Marburgvirus genera (family Filoviridae) have been associated with large outbreaks of hemorrhagic fever in human and nonhuman primates. The first documented cases occurred in primates over 45 years ago, but the amount of virus genetic diversity detected within bat populations, which have recently been identified as potential reservoir hosts, suggests that the filoviruses are much older. Here, detailed Bayesian coalescent phylogenetic analyses are performed on 97 whole-genome sequences, 55 of which are newly reported, to comprehensively examine molecular evolutionary rates and estimate dates of common ancestry for viruses within the family Filoviridae. Molecular evolutionary rates for viruses belonging to different species range from 0.46 x 10(-4) nucleotide substitutions/site/year for Sudan ebolavirus to 8.21 x 10(-4) nucleotide substitutions/ site/year for Reston ebolavirus. Most recent common ancestry can be traced back only within the last 50 years for Reston ebolavirus and Zaire ebolavirus species and suggests that viruses within these species may have undergone recent genetic bottlenecks. Viruses within Marburg marburgvirus and Sudan ebolavirus species can be traced back further and share most recent common ancestors approximately 700 and 850 years before the present, respectively. Examination of the whole family suggests that members of the Filoviridae, including the recently described Lloviu virus, shared a most recent common ancestor approximately 10,000 years ago. These data will be valuable for understanding the evolution of filoviruses in the context of natural history as new reservoir hosts are identified and, further, for determining mechanisms of emergence, pathogenicity, and the ongoing threat to public health. C1 [Carroll, Serena A.; Towner, Jonathan S.; Sealy, Tara K.; McMullan, Laura K.; Rollin, Pierre E.; Nichol, Stuart T.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30329 USA. [Khristova, Marina L.] Ctr Dis Control & Prevent, Biotechnol Core Facil Branch, Atlanta, GA USA. [Burt, Felicity J.; Swanepoel, Robert] Natl Inst Communicable Dis, Special Pathogens Unit, Johannesburg, South Africa. RP Nichol, ST (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30329 USA. EM snichol@cdc.gov NR 52 TC 61 Z9 64 U1 2 U2 83 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD MAR PY 2013 VL 87 IS 5 BP 2608 EP 2616 DI 10.1128/JVI.03118-12 PG 9 WC Virology SC Virology GA 088ZL UT WOS:000314876900022 PM 23255795 ER PT J AU Lindesmith, LC Costantini, V Swanstrom, J Debbink, K Donaldson, EF Vinje, J Baric, RS AF Lindesmith, Lisa C. Costantini, Veronica Swanstrom, Jesica Debbink, Kari Donaldson, Eric F. Vinje, Jan Baric, Ralph S. TI Emergence of a Norovirus GII.4 Strain Correlates with Changes in Evolving Blockade Epitopes SO JOURNAL OF VIROLOGY LA English DT Article ID GENOGROUP-II NOROVIRUSES; NORWALK-LIKE VIRUSES; BLOOD GROUP ANTIGENS; UNITED-STATES; MONOCLONAL-ANTIBODY; EPOCHAL EVOLUTION; GENETIC-ANALYSIS; HERD-IMMUNITY; P2 DOMAIN; GASTROENTERITIS AB The major capsid protein of norovirus GII.4 strains is evolving rapidly, resulting in epidemic strains with altered antigenicity. GII.4.2006 Minerva strains circulated at pandemic levels in 2006 and persisted at lower levels until 2009. In 2009, a new GII.4 variant, GII.4.2009 New Orleans, emerged and since then has become the predominant strain circulating in human populations. To determine whether changes in evolving blockade epitopes correlate with the emergence of the GII.4.2009 New Orleans strains, we compared the antibody reactivity of a panel of mouse monoclonal antibodies (MAbs) against GII.4.2006 and GII.4.2009 virus-like particles (VLPs). Both anti-GII.4.2006 and GII.4.2009 MAbs effectively differentiated the two strains by VLP-carbohydrate ligand blockade assay. Most of the GII.4.2006 MAbs preferentially blocked GII.4.2006, while all of the GII.4.2009 MAbs preferentially blocked GII.4.2009, although 8 of 12 tested blockade MAbs blocked both VLPs. Using mutant VLPs designed to alter predicted antigenic epitopes, binding of seven of the blockade MAbs was impacted by alterations in epitope A, identifying residues 294, 296, 297, 298, 368, and 372 as important antigenic sites in these strains. Convalescent-phase serum collected from a GII.4.2009 outbreak confirmed the immunodominance of epitope A, since alterations of epitope A affected serum reactivity by 40%. These data indicate that the GII.4.2009 New Orleans variant has evolved a key blockade epitope, possibly allowing for at least partial escape from protective herd immunity and provide epidemiological support for the utility of monitoring changes in epitope A in emergent strain surveillance. C1 [Lindesmith, Lisa C.; Swanstrom, Jesica; Donaldson, Eric F.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA. [Costantini, Veronica; Vinje, Jan] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Debbink, Kari; Baric, Ralph S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA. RP Baric, RS (reprint author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA. EM rbaric@email.unc.edu OI Vinje, Jan/0000-0002-1530-3675; Costantini, Veronica/0000-0002-1532-4345 FU National Institutes of Health, Allergy and Infectious Diseases [AI056351]; Gillings Innovation Laboratory award from the UNC Gillings School of Global Public Health FX This study was supported by grant AI056351 from the National Institutes of Health, Allergy and Infectious Diseases, and by a Gillings Innovation Laboratory award from the UNC Gillings School of Global Public Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 57 TC 57 Z9 59 U1 0 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAR PY 2013 VL 87 IS 5 BP 2803 EP 2813 DI 10.1128/JVI.03106-12 PG 11 WC Virology SC Virology GA 088ZL UT WOS:000314876900039 PM 23269783 ER PT J AU Rubinson, L Mutter, R Viboud, C Hupert, N Uyeki, T Creanga, A Finelli, L Iwashyna, TJ Carr, B Merchant, R Katikineni, D Vaughn, F Clancy, C Lurie, N AF Rubinson, Lewis Mutter, Ryan Viboud, Cecile Hupert, Nathaniel Uyeki, Timothy Creanga, Andreea Finelli, Lyn Iwashyna, Theodore J. Carr, Brendan Merchant, Raina Katikineni, Devi Vaughn, Frances Clancy, Carolyn Lurie, Nicole TI Impact of the Fall 2009 Influenza A(H1N1)pdm09 Pandemic on US Hospitals SO MEDICAL CARE LA English DT Article DE pandemic influenza; hospital surge capacity; emergency department ID A H1N1 VIRUS; ACUTE MYOCARDIAL-INFARCTION; UNITED-STATES; INFECTION; BURDEN AB Background: Understanding how hospitals functioned during the 2009 influenza A(H1N1)pdm09 pandemic may improve future public health emergency response, but information about its impact on US hospitals remains largely unknown. Research Design: We matched hospital and emergency department (ED) discharge data from the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project with community-level influenza-like illness activity during each hospital's pandemic period in fall 2009 compared with a corresponding calendar baseline period. We compared inpatient mortality for sentinel conditions at high-surge versus nonsurge hospitals. Results: US hospitals experienced a doubling of pneumonia and influenza ED visits during fall 2009 compared with prior years, along with an 18% increase in overall ED visits. Although no significant increase in total inpatient admissions occurred overall, approximately 10% of all study hospitals experienced high surge, associated with higher acute myocardial infarction and stroke case fatality rates. These hospitals had similar characteristics to other US hospitals except that they had higher mortality for acute cardiac illnesses before the pandemic. After adjusting for 2008 case fatality rates, the association between high-surge hospitals and increased mortality for acute myocardial infarction and stroke patients persisted. Conclusions: The fall 2009 pandemic period substantially impacted US hospitals, mostly through increased ED visits. For a small proportion of hospitals that experienced a high surge in inpatient admissions, increased mortality from selected clinical conditions was associated with both prepandemic outcomes and surge, highlighting the linkage between daily hospital operations and disaster preparedness. C1 [Rubinson, Lewis; Vaughn, Frances; Lurie, Nicole] US Dept HHS, Off Assistant Secretary Preparedness & Response, Washington, DC 20201 USA. [Mutter, Ryan; Clancy, Carolyn] Agcy Healthcare Res & Qual, Rockville, MD 20850 USA. [Viboud, Cecile] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Hupert, Nathaniel] Weill Cornell Med Ctr, New York, NY USA. [Uyeki, Timothy; Finelli, Lyn] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Creanga, Andreea] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Iwashyna, Theodore J.] Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI USA. [Carr, Brendan; Merchant, Raina] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA. [Katikineni, Devi] Social & Sci Syst Inc, Silver Spring, MD USA. RP Mutter, R (reprint author), Agcy Healthcare Res & Qual, Ctr Delivery Org & Markets, 540 Gaither Rd, Rockville, MD 20850 USA. EM Ryan.Mutter@ahrq.hhs.gov OI Iwashyna, Theodore/0000-0002-4226-9310 NR 23 TC 7 Z9 7 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD MAR PY 2013 VL 51 IS 3 BP 259 EP 265 DI 10.1097/MLR.0b013e31827da8ea PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 090NE UT WOS:000314985100009 PM 23295577 ER PT J AU Dowell, D Kirkcaldy, RD AF Dowell, Deborah Kirkcaldy, Robert D. TI Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis (Reprinted from Sex Transm Infect, vol 88, pg 589-94, 2012) SO POSTGRADUATE MEDICAL JOURNAL LA English DT Reprint ID NEISSERIA-GONORRHOEAE; UNITED-STATES; ANTIMICROBIAL SUSCEPTIBILITY; GONOCOCCAL URETHRITIS; MALAWI; MANAGEMENT; THERAPY; FEMALES; MALES AB Objectives The development of resistance to multiple antimicrobial agents has limited treatment options for gonorrhoea. The potential emergence of cephalosporin resistance in Neisseria gonorrhoeae and cephalosporin allergy in some patients make it necessary to evaluate the effectiveness of other available antimicrobial agents. Gentamicin is widely available in the USA and is used for gonorrhoea treatment in several countries. We conducted a systematic review of the medical literature to assess the effectiveness of gentamicin for treatment of uncomplicated urogenital gonococcal infections. Methods Two reviewers assessed relevant articles and independently selected studies that met prespecified selection criteria (including systematic enrolment and assignment to treatment and culture-confirmed diagnosis and outcome). Summary measures for selected studies were pooled using inverse variance-weighted averages with fixed effects. Heterogeneity was assessed using I-2, which estimates proportion (0-100%) of variability attributable to heterogeneity between studies. Pooled percentage with negative follow-up culture was compared with Centers for Disease Control and Prevention (CDC) criteria for selection of recommended therapy (lower 95% CI of efficacy >= 95%). Results Twenty-nine potentially relevant studies were identified; three met inclusion criteria. Two studies used 240 mg intramuscular gentamicin and one used 280 mg. Percentages with negative culture after single-dose treatment were 90.7% (n=86), 91.4% (n=220) and 95.0% (n=40). Pooled percentage with negative culture after single-dose treatment was 91.5% (95% CI 88.1% to 94.0%, I-2=0%). Conclusions Gentamicin does not meet current CDC criteria for recommended treatment of gonorrhoea. However, if cephalosporin resistance emerges, gentamicin may be a useful alternative agent. Evaluation of additional regimens, including combination therapy, is warranted. C1 [Dowell, Deborah; Kirkcaldy, Robert D.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Dowell, D (reprint author), New York City Dept Hlth & Mental Hyg, Off Commissioner, 42-09 28th St,8-62 Queens, New York, NY 11101 USA. EM ddowell1@health.nyc.gov NR 27 TC 7 Z9 8 U1 0 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0032-5473 J9 POSTGRAD MED J JI Postgrad. Med. J. PD MAR PY 2013 VL 89 IS 1049 BP 142 EP 147 DI 10.1136/postgradmedj-2012-050604rep PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 091JT UT WOS:000315046300005 PM 23417685 ER PT J AU Satterwhite, CL Torrone, E Meites, E Dunne, EF Mahajan, R Ocfemia, MCB Su, J Xu, FJ Weinstock, H AF Satterwhite, Catherine Lindsey Torrone, Elizabeth Meites, Elissa Dunne, Eileen F. Mahajan, Reena Ocfemia, M. Cheryl Banez Su, John Xu, Fujie Weinstock, Hillard TI Sexually Transmitted Infections Among US Women and Men: Prevalence and Incidence Estimates, 2008 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID HUMAN-PAPILLOMAVIRUS INFECTION; GENITAL HUMAN-PAPILLOMAVIRUS; HIV/AIDS SURVEILLANCE DATA; ESTIMATING HIV INCIDENCE; UNITED-STATES; NATIONAL-HEALTH; NATURAL-HISTORY; RISK-FACTORS; HEPATITIS-B; DISEASES AB Background: Most sexually active people will be infected with a sexually transmitted infection (STI) at some point in their lives. The number of STIs in the United States was previously estimated in 2000. We updated previous estimates to reflect the number of STIs for calendar year 2008. Methods: We reviewed available data and literature and conservatively estimated incident and prevalent infections nationally for 8 common STIs: chlamydia, gonorrhea, syphilis, herpes, human papillomavirus, hepatitis B, HIV, and trichomoniasis. Where available, data from nationally representative surveys such as the National Health and Nutrition Examination Survey were used to provide national estimates of STI prevalence or incidence. The strength of each estimate was rated good, fair, or poor, according to the quality of the evidence. Results: In 2008, there were an estimated 110 million prevalent STIs among women and men in the United States. Of these, more than 20% of infections (22.1 million) were among women and men aged 15 to 24 years. Approximately 19.7 million incident infections occurred in the United States in 2008; nearly 50% (9.8 million) were acquired by young women and men aged 15 to 24 years. Human papillomavirus infections, many of which are asymptomatic and do not cause disease, accounted for most of both prevalent and incident infections. Conclusions: Sexually transmitted infections are common in the United States, with a disproportionate burden among young adolescents and adults. Public health efforts to address STIs should focus on prevention among at-risk populations to reduce the number and impact of STIs. C1 [Satterwhite, Catherine Lindsey; Torrone, Elizabeth; Meites, Elissa; Dunne, Eileen F.; Mahajan, Reena; Ocfemia, M. Cheryl Banez; Su, John; Xu, Fujie; Weinstock, Hillard] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Satterwhite, Catherine Lindsey] Univ Kansas, Dept Prevent Med & Publ Hlth, Sch Med, Kansas City, KS USA. RP Satterwhite, CL (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd NE,Mailstop E80, Atlanta, GA 30333 USA. EM col8@cdc.gov OI Meites, Elissa/0000-0002-0077-2591 NR 36 TC 271 Z9 274 U1 7 U2 64 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAR PY 2013 VL 40 IS 3 BP 187 EP 193 DI 10.1097/OLQ.0b013e318286bb53 PG 7 WC Infectious Diseases SC Infectious Diseases GA 089KY UT WOS:000314910600001 PM 23403598 ER PT J AU Owusu-Edusei, K Chesson, HW Gift, TL Tao, GY Mahajan, R Ocfemia, MCB Kent, CK AF Owusu-Edusei, Kwame, Jr. Chesson, Harrell W. Gift, Thomas L. Tao, Guoyu Mahajan, Reena Ocfemia, Marie Cheryl Banez Kent, Charlotte K. TI The Estimated Direct Medical Cost of Selected Sexually Transmitted Infections in the United States, 2008 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID CHLAMYDIA-TRACHOMATIS INFECTIONS; HUMAN-PAPILLOMAVIRUS; INSURED POPULATION; INCREMENTAL COST; INSURANCE CLAIMS; AMERICAN YOUTH; LIFETIME COST; PREVENTION; WOMEN; HIV AB Background: Millions of cases of sexually transmitted infections (STIs) occur in the United States each year, resulting in substantial medical costs to the nation. Previous estimates of the total direct cost of STIs are quite dated. We present updated direct medical cost estimates of STIs in the United States. Methods: We assembled recent (i.e., 2002-2011) cost estimates to determine the lifetime cost per case of 8 major STIs (chlamydia, gonorrhea, hepatitis B virus, human immunodeficiency virus (HIV), human papillomavirus, genital herpes simplex virus type 2, trichomoniasis and syphilis). The total direct cost for each STI was computed as the product of the number of new or newly diagnosed cases in 2008 and the estimated discounted lifetime cost per case. All costs were adjusted to 2010 US dollars. Results: Results indicated that the total lifetime direct medical cost of the 19.7 million cases of STIs that occurred among persons of all ages in 2008 in the United States was $15.6 (range, $11.0-$20.6) billion. Total costs were as follows: chlamydia ($516.7 [$258.3-$775.0] million), gonorrhea ($162.1 [$81.1-$243.2] million), hepatitis B virus ($50.7 [$41.3-$55.6] million), HIV ($12.6 [$9.5-$15.7] billion), human papillomavirus ($1.7 [$0.8-$2.9] billion), herpes simplex virus type 2 ($540.7 [$270.3-$811.0] million), syphilis ($39.3 [$19.6-$58.9] million), and trichomoniasis ($24.0 [$12.0-$36.0] million). Costs associated with HIV infection accounted for more than 81% of the total cost. Among the nonviral STIs, chlamydia was the most costly infection. Conclusions: Sexually transmitted infections continue to impose a substantial cost burden on the payers of medical care in the United States. The burden of STIs would be even greater in the absence of STI prevention and control efforts. C1 [Owusu-Edusei, Kwame, Jr.; Chesson, Harrell W.; Gift, Thomas L.; Tao, Guoyu; Kent, Charlotte K.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Mahajan, Reena] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Ocfemia, Marie Cheryl Banez] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Owusu-Edusei, K (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS E-80, Atlanta, GA 30333 USA. EM Kowusuedusei@cdc.gov NR 32 TC 112 Z9 113 U1 4 U2 33 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAR PY 2013 VL 40 IS 3 BP 197 EP 201 DI 10.1097/OLQ.0b013e318285c6d2 PG 5 WC Infectious Diseases SC Infectious Diseases GA 089KY UT WOS:000314910600003 PM 23403600 ER PT J AU Torrone, EA Johnson, RE Tian, LH Papp, JR Datta, SD Weinstock, HS AF Torrone, Elizabeth A. Johnson, Robert E. Tian, Lin H. Papp, John R. Datta, S. Deblina Weinstock, Hillard S. TI Prevalence of Neisseria gonorrhoeae Among Persons 14 to 39 Years of Age, United States, 1999 to 2008 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID CHLAMYDIA-TRACHOMATIS; INFECTIONS; HEALTH; TRENDS; WOMEN AB Background: Prevalence estimates from population-based surveys do not suffer from the same biases as case-report and clinic positivity data and may be better to monitor sexually transmitted disease morbidity over time. Methods: We estimated the prevalence of Neisseria gonorrhoeae in a nationally representative sample of persons aged 14 to 39 years participating in the National Health and Nutrition Examination Survey. Results: From 1999 to 2008, the overall prevalence of gonorrhea was 0.27% (95% confidence interval, 0.13%-0.47%). In the 2005 to 2006 and 2007 to 2008 cycles, prevalence approached 0% and was based on too few positive sample persons to obtain reliable estimates. In 2004, most infections were found in 1 survey location. Discussion: Given the low prevalence and geographic clustering of disease, gonorrhea estimates from national probability surveys are often imprecise and unstable. In 2008, gonorrhea testing in National Health and Nutrition Examination Survey was discontinued. Continued surveillance of gonorrhea should include case reporting and prevalence estimates from local surveys and sentinel surveillance systems. C1 [Torrone, Elizabeth A.; Johnson, Robert E.; Tian, Lin H.; Papp, John R.; Datta, S. Deblina; Weinstock, Hillard S.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Torrone, EA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop E-02, Atlanta, GA 30333 USA. EM ETorrone@cdc.gov NR 21 TC 8 Z9 8 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAR PY 2013 VL 40 IS 3 BP 202 EP 205 DI 10.1097/OLQ.0b013e31827c5a71 PG 4 WC Infectious Diseases SC Infectious Diseases GA 089KY UT WOS:000314910600004 PM 23407466 ER PT J AU Oster, AM Wejnert, C Mena, LA Elmore, K Fisher, H Heffelfinger, JD AF Oster, Alexandra M. Wejnert, Cyprian Mena, Leandro A. Elmore, Kim Fisher, Holly Heffelfinger, James D. TI Network Analysis Among HIV-infected Young Black Men Who Have Sex With Men Demonstrates High Connectedness Around Few Venues SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID AFRICAN-AMERICAN MEN; UNITED-STATES; TRANSMISSION; RISK; DISPARITIES; PERSISTENCE; POPULATION; PREVENTION; BEHAVIORS; ATTITUDES AB Background: Network analysis is useful for understanding sexual transmission of HIV and other sexually transmitted infections. We conducted egocentric and affiliation network analysis among HIV-infected young black men who have sex with men (MSM) in the Jackson, Mississippi, area to understand networks and connectedness of this population. Methods: We interviewed 22 black MSM aged 17 to 25 years diagnosed as having HIV in 2006 to 2008. Participants provided demographic and geographic information about each sex partner during the 12 months before diagnosis and identified venues where they met these partners. We created affiliation network diagrams to understand connectedness of this population and identify venues that linked participants. Results: The median number of partners reported was 4 (range, 1-16); a total of 97 partners (88 of whom were male) were reported. All but 1 participant were connected through a network of venues where they had met partners during the 12 months before diagnosis. Three venues were named as places for meeting partners by 13 of 22 participants. Participants reported having partners from all regions of Mississippi and 5 other states. Conclusions: HIV-infected young black MSM in this analysis were linked by a small number of venues. These venues should be targeted for testing and prevention interventions. The pattern of meeting sex partners in a small number of venues suggests densely connected networks that propagate infection. This pattern, in combination with sexual partnerships with persons from outside Jackson, may contribute to spread of HIV and other sexually transmitted infections into or out the Jackson area. C1 [Oster, Alexandra M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Oster, Alexandra M.; Wejnert, Cyprian; Elmore, Kim; Fisher, Holly; Heffelfinger, James D.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Mena, Leandro A.] Univ Mississippi, Mississippi State Dept Hlth, Sch Med, Jackson, MS 39216 USA. RP Oster, AM (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-46, Atlanta, GA 30333 USA. EM AOster@cdc.gov FU Centers for Disease Control and Prevention; Mississippi State Department of Health FX The authors declare no conflicts of interest. Funding was provided by the Centers for Disease Control and Prevention and the Mississippi State Department of Health. NR 31 TC 19 Z9 19 U1 1 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAR PY 2013 VL 40 IS 3 BP 206 EP 212 DI 10.1097/OLQ.0b013e3182840373 PG 7 WC Infectious Diseases SC Infectious Diseases GA 089KY UT WOS:000314910600005 PM 23403601 ER PT J AU Owusu-Edusei, K Introcaso, CE Chesson, HW AF Owusu-Edusei, Kwame, Jr. Introcaso, Camille E. Chesson, Harrell W. TI Hospitalization Cost of Congenital Syphilis Diagnosis From Insurance Claims Data in the United States SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID ADMINISTRATIVE DATA; PREGNANCY; INFECTION; TANZANIA; HEALTH AB We analyzed medical insurance claims data (2005-2009) to determine the hospitalization costs of newborns with congenital syphilis (CS) diagnoses. We found 44 admission claims with CS diagnosis. The excess cost per case of CS (in 2009 US dollars) was estimated at $9969 (95% confidence interval, $5702-$16,769). (Sexual Trans Dis 2013; 40: 226-229) C1 [Owusu-Edusei, Kwame, Jr.; Introcaso, Camille E.; Chesson, Harrell W.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Owusu-Edusei, K (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-80, Atlanta, GA 30333 USA. EM Kowusuedusei@cdc.gov NR 26 TC 4 Z9 4 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAR PY 2013 VL 40 IS 3 BP 226 EP 229 DI 10.1097/OLQ.0b013e31827c5b9f PG 4 WC Infectious Diseases SC Infectious Diseases GA 089KY UT WOS:000314910600009 PM 23407468 ER PT J AU Liu, Y Croft, JB Chapman, DP Perry, GS Greenlund, KJ Zhao, GX Edwards, VJ AF Liu, Yong Croft, Janet B. Chapman, Daniel P. Perry, Geraldine S. Greenlund, Kurt J. Zhao, Guixiang Edwards, Valerie J. TI Relationship between adverse childhood experiences and unemployment among adults from five US states SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY LA English DT Article DE Adverse childhood experiences; Unemployment; Mediation analysis; Social support ID HOUSEHOLD DYSFUNCTION; SEXUAL-ABUSE; ADOLESCENT VICTIMIZATION; PSYCHIATRIC-DISORDERS; PHYSICAL ABUSE; DRUG-USE; HEALTH; RISK; OUTCOMES; NEGLECT AB Our study assesses the relationships between self-reported adverse childhood experiences (ACEs) (including sexual, physical, or verbal abuse, along with household dysfunction including parental separation or divorce, domestic violence, mental illness, substance abuse, or incarcerated household member) and unemployment status in five US states in 2009. We examined these relationships using the 2009 Behavioral Risk Factor Surveillance System survey data from 17,469 respondents (aged 18-64 years) who resided in five states, completed the ACE Questionnaire, and provided socio-demographic and social support information. We also assessed the mediation of these relationships by respondents' educational attainment, marital status, and social support. About two-third of respondents reported having had at least one ACEs, while 15.1 % of men and 19.3 % of women reported having had a parts per thousand yen4 ACEs. Among both men and women, the unemployment rate in 2009 was significantly higher among those who reported having had any ACE than among those who reported no ACEs (p < 0.05). Educational attainment, marital status, and social support mediated the relationship between ACEs and unemployment, particularly among women. ACEs appear to be associated with increased risk for unemployment among men and women. Further studies may be needed to better understand how education, marital status, and social support mediate the association between multiple ACEs and unemployment. C1 [Liu, Yong; Croft, Janet B.; Chapman, Daniel P.; Perry, Geraldine S.; Greenlund, Kurt J.; Edwards, Valerie J.] Ctr Dis Control & Prevent CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Zhao, Guixiang] Ctr Dis Control & Prevent CDC, Div Behav Surveillance, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30345 USA. RP Liu, Y (reprint author), Ctr Dis Control & Prevent CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mail Stop K-67, Atlanta, GA 30341 USA. EM ikd8@cdc.gov FU Intramural CDC HHS [CC999999] NR 58 TC 17 Z9 17 U1 5 U2 42 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0933-7954 J9 SOC PSYCH PSYCH EPID JI Soc. Psychiatry Psychiatr. Epidemiol. PD MAR PY 2013 VL 48 IS 3 BP 357 EP 369 DI 10.1007/s00127-012-0554-1 PG 13 WC Psychiatry SC Psychiatry GA 087SN UT WOS:000314783000002 PM 22869349 ER PT J AU Knoeller, GE Mazurek, JM Moorman, JE AF Knoeller, Gretchen E. Mazurek, Jacek M. Moorman, Jeanne E. TI Asthma Symptoms among Adults with Work-Related Asthma SO JOURNAL OF ASTHMA LA English DT Article DE asthma; Behavioral Risk Factor Surveillance System; respiratory signs and symptoms; occupational health ID CALL-BACK-SURVEY; OCCUPATIONAL ASTHMA; WORKPLACE; CARE AB Objective. To examine the number of days with asthma symptoms among individuals with work-related asthma (WRA) and non-WRA. Methods. We calculated adjusted prevalence ratios and compared mean number of days with asthma symptoms using 2006-2009 Behavioral Risk Factor Surveillance System Asthma Call-back Survey data for ever-employed adults with current asthma from 38 states and District of Columbia. Results. Compared with persons with non-WRA, those with WRA had higher mean number of days with asthma symptoms. Regardless of WRA status, individuals with higher number of days with asthma symptoms were more likely to be unable to work or carry out their usual activities due to asthma. Associations between frequency of asthma symptoms and activity limitation due to asthma were weaker among currently employed adults and stronger among adults not currently employed than the observed associations for all ever-employed adults. Conclusions. These results suggest higher frequency of asthma symptoms among adults with WRA and underscore the need for optimal asthma management in individuals with WRA. C1 [Knoeller, Gretchen E.; Mazurek, Jacek M.] NIOSH, Ctr Dis Control & Prevent CDC, Morgantown, WV USA. [Moorman, Jeanne E.] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Knoeller, GE (reprint author), 1095 Willowdale Rd,MS HG900, Morgantown, WV 26505 USA. EM GKnoeller@cdc.gov NR 33 TC 6 Z9 6 U1 0 U2 3 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0277-0903 J9 J ASTHMA JI J. Asthma PD MAR PY 2013 VL 50 IS 2 BP 166 EP 173 DI 10.3109/02770903.2012.754029 PG 8 WC Allergy; Respiratory System SC Allergy; Respiratory System GA 085ZE UT WOS:000314652000009 PM 23259750 ER PT J AU Williams, NJ Ghosh, TS Bisgard, KM Vogt, RL AF Williams, Nancy J. Ghosh, Tista S. Bisgard, Kristine M. Vogt, Richard L. TI Comparison of 3 School-Based Influenza Surveillance Indicators: Lessons Learned From 2009 Pandemic Influenza A (H1N1)-Denver Metropolitan Region, Colorado SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE absenteeism; influenza A virus; H1N1 subtype; schools; surveillance ID NEW-YORK-CITY; SYSTEM; H1N1 AB Context: Early in the 2009 pandemic influenza A (H1N1) experience, children aged 5 to 17 years were determined to be disproportionately affected compared with recent influenza seasons. Objective: To characterize the pandemic among school-aged children, to enable timely influenza outbreak identification, and to determine which school-based influenza surveillance indicator correlated most closely with a laboratory-based standard influenza indicator (standard) and, therefore, might be most useful for future school-based influenza surveillance. Design: During the 2009-2010 school year, we monitored students using 3 different surveillance indicators: (1) all-cause absenteeism, (2) influenza-like illness (ILI)-related absenteeism, (3) and ILI-related school health office visits. Thresholds were set for each indicator to identify individual school outbreaks. Each surveillance indicator was compared with the standard, confirmed influenza cases among hospitalized patients. Setting: Tri-County (Denver metropolitan area), Colorado. Participants: Prekindergarten through 12th-grade students in public schools. Main Outcome Measures: Correlation coefficients comparing each influenza surveillance indicator with the standard and graphs comparing weekly rates for each influenza surveillance indicator or weekly outbreak counts with the standard. Results: Correlation between the surveillance indicators and the standard varied greatly. All-cause absenteeism correlated most poorly with the standard (Pearson's r = 0.33) and ILI-related health office visits correlated moderately well (r = 0.63). Influenza-like illness-related absenteeism correlated best (r = 0.92) and could be improved (r = 0.97) by shifting ILI-absenteeism data later by 1 week. Graphs of weekly rates or weekly outbreak counts also illustrated that ILI-related absenteeism correlated best with the standard. Conclusions: For influenza surveillance among school-aged children, when feasible, we recommend using ILI-related absenteeism, which correlated best and its rate peaked more than 1 week sooner than the standard. The other 2 surveillance indicators might be useful in certain situations, such as when resources are limited. C1 [Williams, Nancy J.; Bisgard, Kristine M.] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. [Williams, Nancy J.; Ghosh, Tista S.; Vogt, Richard L.] Tricty Hlth Dept, Greenwood Village, CO USA. RP Williams, NJ (reprint author), So Nevada Hlth Dist, POB 3902, Las Vegas, NV 89127 USA. EM williams@snhdmail.org NR 17 TC 0 Z9 1 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2013 VL 19 IS 2 BP 119 EP 125 DI 10.1097/PHH.0b013e318252f005 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 081SJ UT WOS:000314342300007 PM 23358289 ER PT J AU Kong, DG Watt, JP Marks, S Flood, J AF Kong, Darryl G. Watt, James P. Marks, Suzanne Flood, Jennifer TI HIV Status Determination Among Tuberculosis Patients From California During 2008 SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE HIV; routine HIV testing; tuberculosis ID IMMUNODEFICIENCY-VIRUS-INFECTION; NEW-YORK-CITY; UNITED-STATES; MORTALITY; RESISTANCE; CARE AB Context: Human immunodeficiency virus (HIV) infection complicates care and contributes to poor outcomes among tuberculosis (TB) patients. The Centers for Disease Control and Prevention recommends that providers test all TB patients for HIV. Objective: We assessed completeness of HIV status determination among TB patients and identified key gaps in adherence. Design: We conducted a retrospective review of public health charts to determine the HIV status for all TB patients reported in California during 2008. We then used logistic regression to determine the factors associated with a known (positive or negative) HIV status. A random sample of TB patients was selected for secondary review to characterize the timing of HIV status determination and the providers who had opportunity to test for HIV. Setting: California TB programs. Participants: All TB patients reported from California in 2008. Main Outcome Measures: Proportion of patients with a known HIV status, adjusted odds ratios for having a known HIV status, proportion of patients with a known HIV status before TB diagnosis, and proportion of patients diagnosed with TB by different provider types. Results: Only 1752 (66%) of 2667 TB patients had a known HIV status. Having a known HIV status was strongly associated with those aged between 15 and 44 years and being managed with any public provider involvement. Of 292 patients in the random sample, 12 patients (4%) had a known HIV status before TB diagnosis. Among the remaining 280 patients, 187 patients (67%) were diagnosed with TB by a private provider. Conclusions: The HIV status determination of TB patients was selective and not routine as recommended. Private providers can play a key role in testing for HIV at TB diagnosis. California TB programs should ensure that all TB patients have an HIV status by promulgating national recommendations, educating private providers on the benefits of testing TB patients for HIV, and monitoring completeness of HIV status determination. C1 [Kong, Darryl G.; Flood, Jennifer] Calif Dept Publ Hlth, TB Control Branch, Richmond, CA 94804 USA. [Watt, James P.] Calif Dept Publ Hlth, Div Communicable Dis Control, Richmond, CA 94804 USA. [Marks, Suzanne] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. RP Kong, DG (reprint author), Calif Dept Publ Hlth, TB Control Branch, 850 Marina Bay Pkwy,Bldg P,2nd Floor, Richmond, CA 94804 USA. EM Darryl.Kong@cdph.ca.gov FU Intramural CDC HHS [CC999999]; NCHHSTP CDC HHS [5U52 PS900515-28, U52 PS900515] NR 33 TC 5 Z9 5 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2013 VL 19 IS 2 BP 169 EP 177 DI 10.1097/PHH.0b013e3182550a83 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 081SJ UT WOS:000314342300014 PM 23358296 ER PT J AU Ruiz, R Baker, EL AF Ruiz, Roberto Baker, Edward L. TI The First 6 Months: Transitioning Into a New Position SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Editorial Material C1 [Ruiz, Roberto] Ctr Dis Control & Prevent, Atlanta, GA USA. [Baker, Edward L.] UNC Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC 27599 USA. RP Baker, EL (reprint author), UNC Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Campus Box 7411, Chapel Hill, NC 27599 USA. EM elbaker@email.unc.edu RI Quazi Syed, Zahiruddin/A-6161-2010 OI Quazi Syed, Zahiruddin/0000-0002-1435-899X NR 5 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2013 VL 19 IS 2 BP 187 EP 189 DI 10.1097/PHH.0b013e318283fc9f PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 081SJ UT WOS:000314342300016 PM 23358298 ER PT J AU Campagnolo, ER Moll, ME Tuhacek, K Simeone, AJ Miller, WS Waller, KO Simwale, O Rankin, JT Ostroff, SM AF Campagnolo, E. R. Moll, M. E. Tuhacek, K. Simeone, A. J. Miller, W. S. Waller, K. O. Simwale, O. Rankin, J. T. Ostroff, S. M. TI Concurrent 2009 Pandemic Influenza A (H1N1) Virus Infection in Ferrets and in a Community in Pennsylvania SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Pandemic; pH1N1; ferret; sentinel; zoonoses; influenza A virus; veterinary public health; pneumonia; influenza-like illness; surveillance; pet store; Pennsylvania ID PUBLIC-HEALTH; ANIMAL-MODELS; SENTINELS; TRANSMISSION; PATHOGENESIS; OUTBREAK; DISEASE AB We report a fall 2010 cluster of pandemic influenza A/H1N1 (pH1N1) infections in pet ferrets in Lehigh Valley region of Pennsylvania. The ferrets were associated with one pet shop. The influenza cluster occurred during a period when the existing human surveillance systems had identified little to no pH1N1 in humans in the Lehigh Valley, and there were no routine influenza surveillance systems for exotic pets. The index case was a 2.5-month-old neutered male ferret that was presented to a veterinary clinic with severe influenza-like illness (ILI). In response to laboratory notification of a positive influenza test result, and upon request from the Pennsylvania Department of Health (PADOH), the Pennsylvania Department of Agriculture (PDA) conducted an investigation to identify other ill ferrets and to identify the source and extent of infection. PDA notified the PADOH of the pH1N1 infection in the ferrets, leading to enhanced human surveillance and the detection of pH1N1 human infections in the surrounding community. Five additional ferrets with ILI linked to the pet shop were identified. This simultaneous outbreak of ferret and human pH1N1 demonstrates the important link between animal health and public health and highlights the potential use of veterinary clinics for sentinel surveillance of diseases shared between animals and humans. C1 [Campagnolo, E. R.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Off Sci & Publ Hlth Practice, Atlanta, GA USA. [Campagnolo, E. R.; Moll, M. E.; Waller, K. O.; Simwale, O.; Rankin, J. T.; Ostroff, S. M.] Bur Epidemiol, Penn Dept Hlth, Harrisburg, PA USA. [Tuhacek, K.] Allentown Anim Clin, Allentown, PA USA. [Simeone, A. J.] Bur Anim Hlth & Diagnost Serv, Penn Dept Agr Harrisburg, Collegeville, PA USA. [Miller, W. S.] Bur Community Hlth Syst, Penn Dept Hlth, Wilkes Barre, PA USA. RP Campagnolo, ER (reprint author), NW Dist Off, Penn Dept Hlth, 19 McQuiston Dr, Jackson Ctr, PA 16133 USA. EM ejc5@cdc.gov NR 37 TC 4 Z9 4 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD MAR PY 2013 VL 60 IS 2 BP 117 EP 124 DI 10.1111/j.1863-2378.2012.01503.x PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA 083MT UT WOS:000314469200001 PM 22697485 ER PT J AU Abu Samra, N Thompson, PN Jori, F Frean, J Poonsamy, B du Plessis, D Mogoye, B Xiao, L AF Abu Samra, N. Thompson, P. N. Jori, F. Frean, J. Poonsamy, B. du Plessis, D. Mogoye, B. Xiao, L. TI Genetic Characterization of Cryptosporidium spp. in Diarrhoeic Children from Four Provinces in South Africa SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Cryptosporidium; children; South Africa; genotyping; 18S rRNA; GP60 subtyping ID HUMAN-IMMUNODEFICIENCY-VIRUS; MOLECULAR EPIDEMIOLOGY; PUBLIC-HEALTH; PREVALENCE; INFECTION; DIVERSITY; PARVUM AB The diversity of Cryptosporidium at species, subtype family and subtype level in diarrhoeic children was investigated in four provinces in South Africa. A total of 442 stool samples from children <5years of age were collected under a large rotavirus surveillance programme and analysed by ZiehlNeelsen acid-fast staining. Fifty-four (12.2%) were positive for Cryptosporidium, of which 25 were genotyped by polymerase chain reaction (PCR)restriction fragment length polymorphism (RFLP) and DNA sequence analyses of the 18S rRNA gene. The majority of genotyped specimens were identified as C.hominis (76%), and a high genetic diversity was found with five different C.hominis subtype families (Ia, Ib, Id, Ie and If). Cryptosporidium parvum was found in 20% of the isolates, and three subtype families were identified (IIc, IIe and IIb), with subtype family IIc being the most common. One specimen was identified as C.meleagridis of the subtype family IIId. These results are in accordance with findings from other developing countries and report for the first time the presence in South Africa of C.meleagridis, various subtypes of C.parvum and the subtype family Ie of C.hominis. The results suggest that C.hominis and anthroponotic C.parvum subtypes are the major cause of cryptosporidiosis in South Africa. Further molecular studies are needed to better understand the epidemiology and public health importance of Cryptosporidium in humans in South Africa. C1 [Abu Samra, N.; Thompson, P. N.] Univ Pretoria, Dept Prod Anim Studies, Epidemiol Sect, ZA-0100 Pretoria, South Africa. [Jori, F.] Univ Pretoria, Mammal Res Inst, Dept Zool & Entomol, CIRAD,UR AGIRs, ZA-0100 Pretoria, South Africa. [Frean, J.; Poonsamy, B.; du Plessis, D.; Mogoye, B.] Univ Witwatersrand, Natl Inst Communicable Dis, S African Rotavirus Surveillance Programme, Johannesburg, South Africa. [Xiao, L.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Abu Samra, N (reprint author), Univ Pretoria, Dept Prod Anim Studies, Epidemiol Sect, Private BagX04, ZA-0100 Pretoria, South Africa. EM nada.nada@gmx.de RI Xiao, Lihua/B-1704-2013; Thompson, Peter/J-2534-2013; OI Xiao, Lihua/0000-0001-8532-2727; Thompson, Peter/0000-0002-2268-9748 FU Faculty of Veterinary Science, University of Pretoria, South Africa FX We are grateful to the Faculty of Veterinary Science, University of Pretoria, South Africa, for providing funding for this research. We also acknowledge the support provided by Theresa Dearen of the Centers for Disease Control (CDC), Atlanta, Georgia. We thank the South African Rotavirus Surveillance Programme for providing specimens used in this study. NR 22 TC 9 Z9 10 U1 1 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD MAR PY 2013 VL 60 IS 2 BP 154 EP 159 DI 10.1111/j.1863-2378.2012.01507.x PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA 083MT UT WOS:000314469200006 PM 22712773 ER PT J AU Allemani, C Sant, M Weir, HK Richardson, LC Baili, P Storm, H Siesling, S Torrella-Ramos, A Voogd, AC Aareleid, T Ardanaz, E Berrino, F Bielska-Lasota, M Bolick, S Cirilli, C Colonna, M Contiero, P Cress, R Crocetti, E Fulton, JP Grosclaude, P Hakulinen, T Izarzugaza, MI Malmstrom, P Peignaux, K Primic-Zakelj, M Rachtan, J Diba, CS Sanchez, MJ Schymura, MJ Shen, TF Traina, A Tryggvadottir, L Tumino, R Velten, M Vercelli, M Wolf, HJ Woronoff, AS Wu, XC Coleman, MP AF Allemani, Claudia Sant, Milena Weir, Hannah K. Richardson, Lisa C. Baili, Paolo Storm, Hans Siesling, Sabine Torrella-Ramos, Ana Voogd, Adri C. Aareleid, Tiiu Ardanaz, Eva Berrino, Franco Bielska-Lasota, Magdalena Bolick, Susan Cirilli, Claudia Colonna, Marc Contiero, Paolo Cress, Rosemary Crocetti, Emanuele Fulton, John P. Grosclaude, Pascale Hakulinen, Timo Isabel Izarzugaza, M. Malmstrom, Per Peignaux, Karin Primic-Zakelj, Maja Rachtan, Jadwiga Diba, Chakameh Safaei Sanchez, Maria-Jose Schymura, Maria J. Shen, Tiefu Traina, Adele Tryggvadottir, Laufey Tumino, Rosario Velten, Michel Vercelli, Marina Wolf, Holly J. Woronoff, Anne-Sophie Wu, Xiaocheng Coleman, Michel P. TI Breast cancer survival in the US and Europe: a CONCORD high-resolution study SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE CONCORD; net survival; excess hazard; cancer registries ID FLEXIBLE PARAMETRIC MODELS; UNITED-STATES; RELATIVE SURVIVAL; RANDOMIZED-TRIALS; THERAPY; POPULATION; CARCINOMA; STAGE; WOMEN AB Breast cancer survival is reportedly higher in the US than in Europe. The first worldwide study (CONCORD) found wide international differences in age-standardized survival. The aim of this study is to explain these survival differences. Population-based data on stage at diagnosis, diagnostic procedures, treatment and follow-up were collected for about 20,000 women diagnosed with breast cancer aged 15-99 years during 1996-98 in 7 US states and 12 European countries. Age-standardized net survival and the excess hazard of death up to 5 years after diagnosis were estimated by jurisdiction (registry, country, European region), age and stage with flexible parametric models. Breast cancers were generally less advanced in the US than in Europe. Stage also varied less between US states than between European jurisdictions. Early, node-negative tumors were more frequent in the US (39%) than in Europe (32%), while locally advanced tumors were twice as frequent in Europe (8%), and metastatic tumors of similar frequency (5-6%). Net survival in Northern, Western and Southern Europe (81-84%) was similar to that in the US (84%), but lower in Eastern Europe (69%). For the first 3 years after diagnosis the mean excess hazard was higher in Eastern Europe than elsewhere: the difference was most marked for women aged 70-99 years, and mainly confined to women with locally advanced or metastatic tumors. Differences in breast cancer survival between Europe and the US in the late 1990s were mainly explained by lower survival in Eastern Europe, where low healthcare expenditure may have constrained the quality of treatment. C1 [Allemani, Claudia; Coleman, Michel P.] Univ London London Sch Hyg & Trop Med, Canc Res UK Canc Survival Grp, Dept Noncommunicable Dis Epidemiol, London WC1E 7HT, England. [Allemani, Claudia; Sant, Milena] Fdn IRCCS Ist Nazl Tumori, Analyt Epidemiol Unit, Dept Prevent & Predict Med, Milan, Italy. [Weir, Hannah K.; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Baili, Paolo] Fdn IRCCS Ist Nazl Tumori, Descript Studies & Hlth Planning Unit, Milan, Italy. [Storm, Hans] Danish Canc Soc, Dept Canc Prevent & Documentat, Copenhagen O, Denmark. [Siesling, Sabine] Comprehens Canc Ctr Netherlands, Netherlands Canc Registry, NL-3501 DB Utrecht, Netherlands. [Torrella-Ramos, Ana] Comunitat Valenciana, Canc Registry Castellon, Castellon de La Plana, Spain. [Voogd, Adri C.] Eindhoven Canc Registry, Dept Res, NL-5600 AE Eindhoven, Netherlands. [Aareleid, Tiiu] Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, Estonia. [Ardanaz, Eva] CIBERESP, Navarra Canc Registry, Navarra Publ Hlth Inst, Navarra, Spain. [Berrino, Franco] Fdn IRCCS Ist Nazl Tumori, Unit Etiol Epidemiol & Prevent, Dept Prevent & Predict Med, Milan, Italy. [Bielska-Lasota, Magdalena] Natl Inst Hyg, Bioeth & Hlth Psychol Unit, Dept Hlth Promot & Postgrad Educ, Natl Inst Publ Hlth, PL-00791 Warsaw, Poland. [Bolick, Susan] S Carolina Cent Canc Registry, Columbia, SC USA. [Cirilli, Claudia] Modena Canc Registry, Modena, Italy. [Colonna, Marc] Isere Canc Registry, Meylan, France. [Contiero, Paolo] Fdn IRCSS Ist Nazl Tumori, Canc Registry, Milan, Italy. [Contiero, Paolo] Fdn IRCSS Ist Nazl Tumori, Environm Epidemiol Unit, Milan, Italy. [Cress, Rosemary] Calif Canc Registry, Inst Publ Hlth, Sacramento, CA USA. [Crocetti, Emanuele] ISPO, Tuscany Canc Registry, UO Epidemiol Clin & Descrittiva, Florence, Italy. [Fulton, John P.] Rhode Isl Canc Registry, Providence, RI USA. [Grosclaude, Pascale] Tarn Canc Registry, Albi, France. [Hakulinen, Timo] Finnish Canc Registry, Inst Stat & Epidemiol Canc Res, FIN-00170 Helsinki, Finland. [Isabel Izarzugaza, M.] Registros & Informac Sanitaria, Dpto Sanidad Gobierno Vasco, C Donostia San Sebastian, Vitoria Gasteiz, Spain. [Malmstrom, Per] Skane Univ Hosp, Skane Dept Oncol, Lund, Sweden. [Peignaux, Karin] Ctr Georges Francois Leclerc, Cote dOr Breast & Gynecol Canc Registry, Dijon, France. [Primic-Zakelj, Maja] Inst Oncol Ljubljana, Epidemiol & Canc Registry, Ljubljana, Slovenia. [Rachtan, Jadwiga] M Skodowska Curie Mem Inst, Cracow Canc Registry, Ctr Oncol, Krakow, Poland. [Diba, Chakameh Safaei] Natl Hlth Informat Ctr, Natl Canc Registry Slovakia, Bratislava, Slovakia. [Sanchez, Maria-Jose] Andalusian Sch Publ Hlth, Granada, Spain. [Sanchez, Maria-Jose] CIBER Epidemiol & Salud Publ, Madrid, Spain. [Schymura, Maria J.] New York State Canc Registry, Menands, NY USA. [Shen, Tiefu] Illinois State Canc Registry, Springfield, IL USA. [Traina, Adele] ARNAS Civ, POM Ascoli, Dept Oncol, Palermo, Italy. [Tryggvadottir, Laufey] Univ Iceland, Fac Med, Reykjavik, Iceland. [Tryggvadottir, Laufey] Iceland Canc Registry, IS-125 Reykjavik, Iceland. [Tumino, Rosario] Civile MP Arezzo Hosp, Canc Registry, ASP Ragusa, Ragusa, Italy. [Tumino, Rosario] Civile MP Arezzo Hosp, Histopathol Unit, ASP Ragusa, Ragusa, Italy. RP Allemani, C (reprint author), Univ London London Sch Hyg & Trop Med, Canc Res UK Canc Survival Grp, Dept Noncommunicable Dis Epidemiol, Keppel St, London WC1E 7HT, England. EM claudia.allemani@lshtm.ac.uk RI SANCHEZ-PEREZ, MARIA JOSE/D-1087-2011; Grosclaude, Pascale/B-6079-2015; Baili, Paolo/J-7422-2016; Velten, Michel/R-4242-2016; Sant, Milena/D-2362-2017; Contiero, Paolo/F-6721-2016; OI SANCHEZ-PEREZ, MARIA JOSE/0000-0003-4817-0757; Baili, Paolo/0000-0003-0335-2418; Sant, Milena/0000-0002-4148-8597; Contiero, Paolo/0000-0001-6760-3605; Storm, Hans/0000-0001-7223-8198; Coleman, Michel/0000-0001-8940-3807; Tryggvadottir, Laufey/0000-0001-8067-9030; Vercelli, Marina/0000-0002-9757-2616 FU Health Department of the Navarra Government, Spain [79/2000]; Alleanza Contro il Cancro, the Italian Cancer Network FX Some of the data for this study were collected with the support of the Compagnia di San Paolo, Turin, Italy. Support was also obtained from the Health Department of the Navarra Government, Spain (research grant 79/2000). Alleanza Contro il Cancro, the Italian Cancer Network (http://www.allean-zacontroilcancro.it) supported a CONCORD Working Group meeting in London, 29-30 September 2010. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention. NR 31 TC 29 Z9 33 U1 0 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD MAR 1 PY 2013 VL 132 IS 5 BP 1170 EP 1181 DI 10.1002/ijc.27725 PG 12 WC Oncology SC Oncology GA 078AU UT WOS:000314071300020 PM 22815141 ER PT J AU Freeland, AL Banerjee, SN Dannenberg, AL Wendel, AM AF Freeland, Amy L. Banerjee, Shailendra N. Dannenberg, Andrew L. Wendel, Arthur M. TI Walking Associated With Public Transit: Moving Toward Increased Physical Activity in the United States SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HEALTH IMPACT ASSESSMENT; OBESITY; ENVIRONMENT; INACTIVITY; EPIDEMIC; MODE AB Objectives. We assessed changes in transit-associated walking in the United States from 2001 to 2009 and documented their importance to public health. Methods. We examined transit walk times using the National Household Travel Survey, a telephone survey administered by the US Department of Transportation to examine travel behavior in the United States. Results. People are more likely to transit walk if they are from lower income households, are non-White, and live in large urban areas with access to rail systems. Transit walkers in large urban areas with a rail system were 72% more likely to transit walk 30 minutes or more per day than were those without a rail system. From 2001 to 2009, the estimated number of transit walkers rose from 7.5 million to 9.6 million (a 28% increase); those whose transit-associated walking time was 30 minutes or more increased from approximately 2.6 million to 3.4 million (a 31% increase). Conclusions. Transit walking contributes to meeting physical activity recommendations. Study results may contribute to transportation-related health impact assessment studies evaluating the impact of proposed transit systems on physical activity, potentially influencing transportation planning decisions. C1 [Freeland, Amy L.] Ctr Dis Control & Prevent CDC, Epidem Intelligence Serv, Atlanta, GA USA. [Freeland, Amy L.] Ctr Dis Control & Prevent CDC, Natl Ctr Environm Hlth, Hlth Community Design Initiat, Atlanta, GA USA. [Banerjee, Shailendra N.] CDC, Natl Ctr Environm Hlth, Emergency Serv, Atlanta, GA 30333 USA. [Banerjee, Shailendra N.] CDC, Natl Ctr Environm Hlth, Environm Hlth Serv, Atlanta, GA 30333 USA. [Dannenberg, Andrew L.; Wendel, Arthur M.] CDC, Natl Ctr Environm Hlth, Hlth Community Design Initiat, Atlanta, GA 30333 USA. RP Freeland, AL (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway MS F58, Atlanta, GA 30341 USA. EM afreeland@cdc.gov NR 40 TC 26 Z9 26 U1 5 U2 26 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAR PY 2013 VL 103 IS 3 BP 536 EP 542 DI 10.2105/AJPH.2012.300912 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA0CL UT WOS:000330762600041 PM 23327281 ER PT J AU Farrelly, MC Loomis, BR Han, B Gfroerer, J Kuiper, N Couzens, GL Dube, S Caraballo, RS AF Farrelly, Matthew C. Loomis, Brett R. Han, Beth Gfroerer, Joe Kuiper, Nicole Couzens, G. Lance Dube, Shanta Caraballo, Ralph S. TI A Comprehensive Examination of the Influence of State Tobacco Control Programs and Policies on Youth Smoking SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID IMPACT; TAXES; INITIATION; PRICES AB Objectives. We examined the influence of tobacco control policies (tobacco control program expenditures, smoke-free air laws, youth access law compliance, and cigarette prices) on youth smoking outcomes (smoking susceptibility, past-year initiation, current smoking, and established smoking). Methods. We combined data from the 2002 to 2008 National Surveys on Drug Use and Health with state and municipality population data from the US Census Bureau to assess the associations between state tobacco control policy variables and youth smoking outcomes, focusing on youths aged 12 to 17 years. We also examined the influence of policy variables on youth access when these variables were held at 2002 levels. Results. Per capita funding for state tobacco control programs was negatively associated with all 4 smoking outcomes. Smoke-free air laws were negatively associated with all outcomes except past-year initiation, and cigarette prices were associated only with current smoking. We found no association between these outcomes and retailer compliance with youth access laws. Conclusions. Smoke-free air laws and state tobacco control programs are effective strategies for curbing youth smoking. C1 [Farrelly, Matthew C.; Loomis, Brett R.; Couzens, G. Lance] RTI Int, Res Triangle Pk, NC 27709 USA. [Han, Beth; Gfroerer, Joe] Subst Abuse & Mental Hlth Serv Adm, Ctr Behav Hlth Stat & Qual, Rockville, MD USA. [Kuiper, Nicole; Dube, Shanta; Caraballo, Ralph S.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. RP Farrelly, MC (reprint author), RTI Int, 3040 Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA. EM mcf@rti.org NR 30 TC 25 Z9 25 U1 0 U2 8 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAR PY 2013 VL 103 IS 3 BP 549 EP 555 DI 10.2105/AJPH.2012.300948 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA0CL UT WOS:000330762600043 PM 23327252 ER PT J AU Hawkins, NA Benard, VB Greek, A Roland, KB Manninen, D Saraiya, M AF Hawkins, Nikki A. Benard, Vicki B. Greek, April Roland, Kate B. Manninen, Diane Saraiya, Mona TI PATIENT ATTITUDES ABOUT INTRODUCING HPV TESTING INTO WELL-WOMAN EXAMS AND EXTENDING PAP INTERVALS TO 3 YEARS: FINDINGS FROM CDC'S CERVICAL CANCER (CX3) STUDY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hawkins, Nikki A.; Benard, Vicki B.; Roland, Kate B.; Saraiya, Mona] Ctr Dis Control & Prevent, Canc Prevent & Control, Atlanta, GA 30341 USA. [Greek, April; Manninen, Diane] Ctr Analyt & Publ Hlth, Seattle, WA USA. EM nhawkins@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2013 VL 45 SU 2 MA D-031 BP S265 EP S265 PG 1 WC Psychology, Multidisciplinary SC Psychology GA V47BT UT WOS:000209928002016 ER PT J AU Pinard, C Byker, C Wethington, H Smith, T Maynard, LM Yaroch, A AF Pinard, Courtney Byker, Carmen Wethington, Holly Smith, Teresa Maynard, Leah M. Yaroch, Amy TI SIPS AND SIDES: CAREGIVER ORDERING OF HEALTHIER BEVERAGES AND SIDES FOR CHILDREN AT FAST FOOD AND CHAIN RESTAURANTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Pinard, Courtney; Smith, Teresa; Yaroch, Amy] Gretchen Swanson Ctr Nutr, Omaha, NE 68105 USA. [Byker, Carmen] Montana State Univ, Dept Hlth & Human Dev, Bozeman, MT 59717 USA. [Wethington, Holly; Maynard, Leah M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. EM cpinard@centerfornutrition.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2013 VL 45 SU 2 MA D-115 BP S285 EP S285 PG 1 WC Psychology, Multidisciplinary SC Psychology GA V47BT UT WOS:000209928002093 ER PT J AU Roland, KB Benard, VB Greek, A Hawkins, NA Manninen, D Saraiya, M AF Roland, Katherine B. Benard, Vicki B. Greek, April Hawkins, Nikki A. Manninen, Diane Saraiya, Mona TI PRIMARY CARE PROVIDER ATTITUDES AND BELIEFS ABOUT THE HPV TEST AND EXTENDED CERVICAL SCREENING INTERVALS: FINDINGS FROM CDC'S CERVICAL CANCER (CX3) STUDY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Roland, Katherine B.; Benard, Vicki B.; Hawkins, Nikki A.; Saraiya, Mona] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Greek, April; Manninen, Diane] Battelle Ctr Analyt & Publ Hlth, Seattle, WA USA. EM kroland@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2013 VL 45 SU 2 MA 4053 BP S256 EP S256 PG 1 WC Psychology, Multidisciplinary SC Psychology GA V47BT UT WOS:000209928001578 ER PT J AU Smith, T Pinard, C Byker, C Wethington, H Blanck, HM Yaroch, AL AF Smith, Teresa Pinard, Courtney Byker, Carmen Wethington, Holly Blanck, Heidi M. Yaroch, Amy L. TI FRUIT AND VEGETABLES AS SNACKS IN THE HOME FOOD ENVIRONMENT: FINDINGS FROM A SURVEY OF PARENT-CHILD DYADS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Smith, Teresa; Pinard, Courtney; Yaroch, Amy L.] Gretchen Swanson Ctr Nutr, Omaha, NE USA. [Byker, Carmen] Montana State Univ, Bozeman, MT 59717 USA. [Wethington, Holly; Blanck, Heidi M.] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM tsmith@centerfornutrition.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2013 VL 45 SU 2 MA A-097 BP S26 EP S26 PG 1 WC Psychology, Multidisciplinary SC Psychology GA V47BT UT WOS:000209928000100 ER PT J AU Valverde, E Weiser, J Beer, L Fagan, J Mattson, C DiNenno, E Skarbinski, J AF Valverde, Eduardo Weiser, John Beer, Linda Fagan, Jennifer Mattson, Christine DiNenno, Elizabeth Skarbinski, Jacek TI ASSESSMENT OF MENTAL HEALTH PROBLEMS OF HIV-INFECTED PATIENTS NEW TO MEDICAL CARE, UNITED STATES - MEDICAL MONITORING PROJECT PROVIDER SURVEY, 2009 SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Valverde, Eduardo; Weiser, John; Beer, Linda; Fagan, Jennifer; Mattson, Christine; DiNenno, Elizabeth; Skarbinski, Jacek] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM fhu7@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2013 VL 45 SU 2 MA D-070 BP S274 EP S274 PG 1 WC Psychology, Multidisciplinary SC Psychology GA V47BT UT WOS:000209928002051 ER PT J AU Violanti, JM Mantsakanova, A Baughman, P Hartley, TA Fekedulegn, D Andrew, ME Burchfiel, CM AF Violanti, John M. Mantsakanova, Anna Baughman, Penelope Hartley, Tara A. Fekedulegn, Desta Andrew, Michael E. Burchfiel, Cecil M. TI POLICE STRESS AND DEPRESSIVE SYMPTOMS: POTENTIAL PROTECTIVE FACTORS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Violanti, John M.] SUNY Buffalo, Univ Buffalo, Social & Prevent Med, Buffalo, NY 14214 USA. [Mantsakanova, Anna; Hartley, Tara A.; Fekedulegn, Desta; Andrew, Michael E.; Burchfiel, Cecil M.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Morgantown, WV USA. [Baughman, Penelope] Ctr Dis Control, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM violanti@buffalo.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD MAR PY 2013 VL 45 SU 2 MA A-210 BP S52 EP S52 PG 1 WC Psychology, Multidisciplinary SC Psychology GA V47BT UT WOS:000209928000203 ER PT J AU Siddiqi, A Jordan, LB Parker, CS AF Siddiqi, Azfar-E-Alam Jordan, Lanetta B. Parker, Christopher S. TI SICKLE CELL DISEASE - THE AMERICAN SAGA SO ETHNICITY & DISEASE LA English DT Editorial Material DE Sickle Cell Disease ID RED BLOOD CORPUSCLES; CHEMICAL DIFFERENCE; ANEMIA; HYDROXYUREA; HAEMOGLOBIN; MORTALITY; US C1 [Siddiqi, Azfar-E-Alam; Parker, Christopher S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Jordan, Lanetta B.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. RP Siddiqi, A (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-64, Atlanta, GA 30333 USA. EM Asiddiqi@cdc.gov FU Intramural CDC HHS [CC999999] NR 27 TC 2 Z9 2 U1 1 U2 4 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X EI 1945-0826 J9 ETHNIC DIS JI Ethn. Dis. PD SPR PY 2013 VL 23 IS 2 BP 245 EP 248 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ7QU UT WOS:000343015100018 PM 23530308 ER PT J AU Kato, CY Mayer, RT AF Kato, Cecilia Y. Mayer, Richard T. TI Cost-effective bead-based method for high-throughput homogenization of individual small arthropods SO JOURNAL OF VECTOR BORNE DISEASES LA English DT Article DE Arthropods; biting midges; homogenization; ticks ID BLUETONGUE VIRUS; BITING MIDGES; CERATOPOGONIDAE; DIPTERA; TICKS C1 [Kato, Cecilia Y.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vector Borne Dis, Atlanta, GA 30333 USA. [Kato, Cecilia Y.; Mayer, Richard T.] ARS, Arthropod Borne Anim Dis Res Lab, USDA, Laramie, WY USA. [Mayer, Richard T.] Univ Georgia, Dept Entomol, Athens, GA 30602 USA. RP Kato, CY (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vector Borne Dis, 1600 Clifton Rd NE,MS G-13, Atlanta, GA 30333 USA. EM CKato@CDC.GOV NR 10 TC 0 Z9 0 U1 1 U2 1 PU MALARIA RESEARCH CENTRE, INDIAN COUNCIL MEDICAL RESEARCH-ICMR PI DELHI PA 22 SHAM NATH MARG, DELHI, 00000, INDIA SN 0972-9062 J9 J VECTOR DIS JI J. Vector Borne Dis. PD MAR PY 2013 VL 50 IS 1 BP 62 EP 64 PG 3 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA AN0YU UT WOS:000340310700010 PM 23703442 ER PT J AU Eberth, JM Hossain, MM Tiro, JA Zhang, XY Holt, JB Vernon, SW AF Eberth, Jan M. Hossain, Md Monir Tiro, Jasmin A. Zhang, Xingyou Holt, James B. Vernon, Sally W. TI Human Papillomavirus Vaccine Coverage Among Females Aged 11 to 17 in Texas Counties: An Application of Multilevel, Small Area Estimation SO WOMENS HEALTH ISSUES LA English DT Article ID MANAGED CARE ORGANIZATION; UNITED-STATES; HPV VACCINE; LEGISLATIVE DISTRICTS; YOUNG-WOMEN; PREVALENCE; COMPLETION; ATTITUDES; OUTCOMES; GIRLS AB Background: Local data are often used to plan and evaluate public health interventions and policy. With increasingly fewer public resources to collect sufficient data to support direct estimation of local outcomes, methods for deriving small area estimates are vital. The purpose of this study is to describe the county-level geographic distribution of human papillomavirus (HPV) vaccine coverage among adolescent females in Texas using multilevel small area estimation. Methods: Multilevel (individual, county, public health region) random-intercept logit models were fit to HPV vaccination data (>= 1 dose Gardasil) from the 2008 Behavioral Risk Factor Surveillance System. Using the parameter estimates from the final model, we simulated 10,000 data sets for each regression coefficient from the normal distribution and applied them to the logit model to estimate HPV vaccine coverage in each county. Results: County-level coverage estimates ranged from 7% to 29%, compared with the state average of 18% (95% confidence interval [CI], 13.59-21.88). Many Southwestern border and metropolitan counties exhibited high coverage estimates. Low coverage estimates were noted in the Panhandle, Southeastern border region, and Northeast. Significant correlations were observed between HPV vaccination and Hispanic ethnicity, county poverty, and public health region poverty. Conclusion: Harnessing the flexibility of multilevel small area models to estimate HPV vaccine coverage at the county level, we have provided data that may inform the development of health education programs/policies, the provision of health services, and the planning of new research studies. Additionally, we have provided a framework for modeling other health outcomes at the county level using national survey data. Copyright (C) 2013 by the Jacobs Institute of Women's Health. Published by Elsevier Inc. C1 [Eberth, Jan M.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Div Quantitat Sci, Houston, TX 77030 USA. [Hossain, Md Monir] Cincinnati Childrens Hosp Med Ctr, Div Epidemiol & Biostat, Cincinnati, OH 45229 USA. [Tiro, Jasmin A.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. [Zhang, Xingyou; Holt, James B.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA USA. [Vernon, Sally W.] Univ Texas Sch Publ Hlth, Div Hlth Promot & Behav Sci, Houston, TX USA. RP Eberth, JM (reprint author), Univ S Carolina, SC Canc Prevent & Control Program, 915 Greene St,Room 234, Columbia, SC 29208 USA. EM jmeberth@mailbox.sc.edu RI Eberth, Jan/A-1335-2014; Hossain , Md/N-5360-2015; OI Eberth, Jan/0000-0001-9500-4212; Tiro, Jasmin/0000-0001-8300-0441 FU NCI NIH HHS [P30 CA016672, CA016672, R25 CA057712, R25 CA057730, R25-CA057712, R25-CA57730] NR 32 TC 7 Z9 7 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD MAR-APR PY 2013 VL 23 IS 2 BP E131 EP E141 DI 10.1016/j.whi.2012.12.005 PG 11 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA AO1WD UT WOS:000341105300010 PM 23481692 ER PT J AU Bhatnagar, J Jones, T Blau, DM Shieh, WJ Paddock, CD Drew, C Denison, AM Rollin, DC Patel, M Zaki, SR AF Bhatnagar, Julu Jones, Tara Blau, Dianna M. Shieh, Wun-Ju Paddock, Christopher D. Drew, Clifton Denison, Amy M. Rollin, Dominique C. Patel, Mitesh Zaki, Sherif R. TI Localization of pandemic 2009 H1N1 influenza A virus RNA in lung and lymph nodes of fatal influenza cases by in situ hybridization: New insights on virus replication and pathogenesis SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Pandemic 2009 H1N1 influenza A virus; In situ hybridization; Immunohistochemistry; Pathogenesis; Formalin fixed, paraffin embedded ID A(H1N1) INFLUENZA; RESPIRATORY-TRACT; UNITED-STATES; INFECTION; PATHOLOGY; CHILDREN; H5N1; TRANSMISSION; RECEPTOR; FERRETS AB Background: Pandemic 2009 H1N1 influenza A (pH1N1) virus has caused substantial morbidity and mortality globally and continues to circulate. Although pH1N1 viral antigens have been demonstrated in various human tissues by immunohistochemistry (IHC), cellular localization of pH1N1 RNA in these tissues has largely remained uninvestigated. Objectives: To examine the distribution of pH1N1 RNA in tissues of fatal cases in order to understand the virus tissue tropism, replication and disease pathogenesis. Study design: Formalin-fixed, paraffin embedded autopsy tissues from 21 patients with confirmed pH1N1 infection were analyzed by influenza A IHC and by in situ hybridization (ISH) using DIG-labeled sense (detects viral RNA) and antisense probes (detects positive-stranded mRNA and cRNA) targeting the nucleoprotein gene of pH1N1 virus. Results: pH1N1 RNA was localized by ISH in 57% of cases while viral antigens were detected by IHC in 76%. However, in cases with a short duration of illness (1-3 days), more cases (69%) were positive by ISH than IHC (62%). Strong ISH staining was detected by antisense probes in the alveolar pneumocytes of the lungs, mucous glands and in lymph nodes. IHC staining of viral antigens was demonstrated in the lung pneumocytes and mucous glands, but no immunostaining was detected in any of the lymph nodes examined. Conclusions: This study demonstrates cellular localization of positive-stranded pH1N1 RNA in the lungs, mucous glands and lymph nodes that suggests viral replication in these tissues. The novel ISH assay can be a useful adjunct for the detection of pH1N1 virus in tissues and for pathogenesis studies. Published by Elsevier B.V. C1 [Bhatnagar, Julu; Jones, Tara; Blau, Dianna M.; Shieh, Wun-Ju; Paddock, Christopher D.; Drew, Clifton; Denison, Amy M.; Rollin, Dominique C.; Patel, Mitesh; Zaki, Sherif R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Bhatnagar, J (reprint author), Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,Mailstop G32, Atlanta, GA 30333 USA. EM JBhatnagar@cdc.gov OI Denison, Amy/0000-0002-2163-3849 NR 35 TC 8 Z9 8 U1 0 U2 35 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD MAR PY 2013 VL 56 IS 3 BP 232 EP 237 DI 10.1016/j.jcv.2012.11.014 PG 6 WC Virology SC Virology GA 077IZ UT WOS:000314022500009 PM 23246358 ER PT J AU Halldin, CN Suarthana, E Fedan, KB Lo, YC Turabelidze, G Kreiss, K AF Halldin, Cara N. Suarthana, Eva Fedan, Kathleen B. Lo, Yi-Chun Turabelidze, George Kreiss, Kathleen TI Increased Respiratory Disease Mortality at a Microwave Popcorn Production Facility with Worker Risk of Bronchiolitis Obliterans SO PLOS ONE LA English DT Article ID TABLE ANALYSIS SYSTEM; DIACETYL; HEALTH; PLANT; RATS; POPULATION; FLAVORINGS; EXPOSURE; VAPORS AB Background: Bronchiolitis obliterans, an irreversible lung disease, was first associated with inhalation of butter flavorings (diacetyl) in workers at a microwave popcorn company. Excess rates of lung-function abnormalities were related to cumulative diacetyl exposure. Because information on potential excess mortality would support development of permissible exposure limits for diacetyl, we investigated respiratory-associated mortality during 2000-2011 among current and former workers at this company who had exposure to flavorings and participated in cross-sectional surveys conducted between 2000-2003. Methods: We ascertained workers' vital status through a Social Security Administration search. Causes of death were abstracted from death certificates. Because bronchiolitis obliterans is not coded in the International Classification of Disease 10th revision (ICD-10), we identified respiratory mortality decedents with ICD-10 codes J40-J44 which encompass bronchitis (J40), simple and mucopurulent chronic bronchitis (J41), unspecified chronic bronchitis (J42), emphysema (J43), and other chronic obstructive pulmonary disease (COPD) (J44). We calculated expected number of deaths and standardized mortality ratios (SMRs) with 95% confidence intervals (CI) to determine if workers exposed to diacetyl experienced greater respiratory mortality than expected. Results: We identified 15 deaths among 511 workers. Based on U. S. population estimates, 17.39 deaths were expected among these workers (SMR = 0.86; CI: 0.48-1.42). Causes of death were available for 14 decedents. Four deaths among production and flavor mixing workers were documented to have a multiple cause of 'other COPD' (J44), while 0.98 'other COPD'-associated deaths were expected (SMR = 4.10; CI: 1.12-10.49). Three of the 4 'other COPD'-associated deaths occurred among former workers and workers employed before the company implemented interventions reducing diacetyl exposure in 2001. Conclusion: Workers at the microwave popcorn company experienced normal rates of all-cause mortality but higher rates of COPD-associated mortality, especially workers employed before the company reduced diacetyl exposure. The demonstrated excess in COPD-associated mortality suggests continued efforts to lower flavoring exposure are prudent. C1 [Halldin, Cara N.; Suarthana, Eva; Lo, Yi-Chun] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Atlanta, GA 30333 USA. [Halldin, Cara N.; Suarthana, Eva; Fedan, Kathleen B.; Kreiss, Kathleen] NIOSH, Div Resp Dis Studies, Morgantown, WV 26505 USA. [Lo, Yi-Chun; Turabelidze, George] Missouri Dept Hlth & Senior Serv, Jefferson City, MO USA. RP Halldin, CN (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Atlanta, GA 30333 USA. EM vgx5@cdc.gov OI Halldin, Cara/0000-0002-8050-8407 FU Centers for Disease Control (CDC); National Institute for Occupational Safety and Health (NIOSH); Missouri Department of Health & Senior Services FX The Centers for Disease Control (CDC), National Institute for Occupational Safety and Health (NIOSH), and Missouri Department of Health & Senior Services supported the salaries of the authors, and no other funding was obtained. This work was performed by State and Federal Government employees as part of their work; no non-governmental funding supported this work. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of NIOSH or the CDC. NR 31 TC 7 Z9 7 U1 2 U2 23 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 28 PY 2013 VL 8 IS 2 AR e57935 DI 10.1371/journal.pone.0057935 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 098DA UT WOS:000315524900204 PM 23469109 ER PT J AU Davey, RT Lynfield, R Dwyer, DE Losso, MH Cozzi-Lepri, A Wentworth, D Lane, HC Dewar, R Rupert, A Metcalf, JA Pett, SL Uyeki, TM Bruguera, JM Angus, B Cummins, N Lundgren, J Neaton, JD AF Davey, Richard T., Jr. Lynfield, Ruth Dwyer, Dominic E. Losso, Marcello H. Cozzi-Lepri, Alessandro Wentworth, Deborah Lane, H. Clifford Dewar, Robin Rupert, Adam Metcalf, Julia A. Pett, Sarah L. Uyeki, Timothy M. Maria Bruguera, Jose Angus, Brian Cummins, Nathan Lundgren, Jens Neaton, James D. CA Insight FLU 002 Study Grp Insight FLU 003 Study Grp TI The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies SO PLOS ONE LA English DT Article ID PANDEMIC H1N1 2009; CYTOKINE RESPONSE; SEVERE PNEUMONIA; SURVEILLANCE; PATHOGENESIS; ILLNESS AB Background: Prospective studies establishing the temporal relationship between the degree of inflammation and human influenza disease progression are scarce. To assess predictors of disease progression among patients with influenza A(H1N1)pdm09 infection, 25 inflammatory biomarkers measured at enrollment were analyzed in two international observational cohort studies. Methods: Among patients with RT-PCR-confirmed influenza A(H1N1) pdm09 virus infection, odds ratios (ORs) estimated by logistic regression were used to summarize the associations of biomarkers measured at enrollment with worsened disease outcome or death after 14 days of follow-up for those seeking outpatient care (FLU 002) or after 60 days for those hospitalized with influenza complications (FLU 003). Biomarkers that were significantly associated with progression in both studies (p<0.05) or only in one (p<0.002 after Bonferroni correction) were identified. Results: In FLU 002 28/528 (5.3%) outpatients had influenza A(H1N1) pdm09 virus infection that progressed to a study endpoint of complications, hospitalization or death, whereas in FLU 003 28/170 (16.5%) inpatients enrolled from the general ward and 21/39 (53.8%) inpatients enrolled directly from the ICU experienced disease progression. Higher levels of 12 of the 25 markers were significantly associated with subsequent disease progression. Of these, 7 markers (IL-6, CD163, IL-10, LBP, IL-2, MCP-1, and IP-10), all with ORs for the 3rd versus 1st tertile of 2.5 or greater, were significant (p<0.05) in both outpatients and inpatients. In contrast, five markers (sICAM-1, IL-8, TNF-alpha, D-dimer, and sVCAM-1), all with ORs for the 3rd versus 1st tertile greater than 3.2, were significantly (p <=.002) associated with disease progression among hospitalized patients only. Conclusions: In patients presenting with varying severities of influenza A(H1N1)pdm09 virus infection, a baseline elevation in several biomarkers associated with inflammation, coagulation, or immune function strongly predicted a higher risk of disease progression. It is conceivable that interventions designed to abrogate these baseline elevations might affect disease outcome. C1 [Davey, Richard T., Jr.; Lane, H. Clifford; Metcalf, Julia A.] NIAID, NIH, Bethesda, MD 20892 USA. [Lynfield, Ruth] Minnesota Dept Hlth, Div Infect Dis, St Paul, MN USA. [Dwyer, Dominic E.] Westmead Hosp, Dept Virol, Ctr Infect Dis & Microbiol, Westmead, NSW 2145, Australia. [Dwyer, Dominic E.] Univ Sydney, Westmead, NSW 2145, Australia. [Losso, Marcello H.] Hosp Jose Maria Ramos Mejia, Dept Med, HIV Unit, Buenos Aires, DF, Argentina. [Cozzi-Lepri, Alessandro] UCL, Res Dept Infect & Populat Hlth, London, England. [Wentworth, Deborah; Neaton, James D.] Univ Minnesota, Div Biostat, Minneapolis, MN USA. [Dewar, Robin] SAIC Frederick Inc, Frederick Natl Lab, Virus Isolat & Serol Lab, Frederick, MD USA. [Rupert, Adam] SAIC Frederick Inc, AIDS Monitoring Lab, Frederick, MD USA. [Pett, Sarah L.] Univ New S Wales, Fac Med, Kirby Inst, Sydney, NSW, Australia. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Maria Bruguera, Jose] Hosp Jose Maria Ramos Mejia, Serv Inmunocomprometidos, Buenos Aires, DF, Argentina. [Angus, Brian] Univ Oxford, Nuffield Dept Med, Oxford, England. [Cummins, Nathan] Mayo Clin, Div Infect Dis, Rochester, MN USA. [Lundgren, Jens] Rigshosp, Copenhagen Univ Hosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark. [Lundgren, Jens] Univ Copenhagen, Copenhagen, Denmark. RP Davey, RT (reprint author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. EM rdavey@niaid.nih.gov RI Burgmann, Heinz/N-2409-2013; Emery, Sean/H-4920-2013; OI Emery, Sean/0000-0001-6072-8309; Lundgren, Jens/0000-0001-8901-7850; Angus, Brian/0000-0003-3598-7784 FU United States National Institutes of Health [UOI-AI068641]; SAIC-Frederick, Inc., NCI-Frederick, Maryland [HHSN261200800001E] FX INSIGHT is funded by United States National Institutes of Health Grant UOI-AI068641, and the FLU 002 and FLU 003 studies are partially funded by SAIC-Frederick, Inc., Prime Contract HHSN261200800001E, NCI-Frederick, Maryland 21702. Disclosure: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 11 Z9 11 U1 0 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 27 PY 2013 VL 8 IS 2 AR e57121 DI 10.1371/journal.pone.0057121 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 098BN UT WOS:000315519000064 PM 23468921 ER PT J AU Fuller, JA Summers, A Katz, MA Lindblade, KA Njuguna, H Arvelo, W Khagayi, S Emukule, G Linares-Perez, N McCracken, J Nokes, DJ Ngama, M Kazungu, S Mott, JA Olsen, SJ Widdowson, MA Feikin, DR AF Fuller, James A. Summers, Aimee Katz, Mark A. Lindblade, Kim A. Njuguna, Henry Arvelo, Wences Khagayi, Sammy Emukule, Gideon Linares-Perez, Nivaldo McCracken, John Nokes, D. James Ngama, Mwanajuma Kazungu, Sidi Mott, Joshua A. Olsen, Sonja J. Widdowson, Marc-Alain Feikin, Daniel R. TI Estimation of the National Disease Burden of Influenza-Associated Severe Acute Respiratory Illness in Kenya and Guatemala: A Novel Methodology SO PLOS ONE LA English DT Article ID RURAL WESTERN KENYA; A H1N1 VIRUS; DEMOGRAPHIC SURVEILLANCE; SEASONAL INFLUENZA; PNEUMONIA; MORTALITY; HEALTH; CHILDREN; CARE; HOSPITALIZATIONS AB Background: Knowing the national disease burden of severe influenza in low-income countries can inform policy decisions around influenza treatment and prevention. We present a novel methodology using locally generated data for estimating this burden. Methods and Findings: This method begins with calculating the hospitalized severe acute respiratory illness (SARI) incidence for children <5 years old and persons >= 5 years old from population-based surveillance in one province. This base rate of SARI is then adjusted for each province based on the prevalence of risk factors and healthcare-seeking behavior. The percentage of SARI with influenza virus detected is determined from provincial-level sentinel surveillance and applied to the adjusted provincial rates of hospitalized SARI. Healthcare-seeking data from healthcare utilization surveys is used to estimate non-hospitalized influenza-associated SARI. Rates of hospitalized and non-hospitalized influenza-associated SARI are applied to census data to calculate the national number of cases. The method was field-tested in Kenya, and validated in Guatemala, using data from August 2009-July 2011. In Kenya (2009 population 38.6 million persons), the annual number of hospitalized influenza-associated SARI cases ranged from 17,129-27,659 for children <5 years old (2.9-4.7 per 1,000 persons) and 6,882-7,836 for persons >= 5 years old (0.21-0.24 per 1,000 persons), depending on year and base rate used. In Guatemala (2011 population 14.7 million persons), the annual number of hospitalized cases of influenza-associated pneumonia ranged from 1,065-2,259 (0.5-1.0 per 1,000 persons) among children <5 years old and 779-2,252 cases (0.1-0.2 per 1,000 persons) for persons >= 5 years old, depending on year and base rate used. In both countries, the number of non-hospitalized influenza-associated cases was several-fold higher than the hospitalized cases. Conclusions: Influenza virus was associated with a substantial amount of severe disease in Kenya and Guatemala. This method can be performed in most low and lower-middle income countries. C1 [Fuller, James A.; Summers, Aimee; Feikin, Daniel R.] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Int Hlth, Baltimore, MD 21205 USA. [Katz, Mark A.; Njuguna, Henry; Khagayi, Sammy; Emukule, Gideon; Mott, Joshua A.] Ctr Dis Control & Prevent Publ Hlth Collaborat, Kenya Med Res Inst, Nairobi, Kenya. [Katz, Mark A.; Njuguna, Henry; Khagayi, Sammy; Emukule, Gideon; Mott, Joshua A.] Ctr Dis Control & Prevent Publ Hlth Collaborat, Kenya Med Res Inst, Kisumu, Kenya. [Katz, Mark A.; Linares-Perez, Nivaldo; Mott, Joshua A.; Olsen, Sonja J.; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Lindblade, Kim A.; Arvelo, Wences] Ctr Dis Control & Prevent, Div Global Dis Detect & Emergency Response, Ctr Global Hlth, Atlanta, GA USA. [Lindblade, Kim A.; Arvelo, Wences] Ctr Dis Control & Prevent, Reg Off Cent Amer & Panama, Guatemala City, Guatemala. [Linares-Perez, Nivaldo] Ctr Dis Control & Prevent, Influenza Program, Reg Off Cent Amer, Guatemala City, Guatemala. [McCracken, John] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala. [Nokes, D. James; Ngama, Mwanajuma; Kazungu, Sidi] Ctr Geog Med Res Coast, Kenya Med Res Inst, Kilifi, Kenya. [Nokes, D. James] Univ Warwick, Sch Life Sci, Coventry CV4 7AL, W Midlands, England. [Feikin, Daniel R.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Atlanta, GA USA. RP Feikin, DR (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Int Hlth, Baltimore, MD 21205 USA. EM dfeikin@jhsph.edu OI Fuller, James/0000-0003-4020-3665; Widdowson, Marc-Alain/0000-0002-0682-6933 FU Centers for Disease Control and Prevention [UO1 GH000028-02]; Centers for Disease Control and Prevention; Wellcome Trust [084633, 077092] FX Work in Guatemala was supported by Cooperative Agreement UO1 GH000028-02 from the Centers for Disease Control and Prevention (http://www.cdc.gov/). Work in Kenya was supported by the Centers for Disease Control and Prevention and by the Wellcome Trust (http://www.wellcome.ac.uk/) [084633], [077092]. These funders had no role in they study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 47 TC 12 Z9 12 U1 1 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 27 PY 2013 VL 8 IS 2 AR e56882 DI 10.1371/journal.pone.0056882 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 098BN UT WOS:000315519000041 PM 23573177 ER PT J AU Noti, JD Blachere, FM McMillen, CM Lindsley, WG Kashon, ML Slaughter, DR Beezhold, DH AF Noti, John D. Blachere, Francoise M. McMillen, Cynthia M. Lindsley, William G. Kashon, Michael L. Slaughter, Denzil R. Beezhold, Donald H. TI High Humidity Leads to Loss of Infectious Influenza Virus from Simulated Coughs SO PLOS ONE LA English DT Article ID RELATIVE-HUMIDITY; EXAMINATION ROOM; TRANSMISSION; SURVIVAL; AEROSOLS; TEMPERATURE; VENTILATION; DISPERSION; EXPOSURE AB Background: The role of relative humidity in the aerosol transmission of influenza was examined in a simulated examination room containing coughing and breathing manikins. Methods: Nebulized influenza was coughed into the examination room and Bioaerosol samplers collected size-fractionated aerosols (<1 mu M, 1-4 mu M, and >4 mu M aerodynamic diameters) adjacent to the breathing manikin's mouth and also at other locations within the room. At constant temperature, the RH was varied from 7-73% and infectivity was assessed by the viral plaque assay. Results: Total virus collected for 60 minutes retained 70.6-77.3% infectivity at relative humidity <= 23% but only 14.6-22.2% at relative humidity >= 43%. Analysis of the individual aerosol fractions showed a similar loss in infectivity among the fractions. Time interval analysis showed that most of the loss in infectivity within each aerosol fraction occurred 0-15 minutes after coughing. Thereafter, losses in infectivity continued up to 5 hours after coughing, however, the rate of decline at 45% relative humidity was not statistically different than that at 20% regardless of the aerosol fraction analyzed. Conclusion: At low relative humidity, influenza retains maximal infectivity and inactivation of the virus at higher relative humidity occurs rapidly after coughing. Although virus carried on aerosol particles,4 mM have the potential for remaining suspended in air currents longer and traveling further distances than those on larger particles, their rapid inactivation at high humidity tempers this concern. Maintaining indoor relative humidity >40% will significantly reduce the infectivity of aerosolized virus. C1 [Noti, John D.; Blachere, Francoise M.; McMillen, Cynthia M.; Lindsley, William G.; Kashon, Michael L.; Slaughter, Denzil R.; Beezhold, Donald H.] NIOSH, HELD, Ctr Dis Control & Prevent CDC, Morgantown, WV USA. [McMillen, Cynthia M.] W Virginia Univ, Sch Med, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA. RP Noti, JD (reprint author), NIOSH, HELD, Ctr Dis Control & Prevent CDC, Morgantown, WV USA. EM ivr2@cdc.gov OI Lindsley, William/0000-0003-0720-5829 FU National Institute for Occupational Safety and Health; Centers for Disease Control and Prevention FX This work was supported by the National Institute for Occupational Safety and Health and the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 34 TC 15 Z9 15 U1 3 U2 23 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 27 PY 2013 VL 8 IS 2 AR e57485 DI 10.1371/journal.pone.0057485 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 098BN UT WOS:000315519000120 PM 23460865 ER PT J AU Podnecky, NL Elrod, MG Newton, BR Dauphin, LA Shi, JR Chawalchitiporn, S Baggett, HC Hoffmaster, AR Gee, JE AF Podnecky, Nicole L. Elrod, Mindy G. Newton, Bruce R. Dauphin, Leslie A. Shi, Jianrong Chawalchitiporn, Sutthinan Baggett, Henry C. Hoffmaster, Alex R. Gee, Jay E. TI Comparison of DNA Extraction Kits for Detection of Burkholderia pseudomallei in Spiked Human Whole Blood Using Real-Time PCR SO PLOS ONE LA English DT Article ID POLYMERASE-CHAIN-REACTION; III SECRETION SYSTEM; CLINICAL SPECIMENS; SEPTICEMIC MELIOIDOSIS; ENVIRONMENTAL-SAMPLES; NORTHERN AUSTRALIA; BACILLUS-ANTHRACIS; IDENTIFICATION; ASSAY; HYBRIDIZATION AB Burkholderia pseudomallei, the etiologic agent of melioidosis, is endemic in northern Australia and Southeast Asia and can cause severe septicemia that may lead to death in 20% to 50% of cases. Rapid detection of B. pseudomallei infection is crucial for timely treatment of septic patients. This study evaluated seven commercially available DNA extraction kits to determine the relative recovery of B. pseudomallei DNA from spiked EDTA-containing human whole blood. The evaluation included three manual kits: the QIAamp DNA Mini kit, the QIAamp DNA Blood Mini kit, and the High Pure PCR Template Preparation kit; and four automated systems: the MagNAPure LC using the DNA Isolation Kit I, the MagNAPure Compact using the Nucleic Acid Isolation Kit I, and the QIAcube using the QIAamp DNA Mini kit and the QIAamp DNA Blood Mini kit. Detection of B. pseudomallei DNA extracted by each kit was performed using the B. pseudomallei specific type III secretion real-time PCR (TTS1) assay. Crossing threshold (C-T) values were used to compare the limit of detection and reproducibility of each kit. This study also compared the DNA concentrations and DNA purity yielded for each kit. The following kits consistently yielded DNA that produced a detectable signal from blood spiked with 5.5x10(4) colony forming units per mL: the High Pure PCR Template Preparation, QIAamp DNA Mini, MagNA Pure Compact, and the QIAcube running the QIAamp DNA Mini and QIAamp DNA Blood Mini kits. The High Pure PCR Template Preparation kit yielded the lowest limit of detection with spiked blood, but when this kit was used with blood from patients with confirmed cases of melioidosis, the bacteria was not reliably detected indicating blood may not be an optimal specimen. C1 [Podnecky, Nicole L.; Elrod, Mindy G.; Hoffmaster, Alex R.; Gee, Jay E.] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Newton, Bruce R.; Dauphin, Leslie A.] Ctr Dis Control & Prevent, Bioterrorism Rapid Response & Adv Technol Lab, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Shi, Jianrong] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Chawalchitiporn, Sutthinan] Nakhon Phanom Prov Hlth Off, Nakhon Phanom, Thailand. [Baggett, Henry C.] Thailand Minist Publ Hlth US Ctr Dis Control & Pr, Int Emerging Infect Program, Global Dis Detect Reg Ctr, Nonthaburi, Thailand. RP Gee, JE (reprint author), Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM xzg4@cdc.gov OI Podnecky, Nicole L./0000-0002-1745-934X FU Centers for Disease Control and Prevention; Emerging Infectious Disease Fellowship Program FX Nicole Podnecky was supported by the Emerging Infectious Disease Fellowship Program administered by the Association of Public Health Laboratories and funded by the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 33 TC 7 Z9 7 U1 0 U2 32 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 27 PY 2013 VL 8 IS 2 AR e58032 DI 10.1371/journal.pone.0058032 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 098BN UT WOS:000315519000175 PM 23460920 ER PT J AU Van Sickle, D Magzamen, S Truelove, S Morrison, T AF Van Sickle, David Magzamen, Sheryl Truelove, Shaun Morrison, Teresa TI Remote Monitoring of Inhaled Bronchodilator Use and Weekly Feedback about Asthma Management: An Open-Group, Short-Term Pilot Study of the Impact on Asthma Control SO PLOS ONE LA English DT Article ID CHILDHOOD ASTHMA; TRIAL AB Objective: Adequate symptom control is a problem for many people with asthma. We asked whether weekly email reports on monitored use of inhaled, short-acting bronchodilators might improve scores on composite asthma-control measures. Methods: Through an investigational electronic medication sensor attached to each participant's inhaler, we monitored 4 months' use of inhaled, short-acting bronchodilators. Participants completed surveys, including the Asthma Control Test (TM) (ACT), to assess asthma control at entry and monthly thereafter. After the first month, participants received weekly email reports for 3 months. The reports summarized inhaled bronchodilator use during the preceding week and provided suggestions derived from National Asthma Education and Prevention Program (NAEPP) guidelines. Paired t-tests and random-effects mixed models were implemented to assess changes in primary asthma endpoints. Results: Thirty individuals participated in the 4-month study; 29 provided complete asthma control information. Mean age was 36.8 years (range: 19-74 years); 52% of respondents were female. Mean ACT scores were 17.6 (Standard Deviation [SD] = 3.35) at entry and 18.4 (SD = 3.60) at completion of the first month. No significant difference appeared between ACT values at entry and completion of the first month (p = 0.66); however, after participants began receiving email reports and online information about their inhaler use, mean ACT scores increased 1.40 points (95% CI: 0.61, 2.18) for each subsequent study month. Significant decreases occurred in 2-week histories of daytime symptoms (beta = -1.35, 95% CI: -2.65, -0.04) and nighttime symptoms (beta = -0.84, 95% CI: -1.25, -0.44); no significant change in activity limitation (beta = -0.21, 95% CI: -0.69, 0.26) was observed. Participants reported increased awareness and understanding of asthma patterns, level of control, bronchodilator use (timing, location) and triggers, and improved preventive practices. Conclusions: Weekly email reports and access to online charts summarizing remote monitoring of inhaled bronchodilator frequency and location were associated with improved asthma control and a decline in day-to-day asthma symptoms. C1 [Van Sickle, David; Magzamen, Sheryl; Truelove, Shaun] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Morrison, Teresa] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Van Sickle, D (reprint author), Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI 53706 USA. EM dvansickle@gmail.com FU Robert Wood Johnson Foundation Health and Society Scholars Program; US Centers for Disease Control and Prevention FX The project was supported by the Robert Wood Johnson Foundation Health and Society Scholars Program (http://www.healthandsocietyscholars.org) and the US Centers for Disease Control and Prevention (http://cdc.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 16 TC 13 Z9 15 U1 2 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 27 PY 2013 VL 8 IS 2 AR e55335 DI 10.1371/journal.pone.0055335 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 098BN UT WOS:000315519000008 PM 23460785 ER PT J AU Chang, SJ O'Connor, PM Slade, BA Woo, EJ AF Chang, Soju O'Connor, Patrick M. Slade, Barbara A. Woo, Emily Jane TI U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007 SO VACCINE LA English DT Article DE Tetanus toxoid; Reduced diphtheria toxoid and acellular pertussis (Tdap) vaccines; VAERS; Postlicensure safety ID REPORTING-SYSTEM VAERS; UNITED-STATES; BELLS-PALSY; VACCINATION; IMMUNIZATION; RISK; MYOPERICARDITIS; MYOCARDITIS; CHILDREN; SYNCOPE AB Background: Pre-licensure clinical trials for two U.S. licensed tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccines did not reveal any major safety concerns. However, routine use in large adolescent and adult populations could reveal rare and potentially serious adverse events (AEs). Methods: To characterize reported AEs following Tdap vaccination and identify potential safety concerns warranting further evaluation, we analyzed data from the Vaccine Adverse Event Reporting System (VAERS) and assessed the frequency and proportions of AEs and reporting rates (reports per 100,000 vaccine doses distributed). Results: A total of 2090 reports (7% were serious; 55% listed Tdap alone) involving Tdap vaccines were submitted to VAERS May 2005-June 2007. The crude reporting rate was 10.2 per 100,000 vaccine doses distributed. The median age of vaccinees was 22 years, and the female to male ratio was about 2 to 1. The majority of reports described common local and systemic signs and symptoms, such as injection site reactions, fever, and headache. Rarely reported AEs included myopericarditis, demyelinating diseases of the central nervous system, Guillain-Barre Syndrome, syncope, encephalopathy/encephalitis, seizure, Bell's palsy, anaphylaxis, and thrombocytopenia. Conclusions: Because adolescents and adults were not routinely vaccinated against pertussis in the past, this surveillance summary provides important - and reassuring - information about the use of Tdap in these age groups. Although subject to the limitations of passive surveillance, the findings of this VAERS review support the pre-licensure clinical trial data with regard to the safety of the U.S. licensed Tdap vaccines. Continued monitoring of clinically significant AEs that are temporally associated with Tdap vaccination and further assessment of such events using controlled observational studies may provide additional information about the safety of these vaccines. Published by Elsevier Ltd. C1 [Chang, Soju; Woo, Emily Jane] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA. [O'Connor, Patrick M.] Gen Prevent Med Residency Program, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Slade, Barbara A.] US Ctr Dis Control & Prevent CDC, Immunizat Safety Off, Div Healthcare Qual Promot, Atlanta, GA USA. RP Chang, SJ (reprint author), US FDA, Div Epidemiol, Off Biostat & Epidemiol, Ctr Biol Res & Evaluat, 1401 Rockville Pike,HFM-222, Rockville, MD 20852 USA. EM soju.chang@nih.hhs.gov NR 29 TC 12 Z9 12 U1 0 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD FEB 27 PY 2013 VL 31 IS 10 BP 1447 EP 1452 DI 10.1016/j.vaccine.2012.10.097 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 098HM UT WOS:000315540000016 PM 23142308 ER PT J AU Wheaton, AG Chapman, DP Presley-Cantrell, LR Croft, JB Roehler, DR AF Wheaton, Anne G. Chapman, Daniel P. Presley-Cantrell, Letitia R. Croft, Janet B. Roehler, Douglas R. TI Drowsy Driving-19 States and the District of Columbia, 2009-2010 (Reprinted from MMWR, vol 51, pg 1033-1037, 2013) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID CRASHES; DRIVER C1 [Wheaton, Anne G.; Chapman, Daniel P.; Presley-Cantrell, Letitia R.; Croft, Janet B.] Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA. [Roehler, Douglas R.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Wheaton, AG (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA. EM awheaton@cdc.gov NR 11 TC 0 Z9 0 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 27 PY 2013 VL 309 IS 8 BP 760 EP 762 DI 10.1001/jama.2013.105 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 095KD UT WOS:000315332200007 ER PT J AU Clark, H Hall, I Tang, T Harris, S Johnson, AS Prejean, J AF Clark, Hollie Hall, Irene Tang, Tian Harris, Shericka Johnson, Anna Satcher Prejean, Joseph TI HIV Infections Attributed to Male-to-Male Sexual Contact-Metropolitan Statistical Areas, United States and Puerto Rico, 2010 (Reprinted from MMWR, vol 47, pg 962-966, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Clark, Hollie; Hall, Irene; Tang, Tian; Harris, Shericka; Johnson, Anna Satcher; Prejean, Joseph] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Clark, H (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM hclark@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 27 PY 2013 VL 309 IS 8 BP 762 EP 764 DI 10.1001/jama.2012.165274 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 095KD UT WOS:000315332200008 ER PT J AU Kidder, DP Bachanas, P Medley, A Pals, S Nuwagaba-Biribonwoha, H Ackers, M Howard, A DeLuca, N Mbatia, R Sheriff, M Arthur, G Katuta, F Cherutich, P Somi, G AF Kidder, Daniel P. Bachanas, Pam Medley, Amy Pals, Sherri Nuwagaba-Biribonwoha, Harriet Ackers, Marta Howard, Andrea DeLuca, Nick Mbatia, Redempta Sheriff, Muhsin Arthur, Gilly Katuta, Frieda Cherutich, Peter Somi, Geoffrey CA PwP Evaluation Study Team TI HIV Prevention in Care and Treatment Settings: Baseline Risk Behaviors among HIV Patients in Kenya, Namibia, and Tanzania SO PLOS ONE LA English DT Article ID SUB-SAHARAN AFRICA; ACTIVE ANTIRETROVIRAL THERAPY; SELF-REPORTED ADHERENCE; ALCOHOL-CONSUMPTION; PROSPECTIVE COHORT; INFECTED ADULTS; VIRAL LOAD; TRANSMISSION; UGANDA; METAANALYSIS AB HIV care and treatment settings provide an opportunity to reach people living with HIV/AIDS (PLHIV) with prevention messages and services. Population-based surveys in sub-Saharan Africa have identified HIV risk behaviors among PLHIV, yet data are limited regarding HIV risk behaviors of PLHIV in clinical care. This paper describes the baseline sociodemographic, HIV transmission risk behaviors, and clinical data of a study evaluating an HIV prevention intervention package for HIV care and treatment clinics in Africa. The study was a longitudinal group-randomized trial in 9 intervention clinics and 9 comparison clinics in Kenya, Namibia, and Tanzania (N = 3538). Baseline participants were mostly female, married, had less than a primary education, and were relatively recently diagnosed with HIV. Fifty-two percent of participants had a partner of negative or unknown status, 24% were not using condoms consistently, and 11% reported STI symptoms in the last 6 months. There were differences in demographic and HIV transmission risk variables by country, indicating the need to consider local context in designing studies and using caution when generalizing findings across African countries. Baseline data from this study indicate that participants were often engaging in HIV transmission risk behaviors, which supports the need for prevention with PLHIV (PwP). C1 [Kidder, Daniel P.; Bachanas, Pam; Medley, Amy; Pals, Sherri] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30329 USA. [Nuwagaba-Biribonwoha, Harriet; Howard, Andrea] ICAP Columbia Univ, New York, NY USA. [Ackers, Marta] Ctr Dis Control & Prevent, Nairobi, Kenya. [DeLuca, Nick] Ctr Dis Control & Prevent, Windhoek, Namibia. [Mbatia, Redempta] ICAP Columbia Univ, Dar Es Salaam, Tanzania. [Sheriff, Muhsin] ICAP Columbia Univ, Nairobi, Kenya. [Arthur, Gilly] Ctr Dis Control & Prevent, Dar Es Salaam, Tanzania. [Katuta, Frieda] Minist Hlth & Social Serv, Windhoek, Namibia. [Cherutich, Peter] Minist Hlth, Nairobi, Kenya. [Somi, Geoffrey] Minist Hlth, Dar Es Salaam, Tanzania. RP Kidder, DP (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30329 USA. EM dkidder@cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR) FX This study was funded by the President's Emergency Plan for AIDS Relief (PEPFAR), www.pepfar.gov. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 48 TC 11 Z9 11 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 25 PY 2013 VL 8 IS 2 AR e57215 DI 10.1371/journal.pone.0057215 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 115ZB UT WOS:000316849500079 PM 23459196 ER PT J AU Liu, JM Mei, ZG Ye, RW Serdula, MK Ren, AG Cogswell, ME AF Liu, Jian-meng Mei, Zuguo Ye, Rongwei Serdula, Mary K. Ren, Aiguo Cogswell, Mary E. TI Micronutrient Supplementation and Pregnancy Outcomes Double-Blind Randomized Controlled Trial in China SO JAMA INTERNAL MEDICINE LA English DT Article ID LOW-INCOME COUNTRIES; IRON SUPPLEMENTATION; PERINATAL-MORTALITY; BIRTH-WEIGHT; FOLIC-ACID; FETAL LOSS; METAANALYSIS; WOMEN; ANEMIA; GESTATION AB Background: Beyond perinatal folic acid supplementation, the need for additional prenatal prophylaxis of iron with or without other micronutrients remains unclear. We aim to investigate the maternal and infant health effects of iron plus folic acid and multiple micronutrient supplements vs folic acid alone when provided to pregnant women with no or mild anemia. Methods: In this randomized double-blind controlled trial, 18 775 nulliparous pregnant women with mild or no anemia were enrolled from 5 counties of northern China from May 2006 through April 2009. Women were randomly assigned to daily folic acid (400 mu g) (control), folic acid-iron (30 mg), or folic acid, iron, and 13 additional vitamins and minerals provided before 20 weeks gestation to delivery. Primary outcome was perinatal mortality. Secondary outcomes included neonatal and infant mortality, preterm delivery, birth weight, birth length, gestational duration, and maternal hemoglobin concentration and anemia. Results: A total of 92.7% of women consumed 80% to 100% of supplements as instructed. On average, women consumed 177 supplements. Compared with daily prenatal folic acid, supplementation with iron-folic acid with or without other micronutrients did not affect the rate of perinatal mortality (8.8, 8.7, and 8.3, respectively) per 1000 births, and relative risks (RRs) were 1.00 (95% CI, 0.68-1.46; P=.99) and 0.94(95% CI, 0.64-1.39; P=.76), respectively. Risk of other adverse maternal and infant outcomes also did not differ, except that RRs for third-trimester maternal anemia were 0.72(95% CI, 0.63-0.83; P < .001) and 0.71(95% CI, 0.62-0.82; P < .001), respectively. Conclusion: Prenatal iron-folic acid and other micronutrient supplements provided to Chinese women with no or mild anemia prevented later pregnancy anemia beyond any benefit conferred by folic acid alone but did not affect perinatal mortality or other infant outcomes. Trial Registration: clinicaltrials.gov Identifier: NCT00133744 C1 [Liu, Jian-meng; Ye, Rongwei; Ren, Aiguo] Peking Univ, Hlth Sci Ctr, Inst Reprod & Child Hlth, Minist Hlth,Key Lab Reprod Hlth, Beijing 100191, Peoples R China. [Liu, Jian-meng; Ye, Rongwei; Ren, Aiguo] Peking Univ, Hlth Sci Ctr, Dept Epidemiol & Biostat, Sch Publ Hlth, Beijing 100191, Peoples R China. [Mei, Zuguo; Serdula, Mary K.; Cogswell, Mary E.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Liu, JM (reprint author), Peking Univ, Hlth Sci Ctr, Dept Epidemiol, Inst Reprod & Child Hlth, 38 Coll Rd, Beijing 100191, Peoples R China. EM liujm@pku.edu.cn RI Ren, Aiguo/B-1181-2008 OI Ren, Aiguo/0000-0001-9115-5638 FU Peking University Health Science Center; Centers for Disease Control and Prevention FX The study is supported by a cooperative agreement between Peking University Health Science Center and the Centers for Disease Control and Prevention. NR 41 TC 15 Z9 17 U1 1 U2 17 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB 25 PY 2013 VL 173 IS 4 BP 276 EP 282 DI 10.1001/jamainternmed.2013.1632 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 153NZ UT WOS:000319610400006 PM 23303315 ER PT J AU Dalton, T Cegielski, P Kurbatova, E Ershova, J Caoili, JC AF Dalton, Tracy Cegielski, Peter Kurbatova, Ekaterina Ershova, Julia Campos Caoili, Janice TI Resistance to second-line drugs in multidrug-resistant tuberculosis Reply SO LANCET LA English DT Letter C1 [Dalton, Tracy; Cegielski, Peter; Kurbatova, Ekaterina; Ershova, Julia] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Campos Caoili, Janice] Trop Dis Fdn, Manila, Philippines. RP Dalton, T (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. EM tldalton@cdc.gov NR 3 TC 1 Z9 1 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD FEB 23 PY 2013 VL 381 IS 9867 BP 626 EP 626 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 093JY UT WOS:000315189300022 PM 23439099 ER PT J AU Singh, S Henley, SJ Wilson, R King, J Eheman, C AF Singh, Simple Henley, S. Jane Wilson, Reda King, Jessica Eheman, Christie TI Invasive Cancer Incidence - United States, 2009 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Singh, Simple; Henley, S. Jane; Wilson, Reda; King, Jessica; Eheman, Christie] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Singh, S (reprint author), CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM sdsingh@cdc.gov NR 8 TC 5 Z9 5 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 22 PY 2013 VL 62 IS 7 BP 113 EP 118 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188ER UT WOS:000322175600001 ER PT J AU Jackson, L Jackson, ML Phillips, CH Benoit, J Belongia, EA Cole, D Kopitzke, S Koepel, TAK McLean, HQ Meece, JK Strey, SK Sundaram, ME Vandermause, M Gaglani, M Song, J Clipper, L Kjar, D Robertson, A Murthy, K Dunnahoo, M Oliver, S Weir, M Gonzales, H Zayed, M Ponder, T Nichols, J Reis, M Rivera, C Morgan, D Piedra, P Rivera, C Morgan, D Piedra, P Avadhanula, V Monto, AS Ohmit, SE Petrie, JG Johnson, E Cross, RT Martens, C Zervos, M Lamerato, L Aubuchon, MA Wolff, GG Eng, H Nowalk, MP Wisniewski, SR Zimmerman, RK Rinaldo, CR Bullotta, A Suyama, J Reis, E Middleton, DB Hess, R Raviotta, JM Thompson, MG Fry, AM Thaker, SN Ferdinands, J Cheng, PY Spencer, S Burns, E Berman, L Sessions, W Foust, A Bresee, J Cox, N AF Jackson, Lisa Jackson, Michael L. Phillips, C. Hallie Benoit, Joyce Belongia, Edward A. Cole, Deanna Kopitzke, Sarah Koepel, Tamara A. Kronenwetter McLean, Huong Q. Meece, Jennifer K. Strey, Sandra K. Sundaram, Maria E. Vandermause, Mary Gaglani, Manjusha Song, Juhee Clipper, Lydia Kjar, Dean Robertson, Anne Murthy, Kempapura Dunnahoo, Melinda Oliver, Stephanie Weir, Monica Gonzales, Hope Zayed, Martha Ponder, Teresa Nichols, JoAnn Reis, Michael Rivera, Cathleen Morgan, David Piedra, Pedro Rivera, Cathleen Morgan, David Piedra, Pedro Avadhanula, Vasanthi Monto, Arnold S. Ohmit, Suzanne E. Petrie, Joshua G. Johnson, Emileigh Cross, Rachel T. Martens, Casey Zervos, Marcus Lamerato, Lois Aubuchon, Mary Ann Wolff, Gregory G. Eng, Heather Nowalk, Mary Patricia Wisniewski, Stephen R. Zimmerman, Richard K. Rinaldo, Charles R., Jr. Bullotta, Arlene Suyama, Joe Reis, Evelyn Middleton, Donald B. Hess, Rachel Raviotta, Jonathan M. Thompson, Mark G. Fry, Alicia M. Thaker, Swathi N. Ferdinands, Jill Cheng, Po-Yung Spencer, Sarah Burns, Erin Berman, LaShondra Sessions, Wendy Foust, Angie Bresee, Joseph Cox, Nancy TI Interim Adjusted Estimates of Seasonal Influenza Vaccine Effectiveness - United States, February 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Jackson, Lisa; Jackson, Michael L.; Phillips, C. Hallie; Benoit, Joyce] Grp Hlth Res Inst, Seattle, WA USA. [Belongia, Edward A.; Cole, Deanna; Kopitzke, Sarah; Koepel, Tamara A. Kronenwetter; McLean, Huong Q.; Meece, Jennifer K.; Strey, Sandra K.; Sundaram, Maria E.; Vandermause, Mary] Marshfield Clin Res Fdn, Marshfield, WI USA. [Gaglani, Manjusha; Song, Juhee; Clipper, Lydia; Kjar, Dean; Robertson, Anne; Murthy, Kempapura; Dunnahoo, Melinda; Oliver, Stephanie; Weir, Monica; Gonzales, Hope; Zayed, Martha; Ponder, Teresa; Nichols, JoAnn; Reis, Michael; Rivera, Cathleen; Morgan, David; Piedra, Pedro; Rivera, Cathleen; Morgan, David; Piedra, Pedro; Avadhanula, Vasanthi] Scott & White Healthcare, Temple, TX USA. [Gaglani, Manjusha; Song, Juhee; Clipper, Lydia; Kjar, Dean; Robertson, Anne; Murthy, Kempapura; Dunnahoo, Melinda; Oliver, Stephanie; Weir, Monica; Gonzales, Hope; Zayed, Martha; Ponder, Teresa; Nichols, JoAnn; Reis, Michael; Rivera, Cathleen; Morgan, David; Piedra, Pedro; Rivera, Cathleen; Morgan, David; Piedra, Pedro; Avadhanula, Vasanthi] Baylor Coll Med, Houston, TX 77030 USA. [Monto, Arnold S.; Ohmit, Suzanne E.; Petrie, Joshua G.; Johnson, Emileigh; Cross, Rachel T.; Martens, Casey; Zervos, Marcus; Lamerato, Lois; Aubuchon, Mary Ann; Wolff, Gregory G.] Univ Michigan, Ann Arbor, MI 48109 USA. [Monto, Arnold S.; Ohmit, Suzanne E.; Petrie, Joshua G.; Johnson, Emileigh; Cross, Rachel T.; Martens, Casey; Zervos, Marcus; Lamerato, Lois; Aubuchon, Mary Ann; Wolff, Gregory G.] Henry Ford Hlth Syst, Detroit, MI USA. [Eng, Heather; Nowalk, Mary Patricia; Wisniewski, Stephen R.; Zimmerman, Richard K.; Rinaldo, Charles R., Jr.; Bullotta, Arlene; Suyama, Joe; Reis, Evelyn; Middleton, Donald B.; Hess, Rachel; Raviotta, Jonathan M.] Univ Pittsburgh, Sch Hlth Sci, Pittsburgh, PA USA. [Eng, Heather; Nowalk, Mary Patricia; Wisniewski, Stephen R.; Zimmerman, Richard K.; Rinaldo, Charles R., Jr.; Bullotta, Arlene; Suyama, Joe; Reis, Evelyn; Middleton, Donald B.; Hess, Rachel; Raviotta, Jonathan M.] Univ Pittsburgh, Med Ctr, Sch Hlth Sci, Pittsburgh, PA USA. [Thompson, Mark G.; Fry, Alicia M.; Thaker, Swathi N.; Ferdinands, Jill; Cheng, Po-Yung; Spencer, Sarah; Burns, Erin; Berman, LaShondra; Sessions, Wendy; Foust, Angie; Bresee, Joseph; Cox, Nancy] CDC, Influenza Div, Atlanta, GA 30333 USA. RP Thompson, MG (reprint author), CDC, Influenza Div, Atlanta, GA 30333 USA. EM isq8@cdc.gov RI Raviotta, Jonathan/O-9109-2016; OI Raviotta, Jonathan/0000-0001-7551-0628; Wisniewski, Stephen/0000-0002-3877-9860; Zimmerman, Richard/0000-0001-5941-6092 NR 10 TC 58 Z9 58 U1 0 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 22 PY 2013 VL 62 IS 7 BP 119 EP 123 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188ER UT WOS:000322175600002 ER PT J AU Blanton, L Epperson, S Brammer, L Kniss, K Mustaquim, D Steffens, C Perez, A Chaves, SS Wallis, T Villanueva, J Xu, XY Finelli, L Abd Elal, AI Gubareva, L Bresee, J Klimov, A Cox, N AF Blanton, Lenee Epperson, Scott Brammer, Lynnette Kniss, Krista Mustaquim, Desiree Steffens, Craig Perez, Alejandro Chaves, Sandra S. Wallis, Teresa Villanueva, Julie Xu, Xiyan Finelli, Lyn Abd Elal, Anwar Isa Gubareva, Larisa Bresee, Joseph Klimov, Alexander Cox, Nancy CA World Hlth Org Collaborating Ctr TI Update: Influenza Activity - United States, September 30, 2012-February 9, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Blanton, Lenee; Epperson, Scott; Brammer, Lynnette; Kniss, Krista; Mustaquim, Desiree; Steffens, Craig; Perez, Alejandro; Chaves, Sandra S.; Wallis, Teresa; Villanueva, Julie; Xu, Xiyan; Finelli, Lyn; Abd Elal, Anwar Isa; Gubareva, Larisa; Bresee, Joseph; Klimov, Alexander; Cox, Nancy] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Blanton, L (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM lblanton@cdc.gov NR 6 TC 6 Z9 6 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 22 PY 2013 VL 62 IS 7 BP 124 EP 130 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188ER UT WOS:000322175600003 ER PT J AU Sawyer, M Liang, JL Messonnier, N Clark, TA AF Sawyer, Mark Liang, Jennifer L. Messonnier, Nancy Clark, Thomas A. TI Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women - Advisory Committee on Immunization Practices (ACIP), 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ANTIGEN-CONTENT DIPHTHERIA; HEALTH-CARE PERSONNEL; IMMUNE-RESPONSES; ANTIBODY-RESPONSE; NEONATAL TETANUS; YOUNG-ADULTS; BOOSTER; BOOSTRIX(TM); OUTBREAK; KINETICS C1 [Sawyer, Mark] Univ Calif San Diego, La Jolla, CA 92093 USA. [Liang, Jennifer L.; Messonnier, Nancy; Clark, Thomas A.] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Liang, JL (reprint author), CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM jliang@cdc.gov NR 34 TC 175 Z9 178 U1 0 U2 8 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 22 PY 2013 VL 62 IS 7 BP 131 EP 135 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188ER UT WOS:000322175600004 ER PT J AU Norton, SA Soghier, L Hatfield, J Lapinski, J Barfield, WD AF Norton, Scott A. Soghier, Lamia Hatfield, June Lapinski, Jeffrey Barfield, Wanda D. TI Notes from the Field Zinc Deficiency Dermatitis in Cholestatic Extremely Premature Infants After a Nationwide Shortage of Injectable Zinc - Washington, DC, December 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material C1 [Norton, Scott A.] Childrens Natl Med Ctr, Dept Dermatol, Washington, DC 20010 USA. [Soghier, Lamia; Hatfield, June; Lapinski, Jeffrey] Childrens Natl Med Ctr, Dept Neonatol, Washington, DC 20010 USA. [Barfield, Wanda D.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Norton, SA (reprint author), Childrens Natl Med Ctr, Dept Dermatol, Washington, DC 20010 USA. EM snorton@cnmc.org NR 3 TC 6 Z9 6 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 22 PY 2013 VL 62 IS 7 BP 136 EP 137 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188ER UT WOS:000322175600005 ER PT J AU Young, PW Mahomed, M Horth, RZ Shiraishi, RW Jani, IV AF Young, Peter W. Mahomed, Mussagy Horth, Roberta Z. Shiraishi, Ray W. Jani, Ilesh V. TI Routine data from prevention of mother-to-child transmission (PMTCT) HIV testing not yet ready for HIV surveillance in Mozambique: a retrospective analysis of matched test results SO BMC INFECTIOUS DISEASES LA English DT Article DE HIV prevalence; HIV program data; HIV surveillance; Prevention of mother-to-child transmission; HIV diagnostic tests; Sentinel surveillance; Mozambique ID PROGRAM; PREVALENCE AB Background: Opt-out HIV testing is offered at 70% of antenatal care (ANC) clinics in Mozambique through the prevention of mother-to-child transmission (PMTCT) program. If routine data from this program were of sufficient quality, their heightened coverage and continuous availability could complement or even replace biannual sentinel serosurveys that currently serve as the primary HIV surveillance system in Mozambique. Methods: We assessed the efficacy of routine HIV testing data from prevention of mother-to-child transmission programs for estimating the prevalence of HIV infection among pregnant women. The PMTCT program uses sequential point-of-care rapid tests conducted on site while ANC surveillance surveys use dried blood spots tested sequentially for HIV-1/2 antibodies at a central laboratory. We compared matched routine PMTCT and ANC surveillance test results collected during 2007 and 2009 ANC surveillance surveys from 36 sentinel sites. Results: After excluding 659 women without PMTCT data, including 83 who refused rapid testing, test results from a total of 20,563 women were available. Pooling the data from both years indicated HIV prevalence from routine PMTCT testing was 14.4% versus 15.2% from surveillance testing (relative difference -5.1%; absolute difference -0.78%). Positive percent agreement (PPA) of PMTCT versus surveillance tests was 88.5% (95% Confidence Interval [CI]: 85.7-91.3%), with 19 sites having PPA below 90%; Negative percent agreement (NPA) was 98.9% (CI: 98.5-99.2%). No significant difference was found among three regions (North, Center and South), however both PPA and NPA were significantly higher in 2009 than 2007 (p < 0.05). Conclusions: We found low PPA of PMTCT test results compared to surveillance data which is indicative either of testing errors or data reporting problems. Nonetheless, PPA improved significantly from 2007 to 2009, a possible positive trend that should be investigated further. Although use of PMTCT test results would not dramatically change HIV prevalence estimates among pregnant women, the impact of site-level differences on surveillance models should be evaluated before these data are used to replace or complement ANC surveillance surveys. C1 [Young, Peter W.] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Maputo 10002, Mozambique. [Mahomed, Mussagy; Jani, Ilesh V.] Inst Nacl Saude, Maputo, Mozambique. [Horth, Roberta Z.] Univ Calif San Francisco, Maputo, Mozambique. [Shiraishi, Ray W.] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Atlanta, GA USA. RP Young, PW (reprint author), Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, 193 Av Kenneth Kaunda,POB 783, Maputo 10002, Mozambique. EM youngp@mz.cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR) through the Department of Health and Human Services/Centers for Disease Control and Prevention Division of Global HIV/AIDS [1U2GPS001537] FX The authors are grateful to the staff of the National Immunology Reference Lab that performed the ANC HIV testing, the ANC supervision team that oversaw national data and specimen collection, as well as the field staff in the 11 provinces that implemented the surveys. The authors are particularly grateful to the ANC nurses who collected surveillance data and specimens at the 36 sentinel sites. We would like to thank Nadia Amade, Cynthia Sema, and Dr. Eduardo Samo-Gudo for providing information about the history of the national HIV external quality assessment program. We also wish to acknowledge the in-depth editing and review of the manuscript by Dr. Michael Shodell. This research has been supported in part by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Department of Health and Human Services/Centers for Disease Control and Prevention Division of Global HIV/AIDS Cooperative Agreement 1U2GPS001537. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 18 TC 7 Z9 7 U1 3 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD FEB 22 PY 2013 VL 13 AR 96 DI 10.1186/1471-2334-13-96 PG 8 WC Infectious Diseases SC Infectious Diseases GA 099ON UT WOS:000315631200001 PM 23432847 ER PT J AU Friedman, SR West, BS Pouget, ER Hall, HI Cantrell, J Tempalski, B Chatterjee, S Hu, XH Cooper, HLF Galea, S Jarlais, DCD AF Friedman, Samuel R. West, Brooke S. Pouget, Enrique R. Hall, H. Irene Cantrell, Jennifer Tempalski, Barbara Chatterjee, Sudip Hu, Xiaohong Cooper, Hannah L. F. Galea, Sandro Des Jarlais, Don C. TI Metropolitan Social Environments and Pre-HAART/HAART Era Changes in Mortality Rates (per 10,000 Adult Residents) among Injection Drug Users Living with AIDS SO PLOS ONE LA English DT Article ID ANTIRETROVIRAL THERAPY; UNITED-STATES; INCOME INEQUALITY; TREATMENT COVERAGE; HIV PREVALENCE; AREAS; US; RISK; INCARCERATION; INFECTION AB Background: Among the largest US metropolitan areas, trends in mortality rates for injection drug users (IDUs) with AIDS vary substantially. Ecosocial, risk environment and dialectical theories suggest many metropolitan areas characteristics that might drive this variation. We assess metropolitan area characteristics associated with decline in mortality rates among IDUs living with AIDS (per 10,000 adult MSA residents) after highly active antiretroviral therapy (HAART) was developed. Methods: This is an ecological cohort study of 86 large US metropolitan areas from 1993-2006. The proportional rate of decline in mortality among IDUs diagnosed with AIDS (as a proportion of adult residents) from 1993-1995 to 2004-2006 was the outcome of interest. This rate of decline was modeled as a function of MSA-level variables suggested by ecosocial, risk environment and dialectical theories. In multiple regression analyses, we used 1993-1995 mortality rates to (partially) control for pre-HAART epidemic history and study how other independent variables affected the outcomes. Results: In multivariable models, pre-HAART to HAART era increases in 'hard drug' arrest rates and higher pre-HAART income inequality were associated with lower relative declines in mortality rates. Pre-HAART per capita health expenditure and drug abuse treatment rates, and pre- to HAART-era increases in HIV counseling and testing rates, were weakly associated with greater decline in AIDS mortality. Conclusions: Mortality among IDUs living with AIDS might be decreased by reducing metropolitan income inequality, increasing public health expenditures, and perhaps increasing drug abuse treatment and HIV testing services. Given prior evidence that drug-related arrest rates are associated with higher HIV prevalence rates among IDUs and do not seem to decrease IDU population prevalence, changes in laws and policing practices to reduce such arrests while still protecting public order should be considered. C1 [Friedman, Samuel R.; West, Brooke S.; Pouget, Enrique R.; Tempalski, Barbara; Des Jarlais, Don C.] Natl Dev & Res Inst Inc, Inst Infect Dis Res, New York, NY USA. [Hall, H. Irene; Hu, Xiaohong] Ctr Dis Control, Atlanta, GA 30333 USA. [Cantrell, Jennifer] Legacy Fdn, Washington, DC USA. [Cooper, Hannah L. F.] Emory Univ, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA. [Galea, Sandro] Columbia Univ, Dept Epidemiol, New York, NY USA. [Des Jarlais, Don C.] Beth Israel Deaconess Med Ctr, Baron Edmond de Rothschild Chem Dependency Inst, New York, NY 10003 USA. RP Friedman, SR (reprint author), Natl Dev & Res Inst Inc, Inst Infect Dis Res, New York, NY USA. EM friedman@ndri.org OI Tempalski, Barbara/0000-0002-6128-2510 FU National Institute of Drug Abuse [R01 DA013336, R01 DA 003574, 5T32 DA007233]; Public Health Solutions; National Development and Research Institutes FX This work was supported by National Institute of Drug Abuse grants # R01 DA013336 (Community Vulnerability and Responses to Drug-User-Related HIV/AIDS), R01 DA 003574 (Risk Factors for AIDS among Intravenous Drug Users), and 5T32 DA007233 (Behavioral Sciences Training in Drug Abuse Research program sponsored by Public Health Solutions and National Development and Research Institutes). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 79 TC 12 Z9 12 U1 1 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 21 PY 2013 VL 8 IS 2 AR e57201 DI 10.1371/journal.pone.0057201 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 093IT UT WOS:000315186000084 PM 23437341 ER PT J AU Menon, VK George, S Aladin, F Nawaz, S Sarkar, R Lopman, B Gray, JJ Gomara, MI Kang, G AF Menon, Vipin Kumar George, Santosh Aladin, Farah Nawaz, Sameena Sarkar, Rajiv Lopman, Ben Gray, James J. Gomara, Miren Iturriza Kang, Gagandeep TI Comparison of Age-Stratified Seroprevalence of Antibodies against Norovirus GII in India and the United Kingdom SO PLOS ONE LA English DT Article ID LINKED IMMUNOSORBENT ASSAYS; MEXICO VIRUS-INFECTIONS; NORWALK VIRUS; HUMAN CALICIVIRUSES; ACUTE GASTROENTERITIS; CAPSID ANTIGEN; PREVALENCE; CHILDREN; SOUTH; SEROEPIDEMIOLOGY AB Noroviruses are a common cause of gastroenteritis worldwide, but outbreaks appear to be more common in industrialized countries than in developing countries, possibly reflecting differences in exposure and immunity. In this study, age-stratified sera from India and UK populations were analysed for the presence of norovirus-genogroup II specific IgG by a time resolved immunofluorescence assay and relative levels of antibodies in the two populations were compared. Antibody levels were higher among all age groups in India than in UK and increased with age in India, whereas in the UK, levels of antibody decreased in adulthood. These results indicate different patterns of exposure to noroviruses in the two countries. C1 [Menon, Vipin Kumar; George, Santosh; Sarkar, Rajiv; Kang, Gagandeep] Christian Med Coll & Hosp, Dept Gastrointestinal Sci, Vellore, Tamil Nadu, India. [Aladin, Farah; Nawaz, Sameena] Hlth Protect Agcy, Virus Reference Dept, Ctr Infect, London, England. [Lopman, Ben] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Gray, James J.] Norfolk & Norwich Univ Hosp Specialist Virol Ctr, Dept Microbiol, NRP Innovat Ctr, Norwich, Norfolk, England. [Gomara, Miren Iturriza] Univ Liverpool, Dept Clin Infect Microbiol & Immunol, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. RP Kang, G (reprint author), Christian Med Coll & Hosp, Dept Gastrointestinal Sci, Vellore, Tamil Nadu, India. EM gkang@cmcvellore.ac.in RI Iturriza Gomara, Miren/B-4351-2013; OI Iturriza Gomara, Miren/0000-0001-5816-6423; Menon, Vipin/0000-0001-7404-678X; Kang, Gagandeep/0000-0002-3656-564X FU British Council [SA08-040] FX This study was funded by British Council, with grant number SA08-040. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 32 TC 9 Z9 9 U1 0 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 21 PY 2013 VL 8 IS 2 AR e56239 DI 10.1371/journal.pone.0056239 PG 4 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 093IT UT WOS:000315186000019 PM 23437102 ER PT J AU Lucchi, NW Narayanan, J Karell, MA Xayavong, M Kariuki, S DaSilva, AJ Hill, V Udhayakumar, V AF Lucchi, Naomi W. Narayanan, Jothikumar Karell, Mara A. Xayavong, Maniphet Kariuki, Simon DaSilva, Alexandre J. Hill, Vincent Udhayakumar, Venkatachalam TI Molecular Diagnosis of Malaria by Photo-Induced Electron Transfer Fluorogenic Primers: PET-PCR SO PLOS ONE LA English DT Article ID 18S RIBOSOMAL-RNA; PLASMODIUM-FALCIPARUM; TESTS; EPIDEMIOLOGY; ELIMINATION; GAMETOCYTES; MICROSCOPY; TANZANIA; VIVAX; ASSAY AB There is a critical need for developing new malaria diagnostic tools that are sensitive, cost effective and capable of performing large scale diagnosis. The real-time PCR methods are particularly robust for large scale screening and they can be used in malaria control and elimination programs. We have designed novel self-quenching photo-induced electron transfer (PET) fluorogenic primers for the detection of P. falciparum and the Plasmodium genus by real-time PCR. A total of 119 samples consisting of different malaria species and mixed infections were used to test the utility of the novel PET-PCR primers in the diagnosis of clinical samples. The sensitivity and specificity were calculated using a nested PCR as the gold standard and the novel primer sets demonstrated 100% sensitivity and specificity. The limits of detection for P. falciparum was shown to be 3.2 parasites/mu l using both Plasmodium genus and P. falciparum-specific primers and 5.8 parasites/mu l for P. ovale, 3.5 parasites/mu l for P. malariae and 5 parasites/mu l for P. vivax using the genus specific primer set. Moreover, the reaction can be duplexed to detect both Plasmodium spp. and P. falciparum in a single reaction. The PET-PCR assay does not require internal probes or intercalating dyes which makes it convenient to use and less expensive than other real-time PCR diagnostic formats. Further validation of this technique in the field will help to assess its utility for large scale screening in malaria control and elimination programs. C1 [Lucchi, Naomi W.; Xayavong, Maniphet; DaSilva, Alexandre J.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Narayanan, Jothikumar; Hill, Vincent] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Karell, Mara A.; Udhayakumar, Venkatachalam] Atlanta Res & Educ Fdn, VA Med Ctr, Decatur, GA USA. [Kariuki, Simon] Ctr Dis Control & Prevent, Malaria Branch, Kenya Med Res Inst, Kisumu, Kenya. RP Lucchi, NW (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. EM NLucchi@cdc.gov RI Hill, Vincent/G-1789-2012 OI Hill, Vincent/0000-0001-7069-7737 FU Atlanta Research and Education Foundation, Atlanta, Georgia; Malaria Branch, CDC FX This study was supported by the Atlanta Research and Education Foundation, Atlanta, Georgia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank the Malaria Branch, CDC, for supporting this project and Dr. John W. Barnwell for proving some of the samples used in this study. The use of trade names and names of commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services. The findings and conclusions in this presentation are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention. NR 22 TC 13 Z9 13 U1 2 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 20 PY 2013 VL 8 IS 2 AR e56677 DI 10.1371/journal.pone.0056677 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 093IE UT WOS:000315184200139 PM 23437209 ER PT J AU Polis, CB Phillips, SJ Curtis, KM AF Polis, Chelsea B. Phillips, Sharon J. Curtis, Kathryn M. TI Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence SO AIDS LA English DT Review DE contraception; female-to-male HIV transmission; HIV; hormonal; prevention of mother-to-child transmission ID MARGINAL STRUCTURAL MODELS; SEXUALLY-TRANSMITTED INFECTIONS; IMMUNODEFICIENCY-VIRUS TYPE-1; CONSISTENT CONDOM USE; GENITAL-TRACT; ANTIRETROVIRAL THERAPY; RISK-FACTORS; CERVICOVAGINAL SECRETIONS; HIV-1-INFECTED CELLS; ZIMBABWEAN WOMEN AB Objective: To systematically review epidemiologic evidence assessing whether hormonal contraception alters the risk of HIV transmission from an HIV-positive woman to an HIV-negative male partner. Design: Systematic review. Methods: We included articles published or in press through December 15, 2011. We assessed studies with direct evidence on hormonal contraception use and HIV transmission, and summarized studies with indirect evidence related to genital or plasma viral load. Results: One study provided direct evidence on oral contraceptive pills (OCPs) or injectable contraception and female-to-male HIV transmission; both injectables [Cox-adjusted hazard ratio (adjHR) 1.95, 95% confidence interval (CI) 1.06-3.58; marginal structural model (MSM) adjusted odds ratio (adjOR) 3.01, 95% CI 1.47-6.16] and OCPs (Cox adjHR 2.09, 95% CI 0.75-5.84; MSM adjOR 2.35, 95% CI 0.79-6.95) generated elevated point estimates, but only estimates for injectables were significant. Findings from 11 indirect studies assessing various hormonal contraception methods and viral genital shedding or setpoint were mixed, and seven of eight studies indicated no adverse effect of various hormonal contraception methods on plasma viral load. Conclusion: The only direct study on OCPs or injectable contraception and female-to-male HIV transmission suggests increased risk with the use of injectables. Given the potential for confounding in observational data, the paucity of direct evidence on this subject, and mixed indirect evidence, additional evidence is needed. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:493-505 C1 [Polis, Chelsea B.] United States Agcy Int Dev, Off Populat & Reprod Hlth, Washington, DC USA. [Phillips, Sharon J.] WHO, Dept Reprod Hlth & Res, CH-1211 Geneva, Switzerland. [Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Polis, CB (reprint author), USAID GH PRH RTU, 1201 Pennsylvania Ave NW,Suite 315, Washington, DC 20004 USA. EM cpolis@usaid.gov OI Polis, Chelsea/0000-0002-1031-7074 NR 83 TC 34 Z9 34 U1 0 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD FEB 20 PY 2013 VL 27 IS 4 BP 493 EP 505 DI 10.1097/QAD.0b013e32835ad539 PG 13 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 094SM UT WOS:000315284100001 PM 23079808 ER PT J AU Zipprich, J Murray, EL Winter, K Kong, D Harriman, K Preas, C Wadford, D Messenger, S Talarico, J Watt, JP Berreman, J Gregory, B Cameron, P Buchman, B Nunez, JJ AF Zipprich, Jennifer Murray, Erin L. Winter, Kathleen Kong, Darryl Harriman, Kathleen Preas, Chris Wadford, Debra Messenger, Sharon Talarico, John Watt, James P. Berreman, Janet Gregory, Barbara Cameron, Pat Buchman, Brad Nunez, Jonathan J. TI Mumps Outbreak on a University Campus-California, 2011 (Reprinted from MMWR, vol 61, pg 986-989, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID UPDATE C1 [Berreman, Janet; Gregory, Barbara] City Berkeley, Publ Hlth Div, Berkeley, CA USA. [Cameron, Pat; Buchman, Brad] Univ Calif Berkeley, Univ Hlth Svcs, Berkeley, CA 94720 USA. [Nunez, Jonathan J.] CDC, Atlanta, GA 30333 USA. RP Nunez, JJ (reprint author), CDC, Atlanta, GA 30333 USA. EM vig2@cdc.gov NR 11 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 20 PY 2013 VL 309 IS 7 BP 650 EP 653 DI 10.1001/jama.2012.193374 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 091EK UT WOS:000315032000008 ER PT J AU Shah, N Mase, S Chorba, T Castro, K AF Shah, Neha Mase, Sundari Chorba, Terence Castro, Kenneth TI Notes from the Field: National Shortage of Isoniazid 300 mg Tablets (Reprinted from MMWR, vol 50, pg 1029, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Shah, Neha; Mase, Sundari; Chorba, Terence; Castro, Kenneth] CDC, Div TB Eliminat, Natl Ctr HIV Hepatitis STDs & TB Prevent, Atlanta, GA 30333 USA. RP Shah, N (reprint author), CDC, Div TB Eliminat, Natl Ctr HIV Hepatitis STDs & TB Prevent, Atlanta, GA 30333 USA. EM nshah6@cdc.gov NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 20 PY 2013 VL 309 IS 7 BP 653 EP 653 DI 10.1001/jama.2013.223 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 091EK UT WOS:000315032000009 ER PT J AU Jones, CM Mack, KA Paulozzi, LJ AF Jones, Christopher M. Mack, Karin A. Paulozzi, Leonard J. TI Pharmaceutical Overdose Deaths, United States, 2010 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Jones, Christopher M.; Mack, Karin A.; Paulozzi, Leonard J.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. RP Jones, CM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. EM fjr0@cdc.gov RI Mack, Karin/A-3263-2012 OI Mack, Karin/0000-0001-9274-3001 NR 6 TC 241 Z9 244 U1 6 U2 17 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 20 PY 2013 VL 309 IS 7 BP 657 EP 659 DI 10.1001/jama.2013.272 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 091EK UT WOS:000315032000016 PM 23423407 ER PT J AU Vertefeuille, JF Dowell, SF Domercant, JW Tappero, JW AF Vertefeuille, John F. Dowell, Scott F. Domercant, Jean W. Tappero, Jordan W. TI Cautious optimism on public health in post-earthquake Haiti SO LANCET LA English DT Editorial Material C1 [Vertefeuille, John F.; Domercant, Jean W.] US Ctr Dis Control & Prevent, Haiti Off, Tabarre, Port Au Prince, Haiti. [Vertefeuille, John F.; Dowell, Scott F.; Tappero, Jordan W.] US Ctr Dis Control & Prevent, Div Global Dis Detect & Emergency Response, Ctr Global Hlth, Atlanta, GA 30329 USA. [Domercant, Jean W.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30329 USA. RP Vertefeuille, JF (reprint author), US Ctr Dis Control & Prevent, Haiti Off, Tabarre, Port Au Prince, Haiti. EM dki4@cdc.gov NR 12 TC 5 Z9 5 U1 1 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD FEB 16 PY 2013 VL 381 IS 9866 BP 517 EP 519 DI 10.1016/S0140-6736(13)60051-3 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 089RK UT WOS:000314927500009 PM 23332167 ER PT J AU Murphy, TD Weidenbach, KN Van Houten, C Gerona, RR Moran, JH Kirschner, RI Marraffa, JM Stork, CM Birkhead, GS Newman, A Hendrickson, RG Horowitz, BZ Vian, K Leman, RF Thornton, SL Wood, C Myers, DA Orr, E Devlin, JJ Schwartz, MD Buser, GL AF Murphy, Tracy D. Weidenbach, Kelly N. Van Houten, Clay Gerona, Roy R. Moran, Jeffery H. Kirschner, Ronald I. Marraffa, Jeanna M. Stork, Christine M. Birkhead, Guthrie S. Newman, Andie Hendrickson, Robert G. Horowitz, B. Zane Vian, Karen Leman, Richard F. Thornton, Stephen L. Wood, Clayton Myers, David A. Orr, Erik Devlin, John J. Schwartz, Michael D. Buser, Genevieve L. TI Acute Kidney Injury Associated with Synthetic Cannabinoid Use - Multiple States, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Gerona, Roy R.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Moran, Jeffery H.] Arkansas Dept Hlth, Arkansas Publ Hlth Lab, Little Rock, AR 72205 USA. [Marraffa, Jeanna M.; Stork, Christine M.] SUNY Upstate Med Univ, Upstate New York Poison Ctr, Syracuse, NY 13210 USA. [Birkhead, Guthrie S.; Newman, Andie] New York State Dept Hlth, Albany, NY 12237 USA. [Thornton, Stephen L.] Univ Kansas Hosp, Poison Control Ctr, Kansas City, KS USA. [Wood, Clayton] Univ Kansas Hosp, Dept Emergency Med, Kansas City, KS USA. [Myers, David A.] Univ Oklahoma, Hlth Sci Ctr, Norman, OK 73019 USA. [Buser, Genevieve L.] CDC, Atlanta, GA 30333 USA. EM mschwartz@cdc.gov RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 NR 10 TC 59 Z9 59 U1 0 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 15 PY 2013 VL 62 IS 6 BP 93 EP 98 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188EP UT WOS:000322175300001 ER PT J AU Kirkey, K MacMaster, K Suryaprasad, A Xu, FJ Klevens, M Roberts, H Moorman, A Holmberg, S Webeck, J AF Kirkey, Kim MacMaster, Karen Suryaprasad, Anil Xu, Fujie Klevens, Monina Roberts, Henry Moorman, Anne Holmberg, Scott Webeck, Jenna TI Completeness of Reporting of Chronic Hepatitis B and C Virus Infections - Michigan, 1995-2008 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CHRONIC VIRAL-HEPATITIS; SURVEILLANCE C1 [Webeck, Jenna] CDC, Atlanta, GA 30333 USA. EM asuryaprasad@cdc.gov NR 9 TC 4 Z9 5 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 15 PY 2013 VL 62 IS 6 BP 99 EP 102 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188EP UT WOS:000322175300002 ER PT J AU MacDonald, JK Julian, E Chu, A Dion, J Boden, W Viazis, S Beal, J Lanier, W Nguyen, TA Burnworth, L Williams, I Gieraltowski, L Hancock, WT AF MacDonald, J. Kathryn Julian, Ernest Chu, Alvina Dion, Jamie Boden, William Viazis, Stelios Beal, Jennifer Lanier, William Thai-An Nguyen Burnworth, Laura Williams, Ian Gieraltowski, Laura Hancock, W. Thane TI Salmonella Bredeney Infections Linked to a Brand of Peanut Butter - United States, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [MacDonald, J. Kathryn] Washington State Dept Hlth, Washington, DC USA. [Julian, Ernest] Rhode Isl Dept Hlth, Providence, RI 02908 USA. [Chu, Alvina] Maryland Dept Hlth & Mental Hyg, Baltimore, MD 21201 USA. [Viazis, Stelios; Beal, Jennifer; Lanier, William] US FDA, Coordinated Outbreak Response & Evaluat Network, Rockville, MD 20857 USA. [Hancock, W. Thane] CDC, Atlanta, GA 30333 USA. RP Hancock, WT (reprint author), CDC, Atlanta, GA 30333 USA. EM vie1@cdc.gov NR 3 TC 3 Z9 3 U1 0 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 15 PY 2013 VL 62 IS 6 BP 107 EP 107 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188EP UT WOS:000322175300004 ER PT J AU Pisney, L Barron, M Janelle, SJ Bamberg, W MacCannell, D Kallen, A Gould, C Limbago, B Epson, E Wendt, J AF Pisney, Larissa Barron, Michelle Janelle, Sarah Jackson Bamberg, Wendy MacCannell, Duncan Kallen, Alexander Gould, Carolyn Limbago, Brandi Epson, Erin Wendt, Joyanna TI Hospital Outbreak of Carbapenem-Resistant Klebsiella pneumoniae Producing New Delhi Metallo-Beta-Lactamase - Denver, Colorado, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Pisney, Larissa; Barron, Michelle] Univ Colorado, Div Infect Dis, Boulder, CO 80309 USA. [Epson, Erin; Wendt, Joyanna] CDC, Atlanta, GA 30333 USA. RP Epson, E (reprint author), CDC, Atlanta, GA 30333 USA. EM erin.epson@state.co.us NR 3 TC 17 Z9 18 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 15 PY 2013 VL 62 IS 6 BP 108 EP 108 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188EP UT WOS:000322175300005 ER PT J AU Nguyen, DB Do, NT Shiraishi, RW Le, YN Tran, QH Nguyen, HH Medland, N Nguyen, LT Struminger, BB AF Duc Bui Nguyen Nhan Thi Do Shiraishi, Ray W. Yen Ngoc Le Quang Hong Tran Hai Huu Nguyen Medland, Nicholas Long Thanh Nguyen Struminger, Bruce Baird TI Outcomes of Antiretroviral Therapy in Vietnam: Results from a National Evaluation SO PLOS ONE LA English DT Article ID INJECTION-DRUG USERS; FOLLOW-UP; TREATMENT PROGRAM; PATIENTS LOST; SCALE-UP; MULTIPLE IMPUTATION; MISSING VALUES; SOUTH-AFRICA; RISK-FACTORS; HIV AB Objectives: Vietnam has significantly scaled up its national antiretroviral therapy (ART) program since 2005. With the aim of improving Vietnam's national ART program, we conducted an outcome evaluation of the first five years of the program in this concentrated HIV epidemic where the majority of persons enrolled in HIV care and treatment services are people who inject drugs (PWID). The results of this evaluation may have relevance for other national ART programs with significant PWID populations. Design: Retrospective cohort analysis of patients at 30 clinics randomly selected with probability proportional to size among 120 clinics with at least 50 patients on ART. Methods: Charts of patients whose ART initiation was at least 6 months prior to the study date were abstracted. Depending on clinic size, either all charts or a random sample of 300 charts were selected. Analyses were limited to treatment-naive patients. Multiple imputations were used for missing data. Results: Of 7,587 patient charts sampled, 6,875 were those of treatment-naive patients (74.4% male, 95% confidence interval [CI]: 72.4-76.5, median age 30, interquartile range [IQR]: 26-34, 62.0% reported a history of intravenous drug use, CI: 58.6-65.3). Median baseline CD4 cell count was 78 cells/mm 3 (IQR: 30-162) and 30.4% (CI: 25.8-35.1) of patients were at WHO stage IV. The majority of patients started d4T/3TC/NVP (74.3%) or d4T/3TC/EFV (18.6%). Retention rates after 6, 12, 24, and 36 months were 88.4% (CI: 86.8-89.9), 84.0% (CI: 81.8-86.0), 78.8% (CI: 75.7-81.6), and 74.6% (CI: 69.6-79.0). Median CD4 cell count gains after 6, 12, 24, and 36 months were 94 (IQR: 45-153), 142 (IQR: 78-217), 213 (IQR: 120-329), and 254 (IQR: 135-391) cells/mm(3). Patients who were PWID showed significantly poorer retention. Conclusions: The study showed good retention and immunological response to ART among a predominantly PWID group of patients despite advanced HIV infections at baseline. C1 [Duc Bui Nguyen; Yen Ngoc Le; Medland, Nicholas; Struminger, Bruce Baird] US Ctr Dis Control & Prevent, Hanoi, Vietnam. [Nhan Thi Do; Hai Huu Nguyen; Long Thanh Nguyen] Vietnam Adm HIV AIDS Control, Minist Hlth, Hanoi, Vietnam. [Shiraishi, Ray W.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Quang Hong Tran] Hanoi Sch Publ Hlth, Hanoi, Vietnam. RP Nguyen, DB (reprint author), US Ctr Dis Control & Prevent, Hanoi, Vietnam. EM vif8@cdc.gov FU Emory AIDS International Training and Research Program [NIH/FIC D43 TW01042]; United States's President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention [1U2GPS000747] FX This evaluation was supported by the United States's President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention under the terms of 1U2GPS000747. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to thank the data collection and entry team, as well as the clinic staff whose generous assistance made this survey possible. We would also like to thank the staff from the provincial Departments of Health and AIDS Control Centers where we collected data. We thank Dr. Mitchell Wolfe and Mr. Raymond Ransom from U.S. CDC for their contributions to the protocol development, and we thank Dr. Michelle McConnell, Dr. Anh Van Ho and Patrick Nadol from CDC Vietnam office for their valuable contributions to the study and the manuscript. We thank Dr. Stefan Wiktor and Dr. Andrew Baughman of CDC's Division of Global HIV/AIDS, and Timothy Dondero of CDC's National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention for their scientific reviews. We thank Dr. Michael Iademarco from U.S. CDC for his review of the manuscript. The team also acknowledges general support from the VAAC and U.S. CDC Vietnam office. Dr. Duc Bui Nguyen received training support from the Emory AIDS International Training and Research Program (NIH/FIC D43 TW01042). NR 38 TC 20 Z9 20 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 15 PY 2013 VL 8 IS 2 AR e55750 DI 10.1371/journal.pone.0055750 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 099EQ UT WOS:000315603700017 PM 23457477 ER PT J AU Copeland, DL Basurto-Davila, R Chung, W Kurian, A Fishbein, DB Szymanowski, P Zipprich, J Lipman, H Cetron, MS Meltzer, MI Averhoff, F AF Copeland, Daphne L. Basurto-Davila, Ricardo Chung, Wendy Kurian, Anita Fishbein, Daniel B. Szymanowski, Paige Zipprich, Jennifer Lipman, Harvey Cetron, Martin S. Meltzer, Martin I. Averhoff, Francisco TI Effectiveness of a School District Closure for Pandemic Influenza A (H1N1) on Acute Respiratory Illnesses in the Community: A Natural Experiment SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE H1N1 virus; influenza; pandemics; schools; nonpharmaceutical interventions ID VIRUS-INFECTIONS; TRANSMISSION; IMPACT AB Background. Following detection of pandemic influenza A H1N1 (pH1N1) in Dallas/Fort Worth, Texas, a school district (intervention community, [IC]) closed all public schools for 8 days to reduce transmission. Nearby school districts (control community [CC]) mostly remained open. Methods. We collected household data to measure self-reported acute respiratory illness (ARI), before, during, and after school closures. We also collected influenza-related visits to emergency departments (EDflu). Results. In both communities, self-reported ARIs and EDflu visits increased from before to during the school closure, but the increase in ARI rates was 45% lower in the IC (0.6% before to 1.2% during) than in the CC (0.4% before to 1.5% during) (RRRDuring/Before = 0.55, P < .001; adjusted ORDuring/Before = 0.49, P < .03). For households with school-aged children only (no children 0-5 years), IC had even lower increases in adjusted ARI than in the CC (adjusted ORDuring/Before = 0.28, P < .001). The relative increase of total EDflu visits in the IC was 27% lower (2.8% before to 4.4% during) compared with the CC (2.9% before to 6.2% during). Among children aged 6-18 years, the percentage of EDflu in IC remained constant (5.1% before vs 5.2% during), whereas in the CC it more than doubled (5.2% before vs 10.9% during). After schools reopened, ARI rates and EDflu visits decreased in both communities. Conclusions. Our study documents a reduction in ARI and EDflu visits in the intervention community. Our findings can be used to assess the potential benefit of school closures during pandemics. C1 [Copeland, Daphne L.; Fishbein, Daniel B.; Szymanowski, Paige; Lipman, Harvey; Cetron, Martin S.; Averhoff, Francisco] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Basurto-Davila, Ricardo] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Zipprich, Jennifer] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Meltzer, Martin I.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Atlanta, GA USA. [Chung, Wendy] Dallas Cty Hlth & Human Serv, Ft Worth, TX USA. [Kurian, Anita] Tarrant Cty Publ Hlth, Ft Worth, TX USA. RP Copeland, DL (reprint author), 230 River N Dr, Atlanta, GA 30328 USA. EM dcopela55@gmail.com NR 24 TC 11 Z9 11 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2013 VL 56 IS 4 BP 509 EP 516 DI 10.1093/cid/cis890 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 077UR UT WOS:000314054400007 PM 23087391 ER PT J AU Patel, MM Parashar, UD Santosham, M Richardson, V AF Patel, Manish M. Parashar, Umesh D. Santosham, Mathuram Richardson, Vesta TI The Rotavirus Experience in Mexico: Discovery to Control SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material DE rotavirus; vaccines; diarrhea; mortality ID CHILDHOOD DIARRHEA; VACCINE; CHILDREN; MORTALITY; INFANTS; INTUSSUSCEPTION; GASTROENTERITIS; PROTECTION; INFECTION; EFFICACY AB The recent introduction of a rotavirus vaccine program in Mexico to control rotavirus disease, a common killer of children worldwide, has dramatically reduced the number of Mexican children dying and being hospitalized because of diarrhea. The successful introduction of a rotavirus vaccine program was preceded by several decades of focused research efforts to document the burden of disease and to generate the knowledge base to develop and deploy a vaccine. The postlicensure experience from Mexico demonstrates that evaluating the impact and safety of the vaccination program is vitally necessary for sustaining it. All in all, the immensely successful Mexico experience with control of rotavirus disease, if copied, could yield tremendously favorable results for children and parents worldwide. C1 [Patel, Manish M.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Santosham, Mathuram] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Richardson, Vesta] Minist Hlth, Natl Ctr Child & Adolescent Hlth, Mexico City, DF, Mexico. RP Patel, MM (reprint author), Ctr Dis Control & Prevent, Viral Gastroenteritis Sect, MS A34,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM aul3@cdc.gov NR 32 TC 4 Z9 4 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2013 VL 56 IS 4 BP 548 EP 551 DI 10.1093/cid/cis939 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 077UR UT WOS:000314054400014 PM 23271788 ER PT J AU Bresee, J Hayden, FG AF Bresee, Joseph Hayden, Frederick G. TI Epidemic Influenza - Responding to the Expected but Unpredictable SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID VACCINE C1 [Bresee, Joseph] Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, Atlanta, GA 30333 USA. [Hayden, Frederick G.] Univ Virginia, Sch Med, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA. RP Bresee, J (reprint author), Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, Atlanta, GA 30333 USA. NR 5 TC 9 Z9 11 U1 0 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 14 PY 2013 VL 368 IS 7 BP 589 EP 592 DI 10.1056/NEJMp1300375 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 194VA UT WOS:000322659600002 PM 23343038 ER PT J AU Waldman, RJ Mintz, ED Papowitz, HE AF Waldman, Ronald J. Mintz, Eric D. Papowitz, Heather E. TI The Cure for Cholera - Improving Access to Safe Water and Sanitation SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Waldman, Ronald J.] George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC 20052 USA. [Mintz, Eric D.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Papowitz, Heather E.] UNICEF, Hlth Sect, New York, NY USA. RP Waldman, RJ (reprint author), George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC 20052 USA. NR 5 TC 15 Z9 15 U1 0 U2 15 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 14 PY 2013 VL 368 IS 7 BP 592 EP 594 DI 10.1056/NEJMp1214179 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 194VA UT WOS:000322659600003 PM 23301693 ER PT J AU Barzilay, EJ Schaad, N Magloire, R Mung, KS Boncy, J Dahourou, GA Mintz, ED Steenland, MW Vertefeuille, JF Tappero, JW AF Barzilay, Ezra J. Schaad, Nicolas Magloire, Roc Mung, Kam S. Boncy, Jacques Dahourou, Georges A. Mintz, Eric D. Steenland, Maria W. Vertefeuille, John F. Tappero, Jordan W. TI Cholera Surveillance during the Haiti Epidemic - The First 2 Years SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID VIBRIO-CHOLERAE; TRANSMISSION; DISEASE; INTERVENTIONS; OUTBREAK; STRAIN; WORLD; MODEL AB BACKGROUND In October 2010, nearly 10 months after a devastating earthquake, Haiti was stricken by epidemic cholera. Within days after detection, the Ministry of Public Health and Population established a National Cholera Surveillance System (NCSS). METHODS The NCSS used a modified World Health Organization case definition for cholera that included acute watery diarrhea, with or without vomiting, in persons of all ages residing in an area in which at least one case of Vibrio cholerae O1 infection had been confirmed by culture. RESULTS Within 29 days after the first report, cases of V. cholerae O1 (serotype Ogawa, biotype El Tor) were confirmed in all 10 administrative departments (similar to states or provinces) in Haiti. Through October 20, 2012, the public health ministry reported 604,634 cases of infection, 329,697 hospitalizations, and 7436 deaths from cholera and isolated V. cholerae O1 from 1675 of 2703 stool specimens tested (62.0%). The cumulative attack rate was 5.1% at the end of the first year and 6.1% at the end of the second year. The cumulative case fatality rate consistently trended downward, reaching 1.2% at the close of year 2, with departmental cumulative rates ranging from 0.6% to 4.6% (median, 1.4%). Within 3 months after the start of the epidemic, the rolling 14-day case fatality rate was 1.0% and remained at or below this level with few, brief exceptions. Overall, the cholera epidemic in Haiti accounted for 57% of all cholera cases and 53% of all cholera deaths reported to the World Health Organization in 2010 and 58% of all cholera cases and 37% of all cholera deaths in 2011. CONCLUSIONS A review of NCSS data shows that during the first 2 years of the cholera epidemic in Haiti, the cumulative attack rate was 6.1%, with cases reported in all 10 departments. Within 3 months after the first case was reported, there was a downward trend in mortality, with a 14-day case fatality rate of 1.0% or less in most areas. C1 [Barzilay, Ezra J.; Schaad, Nicolas; Dahourou, Georges A.; Mintz, Eric D.; Steenland, Maria W.; Vertefeuille, John F.; Tappero, Jordan W.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Magloire, Roc] Minist Sante Publ & Populat, Direct Epidemiol Lab & Rech, Port Au Prince, Haiti. [Mung, Kam S.] Pan Amer Hlth Org, Port Au Prince, Haiti. [Boncy, Jacques] Minist Sante Publ & Populat, Lab Natl Sante Publ, Port Au Prince, Haiti. [Dahourou, Georges A.; Vertefeuille, John F.] Ctr Dis Control & Prevent, Haiti Off, Port Au Prince, Haiti. RP Barzilay, EJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-05, Atlanta, GA 30329 USA. EM ebarzilay@cdc.gov NR 48 TC 64 Z9 69 U1 3 U2 41 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 14 PY 2013 VL 368 IS 7 BP 599 EP 609 DI 10.1056/NEJMoa1204927 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 194VA UT WOS:000322659600005 PM 23301694 ER PT J AU Edwards, KM Zhu, YW Griffin, MR Weinberg, GA Hall, CB Szilagyi, PG Staat, MA Iwane, M Prill, MM Williams, JV AF Edwards, Kathryn M. Zhu, Yuwei Griffin, Marie R. Weinberg, Geoffrey A. Hall, Caroline B. Szilagyi, Peter G. Staat, Mary A. Iwane, Marika Prill, Mila M. Williams, John V. CA New Vaccine Surveillance Network TI Burden of Human Metapneumovirus Infection in Young Children SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID RESPIRATORY SYNCYTIAL VIRUS; OBSTRUCTIVE PULMONARY-DISEASE; LUNG-TRANSPLANT RECIPIENTS; POLYMERASE-CHAIN-REACTION; TERM-CARE FACILITY; HOSPITALIZED CHILDREN; TRACT INFECTIONS; HEMATOLOGIC MALIGNANCIES; INFLUENZA-VIRUS; VIRAL LOAD AB BACKGROUND The inpatient and outpatient burden of human metapneumovirus (HMPV) infection among young children has not been well established. METHODS We conducted prospective, population-based surveillance for acute respiratory illness or fever among inpatient and outpatient children less than 5 years of age in three U.S. counties from 2003 through 2009. Clinical and demographic data were obtained from parents and medical records, HMPV was detected by means of a reverse-transcriptase polymerase-chain-reaction assay, and population-based rates of hospitalization and estimated rates of outpatient visits associated with HMPV infection were determined. RESULTS HMPV was detected in 200 of 3490 hospitalized children (6%), 222 of 3257 children in outpatient clinics (7%), 224 of 3001 children in the emergency department (7%), and 10 of 770 asymptomatic controls (1%). Overall annual rates of hospitalization associated with HMPV infection were 1 per 1000 children less than 5 years of age, 3 per 1000 infants less than 6 months of age, and 2 per 1000 children 6 to 11 months of age. Children hospitalized with HMPV infection, as compared with those hospitalized without HMPV infection, were older and more likely to receive a diagnosis of pneumonia or asthma, to require supplemental oxygen, and to have a longer stay in the intensive care unit. The estimated annual burden of outpatient visits associated with HMPV infection was 55 clinic visits and 13 emergency department visits per 1000 children. The majority of HMPV-positive inpatient and outpatient children had no underlying medical conditions, although premature birth and asthma were more frequent among hospitalized children with HMPV infection than among those without HMPV infection. CONCLUSIONS HMPV infection is associated with a substantial burden of hospitalizations and outpatient visits among children throughout the first 5 years of life, especially during the first year. Most children with HMPV infection were previously healthy. C1 [Edwards, Kathryn M.; Williams, John V.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA. [Zhu, Yuwei] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA. [Griffin, Marie R.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA. [Williams, John V.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA. [Weinberg, Geoffrey A.; Hall, Caroline B.; Szilagyi, Peter G.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA. [Hall, Caroline B.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA. [Staat, Mary A.] Cincinnati Childrens Hosp, Dept Pediat, Cincinnati, OH USA. [Iwane, Marika; Prill, Mila M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Williams, JV (reprint author), Vanderbilt Univ, Med Ctr, D-7235 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA. EM john.williams@vanderbilt.edu FU Centers for Disease Control and Prevention; National Institutes of Health FX Funded by the Centers for Disease Control and Prevention and the National Institutes of Health.) NR 55 TC 87 Z9 94 U1 1 U2 8 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 14 PY 2013 VL 368 IS 7 BP 633 EP 643 DI 10.1056/NEJMoa1204630 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 194VA UT WOS:000322659600008 PM 23406028 ER PT J AU Bitencourt, AR Vicentin, EC Jimenez, MC Ricci, R Leite, JA Costa, FT Ferreira, LC Russell, B Nosten, F Renia, L Galinski, MR Barnwell, JW Rodrigues, MM Soares, IS AF Bitencourt, Amanda R. Vicentin, Elaine C. Jimenez, Maria C. Ricci, Ricardo Leite, Juliana A. Costa, Fabio T. Ferreira, Luis C. Russell, Bruce Nosten, Francois Renia, Laurent Galinski, Mary R. Barnwell, John W. Rodrigues, Mauricio M. Soares, Irene S. TI Antigenicity and Immunogenicity of Plasmodium vivax Merozoite Surface Protein-3 SO PLOS ONE LA English DT Article ID LONG SYNTHETIC PEPTIDES; DUFFY BINDING-PROTEIN; BLOOD-STAGE VACCINE; C-TERMINAL REGIONS; MALARIA VACCINE; IMMUNE-RESPONSES; CIRCUMSPOROZOITE PROTEIN; PROTECTIVE EFFICACY; CANDIDATE MSP1(19); ANTIBODY-RESPONSE AB A recent clinical trial in African children demonstrated the potential utility of merozoite surface protein (MSP)-3 as a vaccine against Plasmodium falciparum malaria. The present study evaluated the use of Plasmodium vivax MSP-3 (PvMSP-3) as a target antigen in vaccine formulations against malaria caused by P. vivax. Recombinant proteins representing MSP-3 alpha and MSP-3 beta of P. vivax were expressed as soluble histidine-tagged bacterial fusions. Antigenicity during natural infection was evaluated by detecting specific antibodies using sera from individuals living in endemic areas of Brazil. A large proportion of infected individuals presented IgG antibodies to PvMSP-3 alpha (68.2%) and at least 1 recombinant protein representing PvMSP-3 beta (79.1%). In spite of the large responder frequency, reactivity to both antigens was significantly lower than was observed for the immunodominant epitope present on the 19-kDa C-terminal region of PvMSP-1. Immunogenicity of the recombinant proteins was studied in mice in the absence or presence of different adjuvant formulations. PvMSP-3 beta, but not PvMSP-3 alpha, induced a TLR4-independent humoral immune response in the absence of any adjuvant formulation. The immunogenicity of the recombinant antigens were also tested in formulations containing different adjuvants (Alum, Salmonella enterica flagellin, CpG, Quil A, TiterMax (R) and incomplete Freunds adjuvant) and combinations of two adjuvants (Alum plus flagellin, and CpG plus flagellin). Recombinant PvMSP-3 alpha and PvMSP-3 beta elicited higher antibody titers capable of recognizing P. vivax-infected erythrocytes harvested from malaria patients. Our results confirm that P. vivax MSP-3 antigens are immunogenic during natural infection, and the corresponding recombinant proteins may be useful in elucidating their vaccine potential. C1 [Bitencourt, Amanda R.; Vicentin, Elaine C.; Jimenez, Maria C.; Ricci, Ricardo; Soares, Irene S.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo, Brazil. [Leite, Juliana A.; Costa, Fabio T.] Univ Estadual Campinas, Dept Genet Evolucao & Bioagentes, Inst Biol, Campinas, SP, Brazil. [Ferreira, Luis C.] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, BR-05508 Sao Paulo, Brazil. [Russell, Bruce] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Singapore 117595, Singapore. [Russell, Bruce; Renia, Laurent] Agcy Sci Technol & Res, Singapore Immunol Network, Biopolis, Singapore, Singapore. [Nosten, Francois] Churchill Hosp, Ctr Vaccinol & Trop Med, Oxford OX3 7LJ, England. [Nosten, Francois] Mahidol Oxford Univ Trop Med Res Programme, Shoklo Malaria Res Unit, Mae Sot, Thailand. [Galinski, Mary R.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA. [Galinski, Mary R.] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. [Galinski, Mary R.] Emory Univ, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA. [Barnwell, John W.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis, Chamblee, GA USA. [Rodrigues, Mauricio M.] Univ Fed Sao Paulo, CTCMOL, Dept Microbiol Imunol & Parasitol, Escola Paulista Med, Sao Paulo, Brazil. RP Soares, IS (reprint author), Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo, Brazil. EM isoares@usp.br RI Rodrigues, Mauricio/B-8512-2012; Soares, Irene/C-5974-2012; Vicentin, Elaine/F-2651-2013; Costa, Fabio/E-1181-2012; Leite, Juliana/G-2563-2013; Russell, Bruce/A-9240-2011; OI Russell, Bruce/0000-0003-2333-4348; Nosten, Francois/0000-0002-7951-0745 FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/09893-0]; National Institute for Vaccine Development and Technology (CNPq - INCTV); FAPESP; CNPq; US National Institutes of Health, National Institute for Allergy and Infectious Diseases [1R01AI24710]; SIgN; Horizontal Programme on Infectious Diseases under the Agency for Science, Technology and Research (A*STAR, Singapore); Wellcome Trust of Great Britain, as part of the Oxford Tropical Medicine Research Programme of Wellcome Trust-Mahidol University FX This work was supported by grants from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, 2010/09893-0) and The National Institute for Vaccine Development and Technology (CNPq - INCTV). ARB, MCJ and JAL were supported by fellowships from FAPESP. ECV, RR, FTC, LCF, MMR and ISS were supported by fellowships from CNPq. Support is also acknowledged from the US National Institutes of Health, National Institute for Allergy and Infectious Diseases to MRG (1R01AI24710), from SIgN and from the Horizontal Programme on Infectious Diseases under the Agency for Science, Technology and Research (A*STAR, Singapore). SMRU is sponsored by The Wellcome Trust of Great Britain, as part of the Oxford Tropical Medicine Research Programme of Wellcome Trust-Mahidol University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 11 Z9 11 U1 0 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 14 PY 2013 VL 8 IS 2 AR e56061 DI 10.1371/journal.pone.0056061 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 099EJ UT WOS:000315602700037 PM 23457498 ER PT J AU Roellig, DM Savage, MY Fujita, AW Barnabe, C Tibayrenc, M Steurer, FJ Yabsley, MJ AF Roellig, Dawn M. Savage, Mason Y. Fujita, A. Wendy Barnabe, Christian Tibayrenc, Michel Steurer, Frank J. Yabsley, Michael J. TI Genetic Variation and Exchange in Trypanosoma cruzi Isolates from the United States SO PLOS ONE LA English DT Article ID POLYMERASE-CHAIN-REACTION; ST-CATHERINES ISLAND; CHAGAS-DISEASE; AUTOCHTHONOUS TRANSMISSION; AMERICAN TRYPANOSOMIASIS; PHYLOGENETIC LINEAGES; NUCLEOTIDE-SEQUENCES; BASIC MECHANISM; DIVERSITY; STRAINS AB Trypanosoma cruzi, the causative agent of Chagas disease, is a multiclonal parasite with high levels of genetic diversity and broad host and geographic ranges. Molecular characterization of South American isolates of T. cruzi has demonstrated homologous recombination and nuclear hybridization, as well as the presence of 6 main genetic clusters or "discrete typing units'' (DTUs). Few studies have extensively investigated such exchange events and genetic diversity in North American isolates. In the current study, we genetically characterized over 50 US isolates from wildlife reservoirs (e.g., raccoons, opossums, armadillos, skunks), domestic dogs, humans, nonhuman primates, and reduviid vectors from nine states (TX, CA, OK, SC, FL, GA, MD, LA, TN) using a multilocus sequencing method. Single nucleotide polymorphisms were identified in sequences of the mismatch-repair class 2 (MSH2) and Tc52 genes. Typing based on the two genes often paralleled genotyping by classic methodologies using mini-exon and 18S and 24S alpha rRNA genes. Evidence for genetic exchange was obtained by comparing sequence phylogenies of nuclear and mitochondrial gene targets, dihydrofolate reductase-thymidylate synthase (DHFR-TS) and the cytochrome oxidase subunit II- NADH dehydrogenase subunit I region (COII-ND1), respectively. We observed genetic exchange in several US isolates as demonstrated by incongruent mitochondrial and nuclear genes phylogenies, which confirms a previous finding of a single genetic exchange event in a Florida isolate. The presence of SNPs and evidence of genetic exchange illustrates that strains from the US are genetically diverse, even though only two phylogenetic lineages have been identified in this region. C1 [Roellig, Dawn M.; Savage, Mason Y.; Fujita, A. Wendy; Yabsley, Michael J.] Univ Georgia, Coll Vet Med, Southeastern Cooperat Wildlife Dis Study, Athens, GA 30602 USA. [Roellig, Dawn M.] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA USA. [Barnabe, Christian] Univ Montpellier I, MIVEGEC, IRD, CNRS 5290,IRD 224, La Paz, Bolivia. [Barnabe, Christian] Univ Montpellier 2, MIVEGEC, IRD, CNRS 5290,IRD 224, La Paz, Bolivia. [Tibayrenc, Michel] Univ Montpellier I, Ctr Natl Rech Sci, Inst Rech Dev, MIVEGEC,CNRS 5290,IRD 224,IRD Ctr, Montpellier, France. [Tibayrenc, Michel] Univ Montpellier 2, Univ Montpellier 1, Ctr Natl Rech Sci, MIVEGEC,CNRS 5290,IRD 224,Inst Rech Dev,IRD Ctr, Montpellier, France. [Steurer, Frank J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Yabsley, Michael J.] Univ Georgia, DB Warnell Sch Forestry & Nat Resources, Athens, GA 30602 USA. RP Roellig, DM (reprint author), Univ Georgia, Coll Vet Med, Southeastern Cooperat Wildlife Dis Study, Athens, GA 30602 USA. EM iyd4@cdc.gov RI Barnabe, Christian/R-2904-2016 OI Barnabe, Christian/0000-0003-1857-0741 FU National Institutes of Health, National Institute of Allergy and Infectious Diseases grant [R15 AI067304] FX This study was supported by the National Institutes of Health, National Institute of Allergy and Infectious Diseases grant R15 AI067304. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 61 TC 23 Z9 24 U1 0 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 14 PY 2013 VL 8 IS 2 AR e56198 DI 10.1371/journal.pone.0056198 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 099EJ UT WOS:000315602700060 PM 23457528 ER PT J AU Agaku, I King, B Dube, SR AF Agaku, Israel King, Brian Dube, Shanta R. TI Current Cigarette Smoking Among Adults-United States, 2011 (Reprinted from vol 44, pg 889-894, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Agaku, Israel; King, Brian; Dube, Shanta R.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Agaku, I (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM iagaku@cdc.gov NR 11 TC 4 Z9 4 U1 1 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 13 PY 2013 VL 309 IS 6 BP 539 EP 541 DI 10.1001/jama.2012.114523 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 087PH UT WOS:000314773700009 ER PT J AU Kayentao, K Garner, P van Eijk, AM Naidoo, I Roper, C Mulokozi, A MacArthur, JR Luntamo, M Ashorn, P Doumbo, OK ter Kuile, FO AF Kayentao, Kassoum Garner, Paul van Eijk, Anne Maria Naidoo, Inbarani Roper, Cally Mulokozi, Abdunoor MacArthur, John R. Luntamo, Mari Ashorn, Per Doumbo, Ogobara K. ter Kuile, Feiko O. TI Intermittent Preventive Therapy for Malaria During Pregnancy Using 2 vs 3 or More Doses of Sulfadoxine-Pyrimethamine and Risk of Low Birth Weight in Africa Systematic Review and Meta-analysis SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID PLASMODIUM-FALCIPARUM MALARIA; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; DRUG-RESISTANCE; BURKINA-FASO; MOLECULAR MARKERS; ZAMBIAN WOMEN; EFFICACY; BURDEN; ANEMIA AB Importance Intermittent preventive therapy with sulfadoxine-pyrimethamine to control malaria during pregnancy is used in 37 countries in sub-Saharan Africa, and 31 of those countries use the standard 2-dose regimen. However, 2 doses may not provide protection during the last 4 to 10 weeks of pregnancy, a pivotal period for fetal weight gain. Objective To perform a systematic review and meta-analysis of trials to determine whether regimens containing 3 or more doses of sulfadoxine-pyrimethamine for intermittent preventive therapy during pregnancy are associated with a higher birth weight or lower risk of low birth weight (LBW) (<2500 g) than standard 2-dose regimens. Data Sources and Study Selection ISI Web of Knowledge, EMBASE, SCOPUS, PubMed, LILACS, the Malaria in Pregnancy Library, Cochrane CENTRAL, and trial registries from their inception to December 2012, without language restriction. Eligible studies included randomized and quasi-randomized trials of intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine monotherapy. Data Extraction Data were independently abstracted by 2 investigators. Relative risk (RR), mean differences, and 95% CIs were calculated with random-effects models. Results Of 241 screened studies, 7 trials of 6281 pregnancies were included. The median birth weight in the 2-dose group was 2870 g (range, 2722-3239 g) and on average 56 g higher (95% CI, 29-83 g; I-2=0%) in the >= 3-dose group. Three or more doses were associated with fewer LBW births (RR, 0.80; 95% CI, 0.69-0.94; I-2=0%), with a median LBW risk per 1000 women in the 2-dose group (assumed control group risk) of 167 per 1000 vs 134 per 1000 in the >= 3-dose group (absolute risk reduction, 33 per 1000 [95% CI, 10-52]; number needed to treat=31). The association was consistent across a wide range of sulfadoxine-pyrimethamine resistance (0% to 96% dihydropteroate-synthase K540E mutations). There was no evidence of small-study bias. The >= 3-dose group had less placental malaria (RR, 0.51; 95% CI, 0.38-0.68; I-2=0%, in 6 trials, 63 vs 32 per 1000; absolute risk reduction, 31 per 1000[95% CI, 20-39]). In primigravid plus secundigravid women, the risk of moderate to severe maternal anemia was lower in the >= 3-dose group (RR, 0.60; 95% CI, 0.36-0.99; I-2=20%; in 6 trials, 36 vs 22 per 1000; absolute risk reduction, 14 per 1000 [95% CI, 0.4-23]). There were no differences in rates of serious adverse events. Conclusions and Relevance Among pregnant women in sub-Saharan Africa, intermittent preventive therapy with 3 or more doses of sulfadoxine-pyrimethamine was associated with a higher birth weight and lower risk of LBW than the standard 2-dose regimens. These data provide support for the new WHO recommendations to provide at least 3 doses of intermittent preventive therapy during pregnancy at each scheduled antenatal care visit in the second and third trimester. JAMA. 2013;309(6):594-604 www.jama.com C1 [Kayentao, Kassoum; Garner, Paul; van Eijk, Anne Maria; ter Kuile, Feiko O.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. [Kayentao, Kassoum; Doumbo, Ogobara K.] Univ Bamako, Fac Med Pharm & Dent, Dept Epidemiol Parasit Dis, Malaria Res & Training Ctr, Bamako, Mali. [Naidoo, Inbarani] MRC, Malaria Res Unit, Overport, South Africa. [Roper, Cally] London Sch Hyg & Trop Med, London WC1, England. [Mulokozi, Abdunoor] Ifakara Hlth Res & Dev Ctr, Dar Es Salaam, Tanzania. [MacArthur, John R.] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Ashorn, Per] Univ Tampere, Sch Med, Dept Int Hlth, FIN-33101 Tampere, Finland. RP ter Kuile, FO (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Pembroke Pl, Liverpool L3 5QA, Merseyside, England. EM terkuile@liv.ac.uk RI Roper, Cally/K-2989-2013; OI Roper, Cally/0000-0002-6545-309X; Garner, Paul/0000-0002-0607-6941; ter Kuile, Feiko/0000-0003-3663-5617 FU Centers for Disease Control and Prevention; Academy of Finland; Finnish Cultural Foundation; European and Developing Countries Clinical Trials Partnership, The Hague, the Netherlands; Malaria in Pregnancy Consortium; Bill & Melinda Gates Foundation; National Institute of Allergy and Infectious Diseases (NIH) FX This review was funded by a grant from the Centers for Disease Control and Prevention for salary support through a cooperative agreement between the Division of Parasitic Diseases and Malaria (Centers for Disease Control and Prevention, USA) and the Malaria Epidemiology Unit of the Child and Reproductive Health Group, Liverpool School of Tropical Medicine (LSTM), held by Dr ter Kuile. Dr Ashorn and Dr Luntamo were supported by grants from the Academy of Finland and the Finnish Cultural Foundation. Dr Kayentao was supported by a PhD training grant from the European and Developing Countries Clinical Trials Partnership, The Hague, the Netherlands. Drs ter Kuile and van Eijk are partly funded by the Malaria in Pregnancy Consortium, which is funded through a grant from the Bill & Melinda Gates Foundation to the LSTM. Dr Doumbo reports receiving support from National Institute of Allergy and Infectious Diseases (NIH). NR 48 TC 65 Z9 65 U1 0 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 13 PY 2013 VL 309 IS 6 BP 594 EP 604 DI 10.1001/jama.2012.216231 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 087PH UT WOS:000314773700032 PM 23403684 ER PT J AU Berry, RJ Crider, KS Yeargin-Allsopp, M AF Berry, Robert J. Crider, Krista S. Yeargin-Allsopp, Marshalyn TI Periconceptional Folic Acid and Risk of Autism Spectrum Disorders SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID FOLATE STATUS; PREGNANCY; CHILDREN; SUPPLEMENTATION; GENETICS; DELAY C1 [Berry, Robert J.; Crider, Krista S.; Yeargin-Allsopp, Marshalyn] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disorders, Natl Ctr Birth Defects & Dev Disorders, Atlanta, GA 30333 USA. RP Berry, RJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop E-86, Atlanta, GA 30333 USA. EM rjberry@cdc.gov OI Berry, Robert/0000-0002-7162-5046 FU Intramural CDC HHS [CC999999] NR 16 TC 5 Z9 5 U1 2 U2 24 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 13 PY 2013 VL 309 IS 6 BP 611 EP 613 DI 10.1001/jama.2013.198 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 087PH UT WOS:000314773700036 PM 23403688 ER PT J AU Patil, K El Khoury, M Marks, S Braun, A Visvesvara, GS Wang, GQ AF Patil, Kiran El Khoury, Marc Marks, Stephen Braun, Alex Visvesvara, Govinda S. Wang, Guiqing TI Balamuthia Mandrillaris in Returning Traveler and Aquarium Handler: A Death Sentence SO NEUROLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN) CY MAR 16-23, 2013 CL San Diego, CA SP Amer Acad Neurol C1 [Patil, Kiran] New York Med Coll, Millwood, NY USA. [El Khoury, Marc; Braun, Alex; Wang, Guiqing] New York Med Coll, Valhalla, NY 10595 USA. [Marks, Stephen] New York Med Coll, Tarrytown, NY USA. [Visvesvara, Govinda S.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 12 PY 2013 VL 80 SU S MA P04019 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA AB8VR UT WOS:000332068602258 ER PT J AU Thangarajh, M Yang, GY McKinstry, R Noetzel, M Casella, J Fuchs, D Alok, J Hooper, WC Barron-Casella, E Ponisio, R Vendt, B Bean, C Rodeghier, M Boulet, S Pyle, M Payne, A Driggers, J Trau, H DeBaun, M AF Thangarajh, Mathula Yang, Genyan McKinstry, Robert Noetzel, Michael Casella, James Fuchs, Dana Alok, Jaju Hooper, W. Craig Barron-Casella, Emily Ponisio, Rosanna Vendt, Bruce Bean, Christopher Rodeghier, Mark Boulet, Sheree Pyle, Meredith Payne, Amanda Driggers, Jennifer Trau, Heidi DeBaun, Michael TI Magnetic Resonance Angiography-Defined Intracranial Vasculopathy Is Associated with Silent Cerebral Infarcts, and Glucose-6-Phosphate Dehydrogenase Mutation in Children with Sickle Cell Anemia SO NEUROLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN) CY MAR 16-23, 2013 CL San Diego, CA SP Amer Acad Neurol C1 [Thangarajh, Mathula; McKinstry, Robert; Noetzel, Michael; Fuchs, Dana; Ponisio, Rosanna; Vendt, Bruce] Washington Univ, St Louis, MO USA. [Yang, Genyan; Hooper, W. Craig; Bean, Christopher; Boulet, Sheree; Pyle, Meredith; Payne, Amanda; Driggers, Jennifer; Trau, Heidi] CDC, Atlanta, GA 30333 USA. [Casella, James] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Alok, Jaju] Northwestern Univ, Chicago, IL 60611 USA. [Barron-Casella, Emily] Johns Hopkins, Baltimore, MD USA. [DeBaun, Michael] Vanderbilt Univ, Nashville, TN 37235 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 12 PY 2013 VL 80 SU S MA S29001 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA AB8VR UT WOS:000332068606122 ER PT J AU Allen, JA Li, RW Scanlon, KS Perrine, CG Chen, J Odom, E Black, C AF Allen, Jessica A. Li, Ruowei Scanlon, Kelley S. Perrine, Cria G. Chen, Jian Odom, Erika Black, Carla TI Progress in Increasing Breastfeeding and Reducing Racial/Ethnic Differences - United States, 2000-2008 Births SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Allen, Jessica A.; Li, Ruowei; Scanlon, Kelley S.; Perrine, Cria G.; Chen, Jian] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Odom, Erika] CDC, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Black, Carla] CDC, Div Immunizat, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Allen, JA (reprint author), CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM ixm4@cdc.gov NR 9 TC 71 Z9 71 U1 1 U2 6 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 8 PY 2013 VL 62 IS 5 BP 77 EP 80 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188EM UT WOS:000322175000001 ER PT J AU Gfroerer, J Dube, SR King, BA Garrett, BE Babb, S McAfee, T AF Gfroerer, Joe Dube, Shanta R. King, Brian A. Garrett, Bridgette E. Babb, Stephen McAfee, Timothy TI Vital Signs: Current Cigarette Smoking Among Adults Aged >= 18 Years with Mental Illness - United States, 2009-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PREVALENCE; HEALTH; DEPENDENCE; DISORDERS; CESSATION AB Background: Cigarette smoking remains the leading cause of preventable morbidity and mortality in the United States. Despite overall declines in cigarette smoking, a high prevalence of smoking persists among certain subpopulations, including persons with mental illness. Methods: Combined data from the 2009-2011 National Survey on Drug Use and Health (NSDUH) were used to calculate national and state estimates of cigarette smoking among adults aged >= 18 years who had any mental illness (AMI), defined as having a mental, behavioral, or emotional disorder, excluding developmental and substance use disorders, in the past 12 months. Results: During 2009-2011, an annual average of 19.9% of adults aged >= 18 years had AMI; among these persons, 36.1% were current smokers, compared with 21.4 % among adults with no mental illness. Smoking prevalence among those with AMI was highest among men, adults aged <45 years, and those living below the poverty level; smoking prevalence was lowest among college graduates. During 2009-2011, adults with AMI smoked 30.9% of all cigarettes smoked by adults. By U. S. region, smoking prevalence among those with AMI was lowest in the West (31.5%) and Northeast (34.7%) and highest in the Midwest (39.1%) and South (37.8%), with state prevalence ranging from 18.2% (Utah) to 48.7% (West Virginia). Conclusions: The prevalence of cigarette smoking is high among adults with AMI, especially for younger adults, those with low levels of education, and those living below the poverty level; the prevalence varies by U.S. region. C1 [Gfroerer, Joe] CDC, Ctr Behav Hlth Stat & Qual, Substance Abuse & Mental Hlth Serv Adm, Atlanta, GA 30333 USA. [Dube, Shanta R.; King, Brian A.; Garrett, Bridgette E.; Babb, Stephen; McAfee, Timothy] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Dube, SR (reprint author), CDC, Ctr Behav Hlth Stat & Qual, Substance Abuse & Mental Hlth Serv Adm, Atlanta, GA 30333 USA. EM sdube@cdc.gov NR 22 TC 94 Z9 95 U1 0 U2 6 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 8 PY 2013 VL 62 IS 5 BP 81 EP 87 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188EM UT WOS:000322175000002 ER PT J AU Briggs, G Anderson, S Komatsu, K Weiss, J Henke, E Tsang, CA Vasiq, M Rao, AK Mody, RK Luquez, C Dykes, JK Morris, JF Anderson, TC Adams, LE Yasmin, S AF Briggs, Graham Anderson, Shoana Komatsu, Kenneth Weiss, Joli Henke, Evan Tsang, Clarisse A. Vasiq, Muhammad Rao, Agam K. Mody, Rajal K. Luquez, Carolina Dykes, Janet K. Morris, Jamae F. Anderson, Tara C. Adams, Laura E. Yasmin, Seema TI Botulism From Drinking Prison-Made Illicit Alcohol - Arizona, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Vasiq, Muhammad] Mt Vista Med Ctr, Mesa, AZ USA. [Adams, Laura E.; Yasmin, Seema] CDC, Atlanta, GA 30333 USA. EM syasmin@cdc.gov NR 2 TC 7 Z9 7 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 8 PY 2013 VL 62 IS 5 BP 88 EP 88 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188EM UT WOS:000322175000003 ER PT J AU Green, MD Mayxay, M Beach, R Pongvongsa, T Phompida, S Hongvanthong, B Vanisaveth, V Newton, PN Vizcaino, L Swamidoss, I AF Green, Michael D. Mayxay, Mayfong Beach, Ray Pongvongsa, Tiengkham Phompida, Samlane Hongvanthong, Bouasy Vanisaveth, Viengxay Newton, Paul N. Vizcaino, Lucrecia Swamidoss, Isabel TI Evaluation of a rapid colorimetric field test to assess the effective life of long-lasting insecticide-treated mosquito nets in the Lao PDR SO MALARIA JOURNAL LA English DT Article DE Permanet; ITN; LLIN; Deltamethrin; Colorimetric; Bioassay; Mosquito; Malaria; Net; Lao PDR; Laos AB Background: Malaria morbidity and mortality have been significantly reduced through the proper use of insecticide-treated mosquito nets, but the extra protection afforded by the insecticide diminishes over time. The insecticide depletion rates vary according to location where wash frequency and wear are influenced by cultural habits as well as the availability of water. Monitoring of available insecticides on the net surface is essential for determining the effective life of the net. Therefore, a rapid and inexpensive colorimetric field test for cyanopyrethroids (Cyanopyrethroid Field Test or CFT) was used to measure surface levels of deltamethrin on insecticide-coated polyester nets (PowerNets (TM)) in rural Lao PDR over a two-year period. Methods: Net surface levels of deltamethrin were measured by wiping the net with filter paper and measuring the adsorbed deltamethrin using the CFT. A relationship between surface levels of deltamethrin and whole net levels was established by comparing results of the CFT with whole levels assayed by high-performance liquid chromatography (HPLC). An effective deltamethrin surface concentration (EC80) was determined by comparing mosquito mortality (WHO Cone Test) with CFT and HPLC results. Five positions (roof to bottom) on each of 23 matched nets were assayed for deltamethrin surface levels at 6, 12, and 24 months. Mosquito mortality assays (WHO Cone Tests) were performed on a subset of eleven 24-month old nets and compared with the proportion of failed nets as predicted by the CFT. Results: At six months, the nets retained about 80% of the baseline (new net) levels of deltamethrin with no significant differences between net positions. At 12 months, similar to 15-40%, and at 24 months <10% of deltamethrin was retained on the nets, with significant differences appearing between positions. Results from the CFT show that 93% of the nets failed (deltamethrin surface levels = 3 days from onset) or delayed initiation of antiviral treatment (>= 5 days from onset) were associated with severe illness among non-pregnant patients >= 2 years of age. Conclusions/Significance: We observed a change in high risk groups for hospitalization for 2009 H1N1 during the winter months immediately following the pandemic period compared to the high risk groups identified during the pandemic period. Our nationally notifiable disease surveillance system enabled us to understand the evolving epidemiology of 2009 H1N1 infection after the pandemic period. C1 [Xu, Cuiling; Chen, Min; Chen, Tao; Shi, Jinghong; Yang, Jing; Wang, Lijie; Yuan, Fan; Shu, Yuelong] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Infect Dis Control & Prevent, Beijing, Peoples R China. [Iuliano, A. Danielle; Cheng, Po-Yung; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA. RP Shu, YL (reprint author), Chinese Ctr Dis Control & Prevent, Natl Inst Viral Infect Dis Control & Prevent, Beijing, Peoples R China. EM yshu@cnic.org.cn OI Widdowson, Marc-Alain/0000-0002-0682-6933 FU Ministry of Health, China FX We thank the participating hospitals, local health departments and Centers for Disease Control and Prevention in China for assistance in coordinating data collection, and the Ministry of Health, China for supporting this study. NR 34 TC 1 Z9 1 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 5 PY 2013 VL 8 IS 2 AR e55016 DI 10.1371/journal.pone.0055016 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 086NV UT WOS:000314692800017 PM 23393563 ER PT J AU Slayton, RB Turabelidze, G Bennett, SD Schwensohn, CA Yaffee, AQ Khan, F Butler, C Trees, E Ayers, TL Davis, ML Laufer, AS Gladbach, S Williams, I Gieraltowski, LB AF Slayton, Rachel B. Turabelidze, George Bennett, Sarah D. Schwensohn, Colin A. Yaffee, Anna Q. Khan, Faisal Butler, Cindy Trees, Eija Ayers, Tracy L. Davis, Marjorie L. Laufer, Alison S. Gladbach, Stephen Williams, Ian Gieraltowski, Laura B. TI Outbreak of Shiga Toxin-Producing Escherichia coli (STEC) O157:H7 Associated with Romaine Lettuce Consumption, 2011 SO PLOS ONE LA English DT Article ID FOODBORNE ILLNESS; UNITED-STATES; CALIFORNIA; O157-H7 AB Background: Shiga toxin-producing Escherichia coli (STEC) O157:H7 is the causal agent for more than 96,000 cases of diarrheal illness and 3,200 infection-attributable hospitalizations annually in the United States. Materials and Methods: We defined a confirmed case as a compatible illness in a person with the outbreak strain during 10/07/2011-11/30/2011. Investigation included hypothesis generation, a case-control study utilizing geographically-matched controls, and a case series investigation. Environmental inspections and tracebacks were conducted. Results: We identified 58 cases in 10 states; 67% were hospitalized and 6.4% developed hemolytic uremic syndrome. Any romaine consumption was significantly associated with illness (matched Odds Ratio (mOR) = 10.0, 95% Confidence Interval (CI) = 2.1-97.0). Grocery Store Chain A salad bar was significantly associated with illness (mOR = 18.9, 95% CI = 4.5-176.8). Two separate traceback investigations for romaine lettuce converged on Farm A. Case series results indicate that cases (64.9%) were more likely than the FoodNet population (47%) to eat romaine lettuce (p-value = 0.013); 61.3% of cases reported consuming romaine lettuce from the Grocery Store Chain A salad bar. Conclusions: This multistate outbreak of STEC O157:H7 infections was associated with consumption of romaine lettuce. Traceback analysis determined that a single common lot of romaine lettuce harvested from Farm A was used to supply Grocery Store Chain A and a university campus linked to a case with the outbreak strain. An investigation at Farm A did not identify the source of contamination. Improved ability to trace produce from the growing fields to the point of consumption will allow more timely prevention and control measures to be implemented. C1 [Slayton, Rachel B.; Bennett, Sarah D.; Laufer, Alison S.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Slayton, Rachel B.; Bennett, Sarah D.; Schwensohn, Colin A.; Yaffee, Anna Q.; Trees, Eija; Ayers, Tracy L.; Laufer, Alison S.; Williams, Ian; Gieraltowski, Laura B.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Turabelidze, George; Butler, Cindy; Gladbach, Stephen] Missouri Dept Hlth & Senior Serv, Eastern Dist Off, St Louis, MO USA. [Khan, Faisal] St Louis Cty Dept Hlth, Communicable Dis Control Serv, St Louis, MO USA. [Davis, Marjorie L.] US FDA, Coordinated Outbreak Response & Evaluat Team, College Pk, MD USA. RP Slayton, RB (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM RSlayton@cdc.gov OI Slayton, Rachel/0000-0003-4699-8040; Ayers, Tracy/0000-0003-4140-3263 NR 12 TC 13 Z9 13 U1 1 U2 27 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 4 PY 2013 VL 8 IS 2 AR e55300 DI 10.1371/journal.pone.0055300 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 086NH UT WOS:000314691100041 PM 23390525 ER PT J AU Bousema, T Stevenson, J Baidjoe, A Stresman, G Griffin, JT Kleinschmidt, I Remarque, EJ Vulule, J Bayoh, N Laserson, K Desai, M Sauerwein, R Drakeley, C Cox, J AF Bousema, Teun Stevenson, Jennifer Baidjoe, Amrish Stresman, Gillian Griffin, Jamie T. Kleinschmidt, Immo Remarque, Edmond J. Vulule, John Bayoh, Nabie Laserson, Kayla Desai, Meghna Sauerwein, Robert Drakeley, Chris Cox, Jonathan TI The impact of hotspot-targeted interventions on malaria transmission: study protocol for a cluster-randomized controlled trial SO TRIALS LA English DT Article DE Anopheles; elimination; epidemiology; eradication; falciparum; heterogeneity; immunology; malaria; molecular; transmission ID DAR-ES-SALAAM; DRIED BLOOD SPOTS; PAPUA-NEW-GUINEA; WESTERN KENYA; PLASMODIUM-FALCIPARUM; ANOPHELES-GAMBIAE; CHILD-MORTALITY; LIGHT-TRAP; BED NETS; TANZANIA AB Background: Malaria transmission is highly heterogeneous in most settings, resulting in the formation of recognizable malaria hotspots. Targeting these hotspots might represent a highly efficacious way of controlling or eliminating malaria if the hotspots fuel malaria transmission to the wider community. Methods/design: Hotspots of malaria will be determined based on spatial patterns in age-adjusted prevalence and density of antibodies against malaria antigens apical membrane antigen-1 and merozoite surface protein-1. The community effect of interventions targeted at these hotspots will be determined. The intervention will comprise larviciding, focal screening and treatment of the human population, distribution of long-lasting insecticide-treated nets and indoor residual spraying. The impact of the intervention will be determined inside and up to 500 m outside the targeted hotspots by PCR-based parasite prevalence in cross-sectional surveys, malaria morbidity by passive case detection in selected facilities and entomological monitoring of larval and adult Anopheles populations. Discussion: This study aims to provide direct evidence for a community effect of hotspot-targeted interventions. The trial is powered to detect large effects on malaria transmission in the context of ongoing malaria interventions. Follow-up studies will be needed to determine the effect of individual components of the interventions and the cost-effectiveness of a hotspot-targeted approach, where savings made by reducing the number of compounds that need to receive interventions should outweigh the costs of hotspot-detection. C1 [Bousema, Teun; Stresman, Gillian; Drakeley, Chris] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Immunol & Infect, London WC1, England. [Bousema, Teun; Baidjoe, Amrish; Sauerwein, Robert] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands. [Stevenson, Jennifer; Cox, Jonathan] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Dis Control, London WC1, England. [Griffin, Jamie T.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, MRC Ctr Outbreak Anal & Modelling, London, England. [Kleinschmidt, Immo] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, MRC Trop Epidemiol Grp, London WC1, England. [Remarque, Edmond J.] Biomed Primate Res Ctr, Dept Parasitol, Rijswijk, Netherlands. [Vulule, John; Bayoh, Nabie; Laserson, Kayla; Desai, Meghna] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Laserson, Kayla; Desai, Meghna] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Bousema, T (reprint author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Immunol & Infect, London WC1, England. EM teun.bousema@lshtm.ac.uk RI Sauerwein, Robert/C-8519-2013; Bousema, Teun/N-3574-2014; OI Stresman, Gillian/0000-0002-6897-5459 FU Bill and Melinda Gates Foundation, under the Malaria Transmission Consortium [45114]; Grand Challenge Grant [OPP1024438] FX We thank project staff, the community of Kabondo and Kasipul, Rachuonyo South, and KEMRI/CDC Kisumu. We also thank the project scientific advisory board consisting of Sodiomon Sirima (Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso), Umberto d'Alessandro (Medical Research Council Laboratories, Fajara, The Gambia) and Philip Bejon (Kenya Medical Research Institute, Wellcome Trust Research Programme, Kilifi, Kenya). This project is funded by the Bill and Melinda Gates Foundation, under the Malaria Transmission Consortium, Grant No. 45114 and the Grand Challenge Grant No. OPP1024438. This manuscript has been approved by the Director of the Kenya Medical Research Institute. NR 56 TC 26 Z9 26 U1 3 U2 17 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1745-6215 J9 TRIALS JI Trials PD FEB 2 PY 2013 VL 14 AR 36 DI 10.1186/1745-6215-14-36 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 092KJ UT WOS:000315119400002 PM 23374910 ER PT J AU Will, JC Yoon, PW AF Will, Julie C. Yoon, Paula W. TI Preventable Hospitalizations for Hypertension: Establishing a Baseline for Monitoring Racial Differences in Rates SO PREVENTING CHRONIC DISEASE LA English DT Article ID CARE-SENSITIVE CONDITIONS; UNITED-STATES; HEALTH-CARE; DISPARITIES AB Introduction Preventable hospitalization for hypertension is an ambulatory care-sensitive condition believed to indicate the failure of outpatient and public health systems to prevent and control hypertension. Blacks have higher rates of such hospitalizations than whites. The 2010 Patient Protection and Affordable Care Act (PPACA) seeks to implement higher quality health care, which may help close the racial gap in these rates. The objective of this study was to analyze pre-PPACA baseline rates of preventable hypertension hospitalizations in the United States and racial differences over time. Methods We used data from the 1995-2010 National Hospital Discharge Survey, a stratified, probability-designed survey representing approximately 1% of hospitalizations in the United States. Rates were calculated using specifications published by the Agency for Healthcare Research and Quality requiring census data as denominators for the rates. We combined at least 3 years of data to obtain more precise estimates and conducted a trend analysis by using rates calculated for each of the resulting 5 periods. Results For both sexes, all age groups, and each period, blacks had higher crude rates than whites. Age- and sex-standardized rates confirmed this finding (eg, 2007-2010: blacks, 334 per 100,000; whites, 97.4 per 100,000). Rates were generally flat over time; however, white women aged 65 or older showed increasing rates. Conclusion Using national data, we confirmed higher rates of preventable hypertension hospitalizations for blacks, showing little improvement in disparities over time. This pre-PPACA baseline for blacks and whites allows for ongoing monitoring of preventable hospitalizations for hypertension. C1 [Will, Julie C.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Yoon, Paula W.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Will, JC (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy NE,Mailstop F-72, Atlanta, GA 30341 USA. EM jxw6@cdc.gov RI Dalla Zuanna, Teresa/G-3133-2015 NR 23 TC 4 Z9 5 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD FEB PY 2013 VL 10 AR UNSP 120165 DI 10.5888/pcd10.120165 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JF UT WOS:000329389300008 PM 23411035 ER PT J AU Zwald, M Jernigan, J Payne, G Farris, R AF Zwald, Marissa Jernigan, Jan Payne, Gayle Farris, Rosanne TI Developing Stories From the Field to Highlight Policy, Systems, and Environmental Approaches in Obesity Prevention SO PREVENTING CHRONIC DISEASE LA English DT Article AB As obesity prevention initiatives increasingly shift toward approaches focused on policy, systems, and environmental change, opportunities to share experiences from the field and lessons learned are growing. Stories are a tool to illustrate processes and outcomes of initiatives that can complement quantitative results. The use of stories, however, is not widely recognized, and the methods and tools available to develop stories are limited. Therefore, we describe the methods used to collect, develop, and disseminate stories featuring comprehensive obesity prevention efforts that various state health departments are planning and implementing. We also discuss potential challenges and provide recommendations that public health practitioners may consider when developing similar stories. C1 [Zwald, Marissa] Washington Univ, St Louis, MO 63130 USA. [Zwald, Marissa; Jernigan, Jan; Payne, Gayle; Farris, Rosanne] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Zwald, M (reprint author), Washington Univ, Campus Box 1196,1 Brookings Dr, St Louis, MO 63130 USA. EM MZwald@wustl.edu FU CDC [CDC-DP08-805]; Oak Ridge Institute for Science and Education; State-Based NPAO Program FX The work described in this manuscript was supported by the CDC cooperative agreement CDC-DP08-805 and through the Oak Ridge Institute for Science and Education fellowship program. We thank the state health department staff supported by the State-Based NPAO Program for their story submissions, especially Maribel Garcia Valls and Christina Thi for their willingness to feature their state efforts in this article. NR 15 TC 2 Z9 2 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD FEB PY 2013 VL 10 AR UNSP 120141 DI 10.5888/pcd10.120141 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JF UT WOS:000329389300007 PM 23411034 ER PT J AU Drobeniuc, J Greene-Montfort, T Le, NT Mixson-Hayden, TR Ganova-Raeva, L Dong, C Novak, RT Sharapov, UM Tohme, RA Teshale, E Kamili, S Teo, CG AF Drobeniuc, Jan Greene-Montfort, Tracy Ngoc-Thao Le Mixson-Hayden, Tonya R. Ganova-Raeva, Lilia Dong, Chen Novak, Ryan T. Sharapov, Umid M. Tohme, Rania A. Teshale, Eyasu Kamili, Saleem Teo, Chong-Gee TI Laboratory-based Surveillance for Hepatitis E Virus Infection, United States, 2005-2012 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID ORGAN TRANSPLANT RECIPIENTS; SEROCONVERSION; EPIDEMIOLOGY; TRANSMISSION; TEXAS AB To investigate characteristics of hepatitis E cases in the United States, we tested samples from persons seronegative for acute hepatitis A and B whose clinical specimens were referred to the Centers for Disease Control and Prevention during June 2005 March 2012 for hepatitis E virus (HEV) testing. We found that 26 (17%) of 154 persons tested had hepatitis E. Of these, 15 had not recently traveled abroad (nontravelers), and 11 had (travelers). Compared with travelers, nontravelers were older (median 61 vs. 32 years of age) and more likely to be anicteric (53% vs. 8%); the nontraveler group also had fewer persons of South Asian ethnicity (7% vs. 73%) and more solid-organ transplant recipients (47% vs. 0). HEV genotype 3 was characterized from 8 nontravelers and genotype 1 or 4 from 4 travelers. Clinicians should consider HEV infection in the differential diagnosis of hepatitis, regardless of patient travel history. C1 [Drobeniuc, Jan] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Drobeniuc, Jan; Greene-Montfort, Tracy; Ngoc-Thao Le; Mixson-Hayden, Tonya R.; Ganova-Raeva, Lilia; Dong, Chen; Novak, Ryan T.; Sharapov, Umid M.; Tohme, Rania A.; Teshale, Eyasu; Kamili, Saleem; Teo, Chong-Gee] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Drobeniuc, J (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A33, Atlanta, GA 30333 USA. EM jqd6@cdc.gov NR 25 TC 33 Z9 33 U1 0 U2 9 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2013 VL 19 IS 2 BP 218 EP 222 DI 10.3201/eid1902.120961 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LT UT WOS:000328172900005 PM 23347695 ER PT J AU Nakazawa, Y Emerson, GL Carroll, DS Zhao, H Li, Y Reynolds, MG Karem, KL Olson, VA Lash, RR Davidson, WB Smith, SK Levine, RS Regnery, RL Sammons, SA Frace, MA Mutasim, EM Karsani, MEM Muntasir, MO Babiker, AA Opoka, L Chowdhary, V Damon, IK AF Nakazawa, Yoshinori Emerson, Ginny L. Carroll, Darin S. Zhao, Hui Li, Yu Reynolds, Mary G. Karem, Kevin L. Olson, Victoria A. Lash, R. Ryan Davidson, Whitni B. Smith, Scott K. Levine, Rebecca S. Regnery, Russell L. Sammons, Scott A. Frace, Michael A. Mutasim, Elmangory M. Karsani, Mubarak E. M. Muntasir, Mohammed O. Babiker, Alimagboul A. Opoka, Langova Chowdhary, Vipul Damon, Inger K. TI Phylogenetic and Ecologic Perspectives of a Monkeypox Outbreak, Southern Sudan, 2005 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID CLIMATE-CHANGE; GEOGRAPHIC-DISTRIBUTION; NORTH-AMERICA; UNITED-STATES; WEST-AFRICA; CONGO BASIN; NICHE; VIRUS; ORTHOPOXVIRUS; DISTRIBUTIONS AB Identification of human monkeypox cases during 2005 in southern Sudan (now South Sudan) raised several questions about the natural history of monkeypox virus (MPXV) in Africa. The outbreak area, characterized by seasonally dry riverine grasslands, is not identified as environmentally suitable for MPXV transmission. We examined possible origins of this outbreak by performing phylogenetic analysis of genome sequences of MPXV isolates from the outbreak in Sudan and from differing localities. We also compared the environmental suitability of study localities for monkeypox transmission. Phylogenetically, the viruses isolated from Sudan outbreak specimens belong to a clade identified in the Congo Basin. This finding, added to the political instability of the area during the time of the outbreak, supports the hypothesis of importation by infected animals or humans entering Sudan from the Congo Basin, and person-to-person transmission of virus, rather than transmission of indigenous virus from infected animals to humans. C1 [Nakazawa, Yoshinori] Ctr Dis Control & Prevent, Poxvirus Program, Atlanta, GA 30333 USA. [Nakazawa, Yoshinori; Emerson, Ginny L.; Carroll, Darin S.; Zhao, Hui; Li, Yu; Reynolds, Mary G.; Karem, Kevin L.; Olson, Victoria A.; Lash, R. Ryan; Davidson, Whitni B.; Smith, Scott K.; Levine, Rebecca S.; Regnery, Russell L.; Sammons, Scott A.; Frace, Michael A.; Damon, Inger K.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Mutasim, Elmangory M.; Karsani, Mubarak E. M.] Natl Publ Hlth Lab, Khartoum, Sudan. [Muntasir, Mohammed O.; Babiker, Alimagboul A.] Fed Minist Hlth, Khartoum, Sudan. [Opoka, Langova] World Hlth Org Reg Off Eastern Mediterranean, Cairo, Egypt. [Chowdhary, Vipul] Med Sans Frontieres, Khartoum, Sudan. RP Nakazawa, Y (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G06, Atlanta, GA 30333 USA. EM inp7@cdc.gov RI Lash, R. Ryan/E-4115-2013 NR 39 TC 10 Z9 10 U1 1 U2 13 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2013 VL 19 IS 2 BP 237 EP 245 DI 10.3201/eid1902.121220 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LT UT WOS:000328172900008 PM 23347770 ER PT J AU Aradaib, IE Erickson, BR Elageb, RM Khristova, ML Carroll, SA Elkhidir, IM Karsany, ME Karrar, AE Elbashir, MI Nichol, ST AF Aradaib, Imadeldin E. Erickson, Bobbie R. Elageb, Rehab M. Khristova, Marina L. Carroll, Serena A. Elkhidir, Isam M. Karsany, Mubarak E. Karrar, AbdelRahim E. Elbashir, Mustafa I. Nichol, Stuart T. TI Rift Valley Fever, Sudan, 2007 and 2010 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID RECENT COMMON ANCESTRY; VIRUS-STRAINS; SAUDI-ARABIA; SOUTH-AFRICA; OUTBREAK; KENYA; ANTIBODIES; LIVESTOCK; EPIDEMIC; LINEAGES AB To elucidate whether Rift Valley fever virus (RVFV) diversity in Sudan resulted from multiple introductions or from acquired changes over time from 1 introduction event, we generated complete genome sequences from RVFV strains detected during the 2007 and 2010 outbreaks. Phylogenetic analyses of small, medium, and large RNA segment sequences indicated several genetic RVFV variants were circulating in Sudan, which all grouped into Kenya-1 or Kenya-2 sublineages from the 2006-2008 eastern Africa epizootic. Bayesian analysis of sequence differences estimated that diversity among the 2007 and 2010 Sudan RVFV variants shared a most recent common ancestor circa 1996. The data suggest multiple introductions of RVFV into Sudan as part of sweeping epizootics from eastern Africa. The sequences indicate recent movement of RVFV and support the need for surveillance to recognize when and where RVFV circulates between epidemics, which can make data from prediction tools easier to interpret and preventive measures easier to direct toward high-risk areas. C1 [Aradaib, Imadeldin E.] Univ Khartoum, Fac Vet Med, Dept Clin Med, Mol Biol Lab, Khartoum, Sudan. [Elkhidir, Isam M.; Karrar, AbdelRahim E.; Elbashir, Mustafa I.] Univ Khartoum, Khartoum, Sudan. [Erickson, Bobbie R.; Khristova, Marina L.; Carroll, Serena A.; Nichol, Stuart T.] Ctr Dis Control & Prevent, Atlanta, GA 30033 USA. [Elageb, Rehab M.; Karsany, Mubarak E.] Fed Minist Hlth, Khartoum, Sudan. RP Nichol, ST (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G14, Atlanta, GA 30033 USA. EM snichol@cdc.gov FU Directorate of Scientific Research and Cultural relations, University of Khartoum; CDC FX This study received partial financial support from the Directorate of Scientific Research and Cultural relations, University of Khartoum, and CDC. NR 38 TC 8 Z9 10 U1 0 U2 11 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2013 VL 19 IS 2 BP 246 EP 253 DI 10.3201/eid1902.120834 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LT UT WOS:000328172900009 PM 23347790 ER PT J AU de Perio, MA Niemeier, RT Levine, SJ Gruszynski, K Gibbins, JD AF de Perio, Marie A. Niemeier, R. Todd Levine, Seth J. Gruszynski, Karen Gibbins, John D. TI Campylobacter Infection in Poultry-Processing Workers, Virginia, USA, 2008-2011 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID JEJUNI; PATHOGENS; ABATTOIR AB During a health hazard evaluation, we investigated 29 cases of laboratory-diagnosed Campylobacter infection among workers at a poultry-processing plant. Most infected employees worked at the plant <1 month, worked as live hangers, and lived at a state-operated center. To lessen the infection risk, we recommended improvements to engineering and administrative controls at the plant. C1 [de Perio, Marie A.; Niemeier, R. Todd; Gibbins, John D.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Levine, Seth J.; Gruszynski, Karen] Virginia Dept Hlth, Richmond, VA USA. RP de Perio, MA (reprint author), NIOSH, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,Mailstop R10, Cincinnati, OH 45226 USA. EM mdeperio@cdc.gov NR 11 TC 10 Z9 10 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2013 VL 19 IS 2 BP 286 EP 288 DI 10.3201/eid1902.121147 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LT UT WOS:000328172900018 PM 23347390 ER PT J AU Li, H Liu, W Zhang, GZ Sun, ZZ Bai, JY Jiang, BG Zhang, YY Zhao, XG Yang, H Tian, G Li, YC Zeng, L Kosoy, M Cao, WC AF Li, Hao Liu, Wei Zhang, Guang-Zhou Sun, Zhao-Zeng Bai, Jie-Ying Jiang, Bao-Gui Zhang, Yao-Yun Zhao, Xiao-Guang Yang, Hong Tian, Guang Li, Yu-Chuan Zeng, Lin Kosoy, Michael Cao, Wu-Chun TI Transmission and Maintenance Cycle of Bartonella quintana among Rhesus Macaques, China SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INFECTIONS; FAMILY AB We detected Bartonella quintana in 48.6% of captive rhesus macaques from an animal facility in Beijing, China. Prevalence of infection increased over the period of observation. Our findings suggest that macaques may serve as reservoir hosts for B. quintana and that Pedicinus obtusus lice might act as efficient vectors. C1 [Li, Hao; Liu, Wei; Jiang, Bao-Gui; Zhang, Yao-Yun; Zhao, Xiao-Guang; Yang, Hong; Tian, Guang; Li, Yu-Chuan; Cao, Wu-Chun] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China. [Zhang, Guang-Zhou; Sun, Zhao-Zeng; Bai, Jie-Ying; Zeng, Lin] Acad Mil Med Sci Lab Anim Ctr, Beijing, Peoples R China. [Kosoy, Michael] Ctr Dis Control & Prevent, Ft Collins, CO USA. RP Cao, WC (reprint author), Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, 20 Dong Da St, Beijing 100071, Peoples R China. EM caowc@bmi.ac.cn FU Natural Science Foundation of China [81130086, 81222037, 81072250]; Chinese Basic Research Project [2010CB530201]; Special Fund for Health Research in the Public Interest [201202019] FX This study was supported by the Natural Science Foundation of China (81130086, 81222037, and 81072250), Chinese Basic Research Project (2010CB530201), and Special Fund for Health Research in the Public Interest (201202019). NR 14 TC 3 Z9 4 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2013 VL 19 IS 2 BP 297 EP 300 DI 10.3201/eid1902.120816 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LT UT WOS:000328172900021 PM 23347418 ER PT J AU Knust, B Holman, RC Redd, J Mehal, JM Grube, SM MacNeil, A Cheek, J Rollin, PE AF Knust, Barbara Holman, Robert C. Redd, John Mehal, Jason M. Grube, Steven M. MacNeil, Adam Cheek, James Rollin, Pierre E. TI Lymphocytic Choriomeningitis Virus Infections among American Indians SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID ASSAY C1 [Knust, Barbara; Holman, Robert C.; Mehal, Jason M.; Grube, Steven M.; MacNeil, Adam; Rollin, Pierre E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Redd, John; Cheek, James] Indian Hlth Serv, Albuquerque, NM USA. RP Knust, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G14, Atlanta, GA 30333 USA. EM bknust@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2013 VL 19 IS 2 BP 328 EP 329 DI 10.3201/eid1902.120888 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LT UT WOS:000328172900031 PM 23460992 ER PT J AU Potter, P AF Potter, Polyxeni TI The Iconography of Vermin SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM pmp1@cdc.gov NR 7 TC 0 Z9 0 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2013 VL 19 IS 2 BP 350 EP 351 DI 10.3201/eid1902.AC1902 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LT UT WOS:000328172900043 ER PT J AU Russo, ET Biggerstaff, G Hoekstra, RM Meyer, S Patel, N Miller, B Quick, R AF Russo, Elizabeth T. Biggerstaff, Gwen Hoekstra, R. Michael Meyer, Stephanie Patel, Nehal Miller, Benjamin Quick, Rob CA SALMONELLA AGONA OUTBREAK INVEST T TI A Recurrent, Multistate Outbreak of Salmonella Serotype Agona Infections Associated with Dry, Unsweetened Cereal Consumption, United States, 2008 SO JOURNAL OF FOOD PROTECTION LA English DT Article ID EAT SAVOURY SNACK; TYPHIMURIUM INFECTIONS; FOOD; PATHOGENS; PULSENET AB An outbreak of Salmonella enterica serotype Agona infections associated with nationwide distribution of cereal from Company X was identified in April 2008. This outbreak was detected using PulseNet, the national molecular subtyping network for foodborne disease surveillance, which coincided with Company X's voluntary recall of unsweetened puffed rice and wheat cereals after routine product sampling yielded Salmonella Agona. A case patient was defined as being infected with the outbreak strain of Salmonella Agona, with illness onset from 1 January through 1 July 2008. Case patients were interviewed using a standard questionnaire, and the proportion of ill persons who reported eating Company X puffed rice cereal was compared with Company X's market share data using binomial testing. The Minnesota Department of Agriculture inspected the cereal production facility and collected both product and environmental swab samples. Routine surveillance identified 33 case patients in 17 states. Of 32 patients interviewed, 24 (83%) reported eating Company X puffed rice cereal. Company X puffed rice cereal represented 0.063% of the total ready-to-eat dry cereal market share in the United States at the time of the investigation. Binomial testing suggested that the proportion of exposed case patients would not likely occur by chance (P < 0.0001). Of 17 cereal samples collected from case patient homes for laboratory testing, 2 (12%) yielded Salmonella Agona indistinguishable from the outbreak strain. Twelve environmental swabs and nine product samples from the cereal plant yielded the outbreak strain of Salmonella Agona. Company X cereal was implicated in a similar outbreak of Salmonella Agona infection in 1998 with the same outbreak strain linked to the same production facility. We hypothesize that a recent construction project at this facility created an open wall near the cereal production area allowing reintroduction of Salmonella Agona into the product, highlighting the resilience of Salmonella in dry food production environments. C1 [Russo, Elizabeth T.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Russo, Elizabeth T.; Biggerstaff, Gwen; Hoekstra, R. Michael; Patel, Nehal; Quick, Rob] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Meyer, Stephanie] Minnesota Dept Hlth, St Paul, MN 55164 USA. [Miller, Benjamin] Minnesota Dept Agr, St Paul, MN 55155 USA. RP Russo, ET (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, 1600 Clifton Rd,Mail Stop C-09, Atlanta, GA 30333 USA. EM rxq1@cdc.gov NR 14 TC 13 Z9 13 U1 0 U2 9 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD FEB PY 2013 VL 76 IS 2 BP 227 EP 230 DI 10.4315/0362-028X.JFP-12-209 PG 4 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 240EP UT WOS:000326078000006 PM 23433369 ER PT J AU Bertelsen, RJ Carlsen, KCL Calafat, AM Hoppin, JA Haland, G Mowinckel, P Carlsen, KH Lovik, M AF Bertelsen, Randi J. Carlsen, Karin C. Lodrup Calafat, Antonia M. Hoppin, Jane A. Haland, Geir Mowinckel, Petter Carlsen, Kai-Hakon Lovik, Martinus TI Urinary Biomarkers for Phthalates Associated with Asthma in Norwegian Children SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE asthma; biomarkers; children; endocrine disruptors; phthalates ID NUTRITION EXAMINATION SURVEY; INTERIOR SURFACE MATERIALS; NEW-YORK-CITY; METABOLITE LEVELS; NATIONAL-HEALTH; BIRTH COHORT; EXPOSURE; VARIABILITY; PRODUCTS; OSLO AB BACKGROUND: High-molecular-weight phthalates in indoor dust have been associated with asthma in children, but few studies have evaluated phthalate biomarkers in association with respiratory outcomes. OBJECTIVES: We explored the association between urinary concentrations of phthalate metabolites and current asthma. METHODS: In a cross-sectional analysis, 11 metabolites of 8 phthalates [including four metabolites of di(2-ethylhexyl) phthalate] were measured in one first morning void collected from 2001 through 2004 from 623 10-year-old Norwegian children. Logistic regression models controlling for urine specific gravity, sex, parental asthma, and income were used to estimate associations between current asthma and phthalate metabolite concentrations by quartiles or as log(10)-transformed variables. RESULTS: Current asthma was associated with both mono(carboxyoctyl) phthalate (MCOP) and mono(carboxynonyl) phthalate (MCNP), although the association was limited to those in the highest quartile of these chemicals. The adjusted odds ratio (aOR) for current asthma was 1.9 (95% CI: 1.0, 3.3) for the highest MCOP quartile compared with the lowest quartile, and 1.3 (95% CI: 0.98, 1.7) for an interquartile-range increase. The aOR for current asthma was 2.2 (95% CI: 1.2, 4.0) for the highest MCNP quartile and 1.3 (95% CI: 1.0, 1.7) for an interquartile-range increase. The other phthalate metabolites were not associated with current asthma. CONCLUSIONS: Current asthma was associated with the highest quartiles of MCOP and MCNP, metabolites of two high molecular weight phthalates, diisononyl phthalate and diisodecyl phthalate, respectively. Given the short biological half-life of the phthalates and the cross-sectional design, our findings should be interpreted cautiously. C1 [Bertelsen, Randi J.; Lovik, Martinus] Norwegian Inst Publ Hlth, Dept Food Water & Cosmet, N-0403 Oslo, Norway. [Bertelsen, Randi J.; Hoppin, Jane A.] Natl Inst Environm Hlth Sci, Epidemiol Branch, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC USA. [Carlsen, Karin C. Lodrup; Haland, Geir; Mowinckel, Petter; Carlsen, Kai-Hakon] Oslo Univ Hosp, Dept Pediat, Oslo, Norway. [Carlsen, Karin C. Lodrup; Haland, Geir; Carlsen, Kai-Hakon] Univ Oslo, Fac Med, Oslo, Norway. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Bertelsen, RJ (reprint author), Norwegian Inst Publ Hlth, Dept Food Water & Cosmet, POB 4404 Nydalen, N-0403 Oslo, Norway. EM randi.jacobsen.bertelsen@fhi.no FU Norwegian Institute of Public Health; Research Council of Norway; Oslo University Hospital; Intramural Research Program of the National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS); AstraZeneca Norway; Sixth EU Framework program for research [FOOD-CT-2004-506378] FX The study was funded by the Norwegian Institute of Public Health, Research Council of Norway, and Oslo University Hospital, and supported in part by the Intramural Research Program of the National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS). An unrestricted grant from the AstraZeneca Norway fund for research within pulmonology was given in 2006 to G.H. for the cost of phthalate analyses in urine. The sponsor had no influence on the analyses, interpretation, or presentation. The study was performed within ORAACLE (the Oslo Research Group of Asthma and Allergy in Childhood: the Lung and Environment), a member of GA2LEN (Global Allergy and Asthma European Network), supported by the Sixth EU Framework program for research, contract FOOD-CT-2004-506378. NR 38 TC 40 Z9 40 U1 6 U2 39 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD FEB PY 2013 VL 121 IS 2 BP 251 EP 256 DI 10.1289/ehp.1205256 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 208SX UT WOS:000323700900029 PM 23164678 ER PT J AU Eskenazi, B Chevrier, J Rauch, SA Kogut, K Harley, KG Johnson, C Trujillo, C Sjodin, A Bradman, A AF Eskenazi, Brenda Chevrier, Jonathan Rauch, Stephen A. Kogut, Katherine Harley, Kim G. Johnson, Caroline Trujillo, Celina Sjoedin, Andreas Bradman, Asa TI In Utero and Childhood Polybrominated Diphenyl Ether (PBDE) Exposures and Neurodevelopment in the CHAMACOS Study SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE ADHD; attention; biomarkers; children; cognitive development; flame retardants; human exposure; intelligence quotient; Mexican; motor; neurodevelopment; prenatal ID ORGANOPHOSPHATE PESTICIDE EXPOSURE; MEXICAN-AMERICAN CHILDREN; THYROID-HORMONE DISRUPTION; POLYCHLORINATED-BIPHENYLS; HUMAN-SERUM; NEONATAL EXPOSURE; PRENATAL EXPOSURE; FLAME RETARDANTS; BREAST-MILK; SCHOOL-AGE AB BACKGROUND: California children's exposures to polybrominated diphenyl ether flame retardants (PBDEs) are among the highest worldwide. PBDEs are known endocrine disruptors and neurotoxicants in animals. OBJECTIVE: Here we investigate the relation of in utero and child PBDE exposure to neurobehavioral development among participants in CHAMACOS (Center for the Health Assessment of Mothers and Children of Salinas), a California birth cohort. METHODS: We measured PBDEs in maternal prenatal and child serum samples and examined the association of PBDE concentrations with children's attention, motor functioning, and cognition at 5 (n = 310) and 7 years of age (n = 323). RESULTS: Maternal prenatal PBDE concentrations were associated with impaired attention as measured by a continuous performance task at 5 years and maternal report at 5 and 7 years of age, with poorer fine motor coordination-particularly in the nondominant-at both age points, and with decrements in Verbal and Full-Scale IQ at 7 years. PBDE concentrations in children 7 years of age were significantly or marginally associated with concurrent teacher reports of attention problems and decrements in Processing Speed, Perceptual Reasoning, Verbal Comprehension, and Full-Scale IQ. These associations were not altered by adjustment for birth weight, gestational age, or maternal thyroid hormone levels. CONCLUSIONS: Both prenatal and childhood PBDE exposures were associated with poorer attention, fine motor coordination, and cognition in the CHAMACOS cohort of school-age children. This study, the largest to date, contributes to growing evidence suggesting that PBDEs have adverse impacts on child neurobehavioral development. C1 [Eskenazi, Brenda; Chevrier, Jonathan; Rauch, Stephen A.; Kogut, Katherine; Harley, Kim G.; Johnson, Caroline; Trujillo, Celina; Bradman, Asa] Univ Calif Berkeley, Sch Publ Hlth, CERCH, Berkeley, CA 94720 USA. [Sjoedin, Andreas] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Lab Sci, Atlanta, GA USA. RP Eskenazi, B (reprint author), Univ Calif Berkeley, Sch Publ Hlth, CERCH, 1995 Univ Ave,Suite 265, Berkeley, CA 94720 USA. EM eskenazi@berkeley.edu RI Sjodin, Andreas/F-2464-2010 FU U.S. Environmental Protection Agency (EPA) [RD 83171001, RD 826709]; National Institute of Environmental Health Sciences (NIEHS) [PO1 ES009605, RO1 ES015572]; University of California Institute for Mexico; United States (UC MEXUS) FX This publication was made possible by research supported by grants RD 83171001 and RD 826709 from the U.S. Environmental Protection Agency (EPA), and PO1 ES009605 and RO1 ES015572 from the National Institute of Environmental Health Sciences (NIEHS). Additional funding was provided by the University of California Institute for Mexico and the United States (UC MEXUS). NR 55 TC 134 Z9 135 U1 9 U2 99 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD FEB PY 2013 VL 121 IS 2 BP 257 EP 262 DI 10.1289/ehp.1205597 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 208SX UT WOS:000323700900030 PM 23154064 ER PT J AU Farag, NH Rey, A Noe, R Bayleyegn, T Wood, AD Zane, D AF Farag, Noha H. Rey, Araceli Noe, Rebecca Bayleyegn, Tesfaye Wood, April D. Zane, David TI Evaluation of the American Red Cross Disaster-Related Mortality Surveillance System Using Hurricane Ike Data-Texas 2008 SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE mortality; population surveillance; Texas; epidemiology; American Red Cross; hurricanes; disasters AB Objectives: To evaluate key attributes, strengths, and limitations of the American Red Cross (ARC) disaster-related mortality surveillance system implemented during Hurricane Ike in Texas 2008, and to provide recommendations for system improvement. Methods: We evaluated key attributes of the ARC mortality surveillance system. Evaluation included interviews with stakeholders and linking ARC data with the Texas Department of State Health Services' (DSHS) system for comparison. Results: During September 11 through October 6, 2008, the ARC identified 38 deaths, whereas DSHS identified 74 deaths related to Hurricane Ike (sensitivity=47%; positive predictive value=92%). The ARC had complete data on 61% to 92% of deaths, and an 83% to 97% concordance was observed between the 2 systems for key variables. Conclusions: The ARC surveillance system is simple, flexible, and stable. We recommend establishing written guidelines to improve data quality and representativeness. As an important supporting agency in disaster situations and the sole source of data regarding disaster-related mortality in multiple states, improvement of the ARC system will benefit stakeholders and promote dissemination of useful information for preventing future deaths. C1 [Farag, Noha H.; Rey, Araceli; Noe, Rebecca; Bayleyegn, Tesfaye] Ctr Dis Control & Prevent, Atlanta, GA USA. [Farag, Noha H.; Rey, Araceli; Zane, David] Texas Dept State Hlth Serv, Austin, TX 78714 USA. [Wood, April D.] Amer Red Cross, Disaster Hlth Serv, Washington, DC 20006 USA. RP Farag, NH (reprint author), Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, MC 1964,POB 149347, Austin, TX 78714 USA. EM iym0@cdc.gov FU Centers for Disease Control and Prevention; Texas Department of State Health Services FX This study was supported by the Centers for Disease Control and Prevention and the Texas Department of State Health Services. NR 9 TC 1 Z9 1 U1 2 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD FEB PY 2013 VL 7 IS 1 BP 13 EP 19 DI 10.1001/dmp.2012.54 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 199ZW UT WOS:000323036100004 PM 23223756 ER PT J AU Fullerton, CS McKibben, JBA Reissman, DB Scharf, T Kowalski-Trakofler, KM Shultz, JM Ursano, RJ AF Fullerton, Carol S. McKibben, Jodi B. A. Reissman, Dori B. Scharf, Ted Kowalski-Trakofler, Kathleen M. Shultz, James M. Ursano, Robert J. TI Posttraumatic Stress Disorder, Depression, and Alcohol and Tobacco Use in Public Health Workers After the 2004 Florida Hurricanes SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE PTSD; depression; alcohol use; public health workers; hurricane ID MENTAL-HEALTH; RESCUE WORKERS; PTSD CHECKLIST; PRIMARY-CARE; PRIME-MD; DISASTER; PREVALENCE; SYMPTOMS; COMORBIDITY; VALIDATION AB Objective: We examined the relationship of probable posttraumatic stress disorder (PTSD), probable depression, and increased alcohol and/or tobacco use to disaster exposure and work demand in Florida Department of Health workers after the 2004 hurricanes. Methods: Participants (N=2249) completed electronic questionnaires assessing PTSD, depression, alcohol and tobacco use, hurricane exposure, and work demand. Results: Total mental and behavioral health burden (probable PTSD, probable depression, increased alcohol and/or tobacco use) was 11%. More than 4% had probable PTSD, and 3.8% had probable depression. Among those with probable PTSD, 29.2% had increased alcohol use, and 50% had increased tobacco use. Among those with probable depression, 34% indicated increased alcohol use and 55.6% increased tobacco use. Workers with greater exposure were more likely to have probable PTSD and probable depression (ORs=3.3 and 3.06, respectively). After adjusting for demographics and work demand, those with high exposure were more likely to have probable PTSD and probable depression (ORs=3.21 and 3.13). Those with high exposure had increased alcohol and tobacco use (ORs=3.01 and 3.40), and those with high work demand indicated increased alcohol and tobacco use (ORs=1.98 and 2.10). High exposure and work demand predicted increased alcohol and tobacco use, after adjusting for demographics, work demand, and exposure. Conclusions: Work-related disaster mental and behavioral health burden indicate the need for additional mental health interventions in the public health disaster workforce. C1 [Fullerton, Carol S.; McKibben, Jodi B. A.; Ursano, Robert J.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA. [Reissman, Dori B.] NIOSH, Washington, DC USA. [Scharf, Ted] NIOSH, Work Org & Stress Res Team, Cincinnati, OH 45226 USA. [Kowalski-Trakofler, Kathleen M.] NIOSH, Pittsburgh Res Lab, Washington, DC USA. [Shultz, James M.] Univ Miami, Miller Sch Med, Ctr Disaster & Extreme Event Preparedness, Coral Gables, FL 33124 USA. RP Fullerton, CS (reprint author), Uniformed Serv Univ Hlth Sci, Ctr Study Traumat Str, Dept Psychiat, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. EM cfullert@erols.com FU Intramural CDC HHS [CC999999] NR 29 TC 1 Z9 1 U1 2 U2 5 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD FEB PY 2013 VL 7 IS 1 BP 89 EP 95 DI 10.1017/dmp.2013.6 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 199ZW UT WOS:000323036100013 PM 24618140 ER PT J AU Williams, WW Lu, PJ Greby, S Bridges, CB Ahmed, F Liang, JL Pilishvili, T Hales, C AF Williams, Walter W. Lu, Peng-Jun Greby, Stacie Bridges, Carolyn B. Ahmed, Faruque Liang, Jennifer L. Pilishvili, Tamara Hales, Craig TI Noninfluenza Vaccination Coverage Among Adults - United States, 2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Williams, Walter W.; Lu, Peng-Jun; Greby, Stacie; Bridges, Carolyn B.; Ahmed, Faruque] CDC, Immunizat Serv Div, Atlanta, GA 30333 USA. [Liang, Jennifer L.; Pilishvili, Tamara] CDC, Div Bacterial Dis, Atlanta, GA 30333 USA. [Hales, Craig] CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. RP Williams, WW (reprint author), CDC, Immunizat Serv Div, Atlanta, GA 30333 USA. EM www1@cdc.gov NR 10 TC 48 Z9 49 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 1 PY 2013 VL 62 IS 4 BP 66 EP 72 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188EJ UT WOS:000322174700001 ER PT J AU Marsden-Haug, N Meyer, S Bidol, SA Schmitz, J Culpepper, W Behravesh, CB Morris, J Anderson, TC AF Marsden-Haug, Nicola Meyer, Stephanie Bidol, Sally A. Schmitz, Jennifer Culpepper, Wright Behravesh, Casey Barton Morris, Jamae Anderson, Tara Creel TI Multistate Outbreak of Human Salmonella Typhimurium Infections Linked to Contact with Pet Hedgehogs - United States, 2011-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Marsden-Haug, Nicola] Washington State Dept Health, Washington, DC USA. [Morris, Jamae; Anderson, Tara Creel] CDC, EIS officers, Atlanta, GA 30333 USA. RP Anderson, TC (reprint author), CDC, EIS officers, Atlanta, GA 30333 USA. EM tcanderson1@cdc.gov NR 3 TC 8 Z9 8 U1 0 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 1 PY 2013 VL 62 IS 4 BP 73 EP 73 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188EJ UT WOS:000322174700002 ER PT J AU Safran, MA Hoover, KW Tao, G Butler, MO AF Safran, M. A. Hoover, K. W. Tao, G. Butler, M. O. TI Sexual behaviour and desire to discuss mental health as reported by HIV-infected men who have sex with men SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE HIV; sexually transmitted disease; risk behavior; mental health; communication; health services ID RISK BEHAVIOR; GAY MEN; SUBSTANCE USE; DEPRESSIVE SYMPTOMS; TRANSMISSION RISK; YOUNG MEN; CARE; PREVALENCE; PREDICTORS; STATES AB We assessed sexually transmitted infection risk behaviours and desire to discuss mental health, as reported by 426 HIV-infected men who have sex with men receiving HIV care in eight urban clinics. Most of these patients (90%) had begun HIV care >1 year ago. In the past year, 74% had multiple sexual partners, 75% engaged in anal intercourse, 48% had >1 HIV-uninfected partner and 82% used illegal psychoactive drugs. Among those reporting anal intercourse, approximately 61% reported using a condom during the most recent episode. Among all patients, 70% wanted to talk with their clinicians about how they felt mentally or emotionally. Using a two-tailed chi-squared test, we found that patients who engaged in unprotected receptive anal sex were more likely to want such a conversation than those who did not (80% versus 62%, P < 0.01); and those who engaged in unprotected insertive anal sex were also more likely to want such a conversation (81% versus 63%, P < 0.01). The findings highlight the prevalence of risky sexual behaviour and of mental health concerns in the participating patient population. Patients reporting risky sexual behaviour were more likely to want to discuss how they felt mentally or emotionally than those not reporting such behaviour. C1 [Safran, M. A.; Hoover, K. W.; Tao, G.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Butler, M. O.] Univ Maryland, Dept Anthropol, College Pk, MD 20742 USA. RP Safran, MA (reprint author), Ctr Dis Control & Prevent, Mail Stop E-44,1600 Clifton Rd, Atlanta, GA 30333 USA. EM MSafran@cdc.gov NR 36 TC 0 Z9 1 U1 0 U2 5 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 0956-4624 J9 INT J STD AIDS JI Int. J. STD AIDS PD FEB PY 2013 VL 24 IS 2 BP 93 EP 99 DI 10.1177/0956462412472307 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 142UJ UT WOS:000318822800002 PM 23514829 ER PT J AU Dostalek, M Gardner, I Gurbaxani, BM Rose, RH Chetty, M AF Dostalek, Miroslav Gardner, Iain Gurbaxani, Brian M. Rose, Rachel H. Chetty, Manoranjenni TI Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies SO CLINICAL PHARMACOKINETICS LA English DT Review ID NEONATAL FC-RECEPTOR; ENZYME PRODRUG THERAPY; MEDIATED DRUG DISPOSITION; GROWTH-FACTOR RECEPTOR; SINGLE-CHAIN FV; RHEUMATOID-ARTHRITIS PATIENTS; NON-HODGKINS-LYMPHOMA; I-RELATED RECEPTOR; HUMAN TUMOR XENOGRAFTS; BLOOD-BRAIN-BARRIER AB Development of monoclonal antibodies (mAbs) and their functional derivatives represents a growing segment of the development pipeline in the pharmaceutical industry. More than 25 mAbs and derivatives have been approved for a variety of therapeutic applications. In addition, around 500 mAbs and derivatives are currently in different stages of development. mAbs are considered to be large molecule therapeutics (in general, they are 2-3 orders of magnitude larger than small chemical molecule therapeutics), but they are not just big chemicals. These compounds demonstrate much more complex pharmacokinetic and pharmacodynamic behaviour than small molecules. Because of their large size and relatively poor membrane permeability and instability in the conditions of the gastrointestinal tract, parenteral administration is the most usual route of administration. The rate and extent of mAb distribution is very slow and depends on extravasation in tissue, distribution within the particular tissue, and degradation. Elimination primarily happens via catabolism to peptides and amino acids. Although not definitive, work has been published to define the human tissues mainly involved in the elimination of mAbs, and it seems that many cells throughout the body are involved. mAbs can be targeted against many soluble or membrane-bound targets, thus these compounds may act by a variety of mechanisms to achieve their pharmacological effect. mAbs targeting soluble antigen generally exhibit linear elimination, whereas those targeting membrane-bound antigen often exhibit non-linear elimination, mainly due to target-mediated drug disposition (TMDD). The high-affinity interaction of mAbs and their derivatives with the pharmacological target can often result in non-linear pharmacokinetics. Because of species differences (particularly due to differences in target affinity and abundance) in the pharmacokinetics and pharmacodynamics of mAbs, pharmacokinetic/pharmacodynamic modelling of mAbs has been used routinely to expedite the development of mAbs and their derivatives and has been utilized to help in the selection of appropriate dose regimens. Although modelling approaches have helped to explain variability in both pharmacokinetic and pharmacodynamic properties of these drugs, there is a clear need for more complex models to improve understanding of pharmacokinetic processes and pharmacodynamic interactions of mAbs with the immune system. There are different approaches applied to physiologically based pharmacokinetic (PBPK) modelling of mAbs and important differences between the models developed. Some key additional features that need to be accounted for in PBPK models of mAbs are neonatal Fc receptor (FcRn; an important salvage mechanism for antibodies) binding, TMDD and lymph flow. Several models have been described incorporating some or all of these features and the use of PBPK models are expected to expand over the next few years. C1 [Dostalek, Miroslav] F Hoffmann La Roche & Cie AG, pRED, Pharma Res & Early Dev, Nonclin Safety, Basel, Switzerland. [Gardner, Iain; Rose, Rachel H.; Chetty, Manoranjenni] Simcyp, Blades Enterprise Ctr, Sheffield S2 4SU, S Yorkshire, England. [Gurbaxani, Brian M.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Gardner, I (reprint author), Simcyp, Blades Enterprise Ctr, John St, Sheffield S2 4SU, S Yorkshire, England. EM i.gardner@simcyp.com NR 407 TC 61 Z9 63 U1 6 U2 59 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 0312-5963 EI 1179-1926 J9 CLIN PHARMACOKINET JI Clin. Pharmacokinet. PD FEB PY 2013 VL 52 IS 2 BP 83 EP 124 DI 10.1007/s40262-012-0027-4 PG 42 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 138QP UT WOS:000318523800002 PM 23299465 ER PT J AU Schell, SF Luke, DA Schooley, MW Elliott, MB Herbers, SH Mueller, NB Bunger, AC AF Schell, Sarah F. Luke, Douglas A. Schooley, Michael W. Elliott, Michael B. Herbers, Stephanie H. Mueller, Nancy B. Bunger, Alicia C. TI Public health program capacity for sustainability: a new framework SO IMPLEMENTATION SCIENCE LA English DT Article DE Program sustainability; Concept mapping; Chronic disease programs; Evaluation; Dissemination and implementation ID PROMOTION PROGRAMS; UNITED-STATES; PREVENTION; POLICY; AGENDA; INNOVATIONS; IMPACT AB Background: Public health programs can only deliver benefits if they are able to sustain activities over time. There is a broad literature on program sustainability in public health, but it is fragmented and there is a lack of consensus on core constructs. The purpose of this paper is to present a new conceptual framework for program sustainability in public health. Methods: This developmental study uses a comprehensive literature review, input from an expert panel, and the results of concept-mapping to identify the core domains of a conceptual framework for public health program capacity for sustainability. The concept-mapping process included three types of participants (scientists, funders, and practitioners) from several public health areas (e.g., tobacco control, heart disease and stroke, physical activity and nutrition, and injury prevention). Results: The literature review identified 85 relevant studies focusing on program sustainability in public health. Most of the papers described empirical studies of prevention-oriented programs aimed at the community level. The concept-mapping process identified nine core domains that affect a program's capacity for sustainability: Political Support, Funding Stability, Partnerships, Organizational Capacity, Program Evaluation, Program Adaptation, Communications, Public Health Impacts, and Strategic Planning. Concept-mapping participants further identified 93 items across these domains that have strong face validity-89% of the individual items composing the framework had specific support in the sustainability literature. Conclusions: The sustainability framework presented here suggests that a number of selected factors may be related to a program's ability to sustain its activities and benefits over time. These factors have been discussed in the literature, but this framework synthesizes and combines the factors and suggests how they may be interrelated with one another. The framework presents domains for public health decision makers to consider when developing and implementing prevention and intervention programs. The sustainability framework will be useful for public health decision makers, program managers, program evaluators, and dissemination and implementation researchers. C1 [Schell, Sarah F.; Luke, Douglas A.; Herbers, Stephanie H.] Washington Univ, Ctr Publ Hlth Syst Sci, George Warren Brown Sch Social Work, St Louis, MO 63112 USA. [Elliott, Michael B.] St Louis Univ, Sch Publ Hlth, St Louis, MO 63104 USA. [Mueller, Nancy B.] Washington Univ, Inst Publ Hlth, St Louis, MO 63110 USA. [Schooley, Michael W.] Ctr Dis Control & Prevent, Appl Res & Evaluat Branch, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Bunger, Alicia C.] Ohio State Univ, Coll Social Work, Columbus, OH 43210 USA. RP Luke, DA (reprint author), Washington Univ, Ctr Publ Hlth Syst Sci, George Warren Brown Sch Social Work, 700 Rosedale Ave,Campus Box 1009, St Louis, MO 63112 USA. EM dluke@wustl.edu RI Bunger, Alicia/B-9943-2013; OI Luke, Douglas/0000-0003-1332-8569; Bunger, Alicia/0000-0002-6407-5111 FU National Association of Chronic Disease Directors [1055500590023] FX This project was funded by National Association of Chronic Disease Directors, contract #1055500590023. The authors extend special thanks the project's advisory committee: Ross Brownson, Washington University in St. Louis; Don Compton, CDC Division of Nutrition, Physical Activity, and Obesity; Karen Deleeuw, Colorado Department of Public Health; Geri Lester-Baldasare; South Carolina Department of Public Health and Environmental Control; Enola Proctor, Washington University in St. Louis; Mary Ann Scheirer, Scheirer Consulting; and Elisa Wong, Kaiser Permanente. Concept-mapping analysis and results conducted using The Concept System software: Copyright 2004-Current Year; all rights reserved. Concept Systems Inc. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 37 TC 56 Z9 56 U1 10 U2 47 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD FEB 1 PY 2013 VL 8 AR 15 DI 10.1186/1748-5908-8-15 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 137DI UT WOS:000318414900001 PM 23375082 ER PT J AU Botelho, JC Shacklady, C Cooper, HC Tai, SSC Van Uytfanghe, K Thienpont, LM Vesper, HW AF Botelho, Julianne Cook Shacklady, Christopher Cooper, Hans C. Tai, Susan S. -C. Van Uytfanghe, Katleen Thienpont, Linda M. Vesper, Hubert W. TI Isotope-Dilution Liquid Chromatography-Tandem Mass Spectrometry Candidate Reference Method for Total Testosterone in Human Serum SO CLINICAL CHEMISTRY LA English DT Article ID CLINICAL-PRACTICE GUIDELINE; METABOLIC SYNDROME; ADULT MEN; MORTALITY; THERAPY; SOCIETY; DYSFUNCTION; ANDROGENS; WOMEN AB BACKGROUND: We developed and evaluated a candidate reference measurement procedure (RMP) to standardize testosterone measurements, provide highly accurate and precise value assignments for the CDC Hormone Standardization Program, and ensure accurate and comparable results across testing systems and laboratories. METHODS: After 2 liquid/liquid extractions of serum with a combination of ethyl acetate and hexane, we quantified testosterone by isotope-dilution liquid chromatography-tandem mass spectrometry with electrospray ionization in the positive ion mode monitoring 289 -> 97 m/z (testosterone) and 292 -> 112 m/z (C-3(13) testosterone). We used calibrator bracketing and gravimetric measurements to give higher specificity and accuracy to serum value assignments. The candidate RMP was evaluated for accuracy by use of NIST-certified reference material SRM971 and validated by split-sample comparison to established RMPs. We evaluated intraassay and interassay imprecision, measurement uncertainty, potential interferences, and matrix effects. RESULTS: A weighted Deming regression comparison of the candidate RMP to established RMPs showed agreement with no statistical difference (slope 0.99, 95% CI 0.98-1.00, intercept 0.54, 95% CI -1.24 to 2.32) and a bias of <= 0.3% for NIST SRM971. The candidate RMP gave maximum intraassay, interassay, and total percent CVs of 1.5%, 1.4%, and 1.7% across the concentrations of testosterone typically found in healthy men and women. We tested structural analogs of testosterone and 125 serum samples and found no interferences with the measurement. CONCLUSIONS: This RMP for testosterone can serve as a higher-order standard for measurement traceability and can be used to provide an accuracy base to which routine methods can be compared in the CDC Hormone Standardization Program. (C) 2012 American Association for Clinical Chemistry C1 [Botelho, Julianne Cook; Shacklady, Christopher; Cooper, Hans C.; Vesper, Hubert W.] Ctr Dis Control & Prevent, Clin Chem Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Tai, Susan S. -C.] NIST, Div Analyt Chem, Gaithersburg, MD 20899 USA. [Van Uytfanghe, Katleen; Thienpont, Linda M.] Univ Ghent, Fac Pharmaceut Sci, Analyt Chem Lab, B-9000 Ghent, Belgium. RP Vesper, HW (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,MS-F25, Atlanta, GA 30341 USA. EM hvesper@cdc.gov OI Van Uytfanghe, Katleen/0000-0001-8195-150X FU Abbott Laboratories through the CDC Foundation FX Abbott Laboratories (formerly Solvay Pharmaceuticals) provided the initial funding for this project through the CDC Foundation. The Division of Cancer Prevention and Control at the National Center for Chronic Disease Prevention and Health Promotion provided the Mass Spectrometry instrumentation for this project. Expert Testimony: C. Shacklady, CDC. NR 41 TC 25 Z9 27 U1 2 U2 22 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD FEB PY 2013 VL 59 IS 2 BP 372 EP 380 DI 10.1373/clinchem.2012.190934 PG 9 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 122RY UT WOS:000317337000010 PM 23213081 ER PT J AU Kahn, SE Astles, JR Lo, SF Bennett, MJ AF Kahn, Stephen E. Astles, J. Rex Lo, Stanley F. Bennett, Michael J. TI The AGREE II Instrument Is Helpful for Creation of National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines SO CLINICAL CHEMISTRY LA English DT Letter C1 [Kahn, Stephen E.] Loyola Univ Hlth Syst, Dept Pathol, Clin Labs, Maywood, IL 60153 USA. [Astles, J. Rex] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lo, Stanley F.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. [Bennett, Michael J.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. RP Kahn, SE (reprint author), Loyola Univ Hlth Syst, Dept Pathol, Clin Labs, 2160 South 1st Ave,Bldg 103,Rm 0148, Maywood, IL 60153 USA. EM skahn@lumc.edu NR 4 TC 1 Z9 1 U1 1 U2 1 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 EI 1530-8561 J9 CLIN CHEM JI Clin. Chem. PD FEB PY 2013 VL 59 IS 2 BP 446 EP 447 DI 10.1373/clinchem.2012.197822 PG 2 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 122RY UT WOS:000317337000021 PM 23243222 ER PT J AU Krawczynski, K AF Krawczynski, Kris TI Hepatitis E in 2013: Essential Facts, Emerging Concepts and Challenges Foreword SO SEMINARS IN LIVER DISEASE LA English DT Editorial Material C1 [Krawczynski, Kris] Ctr Dis Control & Prevent, Div Viral Hepatitis, NCHHSTP, Atlanta, GA USA. RP Krawczynski, K (reprint author), CDC, Div Viral Hepatitis, NCHHSTP, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM kzk1@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0272-8087 J9 SEMIN LIVER DIS JI Semin. Liver Dis. PD FEB PY 2013 VL 33 IS 1 BP 1 EP 2 DI 10.1055/s-0033-1338119 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 120FD UT WOS:000317155300001 PM 23564384 ER PT J AU Wedemeyer, H Rybczynska, J Pischke, S Krawczynski, K AF Wedemeyer, Heiner Rybczynska, Jolanta Pischke, Sven Krawczynski, Kris TI Immunopathogenesis of Hepatitis E Virus Infection SO SEMINARS IN LIVER DISEASE LA English DT Review DE hepatitis E virus; HEV; T-cell responses; humoral immunity; animal models ID TRANSMITTED NON-A; NON-B-HEPATITIS; NATURAL-KILLER-CELLS; LIVER-TRANSPLANT RECIPIENTS; ADAPTIVE IMMUNE-RESPONSES; ANTIVIRAL T-CELLS; C VIRUS; CYNOMOLGUS MONKEYS; MONOCLONAL-ANTIBODIES; CAPSID PROTEIN AB The course of hepatitis E virus infection (HEV) can vary substantially between different individuals. Although most infections take a clinically silent asymptomatic course, a few patients may develop severe hepatitis that can progress to fulminant hepatic failure. In addition, cases of chronic hepatitis E have been described in irrimunosuppressed patients. The detailed mechanisms leading to different clinical outcomes of HEV infection are only partially understood. Both viral factors including the HEV genotype and the dose of the infectious inoculum, as well as host factors such as stage of liver disease, pregnancy or distinct genetic polymorphisms determine the course of HEV infection. Recent studies were able to associate T-cell responses, activation of the interferon system and viral evolution with severity or chronicity of hepatitis E. We here summarize the emerging data on the immunopathogenesis of HEV infection. C1 [Wedemeyer, Heiner; Pischke, Sven] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany. [Rybczynska, Jolanta; Krawczynski, Kris] Ctr Dis Control & Prevent CDC, Div Viral Hepatitis, Atlanta, GA USA. [Rybczynska, Jolanta] Med Univ Warsaw, Dept Pathol, Warsaw, Poland. RP Wedemeyer, H (reprint author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover Carl Neuberg Str 1, D-30625 Hannover, Germany. EM Wedemeyer.Heiner@mh-hannover.de NR 81 TC 21 Z9 24 U1 0 U2 12 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0272-8087 J9 SEMIN LIVER DIS JI Semin. Liver Dis. PD FEB PY 2013 VL 33 IS 1 BP 71 EP 78 DI 10.1055/s-0033-1338118 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 120FD UT WOS:000317155300008 PM 23564391 ER PT J AU Ashraf, S Huque, MH Kenah, E Agboatwalla, M Luby, SP AF Ashraf, Sania Huque, M. Hamidul Kenah, Eben Agboatwalla, Mubina Luby, Stephen P. TI Effect of recent diarrhoeal episodes on risk of pneumonia in children under the age of 5 years in Karachi, Pakistan SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Diarrhoea; pneumonia; childhood diseases; malnutrition ID RANDOMIZED CONTROLLED-TRIALS; FAILURE TIME DATA; DEVELOPING-COUNTRIES; RESPIRATORY-INFECTIONS; INTEGRATED MANAGEMENT; REGRESSION-ANALYSIS; NUTRITIONAL-STATUS; CHILDHOOD ILLNESS; RURAL BANGLADESH; POOLED ANALYSIS AB Background We assessed the association between the duration of diarrhoea and the risk ofpneumonia incidence among children <5 years of age. Methods We analysed data from a cluster randomized controlled trial in Karachi, Pakistan, which assessed the effect of promoting hand washing with soap (antibacterial and plain) on child health. Field workers visited households with children < 5 years of age weekly and asked primary caregivers if their child had diarrhoea, cough or difficulty breathing in the preceding week. We used the WHO clinical case definitions for diarrhoea and pneumonia.We used adjusted time-to-event analyses with cumulative diarrhoea prevalence over the previous 2 and 4 weeks as exposure and pneumonia as outcome. We calculated the attributable risk of pneumonia due to recent diarrhoea across the intervention groups. Results 873 households with children < 5 years were visited. Children had an increased risk of pneumonia for every additional day of diarrhoea in the 2 weeks (1.06, 95% CI: 1.03-1.09) and 4 weeks (1.04, 95% CI: 1.03-1.06) prior to the week of pneumonia onset. The attributable risk of pneumonia cases due to recent exposure to diarrhoea was 6%. A lower associated pneumonia risk following diarrhoea was found in the control group: (3%) compared with soap groups (6% in antibacterial soap, 9% in plain soap). Conclusion Children < 5 years of age are at an increased risk of pneumonia following recent diarrhoeal illness. Public health programmes that prevent diarrhoea may also reduce the burden of respiratory illnesses. C1 [Ashraf, Sania; Huque, M. Hamidul; Luby, Stephen P.] Int Ctr Diarrhoeal Dis Res, Ctr Communicable Dis, Water Sanitat & Hyg Res Grp, Dhaka 1000, Bangladesh. [Kenah, Eben] Univ Florida, Dept Biostat, Gainesville, FL USA. [Agboatwalla, Mubina] Hlth Oriented Prevent Educ, Karachi, Pakistan. [Luby, Stephen P.] Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA. RP Ashraf, S (reprint author), Int Ctr Diarrhoeal Dis Res, Ctr Communicable Dis, Water Sanitat & Hyg Res Grp, GPO Box 128, Dhaka 1000, Bangladesh. EM saniashraf@gmail.com OI Huque, Md Hamidul/0000-0002-5605-3801 FU Procter and Gamble; Centers for Disease Control and Prevention FX Procter and Gamble and the Centers for Disease Control and Prevention funded this study. NR 38 TC 8 Z9 8 U1 0 U2 15 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD FEB PY 2013 VL 42 IS 1 BP 194 EP 200 DI 10.1093/ije/dys233 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 113WE UT WOS:000316699300021 PM 23378152 ER PT J AU Remais, JV Zeng, G Li, GW Tian, LL Engelgau, MM AF Remais, Justin V. Zeng, Guang Li, Guangwei Tian, Lulu Engelgau, Michael M. TI Convergence of non-communicable and infectious diseases in low- and middle-income countries SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Chronic disease; infectious disease; development transition ID EPSTEIN-BARR-VIRUS; HEALTH SYSTEM REFORM; AIDS-RELATED MALIGNANCIES; DIABETES-MELLITUS; RISK-FACTORS; ANTIRETROVIRAL THERAPY; ENVIRONMENTAL-HEALTH; CHINA; TUBERCULOSIS; EPIDEMIOLOGY AB The convergence of non-communicable disease (NCD) and infectious disease (ID) in low- and middle-income countries (LMICs) presents new challenges and new opportunities to enact responsive changes in policy and research. Most LMICs have significant dual disease burdens of NCDs such as cardiovascular disease, diabetes and cancer, and IDs including tuberculosis, HIV/AIDS and parasitic diseases. A combined strategy is needed in surveillance and disease control; yet, experts, institutions and policies that support prevention and control of these two overarching disease categories have limited interaction and alignment. NCDs and IDs share common features, such as long-term care needs and overlapping high-risk populations, and there are also notable direct interactions, such as the association between certain IDs and cancers, as well as evidence of increased susceptibility to IDs in individuals with NCDs. Enhanced simultaneous surveillance of NCD and ID comorbidity in LMIC populations would generate the empirical data needed to better understand the dual burden, and to target coordinated care. Where IDs and NCDs are endemic, focusing on vulnerable populations by strengthening social protections and improving access to health services is crucial, as is the re-alignment of efforts to combine NCD and ID screening, treatment programmes, and the assessment of their impact. Integrating public health activities for ID and NCD should extend beyond health care services to prevention, which is widely seen as crucial to successful NCD and ID control campaigns alike. The convergence of NCD and ID in LMICs has the potential to overstretch already strained health systems. With some LMICs now focused on major health system reforms, a unique opportunity is available to address NCD and ID challenges with newfound urgency and novel approaches. C1 [Remais, Justin V.] Emory Univ, Dept Environm Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Remais, Justin V.; Tian, Lulu] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Zeng, Guang] China Ctr Dis Control, Div Field Epidemiol Training, Beijing, Peoples R China. [Li, Guangwei] Fuwai Heart Hosp, Endocrinol & Cardiovasc Dis Ctr, Beijing, Peoples R China. [Tian, Lulu] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Engelgau, Michael M.] US Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Remais, JV (reprint author), Emory Univ, Dept Environm Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA. EM justin.remais@emory.edu FU National Institute for Allergy and Infectious Disease [K01AI091864]; NIH/NSF Ecology of Infectious Disease Program [0622743]; Emory Global Health Institute Faculty Distinction Fund; Federal Government FX This work was supported in part by the National Institute for Allergy and Infectious Disease [grant no. K01AI091864; J.V.R.]; the NIH/NSF Ecology of Infectious Disease Program [grant no. 0622743; J.V.R.] and by the Emory Global Health Institute Faculty Distinction Fund [J.V.R.]. M. E. is a US federal government employee at the US Centers for Disease Control and Prevention and his support is solely from the Federal Government. The funders had no role in the decision to publish or prepare the manuscript. No payment was received on the part of any of the co-authors for the preparation of this manuscript. The corresponding author had final responsibility for the decision to submit for publication. The views expressed in this article are solely those of the authors, and may not reflect the policies or views of their agencies, or the funding agencies. NR 67 TC 39 Z9 41 U1 3 U2 30 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD FEB PY 2013 VL 42 IS 1 BP 221 EP 227 DI 10.1093/ije/dys135 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 113WE UT WOS:000316699300025 PM 23064501 ER PT J AU Huho, B Briet, O Seyoum, A Sikaala, C Bayoh, N Gimnig, J Okumu, F Diallo, D Abdulla, S Smith, T Killeen, G AF Huho, Bernadette Briet, Olivier Seyoum, Aklilu Sikaala, Chadwick Bayoh, Nabie Gimnig, John Okumu, Fredros Diallo, Diadier Abdulla, Salim Smith, Thomas Killeen, Gerry TI Consistently high estimates for the proportion of human exposure to malaria vector populations occurring indoors in rural Africa SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Malaria; plasmodium; vector; transmission; exposure; behavior ID INSECTICIDE-TREATED NETS; WESTERN KENYA; BED NETS; BURKINA-FASO; IMPREGNATED BEDNETS; CHILD-MORTALITY; TRANSMISSION; MOSQUITOS; TANZANIA; BEHAVIOR AB Background Insecticide-treated nets (ITNs) and indoor residual spraying (IRS) are highly effective tools for controlling malaria transmission in Africa because the most important vectors, from the Anopheles gambiae complex and the A. funestus group, usually prefer biting humans indoors at night. Methods Matched surveys of mosquito and human behaviour from six rural sites in Burkina Faso, Tanzania, Zambia, and Kenya, with ITN use ranging from 0.2% to 82.5%, were used to calculate the proportion of human exposure to An. gambiae sensu lato and An. funestus s.l. that occurs indoors (pi(i)), as an indicator of the upper limit of personal protection that indoor vector control measures can provide. This quantity was also estimated through use of a simplified binary analysis (pi(B)(i)) so that the proportions of mosquitoes caught indoors (P-i), and between the first and last hours at which most people are indoors (P-fl) could also be calculated as underlying indicators of feeding by mosquitoes indoors or at night, respectively. Results The vast majority of human exposure to Anopheles bites occurred indoors (pi(B)(i) = 0.79-1.00). Neither An. gambiae s.l. nor An. funestus s.l. strongly preferred feeding indoors (P-i = 0.40-0.63 and 0.22-0.69, respectively), but they overwhelmingly preferred feeding at times when most humans were indoors (P-fl = 0.78-1.00 and 0.86-1.00, respectively). Conclusions These quantitative summaries of behavioural interactions between humans and mosquitoes constitute a remarkably consistent benchmark with which future observations of vector behaviour can be compared. Longitudinal monitoring of these quantities is vital to evaluate the effectiveness of ITNs and IRS and the need for complementary measures that target vectors outdoors. C1 [Huho, Bernadette; Okumu, Fredros; Abdulla, Salim; Killeen, Gerry] Ifakara Hlth Inst, Environm Sci Themat Grp, Dar Es Salaam, Tanzania. [Huho, Bernadette; Briet, Olivier; Smith, Thomas] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Huho, Bernadette; Briet, Olivier; Smith, Thomas] Univ Basel, Basel, Switzerland. [Seyoum, Aklilu; Sikaala, Chadwick; Killeen, Gerry] Univ Liverpool, Liverpool Sch Trop Med, Vector Biol Dept, Liverpool L3 5QA, Merseyside, England. [Sikaala, Chadwick] Chainama Hosp Coll Grounds, Natl Malaria Control Ctr, Lusaka, Zambia. [Bayoh, Nabie] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Bayoh, Nabie] Ctr Dis Control & Prevent, Kisumu, Kenya. [Gimnig, John] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. [Okumu, Fredros] London Sch Hyg & Trop Med, Dis Control & Vector Biol Unit, London WC1, England. [Diallo, Diadier] Ctr Natl Rech & Format Paludisme, Ouagadougou, Burkina Faso. RP Killeen, G (reprint author), Ifakara Hlth Inst, Environm Sci Themat Grp, POB 53, Morogoro, Tanzania. EM gkilleen@ihi.or.tz RI Smith, Thomas/B-5569-2015; Briet, Olivier/K-1917-2015 OI Smith, Thomas/0000-0002-3650-9381; Briet, Olivier/0000-0003-1186-2688 FU Multinational Initiative for Malaria/The Special Programme for Research and Training in Tropical Diseases Research; Roll Back Malaria Programme; Bill & Melinda Gates Foundation [45114]; Stipendienkommission fur Nachwuchs-Krafte aus Entwicklungslandern of Basel Kantonal, Basel, Switzerland FX The MTIMBA project was initiated by the International Network for the Demographic Evaluation of Populations and Their Health (INDEPTH) and was financed by the Multinational Initiative for Malaria/The Special Programme for Research and Training in Tropical Diseases Research and the Roll Back Malaria Programme. The MTC project was funded by the Bill & Melinda Gates Foundation (Award 45114, coordinated by Professor Frank Collins and Dr. Neil Lobo at Notre Dame University, South Bend, IN, USA). Studentship for B. H. was financed by the Stipendienkommission fur Nachwuchs-Krafte aus Entwicklungslandern of Basel Kantonal, Basel, Switzerland. NR 61 TC 39 Z9 39 U1 0 U2 22 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD FEB PY 2013 VL 42 IS 1 BP 235 EP 247 DI 10.1093/ije/dys214 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 113WE UT WOS:000316699300029 PM 23396849 ER PT J AU Lindblade, KA AF Lindblade, Kim A. TI Commentary: Does a mosquito bite when no one is around to hear it? SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Editorial Material ID MALARIA VECTOR CONTROL; INSECTICIDE-TREATED NETS; ANOPHELES-GAMBIAE; EQUATORIAL-GUINEA; WESTERN KENYA; RESISTANCE; POPULATIONS; BEHAVIOR; AFRICAN; ISLAND C1 Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30033 USA. RP Lindblade, KA (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE, Atlanta, GA 30033 USA. EM kil2@cdc.gov NR 23 TC 11 Z9 11 U1 3 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD FEB PY 2013 VL 42 IS 1 BP 247 EP 249 DI 10.1093/ije/dyt004 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 113WE UT WOS:000316699300030 PM 23508414 ER PT J AU Wen, M Zhang, XY Harris, CD Holt, JB Croft, JB AF Wen, Ming Zhang, Xingyou Harris, Carmen D. Holt, James B. Croft, Janet B. TI Spatial Disparities in the Distribution of Parks and Green Spaces in the USA SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Article DE Park; Green space; Neighborhood poverty; Health equity; Environmental justice; Urbanization ID NEIGHBORHOOD SOCIOECONOMIC-STATUS; PHYSICAL-ACTIVITY; ENVIRONMENTAL JUSTICE; PUBLIC PARKS; OBESITY; ACCESS; INEQUALITY; RECREATION; RESOURCES; MORTALITY AB Little national evidence is available on spatial disparities in distributions of parks and green spaces in the USA. This study examines ecological associations of spatial access to parks and green spaces with percentages of black, Hispanic, and low-income residents across the urban-rural continuum in the conterminous USA. Census tract-level park and green space data were linked with data from the 2010 U.S. Census and 2006-2010 American Community Surveys. Linear mixed regression models were performed to examine these associations. Poverty levels were negatively associated with distances to parks and percentages of green spaces in urban/suburban areas while positively associated in rural areas. Percentages of blacks and Hispanics were in general negatively linked to distances to parks and green space coverage along the urban-rural spectrum. Place-based race-ethnicity and poverty are important correlates of spatial access to parks and green spaces, but the associations vary across the urbanization levels. C1 [Wen, Ming] Univ Utah, Dept Sociol, Salt Lake City, UT 84112 USA. [Zhang, Xingyou; Holt, James B.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA 30341 USA. [Harris, Carmen D.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Wen, M (reprint author), Univ Utah, Dept Sociol, 380 S 1530 E Rm 301, Salt Lake City, UT 84112 USA. EM ming.wen@soc.utah.edu; gyx8@cdc.gov; zir9@cdc.gov; jgh4@cdc.gov; jbc0@cdc.gov FU NCI NIH HHS [R01 CA140319, R01CA140319-01A1] NR 67 TC 17 Z9 17 U1 19 U2 93 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD FEB PY 2013 VL 45 SU 1 BP S18 EP S27 DI 10.1007/s12160-012-9426-x PG 10 WC Psychology, Multidisciplinary SC Psychology GA 109QK UT WOS:000316383000006 PM 23334758 ER PT J AU Beezhold, DH Nayak, A Anderson, S Green, B Siegel, P AF Beezhold, Donald H. Nayak, Ajay Anderson, Stacey Green, Brett Siegel, Paul TI Disposition of Toluene Diisocyanate (TDI) Following Dermal Exposure SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) CY FEB 22-26, 2013 CL San Antonio, TX SP Amer Acad Allergy, Asthma & Immunol (AAAAI) C1 [Beezhold, Donald H.; Nayak, Ajay; Anderson, Stacey; Green, Brett; Siegel, Paul] NIOSH, CDC, Morgantown, WV USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2013 VL 131 IS 2 SU S BP AB14 EP AB14 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 111WC UT WOS:000316550800051 ER PT J AU Green, B Nayak, A Law, B Siegel, P Beezhold, DH AF Green, Brett Nayak, Ajay Law, Brandon Siegel, Paul Beezhold, Donald H. TI Production of a Methylenediphenyl Diisocyanate Hapten-Specific Monoclonal Antibody SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) CY FEB 22-26, 2013 CL San Antonio, TX SP Amer Acad Allergy, Asthma & Immunol (AAAAI) C1 [Green, Brett; Nayak, Ajay; Law, Brandon; Siegel, Paul; Beezhold, Donald H.] NIOSH, CDC, Morgantown, WV USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2013 VL 131 IS 2 SU S BP AB15 EP AB15 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 111WC UT WOS:000316550800052 ER PT J AU Greenhawt, MJ Weiss, CC Conte, M Doucet, M Engler, A Camargo, C AF Greenhawt, Matthew J. Weiss, Christopher C. Conte, Marisa Doucet, Marlie Engler, Amy Camargo, Carlos, Jr. TI Racial and Ethnic Disparity in Food Allergy in the United States: A Systematic Review SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) CY FEB 22-26, 2013 CL San Antonio, TX SP Amer Acad Allergy, Asthma & Immunol (AAAAI) C1 [Greenhawt, Matthew J.] Univ Michigan, Sch Med, Dept Internal Med, Div Allergy & Clin Immunol, Ann Arbor, MI USA. [Weiss, Christopher C.] Global Food Protect Inst, Battle Creek, MI USA. [Conte, Marisa] Univ Michigan, Taubman Hlth Sci Lib, Ann Arbor, MI 48109 USA. [Doucet, Marlie] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. [Engler, Amy] Stanford Univ, EHuman Biol Dept, Palo Alto, CA 94304 USA. [Camargo, Carlos, Jr.] Harvard Univ, Dept Emergency Med, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 2 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2013 VL 131 IS 2 SU S BP AB58 EP AB58 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 111WC UT WOS:000316550800208 ER PT J AU Tapp, L Sylvain, D AF Tapp, Loren Sylvain, David TI Skin and Respiratory Symptoms in Peanut Inspectors with Peanut Dust and Endotoxin Exposure SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article C1 [Tapp, Loren; Sylvain, David] NIOSH, US Dept Hlth & Human Serv, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Tapp, L (reprint author), NIOSH, 4676 Columbia Pkwy,MS R-10, Cincinnati, OH 45226 USA. EM LTapp@cdc.gov FU Intramural CDC HHS [CC999999] NR 13 TC 0 Z9 0 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 EI 1545-9632 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD FEB 1 PY 2013 VL 10 IS 2 BP D19 EP D24 DI 10.1080/15459624.2012.747419 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 108XG UT WOS:000316329000001 PM 23256488 ER PT J AU Boulet, SL Okoroh, EM Azonobi, I Grant, A Hooper, WC AF Boulet, Sheree L. Okoroh, Ekwutosi M. Azonobi, Ijeoma Grant, Althea Hooper, W. Craig TI Sickle Cell Disease in Pregnancy: Maternal Complications in a Medicaid-Enrolled Population SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Sickle cell disease; Sickle cell anemia; Pregnancy; Pregnancy complications ID VENOUS THROMBOEMBOLISM; CARE UTILIZATION; UNITED-STATES; MANAGEMENT; EXPENDITURES; RISK AB Higher frequencies of pregnancy complications have been reported among women with sickle cell disease (SCD) compared with those without SCD; however, past studies are limited by small sample size, narrow geographic area, and use of hospital discharge data. We compared the prevalence of maternal complications among intrapartum and postpartum women with SCD to those without SCD in a large, geographically diverse sample. Data from the 2004-2010 Truven Health MarketScan(A (R)) Multi-State Medicaid databases were used to assess the prevalence of maternal complications among intrapartum and postpartum women 15-44 years of age with and without SCD whose race was reported as black. The comparison group of women without SCD was further divided into those with chronic conditions associated with multi-organ failure and those without chronic conditions. Multivariable log-binomial regression models were used to calculate adjusted prevalence ratios for outcomes for women with SCD compared with women in the two comparison groups. Of the 335,348 black women with a delivery during 2004-2010, 1,526 had a diagnosis of SCD (0.5 %). Compared with women without SCD who had chronic conditions, women with SCD had higher prevalence of deep vein thrombosis, pulmonary embolism, obstetric shock, pneumonia, sepsis, postpartum infection, and transfusions. SCD was also positively associated with acute renal failure, cerebrovascular disorder, respiratory distress syndrome, eclampsia, postpartum hemorrhage, preterm birth, and ventilation when compared with women without SCD and chronic conditions. Overall, women with SCD have increased prevalence of pregnancy complications, even when compared with a group of women with similar risk for multi-organ failure. C1 [Boulet, Sheree L.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Okoroh, Ekwutosi M.; Azonobi, Ijeoma; Grant, Althea; Hooper, W. Craig] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. RP Boulet, SL (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,MS-K34, Atlanta, GA 30341 USA. EM sbu1@cdc.gov FU Intramural CDC HHS [CC999999] NR 24 TC 10 Z9 10 U1 0 U2 6 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD FEB PY 2013 VL 17 IS 2 BP 200 EP 207 DI 10.1007/s10995-012-1216-3 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 104PC UT WOS:000316005600002 PM 23315242 ER PT J AU Ramlal, RT Tembo, M Soko, A Chigwenembe, M Tohill, BC Kayira, D King, CC Chasela, C Jamieson, D van der Horst, C Bentley, ME Adair, LS AF Ramlal, Roshan T. Tembo, Martin Soko, Alice Chigwenembe, Maggie Tohill, Beth C. Kayira, Dumbani King, Caroline C. Chasela, Charles Jamieson, Denise van der Horst, Charles Bentley, Margaret E. Adair, Linda S. CA BAN Study Team TI Patterns of Body Composition Among HIV-Infected, Pregnant Malawians and the Effects of Famine Season SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE HIV; Pregnancy; Malawi; Seasonality; Body composition; MUAC ID MATERNAL WEIGHT-GAIN; IMMUNODEFICIENCY-VIRUS-INFECTION; INFANT BIRTH-WEIGHT; HIV-1-INFECTED WOMEN; SOCIOECONOMIC-STATUS; AFRICAN WOMEN; GAMBIAN WOMEN; PREDICTORS; RISK; TERM AB We describe change in weight, midupper arm circumference (MUAC), arm muscle area (AMA) and arm fat area (AFA) in 1130 pregnant HIV-infected women with CD4 counts > 200 as part of the BAN Study (http://www.thebanstudy.org), a randomized, controlled clinical trial to evaluate antiretroviral and nutrition interventions to reduce mother-to-child transmission of HIV during breast feeding. In a longitudinal analysis, we found a linear increase in weight with a mean rate of weight gain of 0.27 kgs/week, from baseline (12 to 30 weeks gestation) until the last follow-up visit (32-38 weeks). Analysis of weight gain showed that 17.1% of the intervals between visits resulted in a weight loss. In unadjusted models, MUAC and AMA increased and AFA declined during late pregnancy. Based on multivariable regression analysis, exposure to the famine season resulted in larger losses in AMA [-0.08, 95% CI -0.14, -0.02; p = 0.01] while AFA losses occurred irrespective of season [-0.55, 95%: -0.95, -0.14, p = 0.01]. CD4 was associated with AFA [0.21, 95% CI 0.01, 0.41, p = .04]. Age was positively associated with MUAC and AMA. Wealth was positively associated with MUAC, AFA, and weight. While patterns of anthropometric measures among HIV-infected, pregnant women were found to be similar to those reported for uninfected women in sub-Saharan Africa, effects of the famine season among undernourished, Malawian women are of concern. Strategies to optimize nutrition during pregnancy for these women appear warranted. C1 [Ramlal, Roshan T.; van der Horst, Charles; Bentley, Margaret E.; Adair, Linda S.] Univ N Carolina, Chapel Hill, NC 27515 USA. [Tembo, Martin; Soko, Alice; Chigwenembe, Maggie; Kayira, Dumbani; Chasela, Charles] UNC Project, Lilongwe, Malawi. [Tohill, Beth C.; King, Caroline C.; Jamieson, Denise] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Ramlal, RT (reprint author), Univ N Carolina, Chapel Hill, NC 27515 USA. EM roshan.m.thomas@gmail.com FU NIAID NIH HHS [P30 AI050410]; NICHD NIH HHS [R24 HD050924, R03 HD057637, R03HD057637] NR 45 TC 3 Z9 3 U1 1 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD FEB PY 2013 VL 17 IS 2 BP 265 EP 273 DI 10.1007/s10995-012-0970-6 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 104PC UT WOS:000316005600009 PM 22395817 ER PT J AU Gurley, ES Salje, H Homaira, N Ram, PK Haque, R Petri, WA Bresee, J Moss, WJ Luby, SP Breysse, P Azziz-Baumgartner, E AF Gurley, Emily S. Salje, Henrik Homaira, Nusrat Ram, Pavani K. Haque, Rashidul Petri, William A., Jr. Bresee, Joseph Moss, William J. Luby, Stephen P. Breysse, Patrick Azziz-Baumgartner, Eduardo TI Seasonal concentrations and determinants of indoor particulate matter in a low-income community in Dhaka, Bangladesh SO ENVIRONMENTAL RESEARCH LA English DT Article DE Particulate matter; Bangladesh; Indoor air; Biomass; Urban health ID ACUTE RESPIRATORY-INFECTIONS; AIR-POLLUTION; DEVELOPING-COUNTRIES; PARTICLE MONITOR; EXPOSURE; CHILDREN; OUTDOOR; QUALITY; SMOKE; CITY AB Indoor exposure to particulate matter (PM) increases the risk of acute lower respiratory tract infections, which are the leading cause of death in young children in Bangladesh. Few studies, however, have measured children's exposures to indoor PM over time. The World Health Organization recommends that daily indoor concentrations of PM less than 2.5 mu m in diameter (PM2.5) not exceed 25 mu g/m(3). This study aimed to describe the seasonal variation and determinants of concentrations of indoor PM2.5 in a low-income community in urban Dhaka, Bangladesh. PM2.5 was measured in homes monthly during May 2009 to April 2010. We calculated the time-weighted average, 90th percentile PM2.5 concentrations and the daily hours PM2.5 exceeded 100 mu g/m(3). Linear regression models were used to estimate the associations between fuel use, ventilation, indoor smoking, and season to each metric describing indoor PM2.5 concentrations. Time-weighted average PM2.5 concentrations were 190 mu g/m(3) (95% CI 170-210). Sixteen percent of 258 households primarily used biomass fuels for cooking and PM2.5 concentrations in these homes had average concentrations 75 mu g/m(3) (95% CI 56-124) greater than other homes. PM2.5 concentrations were also associated with burning both biomass and kerosene, indoor smoking, and ventilation, and were more than twice as high during winter than during other seasons. Young children in this community are exposed to indoor PM2.5 concentrations 7 times greater than those recommended by World Health Organization guidelines. Interventions to reduce biomass burning could result in a daily reduction of 75 mu m(3) (40%) in time-weighted average PM2.5 concentrations. (C) 2012 Elsevier Inc. All rights reserved. C1 [Gurley, Emily S.; Homaira, Nusrat; Haque, Rashidul; Luby, Stephen P.; Azziz-Baumgartner, Eduardo] Icddr B, Ctr Communicable Dis, Dhaka 1212, Bangladesh. [Gurley, Emily S.; Salje, Henrik; Moss, William J.; Breysse, Patrick] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Ram, Pavani K.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14214 USA. [Petri, William A., Jr.] Univ Virginia, Charlottesville, VA 22908 USA. [Bresee, Joseph; Luby, Stephen P.; Azziz-Baumgartner, Eduardo] US Ctr Dis Control & Prevent CDC, Atlanta, GA 30333 USA. RP Gurley, ES (reprint author), Icddr B, Ctr Communicable Dis, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh. EM egurley@icddrb.org; hsalje@jhsph.edu; nhomaira@icddrb.org; pkram@buffalo.edu; rhaque@icddrb.org; wap3g@virginia.edu; jsb6@cdc.gov; wmoss@jhsph.edu; sluby@icddrb.org; pbreysse@jhsph.edu; eha9@cdc.gov RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Salje, Henrik/0000-0003-3626-4254 FU United States Centers for Disease Control and Prevention (CDC) [U01/C1000628-02]; National Institutes of Health, USA (NIH) [5R01 A1043596] FX This study was funded by the United States Centers for Disease Control and Prevention (CDC), Grant no. U01/C1000628-02 and the National Institutes of Health, USA (NIH), Grant no. 5R01 A1043596. icddr,b acknowledges with gratitude the commitment of CDC and NIH to its research efforts. The authors wish to thank the children and their families for their participation in this cohort. We appreciated the statistical assistance of Jaynal Abedin and Yushuf Sharker. NR 32 TC 10 Z9 10 U1 1 U2 24 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 J9 ENVIRON RES JI Environ. Res. PD FEB PY 2013 VL 121 BP 11 EP 16 DI 10.1016/j.envres.2012.10.004 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 101CV UT WOS:000315753700002 PM 23127494 ER PT J AU Luderer, U Kesner, JS Fuller, JM Krieg, EF Meadows, JW Tramma, SL Yang, HO Baker, D AF Luderer, Ulrike Kesner, James S. Fuller, Julie M. Krieg, Edward F., Jr. Meadows, Juliana W. Tramma, Simone L. Yang, Haiou Baker, Dean TI Effects of gestational and lactational exposure to heptachlor epoxide on age at puberty and reproductive function in men and women SO ENVIRONMENTAL RESEARCH LA English DT Article DE Heptachlor; Organochlorine; Puberty; Menstrual cycle; Semen analysis ID IN-UTERO; PROGESTERONE METABOLITES; LUTEINIZING-HORMONE; URINARY ESTROGEN; MENSTRUAL-CYCLE; SEMEN QUALITY; BREAST-MILK; MENARCHE; CONCEPTION; OVULATION AB Background: For 15 months in 1981-1982, the commercial milk supply on the Hawaiian island of Oahu was contaminated with heptachlor epoxide, a metabolite of the insecticide heptachlor, resulting in gestational and/or lactational exposure to offspring of women who drank cow milk during that period. Objective: To determine whether gestational and lactational exposure to heptachlor epoxide alters reproductive function and age at puberty in men or women. Methods: 457 participants were recruited from a prior high school enrollment sampling frame of 20,000 adults born during 1981-1982 who lived on Oahu since at least first grade. Number of glasses of cow milk consumed weekly by the mother during the participant's gestation was used as a surrogate measure of heptachlor epoxide exposure. Reproductive function measures included semen analyses; reproductive hormones or their metabolites in daily urine specimens for one menstrual cycle; serum reproductive hormone levels in both sexes; and reported ages of onset for pubertal milestones. Results: We observed no strong associations of heptachlor epoxide exposure during gestation and lactation with reproductive endpoints. In females, heptachlor epoxide exposure was associated with longer luteal phase length and slower drop in the ratio of estradiol to progesterone metabolites after ovulation. In males, heptachlor epoxide exposure was weakly associated with higher serum follicle stimulating hormone and luteinizing hormone concentrations, but no dose-response relationship was apparent. Conclusions: The results provide limited evidence that gestational and lactational exposure to heptachlor epoxide, due to milk contamination on Oahu in 1981-1982, resulted in clinically significant disturbances of reproductive function in men or women. (C) 2012 Elsevier Inc. All rights reserved. C1 [Luderer, Ulrike; Fuller, Julie M.; Tramma, Simone L.; Yang, Haiou; Baker, Dean] Univ Calif Irvine, Ctr Occupat & Environm Hlth, Irvine, CA 92617 USA. [Luderer, Ulrike; Fuller, Julie M.; Tramma, Simone L.; Yang, Haiou; Baker, Dean] Univ Calif Irvine, Div Occupat & Environm Med, Dept Med, Irvine, CA 92617 USA. [Kesner, James S.; Krieg, Edward F., Jr.; Meadows, Juliana W.] NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, Publ Hlth Serv,US Dept Hlth & Human Serv, Cincinnati, OH 45226 USA. RP Luderer, U (reprint author), Univ Calif Irvine, Ctr Occupat & Environm Hlth, 100 Theory,Suite 100, Irvine, CA 92617 USA. EM uluderer@uci.edu FU US Environmental Protection Agency [R-82943901]; National Institute of Occupational Health Sciences to the Southern California Education and Research Center; University of California Irvine Center for Occupational and Environmental Health FX This project was supported by a grant from the US Environmental Protection Agency (R-82943901), a grant from the National Institute of Occupational Health Sciences to the Southern California Education and Research Center, and the University of California Irvine Center for Occupational and Environmental Health. NR 49 TC 4 Z9 4 U1 0 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 J9 ENVIRON RES JI Environ. Res. PD FEB PY 2013 VL 121 BP 84 EP 94 DI 10.1016/j.envres.2012.11.001 PG 11 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 101CV UT WOS:000315753700012 PM 23194642 ER PT J AU Mendola, P Brett, K DiBari, JN Pollack, AZ Tandon, R Shenassa, ED AF Mendola, Pauline Brett, Kate DiBari, Jessica N. Pollack, Anna Z. Tandon, Rashmi Shenassa, Edmond D. TI Menopause and lead body burden among US women aged 45-55, NHANES 1999-2010 SO ENVIRONMENTAL RESEARCH LA English DT Article DE Lead; Menopause; Women's health; Epidemiology; Environment ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; FOLLICLE-STIMULATING-HORMONE; POSTMENOPAUSAL WOMEN; REPRODUCTIVE HORMONES; LUTEINIZING-HORMONE; MENSTRUAL CYCLES; BONE; TRANSITION; GIRLS AB Background: Environmental factors in menopause have received limited attention. Lead is a known reproductive toxicant associated with delayed puberty in girls that may also affect menopause. Methods: The odds of menopause among US women aged 45-55 were estimated in the National Health and Nutrition Examination Survey, 1999-2010, in relation to quartiles of blood lead. Women still menstruating (n=2158) were compared to women with natural menopause (n=1063). Logistic regression models included age, race/ethnicity, current hormone use, poverty, smoking and where available, bone density or bone alkaline phosphatase. Results: Lead levels (ug/dL) were higher in menopausal women, geometric mean (standard error)=1.71 (0.04) vs. 1.23 (0.02). Adjusted odds of menopause and 95% confidence intervals for lead quartiles (lowest quartile referent) were 1.7 (1.0-2.8), 2.1 (1.2-3.6), and 4.2 (2.5-7.0) respectively. Results adjusting for bone markers were generally similar but had less precision. Conclusions: Blood lead was associated with natural menopause in US women even after adjustment for bone turnover. This raises concern that lead exposure, even at low levels, may shorten women's reproductive lifespan. Published by Elsevier Inc. C1 [Mendola, Pauline; Pollack, Anna Z.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Rockville, MD 20852 USA. [Brett, Kate; Tandon, Rashmi] CDC, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [DiBari, Jessica N.; Shenassa, Edmond D.] Univ Maryland, Dept Family Sci, Sch Publ Hlth, Maternal & Child Hlth Program, College Pk, MD 20742 USA. RP Mendola, P (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Epidemiol Stat & Prevent Res, NIH, 6100 Execut Blvd, Rockville, MD 20852 USA. EM pauline.mendola@nih.gov OI Pollack, Anna/0000-0002-4313-3298; Mendola, Pauline/0000-0001-5330-2844 FU Intramural Research Program of the NIH; Eunice Kennedy Shriver National Institute of Child Health and Human Development FX This research was supported in part by the Intramural Research Program of the NIH, Eunice Kennedy Shriver National Institute of Child Health and Human Development. NR 25 TC 6 Z9 6 U1 0 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 J9 ENVIRON RES JI Environ. Res. PD FEB PY 2013 VL 121 BP 110 EP 113 DI 10.1016/j.envres.2012.12.009 PG 4 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 101CV UT WOS:000315753700015 PM 23352036 ER PT J AU Farooqi, JQ Jabeen, K Saeed, N Iqbal, N Malik, B Lockhart, SR Zafar, A Brandt, ME Hasan, R AF Farooqi, J. Q. Jabeen, K. Saeed, N. Iqbal, N. Malik, B. Lockhart, S. R. Zafar, A. Brandt, M. E. Hasan, R. TI Invasive candidiasis in Pakistan: clinical characteristics, species distribution and antifungal susceptibility SO JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Article ID BLOOD-STREAM INFECTIONS; SURVEILLANCE NETWORK TRANSNET; EPIDEMIOLOGIC CUTOFF VALUES; TRANSPLANT RECIPIENTS; MIC DISTRIBUTIONS; FUNGAL-INFECTIONS; CANDIDEMIA; TROPICALIS; DIFFERENTIATION; IDENTIFICATION AB This study reports for the first time, to our knowledge, descriptive epidemiological data for 188 invasive Candida isolates from Pakistan, including species identification and antifungal susceptibility against fluconazole, itraconazole, voriconazole, caspofungin, micafungin, anidulafungin and amphotericin. Risk factors for invasive candidiasis (IC) were determined for 96 patients from Karachi, Pakistan. In adults and neonates, Candida tropicalis (38 and 36%, respectively) was the most common species, followed in adults by Candida parapsilosis (17.8%), Candida glabrata (15.9%) and Candida albicans (12.3%). C. albicans (21%) was the second most common in neonates. In children, C. albicans (31.9%), C. tropicalis (26.4%) and C. parapsilosis (19.4%) were the most common. C. albicans IC was significantly associated with paediatric age [crude odds ratio (COR) 3.46, 95% confidence interval (CI) 1.63-7.32]. Rare species made up 17.5% of the total isolates studied. Resistance to fluconazole was seen in C. glabrata (15.0%) and Candida krusei (100.0%). Only one isolate (C. glabrata) was resistant to all three echinocandins. Low MICs of fluconazole for 98% (184/188) of isolates tested support its continued use as an empiric therapy for IC. Non-C. albicans IC was associated with the use of beta-lactam inhibitor combinations (COR 3.16, 95% CI 1.05-9.57). Use of healthcare devices was documented in 85.4% of IC patients, whilst 75.0% had been admitted to special care units. Surprisingly, 66.7% of patients with IC were not obviously immunosuppressed. The high frequency of modifiable risk factors in this population indicates that candidaemia can be reduced with stringent antibiotic and infection control measures. These data will be useful for empiric selection of antifungals in Karachi, and contribute to global assessments of antifungal resistance. C1 [Farooqi, J. Q.; Jabeen, K.; Saeed, N.; Malik, B.; Zafar, A.; Hasan, R.] Aga Khan Hosp Karachi, Dept Pathol Microbiol, Karachi, Pakistan. [Iqbal, N.; Lockhart, S. R.; Brandt, M. E.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. RP Farooqi, JQ (reprint author), Aga Khan Hosp Karachi, Dept Pathol Microbiol, Karachi, Pakistan. EM joveria.farooqi@aku.edu RI Hasan, Rumina/F-4420-2015; Jabeen, Kauser/I-8018-2015 FU Joint Pakistan US Academic and Research Program Higher Education Commission/Ministry of Science and Technology/United States Agency for International Development (HEC/MoST/USAID) FX This study was supported through grants from the Joint Pakistan US Academic and Research Program Higher Education Commission/Ministry of Science and Technology/United States Agency for International Development (HEC/MoST/USAID). We would like to acknowledge Eszter Deak and Joyce Peterson from the Centers for Disease Control and Prevention, Atlanta, GA, USA, for their technical support. From AKUH, Karachi, Faisal Malik and Afsheen Ayaz provided help in data entry and statistical analysis and Dr Summiya Nizamuddin in the review of clinical records. The findings and conclusions of this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 39 TC 7 Z9 8 U1 0 U2 6 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-2615 J9 J MED MICROBIOL JI J. Med. Microbiol. PD FEB PY 2013 VL 62 BP 259 EP 268 DI 10.1099/jmm.0.048785-0 PN 2 PG 10 WC Microbiology SC Microbiology GA 098MS UT WOS:000315554000012 PM 23105021 ER PT J AU Newman, L Kamb, M Hawkes, S Gomez, G Say, L Seuc, A Broutet, N AF Newman, Lori Kamb, Mary Hawkes, Sarah Gomez, Gabriela Say, Lale Seuc, Armando Broutet, Nathalie TI Global Estimates of Syphilis in Pregnancy and Associated Adverse Outcomes: Analysis of Multinational Antenatal Surveillance Data SO PLOS MEDICINE LA English DT Article ID MATERNAL SYPHILIS; METAANALYSIS; STILLBIRTHS; MORTALITY; HISTORY; MALAWI; RISK AB Background: The World Health Organization initiative to eliminate mother-to-child transmission of syphilis aims for >= 90% of pregnant women to be tested for syphilis and >= 90% to receive treatment by 2015. We calculated global and regional estimates of syphilis in pregnancy and associated adverse outcomes for 2008, as well as antenatal care (ANC) coverage for women with syphilis. Methods and Findings: Estimates were based upon a health service delivery model. National syphilis seropositivity data from 97 of 193 countries and ANC coverage from 147 countries were obtained from World Health Organization databases. Proportions of adverse outcomes and effectiveness of screening and treatment were from published literature. Regional estimates of ANC syphilis testing and treatment were examined through sensitivity analysis. In 2008, approximately 1.36 million (range: 1.16 to 1.56 million) pregnant women globally were estimated to have probable active syphilis; of these, 80% had attended ANC. Globally, 520,905 (best case: 425,847; worst case: 615,963) adverse outcomes were estimated to be caused by maternal syphilis, including approximately 212,327 (174,938; 249,716) stillbirths (> 28 wk) or early fetal deaths (22 to 28 wk), 91,764 (76,141; 107,397) neonatal deaths, 65,267 (56,929; 73,605) preterm or low birth weight infants, and 151,547 (117,848; 185,245) infected newborns. Approximately 66% of adverse outcomes occurred in ANC attendees who were not tested or were not treated for syphilis. In 2008, based on the middle case scenario, clinical services likely averted 26% of all adverse outcomes. Limitations include missing syphilis seropositivity data for many countries in Europe, the Mediterranean, and North America, and use of estimates for the proportion of syphilis that was "probable active," and for testing and treatment coverage. Conclusions: Syphilis continues to affect large numbers of pregnant women, causing substantial perinatal morbidity and mortality that could be prevented by early testing and treatment. In this analysis, most adverse outcomes occurred among women who attended ANC but were not tested or treated for syphilis, highlighting the need to improve the quality of ANC as well as ANC coverage. In addition, improved ANC data on syphilis testing coverage, positivity, and treatment are needed. C1 [Newman, Lori; Say, Lale; Seuc, Armando; Broutet, Nathalie] World Hlth Org, Dept Reprod Hlth & Res, Geneva, Switzerland. [Kamb, Mary] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA USA. [Hawkes, Sarah] UCL, London, England. [Gomez, Gabriela] Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands. [Gomez, Gabriela] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, London, England. RP Newman, L (reprint author), World Hlth Org, Dept Reprod Hlth & Res, Geneva, Switzerland. EM newmanl@who.int OI Hawkes, Sarah/0000-0003-1062-3538 FU Wellcome Trust [WPIA-P30479] FX GBG was funded by The Wellcome Trust (#WPIA-P30479) while working at Imperial College London. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. LN is a staff member of the World Health Organization. The author alone is responsible for the views expressed in this publication and they do not necessarily represent the decisions or policies of the World Health Organization. MK is a staff member of the CDC. The findings and conclusions in this paper are those of the author and do not necessarily represent the views of the CDC. NR 31 TC 87 Z9 94 U1 1 U2 24 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD FEB PY 2013 VL 10 IS 2 AR e1001396 DI 10.1371/journal.pmed.1001396 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 099BC UT WOS:000315592800013 PM 23468598 ER PT J AU Vernon, A AF Vernon, Andrew TI Treatment of Latent Tuberculosis Infection Preface SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE latent TB; TB preventive therapy; TB prophylaxis; isoniazid; 3HP; rifapentine ID ISONIAZID PREVENTIVE THERAPY; COST-EFFECTIVENESS ANALYSIS; MULTIDRUG-RESISTANT TUBERCULOSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL; 1ST-LINE ANTITUBERCULOSIS DRUGS; PULMONARY TUBERCULOSIS; HIV-INFECTION; CLINICAL-TRIAL; UNITED-STATES AB Latent tuberculosis infection (LTBI) refers to a circumstance in which viable Mycobacterium tuberculosis (MTB) bacilli are present in an individual but symptoms and signs of active disease are lacking, and the bacilli are relatively inactive metabolically. In favorable circumstances, some of these inactive bacilli resume greater metabolic activity and replication, leading to the development of active tuberculosis disease. Treatment of this condition (TLTBI) is designed to prevent (soon, or in the distant future) this progression from asymptomatic infection to symptomatic, potentially lethal, active disease. This narrative review draws upon recent reviews of LTBI and seeks particularly to include recently published or presented data that are not included in those prior reviews. Adverse effects of treatment are considered, as are the special circumstances of human immunodeficiency virus-related LTBI, drug resistance, and use of TLTBI in the context of tumor necrosis factor alpha (TNF-alpha) inhibition. The review describes the main studies underpinning Centers for Disease Control and Prevention recommendations on use of the new 3-month isoniazid-rifapentine regimen and points to evolving data that may support future modification of those recommendations. C1 [Vernon, Andrew] Ctr Dis Control & Prevent, Div TB Eliminat, Clin Res Branch, CDC,OID,Off Infect Dis,NCHHSTP,Natl Ctr HIV AIDS, Atlanta, GA 30333 USA. RP Vernon, A (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, NCHHSTP, OID, 1600 Clifton Rd NE,E-10, Atlanta, GA 30333 USA. EM avernon@cdc.gov NR 165 TC 14 Z9 16 U1 1 U2 21 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 EI 1098-9048 J9 SEMIN RESP CRIT CARE JI Semin. Respir. Crit. Care Med. PD FEB PY 2013 VL 34 IS 1 BP 67 EP 86 DI 10.1055/s-0032-1333544 PG 20 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 101RY UT WOS:000315793300007 PM 23460007 ER PT J AU Kroner, BL Fahimi, M Kenyon, A Thurman, DJ Gaillard, WD AF Kroner, Barbara L. Fahimi, Mansour Kenyon, Anne Thurman, David J. Gaillard, William D. TI Racial and socioeconomic disparities in epilepsy in the District of Columbia SO EPILEPSY RESEARCH LA English DT Article DE Epilepsy; Incidence; Prevalence; Race; Education ID SELF-REPORTED EPILEPSY; FACTOR SURVEILLANCE SYSTEM; CHILDHOOD-ONSET EPILEPSY; LEARNING-DISABILITY; UNITED-STATES; RISK-FACTORS; PREVALENCE; ADULTS; CONSEQUENCES; VALIDATION AB We investigated social and demographic factors as they relate to prevalence and incidence of epilepsy in Washington, DC, a culturally diverse area. Probability-based sampling was used to select 20,000 households to complete a mailed epilepsy screening survey on all household members. Screened individuals with a history of epilepsy were sent a detailed case survey about seizures and treatment. Prevalence and incidence of epilepsy were estimated using weighted data. Lifetime prevalence was 1.53% overall; 0.77% in Whites, 2.13% in Blacks, and 3.4% in those with less than a high school diploma. Prevalence of active epilepsy was 0.79% and followed similar subgroup comparisons as lifetime prevalence. Age-adjusted lifetime and active epilepsy from multivariate analyses demonstrated significantly higher rates for Blacks compared to Whites and for those not completing high school compared to those that attended graduate school. The incidence of epilepsy was 71 per 100,000 persons. Adults with active epilepsy were significantly less likely to live alone than those without epilepsy. Residents of DC for <4 years had the lowest prevalence and incidence of all subgroups indicating a possible healthy mover effect. This is the first study to provide estimates and profiles of the epilepsy population in DC which can help better target resources to improve the health and outcomes of people with epilepsy and their families. (c) 2012 Elsevier B.V. All rights reserved. C1 [Kroner, Barbara L.] RTI Int, Rockville, MD 20852 USA. [Fahimi, Mansour] Mkt Syst Grp, Ft Washington, PA 19034 USA. [Kenyon, Anne] RTI Int, Res Triangle Pk, NC 27709 USA. [Thurman, David J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Gaillard, William D.] Childrens Natl Med Ctr, Washington, DC 20010 USA. RP Kroner, BL (reprint author), RTI Int, 6110 Execut Blvd, Rockville, MD 20852 USA. EM byk@rti.org; mfahimi@m-s-g.com; aek@rti.org; dxt9@cdc.gov; wgaillar@childrensnational.org FU Centers for Disease Control and Prevention (CDC); Association for Prevention Teaching and Research (APTR) Cooperative Agreement [5U50CD300860, TS-1389] FX This study was made possible through the Centers for Disease Control and Prevention (CDC) and the Association for Prevention Teaching and Research (APTR) Cooperative Agreement, No. 5U50CD300860, Project TS-1389. The findings and conclusions in this presentation are those of the authors and do not necessarily represent the views of the CDC or the APTR. NR 30 TC 7 Z9 7 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 J9 EPILEPSY RES JI Epilepsy Res. PD FEB PY 2013 VL 103 IS 2-3 BP 279 EP 287 DI 10.1016/j.eplepsyres.2012.07.005 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 095ZD UT WOS:000315372600018 PM 22858309 ER PT J AU Grass, JE Gould, LH Mahon, BE AF Grass, Julian E. Gould, L. Hannah Mahon, Barbara E. TI Epidemiology of Foodborne Disease Outbreaks Caused by Clostridium perfringens, United States, 1998-2010 SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID VEGETATIVE CELLS; ILLNESS; FOODS; SHOCK; MEAT AB Clostridium perfringens is estimated to be the second most common bacterial cause of foodborne illness in the United States, causing one million illnesses each year. Local, state, and territorial health departments voluntarily report C. perfringens outbreaks to the U.S. Centers for Disease Control and Prevention through the Foodborne Disease Outbreak Surveillance System. Our analysis included outbreaks confirmed by laboratory evidence during 1998-2010. A food item was implicated if C. perfringens was isolated from food or based on epidemiologic evidence. Implicated foods were classified into one of 17 standard food commodities when possible. From 1998 to 2010, 289 confirmed outbreaks of C. perfringens illness were reported with 15,208 illnesses, 83 hospitalizations, and eight deaths. The number of outbreaks reported each year ranged from 16 to 31 with no apparent trend over time. The annual number of outbreak-associated illnesses ranged from 359 to 2,173, and the median outbreak size was 24 illnesses. Outbreaks occurred year round, with the largest number in November and December. Restaurants (43%) were the most common setting of food preparation. Other settings included catering facility (19%), private home (16%), prison or jail (11%), and other (10%). Among the 144 (50%) outbreaks attributed to a single food commodity, beef was the most common commodity (66 outbreaks, 46%), followed by poultry (43 outbreaks, 30%), and pork (23 outbreaks, 16%). Meat and poultry outbreaks accounted for 92% of outbreaks with an identified single food commodity. Outbreaks caused by C. perfringens occur regularly, are often large, and can cause substantial morbidity yet are preventable if contamination of raw meat and poultry products is prevented at the farm or slaughterhouse or, after contamination, if these products are properly handled and prepared, particularly in restaurants and catering facilities. C1 [Grass, Julian E.] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Gould, L. Hannah; Mahon, Barbara E.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Enter Dis Epidemiol Branch, Atlanta, GA 30333 USA. RP Grass, JE (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Enter Dis Epidemiol Branch, 1600 Clifton Rd,MS C-09, Atlanta, GA 30333 USA. EM hij3@cdc.gov FU Intramural CDC HHS [CC999999] NR 25 TC 29 Z9 31 U1 0 U2 22 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD FEB PY 2013 VL 10 IS 2 BP 131 EP 136 DI 10.1089/fpd.2012.1316 PG 6 WC Food Science & Technology SC Food Science & Technology GA 097IU UT WOS:000315468000005 PM 23379281 ER PT J AU Song, J Hochberg, MC Chang, RW Hootman, JM Manheim, LM Lee, J Semanik, PA Sharma, L Dunlop, DD AF Song, Jing Hochberg, Marc C. Chang, Rowland W. Hootman, Jennifer M. Manheim, Larry M. Lee, Jungwha Semanik, Pamela A. Sharma, Leena Dunlop, Dorothy D. CA Osteoarthritis Initiative Investig TI Racial and ethnic differences in physical activity guidelines attainment among people at high risk of or having knee osteoarthritis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID PUBLIC-HEALTH; UNITED-STATES; OLDER-ADULTS; US ADULTS; NATIONAL-HEALTH; ARTHRITIS; PREVALENCE; DISABILITY; AMERICANS; EXERCISE AB Objective This cross-sectional study examined racial/ethnic differences in meeting the 2008 United States Department of Health and Human Services Physical Activity Guidelines aerobic component (150 moderate-to-vigorous minutes/week in bouts of 10 minutes) among persons with or at risk of radiographic knee osteoarthritis (RKOA). Methods We evaluated African American versus white differences in guideline attainment using multiple logistic regression, adjusting for sociodemographic (age, sex, site, income, and education) and health factors (comorbidity, depressive symptoms, overweight/obesity, and knee pain). Our analyses included adults ages 4984 years who participated in accelerometer monitoring at the Osteoarthritis Initiative 48-month visit (n = 1,142 with RKOA and n = 747 at risk of RKOA). Results Two percent of African Americans and 13.0% of whites met the guidelines. For adults with and at risk of RKOA, significantly lower rates of guidelines attainment among African Americans compared to whites were partially attenuated by health factor differences, particularly overweight/obesity and knee pain (with RKOA: adjusted odds ratio [OR] 0.24, 95% confidence interval [95% CI] 0.080.72; at risk of RKOA: OR 0.28, 95% CI 0.071.05). Conclusion Despite known benefits from physical activity, attainment of the physical activity guidelines among persons with and at risk of RKOA was low. African Americans were 7276% less likely than whites to meet the guidelines. Culturally relevant interventions and environmental strategies in the African American community targeting overweight/obesity and knee pain may reduce future racial/ethnic differences in physical activity and improve health outcomes. C1 [Song, Jing; Chang, Rowland W.; Manheim, Larry M.; Lee, Jungwha; Sharma, Leena; Dunlop, Dorothy D.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Hochberg, Marc C.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Hootman, Jennifer M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Semanik, Pamela A.] Rehabil Inst Chicago, Chicago, IL 60611 USA. RP Song, J (reprint author), Northwestern Univ, Inst Healthcare Studies, Feinberg Sch Med, 750 Lakeshore Dr,10th Floor, Chicago, IL 60611 USA. EM j-song1@northwestern.edu FU National Institute of Arthritis and Musculoskeletal and Skin Diseases [P60-AR-48098, R01-AR-055287, R01-AR-054155, R21-AR-059412]; NIH, Department of Health and Human Services [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262]; Merck Research Laboratories; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Pfizer FX Supported in part by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grants P60-AR-48098, R01-AR-055287, R01-AR-054155, and R21-AR-059412). The Osteoarthritis Initiative is a public-private partnership comprised of 5 contracts (N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, and N01-AR-2-2262) funded by the NIH, a branch of the Department of Health and Human Services, and conducted by the Osteoarthritis Initiative Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer. Private sector funding for the Osteoarthritis Initiative is managed by the Foundation for the NIH. NR 48 TC 10 Z9 10 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD FEB PY 2013 VL 65 IS 2 BP 195 EP 202 DI 10.1002/acr.21803 PG 8 WC Rheumatology SC Rheumatology GA 083LW UT WOS:000314466600004 PM 22807352 ER PT J AU Parashar, U Steele, D Neuzil, K De Quadros, C Tharmaphornpilas, P Serhan, F Santosham, M Patel, M Glass, R AF Parashar, Umesh Steele, Duncan Neuzil, Kathleen De Quadros, Ciro Tharmaphornpilas, Piyanit Serhan, Fatima Santosham, Mathu Patel, Manish Glass, Roger TI Progress with rotavirus vaccines: summary of the Tenth International Rotavirus Symposium SO EXPERT REVIEW OF VACCINES LA English DT Editorial Material ID REASSORTANT ROTAVIRUS; AFRICAN INFANTS; GASTROENTERITIS; VACCINATION; CHILDREN; IMMUNOGENICITY; INFECTION; SAFETY; PROTECTION; EFFICACY AB Over 350 scientific, public and private sector experts from 47 countries convened at the Tenth International Rotavirus Symposium in Bangkok, Thailand on 19-21 September 2012 to discuss progress in the prevention and control of rotavirus, the leading cause of diarrhea hospitalizations and deaths among young children worldwide. Participants discussed data on the burden and epidemiology of rotavirus disease, results of trials of rotavirus vaccines, postmarketing data on vaccine impact and safety from countries that have implemented rotavirus vaccination programs, new insights in rotavirus pathogenesis, immunity and strain diversity, and key issues related to vaccine policy and introduction. C1 [Parashar, Umesh; Patel, Manish] CDC, Atlanta, GA USA. [Steele, Duncan] Bill & Melinda Gates Fdn, Seattle, WA USA. [Neuzil, Kathleen] Program Appl Technol Hlth, Seattle, WA USA. [De Quadros, Ciro] Sabin Vaccine Inst, Washington, DC USA. [Tharmaphornpilas, Piyanit] Minist Hlth, Bangkok, Thailand. [Serhan, Fatima] WHO, CH-1211 Geneva, Switzerland. [Santosham, Mathu] Johns Hopkins Univ, Baltimore, MD USA. [Glass, Roger] NIH, Bethesda, MD 20892 USA. RP Parashar, U (reprint author), CDC, Atlanta, GA USA. EM uap2@cdc.gov NR 26 TC 12 Z9 12 U1 0 U2 8 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1476-0584 J9 EXPERT REV VACCINES JI Expert Rev. Vaccines PD FEB PY 2013 VL 12 IS 2 BP 113 EP 117 DI 10.1586/ERV.12.148 PG 5 WC Immunology SC Immunology GA 093BS UT WOS:000315167300009 PM 23414403 ER PT J AU Zheng, Q Abernathy, ES Sun, H Zhu, Z de Filippis, A Akoua-Koffi, C Ahmed, H Morris-Glasgow, V Quist-Therson, M Icenogle, JP AF Zheng, Qi Abernathy, Emily S. Sun, Hong Zhu, Zhen de Filippis, Ana Akoua-Koffi, Chantal Ahmed, Hinda Morris-Glasgow, Victoria Quist-Therson, Margaret Icenogle, Joseph P. TI Genotyping of rubella virus RNA in sera and dried blood spots collected during routine surveillance and in archival sera SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Rubella; Genotyping; Real-time RT-PCR; Dried blood spot ID PHYLOGENETIC ANALYSIS; ELIMINATION; CHALLENGES AB Information on the molecular epidemiology of rubella has been valuable in supporting efforts to control and eliminate rubella in several countries. The preferred samples for virus isolation or RNA detection, such as throat swabs, are often not available making it difficult to obtain a robust database of rubella virus sequences. A method for obtaining rubella virus genotypes from more commonly collected samples such as sera or dried blood spots using real-time RT-PCR to screen samples followed by nested set amplification is described. Rubella genotypes were obtained from dried blood spots and recent and archival sera collections. Eighteen percent of the RNAs extracted from the archival sera were real-time RT-PCR positive, and 44% of these RNAs were amplified successfully by nested RT-PCR and sequenced. Implementation of this technique could provide another tool to improve global rubella molecular surveillance. Published by Elsevier B.V. C1 [Zheng, Qi; Abernathy, Emily S.; Sun, Hong; Icenogle, Joseph P.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. [Zhu, Zhen] China Ctr Dis Control, Natl Lab Measles, Beijing, Peoples R China. [de Filippis, Ana] Inst Oswaldo Cruz, Flavivirus Lab, BR-20001 Rio De Janeiro, Brazil. [Akoua-Koffi, Chantal] Inst Pasteur Cote Ivoire, RRL Measles Rubella, Abidjan, Cote Ivoire. [Ahmed, Hinda] WHO Reg Off Eastern Mediterranean, Cairo, Egypt. [Morris-Glasgow, Victoria] PAHO WHO, CAREC Lab, Port Of Spain, Trinid & Tobago. [Quist-Therson, Margaret] Ghana Hlth Serv, Publ Hlth & Reference Lab, Accra, Ghana. RP Icenogle, JP (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mail Stop C22, Atlanta, GA 30333 USA. EM jci1@cdc.gov NR 17 TC 3 Z9 4 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD FEB PY 2013 VL 187 IS 2 BP 284 EP 287 DI 10.1016/j.jviromet.2012.11.023 PG 4 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 091UI UT WOS:000315074900014 PM 23201287 ER PT J AU Jia, HM Zack, MM Thompson, WW Dube, SR AF Jia, Haomiao Zack, Matthew M. Thompson, William W. Dube, Shanta R. TI Quality-adjusted life expectancy (QALE) loss due to smoking in the United States SO QUALITY OF LIFE RESEARCH LA English DT Article DE Quality of life; Life expectancy; Quality-adjusted life year; Smoking; Mortality; Morbidity ID HEALTHY DAYS; OBESITY; TRENDS; INDEX AB Purpose Estimate quality-adjusted life expectancy (QALE) loss due to smoking and examine trends and state differences in smoking-related QALE loss in the U. S. Methods Population health-related quality of life (HRQOL) scores were estimated from the Behavioral Risk Factor Surveillance System. This study constructed life tables based on U. S. mortality files and the mortality linked National Health Interview Survey and calculated QALE for smokers, non-smokers, and the total population. Results In 2009, an 18-year-old smoker was expected to have 43.5 (SE = 0.2) more years of QALE, and a non-smoker of the same age was expected to have 54.6 (SE = 0.2) more years of QALE. Therefore, smoking contributed 11.0 (SE = 0.2) years of QALE loss for smokers and 4.1 years (37%) of this loss resulted from reductions in HRQOL alone. At the population level, smoking was associated with 1.9 fewer years of QALE for U.S. adults throughout their lifetime, starting at age 18. Conclusions This study demonstrates an application of a recently developed QALE estimation methodology. The analyses show good precision and relatively small bias in estimating QALE-especially at the individual level. Although smokers may live longer today than before, they still have a high disease burden due to morbidities associated with poor HRQOL. C1 [Jia, Haomiao] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY 10032 USA. [Jia, Haomiao] Columbia Univ, Sch Nursing, New York, NY 10032 USA. [Zack, Matthew M.; Thompson, William W.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Dube, Shanta R.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Jia, HM (reprint author), Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, 617 W 168th St, New York, NY 10032 USA. EM hj2198@columbia.edu FU CDC [200-2010-M-35363] FX This study (HJ) is supported by a CDC contract (No. 200-2010-M-35363). NR 29 TC 15 Z9 15 U1 1 U2 8 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 J9 QUAL LIFE RES JI Qual. Life Res. PD FEB PY 2013 VL 22 IS 1 BP 27 EP 35 DI 10.1007/s11136-012-0118-6 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 094QQ UT WOS:000315279300003 PM 22350530 ER PT J AU Rodriguez, JM Xie, YDL Winthrop, KL Schafer, S Sehdev, P Solomon, J Jensen, B Toney, NC Lewis, PF AF Rodriguez, Jan M. Xie, Yingda L. Winthrop, Kevin L. Schafer, Sean Sehdev, Paul Solomon, Joel Jensen, Bette Toney, Nadege C. Lewis, Paul F. TI Mycobacterium chelonae Facial Infections Following Injection of Dermal Filler SO AESTHETIC SURGERY JOURNAL LA English DT Article DE cosmetic medicine; dermal filler; mycobacterium; infection; chelonae; hyaluronic acid; tap water ID PERFORMANCE LIQUID-CHROMATOGRAPHY; NONTUBERCULOUS MYCOBACTERIA; SOFT-TISSUE; SKIN; OUTBREAK; WATER; IDENTIFICATION; FREQUENCY; SURGERY; STRAINS AB A cluster of 3 facial Mycobacterium chelonae infections occurred after cosmetic dermal filler injections at a plastic surgery clinic. Pulsed-field gel electrophoresis showed that M chelonae isolated from the clinic tap water were identical to the patient wound isolates. Review of injection procedures identified application of nonsterile ice to the skin prior to injection as a possible source of M chelonae. Surveys of regional laboratories and a national plastic surgery listserv identified no other cases related to the injection of this brand of dermal filler. This is the first report of cutaneous M chelonae infections following the injection of dermal fillers. It adds to a growing body of literature on postinjedion M chelonae infections and reinforces the importance of optimal skin disinfection steps prior to percutaneous procedures. C1 [Rodriguez, Jan M.; Lewis, Paul F.] Clackamas Cty Community Hlth, Oregon City, OR 97045 USA. [Xie, Yingda L.] Oregon Hlth & Sci Univ, Portland, OR USA. [Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Div Infect Dis Publ Hlth & Preventat Med, Portland, OR USA. [Solomon, Joel] Oregon Hlth & Sci Univ, Dept Plast & Reconstruct Surg, Portland, OR USA. [Schafer, Sean] Oregon Hlth Author, Portland, OR USA. [Sehdev, Paul] Infect Dis Consultants, Providence Med Grp, Portland, OR USA. [Jensen, Bette; Toney, Nadege C.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Rodriguez, JM (reprint author), Clackamas Cty Community Hlth, 2051 SE Kaen Rd,Suite 367, Oregon City, OR 97045 USA. EM Janrod@co.clackamas.or.us FU Intramural CDC HHS [CC999999] NR 28 TC 11 Z9 11 U1 1 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-820X J9 AESTHET SURG J JI Aesthet. Surg. J. PD FEB PY 2013 VL 33 IS 2 BP 265 EP 269 DI 10.1177/1090820X12471944 PG 5 WC Surgery SC Surgery GA 088SB UT WOS:000314856300010 PM 23335647 ER PT J AU Kalokhe, AS Shafiq, M Lee, JC Ray, SM Wang, YF Metchock, B Anderson, AM Nguyen, MLT AF Kalokhe, Ameeta S. Shafiq, Majid Lee, James C. Ray, Susan M. Wang, Yun F. Metchock, Beverly Anderson, Albert M. Nguyen, Minh Ly T. TI Multidrug-Resistant Tuberculosis Drug Susceptibility and Molecular Diagnostic Testing SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Review DE Tuberculosis; Multidrug resistance; Drug susceptibility testing; Molecular diagnostic tools ID LINE-PROBE ASSAY; MYCOBACTERIUM-TUBERCULOSIS; RIFAMPIN RESISTANCE; RAPID DETECTION; ISONIAZID RESISTANCE; MULTICENTER EVALUATION; RPOB GENE; MUTATIONS; INDICATOR; BEACONS AB Multidrug-resistant tuberculosis (MDR TB), defined by resistance to the 2 most effective first-line drugs, isoniazid and rifampin, is on the rise globally and is associated with significant morbidity and mortality. Despite the increasing availability of novel rapid diagnostic tools for Mycobacterium tuberculosis (Mtb) drug susceptibility testing, the clinical applicability of these methods is unsettled. In this study, the mechanisms of action and resistance of Mtb to isoniazid and rifampin, and the utility, advantages and limitations of the available Mtb drug susceptibility testing tools are reviewed, with particular emphasis on molecular methods with rapid turnaround including line probe assays, molecular beacon-based real-time polymerase chain reaction and pyrosequencing. The authors conclude that neither rapid molecular drug testing nor phenotypic methods are perfect in predicting Mtb drug susceptibility and therefore must be interpreted within the clinical context of each patient. C1 [Kalokhe, Ameeta S.; Lee, James C.; Ray, Susan M.; Anderson, Albert M.; Nguyen, Minh Ly T.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30303 USA. [Wang, Yun F.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30303 USA. [Shafiq, Majid] Mayo Clin, Div Hosp Internal Med, Rochester, MN USA. [Metchock, Beverly] Ctr Dis Control & Prevent, Mycobacteriol Lab Branch, Div TB Eliminat, Atlanta, GA USA. RP Kalokhe, AS (reprint author), Emory Univ, Sch Med, Dept Med, Div Infect Dis, 206 Woodruff Res Extens Bldg,49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA. EM akalokh@emory.edu FU National Institutes of Health/National Institute of Allergy and Infectious Diseases [T32AI074492] FX Supported by the National Institutes of Health/National Institute of Allergy and Infectious Diseases (Grant T32AI074492 to A.S.K.). NR 41 TC 19 Z9 20 U1 1 U2 31 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 J9 AM J MED SCI JI Am. J. Med. Sci. PD FEB PY 2013 VL 345 IS 2 BP 143 EP 148 DI 10.1097/MAJ.0b013e31825d32c6 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 079PP UT WOS:000314183700010 PM 22885627 ER PT J AU Bjornard, K Riehle-Colarusso, T Gilboa, SM Correa, A AF Bjornard, Kari Riehle-Colarusso, Tiffany Gilboa, Suzanne M. Correa, Adolfo TI Patterns in the prevalence of congenital heart defects, metropolitan Atlanta, 1978 to 2005 SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE cardiovascular anomalies; congenital heart defect; birth defect surveillance; racial differences; birth defects ID VENTRICULAR SEPTAL-DEFECT; CARDIOVASCULAR MALFORMATIONS; BIRTH-DEFECTS; DOWN-SYNDROME; PRENATAL-DIAGNOSIS; UNITED-STATES; DISEASE; BLACK; WHITE; EPIDEMIOLOGY AB BACKGROUND Knowledge of patterns in prevalence of congenital heart defects (CHDs) is important for clinical care, etiologic research, and prevention. We evaluated temporal and racial/ethnic trends in the birth prevalence of CHDs in metropolitan Atlanta from 1978 to 2005. METHODS Cases of CHDs were obtained from the Metropolitan Atlanta Congenital Defects Program among live born infants, stillborn infants, and pregnancy terminations of at least 20 weeks gestation. We calculated birth prevalence per 10,000 live births and used joinpoint regression analysis to calculate the average annual percent change for total CHDs and for 23 specific subtypes in the total population and among whites and blacks. To evaluate racial/ethnic variations, we calculated prevalence ratios among blacks and Hispanics compared with whites. RESULTS Between 1978 and 2005, 7301 infants and fetuses with major structural CHDs were ascertained among 1,079,062 live births (67.7 per 10,000). The prevalence of all CHDs in aggregate increased from 50.3 per 10,000 in 19781983 to 86.4 per 10,000 in 20002005. The prevalence of septal defects and vascular rings increased and the prevalence of tricuspid atresia decreased, while other CHD prevalences were stable. Racial/ethnic prevalence differences were found for all CHDs combined and muscular ventricular septal defects, aortic stenosis, and atrioventricular septal defects. CONCLUSIONS The prevalence of total CHDs, primarily common, less severe types, are increasing, with some racial/ethnic differences. Further studies could clarify the possible reasons for such variations including differences in ascertainment, risk factors, or susceptibility. Birth Defects Research (Part A) 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Bjornard, Kari; Riehle-Colarusso, Tiffany; Gilboa, Suzanne M.; Correa, Adolfo] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Bjornard, Kari] Ctr Dis Control & Prevent, CDC, Atlanta, GA USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. RP Riehle-Colarusso, T (reprint author), Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mailstop E-86, Atlanta, GA 30333 USA. EM tja4@cdc.gov NR 32 TC 32 Z9 32 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD FEB PY 2013 VL 97 IS 2 BP 87 EP 94 DI 10.1002/bdra.23111 PG 8 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 090ME UT WOS:000314982400003 PM 23404870 ER PT J AU Johnson, CJ Weir, HK Fink, AK German, RR Finch, JL Rycroft, RK Yin, DX AF Johnson, Christopher J. Weir, Hannah K. Fink, Aliza K. German, Robert R. Finch, Jack L. Rycroft, Randi K. Yin, Daixin CA Accuracy Canc Mortality Study Grp TI The impact of National Death Index linkages on population-based cancer survival rates in the United States SO CANCER EPIDEMIOLOGY LA English DT Article DE Death certificate accuracy; National Death Index; Cancer survival ID MORTALITY; ASCERTAINMENT; ACCURACY; FILE AB Background: In order to ensure accurate survival estimates, population-based cancer registries must ascertain all, or nearly all, patients diagnosed with cancer in their catchment area, and obtain complete follow-up information on all deaths that occurred among registered cancer patients. In the US, linkage with state death records may not be sufficient to ascertain all deaths. Since 1979, all state vital statistics offices have reported their death certificate information to the National Death Index (NDI). Objective: This study was designed to measure the impact of linkage with the NDI on population-based relative and cancer cause-specific survival rates in the US. Methods: Central cancer registry records for patients diagnosed 1993-1995 from California, Colorado, and Idaho were linked with death certificate information (deaths 1993-2004) from their individual state vital statistics offices and with the NDI. Two databases were created: one contained incident records with deceased patients linked only to state death records and the second database contained incident records with deceased patients linked to both state death records and the NDI. Survival estimates and 95% confidence intervals from each database were compared by state and primary site category. Results: At 60 months follow-up, 42.1-48.1% of incident records linked with state death records and an additional 0.7-3.4% of records linked with the NDI. Survival point estimates from the analysis without NDI were not contained within the corresponding 95% CIs from the NDI augmented analysis for all sites combined and colorectal, pancreas, lung and bronchus, breast, prostate, non-Hodgkin lymphoma, and Kaposi sarcoma cases in all 3 states using relative survival methods. Additional combinations of state and primary site had significant survival estimate differences, which differed by method (relative versus cause-specific survival). Conclusion: To ensure accurate population-based cancer survival rates, linkage with the National Death Index to ascertain out of state and late registered deaths is a necessary process for US central cancer registries. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Johnson, Christopher J.] Canc Data Registry Idaho, Boise, ID 83701 USA. [Weir, Hannah K.; German, Robert R.] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Fink, Aliza K.] ICF Int, Rockville, MD 20850 USA. [Finch, Jack L.; Rycroft, Randi K.] Colorado Dept Publ Hlth & Environm, Colorado Cent Canc Registry, Denver, CO USA. [Yin, Daixin] Calif Canc Registry, Sacramento, CA USA. RP Johnson, CJ (reprint author), Canc Data Registry Idaho, 615 N 7th St, Boise, ID 83701 USA. EM cjohnson@teamiha.org; hbw4@cdc.gov; Aliza.Fink@icfi.com; BobGerman2010@gmail.com; Jack.Finch@state.co.us; Randi.Rycroft@state.co.us; Dx35y@yahoo.com FU Division of Cancer Prevention and Control at the U.S. Centers for Disease Control and Prevention [2002-002-00574] FX This project was completed by ICF Macro and the state cancer registries of California, Colorado, and Idaho under contract 2002-002-00574 from the Division of Cancer Prevention and Control at the U.S. Centers for Disease Control and Prevention. NR 28 TC 9 Z9 10 U1 2 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1877-7821 J9 CANCER EPIDEMIOL JI Cancer Epidemiol. PD FEB PY 2013 VL 37 IS 1 BP 20 EP 28 DI 10.1016/j.canep.2012.08.007 PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 087IW UT WOS:000314755900006 PM 22959341 ER PT J AU Dara, M Gushulak, BD Posey, DL Zellweger, JP Migliori, GB AF Dara, Masoud Gushulak, Brian D. Posey, Drew L. Zellweger, Jean-Pierre Migliori, Giovanni B. TI The history and evolution of immigration medical screening for tuberculosis SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY LA English DT Article DE chest radiography; control; elimination; immigrants; screening; tuberculosis ID FOREIGN-BORN PERSONS; GAMMA RELEASE ASSAYS; PULMONARY TUBERCULOSIS; LATENT TUBERCULOSIS; COST-EFFECTIVENESS; ASYLUM SEEKERS; UNITED-STATES; CHEST RADIOGRAPHY; EUROPEAN REGION; TB CONTROL AB Expert Rev. Anti Infect. Ther. 11(2), 137-146 (2013) Identifying and managing TB in immigrating populations has been an important aspect of immigration health for over a century, with the primary aim being protecting the host population by preventing the import of communicable diseases carried by the arriving migrants. This review describes the history and development of screening for TB and latent TB infection in the immigration context (describing both screening strategies and diagnostic tests used over the last century), outlining current practices and considering the future impact of new advances in screening. The recent focus of the WHO, regarding their elimination strategy, is further increasing the importance of diagnosing and treating latent TB infection. The last section of this review discusses the latest public health developments in the context of TB screening in immigrant populations. C1 [Dara, Masoud] WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark. [Posey, Drew L.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Zellweger, Jean-Pierre] Swiss Lung Assoc, Bern, Switzerland. [Migliori, Giovanni B.] WHO, Collaborating Ctr TB & Lung Dis, S Maugeri Fdn, Care & Res Inst, I-21049 Tradate, Italy. RP Migliori, GB (reprint author), WHO, Collaborating Ctr TB & Lung Dis, S Maugeri Fdn, Care & Res Inst, Via Roncaccio 16, I-21049 Tradate, Italy. EM giovannibattista.migliori@fsm.it OI Migliori, Giovanni Battista/0000-0002-2597-574X NR 73 TC 12 Z9 12 U1 1 U2 15 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1478-7210 J9 EXPERT REV ANTI-INFE JI Expert Rev. Anti-Infect. Ther. PD FEB PY 2013 VL 11 IS 2 BP 137 EP 146 DI 10.1586/ERI.12.168 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 089SM UT WOS:000314930300010 PM 23409820 ER PT J AU Jemal, A Simard, EP Dorell, C Noone, AM Markowitz, LE Kohler, B Eheman, C Saraiya, M Bandi, P Saslow, D Cronin, KA Watson, M Schiffman, M Henley, SJ Schymura, MJ Anderson, RN Yankey, D Edwards, BK AF Jemal, Ahmedin Simard, Edgar P. Dorell, Christina Noone, Anne-Michelle Markowitz, Lauri E. Kohler, Betsy Eheman, Christie Saraiya, Mona Bandi, Priti Saslow, Debbie Cronin, Kathleen A. Watson, Meg Schiffman, Mark Henley, S. Jane Schymura, Maria J. Anderson, Robert N. Yankey, David Edwards, Brenda K. TI Annual Report to the Nation on the Status of Cancer, 19752009, Featuring the Burden and Trends in Human Papillomavirus (HPV)Associated Cancers and HPV Vaccination Coverage Levels SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID IMMUNIZATION SURVEY-TEEN; UNITED-STATES; CERVICAL-CANCER; ANAL CANCER; INCREASING INCIDENCE; INCIDENCE RATES; THYROID-CANCER; CELL CARCINOMA; BREAST-CANCER; CYTOLOGIC ABNORMALITIES AB The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate annually to provide updates on cancer incidence and death rates and trends in these outcomes for the United States. This year's report includes incidence trends for human papillomavirus (HPV)associated cancers and HPV vaccination (recommended for adolescents aged 1112 years). Data on cancer incidence were obtained from the CDC, NCI, and NAACCR, and data on mortality were obtained from the CDC. Long- (1975/19922009) and short-term (20002009) trends in age-standardized incidence and death rates for all cancers combined and for the leading cancers among men and among women were examined by joinpoint analysis. Prevalence of HPV vaccination coverage during 2008 and 2010 and of Papanicolaou (Pap) testing during 2010 were obtained from national surveys. Death rates continued to decline for all cancers combined for men and women of all major racial and ethnic groups and for most major cancer sites; rates for both sexes combined decreased by 1.5% per year from 2000 to 2009. Overall incidence rates decreased in men but stabilized in women. Incidence rates increased for two HPV-associated cancers (oropharynx, anus) and some cancers not associated with HPV (eg, liver, kidney, thyroid). Nationally, 32.0% (95% confidence interval [CI] 30.3% to 33.6%) of girls aged 13 to 17 years in 2010 had received three doses of the HPV vaccine, and coverage was statistically significantly lower among the uninsured (14.1%, 95% CI 9.4% to 20.6%) and in some Southern states (eg, 20.0% in Alabama [95% CI 13.9% to 27.9%] and Mississippi [95% CI 13.8% to 28.2%]), where cervical cancer rates were highest and recent Pap testing prevalence was the lowest. The overall trends in declining cancer death rates continue. However, increases in incidence rates for some HPV-associated cancers and low vaccination coverage among adolescents underscore the need for additional prevention efforts for HPV-associated cancers, including efforts to increase vaccination coverage. C1 [Jemal, Ahmedin; Simard, Edgar P.; Bandi, Priti] Amer Canc Soc, Surveillance Res Program, Atlanta, GA 30303 USA. [Saslow, Debbie] Amer Canc Soc, Canc Control Sci Dept, Atlanta, GA 30303 USA. [Dorell, Christina; Yankey, David] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Eheman, Christie; Watson, Meg; Henley, S. Jane] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Noone, Anne-Michelle; Cronin, Kathleen A.; Edwards, Brenda K.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Kohler, Betsy; Schymura, Maria J.] N Amer Assoc Cent Canc Registries, Springfield, IL USA. [Anderson, Robert N.] Ctr Dis Control & Prevent, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Schymura, Maria J.] New York State Canc Registry, Albany, NY USA. RP Jemal, A (reprint author), Amer Canc Soc, Surveillance Res Program, 250 Williams St NW, Atlanta, GA 30303 USA. EM ajemal@cancer.org OI Henley, S Jane/0000-0002-2420-306X FU American Cancer Society; Centers for Disease Control and Prevention; National Cancer Institute; National Institutes of Health; North American Association of Central Cancer Registries FX This work was supported by the American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, the National Institutes of Health, and the North American Association of Central Cancer Registries. NR 133 TC 380 Z9 383 U1 18 U2 78 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD FEB PY 2013 VL 105 IS 3 BP 175 EP 201 DI 10.1093/jnci/djs491 PG 27 WC Oncology SC Oncology GA 088VM UT WOS:000314865300007 PM 23297039 ER PT J AU Salone, LR Vann, WF Dee, DL AF Salone, Lindsey Rennick Vann, William F., Jr. Dee, Deborah L. TI Breastfeeding An overview of oral and general health benefits SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article DE Asthma; breastfeeding; primary dentition; occlusion; early childhood caries; gastroenteritis; nonnutritive sucking; obesity; oral habits; otitis media ID EARLY-CHILDHOOD CARIES; HUMAN-MILK; UNITED-STATES; NECROTIZING ENTEROCOLITIS; NONNUTRITIVE SUCKING; PEDIATRIC DENTISTS; OVARIAN-CANCER; OTITIS-MEDIA; RISK; INFANTS AB Background. Breastfeeding is the reference against which alternative infant feeding models must be measured with regard to growth, development and other health outcomes. Although not a systematic review, this report provides an update for dental professionals, including an overview of general and oral health-related benefits associated with breastfeeding. Types of Studies Reviewed. The authors examined the literature regarding general health protections that breastfeeding confers to infants and mothers and explored associations between breastfeeding, occlusion in the primary dentition and early childhood caries. To accomplish these goals, they reviewed systematic reviews when available and supplemented them with comparative studies and with statements and reports from major non-governmental and governmental organizations. Results. When compared with health outcomes among formula-fed children, the health advantages associated with breastfeeding include a lower risk of acute otitis media, gastroenteritis and diarrhea, severe lower respiratory infections, asthma, sudden infant death syndrome, obesity and other childhood diseases and conditions. Evidence also suggests that breastfed children may develop a more favorable occlusion in the primary dentition. The results of a systematic review in which researchers examined the relationship between breastfeeding and early childhood caries were inconclusive. Conclusions and Clinical Implications. The American Academy of Pediatric Dentistry, Chicago, suggests that parents gently clean infants' gums and teeth after breastfeeding. The American Academy of Pediatrics, Elk Grove Village, Ill., recommends that breastfeeding should be exclusive for about the first six months of life and should continue, with the introduction of appropriate complementary foods, to at least age 12 months or beyond, as desired by mother and child. Dentists and staff members can take steps to ensure they are familiar with the evidence and guidelines pertaining to breastfeeding and to oral health. They are encouraged to follow the surgeon general's recommendations to promote and support optimal breastfeeding and oral health practices among their patients. C1 [Salone, Lindsey Rennick] Univ N Carolina, Chapel Hill, NC 27599 USA. [Salone, Lindsey Rennick] Univ N Carolina Hosp, Chapel Hill, NC USA. [Vann, William F., Jr.] Univ N Carolina, Sch Dent, Chapel Hill, NC 27599 USA. [Dee, Deborah L.] Ctr Dis Control & Prevent, Nutr Branch, Div Nutr Phys Act & Obes, Atlanta, GA USA. RP Vann, WF (reprint author), Univ N Carolina, Sch Dent, CB 7450,228 Brauer Hall, Chapel Hill, NC 27599 USA. EM bill_vann@dentistry.unc.edu FU Short-Term Dental Student Research Fellowship at the University of North Carolina at Chapel Hill FX Dr. Salone received a Short-Term Dental Student Research Fellowship at the University of North Carolina at Chapel Hill. NR 91 TC 30 Z9 31 U1 6 U2 78 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD FEB PY 2013 VL 144 IS 2 BP 143 EP 151 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 090WL UT WOS:000315010600013 PM 23372130 ER PT J AU Grummer-Strawn, LM Shealy, KR Perrine, CG MacGowan, C Grossniklaus, DA Scanlon, KS Murphy, PE AF Grummer-Strawn, Laurence M. Shealy, Katherine R. Perrine, Cria G. MacGowan, Carol Grossniklaus, Daurice A. Scanlon, Kelley S. Murphy, Paulette E. TI Maternity Care Practices That Support Breastfeeding: CDC Efforts to Encourage Quality Improvement SO JOURNAL OF WOMENS HEALTH LA English DT Article ID HOSPITAL PRACTICES; UNITED-STATES; DURATION AB Breastfeeding has important consequences for women's health, including lower risk of breast and ovarian cancers as well as type 2 diabetes. Although most pregnant women want to breastfeed, a majority encounter difficulties and are not able to breastfeed as long as they want. Routine maternity care practices can pose significant barriers to successful breastfeeding. To address these practices, CDC has taken on a number of initiatives to promote hospital quality improvements in how new mothers are supported to start breastfeeding. The CDC survey on Maternity Practices in Infant Nutrition and Care is a tool to educate hospitals on how their current practices compare to recommended standards. The Best Fed Beginnings program is working with 90 hospitals across the United States to achieve optimal care and create tools for future hospital changes. CDC-funded programs in numerous state health departments have created programs to instigate improvements across the state. These efforts have begun to show success, with significant hospital quality score increases seen between 2009 and 2011. In 2011, more hospitals were designated as Baby-Friendly than in any previous year. C1 [Grummer-Strawn, Laurence M.; Shealy, Katherine R.; Perrine, Cria G.; MacGowan, Carol; Grossniklaus, Daurice A.; Scanlon, Kelley S.; Murphy, Paulette E.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Grummer-Strawn, LM (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS K-25, Atlanta, GA 30341 USA. EM lxg8@cdc.gov NR 28 TC 6 Z9 6 U1 2 U2 15 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD FEB PY 2013 VL 22 IS 2 BP 107 EP 112 DI 10.1089/jwh.2012.4158 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 088XJ UT WOS:000314870900001 PM 23398126 ER PT J AU Farr, SL Bish, CL AF Farr, Sherry L. Bish, Connie L. TI Preconception Health Among Women with Frequent Mental Distress: A Population-Based Study SO JOURNAL OF WOMENS HEALTH LA English DT Article ID UNITED-STATES; PSYCHIATRIC-DISORDERS; SMOKING-CESSATION; REPRODUCTIVE AGE; US ADULTS; DEPRESSION; RISK; OBESITY; WEIGHT; ASSOCIATION AB Purpose: We examined the extent to which mental distress may be associated with a woman's preconception health. Methods: We analyzed population-based, self-reported data from the 2005, 2007, and 2009 Behavioral Risk Factor Surveillance System (BRFSS) and limited analyses to 213,137 women aged 18-44 years. Women whose mental health was not good for >= 14 days during the past month were categorized as having frequent mental distress. For 15 preconception health indicators, we used chi-square tests to measure differences in prevalence by mental distress and the average marginal predictions approach to logistic regression to assess associations between mental distress and each preconception health indicator in separate models, adjusted for demographic characteristics. We conducted analyses using SUDAAN software to account for the complex sampling design and used weights to produce unbiased estimates. Results: The prevalence of good preconception health for each indicator was higher for women reporting infrequent mental distress (chi-square p value < 0.001 for all). The greatest disparities in preconception health between women with infrequent and frequent mental distress, respectively, were adequate social and emotional support (adjusted prevalence ratio [aPR] = 1.4, prevalence = 83.7% and 54.8%), not smoking (aPR = 1.2, 82.3% and 62.4%), adequate fruit and vegetable consumption (aPR = 1.2, 26.1% and 21.5%), normal weight (aPR = 1.2, 50.4% and 39.0%), and good general health (aPR = 1.2, 91.7% and 71.5%). Conclusions: Interventions tailored for women with poor mental health may be needed to target specific preconception health indicators, such as social support, smoking, weight, and nutrition. C1 [Farr, Sherry L.; Bish, Connie L.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Farr, SL (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,MS K-23, Atlanta, GA 30341 USA. EM sfarr@CDC.gov NR 25 TC 5 Z9 5 U1 4 U2 10 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD FEB PY 2013 VL 22 IS 2 BP 153 EP 158 DI 10.1089/jwh.2012.3722 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 088XJ UT WOS:000314870900007 PM 23268583 ER PT J AU Power, ML Henderson, Z Behler, JE Schulkin, J AF Power, Michael L. Henderson, Zsakeba Behler, Julia E. Schulkin, Jay TI Attitudes and Practices Regarding Late Preterm Birth Among American Obstetrician-Gynecologists SO JOURNAL OF WOMENS HEALTH LA English DT Article ID CESAREAN DELIVERY; UNITED-STATES; GESTATIONS; MORTALITY; FETAL AB Background: Late preterm birth (LPTB) accounts for most preterm births and has been increasing, associated with increases in cesarean sections and inductions at this gestational age. Methods: A self-administered survey, consisting of questions about opinions, knowledge, and practices regarding LPTB, was mailed to 1232 American College of Obstetricians and Gynecologists (ACOG) Fellows and Junior Fellows in Practice in May-July 2010. Results: Surveys were returned by 520 practicing obstetricians. Two thirds of respondents correctly defined LPTB (34-36 weeks completed gestation). Most responding physicians (87%) were aware of the evidence regarding morbidity and mortality of infants born at 34-36 weeks; 81% considered such evidence sufficient to make a clinical judgment. Although 84% were concerned about long-term health problems in these infants, many disagreed that LPTB infants were at increased risk of long-term neurodevelopmental outcomes. Most agreed that the increase in LPTB in the United States is due to increasing rates and complications of multifetal pregnancies and maternal disorders. Almost all responding physicians agreed that certain clinical indications (e.g., severe preeclampsia, placental abruption, premature rupture of the membranes [PROM]) were appropriate reasons for early delivery, and most disagreed with delivering late preterm infants for logistical reasons or convenience. Half of responding physicians reported that concerns about malpractice risks contribute to their decision to induce labor or perform a cesarean section at 34-36 weeks. Conclusions: Many obstetricians underestimate long-term neurodevelopmental outcomes among infants born late preterm and may have a lower threshold to deliver some infants late preterm for indications that are not evidence based. Additional educational efforts regarding LPTB are needed. C1 [Power, Michael L.; Behler, Julia E.; Schulkin, Jay] Amer Coll Obstetricians & Gynecologists, Res Dept, Washington, DC 20090 USA. [Henderson, Zsakeba] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Power, ML (reprint author), Amer Coll Obstetricians & Gynecologists, Res Dept, POB 96920, Washington, DC 20090 USA. EM mpower@acog.org OI Power, Michael/0000-0002-6120-3528 FU U.S. Federal Centers for Disease Control and Prevention (CDC); Maternal and Child Health Bureau (Title V, Social Security Act), Health Resources and Services Administration, Department of Health and Human Services [R60 MC 05674] FX This study was funded by the U.S. Federal Centers for Disease Control and Prevention (CDC); the Collaborative Ambulatory Research Network is supported by grant R60 MC 05674 from the Maternal and Child Health Bureau (Title V, Social Security Act), Health Resources and Services Administration, Department of Health and Human Services. We thank Dr. William Callaghan for his contributions to survey design and analysis. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 23 TC 6 Z9 6 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD FEB PY 2013 VL 22 IS 2 BP 167 EP 172 DI 10.1089/jwh.2012.3814 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 088XJ UT WOS:000314870900009 PM 23350861 ER PT J AU Lakis, N Blair, D Abraham, JL Li, Y Damon, I AF Lakis, N. Blair, D. Abraham, J. L. Li, Y. Damon, I. TI New Archetypal Poxvirus Infection in an Immunosuppressed Man SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 02-08, 2013 CL Baltimore, MD SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura C1 SUNY Upstate Med Univ, Syracuse, NY 13210 USA. CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2013 VL 93 SU 1 MA 1557 BP 372A EP 373A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 087UL UT WOS:000314789302174 ER PT J AU Ko, JY Farr, SL Dietz, PM AF Ko, Jean Y. Farr, Sherry L. Dietz, Patricia M. TI Barriers in the diagnosis and treatment of depression in women in the USA: where are we now? SO NEUROPSYCHIATRY LA English DT Editorial Material ID NATIONAL COMORBIDITY SURVEY; PREVALENCE; CARE; DISORDERS; IMPROVE C1 [Ko, Jean Y.; Farr, Sherry L.; Dietz, Patricia M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Ko, JY (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway NE,MS K22, Atlanta, GA 30341 USA. EM fob1@cdc.gov NR 19 TC 0 Z9 0 U1 2 U2 8 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1758-2008 J9 NEUROPSYCHIATRY-LOND JI Neuropsychiatry PD FEB PY 2013 VL 3 IS 1 BP 1 EP 3 DI 10.2217/NPY.12.76 PG 3 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 088TE UT WOS:000314859200001 PM 28018489 ER PT J AU Wells, K Rivera, M Proctor, S Arroyo, G Quinn, G Meade, C AF Wells, Kristen Rivera, Maria Proctor, Sara Arroyo, Gloria Quinn, Gwendolyn Meade, Cathy TI Efficacy of a Patient Navigation Intervention to Improve Cervical Cancer Care Among Rural Hispanic Women Living in an Agricultural Community: A Nonrandomized Trial SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Wells, Kristen; Quinn, Gwendolyn; Meade, Cathy] Univ S Florida, Tampa, FL USA. [Wells, Kristen; Rivera, Maria; Arroyo, Gloria; Quinn, Gwendolyn; Meade, Cathy] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Rivera, Maria] Ctr Dis Control & Prevent, Atlanta, GA USA. [Proctor, Sara] Catholic Mobile Med Serv, Dover, FL USA. RI Wells, Kristen/J-1838-2012 NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2013 VL 22 SU 2 SI SI BP 28 EP 29 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 089KZ UT WOS:000314910700050 ER PT J AU Machain-Williams, C Reagan, K Wang, T Zeidner, NS Blair, CD AF Machain-Williams, Carlos Reagan, Krystle Wang, Tian Zeidner, Nordin S. Blair, Carol D. TI Immunization with Culex tarsalis Mosquito Salivary Gland Extract Modulates West Nile Virus Infection and Disease in Mice SO VIRAL IMMUNOLOGY LA English DT Article ID HOST IMMUNE-RESPONSE; AEDES-AEGYPTI; IMMUNOMODULATORY FACTORS; CUTANEOUS LEISHMANIASIS; DIFFERENTIAL MODULATION; ARTHROPOD SALIVA; NORTH-AMERICA; DENGUE-VIRUS; CELLS; ENCEPHALITIS AB Mosquito salivary proteins inoculated during blood feeding modulate the host immune response, which can contribute to the pathogenesis of viruses transmitted by mosquito bites. Previous studies with mosquito bite-naive mice indicated that exposure to arthropod salivary proteins resulted in a shift toward a Th2-type immune response in flavivirus-susceptible mice but not flavivirus-resistant animals. In the study presented here, we tested the hypothesis that immunization with high doses of Culex tarsalis salivary gland extracts (SGE) with an adjuvant would prevent Th2 polarization after mosquito bite and enhance resistance to mosquito-transmitted West Nile virus (WNV). Our results indicate that mice immunized with Cx. tarsalis SGE produced increased levels of Th1-type cytokines (IFN gamma and TNF alpha) after challenge with mosquito-transmitted WNV and exhibited both a delay in infection of the central nervous system (CNS) and significantly lower WNV brain titers compared to mock-immunized mice. Moreover, mortality was significantly reduced in the SGE-immunized mice, as none of these mice died, compared to mortality of 37.5% of mock-vaccinated mice by 8 days after infected mosquito bite. These results suggest that development of a mosquito salivary protein vaccine might be a strategy to control arthropod-borne viral pathogens such as WNV. C1 [Machain-Williams, Carlos; Reagan, Krystle; Blair, Carol D.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Arthropod Borne & Infect Dis Lab, Ft Collins, CO 80523 USA. [Wang, Tian] Univ Texas Med Branch Galveston, Dept Pathol, Dept Microbiol & Immunol, Ctr Biodef & Emerging Infect Dis, Galveston, TX USA. [Zeidner, Nordin S.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Blair, CD (reprint author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Arthropod Borne & Infect Dis Lab, 1692 Campus Delivery, Ft Collins, CO 80523 USA. EM carol.blair@colostate.edu FU NIH/National Institute of Allergy and Infectious Diseases [N01-AI-25489] FX This research project was supported in part by contract N01-AI-25489 from the NIH/National Institute of Allergy and Infectious Diseases. NR 42 TC 2 Z9 2 U1 2 U2 13 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0882-8245 EI 1557-8976 J9 VIRAL IMMUNOL JI Viral Immunol. PD FEB PY 2013 VL 26 IS 1 BP 84 EP 92 DI 10.1089/vim.2012.0051 PG 9 WC Immunology; Virology SC Immunology; Virology GA 092DD UT WOS:000315098200010 PM 23362833 ER PT J AU Loharikar, A Russo, E Sheth, A Menon, M Kudzala, A Tauzie, B Masuku, HD Ayers, T Hoekstra, RM Quick, R AF Loharikar, Anagha Russo, Elizabeth Sheth, Anandi Menon, Manoj Kudzala, Amose Tauzie, Blessius Masuku, Humphreys D. Ayers, Tracy Hoekstra, Robert M. Quick, Robert TI Long-term Impact of Integration of Household Water Treatment and Hygiene Promotion with Antenatal Services on Maternal Water Treatment and Hygiene Practices in Malawi SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID EPIDEMIC CHOLERA; RURAL GUATEMALA; INTERVENTION; TRANSMISSION; BEHAVIOR; WOMEN; COMMUNITY; COUNTRIES; DIARRHEA; PROGRAM AB A clinic-based program to integrate antenatal services with distribution of hygiene kits including safe water storage containers, water treatment solution (brand name WaterGuard), soap, and hygiene education, was implemented in Malawi in 2007 and evaluated in 2010. We surveyed 389 participants at baseline in 2007, and found and surveyed 232 (60%) participants to assess water treatment, test stored drinking water for residual chlorine (an objective measure of treatment), and observe handwashing technique at follow-up in 2010. Program participants were more likely to know correct water treatment procedures (67% versus 36%; P < 0.0001), treat drinking water with WaterGuard (24% versus 2%; P < 0.0001), purchase and use WaterGuard (21% versus 1%; P < 0.001), and demonstrate correct handwashing technique (50% versus 21%; P < 0.001) at the three-year follow-up survey than at baseline. This antenatal-clinic-based program may have contributed to sustained water treatment and proper handwashing technique among program participants. C1 Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Div Foodhorne Bacterial & Mycot Dis, Atlanta, GA 30333 USA. [Kudzala, Amose; Tauzie, Blessius] United Nations Childrens Fund Malawi, Lilongwe, Malawi. [Masuku, Humphreys D.] Minist Hlth, Lilongwe, Malawi. RP Loharikar, A (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A38, Atlanta, GA 30333 USA. EM anagha.loharikar@gmail.com; elizabeth.russo@gmail.com; anandisheth@gmail.com; mmenon@cdc.gov; akudzala@unicef.org; btauzie@unicef.org; dzanjom@yahoo.co.uk; tayers@cdc.gov; mhoekstra@cdc.gov; rxq1@cdc.gov OI Ayers, Tracy/0000-0003-4140-3263 FU PATH FX This study was supported by PATH.; We thank Hannah Hausi, Paul Chunga, Young Samanyika, Kondwani M'manga, and Loncy Sajeni (United Nations Children's Fund, Malawi Ministry of Health, and Blantyre and Salim District Health Offices) for providing leadership; the diligent staff members of the health centers in Bangwe, Chileka, Chilomoni, Chinguluwe, Chipoka, Dziwe, Khombedza, Lirangwe, Lundu, Maganga, Makioni, Mpemba, Mtchoka, and South Lunzu, and at Salima District Hospital, whose diligent work made this program possible and successful; our team of enumerators and transport staff whose hard work enabled us to document this program's impact; and the many women whose gracious participation made the evaluation possible. NR 20 TC 9 Z9 9 U1 3 U2 18 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2013 VL 88 IS 2 BP 267 EP 274 DI 10.4269/ajtmh.2012.11-0375 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 082ZG UT WOS:000314431900012 PM 23243106 ER PT J AU Gimnig, JE Walker, ED Otieno, P Kosgei, J Olang, G Ombok, M Williamson, J Marwanga, D Abong'o, D Desai, M Kariuki, S Hamel, MJ Lobo, NF Vulule, J Bayoh, MN AF Gimnig, John E. Walker, Edward D. Otieno, Peter Kosgei, Jackline Olang, George Ombok, Maurice Williamson, John Marwanga, Doris Abong'o, Daisy Desai, Meghna Kariuki, Simon Hamel, Mary J. Lobo, Neil F. Vulule, John Bayoh, M. Nabie TI Incidence of Malaria among Mosquito Collectors Conducting Human Landing Catches in Western Kenya SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID TREATED BED NETS; PLASMODIUM-FALCIPARUM MALARIA; DOUBLE-BLIND; ATOVAQUONE-PROGUANIL; ANOPHELES-GAMBIAE; CHLOROQUINE-PROGUANIL; NONIMMUNE TRAVELERS; INOCULATION RATES; PROPHYLAXIS; CHEMOPROPHYLAXIS AB The human landing catch (HLC) has long been the gold standard for estimating malaria transmission by mosquitoes, but has come under scrutiny because of ethical concerns of exposing collectors to infectious bites. We estimated the incidence of Plasmodium falciparum malaria infection in a cohort of 152 persons conducting HLCs and compared it with that of 147 non-collectors in western Kenya. Participants were presumptively cleared of malaria with Coartem (TM) (artemether-lumefantrine) and tested for malaria every 2 weeks for 12 weeks. The HLC collections were conducted four nights per week for six weeks. Collectors were provided chemoprophylaxis with Malarone (TM) (atovaquone-proguanil) during the six weeks of HLC activities and one week after HLC activities were completed. The incidence of malaria was 96.6% lower in collectors than in non-collectors (hazard ratio = 0.034, P < 0.0001). Therefore, with proper prophylaxis, concern about increased risk of malaria among collectors should not be an impediment to conducting HLC studies. C1 [Gimnig, John E.; Hamel, Mary J.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30329 USA. [Walker, Edward D.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA. [Vulule, John] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Lobo, Neil F.] Univ Notre Dame, Dept Biol Sci, Eck Inst Global Hlth, Notre Dame, IN 46556 USA. RP Gimnig, JE (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Mailstop G-49,1600 Clifton Rd, Atlanta, GA 30329 USA. EM jgimnig@cdc.gov; walker@msu.edu; potieno@kemricdc.org; jkosgei@kemricdc.org; golang@kemricdc.org; mombok@kemricdc.org; dmarwanga@kemricdc.org; dabongo@kemricdc.org; mdesai@kemricdc.org; skariuki@kemricdc.org; mhamel@cdc.gov; nlobo@nd.edu; jvulule@kemricdc.org; nbayoh@kemricdc.org FU Bill and Melinda Gates Foundation through the Malaria Transmission Consortium [45114]; National Science Foundation [EF-072377] FX This study was supported by the Bill and Melinda Gates Foundation through the Malaria Transmission Consortium (grant no. 45114) and by a National Science Foundation Ecology of Infectious Diseases grant (grant no. EF-072377). NR 39 TC 21 Z9 21 U1 1 U2 32 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2013 VL 88 IS 2 BP 301 EP 308 DI 10.4269/ajtmh.2012.12-0209 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 082ZG UT WOS:000314431900017 PM 23249685 ER PT J AU LaRocque, RC Deshpande, BR Rao, SR Brunette, GW Sotir, MJ Jentes, ES Ryan, ET AF LaRocque, Regina C. Deshpande, Bhushan R. Rao, Sowmya R. Brunette, Gary W. Sotir, Mark J. Jentes, Emily S. Ryan, Edward T. CA Global TravEpiNet Consortium TI Pre-Travel Health Care of Immigrants Returning Home to Visit Friends and Relatives SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID GEOSENTINEL SURVEILLANCE NETWORK; US INTERNATIONAL TRAVELERS; UNITED-STATES; ILLNESS; KNOWLEDGE; ATTITUDES; DISEASES; CLINICS; AIRPORT; RISK AB Immigrants returning home to visit friends and relatives (VFR travelers) are at higher risk of travel-associated illness than other international travelers. We evaluated 3,707 VFR and 17,507 non-VFR travelers seen for pre-travel consultation in Global TravEpiNet during 2009-2011; all were traveling to resource-poor destinations. VFR travelers more commonly visited urban destinations than non-VFR travelers (42% versus 30%, P < 0.0001); 54% of VFR travelers were female, and 18% of VFR travelers were under 6 years old. VFR travelers sought health advice closer to their departure than non-VFR travelers (median days before departure was 17 versus 26, P < 0.0001). In multivariable analysis, being a VFR traveler was an independent predictor of declining a recommended vaccine. Missed opportunities for vaccination could be addressed by improving the timing of pre-travel health care and increasing the acceptance of vaccines. Making pre-travel health care available in primary care settings may be one step to this goal. C1 [LaRocque, Regina C.; Ryan, Edward T.] Massachusetts Gen Hosp, Travelers Advice & Immunizat Ctr, Boston, MA 02114 USA. [LaRocque, Regina C.; Ryan, Edward T.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA. [Deshpande, Bhushan R.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Deshpande, Bhushan R.] Tufts Univ, Dept Econ, Medford, MA USA. [Rao, Sowmya R.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Rao, Sowmya R.] Bedford Vet Affairs Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Brunette, Gary W.; Jentes, Emily S.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Sotir, Mark J.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP LaRocque, RC (reprint author), Massachusetts Gen Hosp, Travelers Advice & Immunizat Ctr, 55 Fruit St, Boston, MA 02114 USA. EM rclarocque@partners.org; bdeshpande@partners.org; Sowmya.Rao@umassmed.edu; fvd3@cdc.gov; mps6@cdc.gov; ejentes@cdc.gov; etryan@partners.org FU US Centers for Disease Control and Prevention [U19CI000514, U01CK000175] FX This work was supported by US Centers for Disease Control and Prevention Grants U19CI000514 and U01CK000175. NR 22 TC 17 Z9 17 U1 0 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2013 VL 88 IS 2 BP 376 EP 380 DI 10.4269/ajtmh.2012.12-0460 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 082ZG UT WOS:000314431900029 PM 23149585 ER PT J AU Graham, CB Borchert, JN Black, WC Atiku, LA Mpanga, JT Boegler, KA Moore, SM Gage, KL Eisen, RJ AF Graham, Christine B. Borchert, Jeff N. Black, William C. Atiku, Linda A. Mpanga, Joseph T. Boegler, Karen A. Moore, Sean M. Gage, Kenneth L. Eisen, Rebecca J. TI Blood Meal Identification in Off-Host Cat Fleas (Ctenocephalides felis) from a Plague-Endemic Region of Uganda SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID EARLY-PHASE TRANSMISSION; DOMESTIC-ANIMALS; YERSINIA-PESTIS; NORTHWEST UGANDA; RICKETTSIA-FELIS; PULEX-IRRITANS; CYTOCHROME-B; EPIDEMIOLOGY; SIPHONAPTERA; VECTOR AB The cat flea, Ctenocephalides felis, is an inefficient vector of the plague bacterium (Yersinia pestis) and is the predominant off-host flea species in human habitations in the West Nile region, an established plague focus in northwest Uganda. To determine if C. felis might serve as a Y. pestis bridging vector in the West Nile region, we collected on- and off-host fleas from human habitations and used a real-time polymerase chain reaction-based assay to estimate the proportion of off-host C. felis that had fed on humans and the proportion that had fed on potentially infectious rodents or shrews. Our findings indicate that cat fleas in human habitations in the West Nile region feed primarily on domesticated species. We conclude that C. felis is unlikely to serve as a Y. pestis bridging vector in this region. C1 [Graham, Christine B.; Borchert, Jeff N.; Boegler, Karen A.; Moore, Sean M.; Gage, Kenneth L.; Eisen, Rebecca J.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Atiku, Linda A.; Mpanga, Joseph T.] Uganda Virus Res Inst, Entebbe, Uganda. [Black, William C.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. RP Graham, CB (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM hyb4@cdc.gov; gqx1@ug.cdc.gov; william.black@colostate.edu; l_atikupraise@yahoo.com; joe1ug@msn.com; kje5@cdc.gov; kfy0@cdc.gov; klg0@cdc.gov; dyn2@cdc.gov NR 66 TC 5 Z9 5 U1 0 U2 18 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2013 VL 88 IS 2 BP 381 EP 389 DI 10.4269/ajtmh.2012.12-0532 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 082ZG UT WOS:000314431900030 PM 23208882 ER PT J AU Jensenius, M Han, PV Schlagenhauf, P Schwartz, E Parola, P Castelli, F von Sonnenburg, F Loutan, L Leder, K Freedman, DO AF Jensenius, Mogens Han, Pauline V. Schlagenhauf, Patricia Schwartz, Eli Parola, Philippe Castelli, Francesco von Sonnenburg, Frank Loutan, Louis Leder, Karin Freedman, David O. CA GeoSentinel Surveillance Network TI Acute and Potentially Life-Threatening Tropical Diseases in Western Travelers-A GeoSentinel Multicenter Study, 1996-2011 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SURVEILLANCE NETWORK; RETURNED TRAVELERS; IMPORTED MALARIA; UNITED-KINGDOM; ENTERIC FEVER; EPIDEMIOLOGY; COUNTRIES; FRANCE AB We performed a descriptive analysis of acute and potentially life-threatening tropical diseases among 82,825 ill western travelers reported to GeoSentinel from June of 1996 to August of 2011. We identified 3,655 patients (4.4%) with a total of 3,666 diagnoses representing 13 diseases, including falciparum malaria (76.9%), enteric fever (18.1%), and leptospirosis (2.4%). Ninety-one percent of the patients had fever; the median time from travel to presentation was 16 days. Thirteen (0.4%) patients died: 10 with falciparum malaria, 2 with melioidosis, and 1 with severe dengue. Falciparum malaria was mainly acquired in West Africa, and enteric fever was largely contracted on the Indian subcontinent; leptospirosis, scrub typhus, and murine typhus were principally acquired in Southeast Asia. Western physicians seeing febrile and recently returned travelers from the tropics need to consider a wide profile of potentially life-threatening tropical illnesses, with a specific focus on the most likely diseases described in our large case series. C1 [Jensenius, Mogens] Oslo Univ Hosp, Dept Infect Dis, NO-0424 Oslo, Norway. [Jensenius, Mogens] Univ Oslo, Oslo, Norway. [Han, Pauline V.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Schlagenhauf, Patricia] Univ Zurich, Ctr Travel Med, World Hlth Org Collaborating Ctr Travellers Hlth, Zurich, Switzerland. [Schwartz, Eli] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel. [Schwartz, Eli] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel. [Parola, Philippe] Hop Nord Marseille, Marseille, France. Univ Brescia, Univ Div Infect & Trop Dis, Brescia, Italy. [Castelli, Francesco] Brescia Spedali Civili Gen Hosp, Brescia, Italy. [von Sonnenburg, Frank] Univ Munich, Munich, Germany. [Loutan, Louis] Univ Geneva, Univ Hosp Geneva, Geneva, Switzerland. [Leder, Karin] Royal Melbourne Hosp, Parkville, Vic 3050, Australia. [Leder, Karin] Monash Univ, Melbourne, Vic 3004, Australia. [Freedman, David O.] Univ Alabama Birmingham, Birmingham, AL USA. RP Jensenius, M (reprint author), Oslo Univ Hosp, Dept Infect Dis, PB 4956 Nydalen, NO-0424 Oslo, Norway. EM mogens.jensenius@ioks.uio.no OI Leder, Karin/0000-0003-1368-1039; Aoun, Olivier/0000-0001-9554-8439; Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330 NR 27 TC 41 Z9 41 U1 0 U2 6 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2013 VL 88 IS 2 BP 397 EP 404 DI 10.4269/ajtmh.12-0551 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 082ZG UT WOS:000314431900032 PM 23324216 ER PT J AU Khandelwal, P Marsh, RA Schmid, DS Radford, KW Bleesing, J Jordan, M Davies, S Filipovich, A AF Khandelwal, Pooja Marsh, Rebecca A. Schmid, D. Scott Radford, Kay W. Bleesing, Jack Jordan, Michael Davies, Stella Filipovich, Alexandra TI Case Series of Vaccine Associated Varicella Zoster Virus Infection in Immune Compromised Patients SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 13-17, 2013 CL Salt Lake City, UT C1 [Khandelwal, Pooja; Marsh, Rebecca A.; Bleesing, Jack; Jordan, Michael; Davies, Stella; Filipovich, Alexandra] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA. [Schmid, D. Scott; Radford, Kay W.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2013 VL 19 IS 2 SU 2 MA 276 BP S250 EP S250 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 083DC UT WOS:000314441900274 ER PT J AU Lam, TK Spitz, M Schully, SD Khoury, MJ AF Lam, Tram Kim Spitz, Margaret Schully, Sheri D. Khoury, Muin J. TI "Drivers" of Translational Cancer Epidemiology in the 21st Century: Needs and Opportunities SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID INVASIVE CERVICAL-CANCER; HUMAN-PAPILLOMAVIRUS; HPV VACCINATION; MOLECULAR EPIDEMIOLOGY; KNOWLEDGE INTEGRATION; UNITED-STATES; TEAM SCIENCE; GENOMICS; PREVENTION; WORLDWIDE AB Cancer epidemiology is at the cusp of a paradigm shift-propelled by an urgent need to accelerate the pace of translating scientific discoveries into health care and population health benefits. As part of a strategic planning process for cancer epidemiologic research, the Epidemiology and Genomics Research Program (EGRP) at the National Cancer Institute (NCI) is leading a "longitudinal" meeting with members of the research community to engage in an on-going dialogue to help shape and invigorate the field. Here, we review a translational framework influenced by "drivers" that we believe have begun guiding cancer epidemiology toward translation in the past few years and are most likely to drive the field further in the next decade. The drivers include: (i) collaboration and team science, (ii) technology, (iii) multilevel analyses and interventions, and (iv) knowledge integration from basic, clinical, and population sciences. Using the global prevention of cervical cancer as an example of a public health endeavor to anchor the conversation, we discuss how these drivers can guide epidemiology from discovery to population health impact, along the translational research continuum. Cancer Epidemiol Biomarkers Prev; 22(2); 181-8. (c) 2013 AACR. C1 [Lam, Tram Kim; Spitz, Margaret; Schully, Sheri D.; Khoury, Muin J.] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, NIH, Rockville, MD 20852 USA. [Spitz, Margaret] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. RP Lam, TK (reprint author), NCI, Div Canc Control & Populat Sci, NIH, Rockville, MD 20852 USA. EM lamt@mail.nih.gov FU Intramural NIH HHS [Z99 CA999999] NR 63 TC 20 Z9 20 U1 1 U2 22 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD FEB PY 2013 VL 22 IS 2 BP 181 EP 188 DI 10.1158/1055-9965.EPI-12-1262 PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 086QJ UT WOS:000314700800001 PM 23322363 ER PT J AU Dorell, C Yankey, D Kennedy, A Stokley, S AF Dorell, Christina Yankey, David Kennedy, Allison Stokley, Shannon TI Factors That Influence Parental Vaccination Decisions for Adolescents, 13 to 17 Years Old: National Immunization Survey-Teen, 2010 SO CLINICAL PEDIATRICS LA English DT Article DE vaccination; adolescent; parental attitudes; acceptance; HPV; Tdap; MenACWY ID HUMAN-PAPILLOMAVIRUS VACCINE; UNITED-STATES; ADVISORY-COMMITTEE; COVERAGE LEVELS; PRACTICES ACIP; HEALTH; HPV; RECOMMENDATIONS; EPIDEMIOLOGY; ACCEPTANCE AB Objectives. We aim to describe factors that influence parental decisions to vaccinate their adolescents. Methods. Data from the July to December 2010 National Immunization Survey-Teen Parental Concerns Module were analyzed to determine factors that influence parental decisions to vaccinate their adolescents. Results. Parents reported that their adolescent's health care provider recommended tetanus toxoid/tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Td/Tdap; 74.4%), meningococcal conjugate (MenACWY; 60.3%), and human papillomavirus (HPV; 71.3%). Vaccination coverage estimates were significantly higher among parents who reported receiving a provider recommendation: 85.2% versus 76.7% (Td/Tdap), 77.3% versus 49.7% (MenACWY), and 62.2% versus 21.5% (HPV). Compared with Td/Tdap and MenACWY, fewer HPV vaccination conversations included recommendations for vaccination. Other than health care providers, school requirements (46.1%), news coverage (31.2%), and family (31.0%) were most frequently reported influences on parental vaccination decisions. Conclusions. Many factors influence parental decisions to vaccinate their adolescents; one of the most important factors is the provider recommendation. Missed opportunities for vaccination persist when strong vaccination recommendations are not given or are delayed. C1 [Dorell, Christina; Yankey, David; Kennedy, Allison; Stokley, Shannon] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Dorell, C (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, 1600 Clifton Rd,MS A-19, Atlanta, GA 30333 USA. EM cdorell@cdc.gov NR 48 TC 33 Z9 33 U1 4 U2 17 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0009-9228 J9 CLIN PEDIATR JI Clin. Pediatr. PD FEB PY 2013 VL 52 IS 2 BP 162 EP 170 DI 10.1177/0009922812468208 PG 9 WC Pediatrics SC Pediatrics GA 083OV UT WOS:000314475300008 PM 23221308 ER PT J AU Payne, AB Miller, CH Kelly, FM Soucie, JM Hooper, WC AF Payne, Amanda B. Miller, Connie H. Kelly, Fiona M. Soucie, J. Michael Hooper, W. Craig TI The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: A New Online Resource SO HUMAN MUTATION LA English DT Article DE hemophilia A; mutation database; locus-specific database; F8 gene ID VIII B DOMAIN; DATABASE; GENE AB Genotyping efforts in hemophilia A (HA) populations in many countries have identified large numbers of unique mutations in the Factor VIII gene (F8). To assist HA researchers conducting genotyping analyses, we have developed a listing of F8 mutations including those listed in existing locus-specific databases as well as those identified in patient populations and reported in the literature. Each mutation was reviewed and uniquely identified using Human Genome Variation Society (HGVS) nomenclature standards for coding DNA and predicted protein changes as well as traditional nomenclature based on the mature, processed protein. Listings also include the associated hemophilia severity classified by International Society of Thrombosis and Haemostasis (ISTH) criteria, associations of the mutations with inhibitors, and reference information. The mutation list currently contains 2,537 unique mutations known to cause HA. HA severity caused by the mutation is available for 2,022 mutations (80%) and information on inhibitors is available for 1,816 mutations (72%). The CDC Hemophilia A Mutation Project (CHAMP) Mutation List is available at http://www.cdc.gov/hemophiliamutations for download and search and will be updated quarterly based on periodic literature reviews and submitted reports. C1 [Payne, Amanda B.; Miller, Connie H.; Kelly, Fiona M.; Soucie, J. Michael; Hooper, W. Craig] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Payne, AB (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS D02, Atlanta, GA 30333 USA. EM bvx2@cdc.gov OI Miller, Connie H/0000-0002-3989-7973 FU CDC Foundation from Pfizer Inc. FX This work was supported by the CDC Foundation through a grant from Pfizer Inc. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. The authors have no conflicts of interest to declare. NR 13 TC 9 Z9 9 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1059-7794 J9 HUM MUTAT JI Hum. Mutat. PD FEB PY 2013 VL 34 IS 2 BP E2382 EP E2391 DI 10.1002/humu.22247 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 083PP UT WOS:000314477700022 PM 23280990 ER PT J AU Meinke, DK Finan, DS Soendergaard, J Flamme, GA Murphy, WJ Lankford, JE Stewart, M AF Meinke, Deanna K. Finan, Donald S. Soendergaard, Jacob Flamme, Gregory A. Murphy, William J. Lankford, James E. Stewart, Michael TI Impulse noise generated by starter pistols SO INTERNATIONAL JOURNAL OF AUDIOLOGY LA English DT Article DE Impulse noise; starter pistol; noise level; noise exposure; noise-induced hearing loss; sports injury; occupational health and safety; track and field ID BLANK CARTRIDGES; AUDITORY RISK; ACOUSTIC TRAUMA; EXPOSURE; GUNSHOTS; SHOTS AB Objective: This study describes signals generated by .22 and .32 caliber starter pistols in the context of noise-induced hearing loss risk for sports officials and athletes. Design: Acoustic comparison of impulses generated from typical .22 and .32 caliber starter pistols firing blanks were made to impulses generated from comparable firearms firing both blanks and live rounds. Acoustic characteristics are described in terms of directionality and distance from the shooter in a simulated outdoor running track. Metrics include peak sound pressure levels (SPL), A-weighted equivalent 8-hour level (L-eqA8), and maximum permissible number of individual shots, or maximum permissible exposures (MPE) for the unprotected ear. Results: Starter pistols produce peak SPLs above 140 dB. The numbers of MPEs are as few as five for the .22-caliber starter pistol, and somewhat higher (<= 25) for the .32-caliber pistol. Conclusion: The impulsive sounds produced by starter pistols correspond to MPE numbers that are unacceptably small for unprotected officials and others in the immediate vicinity of the shooter. At the distances included in this study, the risk to athletes appears to be low (when referencing exposure criteria for adults), but the sound associated with the starter pistol will contribute to the athlete's overall noise exposure. C1 [Meinke, Deanna K.; Finan, Donald S.] Univ No Colorado, Greeley, CO 80639 USA. [Soendergaard, Jacob] GRAS Sound & Vibrat, Twinsburg, OH USA. [Flamme, Gregory A.] Western Michigan Univ, Dept Speech Pathol & Audiol, Kalamazoo, MI 49008 USA. [Murphy, William J.] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. [Lankford, James E.] No Illinois Univ, Allied Hlth & Communicat Disorders Dept, De Kalb, IL USA. [Stewart, Michael] Cent Michigan Univ, Dept Commun Disorders, Mt Pleasant, MI 48859 USA. RP Meinke, DK (reprint author), Univ No Colorado, Campus Box 140, Greeley, CO 80639 USA. EM Deanna.Meinke@unco.edu FU Intramural CDC HHS [CC999999] NR 41 TC 6 Z9 6 U1 0 U2 7 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1499-2027 J9 INT J AUDIOL JI Int. J. Audiol. PD FEB PY 2013 VL 52 SU 1 BP S9 EP S19 DI 10.3109/14992027.2012.745650 PG 11 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 084IO UT WOS:000314532400003 PM 23373743 ER PT J AU Justice, AC Modur, SP Tate, JP Althoff, KN Jacobson, LP Gebo, KA Kitahata, MM Horberg, MA Brooks, JT Buchacz, K Rourke, SB Rachlis, A Napravnik, S Eron, J Willig, JH Moore, R Kirk, GD Bosch, R Rodriguez, B Hogg, RS Thorne, J Goedert, JJ Klein, M Gill, J Deeks, S Sterling, TR Anastos, K Gange, SJ AF Justice, Amy C. Modur, Sharada P. Tate, Janet P. Althoff, Keri N. Jacobson, Lisa P. Gebo, Kelly A. Kitahata, Mari M. Horberg, Michael A. Brooks, John T. Buchacz, Kate Rourke, Sean B. Rachlis, Anita Napravnik, Sonia Eron, Joseph Willig, James H. Moore, Richard Kirk, Gregory D. Bosch, Ronald Rodriguez, Benigno Hogg, Robert S. Thorne, Jennifer Goedert, James J. Klein, Marina Gill, John Deeks, Steven Sterling, Timothy R. Anastos, Kathryn Gange, Stephen J. CA NA-ACCORD Project Team VACS Project Team TI Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection: A North American Cross Cohort Analysis SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; aging; prognosis ID HEALTH-RISK APPRAISAL; ACTIVE ANTIRETROVIRAL THERAPY; COLLABORATIVE ANALYSIS; CLINICAL GUIDELINES; CARDIOVASCULAR RISK; RANDOMIZED-TRIAL; LIFE EXPECTANCY; STAGING SYSTEM; OLDER-ADULTS; DISEASE AB Background: By supplementing an index composed of HIV biomarkers and age (restricted index) with measures of organ injury, the Veterans Aging Cohort Study (VACS) index more completely reflects risk of mortality. We compare the accuracy of the VACS and restricted indices (1) among subjects outside the Veterans Affairs Healthcare System, (2) more than 1-5 years of prior exposure to antiretroviral therapy (ART), and (3) within important patient subgroups. Methods: We used data from 13 cohorts in the North American AIDS Cohort Collaboration (n = 10, 835) limiting analyses to HIV-infected subjects with at least 12 months exposure to ART. Variables included demographic, laboratory (CD4 count, HIV-1 RNA, hemoglobin, platelets, aspartate and alanine transaminase, creatinine, and hepatitis C status), and survival. We used C-statistics and net reclassification improvement (NRI) to test discrimination varying prior ART exposure from 1 to 5 years. We then combined Veterans Affairs Healthcare System (n = 5066) and North American AIDS Cohort Collaboration data, fit a parametric survival model, and compared predicted to observed mortality by cohort, gender, age, race, and HIV-1 RNA level. Results: Mean follow-up was 3.3 years (655 deaths). Compared with the restricted index, the VACS index showed greater discrimination (C-statistics: 0.77 vs. 0.74; NRI: 12%; P < 0.0001). NRI was highest among those with HIV-1 RNA,500 copies per milliliter (25%) and age >= 50 years (20%). Predictions were similar to observed mortality among all subgroups. Conclusions: VACS index scores discriminate risk and translate into accurate mortality estimates over 1-5 years of exposure to ART and for diverse patient subgroups from North American. C1 [Justice, Amy C.] Yale Univ, Dept Internal Med, West Haven, CT USA. [Justice, Amy C.; Tate, Janet P.] Vet Affairs Healthcare Syst, West Haven, CT USA. [Modur, Sharada P.; Althoff, Keri N.; Jacobson, Lisa P.; Gange, Stephen J.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. [Tate, Janet P.] Yale Univ, Dept Biostat, West Haven, CT USA. [Gebo, Kelly A.] Johns Hopkins Univ, Dept Infect Dis, Baltimore, MD USA. [Kitahata, Mari M.] Univ Washington, Dept Allergy & Infect Dis, Seattle, WA 98195 USA. [Horberg, Michael A.] Mid Atlantic Permanente Res Inst, Div Res, Rockville, MD USA. [Brooks, John T.; Buchacz, Kate] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Rourke, Sean B.] Univ Toronto, Dept Psychiat, Ontario Treatment Network, Toronto, ON, Canada. [Rachlis, Anita] Univ Toronto, Dept Med, Ontario Treatment Network, Toronto, ON, Canada. [Napravnik, Sonia; Eron, Joseph] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Willig, James H.] Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL USA. [Moore, Richard] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Kirk, Gregory D.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. [Bosch, Ronald] Harvard Univ, Sch Med, Dept Biostat, Boston, MA USA. [Rodriguez, Benigno] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. [Hogg, Robert S.] British Columbia Ctr Excellence & HIV AIDS, Dept Hlth Sci, Vancouver, BC, Canada. [Hogg, Robert S.] Simon Fraser Univ, Vancouver, BC, Canada. [Thorne, Jennifer] Johns Hopkins Univ, Dept Ophthalmol & Epidemiol, Baltimore, MD USA. [Goedert, James J.] NIH, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Klein, Marina] McGill Univ, Dept Med, Montreal, PQ, Canada. [Gill, John] Univ Calgary, Dept Med, Calgary, AB, Canada. [Deeks, Steven] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Sterling, Timothy R.] Vanderbilt Univ, Dept Med, Nashville, TN USA. [Anastos, Kathryn] Einstein Med Sch, Dept Med, New York, NY USA. RP Justice, AC (reprint author), Vet Affairs Connecticut Healthcare System, 11ACSLG,Bldg 35A,Room 2-212,950 Campbell Ave, West Haven, CT 06516 USA. EM amy.justice2@va.gov RI Rodriguez, Benigno/C-3365-2009; OI Rodriguez, Benigno/0000-0001-9736-7957; Gange, Stephen/0000-0001-7842-512X; Hogg, Robert/0000-0003-3463-5488 FU National Institutes of Health, NIAAA [U10-AA13566]; National Institutes of Health, NHLBI [R01-HL095136, R01-HL090342, RCI-HL100347]; NIA [R01-AG029154, K23 AG024896]; Training Program in Environmental Epidemiology [T32 ES07069]; National Institutes of Health [U01-AI069918, U01-AA013566, UO1-AI-35042, 5-MO1-RR-00052, UO1-AI-35043, UO1-AI-35039, UO1-AI-35040, UO1-AI-35041, U01-AI38855, U01-AI38858, U01-AI68634, U01-AI68636, AI-69432, AI69434, UO1-AI-35004, UO1-AI-31834] FX Supported financially by National Institutes of Health: NIAAA (U10-AA13566), NHLBI (R01-HL095136; R01-HL090342; RCI-HL100347), and NIA (R01-AG029154; K23 AG024896). Ms. J.P. Tate was supported by the Training Program in Environmental Epidemiology funded under grant no. T32 ES07069. This work was supported by grants from the National Institutes of Health: U01-AI069918, U01-AA013566, UO1-AI-35042, 5-MO1-RR-00052 (GCRC), UO1-AI-35043, UO1-AI-35039, UO1-AI-35040, UO1-AI-35041, U01-AI38855: ALLRT; U01-AI38858; U01-AI68634; U01-AI68636; AI-69432; AI69434, UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590, UO1-HD-32632, UL1-RR024131, P30AI27757; K23-AI-61-0320, P30-AI27767, P30-AI50410; RR025747, P30-AI54999, R01-DA04334; R01-DA12568, R01-MH54907, R24-AI067039, N02CP55504; Z01-CP010176, AHQ290-01-0012, K01-AI071754, K24-00432; R01-DA11602, K01-AI071725, R01 AG026250 to K. A. Gebo. This work was also supported by the Centers for Disease Control (CDC200-2006-18797), the Canadian Institutes for Health Research (CIHR: TGF-96118; HCP-97105; CBR-86906; CBR-94036; KRS-86251; 169621), and the Canadian Trials Network (project number 242). NR 58 TC 56 Z9 56 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD FEB 1 PY 2013 VL 62 IS 2 BP 149 EP 163 DI 10.1097/QAI.0b013e31827df36c PG 15 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 083JM UT WOS:000314459500011 PM 23187941 ER PT J AU Dalal, W Feikin, DR Amolloh, M Ransom, R Burke, H Lugalia, F Ouma, A Laserson, KF Mermin, J Breiman, RF Bunnell, R AF Dalal, Warren Feikin, Daniel R. Amolloh, Manase Ransom, Ray Burke, Heather Lugalia, Fillet Ouma, Alice Laserson, Kayla F. Mermin, Jonathan Breiman, Robert F. Bunnell, Rebecca TI Home-Based HIV Testing and Counseling in Rural and Urban Kenyan Communities SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; home-based counseling and testing; universal ccess; Kenya; discordant couples; HIV prevention; CD4 count ID SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; TRANSMISSION RISK; RANDOMIZED-TRIAL; WESTERN KENYA; HEALTH-CARE; VOLUNTARY; UGANDA; PREVENTION; ACCEPTABILITY AB Background: In sub-Saharan Africa, most people with HIV do not know they are infected. Methods: We conducted door-to-door home-based testing and counseling (HBTC) in rural western Kenya (Lwak) and an informal urban settlement in Nairobi (Kibera) in 2008. After consent, eligible persons (adults and adolescents aged 13 years or older and children aged 12 years or younger, whose biologic mother was HIV-infected or deceased) received parallel fingerstick HIV rapid testing and counseling. Persons newly diagnosed with HIV were referred to care services, fingerstick blood for CD4 testing was collected, and a one-month follow-up home visit was conducted. Results: Among 24,450 people who were offered HBTC, 19,966 (81.7%) accepted; 65.4% of whom were HIV-tested for the first time. Prevalence in adults aged 18 years or older being HIV-tested for the first time was 13.5% (12.6%, Kibera; 14.2%, Lwak). Among adults who reported a previously negative test, HIV prevalence was 7.4% (7.2%, Kibera; 7.6%, Lwak). Among all persons with HIV in these communities, two-thirds were newly diagnosed through HBTC. Median CD4 count among newly diagnosed adults was 403 [interquartile range (IQR) = 252-594]. Among couples, 38.0% in Kibera and 51.7% in Lwak were counseled together. Among HIV-infected people in a couple, 34.6% had an HIV-uninfected partner. Among newly diagnosed HIV-infected persons, at the one-month follow-up visit, 53.6% in Kibera and 43.6% in Lwak reported having visited an HIV patient support center. Conclusions: HBTC acceptance was high and most HIV-infected persons did not previously know they had HIV. HBTC can be an effective strategy for early HIV diagnosis and treatment referral. C1 [Dalal, Warren; Bunnell, Rebecca] Ctr Dis Control & Prevent, Global AIDS Program, Nairobi, Kenya. [Feikin, Daniel R.] Ctr Dis Control & Prevent, Kisumu, Kenya. [Amolloh, Manase] Kenya Govt Med Res Ctr, Global AIDS Program, Kisumu, Kenya. [Ransom, Ray] CDC, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Burke, Heather; Breiman, Robert F.] Ctr Dis Control & Prevent, Nairobi, Kenya. [Lugalia, Fillet; Ouma, Alice] Kenya Govt Med Res Ctr, Global AIDS Program, Nairobi, Kenya. [Laserson, Kayla F.; Mermin, Jonathan] Ctr Dis Control & Prevent, Coordinating Off Global Hlth, Kisumu, Kenya. [Mermin, Jonathan] Ctr Dis Control & Prevent, Coordinating Off Global Hlth, Nairobi, Kenya. RP Feikin, DR (reprint author), 814 N Wolfe St,Suite 600, Baltimore, MD 21205 USA. EM dfeikin@jhsph.edu FU United States President's Emergency Plan for AIDS Relief; Centers for Disease Control and Prevention; Department of Health and Human Services FX Supported by the United States President's Emergency Plan for AIDS Relief; the Centers for Disease Control and Prevention; Department of Health and Human Services. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 44 TC 40 Z9 40 U1 2 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD FEB 1 PY 2013 VL 62 IS 2 BP E47 EP E54 DI 10.1097/QAI.0b013e318276bea0 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 083JM UT WOS:000314459500003 PM 23075916 ER PT J AU Spears, DR McNeil, C Warnock, E Trapp, J Oyinloye, O Whitehurst, V Decker, KC Chapman, S Campbell, M Meechan, P AF Spears, D. Ross McNeil, Carrie Warnock, Eli Trapp, Jonathan Oyinloye, Oluremi Whitehurst, Vanessa Decker, K. C. Chapman, Sandy Campbell, Morris Meechan, Paul TI Predicting Temporal Trends in Sickness Absence Rates for Civil Service Employees of a Federal Public Health Agency SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID WORKER ABSENTEEISM; WHITEHALL-II; LEAVE; SWEDEN AB Objective: To determine whether trends of sickness in employees at a federal agency are predictable, and whether the variance was minimal enough to detect unusual levels of employee illness for further investigation. Methods: Ten years of absenteeism data from an attendance system were analyzed for rates of sickness absence. Specifically, week of year and day of week were used to describe temporal trends. Results: This study evaluates the predictability in temporal absence trends due to sickness among employees at a federal agency. Trends follow regular patterns during a given year that correspond to seasonal illnesses. Temporal trends in sick leave have been proven to be very predictable. Conclusion: The minimal variance allows the detection of sick leave anomalies that may be ascribable to specific causes, allowing the business or agency to follow-up and develop interventions. C1 [Spears, D. Ross; McNeil, Carrie; Warnock, Eli; Meechan, Paul] Ctr Dis Control & Prevent, Off Safety Hlth & Environm, Atlanta, GA 30333 USA. [Trapp, Jonathan] Ctr Dis Control & Prevent, Off Secur & Emergency Preparedness, Atlanta, GA 30333 USA. [Chapman, Sandy; Campbell, Morris] Ctr Dis Control & Prevent, Management Informat Syst Off, Atlanta, GA 30333 USA. [Oyinloye, Oluremi; Whitehurst, Vanessa; Decker, K. C.] Booz Allen Hamilton, Mclean, VA USA. RP Spears, DR (reprint author), Ctr Dis Control & Prevent, US Publ Hlth Serv, Occupat Hlth & Prevent Serv, Off Safety Hlth & Environm, 1600 Clifton Rd NE,MS F-05, Atlanta, GA 30333 USA. EM ava3@cdc.gov NR 34 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD FEB PY 2013 VL 55 IS 2 BP 179 EP 190 DI 10.1097/JOM.0b013e3182717eb5 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 086FP UT WOS:000314669800012 PM 23171916 ER PT J AU Lakis, N Blair, D Abraham, JL Li, Y Damon, I AF Lakis, N. Blair, D. Abraham, J. L. Li, Y. Damon, I. TI New Archetypal Poxvirus Infection in an Immunosuppressed Man SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 02-08, 2013 CL Baltimore, MD SP US & Canadian Acad Pathol (USCAP), Dako, Biocare Med, Leica Biosyst, Integrated Oncol, Definiens, Ventana, Philips, USCAP Fdn, Nephropath, Sakura C1 SUNY Upstate Med Univ, Syracuse, NY 13210 USA. CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2013 VL 26 SU 2 MA 1557 BP 372A EP 373A PG 2 WC Pathology SC Pathology GA 083EB UT WOS:000314444402184 ER PT J AU Bali, D Dickerson, G Zhou, H DeJesus, V Hopkins, P Klug, T Millington, D AF Bali, Deeksha Dickerson, Gwen Zhou, Hui DeJesus, Victor Hopkins, Patrick Klug, Tracy Millington, David TI Comparison of methods for the analysis of lysosomal enzyme activities in quality control dried blood spot specimens SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 9th Annual World Symposium of the Lysosomal-Disease-Network (LDN) CY FEB 12-15, 2013 CL Orlando, FL SP Lysosomal Dis Network (LDN) C1 [Bali, Deeksha; Dickerson, Gwen; Millington, David] Duke Univ, Med Ctr, Durham, NC USA. [Zhou, Hui; DeJesus, Victor] Ctr Dis Control & Prevent, Newborn Screening & Mol Biol Branch, Atlanta, GA 30341 USA. [Hopkins, Patrick; Klug, Tracy] Newborn Screening, Missouri State Publ Hlth Lab, Jefferson City, MO 65101 USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2013 VL 108 IS 2 MA 17 BP S22 EP S22 DI 10.1016/j.ymgme.2012.11.031 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 086FW UT WOS:000314670500019 ER PT J AU Hechter, RC Qian, L Sy, LS Greene, SK Weintraub, ES Naleway, AL Rowhani-Rahbar, A Donahue, JG Daley, MF Vazquez-Benitez, G Lugg, MM Jacobsen, SJ AF Hechter, Rulin C. Qian, Lei Sy, Lina S. Greene, Sharon K. Weintraub, Eric S. Naleway, Allison L. Rowhani-Rahbar, Ali Donahue, James G. Daley, Matthew F. Vazquez-Benitez, Gabriela Lugg, Marlene M. Jacobsen, Steven J. TI Secular trends in diagnostic code density in electronic healthcare data from health care systems in the Vaccine Safety Datalink Project SO VACCINE LA English DT Article DE Vaccine; Safety; Surveillance; Secular trends; Coding; Data quality ID ADVERSE EVENTS; ACTIVE SURVEILLANCE; INFLUENZA VACCINE; UNITED-STATES; ADULTS; SIGNS AB Large observational vaccine safety studies often use automated diagnoses extracted from medical care databases to identify pre-specified potential adverse events following immunization (AEFI). We assessed the secular trends and variability in the number of diagnoses per encounter regardless of immunization status referred as diagnostic code density, by healthcare setting, age, and pre-specified condition in eight large health care systems of the Vaccine Safety Datalink project during 2001-2009. An increasing trend in diagnostic code density was observed in all healthcare settings and age groups, with variations across the sites. Sudden increases in diagnostic code density were observed at certain sites when changes in coding policies or data inclusion criteria took place. When vaccine safety studies use an historical comparator, the increased diagnostic code density over time may generate low expected rates (based on historical data) and high observed rates (based on current data), suggesting a false positive association between a vaccine and AEFI. The ongoing monitoring of the diagnostic code density can provide guidance on study design and choice of appropriate comparison groups. It can also be used to ensure data quality and allow timely correction of errors in an active safety surveillance system. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Hechter, Rulin C.; Qian, Lei; Sy, Lina S.; Lugg, Marlene M.; Jacobsen, Steven J.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Greene, Sharon K.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Greene, Sharon K.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Weintraub, Eric S.] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. [Naleway, Allison L.] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA. [Rowhani-Rahbar, Ali] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA. [Donahue, James G.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Daley, Matthew F.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Vazquez-Benitez, Gabriela] Hlth Partners Inst Educ & Res, Bloomington, MN USA. RP Hechter, RC (reprint author), Kaiser Permanente So Calif, Dept Res & Evaluat, 100 S Los Robles Ave,2nd Floor, Pasadena, CA 91101 USA. EM Rulin.C.Hechter@kp.org OI Naleway, Allison/0000-0001-5747-4643; Jacobsen, Steven/0000-0002-8174-8533 FU America's Health Insurance Plans (AHIP) from the Centers for Disease Control and Prevention (CDC) [200-2002-00732] FX This work was supported by a subcontract with America's Health Insurance Plans (AHIP) under contract 200-2002-00732 from the Centers for Disease Control and Prevention (CDC). The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position or views of the CDC. NR 15 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD FEB PY 2013 VL 31 IS 7 BP 1080 EP 1085 DI 10.1016/j.vaccine.2012.12.030 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 083TA UT WOS:000314486900012 PM 23267842 ER PT J AU Nett, RJ Helgerson, SD Anderson, AD AF Nett, Randall J. Helgerson, Steven D. Anderson, Alicia D. TI Clinician Assessment for Coxiella burnetii Infection in Hospitalized Patients with Potentially Compatible Illnesses During Q Fever Outbreaks and Following a Health Alert, Montana, 2011 SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Q fever; Coxiella burnetii; Montana; Information dissemination AB Background: Coxiella burnetii is an endemic bacterial pathogen in the United States and the causative agent of Q fever. Two outbreaks of Q fever occurred in Montana during 2011, which led to the issuance of a health alert urging clinicians to test patients with Q fever-compatible illnesses for C. burnetii infection. Methods: We retrospectively evaluated the medical records of patients hospitalized for fever, pneumonia, chest pain, and viral infection of unknown etiologies during the two Q fever outbreaks and following the health alert. Results: A total of 103 patients were included in the analysis. Clinicians assessed < 1% of patients suffering illnesses compatible with Q fever for known risk factors or C. burnetii infection. Only 1 patient had Q fever excluded as a diagnosis. Conclusion: Clinicians should assess for Q fever risk factors and consider the diagnosis in patients hospitalized with Q fever-compatible illnesses when the etiology of illness is unknown. Work is warranted to evaluate the effectiveness of current healthcare alert practices for zoonotic diseases. C1 [Nett, Randall J.] Ctr Dis Control & Prevent CDC, Career Epidemiol Field Officer Program, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Anderson, Alicia D.] Ctr Dis Control & Prevent CDC, Rickettsial Zoonoses Branch, Div Vector Borne Dis, Atlanta, GA USA. [Nett, Randall J.; Helgerson, Steven D.] Montana Dept Publ Hlth & Human Serv, Publ Hlth & Safety Div, Helena, MT USA. RP Nett, RJ (reprint author), Montana Dept Publ Hlth & Human Serv, Cogswell Bldg,Room B-201,1400 Broadway, Helena, MT 59610 USA. EM ggE5@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2013 VL 13 IS 2 BP 128 EP 130 DI 10.1089/vbz.2012.1007 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 082AM UT WOS:000314364100008 PM 23289392 ER PT J AU Li, XL Fu, SH Liu, WB Wang, HY Lu, Z Tong, SX Li, ZX Nasci, RS Kosoy, O Cui, Y Liang, GD AF Li, Xin-Lan Fu, Shi-Hong Liu, Wei-Bin Wang, Huan-Yu Lu, Zhi Tong, Su-Xiang Li, Zhao-Xia Nasci, Roger S. Kosoy, Olga Cui, Ying Liang, Guo-Dong TI West Nile Virus Infection in Xinjiang, China SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE West Nile; Flavivirus; Arbovirus; China ID ARBOVIRAL INFECTIONS; ENCEPHALITIS AB An outbreak of fever and meningitis/encephalitis occurred in Xinjiang, China, from August 5 to September 3, 2004. In preliminary diagnostic testing, several cerebrospinal fluid (CSF) and serum samples showed positive immunoglobulin M (IgM) antibody to Japanese encephalitis virus. Here, the CSF and serum samples of 6 cases collected at that time were tested by immunofluorescence assay (IFA), enzyme-linked immunosorbent assay (ELISA), and plaque reduction neutralization assay (PRNT) for the existence of IgM antibody or neutralization antibody against West Nile virus (WNV) or other arboviruses. The results demonstrate the evidence of West Nile infection in Xinjiang, China. C1 [Li, Xin-Lan; Tong, Su-Xiang; Cui, Ying] Xinjiang Ctr Dis Control & Prevent, Xinjiang, Peoples R China. [Fu, Shi-Hong; Liu, Wei-Bin; Wang, Huan-Yu; Lu, Zhi; Liang, Guo-Dong] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China. [Li, Zhao-Xia] Kashi Ctr Dis Control & Prevent, Xinjiang, Peoples R China. [Nasci, Roger S.; Kosoy, Olga] Ctr Dis Control & Prevent, Ft Collins, CO USA. RP Li, XL (reprint author), Care of Liang GP, State Key Lab Infect Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Chinese Ctr Dis Control & Prevent, 155 Changbai Rd, Beijing 102206, Peoples R China. EM gdliang@hotmail.com NR 14 TC 7 Z9 17 U1 0 U2 9 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2013 VL 13 IS 2 BP 131 EP 133 DI 10.1089/vbz.2012.0995 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 082AM UT WOS:000314364100009 PM 23289395 ER PT J AU Liu, Q Cao, LL Zhang, YG Xu, D Shang, LM Wang, XL Wei, F Xiao, LH Ma, RL Cai, JS Zhao, QB AF Liu, Quan Cao, Lili Zhang, Yingguang Xu, Dan Shang, Limin Wang, Xinglong Wei, Feng Xiao, Lihua Ma, Ruilin Cai, Jinshan Zhao, Quanbang TI Genotypes of Echinococcus granulosus in Animals from Yushu, Northeastern China SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Echinococcus; Genotype; Northeastern China ID GENUS ECHINOCOCCUS; CYSTIC ECHINOCOCCOSIS AB Echinococcus granulosus is the causative agent of cystic echinococcosis with medical and veterinary importance worldwide. The aim of this study was to determine the genotype distribution of E. granulosus in animals in Yushu, Qinghai Province, northeastern China. The mitochondrial nicotinamide adenine dinucleotide + hydrogen (NADH) dehydrogenase subunit 1 (nad1) and cytochrome c oxidase subunit 1 (cox1) genes from 30 echinococcosis isolates were analyzed by sequence alignment, generating two unique sequence profiles at both nad1 and cox1 loci. Phylogenetic analysis demonstrated that 28 isolates (93.3%) belonged to the well-known G1-G3 complex (E. granulosus sensu stricto), and 2 (6.7%) were placed in G6-G10 complex (E. canadensis). The present study provides the genetic composition of E. granulosus from animals in Yushu, Qinghai Province, and confirms that, for the first time, the E. granulosus G6-G10 complex (E. canadensis) is not only limited to Xinjiang and might be of greater public health significance than previously believed in China. C1 [Liu, Quan; Zhang, Yingguang; Xu, Dan; Shang, Limin; Wang, Xinglong] Acad Mil Med Sci, Inst Mil Vet, Key Lab Jilin Prov Zoonosis Prevent & Control, Changchun 130122, Jilin Province, Peoples R China. [Cao, Lili] Jilin Acad Anim Husb & Vet Med, Changchun, Jilin Province, Peoples R China. [Wei, Feng] Jilin Agr Univ, Coll Life Sci, Changchun, Jilin Province, Peoples R China. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Ma, Ruilin; Cai, Jinshan; Zhao, Quanbang] Anim Dis Control & Prevent Ctr Qinghai Prov, Xining, Qinghai Provinc, Peoples R China. RP Liu, Q (reprint author), Acad Mil Med Sci, Inst Mil Vet, Key Lab Jilin Prov Zoonosis Prevent & Control, 666 Liuying Xilu, Changchun 130122, Jilin Province, Peoples R China. EM liuquan1973@hotmail.com RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 FU National Basic Research Program of China ("973" Program) [2012CB722501] FX We thank the staff of the Veterinary Stations in Yushu, Qinghai Province, China for collection of echinococcosis cysts. This study was supported by the National Basic Research Program of China ("973" Program) (2012CB722501). NR 18 TC 5 Z9 6 U1 0 U2 10 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2013 VL 13 IS 2 BP 134 EP 137 DI 10.1089/vbz.2012.1050 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 082AM UT WOS:000314364100010 PM 23289393 ER PT J AU Carter, MW Bailey, A Snead, MC Costenbader, E Townsend, M Macaluso, M Jamieson, DJ Hylton-Kong, T Warner, L Steiner, MJ AF Carter, Marion W. Bailey, Althea Snead, Margaret C. Costenbader, Elizabeth Townsend, Malene Macaluso, Maurizio Jamieson, Denise J. Hylton-Kong, Tina Warner, Lee Steiner, Markus J. TI Exploring Discordance Between Biologic and Self-Reported Measures of Semen Exposure: A Qualitative Study Among Female Patients Attending an STI Clinic in Jamaica SO AIDS AND BEHAVIOR LA English DT Article DE Qualitative study; Self-reported data; Semen biomarker; Prostate-specific antigen; Jamaica ID PROSTATE-SPECIFIC ANTIGEN; INTERVIEW MODE EXPERIMENT; SEXUAL-BEHAVIOR; MICROBICIDE TRIAL; UNPROTECTED SEX; CONDOM FAILURE; VALIDITY; BIOMARKERS; COUNTRIES; WORKERS AB We explored the use of qualitative interviews to discuss discrepancies between two sources of information on unprotected sex: biomarker results and self-reported survey data. The study context was a randomized trial in Kingston, Jamaica examining the effect of STI counseling messages on recent sexual behavior using prostate-specific antigen (PSA) as the primary study outcome. Twenty women were interviewed. Eleven participants were selected because they tested positive for PSA indicating recent semen exposure, yet reported no unprotected sex in a quantitative survey ("discordant"): 5 reported abstinence and 6 reported condom use. Nine participants who also tested positive for PSA but reported unprotected sex in the survey were interviewed for comparison ("concordant"). Qualitative interviews with 6 of the 11 discordant participants provided possible explanations for their PSA test results, and 5 of those were prompted by direct discussion of those results. Rapid PSA testing combined with qualitative interviews provides a novel tool for investigating and complementing self-reported sexual behavior. C1 [Carter, Marion W.; Snead, Margaret C.; Jamieson, Denise J.; Warner, Lee] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Bailey, Althea] Univ W Indies, Dept Community Hlth & Psychiat, Kingston 7, Jamaica. [Costenbader, Elizabeth] FHI 360, Behav & Social Sci Dept, Durham, NC USA. [Townsend, Malene; Hylton-Kong, Tina] Jama Minist Hlth, CHC, ERTU, Kingston, Jamaica. [Macaluso, Maurizio] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA. [Steiner, Markus J.] FHI 360, Dept Clin Sci, Durham, NC USA. RP Carter, MW (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,MS-K-34, Atlanta, GA 30341 USA. EM acq0@cdc.gov RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 FU Intramural CDC HHS [CC999999] NR 32 TC 3 Z9 3 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD FEB PY 2013 VL 17 IS 2 BP 728 EP 736 DI 10.1007/s10461-012-0286-y PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 081FL UT WOS:000314302800029 PM 22893195 ER PT J AU Tyler, CP AF Tyler, Crystal P. CA ELGAN Study Authors TI The use of aspirin during pregnancy REPLY SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Letter C1 [Tyler, Crystal P.; ELGAN Study Authors] CDC, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Tyler, CP (reprint author), CDC, Div Reprod Hlth, 4770 Buford Highway MS K-22, Atlanta, GA 30341 USA. EM ctyler@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD FEB PY 2013 VL 208 IS 2 BP 162 EP 162 DI 10.1016/j.ajog.2012.11.023 PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 077HO UT WOS:000314018700032 PM 23174284 ER PT J AU Henderson, JT Harper, CC Gutin, S Saraiya, M Chapman, J Sawaya, GF AF Henderson, Jillian T. Harper, Cynthia C. Gutin, Sarah Saraiya, Mona Chapman, Jocelyn Sawaya, George F. TI Routine bimanual pelvic examinations: practices and beliefs of US obstetrician-gynecologists SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE bimanual pelvic examination; cancer screening; clinical practice; provider views ID NATIONAL-SURVEY; OVARIAN-CANCER; PHYSICIANS; VIGNETTES; QUALITY; WOMEN; CARE AB OBJECTIVE: Less-than-annual cervical cancer screening is now recommended for most US women, raising questions about the need for routine annual bimanual pelvic examinations. Little is known about clinicians' bimanual pelvic examination practices, their beliefs about its importance, or the reasoning underlying its performance in asymptomatic women. STUDY DESIGN: We conducted a nationwide survey of US obstetrician-gynecologists. Respondents (n = 521) reported their examination practices and beliefs based on vignettes for asymptomatic women across the lifespan. RESULTS: Nearly all obstetrician-gynecologists perform bimanual pelvic examinations in asymptomatic women across the lifespan, although it is viewed as less important for a newly sexually active 18-year-old. Reasons cited as very important included adherence to standard medical practices (45%), patient reassurance (49%), detection of ovarian cancer (47%), and identification of benign uterine (59%) and ovarian (54%) conditions. CONCLUSION: Obstetrician-gynecologists perform bimanual pelvic examinations in the vast majority of asymptomatic women, but the importance placed on the examinations and reasons for conducting them vary. C1 [Henderson, Jillian T.; Harper, Cynthia C.; Chapman, Jocelyn; Sawaya, George F.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, Sch Med, San Francisco, CA 94118 USA. [Gutin, Sarah] Univ Calif San Francisco, Dept Community Hlth Syst, Sch Nursing, San Francisco, CA 94118 USA. [Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Sawaya, GF (reprint author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, Sch Med, 3333 Calif St,Suite 335, San Francisco, CA 94118 USA. EM sawayag@obgyn.ucsf.edu FU University of California, San Francisco; Mt. Zion Health Foundation; Dr Henderson's Mentored Research Scientist Development Award in Population Research [K01HD054495]; National Institutes of Health/National Center for Research Resources/Office of the Director, University of California, San Francisco-Clinical and Translational Science Institute [KL2 RR024130] FX Funding for this study was provided by a grant from the University of California, San Francisco, Mt. Zion Health Foundation; Dr Henderson's Mentored Research Scientist Development Award in Population Research (K01HD054495); and resources from the National Institutes of Health/National Center for Research Resources/Office of the Director, University of California, San Francisco-Clinical and Translational Science Institute (KL2 RR024130) program. NR 21 TC 6 Z9 6 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD FEB PY 2013 VL 208 IS 2 AR 109.e1 DI 10.1016/j.ajog.2012.11.015 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 077HO UT WOS:000314018700007 PM 23159688 ER PT J AU Lanier, Y Sutton, MY AF Lanier, Yzette Sutton, Madeline Y. TI Reframing the Context of Preventive Health Care Services and Prevention of HIV and Other Sexually Transmitted Infections for Young Men: New Opportunities to Reduce Racial/Ethnic Sexual Health Disparities SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID AFRICAN-AMERICAN MEN; UNITED-STATES; REPRODUCTIVE HEALTH; MISSED OPPORTUNITIES; ADOLESCENTS; SETTINGS; ADULTS; TRANSMISSION; BEHAVIOR; DISEASES AB Young Black males, aged 13 to 29 years, have the highest annual rates of HIV infections in the United States. Young Black men who have sex with men (MSM) are the only subgroup with significant increases in HIV incident infections in recent years. Black men, particularly MSM, are also disproportionately affected by other sexually transmitted infections (STIs). Therefore, we must strengthen HIV and STI prevention opportunities during routine, preventive health care visits and at other, nontraditional venues accessed by young men of color, with inclusive, nonjudgmental approaches. The Affordable Care Act and National HIV/AIDS Strategy present new opportunities to reframe and strengthen sexual health promotion and HIV and STI prevention efforts with young men of color. (Am J Public Health. 2013;103:262-269. doi:10.2105/AJPH.2012.300921) C1 [Lanier, Yzette; Sutton, Madeline Y.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Sutton, MY (reprint author), CDC, Div HIV AIDS Prevent, 1600 Clifton Rd,Mail Stop E-45, Atlanta, GA 30333 USA. EM msutton@cdc.gov NR 75 TC 8 Z9 8 U1 1 U2 20 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD FEB PY 2013 VL 103 IS 2 BP 262 EP 269 DI 10.2105/AJPH.2012.300921 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 078GE UT WOS:000314085900012 PM 23237172 ER PT J AU Karlsson, L Cragin, L Center, G Giguere, C Comstock, J Boccuzzo, L Sumner, A AF Karlsson, Lee Cragin, Lori Center, Gail Giguere, Cary Comstock, Jeff Boccuzzo, Linda Sumner, Austin TI Pentachlorophenol Contamination of Private Drinking Water From Treated Utility Poles SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article AB In 2009, after resident calls regarding an odor, the Vermont Department of Health and state partners responded to 2 scenarios of private drinking water contamination from utility poles treated with pentachlorophenol (PCP), an organochlorine wood preservative used in the United States. Public health professionals should consider PCP contamination of private water if they receive calls about a chemical or gasoline-like odor with concurrent history of nearby utility pole replacement. (Am J Public Health. 2013;103:276-277. doi:10.2105/AJPH.2012.300910) C1 [Karlsson, Lee; Cragin, Lori; Center, Gail; Boccuzzo, Linda; Sumner, Austin] Vermont Agcy Human Serv, Dept Hlth, Burlington, VT USA. [Karlsson, Lee] Ctr Dis Control & Prevent, Council State & Territorial Epidemiologists Appl, Atlanta, GA USA. [Giguere, Cary; Comstock, Jeff] Vermont Agcy Agr Food & Markets, Montpelier, VT USA. RP Karlsson, L (reprint author), Vermont Dept Hlth, 108 Cherry St,POB 70,Drawer 30, Burlington, VT 05402 USA. EM Lee.h.karlsson@gmail.com FU Applied Epidemiology Fellowship Program; Centers for Disease Control and Prevention Cooperative Agreement [5U38HM000414] FX This article was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists and funded by the Centers for Disease Control and Prevention Cooperative Agreement (5U38HM000414). NR 8 TC 1 Z9 1 U1 0 U2 19 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD FEB PY 2013 VL 103 IS 2 BP 276 EP 277 DI 10.2105/AJPH.2012.300910 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 078GE UT WOS:000314085900015 PM 23237185 ER PT J AU Whitmore, SK Kann, L Prejean, J Koenig, LJ Branson, BM Hall, HI Fasula, AM Tracey, A Mermin, J Valleroy, LA AF Whitmore, Suzanne K. Kann, Laura Prejean, Joseph Koenig, Linda J. Branson, Bernard M. Hall, H. Irene Fasula, Amy M. Tracey, Angie Mermin, Jonathan Valleroy, Linda A. TI Vital Signs: HIV Infection, Testing, and Risk Behaviors Among Youths - United States SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material ID MEN; ADOLESCENTS; SEX AB Background In 2009, 6.7% of the estimated 1.1 million persons living with human immunodeficiency virus ?(HIV) infection in the United States were youths (defined in this report as persons aged 1324 years); more than half of youths with HIV (59.5%) were unaware of their infection. Methods CDC used National HIV Surveillance System data to estimate, among youths, prevalence rates of -diagnosed HIV infection in 2009 and the number of new infections (incidence) in 2010. To assess the -prevalence of risk factors and HIV testing among youths, CDC used the 2009 and 2011 Youth Risk -Behavior Surveillance -System for 9th12th grade students and the 2010 National Health Interview Survey (NHIS) for persons 1824 years. Results Prevalence of diagnosed HIV was 69.5 per 100,000 youths at the end of 2009. Youths accounted for 12,200 (25.7%) new HIV infections in 2010. Of these, 7,000 (57.4%) were among blacks/African Americans, 2,390 (19.6%) among Hispanics/Latinos, and 2,380 (19.5%) among whites; 8,800 (72.1%) were attributed to male-to-male sexual contact. The percentage of youths tested for HIV overall was 12.9% among high school students and 34.5% among those aged 1824 years; it was lower among males than females, and lower among whites and Hispanics/Latinos than blacks/African Americans. Conclusions A disproportionate number of new HIV -infections occurs among youths, especially blacks/African Americans, Hispanics/Latinos, and men who have sex with men (MSM). The percentage of youths tested for HIV, however, was low, particularly among males. Implications for Public Health: More effort is needed to provide effective school- and community-based interventions to ensure all youths, particularly MSM, have the knowledge, skills, resources, and support necessary to avoid HIV infection. Health-care providers and public health agencies should ensure that youths are tested for HIV and have -access to sexual health services, and that HIV-positive youths receive ongoing health-care and prevention services. C1 [Whitmore, Suzanne K.; Kann, Laura; Prejean, Joseph; Koenig, Linda J.; Branson, Bernard M.; Hall, H. Irene; Fasula, Amy M.; Tracey, Angie; Mermin, Jonathan; Valleroy, Linda A.] CDC, Div HIV AIDS Prevent, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Whitmore, SK (reprint author), CDC, Div HIV AIDS Prevent, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM swhitmore@cdc.gov NR 16 TC 5 Z9 5 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD FEB PY 2013 VL 13 IS 2 BP 510 EP 515 DI 10.1111/ajt.12172 PG 6 WC Surgery; Transplantation SC Surgery; Transplantation GA 079LE UT WOS:000314171100036 ER PT J AU Nelson, AE Golightly, YM Renner, JB Schwartz, TA Kraus, VB Helmick, CG Jordan, JM AF Nelson, Amanda E. Golightly, Yvonne M. Renner, Jordan B. Schwartz, Todd A. Kraus, Virginia B. Helmick, Charles G. Jordan, Joanne M. TI Differences in Multijoint Symptomatic Osteoarthritis Phenotypes by Race and Sex: The Johnston County Osteoarthritis Project SO ARTHRITIS AND RHEUMATISM LA English DT Article ID KNEE OSTEOARTHRITIS; AFRICAN-AMERICANS; RADIOGRAPHIC OSTEOARTHRITIS; HIP OSTEOARTHRITIS; JOINT INVOLVEMENT; HAND; CAUCASIANS; POPULATION; PREVALENCE; WOMEN AB Objective. To determine differences in the phenotypes (patterns) of multiple-joint symptomatic osteoarthritis (OA) involvement by race and sex. Methods. A cross-sectional analysis of symptomatic OA phenotypes was performed in a community-based cohort, comprising subjects for whom data were collected from 4 sites of symptomatic OA involvement (the hands, knees, hips, and lumbosacral [LS] spine) at a single visit (2003-2010). Mutually exclusive phenotypes describing all combinations of these 4 sites were compared by race and by sex, using Fisher's exact tests. For those phenotypes occurring in >40 subjects, logistic regression was performed, with adjustments for race, sex, age, and body mass index (BMI), and interactions of race and sex were assessed. Results. The sample included 1,650 participants, of whom 36% were men and 32% were African American. The mean age of the subjects was 66 years, and the mean BMI was 31 kg/m(2). Overall, in this sample, 13% of subjects had symptomatic hand OA, 25% had symptomatic knee OA, 11% had symptomatic hip OA, and 28% had symptomatic LS spine OA. African Americans, as compared with Caucasians, were less likely to have involvement of symptomatic OA in the hand only, or in some combination of the hand and other sites, but were more likely to have involvement of the knee only. Men, as compared to women, were less likely to have involvement of the hand only, but were more likely to have involvement of the LS spine only. Conclusion. There are differences in the phenotypes of multiple-joint symptomatic OA involvement by race and by sex that may influence the definitions of multiple-joint, or generalized, OA. C1 [Nelson, Amanda E.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA. [Kraus, Virginia B.] Duke Univ, Med Ctr, Durham, NC USA. [Helmick, Charles G.] CDC, Atlanta, GA 30333 USA. RP Nelson, AE (reprint author), Univ N Carolina, Thurston Arthrit Res Ctr, 3300 Doc J Thurston Bldg,CB 7280, Chapel Hill, NC 27599 USA. EM aenelson@med.unc.edu RI Schwartz, Todd/D-4995-2012 OI Schwartz, Todd/0000-0002-0232-2543 FU Rheumatology Research Foundation of the American College of Rheumatology; NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases) [K23-AR-061406, P60-AR-30701, P01-AR-050245]; Arthritis Foundation; CDC/Association of Schools of Public Health [S043, S3486]; NIH (National Institute on Aging) [5-P30-AG028716] FX Dr. Nelson's work was supported in part by a 2009 Clinical Investigator Fellowship Award from the Rheumatology Research Foundation of the American College of Rheumatology and by the NIH (grant K23-AR-061406 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases). Dr. Golightly is recipient of an Arthritis Foundation Postdoctoral Fellowship Award. Drs. Renner and Jordan's work was supported by grants from the CDC/Association of Schools of Public Health (grants S043 and S3486). Drs. Renner, Schwartz, and Jordan's work was supported by the NIH (grant P60-AR-30701 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases). Dr. Kraus' work was supported by the NIH (Claude D. Pepper grant 5-P30-AG028716 from the National Institute on Aging and grant P01-AR-050245 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases). NR 17 TC 7 Z9 7 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD FEB PY 2013 VL 65 IS 2 BP 373 EP 377 DI 10.1002/art.37775 PG 5 WC Rheumatology SC Rheumatology GA 079KQ UT WOS:000314169400012 PM 23359309 ER PT J AU Dunne, EF Klein, NP Naleway, AL Baxter, R Weinmann, S Riedlinger, K Fetterman, B Steinau, M Scarbrough, MZ Gee, J Markowitz, LE Unger, ER AF Dunne, Eileen F. Klein, Nicola P. Naleway, Allison L. Baxter, Roger Weinmann, Sheila Riedlinger, Karen Fetterman, Barbara Steinau, Martin Scarbrough, Mariela Z. Gee, Julianne Markowitz, Lauri E. Unger, Elizabeth R. TI Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact SO CANCER CAUSES & CONTROL LA English DT Article DE HPV; HPV vaccine; Vaccine impact; Surveillance; Cervical cytology ID NUTRITION EXAMINATION SURVEY; HUMAN-PAPILLOMAVIRUS; UNITED-STATES; QUADRIVALENT VACCINE; NATIONAL-HEALTH; FEMALES; RECOMMENDATIONS; CLASSIFICATION; INFECTION; CANCER AB Two human papillomavirus (HPV) vaccines are available to prevent cervical cancer. One early measure of HPV vaccine impact would be a reduction in vaccine-related HPV types (HPV 6, 11, 16, or 18, or HPV 16, 18) in cervical samples from young women. We aimed to assess feasibility of specimen collection and baseline HPV prevalence in an integrated healthcare delivery system. Residual cervical specimens collected during routine cervical cancer screening (2006-2008) were retained consecutively from eligible females aged 11-29 years, stratified by age group. Specimens were evaluated for 37 HPV genotypes using the Roche Linear Array assay. Of 10,124 specimens submitted, 10,103 (99 %) were adequate for HPV testing. Prevalence of HPV 6, 11, 16, or 18 genotype was 11.4 % overall and was the highest in the youngest age group (18.1 % in the 11-19-year-olds, 12.5 % in the 20-24-year-olds, and 7.0 % in the 25-29-year-olds). HPV types 6, 11, 16, or 18 prevalence could be measured over time to assess early HPV vaccine impact using residual specimens from an integrated healthcare delivery system, particularly if sampling focused on young women. C1 [Dunne, Eileen F.; Markowitz, Lauri E.] Ctr Dis Control & Prevent CDC, Div STD Prevent, Atlanta, GA 30333 USA. [Klein, Nicola P.; Baxter, Roger; Fetterman, Barbara] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA. [Naleway, Allison L.; Weinmann, Sheila; Riedlinger, Karen] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA. [Steinau, Martin; Scarbrough, Mariela Z.; Unger, Elizabeth R.] CDC, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Gee, Julianne] CDC, Immunizat Safety Off, Atlanta, GA 30333 USA. RP Dunne, EF (reprint author), Ctr Dis Control & Prevent CDC, Div STD Prevent, 1600 Clifton Rd,MS E-02, Atlanta, GA 30333 USA. EM dde9@cdc.gov OI Naleway, Allison/0000-0001-5747-4643; Unger, Elizabeth/0000-0002-2925-5635 FU CDC through America's Health Insurance Plans (AHIP) [200-2002-00732]; Merck; GSK FX The authors would like to acknowledge the important contributions of Charlie Chao and Kristine Bennett for assistance with identifying and shipping specimens, and Jim Braxton and Suzanne Powell for assistance with the database and analysis. This study was funded by CDC through America's Health Insurance Plans (AHIP) contract number: 200-2002-00732.; All CDC authors and K Reidlinger have no conflicts of interest. R Baxter and NP Klein have received research grants from Merck and GSK. A Naleway and S Weinmann have received research grants from GSK. NR 16 TC 2 Z9 3 U1 0 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD FEB PY 2013 VL 24 IS 2 BP 403 EP 407 DI 10.1007/s10552-012-0085-9 PG 5 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 077XY UT WOS:000314063900022 PM 23292130 ER PT J AU Kersh, GJ Fitzpatrick, KA Self, JS Biggerstaff, BJ Massung, RF AF Kersh, Gilbert J. Fitzpatrick, Kelly A. Self, Joshua S. Biggerstaff, Brad J. Massung, Robert F. TI Long-Term Immune Responses to Coxiella burnetii after Vaccination SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID Q-FEVER; UNITED-STATES; INFECTION; SEROPREVALENCE; ANTIGENS; ASSAY; MICE AB Q fever is a zoonotic disease caused by infection with the bacterium Coxiella burnetii. Infection with C. burnetii results in humoral and cellular immune responses, both of which are thought to contribute to protection against subsequent infection. Whole-cell formalin-inactivated vaccines have also been shown to induce both humoral and cellular immunity and provide protection. Whether measurement of cellular or humoral immunity is a better indicator of immune protection is not known, and the duration of immunity induced by natural infection or vaccination is also poorly understood. To better understand the measurement and duration of C. burnetii immunity, 16 people vaccinated against Q fever (0.2 to 10.3 years before analysis) and 29 controls with a low risk of Q fever exposure were tested for immune responses to C. burnetii by an indirect fluorescent-antibody test (IFA) to measure circulating antibody and by a gamma interferon release assay (IGRA) to measure cellular immunity. Among vaccinated subjects, the IFA detected antibodies in 13/16, and the IGRA also detected positive responses in 13/16. All of the vaccinated subjects had a positive response in at least one of the assays, whereas 8/29 control subjects were positive in at least one assay. There was not a correlation between time since vaccination and responses in these assays. These results show that IFA and IGRA perform similarly in detection of C. burnetii immune responses and that Q fever vaccination establishes long-lived immune responses to C. burnetii. C1 [Kersh, Gilbert J.; Fitzpatrick, Kelly A.; Self, Joshua S.; Massung, Robert F.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA 30333 USA. [Biggerstaff, Brad J.] Ctr Dis Control & Prevent, Off Director, Div Vector Borne Dis, Ft Collins, CO USA. RP Kersh, GJ (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA 30333 USA. EM gkersh@cdc.gov NR 23 TC 5 Z9 5 U1 1 U2 13 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD FEB PY 2013 VL 20 IS 2 BP 129 EP 133 DI 10.1128/CVI.00613-12 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 079JI UT WOS:000314166000001 PM 23192629 ER PT J AU Polack, FP Lydy, SL Lee, SH Rota, PA Bellini, WJ Adams, RJ Robinson, HL Griffin, DE AF Polack, Fernando P. Lydy, Shari L. Lee, Sok-Hyong Rota, Paul A. Bellini, William J. Adams, Robert J. Robinson, Harriet L. Griffin, Diane E. TI Poor Immune Responses of Newborn Rhesus Macaques to Measles Virus DNA Vaccines Expressing the Hemagglutinin and Fusion Glycoproteins SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID NEUTRALIZING ANTIBODY; MATERNAL ANTIBODY; ATYPICAL MEASLES; HUMORAL-IMMUNE; T-LYMPHOCYTES; IFN-GAMMA; VACCINATION; INFECTION; INFANTS; PROTECTION AB A vaccine that would protect young infants against measles could facilitate elimination efforts and decrease morbidity and mortality in developing countries. However, immaturity of the immune system is an important obstacle to the development of such a vaccine. In this study, DNA vaccines expressing the measles virus (MeV) hemagglutinin (H) protein or H and fusion (F) proteins, previously shown to protect juvenile macaques, were used to immunize groups of 4 newborn rhesus macaques. Monkeys were inoculated intradermally with 200 mu g of each DNA at birth and at 10 months of age. As controls, 2 newborn macaques were similarly vaccinated with DNA encoding the influenza virus H5, and 4 received one dose of the current live attenuated MeV vaccine (LAV) intramuscularly. All monkeys were monitored for development of MeV-specific neutralizing and binding IgG antibody and cytotoxic T lymphocyte (CTL) responses. These responses were poor compared to the responses induced by LAV. At 18 months of age, all monkeys were challenged intratracheally with a wild-type strain of MeV. Monkeys that received the DNA vaccine encoding H and F, but not H alone, were primed for an MeV-specific CD8(+) CTL response but not for production of antibody. LAV-vaccinated monkeys were protected from rash and viremia, while DNA-vaccinated monkeys developed rashes, similar to control monkeys, but had 10-fold lower levels of viremia. We conclude that vaccination of infant macaques with DNA encoding MeV H and F provided only partial protection from MeV infection. C1 [Polack, Fernando P.; Lee, Sok-Hyong; Griffin, Diane E.] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA. [Polack, Fernando P.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA. [Adams, Robert J.] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD USA. [Lydy, Shari L.; Robinson, Harriet L.] Emory Univ, Dept Mol Microbiol & Immunol, Atlanta, GA 30322 USA. [Rota, Paul A.; Bellini, William J.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Griffin, DE (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA. EM dgriffin@jhsph.edu FU Bill and Melinda Gates Foundation; National Institutes of Health [R01 AI35149]; Centers for Disease Control and Prevention [PA99066] FX This research was supported by research grants from The Bill and Melinda Gates Foundation, the National Institutes of Health (R01 AI35149), and the Centers for Disease Control and Prevention (PA99066). NR 49 TC 6 Z9 6 U1 1 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD FEB PY 2013 VL 20 IS 2 BP 205 EP 210 DI 10.1128/CVI.00394-12 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 079JI UT WOS:000314166000011 PM 23239799 ER PT J AU Nygren, BL Schilling, KA Blanton, EM Silk, BJ Cole, DJ Mintz, ED AF Nygren, B. L. Schilling, K. A. Blanton, E. M. Silk, B. J. Cole, D. J. Mintz, E. D. TI Foodborne outbreaks of shigellosis in the USA, 1998-2008 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Food safety; foodborne infections; outbreaks; Shigella; surveillance ID UNITED-STATES; SONNEI; ILLNESS; FOOD; TRANSMISSION; INFECTION; EPIDEMIOLOGY; SURVEILLANCE; SURVIVAL; FLEXNERI AB We examined reported outbreaks of foodborne shigellosis in the USA from 1998 to 2008 and summarized demographic and epidemiological characteristics of 120 confirmed outbreaks resulting in 6208 illnesses. Most reported foodborne shigellosis outbreaks (n=70, 58 %) and outbreak-associated illnesses (n=3383, 54%) were restaurant-associated. The largest outbreaks were associated with commercially prepared foods distributed in multiple states and foods prepared in institutional settings. Foods commonly consumed raw were implicated in 29 (24 %) outbreaks and infected food handlers in 28 (23 %) outbreaks. Most outbreaks (n=86, 72%) were caused by Shigella sonnei. Targeted efforts to reduce contamination during food handling at multiple points in the food processing and distribution system, including food preparation in restaurants and institutional settings, could prevent many foodborne disease outbreaks and outbreak-related illnesses including those due to Shigella. C1 [Nygren, B. L.] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Nygren, BL (reprint author), Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,MS-A38, Atlanta, GA 30333 USA. EM ghz8@cdc.gov FU Intramural CDC HHS [CC999999] NR 32 TC 9 Z9 10 U1 0 U2 11 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD FEB PY 2013 VL 141 IS 2 BP 233 EP 241 DI 10.1017/S0950268812000222 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 077FN UT WOS:000314013400002 PM 22361246 ER PT J AU Majeed, B Sobel, J Nawar, A Badri, S Muslim, H AF Majeed, B. Sobel, J. Nawar, A. Badri, S. Muslim, H. TI The persisting burden of visceral leishmaniasis in Iraq: data of the National Surveillance System, 1990-2009 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Epidemiology; Iraq; surveillance; visceral leishmaniasis ID TALLIL-AIR-BASE; PHLEBOTOMINE SAND FLIES; US MILITARY OPERATIONS; CONTROL PROGRAM; IMPACT AB Visceral leishmaniasis (VL) is an endemic parasitic disease transmitted by the bite of sand flies. To describe trends and demographics of reported VL cases, we reviewed surveillance data from 1990-2009. Reported VL incidence per 100 000 population was 2.6 in 2007, 3.1 in 2008, and 4.8 in 2009, mostly in children aged <5 years. The number of cases varied greatly in step with prevailing economic and security conditions, raising concerns about the completeness and quality of surveillance data. Nevertheless, we conclude that VL remains an important endemic disease in Iraq and that surveillance system is recovering the capacity to detect cases as the country experiences greater stability. We recommend conducting formal entomological investigations, and evaluating existing control measures. C1 [Majeed, B.; Sobel, J.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30333 USA. [Nawar, A.; Badri, S.; Muslim, H.] Communicable Dis Control Ctr, Minist Hlth, Bagneux, France. RP Majeed, B (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM bancomm2000@yahoo.com FU Centers for Disease Control and Prevention (CDC) through TEPHINET; Task Force for Global Health, Inc. FX This publication was supported by a grant from the Centers for Disease Control and Prevention (CDC) through TEPHINET, a programme of the Task Force for Global Health, Inc. Its contents are solely the responsibility of the authors and do not represent the views of the Task Force for Global Health, Inc. TEPHINET or the CDC. NR 8 TC 3 Z9 3 U1 0 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD FEB PY 2013 VL 141 IS 2 BP 443 EP 446 DI 10.1017/S0950268812000556 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 077FN UT WOS:000314013400027 PM 22475358 ER PT J AU Cooper, CP Polonec, L Stewart, SL Gelb, CA AF Cooper, Crystale Purvis Polonec, Lindsey Stewart, Sherri L. Gelb, Cynthia A. TI Gynaecologic cancer symptom awareness, concern and care seeking among US women: a multi-site qualitative study SO FAMILY PRACTICE LA English DT Article DE Neoplasms; women's health; early detection of cancer; qualitative research; focus groups ID OVARIAN-CANCER; CERVICAL-CANCER; KNOWLEDGE AB With limited screening options, early detection of gynaecologic cancers can depend on women recognizing the potential significance of symptoms and seeking care. We investigated women's concern about symptoms that might be related to gynaecologic cancers, the underlying conditions they associated with symptoms and their actual and hypothetical response to symptoms. Fifteen focus groups with women aged 4060 years were conducted in Chicago, Los Angeles, Miami and New York City. Participants were given an untitled list of symptoms that could indicate various gynaecologic cancers and asked if any would concern them, what could cause each and what they would do if they experienced any of them. Overall, participants expressed greater concern about symptoms clearly gynaecologic in nature than other symptoms. Participants generally did not associate symptoms with any form of cancer. Some women who had experienced symptoms reported waiting an extended period before seeking care or not seeking care at all. The belief that a symptom indicated a benign condition was the most common reason given for delaying or foregoing care seeking. Strategies participants reported using to supplement or replace consultations with health care providers included Internet research and self-care. Raising awareness of symptoms that can indicate gynaecologic cancers may lead to earlier detection and improved survival. In particular, women should be informed that gynaecologic cancers can cause symptoms that may not seem related to the reproductive organs (e.g. back pain) and that unusual vaginal bleeding should prompt them to seek care immediately. C1 [Polonec, Lindsey; Stewart, Sherri L.; Gelb, Cynthia A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Cooper, Crystale Purvis] Soltera Ctr Canc Prevent & Control, Tucson, AZ USA. RP Gelb, CA (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS K-64, Atlanta, GA 30341 USA. EM cgelb@cdc.gov FU Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention FX Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. NR 20 TC 6 Z9 6 U1 2 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0263-2136 J9 FAM PRACT JI Fam. Pr. PD FEB PY 2013 VL 30 IS 1 BP 96 EP 104 DI 10.1093/fampra/cms040 PG 9 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 079DL UT WOS:000314150300013 PM 22948336 ER PT J AU Farrelly, M Mann, N Watson, K Pechacek, T AF Farrelly, Matthew Mann, Nathan Watson, Kimberly Pechacek, Terry TI The influence of television advertisements on promoting calls to telephone quitlines SO HEALTH EDUCATION RESEARCH LA English DT Article ID SMOKING-CESSATION; MEDIA CAMPAIGN; PROGRAM; PLACEMENT; SERVICE AB The aim of the study was to assess the relative effectiveness of cessation, secondhand smoke and other tobacco control television advertisements in promoting quitlines in nine states from 2002 through 2005. Quarterly, the number of individuals who used quitlines per 10 000 adult smokers in a media market are measured. Negative binomial regression analysis was used to link caller rates to market-level exposure to tobacco control television advertisements overall and by message theme. The relationship between caller rates and advertising exposure was positive and statistically significant (P < 0.001). Advertisements that focus on promoting cessation (P < 0.001), highlighting the dangers of secondhand smoke (P = 0.037), and all other tobacco countermarketing advertisements (P = 0.027) were significantly associated with quitline caller rates. For every 10% increase in exposure to cessation, secondhand smoke and other tobacco countermarketing advertisements, caller rates increased by 1.1, 0.2 and 0.4%, respectively. Caller rates significantly increased in quarters when cigarette excise tax increased (P < 0.001) and when the percentage of the population covered by comprehensive smoke-free air laws increased (P = 0.022). Although advertisements promoting cessation are the most effective in driving quitline use, other topics, such as messages highlighting the dangers of secondhand smoke, also prompt their quitlines. C1 [Farrelly, Matthew; Mann, Nathan; Watson, Kimberly] RTI Int, Res Triangle Pk, NC USA. [Pechacek, Terry] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30333 USA. RP Pechacek, T (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30333 USA. EM TPechacek@cdc.gov NR 27 TC 9 Z9 9 U1 0 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1153 J9 HEALTH EDUC RES JI Health Educ. Res. PD FEB PY 2013 VL 28 IS 1 BP 15 EP 22 DI 10.1093/her/cys113 PG 8 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA 079EF UT WOS:000314152400002 PM 23221593 ER PT J AU Sibanda, T Tedla, Z Nyirenda, S Agizew, T Marape, M Miranda, AG Reuter, H Johnson, JL Samandari, T AF Sibanda, T. Tedla, Z. Nyirenda, S. Agizew, T. Marape, M. Miranda, A. G. Reuter, H. Johnson, J. L. Samandari, T. TI Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; HIV infection; antiretroviral therapy; tuberculosis drug resistance; cohort study ID RANDOMIZED CONTROLLED-TRIAL; ANTIRETROVIRAL THERAPY; PULMONARY TUBERCULOSIS; RESISTANT TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; DISEASE; ZAMBIA AB SETTING: Eight public health clinics in Gaborone and Francistown, Botswana. OBJECTIVES: To describe the characteristics and outcomes of incident tuberculosis (TB) cases in human immunodeficiency virus (HIV) infected adults exposed to isoniazid preventive therapy (IPT) with access to antiretroviral and anti-tuberculosis treatment. DESIGN: In 1995 HIV-infected adults, TB disease was excluded before commencing IPT. During and after receipt of 6 or 36 months of IPT, symptomatic participants were evaluated using chest radiographs, sputum microscopy, cultures and drug susceptibility testing (DST). Incident TB cases received >= 6 months of anti-tuberculosis treatment. RESULTS: Seventy-five incident TB cases were identified among 619 symptomatic participants. The median duration of IPT in these cases was 6 months (range 1-35), and the median time to initiation of anti-tuberculosis treatment was 12 months after IPT cessation. Antiretroviral therapy (ART) was initiated before anti-tuberculosis treatment in 37 cases. Culture was positive in 43/58 (74%) TB cultures. DST was available for 38 cases, of which six (16%) were resistant to isoniazid (INH); 67/75 (89%) cases, including four with INH-monoresistant TB, completed anti-tuberculosis treatment or were cured. CONCLUSIONS: With prompt initiation of anti-tuberculosis treatment and access to ART, excellent outcomes were achieved in a public health setting in HIV-infected adults who developed TB disease. C1 [Sibanda, T.; Tedla, Z.; Nyirenda, S.; Agizew, T.; Samandari, T.] Ctr Dis Control & Prevent CDC Botswana, Gaborone, Botswana. [Sibanda, T.; Tedla, Z.; Nyirenda, S.; Agizew, T.; Samandari, T.] Ctr Dis Control & Prevent CDC Botswana, Francistown, Botswana. [Marape, M.] Botswana Baylor Childrens Clin Ctr Excellence, Gaborone, Botswana. [Miranda, A. G.] CDC, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Reuter, H.] Univ Stellenbosch, Cape Town, South Africa. [Johnson, J. L.] Univ Hosp, Case Med Ctr, Cleveland, OH USA. [Samandari, T.] CDC, Div TB Eliminat, Atlanta, GA 30333 USA. RP Samandari, T (reprint author), CDC, Div TB Eliminat, 1600 Clifton Rd NE,Mailstop E 45, Atlanta, GA 30333 USA. EM tts0@cdc.gov NR 34 TC 2 Z9 3 U1 0 U2 6 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD FEB PY 2013 VL 17 IS 2 BP 178 EP 185 DI 10.5588/ijtld.12.0314 PG 8 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 081MW UT WOS:000314327300009 PM 23317952 ER PT J AU Auld, SC Kim, L Webb, EK Podewils, LJ Uys, M AF Auld, S. C. Kim, L. Webb, E. K. Podewils, L. J. Uys, M. TI Completeness and concordance of TB and HIV surveillance systems for TB-HIV co-infected patients in South Africa SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE integration; electronic register; health information systems ID HEALTH SYSTEMS; TUBERCULOSIS SURVEILLANCE; INFORMATION AB SETTING: South Africa currently maintains separate surveillance systems for tuberculosis (TB) and human immunodeficiency virus (HIV). There are future plans for integration of these systems; however, the consistency of information across the existing systems has not previously been assessed. OBJECTIVE: To determine the completeness and concordance of data in the TB and HIV surveillance systems for TB-HIV co-infected patients. DESIGN: In a retrospective cohort evaluation of the records of TB-HIV co-infected patients in the Eden District of the Western Cape, data were abstracted from paper-based and electronic TB and HIV surveillance sources. Concordance was measured using Fleiss' kappa coefficient. RESULTS: Demographic variables had high completeness and concordance across the TB and HIV systems. Completeness and concordance for clinical variables was somewhat lower, particularly for TB variables in the HIV systems and HIV variables in the TB systems. CONCLUSION: Varying levels of completeness and concordance of surveillance data for TB-HIV co-infected patients highlight challenges in the current TB and HIV surveillance systems. Future integration of TB and HIV programs in this region will need to support more accurate data collection at all levels. C1 [Auld, S. C.; Kim, L.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Auld, S. C.; Kim, L.; Podewils, L. J.] CDC, Div TB Eliminat, Atlanta, GA 30333 USA. [Uys, M.] TB HIVAIDS Treatment Support & Integrated Therapy, Johannesburg, South Africa. RP Auld, SC (reprint author), CDC, Div TB Elimination Int Res & Programs Branch, 1600 Clifton Rd,MS E-10, Atlanta, GA 30333 USA. EM via1@cdc.gov FU US Centers for Disease Control and Prevention FX This project was supported by the US Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 18 TC 5 Z9 5 U1 0 U2 5 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD FEB PY 2013 VL 17 IS 2 BP 186 EP 191 DI 10.5588/ijtld.12.0530 PG 6 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 081MW UT WOS:000314327300010 PM 23317953 ER PT J AU Bradley, H Markowitz, LE AF Bradley, Heather Markowitz, Lauri E. TI SEROPREVALENCE OF HERPES SIMPLEX VIRUS TYPE 1 AMONG ADOLESCENTS IN THE UNITED STATES, 1999-2004 AND 2005-2010 SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Bradley, Heather] CDC, NCHHSTP, Div STD Prevent, Atlanta, GA 30333 USA. [Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S64 EP S64 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000129 ER PT J AU Castellanos, TJ Gaul, Z Willis, L Sutton, M Sneed, C AF Castellanos, Ted J. Gaul, Zaneta Willis, Leigh Sutton, Madeline Sneed, Carl TI "I TRY TO TALK TO MY CHILDREN": SEXUAL HEALTH DISCUSSIONS AND USING NATURAL SETTINGS TO INITIATE CONVERSATIONS ABOUT SEX BETWEEN AFRICAN AMERICAN AND LATINA MOTHERS AND THEIR CHILDREN SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Castellanos, Ted J.; Gaul, Zaneta; Willis, Leigh; Sutton, Madeline] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sneed, Carl] Calif State Univ Dominguez Hills, Carson, CA 90747 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S63 EP S63 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000127 ER PT J AU Dittus, P Jeffries, R De Rosa, C Loosier, P Ethier, K AF Dittus, Patricia Jeffries, Robin De Rosa, Christine Loosier, Penny Ethier, Kathleen TI SEXUAL BEHAVIOR AND RECEIPT OF SEXUAL AND REPRODUCTIVE HEALTHCARE AMONG SEXUALLY EXPERIENCED SEXUAL MINORITY YOUTH: THE ROLE OF PARENTING BEHAVIORS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Dittus, Patricia; Loosier, Penny; Ethier, Kathleen] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jeffries, Robin; De Rosa, Christine] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S13 EP S14 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000027 ER PT J AU Dittus, P Michael, S Becasen, J Gloppen, K Guilamo-Ramos, V AF Dittus, Patricia Michael, Shannon Becasen, Jeffrey Gloppen, Kari Guilamo-Ramos, Vincent TI PROTECTIVE EFFECTS OF PARENTAL MONITORING KNOWLEDGE AND ENFORCEMENT OF RULES ON ADOLESCENT SEXUAL BEHAVIOR: A META-ANALYSIS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Dittus, Patricia; Michael, Shannon; Becasen, Jeffrey] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gloppen, Kari] Univ Washington, Seattle, WA 98195 USA. [Guilamo-Ramos, Vincent] NYU, New York, NY 10003 USA. NR 0 TC 2 Z9 2 U1 1 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S14 EP S14 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000028 ER PT J AU Haderxhanaj, L Dittus, P Loosier, P Rhodes, S Bloom, F Leichliter, J AF Haderxhanaj, Laura Dittus, Patricia Loosier, Penny Rhodes, Scott Bloom, Fred Leichliter, Jami TI ACCULTURATION, SEXUAL BEHAVIORS AND HEALTH CARE ACCESS AMONG A NATIONAL SAMPLE OF HISPANIC AND NON-HISPANIC WHITE ADOLESCENTS AND YOUNG ADULTS, 2006-2010 SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Haderxhanaj, Laura; Dittus, Patricia; Loosier, Penny; Bloom, Fred; Leichliter, Jami] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Rhodes, Scott] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC 27109 USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S62 EP S62 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000125 ER PT J AU Hatfield-Timajchy, K Gaydos, LMD Blake, SC Kraft, JM Murray, CC Kottke, M Whiteman, MK DiClemente, R AF Hatfield-Timajchy, Kendra Gaydos, Laura M. D. Blake, Sarah C. Kraft, Joan Marie Murray, Colleen Crittenden Kottke, Melissa Whiteman, Maura K. DiClemente, Ralph TI PROVIDER PERSPECTIVES ON COUNSELING AND PROVIDER-CLIENT RELATIONSHIPS WITH YOUNG WOMEN SEEKING FAMILY PLANNING SERVICES SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Hatfield-Timajchy, Kendra; Kraft, Joan Marie; Whiteman, Maura K.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Kottke, Melissa] Emory Univ, Sch Med, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S58 EP S59 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000118 ER PT J AU Kachur, R McFarlane, M Habel, M Friedman, A Ford, J Kinsey, J Hogben, M AF Kachur, Rachel McFarlane, Mary Habel, Melissa Friedman, Allison Ford, Jessie Kinsey, Jennine Hogben, Matthew TI STD INFORMATION SEEKING, COMMUNICATION AND TESTING AMONG AMERICAN YOUTH: EXPLORING EXPOSURE TO THE NATIONAL GET YOURSELF TESTED (GYT) CAMPAIGN SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Kachur, Rachel; McFarlane, Mary; Habel, Melissa; Friedman, Allison; Ford, Jessie; Kinsey, Jennine; Hogben, Matthew] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 3 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S7 EP S7 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000014 ER PT J AU Kavanaugh, M Frohwirth, L Jerman, J Popkin, R Ethier, K AF Kavanaugh, Megan Frohwirth, Lori Jerman, Jenna Popkin, Ronna Ethier, Kathleen TI LONG-ACTING REVERSIBLE CONTRACEPTION FOR ADOLESCENTS AND YOUNG ADULTS: SERVICE AVAILABILITY, PROVIDER ATTITUDES AND PATIENT PERSPECTIVES SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Popkin, Ronna] Columbia Univ, New York, NY 10027 USA. [Ethier, Kathleen] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S88 EP S89 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000182 ER PT J AU Kottke, M Whiteman, M Kraft, J Goedken, P Murray, CC Snead, MC DiClemente, R AF Kottke, Melissa Whiteman, Maura Kraft, Joan Goedken, Peggy Murray, Colleen Crittenden Snead, M. Christine DiClemente, Ralph TI NEGATIVE PARTNER RESPONSES TO COMMUNICATION ABOUT REPRODUCTIVE HEALTH IN ADOLESCENT RELATIONSHIPS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Kottke, Melissa] Emory Univ, Jane Fonda Ctr, Atlanta, GA 30322 USA. [Whiteman, Maura; Kraft, Joan; Snead, M. Christine] Ctr Dis Control & Prevent, Atlanta, GA USA. [Murray, Colleen Crittenden; DiClemente, Ralph] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S51 EP S52 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000104 ER PT J AU Liddon, N AF Liddon, Nicole TI WITHDRAWAL AS PREGNANCY PREVENTION AND ASSOCIATIONS WITH SEXUAL AND HEALTH RISK BEHAVIORS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Liddon, Nicole] CDC, Div Adolescent & Sch Hlth, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S63 EP S64 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000128 ER PT J AU Morales-Aleman, MM Opoku, J Lanier, Y West-Ojo, T Pappas, G Sutton, MY AF Morales-Aleman, Mercedes M. Opoku, Jenevieve Lanier, Yzette West-Ojo, Tiffany Pappas, Gregory Sutton, Madeline Y. TI CORRELATES OF HIV DISEASE PROGRESSION AMONG YOUNG BLACK/AFRICAN AMERICAN AND HISPANIC/LATINO MEN WHO HAVE SEX WITH MEN IN THE DISTRICT OF COLUMBIA, 2005-2009 SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Morales-Aleman, Mercedes M.; Lanier, Yzette; Sutton, Madeline Y.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Opoku, Jenevieve; West-Ojo, Tiffany; Pappas, Gregory] Dept Hlth, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S62 EP S63 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000126 ER PT J AU Morris, E Rasberry, C Lesane, C Carver, L Stallworth, L Xu, L AF Morris, Elana Rasberry, Catherine Lesane, Catherine Carver, Lisa Stallworth, LaSamuel Xu, Le TI WHAT DO BLACK AND LATINO TEEN MEN WHO HAVE SEX WITH MEN HAVE TO SAY ABOUT HIV PREVENTION SERVICES IN THEIR SCHOOLS AND COMMUNITY? SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Morris, Elana; Rasberry, Catherine] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S58 EP S58 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000117 ER PT J AU Romero, L Fuller, T Spitz, A AF Romero, Lisa Fuller, Taleria Spitz, Alison TI CDC'S INTEGRATING SERVICES, PROGRAMS, AND STRATEGIES THROUGH A COMMUNITY-WIDE INITIATIVE: INCREASING ACCESS TO REPRODUCTIVE HEALTH CARE SERVICES AND USE OF CONTRACEPTION AMONG YOUTH OF COLOR SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Romero, Lisa; Fuller, Taleria; Spitz, Alison] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S59 EP S59 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000119 ER PT J AU Sutton, M Lasswell, S Lanier, Y Willis, L Miller, K AF Sutton, Madeline Lasswell, Sarah Lanier, Yzette Willis, Leigh Miller, Kim TI IMPACT OF PARENT-CHILD COMMUNICATION INTERVENTIONS ON SEXUAL BEHAVIORS AND SEX-RELATED COGNITIVE OUTCOMES OF BLACK/AFRICAN AMERICAN AND HISPANIC/LATINO YOUTH: IMPLICATIONS FOR HIV/STI DISPARITIES AND PREVENTION EFFORTS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Sutton, Madeline; Lasswell, Sarah; Lanier, Yzette; Willis, Leigh; Miller, Kim] CDC, Atlanta, GA 30333 USA. NR 0 TC 1 Z9 1 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S56 EP S57 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000114 ER PT J AU Whiteman, M Kottke, M Kraft, J Murray, CC Snead, MC Goedken, P DiClemente, R AF Whiteman, Maura Kottke, Melissa Kraft, Joan Murray, Colleen Crittenden Snead, M. Christine Goedken, Peggy DiClemente, Ralph TI PERCEIVED INFERTILITY AMONG ADOLESCENTS: CORRELATES AND CONSEQUENCES SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Whiteman, Maura; Kraft, Joan; Snead, M. Christine] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kottke, Melissa; Goedken, Peggy] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Murray, Colleen Crittenden; DiClemente, Ralph] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2013 VL 52 IS 2 SU 1 BP S57 EP S58 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 078MV UT WOS:000314104000116 ER PT J AU Selvaraju, SB Nix, WA Oberste, MS Selvarangan, R AF Selvaraju, Suresh B. Nix, W. Allan Oberste, M. Steven Selvarangan, Rangaraj TI Optimization of a Combined Human Parechovirus-Enterovirus Real-Time Reverse Transcription-PCR Assay and Evaluation of a New Parechovirus 3-Specific Assay for Cerebrospinal Fluid Specimen Testing SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID POLYMERASE-CHAIN-REACTION; CLINICAL-SAMPLES; RAPID DETECTION; INFECTIONS; MENINGITIS; PATHOGENS; DIAGNOSIS; CHILDREN; VIRUS; RNA AB Human parechoviruses (HPeVs), particularly type 3 (HPeV3), are known central nervous system (CNS) pathogens, causing serious infections in infants similar to those caused by enteroviruses (EVs). The primary aim of this study was to combine and validate HPeV and EV real-time reverse transcription-PCR (RT-PCR) detection assays with the best available RT-PCR reagents and conditions for parallel detection of HPeV and EV on a single platform. The secondary aim was to develop and validate a newly developed HPeV3-specific real-time RT-PCR assay. Five commercially available RT-PCR kits were evaluated with the pan-HPeV and EV assays in one-step and two-step RT-PCRs. Two-step RT-PCR with the AgPath ID RT-PCR (AGP) kit performed best for both pan-HPeV and EV assays. The pan-HPeV-specific assay performed best with the AGP kit in a one-step RT-PCR. Frozen ali-quots of 145 (for HPeV, n = 70; for EV, n = 75) previously characterized cerebrospinal fluid (CSF) specimens were tested by EV-, pan-HPeV-, and HPeV3-specific (HPeV specimens only) assays. The pan-HPeV and EV assays demonstrated 100% analytical sensitivity and specificity compared to historic results, while the HPeV3-specific assay demonstrated 97% sensitivity and 100% specificity. We propose a real-time pan-HPeV, EV two-step RT-PCR algorithm for simultaneous detection of HPeV and EV from CSF specimens on a single platform. The HPeV3-specific one-step RT-PCR assay can be used as a rapid and cost-effective assay to detect and identify HPeV3 in pan-HPeV RT-PCR assay-positive CSF specimens. C1 [Selvaraju, Suresh B.; Selvarangan, Rangaraj] Childrens Mercy Hosp & Clin, Dept Pathol & Lab Med, Kansas City, MO USA. [Selvaraju, Suresh B.; Selvarangan, Rangaraj] Univ Missouri, Sch Med, Kansas City, MO 64108 USA. [Nix, W. Allan; Oberste, M. Steven] Ctr Dis Control & Prevent, Polio & Picornavirus Lab Branch, Atlanta, GA USA. RP Selvarangan, R (reprint author), Childrens Mercy Hosp & Clin, Dept Pathol & Lab Med, Kansas City, MO USA. EM rselvarangan@cmh.edu NR 26 TC 7 Z9 7 U1 1 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2013 VL 51 IS 2 BP 452 EP 458 DI 10.1128/JCM.01982-12 PG 7 WC Microbiology SC Microbiology GA 078OH UT WOS:000314108000011 PM 23175256 ER PT J AU Inzaule, S Yang, CF Kasembeli, A Nafisa, L Okonji, J Oyaro, B Lando, R Mills, LA Laserson, K Thomas, T Nkengasong, J Zeh, C AF Inzaule, Seth Yang, Chunfu Kasembeli, Alex Nafisa, Lillian Okonji, Jully Oyaro, Boaz Lando, Richard Mills, Lisa A. Laserson, Kayla Thomas, Timothy Nkengasong, John Zeh, Clement TI Field Evaluation of a Broadly Sensitive HIV-1 In-House Genotyping Assay for Use with both Plasma and Dried Blood Spot Specimens in a Resource-Limited Country SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID ANTIRETROVIRAL DRUG-RESISTANCE; SCALING-UP; HEALTH; SURVEILLANCE; INFECTION; SYSTEMS; AFRICA; RECOMMENDATIONS; SPECIFICITY; PREVENTION AB HIV-1 drug resistance (HIVDR) assays are important tools in clinical management of HIV-infected patients on antiretroviral therapy (ART) and surveillance of drug-resistant variants at population levels. The high cost associated with commercial assays hinders their use in resource-limited settings. We adopted and validated a low-cost in-house assay using 68 matched plasma and dried blood spot (DBS) samples with a median viral load (VL) of 58,187 copies/ml, ranging from 253 to 3,264,850 against the commercial assay ViroSeq. Results indicated that the in-house assay not only had a higher plasma genotyping rate than did ViroSeq (94% versus 78%) but also was able to genotype 89.5% (51/57) of the matched DBS samples with VLs of >= 1,000 copies/ml. The sensitivity in detecting DR mutations by the in-house assay was 98.29% (95% confidence interval [CI], 97.86 to 98.72) on plasma and 96.54 (95% CI, 95.93 to 97.15) on DBS, and the specificity was 99.97% (95% CI, 99.91 to 100.00) for both sample types compared to ViroSeq. The minor DR mutation differences detected by the in-house assay against ViroSeq did not result in clinical significance. In addition, cost analysis showed that the in-house assay could reduce the genotyping cost by about 60% for both plasma and DBS compared to ViroSeq. This field condition evaluation highlights the potential utility of a cost-effective, subtype-independent, in-house genotyping assay using both plasma and DBS specimens for HIVDR clinical monitoring and population-based surveillance in resource-limited settings. C1 [Inzaule, Seth; Kasembeli, Alex; Nafisa, Lillian; Okonji, Jully; Oyaro, Boaz; Lando, Richard] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Mills, Lisa A.; Laserson, Kayla; Thomas, Timothy; Zeh, Clement] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Kisumu, Kenya. [Yang, Chunfu; Nkengasong, John] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. RP Zeh, C (reprint author), US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Kisumu, Kenya. EM Czeh@ke.cdc.gov RI Yang, Chunfu/G-6890-2013 FU Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA; President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention FX We also thank GlaxoSmithKline and Boehringer Ingelheim for providing the study medications and the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, for funding. This research has also been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention. NR 50 TC 9 Z9 9 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2013 VL 51 IS 2 BP 529 EP 539 DI 10.1128/JCM.02347-12 PG 11 WC Microbiology SC Microbiology GA 078OH UT WOS:000314108000022 PM 23224100 ER PT J AU Wang, L Zhang, HW Zhao, XD Zhang, LX Zhang, GQ Guo, MJ Liu, LL Feng, YY Xiao, LH AF Wang, Lin Zhang, Hongwei Zhao, Xudong Zhang, Longxian Zhang, Guoqing Guo, Meijin Liu, Lili Feng, Yaoyu Xiao, Lihua TI Zoonotic Cryptosporidium Species and Enterocytozoon bieneusi Genotypes in HIV-Positive Patients on Antiretroviral Therapy SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTED PATIENTS; INTESTINAL MICROSPORIDIOSIS; PARASITIC INFECTIONS; HIV/AIDS PATIENTS; PLASMA DONORS; CHINA; PREVALENCE; STRAINS; DIARRHEA AB Molecular diagnostic tools have been used increasingly in the characterization of the transmission of cryptosporidiosis and microsporidiosis in developing countries. However, few studies have examined the distribution of Cryptosporidium species and Enterocytozoon bieneusi genotypes in AIDS patients receiving antiretroviral therapy. In the present study, 683 HIV-positive patients in the National Free Antiretroviral Therapy Program in China and 683 matched HIV-negative controls were enrolled. Cryptosporidium species and subtypes and Enterocytozoon bieneusi genotypes were detected and differentiated by PCR and DNA sequencing. The infection rates were 1.5% and 0.15% for Cryptosporidium and 5.7% and 4.2% for E. bieneusi in HIV-positive and HIV-negative participants, respectively. The majority (8/11) of Cryptosporidium cases were infections by zoonotic species, including Cryptosporidium meleagridis (5), Cryptosporidium parvum (2), and Cryptosporidium suis (1). Prevalent E. bieneusi genotypes detected, including EbpC (39), D (12), and type IV (7), were also potentially zoonotic. The common occurrence of EbpC was a feature of E. bieneusi transmission not seen in other areas. Contact with animals was a risk factor for both cryptosporidiosis and microsporidiosis. The results suggest that zoonotic transmission was significant in the epidemiology of both diseases in rural AIDS patients in China. C1 [Wang, Lin; Guo, Meijin; Liu, Lili; Feng, Yaoyu] E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Sch Resources & Environm Engn, Shanghai 200237, Peoples R China. [Zhang, Hongwei; Zhao, Xudong] Henan Ctr Dis Control & Prevent, Inst Parasite Dis Prevent & Control, Zhengzhou, Peoples R China. [Zhang, Longxian] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou, Peoples R China. [Zhang, Guoqing; Xiao, Lihua] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Feng, YY (reprint author), E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Sch Resources & Environm Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn RI Xiao, Lihua/B-1704-2013; Zhang, Guoqing/C-9523-2014; Feng, Yaoyu/B-3076-2014 OI Xiao, Lihua/0000-0001-8532-2727; FU National Natural Science Foundation of China [31110103901, 31229005, 41001316]; National Basic Research Program of China (973 Project) [2011CB200903]; Project of Medical Science and Technique of Henan, China [201003142]; Henan Health Science and Technology Innovation Talent Project; Fundamental Research Funds for the Central Universities, China; Open Funding Projects of the State Key Laboratory of Veterinary Etiological Biology at the Lanzhou Veterinary Research Institute; State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology FX This work was supported by the National Natural Science Foundation of China (grants 31110103901, 31229005, and 41001316); the National Basic Research Program of China (973 Project) (2011CB200903); Project of Medical Science and Technique of Henan, China (No. 201003142); Special Funding of the Henan Health Science and Technology Innovation Talent Project; Fundamental Research Funds for the Central Universities, China; and Open Funding Projects of the State Key Laboratory of Veterinary Etiological Biology at the Lanzhou Veterinary Research Institute and State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology. NR 52 TC 68 Z9 72 U1 0 U2 21 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2013 VL 51 IS 2 BP 557 EP 563 DI 10.1128/JCM.02758-12 PG 7 WC Microbiology SC Microbiology GA 078OH UT WOS:000314108000025 PM 23224097 ER PT J AU Westblade, LF Chamberland, RR MacCannell, D Collins, R Dubberke, ER Dunne, WM Burnham, CAD AF Westblade, Lars F. Chamberland, Robin R. MacCannell, Duncan Collins, Rachel Dubberke, Erik R. Dunne, W. Michael, Jr. Burnham, Carey-Ann D. TI Development and Evaluation of a Novel, Semiautomated Clostridium difficile Typing Platform SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID TANDEM-REPEAT ANALYSIS; FIELD GEL-ELECTROPHORESIS; PCR; INFECTION; DIVERSITY; STRAINS AB We describe a novel, semiautomated Clostridium difficile typing platform that is based on PCR-ribotyping in conjunction with a semiautomated molecular typing system. The platform is reproducible with minimal intra- or interassay variability. This method exhibited a discriminatory index of 0.954 and is therefore comparable to more arduous typing systems, such as pulsed-field gel electrophoresis. C1 [Westblade, Lars F.; Chamberland, Robin R.; Collins, Rachel; Dunne, W. Michael, Jr.; Burnham, Carey-Ann D.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63130 USA. [Dubberke, Erik R.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. [Burnham, Carey-Ann D.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA. [MacCannell, Duncan] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Burnham, CAD (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63130 USA. EM cburnham@path.wustl.edu OI Burnham, Carey-Ann/0000-0002-1137-840X FU DDRCC [P30 DK52574]; NIH [K23AI065806] FX Funding for this work was provided by DDRCC grant P30 DK52574 and NIH grant K23AI065806. NR 17 TC 12 Z9 12 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2013 VL 51 IS 2 BP 621 EP 624 DI 10.1128/JCM.02627-12 PG 4 WC Microbiology SC Microbiology GA 078OH UT WOS:000314108000039 PM 23175261 ER PT J AU Cruz-Rivera, M Carpio-Pedroza, JC Escobar-Gutierrez, A Lozano, D Vergara-Castaneda, A Rivera-Osorio, P Martinez-Guarneros, A Chacon, CAV Fonseca-Coronado, S Vaughan, G AF Cruz-Rivera, Mayra Carlos Carpio-Pedroza, Juan Escobar-Gutierrez, Alejandro Lozano, Daniela Vergara-Castaneda, Arely Rivera-Osorio, Pilar Martinez-Guarneros, Armando Vazquez Chacon, Carlos A. Fonseca-Coronado, Salvador Vaughan, Gilberto TI Rapid Hepatitis C Virus Divergence among Chronically Infected Individuals SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID EVOLUTION; THERAPY; HCV; POLYMORPHISM; POPULATION; TELAPREVIR; REGION; ASSAY AB Here, we analyze the viral divergence among hepatitis C virus (HCV) chronic cases infected with genotype 1. The intrahost viral evolution was assessed by deep sequencing using the 454 Genome Sequencer platform. The results showed a rapid nucleotide sequence divergence. This notorious short-term viral evolution is of the utmost importance for the study of HCV transmission, because direct links between related samples were virtually lost. Thus, rapid divergence of HCV significantly affects genetic relatedness studies and outbreak investigations. C1 [Cruz-Rivera, Mayra] Univ Nacl Autonoma Mexico, Fac Med, Mexico City 04510, DF, Mexico. [Carlos Carpio-Pedroza, Juan; Escobar-Gutierrez, Alejandro; Rivera-Osorio, Pilar; Martinez-Guarneros, Armando; Vazquez Chacon, Carlos A.; Vaughan, Gilberto] Inst Diagnost & Referencia Epidemiol, Mexico City, DF, Mexico. [Lozano, Daniela] Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Biomed Mol, Mexico City, DF, Mexico. [Vergara-Castaneda, Arely] La Salle Univ, Fac Ciencias Quim, Mexico City, DF, Mexico. [Fonseca-Coronado, Salvador] Univ Nacl Autonoma Mexico, Fac Estudios Superiores Cuautitlan, Unidad Invest Multidisciplinaria, Lab Inmunobiol Enfermedades Infecciosas, Mexico City, Estado De Mexic, Mexico. RP Vaughan, G (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM gilvaughan@yahoo.com OI Martinez, Armando/0000-0003-4042-9680 FU Proyecto PAPIIT, Direccion General de Asuntos del Personal Academico, Universidad Nacional Autonoma de Mexico [TA200112] FX This work was partially supported by Proyecto PAPIIT TA200112, Direccion General de Asuntos del Personal Academico, Universidad Nacional Autonoma de Mexico. NR 30 TC 13 Z9 13 U1 1 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2013 VL 51 IS 2 BP 629 EP 632 DI 10.1128/JCM.03042-12 PG 4 WC Microbiology SC Microbiology GA 078OH UT WOS:000314108000041 PM 23224093 ER PT J AU Pimenta, FC Roundtree, A Soysal, A Bakir, M du Plessis, M Wolter, N von Gottberg, A Mcgee, L Carvalho, MD Beall, B AF Pimenta, Fabiana C. Roundtree, Alexis Soysal, Ahmet Bakir, Mustafa du Plessis, Mignon Wolter, Nicole von Gottberg, Anne McGee, Lesley Carvalho, Maria da Gloria Beall, Bernard TI Sequential Triplex Real-Time PCR Assay for Detecting 21 Pneumococcal Capsular Serotypes That Account for a High Global Disease Burden SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID STREPTOCOCCUS-PNEUMONIAE SEROTYPES; BLOT HYBRIDIZATION ASSAY; MULTIPLEX PCR; INVASIVE DISEASE; CEREBROSPINAL-FLUID; ITALIAN CHILDREN; IDENTIFICATION; SAMPLES; DIAGNOSIS; 6C AB We developed and validated a real-time PCR assay consisting of 7 triplexed reactions to identify 11 individual serotypes plus 10 small serogroups representing the majority of disease-causing isolates of Streptococcus pneumoniae. This assay targets the 13 serotypes included within the 13-valent conjugate vaccine and 8 additional key serotypes or serogroups. Advantages over other serotyping assays are described. The assay will be expanded to 40 serotypes/serogroups. We will provide periodic updates at our protocol website. C1 [Pimenta, Fabiana C.; Roundtree, Alexis; McGee, Lesley; Carvalho, Maria da Gloria; Beall, Bernard] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30333 USA. [Soysal, Ahmet; Bakir, Mustafa] Marmara Univ, Sch Med, Div Pediat Infect Dis, Istanbul, Turkey. [du Plessis, Mignon; Wolter, Nicole; von Gottberg, Anne] Ctr Resp Dis & Meningitis, Natl Inst Communicable Dis, Natl Hlth Lab Serv, Johannesburg, South Africa. RP Beall, B (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30333 USA. EM bbeall@cdc.gov OI du Plessis, Mignon/0000-0001-9186-0679 NR 22 TC 30 Z9 31 U1 0 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2013 VL 51 IS 2 BP 647 EP 652 DI 10.1128/JCM.02927-12 PG 6 WC Microbiology SC Microbiology GA 078OH UT WOS:000314108000046 PM 23224094 ER PT J AU Sejvar, JJ Kakooza, AM Foltz, JL Makumbi, I Atai-Omoruto, AD Malimbo, M Ndyomugyenyi, R Alexander, LN Abang, B Downing, RG Ehrenberg, A Guilliams, K Helmers, S Melstrom, P Olara, D Perlman, S Ratto, J Trevathan, E Winkler, AS Dowell, SF Lwamafa, DKW AF Sejvar, James J. Kakooza, Angelina M. Foltz, Jennifer L. Makumbi, Issa Atai-Omoruto, Anne Deborah Malimbo, Mugagga Ndyomugyenyi, Richard Alexander, Lorraine N. Abang, Betty Downing, Robert G. Ehrenberg, Andrew Guilliams, Kristin Helmers, Sandra Melstrom, Paul Olara, Dennis Perlman, Seth Ratto, Jeffrey Trevathan, Edwin Winkler, Andrea S. Dowell, Scott F. Lwamafa, D. K. W. TI Clinical, neurological, and electrophysiological features of nodding syndrome in Kitgum, Uganda: an observational case series SO LANCET NEUROLOGY LA English DT Article ID LENNOX-GASTAUT SYNDROME; MILD COGNITIVE IMPAIRMENT; SCREENING-TEST; EPILEPSY; PREVALENCE; TANZANIA; ONCHOCERCIASIS; MALNUTRITION; CHILDREN AB Background Nodding syndrome is an unexplained illness characterised by head-bobbing spells. The clinical and epidemiological features are incompletely described, and the explanation for the nodding and the underlying cause of nodding syndrome are unknown. We aimed to describe the clinical and neurological diagnostic features of this illness. Methods In December, 2009, we did a multifaceted investigation to assess epidemiological and clinical illness features in 13 parishes in Kitgum District, Uganda. We defined a case as a previously healthy child aged 5-15 years with reported nodding and at least one other neurological deficit. Children from a systematic sample of a case-control investigation were enrolled in a clinical case series which included history, physical assessment, and neurological examinations; a subset had electroencephalography (EEG), electromyography, brain MRI, CSF analysis, or a combination of these analyses. We reassessed the available children 8 months later. Findings We enrolled 23 children (median age 12 years, range 7-15 years) in the case-series investigation, all of whom reported at least daily head nodding. 14 children had reported seizures. Seven (30%) children had gross cognitive impairment, and children with nodding did worse on cognitive tasks than did age-matched controls, with significantly lower scores on tests of short-term recall and attention, semantic fluency and fund of knowledge, and motor praxis. We obtained CSF samples from 16 children, all of which had normal glucose and protein concentrations. EEG of 12 children with nodding syndrome showed disorganised, slow background (n=10), and interictal generalised 2.5-3.0 Hz spike and slow waves (n=10). Two children had nodding episodes during EEG, which showed generalised electrodecrement and paraspinal electromyography dropout consistent with atonic seizures. MRI in four of five children showed generalised cerebral and cerebellar atrophy. Reassessment of 12 children found that six worsened in their clinical condition between the first evaluation and the follow-up evaluation interval, as indicated by more frequent head nodding or seizure episodes, and none had cessation or decrease in frequency of these episodes. Interpretation Nodding syndrome is an epidemic epilepsy associated with encephalopathy, with head nodding caused by atonic seizures. The natural history, cause, and management of the disorder remain to be determined. C1 [Sejvar, James J.] Ctr Dis Control & Prevent CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Kakooza, Angelina M.] Makerere Univ, Dept Pediat & Child Hlth, Coll Hlth Sci, Kampala, Uganda. [Foltz, Jennifer L.; Melstrom, Paul] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Foltz, Jennifer L.] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot NCCDHP, Atlanta, GA 30333 USA. [Makumbi, Issa; Atai-Omoruto, Anne Deborah; Malimbo, Mugagga; Ndyomugyenyi, Richard; Lwamafa, D. K. W.] Uganda Minist Hlth, Kampala, Uganda. [Alexander, Lorraine N.; Abang, Betty; Downing, Robert G.; Olara, Dennis] CDC Uganda, Global AIDS Program, Ctr Global Hlth, Entebbe, Uganda. [Ehrenberg, Andrew; Helmers, Sandra] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Guilliams, Kristin; Perlman, Seth] Washington Univ, Div Pediat & Dev Neurol, Dept Neurol, St Louis, MO USA. [Guilliams, Kristin] Washington Univ, Dept Pediat, Div Crit Care, St Louis, MO 63130 USA. [Melstrom, Paul] CDC, Off Smoking & Hlth, NCCDHP, Atlanta, GA 30333 USA. [Ratto, Jeffrey] CDC, Int Refugee Hlth Branch, CGH, Atlanta, GA 30333 USA. [Trevathan, Edwin] St Louis Univ, Sch Publ Hlth, Dept Epidemiol, St Louis, MO 63103 USA. [Trevathan, Edwin] St Louis Univ, Sch Publ Hlth, Dept Pediat, St Louis, MO 63103 USA. [Trevathan, Edwin] St Louis Univ, Sch Publ Hlth, Dept Neurol, St Louis, MO 63103 USA. [Winkler, Andrea S.] Tech Univ Munich, Dept Neurol, D-80290 Munich, Germany. [Dowell, Scott F.] CDC, Div Global Dis Detect & Emergency Response, CGH, Atlanta, GA 30333 USA. RP Sejvar, JJ (reprint author), Ctr Dis Control & Prevent CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. EM zea3@cdc.gov OI Guilliams, Kristin/0000-0002-5518-3778 FU Division of Global Disease Detection and Emergency Response, US Centers for Disease Control and Prevention FX Funding Division of Global Disease Detection and Emergency Response, US Centers for Disease Control and Prevention. NR 31 TC 34 Z9 34 U1 0 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 J9 LANCET NEUROL JI Lancet Neurol. PD FEB PY 2013 VL 12 IS 2 BP 166 EP 174 DI 10.1016/S1474-4422(12)70321-6 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 081NZ UT WOS:000314330200017 PM 23305742 ER PT J AU Oliver-Kozup, H Martin, KH Schwegler-Berry, D Green, BJ Betts, C Shinde, AV Van De Water, L Lukomski, S AF Oliver-Kozup, Heaven Martin, Karen H. Schwegler-Berry, Diane Green, Brett J. Betts, Courtney Shinde, Arti V. Van De Water, Livingston Lukomski, Slawomir TI The group A streptococcal collagen-like protein-1, Scl1, mediates biofilm formation by targeting the extra domain A-containing variant of cellular fibronectin expressed in wounded tissue SO MOLECULAR MICROBIOLOGY LA English DT Article ID SERUM OPACITY FACTOR; BINDING PROTEIN; SURFACE PROTEIN; INTEGRIN ALPHA-9-BETA-1; LIGAND-BINDING; ACUTE GLOMERULONEPHRITIS; DENSITY-LIPOPROTEIN; EPITHELIAL-CELLS; SKIN INFECTIONS; EIIIA SEGMENT AB Wounds are known to serve as portals of entry for group A Streptococcus (GAS). Subsequent tissue colonization is mediated by interactions between GAS surface proteins and host extracellular matrix components. We recently reported that the streptococcal collagen-like protein-1, Scl1, selectively binds the cellular form of fibronectin (cFn) and also contributes to GAS biofilm formation on abiotic surfaces. One structural feature of cFn, which is predominantly expressed in response to tissue injury, is the presence of a spliced variant containing extra domain A (EDA/EIIIA). We now report that GAS biofilm formation is mediated by the Scl1 interaction with EDA-containing cFn. Recombinant Scl1 proteins that bound cFn also bound recombinant EDA within the C-C loop region recognized by the alpha 9 beta 1 integrin. The extracellular 2-D matrix derived from human dermal fibroblasts supports GAS adherence and biofilm formation. Altogether, this work identifies and characterizes a novel molecular mechanism by which GAS utilizes Scl1 to specifically target an extracellular matrix component that is predominantly expressed at the site of injury in order to secure host tissue colonization. C1 [Oliver-Kozup, Heaven; Lukomski, Slawomir] W Virginia Univ, Sch Med, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA. [Martin, Karen H.] W Virginia Univ, Sch Med, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA. [Martin, Karen H.] W Virginia Univ, Sch Med, Microscope Imaging Facil, Morgantown, WV 26506 USA. [Schwegler-Berry, Diane] Ctr Dis Control & Prevent, Pathol & Physiol Res Branch, Hlth Effects Lab Div, NIOSH, Morgantown, WV 26506 USA. [Green, Brett J.] Ctr Dis Control & Prevent, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, NIOSH, Morgantown, WV 26506 USA. [Betts, Courtney; Shinde, Arti V.; Van De Water, Livingston] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA. RP Lukomski, S (reprint author), W Virginia Univ, Sch Med, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA. EM slukomski@hsc.wvu.edu FU National Institutes of Health [AI50666, GM056442, P20 RR016440, P30 RR032138/GM103488, P20 RR016477]; West Virginia Graduate Student Fellowship in Science, Technology, Engineering and Mathematics (STEM); Mary Babb Randolph Cancer Center; Research Funding Development Grant (RFDG) FX We thank Joan Olson and Fred Minnear for the critical reading of the manuscript. The support of Xin-Xing Gu is greatly appreciated. This work was supported in part by National Institutes of Health Grant AI50666 (to S. Lukomski) and GM056442 (to L. Van De Water). Authors also wish to acknowledge the WVU Research Office's Program to Stimulate Competitive Research (PSCoR), as well as the Research Funding Development Grant (RFDG) (to S. Lukomski). H. Oliver-Kozup was supported by a grant from the West Virginia Graduate Student Fellowship in Science, Technology, Engineering and Mathematics (STEM). Confocal microscopy experiments were performed in the West Virginia University Microscope Imaging Facility, which has been supported by the Mary Babb Randolph Cancer Center and NIH grants P20 RR016440, P30 RR032138/GM103488 and P20 RR016477. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute of Occupational Safety and Health. NR 87 TC 17 Z9 17 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0950-382X J9 MOL MICROBIOL JI Mol. Microbiol. PD FEB PY 2013 VL 87 IS 3 BP 672 EP 689 DI 10.1111/mmi.12125 PG 18 WC Biochemistry & Molecular Biology; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA 078SA UT WOS:000314118600017 PM 23217101 ER PT J AU Ruder, AM Yiin, JH Waters, MA Carreon, T Hein, MJ Butler, MA Calvert, GM Davis-King, KE Schulte, PA Mandel, JS Morton, RF Reding, DJ Rosenman, KD Stewart, PA AF Ruder, Avima M. Yiin, James H. Waters, Martha A. Carreon, Tania Hein, Misty J. Butler, Mary A. Calvert, Geoffrey M. Davis-King, Karen E. Schulte, Paul A. Mandel, Jack S. Morton, Roscoe F. Reding, Douglas J. Rosenman, Kenneth D. Stewart, Patricia A. CA Brain Canc Collaborative Study Grp TI The Upper Midwest Health Study: gliomas and occupational exposure to chlorinated solvents SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID ADULT BRAIN-TUMORS; GENETIC POLYMORPHISMS; RISK-FACTORS; ALIPHATIC-HYDROCARBONS; CASE-REFERENT; TRANSFERASE; SUSCEPTIBILITY; METABOLISM; CANCER; ASSOCIATION AB Objectives Occupational exposure to chlorinated aliphatic solvents has been associated with an increased cancer risk, including brain cancer. However, many of these solvents remain in active, large-volume use. We evaluated glioma risk from non-farm occupational exposure (ever/never and estimated cumulative exposure) to any of the six chlorinated solvents-carbon tetrachloride, chloroform, methylene chloride, trichloroethylene, tetrachloroethylene or 1,1,1-trichloroethane-among 798 cases and 1175 population-based controls, aged 18-80 years and non-metropolitan residents of Iowa, Michigan, Minnesota and Wisconsin. Methods Solvent use was estimated based on occupation, industry and era, using a bibliographic database of published exposure levels and exposure determinants. Unconditional logistic regression was used to calculate ORs adjusted for frequency matching variables age group and sex, and age and education. Additional analyses were limited to 904 participants who donated blood specimens (excluding controls reporting a previous diagnosis of cancer) genotyped for glutathione-S-transferases GSTP1, GSTM3 and GSTT1. Individuals with functional GST genes might convert chlorinated solvents crossing the blood-brain barrier into cytotoxic metabolites. Results Both estimated cumulative exposure (ppm-years) and ever exposure to chlorinated solvents were associated with decreased glioma risk and were statistically significant overall and for women. In analyses comparing participants with a high probability of exposure with the unexposed, no associations were statistically significant. Solvent-exposed participants with functional GST genes were not at increased risk of glioma. Conclusions We observed no associations of glioma risk and chlorinated solvent exposure. Large pooled studies are needed to explore the interaction of genetic pathways and environmental and occupational exposures in glioma aetiology. C1 [Ruder, Avima M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Mandel, Jack S.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [Morton, Roscoe F.] St Johns Mercy Med Ctr, Des Moines, IA USA. [Reding, Douglas J.] Marshfield Clin Fdn Med Res & Educ, Natl Farm Med Ctr, Marshfield, WI USA. [Rosenman, Kenneth D.] Michigan State Univ, Dept Med, E Lansing, MI 48824 USA. [Stewart, Patricia A.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. RP Ruder, AM (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,Mailstop R-16, Cincinnati, OH 45226 USA. EM amr2@cdc.gov FU NIOSH Initiative for Cancer Control Projects for Farmers; CDC/NIOSH operating funds; National Cancer Institute FX This study was funded in part by the NIOSH Initiative for Cancer Control Projects for Farmers and in part by CDC/NIOSH operating funds. Funding for the GSTM3 genotyping was provided by an Interagency Agreement with the National Cancer Institute. NR 43 TC 5 Z9 5 U1 2 U2 17 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD FEB PY 2013 VL 70 IS 2 BP 73 EP 80 DI 10.1136/oemed-2011-100588 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 074FC UT WOS:000313797300001 PM 23104734 ER PT J AU Poehling, KA Edwards, KM Griffin, MR Szilagyi, PG Staat, MA Iwane, MK Snively, BM Suerken, CK Hall, CB Weinberg, GA Chaves, SS Zhu, YW McNeal, MM Bridges, CB AF Poehling, Katherine A. Edwards, Kathryn M. Griffin, Marie R. Szilagyi, Peter G. Staat, Mary A. Iwane, Marika K. Snively, Beverly M. Suerken, Cynthia K. Hall, Caroline B. Weinberg, Geoffrey A. Chaves, Sandra S. Zhu, Yuwei McNeal, Monica M. Bridges, Carolyn B. TI The Burden of Influenza in Young Children, 2004-2009 SO PEDIATRICS LA English DT Article DE influenza; epidemiology; influenza vaccine; hospitalization; ambulatory care ID SYSTEM SENTINEL SITES; IMMUNIZATION PRACTICES ACIP; AGED 6-23 MONTHS; LABORATORY-CONFIRMED INFLUENZA; RAPID DIAGNOSTIC-TEST; VACCINATION COVERAGE; UNITED-STATES; ADVISORY-COMMITTEE; OSELTAMIVIR TREATMENT; SEASONAL INFLUENZA AB OBJECTIVE: To characterize the health care burden of influenza from 2004 through 2009, years when influenza vaccine recommendations were expanded to all children aged >= 6 months. METHODS: Population-based surveillance for laboratory-confirmed influenza was performed among children aged <5 years presenting with fever and/or acute respiratory illness to inpatient and outpatient settings during 5 influenza seasons in 3 US counties. Enrolled children had nasal/throat swabs tested for influenza by reverse transcriptase-polymerase chain reaction and their medical records reviewed. Rates of influenza hospitalizations per 1000 population and proportions of outpatients (emergency department and clinic) with influenza were computed. RESULTS: The study population comprised 2970, 2698, and 2920 children from inpatient, emergency department, and clinic settings, respectively. The single-season influenza hospitalization rates were 0.4 to 1.0 per 1000 children aged <5 years and highest for infants <6 months. The proportion of outpatient children with influenza ranged from 10% to 25% annually. Among children hospitalized with influenza, 58% had physician-ordered influenza testing, 35% had discharge diagnoses of influenza, and 2% received antiviral medication. Among outpatients with influenza, 7% were tested for influenza, 7% were diagnosed with influenza, and <1% had antiviral treatment. Throughout the 5 study seasons, <45% of influenza-negative children >= 6 months were fully vaccinated against influenza. CONCLUSIONS: Despite expanded vaccination recommendations, many children are insufficiently vaccinated, and substantial influenza burden remains. Antiviral use was low. Future studies need to evaluate trends in use of vaccine and antiviral agents and their impact on disease burden and identify strategies to prevent influenza in young infants. Pediatrics 2013; 131: 207-216 C1 [Poehling, Katherine A.] Wake Forest Sch Med, Dept Pediat, Winston Salem, NC 27157 USA. [Poehling, Katherine A.] Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC 27157 USA. [Snively, Beverly M.; Suerken, Cynthia K.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC 27157 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA. [Griffin, Marie R.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. [Griffin, Marie R.] Vanderbilt Univ, Med Ctr, Dept Prevent Med, Nashville, TN USA. [Zhu, Yuwei] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA. [Szilagyi, Peter G.; Hall, Caroline B.] Univ Rochester, Sch Med, Dept Pediat, Rochester, NY 14642 USA. [Hall, Caroline B.] Univ Rochester, Sch Med, Dept Med, Rochester, NY USA. [Szilagyi, Peter G.; Hall, Caroline B.] Univ Rochester, Dept Pediat, Sch Dent, Rochester, NY USA. [Hall, Caroline B.] Univ Rochester, Dept Med, Sch Dent, Rochester, NY USA. [Staat, Mary A.; McNeal, Monica M.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Iwane, Marika K.; Chaves, Sandra S.; Bridges, Carolyn B.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Poehling, KA (reprint author), Wake Forest Sch Med, Dept Pediat, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM kpoehlin@wakehealth.edu FU Novartis; BD Diagnostics; US Centers for Disease Control and Prevention [U38/CCU217969, U38/CCU417958, U38/CCU522352, U01/IP000017, U01/IP000022, U01/IP000147]; Wachovia Research Fund; National Institute of Allergy and Infectious Diseases [R01 AI079226]; National Institutes of Health (NIH) FX Dr Edwards received grant support from Novartis (for meningococcus); Dr Hall was a consultant for MedImmune (for respiratory syncytial virus [RSV]) and a past consultant for GlaxoSmithKline (for RSV); Dr Staat received research support and was a consultant for MedImmune (for RSV); Dr Weinberg was a consultant for MedImmune and speaker's bureaus of Merck & Co., GlaxoSmithKline, and Sanofi Pasteur; and Dr Poehling received research support from BD Diagnostics. The other authors have indicated they have no financial relationships relevant to this article to disclose.; The primary support for the NVSN was the US Centers for Disease Control and Prevention (cooperative agreement numbers U38/CCU217969, U38/CCU417958, U38/CCU522352, U01/IP000017, U01/IP000022, and U01/IP000147). In addition, Dr Poehling received research support from Wachovia Research Fund and National Institute of Allergy and Infectious Diseases (grant R01 AI079226). Funded by the National Institutes of Health (NIH). NR 54 TC 52 Z9 54 U1 0 U2 14 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD FEB PY 2013 VL 131 IS 2 BP 207 EP 216 DI 10.1542/peds.2012-1255 PG 10 WC Pediatrics SC Pediatrics GA 081XG UT WOS:000314355100045 PM 23296444 ER PT J AU Jackson, LA Peterson, D Nelson, JC Marcy, SM Naleway, AL Nordin, JD Donahue, JG Hambidge, SJ Balsbaugh, C Baxter, R Marsh, T Madziwa, L Weintraub, E AF Jackson, Lisa A. Peterson, Do Nelson, Jennifer C. Marcy, S. Michael Naleway, Allison L. Nordin, James D. Donahue, James G. Hambidge, Simon J. Balsbaugh, Carolyn Baxter, Roger Marsh, Tracey Madziwa, Lawrence Weintraub, Eric TI Vaccination Site and Risk of Local Reactions in Children 1 Through 6 Years of Age SO PEDIATRICS LA English DT Article DE diphtheria-tetanus-acellular pertussis vaccines; injections; intramuscular; vaccine safety; children ID SAFETY DATALINK; IMMUNIZATION AB OBJECTIVE: Our objective was to assess whether the occurrence of medically attended local reactions to intramuscularly administered vaccines varies by injection site (arm versus thigh) in children 1 to 6 years of age. METHODS: This is a retrospective cohort study of children in the Vaccine Safety Datalink population from 2002 to 2009. Site of injection and the outcome of medically attended local reactions were identified from administrative data. RESULTS: The study cohort of 1.4 million children received 6.0 million intramuscular (IM) vaccines during the study period. The primary analyses evaluated the IM vaccines most commonly administered alone, which included inactivated influenza, hepatitis A, and diphtheria-tetanus-acellular pertussis (DTaP) vaccines. For inactivated influenza and hepatitis A vaccines, local reactions were relatively uncommon, and there was no difference in risk of these events with arm versus thigh injections. The rate of local reactions after DTaP vaccines was higher, and vaccination in the arm was associated with a significantly greater risk of this outcome compared with vaccination in the thigh, both for children 12 to 35 months (relative risk: 1.88 [95% confidence interval: 1.34-2.65]) and 3 to 6 years of age (relative risk: 1.41 [95% confidence interval: 0.84-2.34]), although this difference was not statistically significant in the older age group. CONCLUSIONS: Injection in the thigh is associated with a significantly lower risk of a medically attended local reaction to a DTaP vaccination among children 12 to 35 months of age, supporting current recommendations to administer IM vaccinations in the thigh for children younger than 3 years of age. Pediatrics 2013;131:283-289 C1 [Jackson, Lisa A.; Peterson, Do; Nelson, Jennifer C.; Marsh, Tracey; Madziwa, Lawrence] Grp Hlth Res Inst, Seattle, WA 98101 USA. [Nelson, Jennifer C.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Marcy, S. Michael] Kaiser Permanente So Calif, Pasadena, CA USA. [Naleway, Allison L.] Kaiser Permanente NW, Portland, OR USA. [Nordin, James D.] HealthPartners Res Fdn, Ctr Hlth Res, Minneapolis, MN USA. [Donahue, James G.] Marshfield Clin Res Fdn, Epidemiol Res Ctr, Marshfield, WI USA. [Hambidge, Simon J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Hambidge, Simon J.] Denver Hlth Community Hlth Serv, Denver, CO USA. [Balsbaugh, Carolyn] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA. [Balsbaugh, Carolyn] Harvard Vanguard Med Associates, Boston, MA USA. [Baxter, Roger] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA. [Weintraub, Eric] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. RP Jackson, LA (reprint author), Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. EM jackson.l@ghc.org OI Naleway, Allison/0000-0001-5747-4643 FU Sanofi Pasteur; Pfizer; Novartis; GSK; MedImmune; Merck; Centers for Disease Control and Prevention through America's Health Insurance Plans [200-2002-00732] FX Dr Jackson has received research funding from Sanofi Pasteur, Pfizer, Novartis, and GSK and has received travel support from Pfizer to present findings from an unrelated study; Dr Baxter has received research funding from Sanofi Pasteur, MedImmune, Pfizer, Novartis, GSK, and Merck; Dr Donahue has received research funding from MedImmune; Dr Naleway has received research funding from GSK; the other authors have indicated they have no financial relationships relevant to this article to disclose.; Supported by the Centers for Disease Control and Prevention (contract 200-2002-00732), through America's Health Insurance Plans. NR 11 TC 7 Z9 7 U1 1 U2 11 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD FEB PY 2013 VL 131 IS 2 BP 283 EP 289 DI 10.1542/peds.2012-2617 PG 7 WC Pediatrics SC Pediatrics GA 081XG UT WOS:000314355100054 PM 23319538 ER PT J AU Fuchs, J Neuberger, T Rolletschek, H Schiebold, S Nguyen, TH Borisjuk, N Borner, A Melkus, G Jakob, P Borisjuk, L AF Fuchs, Johannes Neuberger, Thomas Rolletschek, Hardy Schiebold, Silke Thuy Ha Nguyen Borisjuk, Nikolai Boerner, Andreas Melkus, Gerd Jakob, Peter Borisjuk, Ljudmilla TI A Noninvasive Platform for Imaging and Quantifying Oil Storage in Submillimeter Tobacco Seed SO PLANT PHYSIOLOGY LA English DT Article ID MAGNETIC-RESONANCE; IN-VIVO; BRASSICA-NAPUS; WATER-UPTAKE; ARABIDOPSIS; PLANTS; LIPIDS; EMBRYOS; GENES; ACCUMULATION AB While often thought of as a smoking drug, tobacco (Nicotiana spp.) is now considered as a plant of choice for molecular farming and biofuel production. Here, we describe a noninvasive means of deriving both the distribution of lipid and the microtopology of the submillimeter tobacco seed, founded on nuclear magnetic resonance (NMR) technology. Our platform enables counting of seeds inside the intact tobacco capsule to measure seed sizes, to model the seed interior in three dimensions, to quantify the lipid content, and to visualize lipid gradients. Hundreds of seeds can be simultaneously imaged at an isotropic resolution of 25 mm, sufficient to assess each individual seed. The relative contributions of the embryo and the endosperm to both seed size and total lipid content could be assessed. The extension of the platform to a range of wild and cultivated Nicotiana species demonstrated certain evolutionary trends in both seed topology and pattern of lipid storage. The NMR analysis of transgenic tobacco plants with seed-specific ectopic expression of the plastidial phosphoenolpyruvate/phosphate translocator, displayed a trade off between seed size and oil concentration. The NMR-based assay of seed lipid content and topology has a number of potential applications, in particular providing a means to test and optimize transgenic strategies aimed at the manipulation of seed size, seed number, and lipid content in tobacco and other species with submillimeter seeds. C1 [Fuchs, Johannes; Rolletschek, Hardy; Schiebold, Silke; Boerner, Andreas; Borisjuk, Ljudmilla] Leibniz Inst Pflanzengenet & Kulturpflanzenforsch, D-06466 Gatersleben, Germany. [Fuchs, Johannes; Jakob, Peter] Univ Wurzburg, Inst Expt Phys 5, D-97074 Wurzburg, Germany. [Neuberger, Thomas] Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA. [Neuberger, Thomas] Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA. [Thuy Ha Nguyen] Ctr Dis Control & Prevent, Atlanta Res & Educ Fdn, Mol Epidemiol Team, Influenza Div,Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Borisjuk, Nikolai] Rutgers State Univ, New Brunswick, NJ 08901 USA. [Melkus, Gerd] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Jakob, Peter] Res Ctr Magnet Resonance Bavaria, D-97074 Wurzburg, Germany. RP Borisjuk, L (reprint author), Leibniz Inst Pflanzengenet & Kulturpflanzenforsch, D-06466 Gatersleben, Germany. EM borysyuk@ipk-gatersleben.de OI Melkus, Gerd/0000-0001-5387-8958; Borisjuk, Nikolai/0000-0001-5250-9771; Jakob, Peter/0000-0002-3481-5545 FU German Plant Phenotyping Network FX This work was supported by the German Plant Phenotyping Network. NR 57 TC 14 Z9 14 U1 2 U2 40 PU AMER SOC PLANT BIOLOGISTS PI ROCKVILLE PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA SN 0032-0889 J9 PLANT PHYSIOL JI Plant Physiol. PD FEB PY 2013 VL 161 IS 2 BP 583 EP 593 DI 10.1104/pp.112.210062 PG 11 WC Plant Sciences SC Plant Sciences GA 081ZA UT WOS:000314360100002 PM 23232144 ER PT J AU Fouchier, RAM Garcia-Sastre, A Kawaoka, Y Barclay, WS Bouvier, NM Brown, IH Capua, I Chen, HL Compans, RW Couch, RB Cox, NJ Doherty, PC Donis, RO Feldmann, H Guan, Y Katz, JM Kiselev, OI Klenk, HD Kobinger, G Liu, JH Liu, XF Lowen, A Mettenleiter, TC Osterhaus, ADME Palese, P Peiris, JSM Perez, DR Richt, JA Schultz-Cherry, S Steel, J Subbarao, K Swayne, DE Takimoto, T Tashiro, M Taubenberger, JK Thomas, PG Tripp, RA Tumpey, TM Webby, RJ Webster, RG AF Fouchier, Ron A. M. Garcia-Sastre, Adolfo Kawaoka, Yoshihiro Barclay, Wendy S. Bouvier, Nicole M. Brown, Ian H. Capua, Ilaria Chen, Hualan Compans, Richard W. Couch, Robert B. Cox, Nancy J. Doherty, Peter C. Donis, Ruben O. Feldmann, Heinz Guan, Yi Katz, Jacqueline M. Kiselev, Oleg I. Klenk, H. D. Kobinger, Gary Liu, Jinhua Liu, Xiufan Lowen, Anice Mettenleiter, Thomas C. Osterhaus, Albert D. M. E. Palese, Peter Peiris, J. S. Malik Perez, Daniel R. Richt, Juergen A. Schultz-Cherry, Stacey Steel, John Subbarao, Kanta Swayne, David E. Takimoto, Toru Tashiro, Masato Taubenberger, Jeffery K. Thomas, Paul G. Tripp, Ralph A. Tumpey, Terrence M. Webby, Richard J. Webster, Robert G. TI Transmission Studies Resume For Avian Flu SO SCIENCE LA English DT Letter ID VIRUS; ADAPTATION; FERRETS C1 [Fouchier, Ron A. M.; Osterhaus, Albert D. M. E.] Erasmus MC, Dept Virol, NL-3015 GE Rotterdam, Netherlands. [Garcia-Sastre, Adolfo; Bouvier, Nicole M.; Palese, Peter] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA. [Kawaoka, Yoshihiro] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53711 USA. [Kawaoka, Yoshihiro] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Virol,Minato Ku, Tokyo 1088639, Japan. [Barclay, Wendy S.] Univ London Imperial Coll Sci Technol & Med, Dept Med, London W2 1PG, England. [Bouvier, Nicole M.] Icahn Sch Med Mt Sinai, Div Infect Dis, New York, NY 10029 USA. [Brown, Ian H.] Anim Hlth & Vet Labs Agcy, Dept Virol, Addlestone KT15, Surrey, England. [Capua, Ilaria] Ist Zooprofilatt Sperimentale Venezie, I-35020 Padua, Italy. [Chen, Hualan] CAAS, Harbin Vet Res Inst, Harbin 150001, Peoples R China. [Compans, Richard W.] Emory Univ, Sch Med, Influenza Pathogenesis & Immunol Res Ctr, Atlanta, GA 30322 USA. [Couch, Robert B.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Cox, Nancy J.; Donis, Ruben O.; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Doherty, Peter C.; Thomas, Paul G.] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA. [Feldmann, Heinz] NIAID, Virol Lab, NIH, Rocky Mt Labs, Hamilton, MT 59840 USA. [Guan, Yi] Univ Hong Kong, Sch Publ Hlth, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China. [Kiselev, Oleg I.] Minist Publ Hlth Russia, DI Ivanovsky Inst Virol, Moscow, Russia. [Klenk, H. D.] Inst Virol, D-35043 Marburg, Germany. [Kobinger, Gary] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada. [Liu, Jinhua] China Agr Univ, Dept Vet Prevent Med, Beijing 100193, Peoples R China. [Liu, Xiufan] Yangzhou Univ, Sch Vet Med, Anim Infect Dis Lab, Yangzhou 225009, Jiangsu, Peoples R China. [Lowen, Anice; Steel, John] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA. [Mettenleiter, Thomas C.] Friedrich Loeffler Inst, D-17493 Greifswald, Germany. [Peiris, J. S. Malik] Univ Hong Kong, Sch Publ Hlth, Ctr Influenza Res, Hong Kong, Hong Kong, Peoples R China. [Perez, Daniel R.] Univ Maryland, Dept Vet Med, College Pk, MD 20742 USA. [Richt, Juergen A.] Kansas State Univ, Coll Vet Med, Manhattan, KS 66506 USA. [Schultz-Cherry, Stacey; Webby, Richard J.; Webster, Robert G.] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA. [Subbarao, Kanta] NIAID, Emerging Resp Viruses Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. [Swayne, David E.] ARS, SE Poultry Res Lab, USDA, Athens, GA 30605 USA. [Takimoto, Toru] Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA. [Tashiro, Masato] Natl Inst Infect Dis, Influenza Virus Res Ctr, Tokyo 2080011, Japan. [Taubenberger, Jeffery K.] NIAID, Viral Pathogenesis & Evolut Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. [Tripp, Ralph A.] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA. RP Kawaoka, Y (reprint author), Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53711 USA. EM kawaokay@svm.vetmed.wisc.edu RI Compans, Richard/I-4087-2013; Fouchier, Ron/A-1911-2014; Brown, Ian/E-1119-2011; APHA, Staff publications/E-6082-2010; Doherty, Peter Charles/C-4185-2013; OI Thomas, Paul G./0000-0001-7955-0256; Perez, Daniel/0000-0002-6569-5689; Compans, Richard/0000-0003-2360-335X; Fouchier, Ron/0000-0001-8095-2869; Tripp, Ralph/0000-0002-2924-9956; Bouvier, Nicole/0000-0002-4530-2841; Doherty, Peter Charles/0000-0002-5028-3489; Osterhaus, Albert/0000-0002-6074-1172; Palese, Peter/0000-0002-0337-5823; Garcia-Sastre, Adolfo/0000-0002-6551-1827 FU Intramural NIH HHS [ZIA AI001088-03, ZIA AI001088-01, ZIA AI001088-04, ZIA AI001088-05, ZIA AI001088-02] NR 17 TC 13 Z9 13 U1 1 U2 69 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD FEB 1 PY 2013 VL 339 IS 6119 BP 520 EP 521 DI 10.1126/science.1235140 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 080UR UT WOS:000314270000035 PM 23345603 ER PT J AU Gottlieb, SL Xu, FJ Brunham, RC AF Gottlieb, Sami L. Xu, Fujie Brunham, Robert C. TI Screening and Treating Chlamydia trachomatis Genital Infection to Prevent Pelvic Inflammatory Disease: Interpretation of Findings From Randomized Controlled Trials SO SEXUALLY TRANSMITTED DISEASES LA English DT Review ID NEISSERIA-GONORRHOEAE; FOLLOW-UP; PARTNER NOTIFICATION; ECTOPIC PREGNANCY; NATURAL COURSE; UNITED-STATES; WOMEN; SEQUELAE; IMMUNITY; TRENDS AB We critically reviewed randomized controlled trials evaluating chlamydia screening to prevent pelvic inflammatory disease (PID) and explored factors affecting interpretation and translation of trial data into public health prevention. Taken together, data from these trials offer evidence that chlamydia screening and treatment is an important and useful intervention to reduce the risk of PID among young women. However, the magnitude of benefit to be expected from screening may have been overestimated based on the earliest trials. It is likely that chlamydia screening programs have contributed to declines in PID incidence through shortening prevalent infections, although the magnitude of their contribution remains unclear. Program factors such as screening coverage as well as natural history factors such as risk of PID after repeat chlamydia infection can be important in determining the impact of chlamydia screening on PID incidence in a population. Uptake of chlamydia screening is currently suboptimal, and expansion of screening among young, sexually active women remains a priority. To reduce transmission and repeat infections, implementation of efficient strategies to treat partners of infected women is also essential. Results of ongoing randomized evaluations of the effect of screening on community-wide chlamydia prevalence and PID will also be valuable. C1 [Gottlieb, Sami L.; Xu, Fujie] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Brunham, Robert C.] British Columbia Ctr Dis Control, Vancouver, BC, Canada. RP Gottlieb, SL (reprint author), World Hlth Org, Dept Reprod Hlth & Res, 20 Ave Appia, CH-1211 Geneva 27, Switzerland. EM gottliebs@who.int NR 37 TC 24 Z9 26 U1 0 U2 24 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2013 VL 40 IS 2 BP 97 EP 102 DI 10.1097/OLQ.0b013e31827bd637 PG 6 WC Infectious Diseases SC Infectious Diseases GA 071TR UT WOS:000313618100003 PM 23324973 ER PT J AU Anderson, C Gallo, MF Hylton-Kong, T Steiner, MJ Hobbs, MM Macaluso, M Figueroa, JP Jamieson, DJ Legardy-Williams, J Wiener, J Warner, L AF Anderson, Clive Gallo, Maria F. Hylton-Kong, Tina Steiner, Markus J. Hobbs, Marcia M. Macaluso, Maurizio Figueroa, J. Peter Jamieson, Denise J. Legardy-Williams, Jennifer Wiener, Jeffrey Warner, Lee TI Randomized Controlled Trial on the Effectiveness of Counseling Messages for Avoiding Unprotected Sexual Intercourse During Sexually Transmitted Infection and Reproductive Tract Infection Treatment Among Female Sexually Transmitted Infection Clinic Patients SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID PROSTATE-SPECIFIC ANTIGEN; VAGINAL FLUID; EXPOSURE; WOMEN; SEMEN; VALIDATION; BIOMARKER; DISEASES; JAMAICA; WORKERS AB Background: The effectiveness of counseling messages to avoid unprotected sex during short-term treatment for curable sexually transmitted infections is unknown. Methods: We randomized 300 female STI clinic patients 18 years or older with cervicitis and/or vaginal discharge in Kingston, Jamaica, in 2010 to 2011, to 1 of 2 counseling messages for their course of syndromic treatment: abstinence only or abstinence backed up by condom use. At a follow-up visit 6 days afterward, we collected vaginal swabs to test for prostate-specific antigen (PSA), a biological marker of recent semen exposure, and administered a questionnaire assessing sexual behavior. Results: No differences were found in the proportions of women testing positive for PSA at follow-up in the abstinence-plus-condom group (11.9%) and abstinence-only group (8.4%) (risk difference, 3.5; 95% confidence interval, -3.5 to 10.5). There also was no significant difference in reporting of unprotected sex between groups. Reporting a history of condom use before enrollment significantly modified the effect of counseling arm on PSA positivity (P = 0.03). Among those reporting recent condom use, 10.3% in the abstinence-only arm and 4.8% in the abstinence-plus-condom arm tested positive for PSA. Conversely, among those not reporting recent condom use, 6.5% in the abstinence-only arm and 17.3% in the abstinence-plus-condom arm had PSA detected. Conclusions: We found no evidence to support the superiority of either counseling message. Post hoc analyses suggest that women with recent condom experience may benefit significantly more from abstinence-plus-condom messages, whereas women without such experience may benefit significantly more from abstinence-only messages. Providers should weigh individual condom use history when determining the most appropriate counseling message. C1 [Anderson, Clive; Hylton-Kong, Tina] Jama Minist Hlth, Epidemiol Res & Training Unit, Comprehens Hlth Ctr, Kingston, Jamaica. [Gallo, Maria F.; Macaluso, Maurizio; Jamieson, Denise J.; Legardy-Williams, Jennifer; Wiener, Jeffrey; Warner, Lee] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Steiner, Markus J.] Div Clin Sci, Durham, NC USA. [Hobbs, Marcia M.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Macaluso, Maurizio] MLC, Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA. [Figueroa, J. Peter] Univ W Indies, Dept Community Hlth & Psychiat, Kingston 7, Jamaica. RP Gallo, MF (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,Mail Stop K-34, Atlanta, GA 30341 USA. EM mgallo@cdc.gov RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 FU Women's Health and Fertility Branch, Division of Reproductive Health, Centers for Disease Control and Prevention [GPO-A-00-05-00022]; Southeastern Sexually Transmitted Infections Cooperative Research Center of the National Institute of Allergy and Infectious Diseases [U19-AI031496] FX Supported by Women's Health and Fertility Branch, Division of Reproductive Health, Centers for Disease Control and Prevention, through a cooperative agreement maintained by US Agency for International Development with FHI 360 (Contraceptive and Reproductive Health Technology Research and Utilization Project, Agreement no. GPO-A-00-05-00022). Laboratory activities for the study were supported, in part, by the Southeastern Sexually Transmitted Infections Cooperative Research Center of the National Institute of Allergy and Infectious Diseases (U19-AI031496). NR 26 TC 12 Z9 12 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2013 VL 40 IS 2 BP 105 EP 110 DI 10.1097/OLQ.0b013e31827938a1 PG 6 WC Infectious Diseases SC Infectious Diseases GA 071TR UT WOS:000313618100005 PM 23321990 ER PT J AU Hoots, BE Peterman, TA Torrone, EA Weinstock, H Meites, E Bolan, GA AF Hoots, Brooke E. Peterman, Thomas A. Torrone, Elizabeth A. Weinstock, Hillard Meites, Elissa Bolan, Gail A. TI A Trich-y Question: Should Trichomonas vaginalis Infection be Reportable? SO SEXUALLY TRANSMITTED DISEASES LA English DT Editorial Material ID SEXUALLY-TRANSMITTED-DISEASES; LOW-BIRTH-WEIGHT; RISK-FACTORS; CONDOM PROMOTION; AMERICAN YOUTH; UNITED-STATES; SEX WORKERS; WOMEN; PREVALENCE; HIV C1 [Hoots, Brooke E.; Peterman, Thomas A.; Torrone, Elizabeth A.; Weinstock, Hillard; Meites, Elissa; Bolan, Gail A.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Hoots, Brooke E.] Ctr Dis Control & Prevent, Div Appl Sci, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. RP Hoots, BE (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,M-S E-02, Atlanta, GA 30333 USA. EM bhoots@cdc.gov OI Meites, Elissa/0000-0002-0077-2591 FU Intramural CDC HHS [CC999999] NR 31 TC 18 Z9 18 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2013 VL 40 IS 2 BP 113 EP 116 DI 10.1097/OLQ.0b013e31827c08c3 PG 4 WC Infectious Diseases SC Infectious Diseases GA 071TR UT WOS:000313618100007 PM 23321992 ER PT J AU Singa, B Glick, SN Bock, N Walson, J Chaba, L Odek, J McClelland, RS Djomand, G Gao, HJ John-Stewart, G AF Singa, Benson Glick, Sara Nelson Bock, Naomi Walson, Judd Chaba, Linda Odek, James McClelland, R. Scott Djomand, Gaston Gao, Hongjiang John-Stewart, Grace TI Sexually Transmitted Infections Among HIV-Infected Adults in HIV Care Programs in Kenya: A National Sample of HIV Clinics SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID FEMALE GENITAL-TRACT; ANTIRETROVIRAL THERAPY; EDUCATIONAL-ATTAINMENT; EPIDEMIOLOGIC SYNERGY; CERVICAL INFLAMMATION; BACTERIAL VAGINOSIS; DISEASES; ASSOCIATION; RISK; PREVENTION AB Background: Identifying sexually transmitted infections (STI) in HIV-infected individuals has potential to benefit individual and public health. There are few guidelines regarding routine STI screening in sub-Saharan African HIV programs. We determined sexual risk behavior and prevalence and correlates of STI in a national survey of large HIV treatment programs in Kenya. Methods: A mobile screening team visited 39 (95%) of the 42 largest HIV care programs in Kenya and enrolled participants using population-proportionate systematic sampling. Participants provided behavioral and clinical data. Genital and blood specimens were tested for trichomoniasis, gonorrhea, chlamydia, syphilis, and CD4 T-lymphocyte counts. Results: Among 1661 adults, 41% reported no sexual partners in the past 3 months. Among those who reported sex in the past 3 months, 63% of women reported condom use during this encounter compared with 77% of men (P < 0.001). Trichomoniasis was the most common STI in women (10.9%) and men (2.8%); prevalences of gonorrhea, chlamydia, and syphilis were low (<1%-2%). Among women, younger age (adjusted odds ratio [OR], 0.96 per year; 95% confidence interval [CI], 0.94-0.98) and primary school education or lower level (adjusted OR, 2.16; 95% CI, 1.37-3.40) were independently associated with trichomoniasis, whereas CD4 count, cotrimoxazole use, and reported condom use were not. Reported condom use at last sex was associated with reporting that the clinic provided condoms among both women (OR, 1.7; 95% CI, 1.17-2.35) and men (OR, 2.4; 95% CI, 1.18-4.82). Conclusions: Women attending Kenyan HIV care programs had a 10.9% prevalence of trichomoniasis, suggesting that screening for this infection may be useful. Condom provision at clinics may enhance secondary HIV prevention efforts. C1 [Singa, Benson; Chaba, Linda] Kenya Govt Med Res Ctr, Nairobi, Kenya. [Glick, Sara Nelson] George Washington Univ, Dept Epidemiol & Biostat, Washington, DC USA. [Bock, Naomi; Djomand, Gaston; Gao, Hongjiang] US Ctr Dis Control & Prevent, Atlanta, GA USA. [John-Stewart, Grace] Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA. [Walson, Judd; McClelland, R. Scott; John-Stewart, Grace] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA. [Walson, Judd; McClelland, R. Scott; John-Stewart, Grace] Univ Washington, Dept Global Hlth, Seattle, WA 98104 USA. [Odek, James] Ctr Dis Control & Prevent Kenya, Nairobi, Kenya. RP John-Stewart, G (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, 325 9th Ave,Box 359909, Seattle, WA 98104 USA. EM gjohn@u.washington.edu FU Centers for Disease Control and Prevention [U62/CCU024512]; President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention [U62PS024512-05] FX Supported by the Centers for Disease Control and Prevention (U62/CCU024512) and the President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention under the terms of cooperative agreement U62PS024512-05. NR 30 TC 4 Z9 4 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2013 VL 40 IS 2 BP 148 EP 153 DI 10.1097/OLQ.0b013e31827aab89 PG 6 WC Infectious Diseases SC Infectious Diseases GA 071TR UT WOS:000313618100012 PM 23324977 ER PT J AU Meites, E Krishna, NK Markowitz, LE Oster, AM AF Meites, Elissa Krishna, Nevin K. Markowitz, Lauri E. Oster, Alexandra M. TI Health Care Use and Opportunities for Human Papillomavirus Vaccination Among Young Men Who Have Sex With Men SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID BEHAVIORAL SURVEILLANCE SYSTEM; UNITED-STATES; HIV RISK; PREVENTION; INFECTION AB We studied 2941 young gay, bisexual, and other men who have sex with men using National HIV Behavioral Surveillance System data. Within the past 12 months, 88.9% used health care, suggesting many opportunities for recommended care including human papillomavirus vaccination. However, only 61.3% disclosed male-male sexual attraction/behavior to a provider, which may result in some opportunities being missed. C1 [Meites, Elissa; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Krishna, Nevin K.; Oster, Alexandra M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Meites, E (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd NE,MS E-02, Atlanta, GA 30333 USA. EM emeites@cdc.gov OI Meites, Elissa/0000-0002-0077-2591 FU CDC FX Supported by the CDC. NR 17 TC 11 Z9 11 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2013 VL 40 IS 2 BP 154 EP 157 DI 10.1097/OLQ.0b013e31827b9e89 PG 4 WC Infectious Diseases SC Infectious Diseases GA 071TR UT WOS:000313618100013 PM 23321994 ER PT J AU Miller, RA Burdette, SD Levi, M Beekmann, SE Polgreen, PM Kuehnert, MJ AF Miller, R. A. Burdette, S. D. Levi, M. Beekmann, S. E. Polgreen, P. M. Kuehnert, M. J. TI Communication gaps for solid organ transplant-transmitted infections among infectious disease physicians: an Emerging Infections Network survey SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE organ transplant; donor-derived infection; donor screening; transmission; transplant infections ID TRANSMISSION AB Infectious disease (ID) physicians were surveyed concerning knowledge and management of potential transplant-transmitted infections (TTIs). On the basis of cumulative responses to 4 questions that assessed solid organ transplant-related clinical exposures and experience, respondents were divided into 3 groups: most, some, or little transplant experience. Rapid access to donor data was identified as the most important factor when evaluating a potential TTI. Despite varying experience in transplant infections, ID physicians are frequently asked for opinions regarding donor suitability and TTI management. Improved ID physician access to donor information and educational resources will allow more optimal management of potential TTIs. C1 [Miller, R. A.; Beekmann, S. E.; Polgreen, P. M.] Univ Iowa, Carver Coll Med, Dept Internal Med, Div Infect Dis, Iowa City, IA 52242 USA. [Burdette, S. D.] Wright State Univ, Dept Internal Med, Div Infect Dis, Dayton, OH 45435 USA. [Levi, M.] Univ Colorado Denver, Dept Internal Med, Div Infect Dis, Aurora, CO USA. [Kuehnert, M. J.] Ctr Dis Control & Prevent, Off Blood Organ & Other Tissue Safety, Atlanta, GA USA. RP Miller, RA (reprint author), Univ Iowa, Dept Internal Med, SE418 GH,200 Hawkins Dr, Iowa City, IA 52242 USA. EM rachel-miller@uiowa.edu FU Centers for Disease Control and Prevention [U50 CCU112346] FX This study was supported by Grant/Cooperative Agreement Number U50 CCU112346 from the Centers for Disease Control and Prevention. NR 16 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-2273 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD FEB PY 2013 VL 15 IS 1 BP 8 EP 13 DI 10.1111/tid.12002 PG 6 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA 085ZA UT WOS:000314651600012 PM 22958217 ER PT J AU Hung, OY Keenan, NL Fang, J AF Hung, Olivia Y. Keenan, Nora L. Fang, Jing TI Physicians' Health Habits are associated with Lifestyle Counseling for Hypertensive Patients SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE blood pressure; counseling; hypertension; JNC VII lifestyle modification recommendations; personal habits; primary care physicians ID HIGH BLOOD-PRESSURE; JOINT NATIONAL COMMITTEE; PRIMARY-CARE PHYSICIANS; CARDIOVASCULAR-DISEASE; UNITED-STATES; 7TH REPORT; PREVENTION; ADVICE; BARRIERS; ADULTS AB BACKGROUND The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII) recommended lifestyle interventions, either with or without pharmacologic treatment, for all patients with high blood pressure. The objective of this study is to determine the association of physicians' personal habits with their attitudes and behaviors regarding JNC VII lifestyle modification guidelines. METHODS One thousand primary care physicians completed DocStyles 2010, a voluntary web-based survey designed to provide insight into physician attitudes and behaviors regarding various health issues. RESULTS The respondents' average age was 45.3 years, and 68% were male. In regards to physician behavior, 4.0% smoked at least once a week, 38.6% ate >= 5 cups of fruits and/or vegetables >= 5 days/week, and 27.4% exercised >= 5 days/week. When asked about specific types of advice offered to their hypertensive patients, physicians reported recommending that their patients eat a healthy diet (92.2%), or cut down on salt (96.1%), or attain or maintain a healthy weight (94.8%), or limit the use of alcohol (75.4%), or be physically active (94.4%). Collectively, 66.5% made all 5 lifestyle modification recommendations. Nonsmoking physicians were more likely to recommend each lifestyle intervention to their hypertensive patients. Those who exercised at least 1 day per week were more likely to recommend limiting alcohol use. CONCLUSIONS The probability of recommending all 5 JNC VII interventions was greater for physicians who were nonsmoking and who exercised at least 1 day a week. C1 [Hung, Olivia Y.] Emory Univ, Sch Med, Internal Med Residency Program, Atlanta, GA USA. [Keenan, Nora L.; Fang, Jing] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Fang, J (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM jfang@cdc.gov NR 30 TC 7 Z9 7 U1 0 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD FEB PY 2013 VL 26 IS 2 BP 201 EP 208 DI 10.1093/ajh/hps022 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 076RO UT WOS:000313975500012 PM 23382404 ER PT J AU Nakazawa, Y AF Nakazawa, Yoshinori TI Niche breadth, environmental landscape, and physical barriers: their importance as determinants of species distributions SO BIOLOGICAL JOURNAL OF THE LINNEAN SOCIETY LA English DT Article DE biogeography; geographical barriers; range size; virtual species ID BIODIVERSITY HOTSPOTS; CONSERVATION PRIORITIES; LATITUDINAL GRADIENT; DISPERSAL LIMITATION; GEOGRAPHICAL RANGES; SPATIAL-PATTERNS; MOUNTAIN PASSES; POTENTIAL RANGE; SOUTH-AMERICA; RICHNESS AB Species distributions and their patterns in geographical space have been studied for several decades and explained by theories such as Janzen's, with respect to the nature of dispersal barriers in the Tropics, and Rapoport's, with respect to range size. However, the roles of specific environmental and geographical factors (e.g. ecological niche breadth, geographical barriers, etc.) in shaping species ranges and distributional patterns remain largely unexplored. The present study analyzed predictions from these two theories via analysis of virtual species with respect to biogeographical patterns: virtual species were created across South America, covering all major environments on the continent, and were used to compare effects of niche breadth, environmental availability, connectivity, seasonality, and the presence of known biogeographical barriers (rivers) in shaping species distributions and biodiversity patterns. Geographical ranges varied from narrow to broad, depending on the location of the seed point when comparing species produced with the same niche breadth. Analysis without consideration of seasonality and barriers produced species with broader distributions in the Tropics and narrower distributions in montane and temperate regions of the continent. When seasonality was included, however, broader ranges were concentrated in temperate regions, thus supporting Janzen's idea. Rapoport's rule of broader geographical ranges at higher latitudes was supported only when seasonality and physical barriers were included but not in species with very narrow or very broad niches, suggesting that this rule results from interactions among niche breadth, dispersal capabilities, and dispersal barriers. (c) 2012 The Linnean Society of London, Biological Journal of the Linnean Society, 2012, 108, 241250. C1 [Nakazawa, Yoshinori] Univ Kansas, Biodivers Inst, Lawrence, KS 66045 USA. [Nakazawa, Yoshinori] Univ Kansas, Dept Geog, Lawrence, KS 66045 USA. RP Nakazawa, Y (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop G-06, Atlanta, GA 30333 USA. EM ynakazawa@gmail.com FU CONACyT [187671] FX Town Peterson and Jorge Soberon are thanked for their help with the preparation of this manuscript; Andres Lira Noriega and Alberto Jimenez Valverde are thanked for input to the development of the ideas presented in this manuscript; and Mark Robbins is thanked for help with the selection of geographical barriers. Four anonymous reviewers provided helpful comments on earlier versions of the manuscript. I thank CONACyT (187671) for support during the time that this research was conducted. NR 45 TC 5 Z9 5 U1 4 U2 62 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0024-4066 J9 BIOL J LINN SOC JI Biol. J. Linnean Soc. PD FEB PY 2013 VL 108 IS 2 BP 241 EP 250 DI 10.1111/j.1095-8312.2012.02018.x PG 10 WC Evolutionary Biology SC Evolutionary Biology GA 074AP UT WOS:000313784500001 ER PT J AU Shults, RA Bergen, G AF Shults, Ruth A. Bergen, Gwen TI Attitudes towards requiring ignition interlocks for all driving while intoxicated offenders: findings from the 2010 HealthStyles Survey SO INJURY PREVENTION LA English DT Article AB Ignition interlocks are effective in reducing recidivism among driving while intoxicated (DWI) offenders while installed on their vehicles. However, the devices are not widely used in the USA. This survey gauged public support for requiring ignition interlocks for all convicted DWI offenders including first-time offenders. 69% of respondents supported such a policy. Support was lowest (38%) among persons who reported drinking and driving in the past 30 days. Multivariate regression analysis indicated that support varied little by region, community size or most measured individual characteristics. Persons who did not drink and drive were 80% more likely to support the requirement than those who drink and drive. These findings suggest that laws requiring ignition interlocks for all convicted DWI offenders may face the most opposition in communities with high levels of drinking and driving. C1 [Shults, Ruth A.; Bergen, Gwen] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Shults, RA (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30341 USA. EM rshults@cdc.gov NR 16 TC 3 Z9 3 U1 1 U2 9 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 J9 INJURY PREV JI Inj. Prev. PD FEB PY 2013 VL 19 IS 1 BP 68 EP 71 DI 10.1136/injuryprev-2012-040367 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 074ON UT WOS:000313822100012 PM 22773020 ER PT J AU Pollack, KM Gielen, AC Williams, AN Degutis, LC AF Pollack, Keshia M. Gielen, Andrea C. Williams, Amber N. Degutis, Linda C. TI Professional conferences enrich and energise SO INJURY PREVENTION LA English DT Editorial Material C1 [Pollack, Keshia M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Johns Hopkins Ctr Injury Res & Policy, Baltimore, MD 21205 USA. [Gielen, Andrea C.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Johns Hopkins Ctr Injury Res & Policy, Baltimore, MD 21205 USA. [Williams, Amber N.] Safe States Alliance, Atlanta, GA USA. [Degutis, Linda C.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Pollack, KM (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Johns Hopkins Ctr Injury Res & Policy, 624 N Broadway,Room 557, Baltimore, MD 21205 USA. EM kpollack@jhsph.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 J9 INJURY PREV JI Inj. Prev. PD FEB PY 2013 VL 19 IS 1 BP 72 EP 72 DI 10.1136/injuryprev-2012-040725 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 074ON UT WOS:000313822100013 PM 23340681 ER PT J AU Waggoner, JK Henneberger, PK Kullman, GJ Umbach, DM Kamel, F Freeman, LEB Alavanja, MCR Sandler, DP Hoppin, JA AF Waggoner, Jenna K. Henneberger, Paul K. Kullman, Greg J. Umbach, David M. Kamel, Freya Freeman, Laura E. Beane Alavanja, Michael C. R. Sandler, Dale P. Hoppin, Jane A. TI Pesticide use and fatal injury among farmers in the Agricultural Health Study SO INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH LA English DT Article DE Pesticides; Mortality; Wounds and injuries ID RISK-FACTORS; NORTH-CAROLINA; UNITED-STATES; IOWA FARMERS; APPLICATORS; MORTALITY; WORKERS; EXPOSURES; SYMPTOMS; OLDER AB To assess whether pesticide use practices were associated with injury mortality among 51,035 male farmers from NC and IA enrolled in the Agricultural Health Study. We used Cox proportional hazards models adjusted for age and state to estimate fatal injury risk associated with self-reported use of 49 specific pesticides, personal protective equipment, specific types of farm machinery, and other farm factors collected 1-15 years preceding death. Cause-specific mortality was obtained through linkage to mortality registries. We observed 338 injury fatalities over 727,543 person-years of follow-up (1993-2008). Fatal injuries increased with days/year of pesticide application, with the highest risk among those with 60+ days of pesticide application annually [hazard ratio (HR) = 1.87; 95% confidence interval (CI) = 1.10, 3.18]. Chemical-resistant glove use was associated with decreased risk (HR = 0.73; 95% CI = 0.58, 0.93), but adjusting for glove use did not substantially change estimates for individual pesticides or pesticide use overall. Herbicides were associated with fatal injury, even after adjusting for operating farm equipment, which was independently associated with fatal injury. Ever use of five of 18 herbicides (2,4,5-T, paraquat, alachlor, metribuzin, and butylate) were associated with elevated risk. In addition, 2,4-D and cyanazine were associated with fatal injury in exposure-response analyses. There was no evidence of confounding of these results by other herbicides. The association between application of pesticides, particularly certain herbicides, and fatal injuries among farmers should be interpreted cautiously but deserves further evaluation, with particular focus on understanding timing of pesticide use and fatal injury. C1 [Waggoner, Jenna K.; Henneberger, Paul K.; Kullman, Greg J.] NIOSH, Div Resp Dis Studies, CDC, DHHS, Morgantown, WV 26505 USA. [Waggoner, Jenna K.; Kamel, Freya; Sandler, Dale P.; Hoppin, Jane A.] NIEHS, Epidemiol Branch, NIH, DHHS, Res Triangle Pk, NC 27709 USA. [Umbach, David M.] NIEHS, Biostat Branch, NIH, DHHS, Res Triangle Pk, NC 27709 USA. [Freeman, Laura E. Beane; Alavanja, Michael C. R.] NCI, Div Canc Epidemiol & Genet, NIH, DHHS, Rockville, MD USA. RP Hoppin, JA (reprint author), NIEHS, Epidemiol Branch, NIH, DHHS, MD A3-05,POB 12233, Res Triangle Pk, NC 27709 USA. EM hoppin1@niehs.nih.gov RI Beane Freeman, Laura/C-4468-2015; OI Beane Freeman, Laura/0000-0003-1294-4124; Sandler, Dale/0000-0002-6776-0018 FU Association of Schools of Public Health/Centers for Disease Control Fellowship program; National Institute for Occupational Safety and Health; National Institutes of Health, National Institute of Environmental Health Sciences [Z01-ES049030]; National Institutes of Health National Cancer Institute [Z01-CP010119] FX The authors thank Stuart Long for assistance with data analysis. This work was supported by the Association of Schools of Public Health/Centers for Disease Control Fellowship program; the National Institute for Occupational Safety and Health and the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (Z01-ES049030) and the National Institutes of Health National Cancer Institute (Z01-CP010119). NR 30 TC 4 Z9 4 U1 2 U2 48 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-0131 J9 INT ARCH OCC ENV HEA JI Int. Arch. Occup. Environ. Health PD FEB PY 2013 VL 86 IS 2 BP 177 EP 187 DI 10.1007/s00420-012-0752-x PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 077SO UT WOS:000314048400006 PM 22419121 ER PT J AU Park, JB Nakata, A Swanson, NG Chun, H AF Park, Jae Bum Nakata, Akinori Swanson, Naomi G. Chun, Heekyoung TI Organizational factors associated with work-related sleep problems in a nationally representative sample of Korean workers SO INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH LA English DT Article DE Sleep problems; Work organization; Korean Working Conditions Survey; Psychosocial job characteristics; Korea ID EFFORT-REWARD IMBALANCE; PSYCHOSOCIAL JOB STRESS; POOR SLEEP; SICKNESS ABSENCE; MENTAL-HEALTH; SOCIAL SUPPORT; PERCEIVED DISCRIMINATION; OCCUPATIONAL INJURIES; SEXUAL-HARASSMENT; DISTURBED SLEEP AB The purpose of this study was to assess the association of organizational factors with work-related sleep problems (WRSP) among Korean workers. The data were derived from the First Korean Working Conditions Survey conducted in 2006 with a representative sample of the Korean working population (n = 10,039). The overall prevalence of WRSP was 5.1 % (95 % confidence interval (CI) 4.7-5.5). Those who experienced sexual harassment at work (adjusted odds ratio (aOR) 3.47: 95 % CI 1.77-6.81), discrimination due to sex (aOR 2.44: 95 % CI 1.36-4.36) or age (aOR 2.22: 95 % CI 1.52-3.23), violence at work (aOR 1.98: 95 % CI 1.06-3.68), threat of violence (aOR 1.96: 95 % CI 1.05-3.66), poor work-life balance (aOR 1.78: 95 % CI 1.44-2.20), low job satisfaction (aOR 1.69: 95 % CI 1.37-2.09), high cognitive (OR 1.64: 95 % CI 1.32-2.03) and emotional (aOR 1.53: 95 % CI 1.22-1.91) demands, job insecurity (aOR 1.32: 95 % CI 1.07-1.63), and high work intensity (aOR 1.55: 95 % CI: 95 % CI 1.25-1.92) had an increased risk of WRSP compared to their respective counterparts (p < 0.01). Low social support was not significantly associated with WRSP (aOR 0.88: 95 % CI 0.67-1.15). The results revealed that poor psychosocial working conditions may be related to a high prevalence of WRSP among representative Korean workers. C1 [Park, Jae Bum] Ajou Univ, Sch Med, Dept Occupat & Environm Med, Suwon 441749, South Korea. [Park, Jae Bum; Nakata, Akinori; Swanson, Naomi G.] NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Chun, Heekyoung] NIOSH, Educ & Informat Div, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Nakata, A (reprint author), NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM nakataa-tky@umin.ac.jp NR 83 TC 7 Z9 7 U1 6 U2 30 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-0131 J9 INT ARCH OCC ENV HEA JI Int. Arch. Occup. Environ. Health PD FEB PY 2013 VL 86 IS 2 BP 211 EP 222 DI 10.1007/s00420-012-0759-3 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 077SO UT WOS:000314048400009 PM 22426500 ER PT J AU Stanley, SL King, JB Thomas, CC Richardson, LC AF Stanley, Sandte L. King, Jessica B. Thomas, Cheryll C. Richardson, Lisa C. TI Factors Associated with Never Being Screened for Colorectal Cancer SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Colorectal cancer screening; Health disparities; Never screened; Health belief model ID FACTOR SURVEILLANCE SYSTEM; UNITED-STATES; PREVENTIVE SERVICES; INSURANCE-COVERAGE; AFRICAN-AMERICANS; DISPARITIES; INCREASE; ADULTS; OLDER; CARE AB Colorectal cancer (CRC) screening is underused in the United States, and non-adherence with screening recommendations is high in some populations. This study describes the characteristics of people who have never been screened for CRC. In addition, we use the health belief model to examine the constructs associated with screening behavior. We used data from the 2010 Behavioral Risk Factor Surveillance System (BRFSS) to create three study outcomes: people who have been screened for CRC and are up-to-date with current recommendations, people who have been screened but are not up-to-date, and people who have never been screened. We used multivariate logistic regression modeling to calculate predicted marginal estimates examining the associations between the screening outcomes and demographic and Health Belief Model (HBM) characteristics. Overall 29 % of respondents had never been screened for CRC. In the adjusted model, 36.6 % of US adults age 50-59 years and 29.1 % of US men reported never being screened for CRC. More Asian/Native Hawaiian/Pacific Islander, non-Hispanics (38.2 %) reported never being screened than members of other racial and ethnic groups. Nearly 37 % of people with less than a high school diploma reported never being screened. We found statistically significant differences among screening outcomes for all demographics and HBM constructs except could not see a doctor because of costs in the last 12 months, where approximately 29 % reported no CRC screening. New interventions should focus on those subpopulations that have never been screened for CRC. C1 [Stanley, Sandte L.; King, Jessica B.; Thomas, Cheryll C.; Richardson, Lisa C.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Richardson, LC (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,MS K-52, Atlanta, GA 30341 USA. EM lfr8@cdc.gov NR 47 TC 11 Z9 11 U1 1 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 J9 J COMMUN HEALTH JI J. Community Health PD FEB PY 2013 VL 38 IS 1 BP 31 EP 39 DI 10.1007/s10900-012-9600-x PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 073EX UT WOS:000313727400004 PM 22875234 ER PT J AU Shipitsyna, E Zolotoverkhaya, E Chen, CY Chi, KH Grigoryev, A Savicheva, A Ballard, R Domeika, M Unemo, M AF Shipitsyna, E. Zolotoverkhaya, E. Chen, C. Y. Chi, K. H. Grigoryev, A. Savicheva, A. Ballard, R. Domeika, M. Unemo, M. TI Evaluation of polymerase chain reaction assays for the diagnosis of Trichomonas vaginalis infection in Russia SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; FEMALE GENITAL SPECIMENS; WET-MOUNT MICROSCOPY; RISK-FACTORS; CHLAMYDIA-TRACHOMATIS; ADOLESCENT FEMALES; URINE SPECIMENS; PCR; WOMEN; CULTURE AB Background In Russia, the microscopy- and culture-based diagnostics of trichomoniasis is mainly suboptimal. Recent years, domestically produced diagnostic PCR assays have been implemented; however, any evaluation of these PCRs has never been internationally reported. Objective To assess the performance characteristics of PCR assays developed and currently used in Russia to detect Trichomonas vaginalis. Materials and methods Five PCR assays were assessed on 448 samples (317 vaginal and 131 male urethral) collected from symptomatic attendees of youth centres (n = 415) and patients of a dermatovenereological dispensary that were previously diagnosed with trichomoniasis (n = 33). As reference assay, a sensitive and specific real-time multiplex PCR was used. Results T. vaginalis DNA was detected in five (all females) of the 415 patients of youth centres (1.2%). All 33 patients previously diagnosed at the venereological dispensary proved to be true positive. For 445 (99.3%) of these 448 samples identical results were obtained by all PCRs, 35 positive and 410 negative. The three discordant samples were positive in all PCRs except one conventional PCR assay. The sensitivities of the PCRs were 94.3-100% and 66.7-100% for vaginal and urethral swabs, respectively. All evaluated assays were 100% specific. The detection limits of the different PCRs ranged from 0.1 to 5 genome equivalents per reaction. Conclusion The PCR assays currently used in Russia for the detection of T. vaginalis have in general high sensitivities and excellent specificities for both vaginal samples and urethral samples from males. Received: 3 October 2011; Accepted: 3 May 2012 C1 [Shipitsyna, E.; Zolotoverkhaya, E.; Grigoryev, A.; Savicheva, A.] DO Ott Res Inst Obstet & Gynaecol, Microbiol Lab, St Petersburg, Russia. [Chen, C. Y.; Chi, K. H.; Ballard, R.] Ctr Dis Control & Prevent CDC, Lab Reference, Atlanta, GA USA. [Chen, C. Y.; Chi, K. H.; Ballard, R.] Ctr Dis Control & Prevent CDC, Res Branch, Div STD Prevent, Atlanta, GA USA. [Domeika, M.] Uppsala Univ, Dept Med Sci, Uppsala, Sweden. [Unemo, M.] Orebro Univ Hosp, WHO Collaborating Ctr Gonorrhoea & Other STIs, Natl Reference Lab Pathogen Neisseria, Dept Lab Med, Orebro, Sweden. RP Unemo, M (reprint author), Orebro Univ Hosp, WHO Collaborating Ctr Gonorrhoea & Other STIs, Natl Reference Lab Pathogen Neisseria, Dept Lab Med, Orebro, Sweden. EM magnus.unemo@orebroll.se FU Eastern European Network for Sexual and Reproductive Health (EE SRH Network) FX This study was supported by the Eastern European Network for Sexual and Reproductive Health (EE SRH Network). NR 30 TC 3 Z9 4 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0926-9959 EI 1468-3083 J9 J EUR ACAD DERMATOL JI J. Eur. Acad. Dermatol. Venereol. PD FEB PY 2013 VL 27 IS 2 BP E217 EP E223 DI 10.1111/j.1468-3083.2012.04593.x PG 7 WC Dermatology SC Dermatology GA 075KH UT WOS:000313883900013 PM 22672184 ER PT J AU Edmonds, J van Grinsven, E Prow, N Bosco-Lauth, A Brault, AC Bowen, RA Hall, RA Khromykh, AA AF Edmonds, Judith van Grinsven, Erinke Prow, Natalie Bosco-Lauth, Angela Brault, Aaron C. Bowen, Richard A. Hall, Roy A. Khromykh, Alexander A. TI A Novel Bacterium-Free Method for Generation of Flavivirus Infectious DNA by Circular Polymerase Extension Reaction Allows Accurate Recapitulation of Viral Heterogeneity SO JOURNAL OF VIROLOGY LA English DT Article ID WEST-NILE-VIRUS; JAPANESE-ENCEPHALITIS-VIRUS; FULL-LENGTH CDNA; ENVELOPE PROTEIN; KUNJIN VIRUS; IN-VITRO; RT-PCR; RNA; STRAIN; CLONE AB A novel bacterium-free approach for rapid assembly of flavivirus infectious cDNAs using circular polymerase extension reaction was applied to generate infectious cDNA for the virulent New South Wales isolate of the Kunjin strain of West Nile virus (KUNV) that recently emerged in Australia. Recovered virus recapitulated the genetic heterogeneity present in the original isolate. The approach was utilized to generate viral mutants with designed phenotypic properties and to identify E protein glycosylation as one of the virulence determinants. C1 [Edmonds, Judith; van Grinsven, Erinke; Prow, Natalie; Hall, Roy A.; Khromykh, Alexander A.] Univ Queensland, Sch Chem & Mol Biosci, Australian Infect Dis Res Ctr, Brisbane, Qld, Australia. [van Grinsven, Erinke] Univ Utrecht, Grad Sch Life Sci, Utrecht, Netherlands. [Bosco-Lauth, Angela; Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Bowen, Richard A.] Colorado State Univ, Ft Collins, CO 80523 USA. RP Khromykh, AA (reprint author), Univ Queensland, Sch Chem & Mol Biosci, Australian Infect Dis Res Ctr, Brisbane, Qld, Australia. EM a.khromykh@uq.edu.au OI Khromykh, Alexander/0000-0001-6206-6935 FU National Health and Medical Research Council FX The work was supported by grants to A.A.K. from the National Health and Medical Research Council. NR 26 TC 13 Z9 13 U1 1 U2 17 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD FEB PY 2013 VL 87 IS 4 BP 2367 EP 2372 DI 10.1128/JVI.03162-12 PG 6 WC Virology SC Virology GA 078BB UT WOS:000314072000044 PM 23236063 ER PT J AU Dube, SR Thompson, W Homa, DM Zack, MM AF Dube, Shanta R. Thompson, William Homa, David M. Zack, Matthew M. TI Smoking and Health-Related Quality of Life Among U.S. Adolescents SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID ADVERSE CHILDHOOD EXPERIENCES; PSYCHOLOGICAL DISTRESS; NICOTINE DEPENDENCE; RISK BEHAVIORS; MENTAL-HEALTH; YOUTH ASSETS; POPULATION; COMMUNITY; ASSOCIATIONS; NONSMOKERS AB Smoking continues to be a public health problem among youth. Developmentally, adolescence is a period marked by the vulnerability to initiate risk behaviors such as smoking. While studies have documented associations between smoking and poor health related quality of life (HRQOL) among adults, little is known about the association among adolescents. Data on smoking and HRQOL from a sample of 4,848 adolescents aged 1217 years from the 20012008 National Health and Nutrition Examination Surveys were analyzed. Smoking status (current, not current, and never) was determined using self-report data and serum cotinine levels. HRQOL was assessed based on self-reported physical and mental health in the last 30 days, activity limitations in the last 30 days, and general self-rated health. Compared with never smokers, adolescents who ever smoked reported more recent physically unhealthy days (p < .001), mentally unhealthy days (p < .0001), and activity limitation days (p < .01). Compared with never smokers, adolescents who ever smoked or who were current smokers were more likely to report epsilon 14 physically unhealthy days, epsilon 14 mentally unhealthy, epsilon 14 activity limitation days, and fair or poor health; not current smokers were also more likely than never smokers to report epsilon 14 days for being both physically unhealthy and mentally unhealthy. Among a nationally representative sample of adolescents, this study found strong associations between smoking and HRQOL measures. The relationship of smoking to self-reported activity limitations warrants attention and further research. The findings underscore the importance of addressing smoking and subjective well-being early in the lifespan. C1 [Dube, Shanta R.; Homa, David M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30341 USA. [Thompson, William; Zack, Matthew M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA. RP Dube, SR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, 4770 Buford Highway NE,MS K-50, Atlanta, GA 30341 USA. EM skd7@cdc.gov NR 47 TC 12 Z9 12 U1 3 U2 20 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD FEB PY 2013 VL 15 IS 2 BP 492 EP 500 DI 10.1093/ntr/nts163 PG 9 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 074QD UT WOS:000313826600024 PM 22965787 ER PT J AU King, BA Dube, SR Tynan, MA AF King, Brian A. Dube, Shanta R. Tynan, Michael A. TI Flavored Cigar Smoking Among US Adults: Findings From the 2009-2010 National Adult Tobacco Survey SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID BRANDS AB Introduction: Under its authority to regulate tobacco products, the U.S. Food and Drug Administration prohibited certain characterizing flavors in cigarettes in September 2009; however, flavored cigars are still permitted to be manufactured, distributed, and sold. This study assessed the prevalence and correlates of flavored cigar smoking among U.S. adults. Methods: Data were obtained from the 2009-2010 National Adult Tobacco Survey, a national landline and cell phone survey of adults aged >= 18 years old residing in the 50 U.S. states and the District of Columbia. National and state estimates of flavored cigar use were calculated overall and among current cigar smokers; national estimates were calculated by sex, age, race/ethnicity, educational attainment, annual household income, U.S. Census Region, and sexual orientation. Results: The national prevalence of flavored cigar smoking was 2.8% (95% confidence interval [CI] = 2.6%-3.1%; state range: 0.6%-5.7%) and was greater among those who were male, younger in age, non-Hispanic Other race, less educated, less wealthy, and lesbian, gay, bisexual, or transgendered (LGBT). Nationally, the prevalence of flavored cigar use among cigar smokers was 42.9% (95% CI = 40.1%-45.7%; state range: 11.1%-71.6%) and was greater among those who were female, younger in age, Hispanic, non-Hispanic Other race, less educated, less wealthy, and LGBT. Conclusions: More than two fifths of current cigar smokers report using flavored cigars. Disparities in flavored cigar use also exist across states and subpopulations. Efforts to curb flavored cigar smoking have the potential to reduce the prevalence of overall cigar smoking among U.S. adults, particularly among subpopulations with the greatest burden. C1 [King, Brian A.; Dube, Shanta R.; Tynan, Michael A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [King, Brian A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Profess Dev Program Off, Atlanta, GA 30341 USA. RP King, BA (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS K-50, Atlanta, GA 30341 USA. EM baking@cdc.gov NR 26 TC 26 Z9 26 U1 0 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD FEB PY 2013 VL 15 IS 2 BP 608 EP 614 DI 10.1093/ntr/nts178 PG 7 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 074QD UT WOS:000313826600041 PM 22927687 ER PT J AU Pahud, BA Williams, SE Dekker, CL Halsey, N LaRussa, P Baxter, RP Klein, NP Marchant, CD Sparks, RC Jakob, K Aukes, L Swope, S Barnett, E Lewis, P Berger, M Dreskin, SC Donofrio, PD Sejvar, JJ Slade, BA Gidudu, J Vellozzi, C Edwards, KM AF Pahud, Barbara A. Williams, S. Elizabeth Dekker, Cornelia L. Halsey, Neal LaRussa, Philip Baxter, Roger P. Klein, Nicola P. Marchant, Colin D. Sparks, Robert C. Jakob, Kathleen Aukes, Laurie Swope, Susan Barnett, Elizabeth Lewis, Paige Berger, Melvin Dreskin, Stephen C. Donofrio, Peter D. Sejvar, James J. Slade, Barbara A. Gidudu, Jane Vellozzi, Claudia Edwards, Kathryn M. TI Clinical Assessment of Serious Adverse Events in Children Receiving 2009 H1N1 Vaccination SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE monovalent 2009-H1N1 influenza vaccine; adverse event following immunization; influenza vaccine safety; children and adolescents ID GUILLAIN-BARRE-SYNDROME; INFLUENZA-A H1N1; REPORTING SYSTEM; MONOVALENT VACCINES; UNITED-STATES; SAFETY; IMMUNOGENICITY; ADOLESCENTS; NETWORK; VIRUS AB Background: Monovalent 2009 H1N1 influenza vaccines were licensed and administered in the United States during the H1N1 influenza pandemic between 2009 and 2013. Methods: Vaccine Adverse Event Reporting System received reports of adverse events following immunization (AEFI) after H1N1 vaccination. Selected reports were referred to the Centers for Disease Control and Prevention's Clinical Immunization Safety Assessment network for additional review. We assessed causality using modified World Health Organization criteria. Results: There were 3,928 reports of AEFI in children younger than age 18 years after 2009 H1N1 vaccination received by January 31, 2010. Of these, 214 (5.4%) were classified as serious nonfatal and 109 were referred to Clinical Immunization Safety Assessment for further evaluation. Ninety-nine (91%) had sufficient initial information to begin investigation and are described here. The mean age was 8 years (range, 6 months-17 years) and 38% were female. Median number of days between vaccination and symptom onset was 2 (range, -11 days to +41 days). Receipt of inactivated, live attenuated, or unknown type of 2009 H1N1 vaccines was reported by 68, 26 and 5 cases, respectively. Serious AEFI were categorized as neurologic events in 47 cases, as hypersensitivity in 15 cases and as respiratory events in 10 cases. At the time of evaluation, recovery was described as complete (61), partial (16), no improvement (1), or unknown (21). Causality assessment yielded the following likelihood of association with 2009 H1N1 vaccination: 8 definitely; 8 probably; 21 possibly; 43 unlikely; 17 unrelated; and 2 unclassifiable. Conclusions: Most AEFI in children evaluated were not causally related to vaccine and resolved without sequelae. Detailed clinical assessment of individual serious AEFI can provide reassurance of vaccine safety. C1 [Pahud, Barbara A.; Dekker, Cornelia L.; Swope, Susan] Stanford Univ, Med Ctr, Div Pediat Infect Dis, Stanford, CA 94305 USA. [Williams, S. Elizabeth; Sparks, Robert C.; Donofrio, Peter D.; Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Res Program, Nashville, TN USA. [Halsey, Neal] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [LaRussa, Philip; Jakob, Kathleen] Columbia Univ, Coll Phys & Surg, Div Pediat Infect Dis, New York, NY USA. [Baxter, Roger P.; Klein, Nicola P.; Aukes, Laurie] No Calif Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA. [Marchant, Colin D.] Boston Med Ctr, Boston, MA USA. [Lewis, Paige; Sejvar, James J.; Slade, Barbara A.; Gidudu, Jane; Vellozzi, Claudia] Ctr Dis Control & Prevent, Atlanta, GA USA. [Berger, Melvin] CSL Behring LLC, Immunol Res & Dev, King Of Prussia, PA USA. [Dreskin, Stephen C.] Univ Colorado, Dept Med, Div Allergy & Clin Immunol, Denver, CO USA. RP Pahud, BA (reprint author), Childrens Mercy Hosp & Clin, Infect Dis Sect, 2401 Gillham Rd, Kansas City, MO 64108 USA. EM bapahud@cmh.edu OI Barnett, Elizabeth/0000-0003-4822-5949 FU Centers for Disease Control and Prevention (CDC) [200-2002-00732]; Pfizer; PharmaJet, Inc,; Novartis; Sanofi Pasteur; GSK; Merck; Sanofi; MedImmune; SanofiPastuer; Intercell; CSL Behring; DIME FX Supported by a subcontract with America's Health Insurance Plans (AHIP) under contract 200-2002-00732 from the Centers for Disease Control and Prevention (CDC) for the Clinical Immunization Safety Assessment Network. BAP has received a research award from Pfizer. CLD receives support from PharmaJet, Inc, for being part of the Scientific Advisory Board, HVTN as a Safety Monitoring Board consultant and Pfizer as a data monitoring committee consultant. NH receives support from Novartis as a Safety Monitoring Board consultant. PL serves on Data Safety Monitoring Committees for Novaritis. RPB and NPK have received research grants from Sanofi Pasteur, GSK, Novartis, Pfizer, and Merck. CDM receives support from Merck, Sanofi, Pfizer, Novartis, GSK, and MedImmune. EB receives support from SanofiPastuer, Intercell, and Novartis. MB is a consultant for CSL Behring, LLC, for employment and stock options. PDD receives support from CSL Behring and DIME. NR 40 TC 3 Z9 3 U1 0 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD FEB PY 2013 VL 32 IS 2 BP 163 EP 168 DI 10.1097/INF.0b013e318271b90a PG 6 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 075HD UT WOS:000313874500020 PM 23334340 ER PT J AU Ibraheem, M Marin, M Leung, J Bryce, CH Schmid, DS Zaki, SR Drew, C Liu, L Smelser, C AF Ibraheem, Mam Marin, Mona Leung, Jessica Bryce, Clare H. Schmid, D. Scott Zaki, Sherif R. Drew, Clifton Liu, Lindy Smelser, Chad TI FATAL WILD-TYPE VARICELLA-ZOSTER VIRUS ENCEPHALITIS WITHOUT A RASH IN A VACCINATED CHILD SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE encephalitis; varicella aoster; fatal outcome; chickenpox vaccine; zoster sine herpete ID ASEPTIC-MENINGITIS; TIME AB Encephalitis associated with varicella-zoster virus, rare among children in the varicella vaccine era, has generally been associated with a rash. We report fatal wild-type varicella-zoster virus encephalitis without a rash in a child who had received 1 dose of varicella vaccine. Varicella-zoster virus encephalitis should be considered in the differential diagnosis for children presenting with acute neurologic symptoms, even vaccine recipients. C1 [Ibraheem, Mam] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Ibraheem, Mam; Smelser, Chad] New Mexico Dept Hlth, Santa Fe, NM USA. [Marin, Mona; Leung, Jessica; Schmid, D. Scott] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Bryce, Clare H.] Univ New Mexico, Albuquerque, NM 87131 USA. [Zaki, Sherif R.; Drew, Clifton; Liu, Lindy] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Ibraheem, M (reprint author), 1190 St Francis Dr,Suite N1320,POB 26110, Santa Fe, NM 87505 USA. EM mamibraheem@yahoo.com NR 11 TC 4 Z9 4 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD FEB PY 2013 VL 32 IS 2 BP 183 EP 185 DI 10.1097/INF.0b013e318273e43d PG 3 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 075HD UT WOS:000313874500025 PM 22982982 ER PT J AU Thyssen, A Mitchell, M Qvarnstrom, Y Rao, S Benke, TA Glode, MP AF Thyssen, Andreas Mitchell, Michelle Qvarnstrom, Yvonne Rao, Suchitra Benke, Timothy A. Glode, Mary P. TI Eosinophilic Meningitis in a Previously Healthy 13-year-old Child SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Editorial Material DE eosinophilic meningitis; Angiostrongylus; cantonensis; rat lung worm C1 [Thyssen, Andreas; Mitchell, Michelle; Rao, Suchitra; Benke, Timothy A.; Glode, Mary P.] Univ Colorado, Sch Med, Aurora, CO 80045 USA. [Mitchell, Michelle; Rao, Suchitra; Glode, Mary P.] Childrens Hosp Colorado, Dept Infect Dis, Aurora, CO USA. [Qvarnstrom, Yvonne] Ctr Dis Control & Prevent, Atlanta, GA USA. [Benke, Timothy A.] Childrens Hosp Colorado, Dept Neurol Pharmacol & Otolaryngol, Aurora, CO USA. RP Thyssen, A (reprint author), Univ Colorado, Sch Med, Aurora, CO 80045 USA. EM Andreas.Thyssen@ucden-ver.edu FU Intramural CDC HHS [CC999999] NR 0 TC 5 Z9 5 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD FEB PY 2013 VL 32 IS 2 BP 194 EP + DI 10.1097/INF.0b013e31827c9726 PG 6 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 075HD UT WOS:000313874500030 PM 23328824 ER PT J AU Sharma, D Baughman, W Holst, A Thomas, S Jackson, D Carvalho, MD Beall, B Satola, S Jerris, R Jain, S Farley, MM Nuorti, JP AF Sharma, Dolly Baughman, Wendy Holst, Amy Thomas, Stephanie Jackson, Delois Carvalho, Maria da Gloria Beall, Bernard Satola, Sarah Jerris, Robert Jain, Shabnam Farley, Monica M. Nuorti, J. Pekka TI Pneumococcal Carriage and Invasive Disease in Children Before Introduction of the 13-valent Conjugate Vaccine: Comparison With the Era Before 7-valent Conjugate Vaccine SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE Streptococcus pneumoniae; carriage; invasive pneumococcal disease; conjugate vaccines; antimicrobial resistance ID RESISTANT STREPTOCOCCUS-PNEUMONIAE; DAY-CARE-CENTERS; ACUTE OTITIS-MEDIA; UNITED-STATES; SEROTYPE 19A; NASOPHARYNGEAL CARRIAGE; NONVACCINE SEROTYPES; CAPSULAR SEROTYPE; GENETIC-STRUCTURE; INFECTIONS AB Background: Nasopharyngeal (NP) carriage and invasive pneumococcal disease (IPD) attributable to serotypes in the 7-valent pneumococcal conjugate vaccine (PCV7) declined dramatically after vaccine introduction, whereas non-PCV7 serotypes increased modestly. Characteristics of pneumococcal carriage and IPD among children in Atlanta, GA, were compared during 2 time periods: before PCV7 introduction and before 13-valent PCV (PCV13) introduction. Methods: NP swabs from 231 and 451 children 6-59 months old receiving outpatient medical care were obtained in 1995 and 2009, respectively. A total of 202 and 47 IPD cases were identified in children younger than 5 years of age in 1995 and in 2008 to 2009, respectively, through active, population-based surveillance in Atlanta. Isolates were serotyped, sequence-typed (ST) and tested for antimicrobial susceptibility. Results: Forty percent (93/231) of children in 1995 and 31% (139/451) in 2009 were colonized with Streptococcus pneumoniae; 60% and 0.7% were PCV7 serotypes, respectively. In 1995, PCV7 serotypes accounted for 83% and 19A accounted for 5% of IPD compared with no PCV7 serotypes and 19A accounting for 49% of IPD in 2009 (P < 0.001). In 2009, PCV13 serotypes accounted for 22% of carriage (mostly 19A) and 60% of invasive isolates (P < 0.001). ST320 accounted for 66% and 52% of 19A carriage and IPD isolates in 2009, respectively; all ST320 isolates were multidrug-resistant. No ST320 NP or IPD isolates were identified before PCV7. Conclusions: Serotype distribution among NP and IPD isolates in Atlanta has shifted to non-PCV7 serotypes; 19A was the leading serotype for both. The multidrug-resistant ST320 strain was responsible for two-thirds of 19A carriage isolates and half of IPD isolates. The predominance of serotype 19A in carriage and IPD among children in Atlanta highlights the potential direct and indirect benefits anticipated by implementation of PCV13 in the community. C1 [Sharma, Dolly; Satola, Sarah; Jain, Shabnam; Farley, Monica M.] Emory Univ, Sch Med, Atlanta, GA USA. [Sharma, Dolly; Jerris, Robert; Jain, Shabnam] Childrens Healthcare Atlanta, Atlanta, GA USA. [Baughman, Wendy; Holst, Amy; Thomas, Stephanie; Satola, Sarah; Farley, Monica M.] Georgia Emerging Infect Program, Atlanta, GA USA. [Baughman, Wendy; Holst, Amy; Thomas, Stephanie; Satola, Sarah; Farley, Monica M.] Vet Affairs Med Ctr, Atlanta, GA 30033 USA. [Jackson, Delois; Carvalho, Maria da Gloria; Beall, Bernard; Nuorti, J. Pekka] Ctr Dis Control & Prevent CDC, Resp Dis Branch, Atlanta, GA USA. RP Nuorti, JP (reprint author), Univ Tampere, Sch Hlth Sci, FIN-33014 Tampere, Finland. EM Pekka.Nuorti@uta.fi FU Children's Healthcare of Atlanta; Centers for Disease Control and Prevention (CDC), Atlanta, GA; CDC; Children's Healthcare of Atlanta Research Department; ABCs Program of CDC's Emerging Infections Program FX This study was funded by Children's Healthcare of Atlanta and the Centers for Disease Control and Prevention (CDC), Atlanta, GA. WB, AH, ST, SS and MMF participated in a cooperative agreement with the CDC for funding of the Georgia Emerging Infections Program. The authors have no other funding or conflicts of interest to disclose.; The authors thank Jay Butler, Robert Breiman, Daniel Jernigan, Diane Krause, Richard Facklam, John Elliot, Beverly Metchock and Harry Keyserling for their assistance in the 1995 NP survey. The authors thank Georgia Emerging Infections Program personnel for ongoing pneumococcal surveillance activities and laboratory support; Christal Hembree and Emily Crispell for MLST; Matthew Moore at Centers for Disease Control and Prevention (CDC) for ongoing support and guidance; the CDC Respiratory Diseases Branch Streptococcal laboratory for serotype identification and antimicrobial susceptibility testing; the Children's Healthcare of Atlanta Egleston Emergency Department personnel for their contributions toward enrolling and obtaining NP specimens; the Children's Healthcare of Atlanta Egleston Microbiology Laboratory for helping with pneumococcal identification; the Children's Healthcare of Atlanta Research Department for providing funding for the 2009 carriage study, and the ABCs Program of CDC's Emerging Infections Program for providing funding for IPD surveillance. NR 56 TC 33 Z9 35 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD FEB PY 2013 VL 32 IS 2 BP E45 EP E53 DI 10.1097/INF.0b013e3182788fdd PG 9 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 075HD UT WOS:000313874500001 PM 23080290 ER PT J AU Shinoda, N Sullivan, KM Tripp, K Erhardt, JG Haynes, BMH Temple, VJ Woodruff, B AF Shinoda, Naomi Sullivan, Kevin M. Tripp, Katie Erhardt, Juergen G. Haynes, Bridgette M. H. Temple, Victor J. Woodruff, Bradley TI Relationship between markers of inflammation and anaemia in children of Papua New Guinea SO PUBLIC HEALTH NUTRITION LA English DT Article DE Anaemia; Inflammation; C-reactive protein; alpha(1)-Acid glycoprotein; Acute-phase response; Acute-phase proteins; Hb ID C-REACTIVE PROTEIN; VITAMIN-A-DEFICIENCY; ACUTE-PHASE RESPONSE; IRON-DEFICIENCY; ALPHA-1-ACID GLYCOPROTEIN; PREVALENCE; INDICATORS; INFECTION; INFANTS; MALARIA AB Objective: To assess the association of the acute-phase protein biomarkers, C-reactive protein (CRP) and alpha(1)-acid glycoprotein (AGP), with anaemia in children aged 6-59.9 months in Papua New Guinea. Design: A nationally representative household-based cross-sectional survey of children aged 6-59.9 months was used to assess the relationships between various combinations of elevated CRP (>5 mg/l) and AGP (>1.2 g/l) with anaemia. Logistic regression was used to determine if other factors, such as age, sex, measures of anthropometry, region, urban/rural residence and household size, modified or confounded the acute-phase protein-anaemia association. Setting: Papua New Guinea. Subjects: A total of 870 children aged 6-59.9 months from the 2005 Papua New Guinea National Micronutrient Survey were assessed. Results: The following prevalence estimates were found: anaemia 48 %; elevated CRP 32%; and elevated AGP 33%. Children with elevated CRP had a prevalence of anaemia of 66% compared with children with normal CRP who had a prevalence of 40 %. Corresponding estimates for AGP were 61% and 42 %, respectively. Similar results were found with combinations of elevated CRP and AGP. The higher prevalence of anaemia in children with elevated CRP and/or AGP was still present after controlling for confounders. Conclusions: Elevated levels of CRP and AGP were significantly associated with a higher prevalence of anaemia in the children surveyed. There are no expert group recommendations on whether to or how to account for markers of inflammation in presenting results on anaemia prevalence. Additional research would be helpful to clarify this issue. C1 [Shinoda, Naomi; Sullivan, Kevin M.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Sullivan, Kevin M.; Tripp, Katie; Haynes, Bridgette M. H.; Woodruff, Bradley] Ctr Dis Control & Prevent, Atlanta, GA USA. [Erhardt, Juergen G.] Univ Indonesia, SEAMEO TROPMED, Jakarta, Indonesia. [Temple, Victor J.] Univ Papua New Guinea, Sch Med & Hlth Sci, Waigani, Papua N Guinea. RP Sullivan, KM (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Claudia Nance Rollins Bldg CNR,Room 3051,1518 Cli, Atlanta, GA 30322 USA. EM cdckms@emory.edu FU UNICEF; CDC FX The funding sources for this survey were UNICEF and CDC. The findings and conclusions in this publication are those of the authors and do not necessarily represent the official position of the CDC or of the other organizations involved. The authors declare no conflicts of interest. All authors made a substantial contribution to the concept and design, acquisition or analysis and interpretation of data, were involved in drafting or revising the article for intellectual content, and have given approval to the final version of the article. The authors would like to thank the Department of Health Papua New Guinea, UNICEF Papua New Guinea and the University of Papua New Guinea for their continued support in conducting the first Papua New Guinea National Micronutrient Survey. The dedicated efforts of the field workers and data entry team are much appreciated. Special thanks are extended to Wila Saweri and Enoch Posani from the Department of Health and Clementine Yaman, Florence Addo and Karen Codling from UNICEF for their leadership in implementing the survey. The authors also thank Drs David Thurnham and Christine Northrop-Clewes for their insights into this issue of biomarkers of inflammation. NR 26 TC 4 Z9 4 U1 1 U2 4 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 1368-9800 J9 PUBLIC HEALTH NUTR JI Public Health Nutr. PD FEB PY 2013 VL 16 IS 2 BP 289 EP 295 DI 10.1017/S1368980012001267 PG 7 WC Public, Environmental & Occupational Health; Nutrition & Dietetics SC Public, Environmental & Occupational Health; Nutrition & Dietetics GA 076RT UT WOS:000313976100014 PM 22607654 ER PT J AU Heijne, JCM Herzog, SA Althaus, CL Tao, GY Kent, CK Low, N AF Heijne, Janneke Cornelia Maria Herzog, Sereina Annik Althaus, Christian Lorenz Tao, Guoyu Kent, Charlotte Kathleen Low, Nicola TI Insights into the timing of repeated testing after treatment for Chlamydia trachomatis: data and modelling study SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Article ID GENITOURINARY MEDICINE CLINICS; PARTNER NOTIFICATION; INFECTION; WOMEN; REINFECTION; GONORRHEA; COHORT AB Objectives The objective of this study was to determine the optimal time interval for a repeated Chlamydia trachomatis (chlamydia) test. Methods The authors used claims data for US women aged 15-25 years who were enrolled in commercial health insurance plans in the MarketScan database between 2002 and 2006. The authors determined the numbers of initial positive and negative tests that were followed by a repeated test and the positivity of repeated tests. The authors used a dynamic transmission pair model that reflects the partnership formation and separation processes in 15-25 year olds to determine the time course of repeated infections in women under different levels of notifying the current partner. The authors then explored the additional impact of repeated testing uptake on reducing chlamydia prevalence. Results 40% (4949/12 413) of positive tests were followed by a repeated test compared with 22% (89 119/402 659) of negative tests at any time. Positivity of repeated tests followed by an initial positive test was high: 15% (736) after a positive test versus 3% (2886) after a negative test. The transmission model showed a peak in repeated infections between 2 and 5 months after treatment. For a chlamydia testing uptake of 10% per year, the additional impact of repeated testing on reducing chlamydia population prevalence was modest. Conclusions The mathematical model predictions support the recommended interval for repeat chlamydia testing. This study provides information that can be used to design randomised controlled trials to determine more effective interventions to prevent chlamydial reinfection. C1 [Heijne, Janneke Cornelia Maria] Univ Bern, Inst Social & Prevent Med ISPM, Div Clin Epidemiol & Biostat, CH-3012 Bern, Switzerland. [Tao, Guoyu; Kent, Charlotte Kathleen] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Heijne, JCM (reprint author), Univ Bern, Inst Social & Prevent Med ISPM, Div Clin Epidemiol & Biostat, Finkenhubelweg 11, CH-3012 Bern, Switzerland. EM jheijne@ispm.unibe.ch RI Althaus, Christian/F-6008-2015; OI Althaus, Christian/0000-0002-5230-6760; Low, Nicola/0000-0003-4817-8986 FU Swiss National Science Foundation [320030_118424, 320030_135654, PDFMP3-124952, PZ00P3_136737]; US Centers for Disease Control and Prevention (Atlanta, USA) FX This work was supported by the Swiss National Science Foundation (grant numbers 320030_118424, 320030_135654, PDFMP3-124952 and PZ00P3_136737) and the US Centers for Disease Control and Prevention (Atlanta, USA). The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 25 TC 10 Z9 10 U1 2 U2 12 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD FEB PY 2013 VL 89 IS 1 SI SI BP 57 EP 62 DI 10.1136/sextrans-2011-050468 PG 6 WC Infectious Diseases SC Infectious Diseases GA 075LN UT WOS:000313887900017 PM 22683893 ER PT J AU Sasso, AF Schlosser, PM Kedderis, GL Genter, MB Snawder, JE Li, Z Rieth, S Lipscomb, JC AF Sasso, Alan F. Schlosser, Paul M. Kedderis, Gregory L. Genter, Mary Beth Snawder, John E. Li, Zheng Rieth, Susan Lipscomb, John C. TI Application of an Updated Physiologically Based Pharmacokinetic Model for Chloroform to Evaluate CYP2E1-Mediated Renal Toxicity in Rats and Mice SO TOXICOLOGICAL SCIENCES LA English DT Article DE PBPK; chloroform; kidney; renal toxicity; model ID CYTOCHROME P450-DEPENDENT METABOLISM; N-NITROSODIMETHYLAMINE-DEMETHYLASE; REGENERATIVE CELL-PROLIFERATION; CANCER-RISK ASSESSMENT; OSBORNE-MENDEL RATS; FEMALE B6C3F1 MICE; DRINKING-WATER; COMBINED INHALATION; HEPATIC MICROSOMES; SAFETY EVALUATION AB Physiologically based pharmacokinetic (PBPK) models are tools for interpreting toxicological data and extrapolating observations across species and route of exposure. Chloroform (CHCl3) is a chemical for which there are PBPK models available in different species and multiple sites of toxicity. Because chloroform induces toxic effects in the liver and kidneys via production of reactive metabolites, proper characterization of metabolism in these tissues is essential for risk assessment. Although hepatic metabolism of chloroform is adequately described by these models, there is higher uncertainty for renal metabolism due to a lack of species-specific data and direct measurements of renal metabolism. Furthermore, models typically fail to account for regional differences in metabolic capacity within the kidney. Mischaracterization of renal metabolism may have a negligible effect on systemic chloroform levels, but it is anticipated to have a significant impact on the estimated site-specific production of reactive metabolites. In this article, rate parameters for chloroform metabolism in the kidney are revised for rats, mice, and humans. New in vitro data were collected in mice and humans for this purpose and are presented here. The revised PBPK model is used to interpret data of chloroform-induced kidney toxicity in rats and mice exposed via inhalation and drinking water. Benchmark dose (BMD) modeling is used to characterize the dose-response relationship of kidney toxicity markers as a function of PBPK-derived internal kidney dose. Applying the PBPK model, it was also possible to characterize the dose response for a recent data set of rats exposed via multiple routes simultaneously. Consistent BMD modeling results were observed regardless of species or route of exposure. C1 [Sasso, Alan F.; Li, Zheng; Rieth, Susan] US EPA, Natl Ctr Environm Assessment, Off Res & Dev, Washington, DC 20460 USA. [Schlosser, Paul M.] US EPA, Natl Ctr Environm Assessment, Off Res & Dev, Res Triangle Pk, NC 27711 USA. [Genter, Mary Beth] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH USA. [Genter, Mary Beth] Univ Cincinnati, Ctr Environm Genet, Cincinnati, OH USA. [Snawder, John E.] NIOSH, Biomonitoring & Hlth Assessment Branch, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Lipscomb, John C.] US EPA, Natl Ctr Environm Assessment, Off Res & Dev, Cincinnati, OH 45268 USA. RP Sasso, AF (reprint author), 1200 Penn Ave,NW Mail Code 8601P, Washington, DC 20460 USA. EM sasso.alan@epa.gov OI Schlosser, Paul/0000-0002-9699-9108 NR 70 TC 11 Z9 11 U1 0 U2 25 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1096-6080 J9 TOXICOL SCI JI Toxicol. Sci. PD FEB PY 2013 VL 131 IS 2 BP 360 EP 374 DI 10.1093/toxsci/kfs320 PG 15 WC Toxicology SC Toxicology GA 079EL UT WOS:000314153100004 PM 23143927 ER PT J AU Schantz, MM Eppe, G Focant, JF Hamilton, C Heckert, NA Heltsley, RM Hoover, D Keller, JM Leigh, SD Patterson, DG Pintar, AL Sharpless, KE Sjodin, A Turner, WE Vander Pol, SS Wise, SA AF Schantz, Michele M. Eppe, Gauthier Focant, Jean-Francois Hamilton, Coreen Heckert, N. Alan Heltsley, Rebecca M. Hoover, Dale Keller, Jennifer M. Leigh, Stefan D. Patterson, Donald G., Jr. Pintar, Adam L. Sharpless, Katherine E. Sjoedin, Andreas Turner, Wayman E. Vander Pol, Stacy S. Wise, Stephen A. TI Milk and serum standard reference materials for monitoring organic contaminants in human samples SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY LA English DT Article DE Human Serum; Human Milk; SRMs; PCBs; Pesticides PBDEs; PCDFs; PCDDs ID POLYBROMINATED DIPHENYL ETHERS; HIGH-THROUGHPUT EXTRACTION; POLYCHLORINATED-BIPHENYLS; BREAST-MILK; ENVIRONMENTAL-SAMPLES; CLEANUP METHOD; UNITED-STATES; PCB MIXTURES; PBDES; POPULATION AB Four new Standard Reference Materials (SRMs) have been developed to assist in the quality assurance of chemical contaminant measurements required for human biomonitoring studies, SRM 1953 Organic Contaminants in Non-Fortified Human Milk, SRM 1954 Organic Contaminants in Fortified Human Milk, SRM 1957 Organic Contaminants in Non-Fortified Human Serum, and SRM 1958 Organic Contaminants in Fortified Human Serum. These materials were developed as part of a collaboration between the National Institute of Standards and Technology (NIST) and the Centers for Disease Control and Prevention (CDC) with both agencies contributing data used in the certification of mass fraction values for a wide range of organic contaminants including polychlorinated biphenyl (PCB) congeners, chlorinated pesticides, polybrominated diphenyl ether (PBDE) congeners, and polychlorinated dibenzo-p-dioxin (PCDD) and dibenzofuran (PCDF) congeners. The certified mass fractions of the organic contaminants in unfortified samples, SRM 1953 and SRM 1957, ranged from 12 ng/kg to 2200 ng/kg with the exception of 4,4'-DDE in SRM 1953 at 7400 ng/kg with expanded uncertainties generally < 14 %. This agreement suggests that there were no significant biases existing among the multiple methods used for analysis. C1 [Schantz, Michele M.; Sharpless, Katherine E.; Wise, Stephen A.] NIST, Div Analyt Chem, Gaithersburg, MD 20899 USA. [Eppe, Gauthier; Focant, Jean-Francois] Univ Liege, Mass Spectrometry Lab, B-4000 Liege, Belgium. [Hamilton, Coreen; Hoover, Dale] AXYS Analyt Serv Ltd, Sidney, BC V8L 5X2, Canada. [Heckert, N. Alan; Leigh, Stefan D.; Pintar, Adam L.] NIST, Stat Engn Div, Gaithersburg, MD 20899 USA. [Heltsley, Rebecca M.; Keller, Jennifer M.; Vander Pol, Stacy S.] NIST, Div Analyt Chem, Charleston, SC 29412 USA. [Patterson, Donald G., Jr.; Sjoedin, Andreas; Turner, Wayman E.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Schantz, MM (reprint author), NIST, Div Analyt Chem, 100 Bur Dr, Gaithersburg, MD 20899 USA. EM michele.schantz@nist.gov RI Sjodin, Andreas/F-2464-2010; OI Sharpless, Katherine/0000-0001-6569-198X FU Intramural CDC HHS [CC999999] NR 31 TC 8 Z9 8 U1 3 U2 57 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1618-2642 J9 ANAL BIOANAL CHEM JI Anal. Bioanal. Chem. PD FEB PY 2013 VL 405 IS 4 BP 1203 EP 1211 DI 10.1007/s00216-012-6524-3 PG 9 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 073HV UT WOS:000313735000007 PM 23132544 ER PT J AU Tseng, HF Sy, LS Qian, L Marcy, SM Jackson, LA Glanz, J Nordin, J Baxter, R Naleway, A Donahue, J Weintraub, E Jacobsen, SJ AF Tseng, Hung Fu Sy, Lina S. Qian, Lei Marcy, S. Michael Jackson, Lisa A. Glanz, Jason Nordin, Jim Baxter, Roger Naleway, Allison Donahue, James Weintraub, Eric Jacobsen, Steven J. CA Vaccine Safety Datalink VSD Team TI Safety of a Tetanus-Diphtheria-Acellular Pertussis Vaccine When Used Off-Label in an Elderly Population SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Tdap vaccine; matched cohort study; pertussis prevention; adult vaccination ID CONTROLLED CASE-SERIES; REPORTING SYSTEM VAERS; ADVERSE EVENTS; TDAP VACCINE; YOUNG-ADULTS; DATALINK; OUTBREAK AB Background. Published data on the safety of tetanus-diphtheria-acellular pertussis vaccine (Tdap) in persons aged >= 65 years are limited. This study aims to examine a large cohort of Tdap users >= 65 years for evidence of increased risk of adverse events following vaccination. Methods. A matched cohort study design and a self-controlled case series (SCCS) design were used. The study population was adults aged >= 65 years who received the Tdap or tetanus and diphtheria (Td) vaccine during 1 January 2006-31 December 2010 at 7 health maintenance organizations in the United States. Seven major groups of prespecified events were identified electronically by diagnostic codes. Results. The study included 119 573 Tdap vaccinees and the same number of Td vaccinees. The results indicated that the risk of the prespecified events following Tdap was comparable to that following Td vaccination in this elderly population. There was a small increased rate of codes suggesting medically attended inflammatory or allergic events in 1-6 days following Tdap in the SCCS analysis (incidence rate ratio, 1.59 [95% confidence interval, 1.40-1.81]). Conclusion. Although there is a small increased risk of medically attended inflammatory or allergic events in 1-6 days following Tdap compared to other time periods, it is no more common than that following Td. This study provides empirical safety data suggesting that immunizing adults aged >= 65 years with Tdap to reduce the risk of pertussis in the elderly and their contacts should not have untoward safety consequences. C1 [Tseng, Hung Fu; Sy, Lina S.; Qian, Lei; Marcy, S. Michael; Jacobsen, Steven J.] Kaiser Permanente So Calif, Pasadena, CA USA. [Jackson, Lisa A.] Grp Hlth Res Inst, Seattle, WA USA. [Glanz, Jason] Kaiser Permanente Colorado, Denver, CO USA. [Nordin, Jim] Hlth Partners Res Fdn, Minneapolis, MN USA. [Baxter, Roger] Kaiser Permanente No Calif, Oakland, CA USA. [Naleway, Allison] Kaiser Permanente NW, Portland, OR USA. [Donahue, James] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA. [Weintraub, Eric] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. RP Tseng, HF (reprint author), Kaiser Permanente, So Calif Permanente Med Grp, Dept Res & Evaluat, 100 S Los Robles Ave,2nd Floor, Pasadena, CA 91101 USA. EM hung-fu.x.tseng@kp.org OI Naleway, Allison/0000-0001-5747-4643; Jacobsen, Steven/0000-0002-8174-8533 FU America's Health Insurance Plans from the CDC [200-2002-00732]; Novartis Vaccine; Merck Co; Novartis; Pfizer; Sanofi Pasteur; GlaxoSmithKline FX This work was supported by a subcontract with America's Health Insurance Plans (contract 200-2002-00732 from the CDC).; H. F. T., L. S. S., and S. J. J. have received support from Novartis Vaccine. S. J. J. has served as an unpaid consultant for Merck. R. B. has received research support from Merck & Co, Novartis, Pfizer, and Sanofi Pasteur. L. A. J. has received research support from GlaxoSmithKline, Sanofi Pasteur, Pfizer, and Novartis Vaccine. All other authors report no potential conflicts. NR 22 TC 8 Z9 8 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2013 VL 56 IS 3 BP 315 EP 321 DI 10.1093/cid/cis871 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 071TM UT WOS:000313617400006 PM 23196953 ER PT J AU Rodgers, L Martin, SW Cohn, A Budd, J Marcon, M Terranella, A Mandal, S Salamon, D Leber, A Tondella, ML Tatti, K Spicer, K Emanuel, A Koch, E McGlone, L Pawloski, L LeMaile-Williams, M Tucker, N Iyer, R Clark, TA DiOrio, M AF Rodgers, Loren Martin, Stacey W. Cohn, Amanda Budd, Jeremy Marcon, Mario Terranella, Andrew Mandal, Sema Salamon, Douglas Leber, Amy Tondella, Maria-Lucia Tatti, Kathleen Spicer, Kevin Emanuel, Allen Koch, Elizabeth McGlone, Londell Pawloski, Lucia LeMaile-Williams, Mysheika Tucker, Naomi Iyer, Radhika Clark, Thomas A. DiOrio, Mary TI Epidemiologic and Laboratory Features of a Large Outbreak of Pertussis-Like Illnesses Associated With Cocirculating Bordetella holmesii and Bordetella pertussis-Ohio, 2010-2011 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE pertussis; Bordetella holmesii; PCR; outbreak; Bordetella pertussis ID TIME PCR ASSAY; POLYMERASE-CHAIN-REACTION; SUSPECTED PERTUSSIS; UNITED-STATES; BRONCHISEPTICA; SYMPTOMS; SEQUENCE; DNA; ADOLESCENTS; BACTEREMIA AB Background. During 9 May 2010-7 May 2011, an outbreak of pertussis-like illness (incidence, 80 cases per 100 000 persons) occurred in Franklin County, Ohio. The majority of cases were identified by IS481-directed polymerase chain reaction (PCR), which does not differentiate among Bordetella species. We sought to determine outbreak etiology and epidemiologic characteristics. Methods. We obtained demographic, clinical, and vaccination-related data from the Ohio Disease Reporting System and Impact Statewide Immunization Information System. We tested sera from 14 patients for anti-pertussis toxin (PT) antibodies and used species-specific PCR on 298 nasopharyngeal specimens. Results. Reported cases totaled 918. IS481 results were available for 10 serologically tested patients; 5 of 10 had discordant anti-PT antibody and IS481 results, suggestive of Bordetella holmesii, which lacks PT and harbors IS481. We identified specific Bordetella species in 164 of 298 specimens tested with multitarget PCR; B. holmesii and Bordetella pertussis were exclusively detected among 48 (29%) and 112 (68%), respectively; both were detected in 4 (2%). Among 48 patients with B. holmesii infections, 63% were aged 11-18 years, compared with 35% of 112 patients with B. pertussis infections (P =.001). Symptoms were similar among B. holmesii- and B. pertussis-infected patients. Adolescent pertussis ("Tdap") booster vaccinations were more effective against B. pertussis than B. holmesii (effectiveness: 67% and 36%, respectively; 95% confidence intervals, 38%-82% and -33% to 69%, respectively). Conclusions. We report the first documented mixed outbreak of B. pertussis and B. holmesii infections. Bordetella holmesii particularly affected adolescents. Although laboratory capacity limitations might inhibit routine use of multitarget PCR for clinical diagnosis, focused testing and enhanced surveillance might improve understanding the burden of B. holmesii infection. C1 [Rodgers, Loren] Ctr Dis Control & Prevent, Immunizat Informat Syst Support Branch, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off,Off Surveillan, Atlanta, GA 30333 USA. [Martin, Stacey W.; Cohn, Amanda; Terranella, Andrew; Mandal, Sema; Tondella, Maria-Lucia; Tatti, Kathleen; McGlone, Londell; Pawloski, Lucia; Clark, Thomas A.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Rodgers, Loren; Budd, Jeremy; DiOrio, Mary] Ohio Dept Hlth, Columbus, OH 43266 USA. [Marcon, Mario; Salamon, Douglas; Leber, Amy; Spicer, Kevin] Nationwide Childrens Hosp, Dept Lab Med, Columbus, OH USA. [Marcon, Mario; Leber, Amy; Spicer, Kevin] Ohio State Univ, Coll Med, Columbus, OH 43210 USA. [Emanuel, Allen; Koch, Elizabeth; LeMaile-Williams, Mysheika; Tucker, Naomi] Columbus Publ Hlth, Columbus, OH USA. [Iyer, Radhika] Franklin Cty Publ Hlth, Columbus, OH USA. RP Rodgers, L (reprint author), Ctr Dis Control & Prevent, Immunizat Informat Syst Support Branch, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off,Off Surveillan, 1600 Clifton Rd NE,Mailstop A-19, Atlanta, GA 30333 USA. EM lrodgers@cdc.gov NR 31 TC 57 Z9 60 U1 2 U2 14 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2013 VL 56 IS 3 BP 322 EP 331 DI 10.1093/cid/cis888 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 071TM UT WOS:000313617400007 PM 23087388 ER PT J AU Kristiansen, PA Diomande, F Ba, AK Sanou, I Ouedraogo, AS Ouedraogo, R Sangare, L Kandolo, D Ake, F Saga, IM Clark, TA Misegades, L Martin, SW Thomas, JD Tiendrebeogo, SR Hassan-King, M Djingarey, MH Messonnier, NE Preziosi, MP LaForce, FM Caugant, DA AF Kristiansen, Paul A. Diomande, Fabien Ba, Absatou Ky Sanou, Idrissa Ouedraogo, Abdoul-Salam Ouedraogo, Rasmata Sangare, Lassana Kandolo, Denis Ake, Flavien Saga, Inger Marie Clark, Thomas A. Misegades, Lara Martin, Stacey W. Thomas, Jennifer Dolan Tiendrebeogo, Sylvestre R. Hassan-King, Musa Djingarey, Mamoudou H. Messonnier, Nancy E. Preziosi, Marie-Pierre LaForce, F. Marc Caugant, Dominique A. TI Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Neisseria meningitidis; meningitis belt; conjugate vaccine; carriage; herd immunity ID PNEUMOCOCCAL CONJUGATE; BURKINA-FASO; NEISSERIA-MENINGITIDIS; DISEASE; IMMUNIZATION; EXPERIENCE; EPIDEMIC; CHILDREN; AFRICA AB Background. The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first introduced in mass vaccination campaigns of 1-29-year-olds in Burkina Faso in 2010. It is not known whether MenAfriVac has an impact on NmA carriage. Methods. We conducted a repeated cross-sectional meningococcal carriage study in a representative portion of the 1-29-year-old population in 3 districts in Burkina Faso before and up to 13 months after vaccination. One district was vaccinated in September 2010, and the other 2 were vaccinated in December 2010. We analyzed 25 521 oropharyngeal samples, of which 22 093 were obtained after vaccination. Results. In October-November 2010, NmA carriage prevalence in the unvaccinated districts was comparable to the baseline established in 2009, but absent in the vaccinated district. Serogroup X N. meningitidis (NmX) dominated in both vaccinated and unvaccinated districts. With 4 additional sampling campaigns performed throughout 2011 in the 3 districts, overall postvaccination meningococcal carriage prevalence was 6.95%, with NmX dominating but declining for each campaign (from 8.66% to 1.97%). Compared with a baseline NmA carriage prevalence of 0.39%, no NmA was identified after vaccination. Overall vaccination coverage in the population sampled was 89.7%, declining over time in 1-year-olds (from 87.1% to 26.5%), as unvaccinated infants reached 1 year of age. NmA carriage was eliminated in both the vaccinated and unvaccinated population from 3 weeks up to 13 months after mass vaccination (P = .003). Conclusions. The disappearance of NmA carriage among both vaccinated and unvaccinated populations is consistent with a vaccine-induced herd immunity effect. C1 [Kristiansen, Paul A.] Univ Oslo, WHO Collaborating Ctr Reference & Res Meningococc, Norwegian Inst Publ Hlth, N-0403 Oslo, Norway. [Caugant, Dominique A.] Univ Oslo, Fac Med, N-0403 Oslo, Norway. [Diomande, Fabien; Kandolo, Denis; Djingarey, Mamoudou H.] WHO Intercountry Support Team, Ouagadougou, Burkina Faso. [Ba, Absatou Ky] Lab Natl Sante Publ, Ouagadougou, Burkina Faso. [Sanou, Idrissa; Sangare, Lassana] Ctr Hosp Univ Yalgado Ouedraogo, Ouagadougou, Burkina Faso. [Ouedraogo, Rasmata] Ctr Hosp Univ Pediat Charles de Gaulle, Ouagadougou, Burkina Faso. [Kandolo, Denis; Ake, Flavien] WHO Multidis Surveillance Ctr, Ouagadougou, Burkina Faso. [Tiendrebeogo, Sylvestre R.] Minist Hlth, Direct Lutte Malad, Ouagadougou, Burkina Faso. [Sanou, Idrissa; Ouedraogo, Abdoul-Salam] Ctr Hosp Univ Souro Sanou, Bobo Dioulasso, Burkina Faso. [Diomande, Fabien; Clark, Thomas A.; Misegades, Lara; Martin, Stacey W.; Thomas, Jennifer Dolan; Messonnier, Nancy E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hassan-King, Musa; Preziosi, Marie-Pierre; LaForce, F. Marc] Meningitis Vaccine Project, Ferney Voltaire, France. [Preziosi, Marie-Pierre] WHO Initiat Vaccine Res, Geneva, Switzerland. RP Kristiansen, PA (reprint author), Univ Oslo, WHO Collaborating Ctr Reference & Res Meningococc, Norwegian Inst Publ Hlth, POB 4404 Nydalen, N-0403 Oslo, Norway. EM paul.kristiansen@fhi.no FU Research Council of Norway [185784, 196327] FX This project was supported by the Research Council of Norway (grants 185784, 196327 to D. A. C.). NR 32 TC 83 Z9 83 U1 1 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2013 VL 56 IS 3 BP 354 EP 363 DI 10.1093/cid/cis892 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 071TM UT WOS:000313617400012 PM 23087396 ER PT J AU Juliao, PC Maslanka, S Dykes, J Gaul, L Bagdure, S Granzow-Kibiger, L Salehi, E Zink, D Neligan, RP Barton-Behravesh, C Luquez, C Biggerstaff, M Lynch, M Olson, C Williams, I Barzilay, EJ AF Juliao, Patricia C. Maslanka, Susan Dykes, Janet Gaul, Linda Bagdure, Satish Granzow-Kibiger, Lynae Salehi, Ellen Zink, Donald Neligan, Robert P. Barton-Behravesh, Casey Luquez, Carolina Biggerstaff, Matthew Lynch, Michael Olson, Christine Williams, Ian Barzilay, Ezra J. TI National Outbreak of Type A Foodborne Botulism Associated With a Widely Distributed Commercially Canned Hot Dog Chili Sauce SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE botulism; commercial canning; outbreak; foodborne botulism ID CLOSTRIDIUM-BOTULINUM; UNITED-STATES; FOOD AB Background. On 7 and 11 July 2007, health officials in Texas and Indiana, respectively, reported 4 possible cases of type A foodborne botulism to the US Centers for Disease Control and Prevention. Foodborne botulism is a rare and sometimes fatal illness caused by consuming foods containing botulinum neurotoxin. Methods. Investigators reviewed patients' medical charts and food histories. Clinical specimens and food samples were tested for botulinum toxin and neurotoxin-producing Clostridium species. Investigators conducted inspections of the cannery that produced the implicated product. Results. Eight confirmed outbreak associated cases were identified from Indiana (n = 2), Texas (n = 3), and Ohio (n = 3). Botulinum toxin type A was identified in leftover chili sauce consumed by the Indiana patients and 1 of the Ohio patients. Cannery inspectors found violations of federal canned-food regulations that could have led to survival of Clostridium botulinum spores during sterilization. The company recalled 39 million cans of chili. Following the outbreak, the US Food and Drug Administration inspected other canneries with similar canning systems and issued warnings to the industry about the danger of C. botulinum and the importance of compliance with canned food manufacturing regulations. Conclusions. Commercially produced hot dog chili sauce caused these cases of type A botulism. This is the first US foodborne botulism outbreak involving a commercial cannery in >30 years. Sharing of epidemiologic and laboratory findings allowed for the rapid identification of implicated food items and swift removal of potentially deadly products from the market by US food regulatory authorities. C1 [Juliao, Patricia C.; Barton-Behravesh, Casey; Biggerstaff, Matthew; Lynch, Michael; Olson, Christine; Williams, Ian; Barzilay, Ezra J.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA USA. [Juliao, Patricia C.; Barton-Behravesh, Casey; Williams, Ian] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Maslanka, Susan; Dykes, Janet; Luquez, Carolina] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA USA. [Gaul, Linda; Bagdure, Satish] Texas Dept State Hlth Serv, Austin, TX USA. [Granzow-Kibiger, Lynae] Indiana State Dept Hlth, Indianapolis, IN 46202 USA. [Salehi, Ellen] Ohio Dept Hlth, Columbus, OH 43266 USA. [Zink, Donald; Neligan, Robert P.] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA. RP Juliao, PC (reprint author), 179 Pine Bluffs, Roscommon, MI 48653 USA. EM pcjuliao@gmail.com RI bagdure, satish/L-5622-2013 FU CDC; US Food and Drug Administration; USDA; state health department of Texas, Indiana; state health department of Texas, Ohio FX This work was supported by the CDC; the US Food and Drug Administration; the USDA; and the state health departments of Texas, Indiana, and Ohio. NR 26 TC 8 Z9 8 U1 1 U2 37 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2013 VL 56 IS 3 BP 376 EP 382 DI 10.1093/cid/cis901 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 071TM UT WOS:000313617400016 PM 23097586 ER PT J AU Pollack, LA Gould, CV Srinivasan, A AF Pollack, Lori A. Gould, Carolyn V. Srinivasan, Arjun TI If Not Now, When? Seizing the Moment for Antibiotic Stewardship SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Editorial Material ID CLOSTRIDIUM-DIFFICILE INFECTION; IMPACT; RISK C1 [Pollack, Lori A.; Gould, Carolyn V.; Srinivasan, Arjun] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Srinivasan, A (reprint author), 1600 Clifton Rd,Mailstop A-07, Atlanta, GA 30333 USA. EM beu8@cdc.gov NR 11 TC 3 Z9 3 U1 0 U2 6 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD FEB PY 2013 VL 34 IS 2 BP 117 EP 118 DI 10.1086/669228 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 068KS UT WOS:000313366200002 PM 23295555 ER PT J AU Yanni, EA Naoum, M Odeh, N Han, P Coleman, M Burke, H AF Yanni, Emad A. Naoum, Marwan Odeh, Nedal Han, Pauline Coleman, Margaret Burke, Heather TI The Health Profile and Chronic Diseases Comorbidities of US-Bound Iraqi Refugees Screened by the International Organization for Migration in Jordan: 2007-2009 SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Iraqi refugees; Chronic disease comorbidities; Hypertension; Diabetes; Obesity; Hereditary blood disorders; Consanguinity ID ARAB-AMERICANS; COST-EFFECTIVENESS; UNITED-STATES; HYPERTENSION; RISK; IMMIGRANTS; MICHIGAN; CARE AB More than 63,000 Iraqi refugees were resettled in the United States from 1994 to 2010. We analyzed data for all US-bound Iraqi refugees screened in International Organization for Migration clinics in Jordan during June 2007-September 2009 (n = 18,990), to describe their health profile before arrival in the United States. Of 14,077 US-bound Iraqi refugees a parts per thousand yen15 years of age, one had active TB, 251 had latent TB infection, and 14 had syphilis. No HIV infections were reported. Chronic diseases comorbidities accounted for a large burden of disease in this population: 35% (n = 4,105) of screened Iraqi refugees had at least one of three chronic medical conditions; hypertension, diabetes mellitus, or obesity. State health departments and clinicians who screen refugees need to be aware of the high prevalence of chronic diseases among Iraqi refugees resettled in the United States. These results will help public health specialists develop policies to reduce morbidity and mortality among US-bound Iraqi refugees. C1 [Yanni, Emad A.; Han, Pauline; Coleman, Margaret; Burke, Heather] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30333 USA. [Naoum, Marwan; Odeh, Nedal] Int Org Migrat, Migrat Hlth Assessment Ctr IOM, Amman, Jordan. RP Yanni, EA (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging Zoonot & Infect Dis, 1600 Clifton Rd NE,MS E03, Atlanta, GA 30333 USA. EM eyanni@cdc.gov NR 38 TC 16 Z9 16 U1 1 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD FEB PY 2013 VL 15 IS 1 BP 1 EP 9 DI 10.1007/s10903-012-9578-6 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 070GB UT WOS:000313493400001 PM 22307545 ER PT J AU Baddley, JW Andes, DR Marr, KA Kauffman, CA Kontoyiannis, DP Ito, JI Schuster, MG Brizendine, KD Patterson, TF Lyon, GM Boeckh, M Oster, RA Chiller, T Pappas, PG AF Baddley, John W. Andes, David R. Marr, Kieren A. Kauffman, Carol A. Kontoyiannis, Dimitrios P. Ito, James I. Schuster, Mindy G. Brizendine, Kyle D. Patterson, Thomas F. Lyon, G. Marshall Boeckh, Michael Oster, Robert A. Chiller, Tom Pappas, Peter G. TI Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis SO MEDICAL MYCOLOGY LA English DT Article DE aspergillosis; combination therapy; voriconazole; Aspergillus ID HEMATOPOIETIC STEM-CELL; SURVEILLANCE NETWORK TRANSNET; FUNGAL-INFECTIONS; IMMUNOCOMPROMISED PATIENTS; UNITED-STATES; AMPHOTERICIN-B; MORTALITY; RECIPIENTS; OUTCOMES; COSTS AB The impact of antifungal therapy on economic outcomes in patients with invasive aspergillosis (IA) needs further exploration. The purpose of this study was to describe antifungal therapy and factors associated with hospital length of stay (LOS) in transplant patients with IA. Patients were enrolled from March 2001 to October 2005 and IA cases identified through March 2006 from a sub-group of patients in the Transplant Associated Infection Surveillance Network (TRANSNET). Factors associated with hospital LOS were determined by logistic regression analysis. Of 361 patients, the mean age was 49 years, 60.7% were male, and 63% were hematopoietic stem cell transplantation (HSCT) recipients. Primary monotherapy was used in 233 (64.5%) patients, of which voriconazole (93/233, 39.9%) was most commonly used antifungal. Primary combination therapy was used in 128 (35.4%) of 361 patients, with voriconazole plus caspofungin (81/361, 22.4%) the most frequently employed. Mean duration of therapy was 115 days (HSCT 109.7; solid organ transplant [SOT] 125.3). Mean hospital LOS was 35.3 days (HSCT 38.7; SOT 29.7). Regression analysis identified disseminated IA, neutropenia, malnutrition and length of ICU stay as factors associated with increased hospital LOS. Initial voriconazole use was associated with decreased LOS. Further investigation on impact of antifungal therapy on economic outcomes is needed. C1 [Baddley, John W.] Univ Alabama Birmingham, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA. [Baddley, John W.; Brizendine, Kyle D.; Oster, Robert A.; Pappas, Peter G.] Birmingham VA Med Ctr, Birmingham, AL USA. [Andes, David R.] Univ Wisconsin, Dept Med, Madison, WI USA. [Marr, Kieren A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Kauffman, Carol A.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Kauffman, Carol A.] Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Med, Houston, TX 77030 USA. [Ito, James I.] City Hope Natl Med Ctr, Dept Med, Los Angeles, CA USA. [Schuster, Mindy G.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Patterson, Thomas F.] S Texas Vet Healthcare Syst, San Antonio, TX USA. [Lyon, G. Marshall] Emory Univ, Dept Med, Atlanta, GA 30322 USA. [Boeckh, Michael] Fred Hutchinson Canc Res Ctr, Dept Med, Seattle, WA 98104 USA. [Chiller, Tom] Ctr Dis Control, Mycot Dis Branch, Atlanta, GA 30333 USA. RP Baddley, JW (reprint author), Univ Alabama Birmingham, Div Infect Dis, Dept Med, 1900 Univ Blvd,229 Tinsley Harrison Tower, Birmingham, AL 35294 USA. EM jbaddley@uab.edu FU Centers for Disease Control (CDC); Astellas; Pfizer; Merck; Schering Plough; NIH [K23AI064613, K24AI085118]; Schering-Plough; Astella Pharma Inc.; Enzon Pharmaceuticals; Merck and Co., Inc.; Basilea; Qiagen; T2 Biosystems FX TRANSNET was sponsored by the Centers for Disease Control (CDC), Astellas, Pfizer, Merck, and Schering Plough. Pfizer sponsored additional treatment data collection. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Centers of Disease Control and Prevention.; JWB was sponsored in part by NIH K23AI064613. He is on the advisory board or consulting for Pfizer and Merck. DRA receives research grants from Merck, Astellas and Pfizer and is a consultant for Astellas, Novartis, Merck, Schering Plough. KAM is sponsored in part by NIH K24AI085118 and receives research grants from Merck, Astellas and Pfizer. He is on the advisory board or consulting for Astellas, Basilea, Merck, Pfizer, Schering Plough. CAK receives research grants from Merck and is on the data adjudication Board, Pfizer, and the Data Safety Monitoring Board, Merck. DPK has received research support and honoraria from Schering-Plough, Pfizer, Astella Pharma Inc., Enzon Pharmaceuticals, and Merck and Co., Inc. JII is on the speakers' bureaux for Astellas, Enzon, Merck, Pfizer, Schering-Plough and is a consultant for Enzon, Sigma Tau. TFP receives research grants from Astellas, Basilea, Merck, Pfizer and Schering-Plough and is on the advisory boards or consulting for Astellas, Basilea, Merck, Pfizer and Toyoma. GML is on the advisory board for Merck and receives research funding from Pfizer, Astellas and Qiagen. PGP receives research support and is an ad hoc advisor for Merck, Pfizer, Astellas, Basilea and T2 Biosystems. The remaining authors have no conflicts of interest for this subject matter. The authors alone are responsible for the content and writing of the paper. NR 20 TC 13 Z9 14 U1 2 U2 9 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1369-3786 J9 MED MYCOL JI Med. Mycol. PD FEB PY 2013 VL 51 IS 2 BP 128 EP 135 DI 10.3109/13693786.2012.690108 PG 8 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA 072MQ UT WOS:000313676100003 PM 22680976 ER PT J AU Hayman, DTS Bowen, RA Cryan, PM McCracken, GF O'Shea, TJ Peel, AJ Gilbert, A Webb, CT Wood, JLN AF Hayman, D. T. S. Bowen, R. A. Cryan, P. M. McCracken, G. F. O'Shea, T. J. Peel, A. J. Gilbert, A. Webb, C. T. Wood, J. L. N. TI Ecology of Zoonotic Infectious Diseases in Bats: Current Knowledge and Future Directions SO ZOONOSES AND PUBLIC HEALTH LA English DT Review DE Epidemiology; zoonoses; mathematical modeling; Nipah virus; public health; rabies; filovirus; coronavirus ID BIG BROWN BATS; FREE-TAILED BATS; WHITE-NOSE SYNDROME; HENDRA VIRUS-INFECTION; MIGRATORY TREE-BATS; SILVER-HAIRED BATS; RABIES-VIRUS; NIPAH VIRUS; FRUIT BAT; EPTESICUS-FUSCUS AB Bats are hosts to a range of zoonotic and potentially zoonotic pathogens. Human activities that increase exposure to bats will likely increase the opportunity for infections to spill over in the future. Ecological drivers of pathogen spillover and emergence in novel hosts, including humans, involve a complex mixture of processes, and understanding these complexities may aid in predicting spillover. In particular, only once the pathogen and host ecologies are known can the impacts of anthropogenic changes be fully appreciated. Cross-disciplinary approaches are required to understand how host and pathogen ecology interact. Bats differ from other sylvatic disease reservoirs because of their unique and diverse lifestyles, including their ability to fly, often highly gregarious social structures, long lifespans and low fecundity rates. We highlight how these traits may affect infection dynamics and how both host and pathogen traits may interact to affect infection dynamics. We identify key questions relating to the ecology of infectious diseases in bats and propose that a combination of field and laboratory studies are needed to create data-driven mechanistic models to elucidate those aspects of bat ecology that are most critical to the dynamics of emerging bat viruses. If commonalities can be found, then predicting the dynamics of newly emerging diseases may be possible. This modelling approach will be particularly important in scenarios when population surveillance data are unavailable and when it is unclear which aspects of host ecology are driving infection dynamics. C1 [Hayman, D. T. S.; Peel, A. J.; Wood, J. L. N.] Univ Cambridge, Dept Vet Med, Dis Dynam Unit, Cambridge, England. [Hayman, D. T. S.; Webb, C. T.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA. [Hayman, D. T. S.; Peel, A. J.] Zool Soc London, Inst Zool, London NW1 4RY, England. [Hayman, D. T. S.] Anim Hlth & Vet Labs Agcy, Weybridge, Surrey, England. [Bowen, R. A.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA. [Cryan, P. M.; O'Shea, T. J.] US Geol Survey, Ft Collins Sci Ctr, Ft Collins, CO USA. [McCracken, G. F.] Univ Tennessee, Dept Ecol & Evolutionary Biol, Knoxville, TN USA. [Gilbert, A.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Hayman, DTS (reprint author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA. EM davidtshayman@gmail.com RI Wood, James/A-1626-2008; APHA, Staff publications/E-6082-2010; Peel, Alison/I-3202-2012; OI McCracken, Gary/0000-0002-2493-8103; Wood, James/0000-0002-0258-3188; Peel, Alison/0000-0003-3538-3550; Cryan, Paul/0000-0002-2915-8894 FU Wellcome Trust; David H. Smith Conservation Research Fellowship; Research and Policy for Infectious Disease Dynamics program of the Science and Technology Directorate; Department of Homeland Security; Fogarty International Center; National Institutes of Health; Oak Ridge Institute for Science and Education (ORISE); Alborada Trust FX We thank Dr. Gudrun Wibbelt for the invitation to contribute to this special edition and anonymous reviewers for their constructive advice. The authors are funded by the Wellcome Trust (DTSH), a David H. Smith Conservation Research Fellowship (DTSH), the Research and Policy for Infectious Disease Dynamics program of the Science and Technology Directorate, Department of Homeland Security, Fogarty International Center, National Institutes of Health (DTSH, JLNW, TJO, RAB, CTW). AG is supported by a fellowship through the Oak Ridge Institute for Science and Education (ORISE). JLNW is supported by the Alborada Trust. The findings and conclusions in this report are those of the authors and the US Geological Survey, but not of the other institutions. Any use of trade product or firm names is for descriptive purposes only and does not imply endorsement by the US Government. NR 180 TC 36 Z9 36 U1 11 U2 239 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD FEB PY 2013 VL 60 IS 1 SI SI BP 2 EP 21 DI 10.1111/zph.12000 PG 20 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA 070DU UT WOS:000313487000002 PM 22958281 ER PT J AU Ellison, JA Johnson, SR Kuzmina, N Gilbert, A Carson, WC VerCauteren, KC Rupprecht, CE AF Ellison, J. A. Johnson, S. R. Kuzmina, N. Gilbert, A. Carson, W. C. VerCauteren, K. C. Rupprecht, C. E. TI Multidisciplinary Approach to Epizootiology and Pathogenesis of Bat Rabies Viruses in the United States SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Bats; experimental infection; rabies virus pathogenesis; thermography; surveillance ID HUMAN MONOCLONAL-ANTIBODY; INFRARED THERMOGRAPHY; INSECTIVOROUS BATS; NORTH-AMERICA; TEMPERATURE; LYSSAVIRUS; INFECTION; ECOLOGY; HOST; IDENTIFICATION AB Zoonotic disease surveillance is typically initiated after an animal pathogen has caused disease in humans. Early detection of potentially high-risk pathogens within animal hosts may facilitate medical interventions to cope with an emerging disease. To effectively spillover to a novel host, a pathogen may undergo genetic changes resulting in varying transmission potential in the new host and potentially to humans. Rabies virus (RABV) is one model pathogen to consider for studying the dynamics of emerging infectious diseases under both laboratory and field conditions. The evolutionary history of RABV is characterized by regularly documented spillover infections and a series of notable host shifts. Within this context, enhanced field surveillance to improve detection of spillover infections will require validated techniques to non-invasively differentiate infected from non-infected individuals. In this study, we evaluate the use of infrared thermography to detect thermal changes associated with experimental RABV infection in big brown bats (Eptesicus fuscus) in a captive colony. Our results indicated that 62% of rabid bats had detectable facial temperature decreases (-4.6 degrees C, SD +/- 2.5) compared with pre-inoculation baseline values. These data suggest potential utility for discriminating rabid bats in natural field settings. In addition, focusing upon RABV circulating in the United States between 2008 and 2011, we confirmed spillover events of bat RABV among carnivores and identified cross-species transmission events caused by four lineages of RABV associated with insectivorous bats. Additionally, our analysis of RABV glycoprotein sequences identified substitutions in antigenic sites that may affect neutralizing activity associated with monoclonal antibodies proposed for use in human post-exposure prophylaxis. This study provides a glimpse into RABV pathobiology and spillover dynamics among and between bats and a variety of mesocarnivores. C1 [Ellison, J. A.; Kuzmina, N.; Gilbert, A.; Carson, W. C.; Rupprecht, C. E.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Johnson, S. R.; VerCauteren, K. C.] USDA, Natl Wildlife Res Ctr, Ft Collins, CO USA. RP Rupprecht, CE (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd NE,Mail Stop G-33, Atlanta, GA 30333 USA. EM cyr5@cdc.gov RI Ellison, James/C-1402-2013 OI Ellison, James/0000-0003-4492-4857 NR 60 TC 7 Z9 7 U1 0 U2 37 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD FEB PY 2013 VL 60 IS 1 SI SI BP 46 EP 57 DI 10.1111/zph.12019 PG 12 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA 070DU UT WOS:000313487000005 PM 23137052 ER PT J AU Robinson, BE Galbraith, JS Romine, RES Zhang, Q Herbst, JH AF Robinson, Beatrice 'Bean' E. Galbraith, Jennifer S. Romine, Rebecca E. Swinburne Zhang, Qing Herbst, Jeffrey H. TI Differences Between HIV-Positive and HIV-Negative African American Men Who Have Sex with Men in Two Major U.S. Metropolitan Areas SO ARCHIVES OF SEXUAL BEHAVIOR LA English DT Article DE HIV prevention; African American MSM; HIV serostatus; Sexual risk behaviors ID RANDOMIZED CONTROLLED-TRIALS; UNITED-STATES; BEHAVIORAL INTERVENTIONS; RISK BEHAVIORS; BLACK-MEN; PREVENTION INTERVENTION; ANTIRETROVIRAL THERAPY; CONFOUNDER-SELECTION; GAY MEN; METAANALYSIS AB Alarmingly high HIV prevalence rates among African American men who have sex with men (AAMSM) require the development of effective prevention interventions. In this study of AAMSM conducted in two cities, we explored similarities and differences between HIV-positive and HIV-negative AAMSM on sociodemographic variables, HIV-related risk behaviors, and attitudinal constructs. Differences emerged in several major life areas: (1) poverty, employment, and use of mental health services, (2) sexual risk behaviors, and (3) self-identification with gay identity and culture. With regard to sociodemographic indicators, HIV-positive AAMSM were doing worse than HIV-negative AAMSM in that they were more likely to be disabled, to be living below the poverty level, and accessing mental health services. With regard to risk behaviors and partner characteristics, HIV-positive AAMSM were acting more responsibly than their HIV-negative counterparts, as they were more likely to have used a condom the last time they had sex. In addition, when compared to their HIV-negative counterparts, HIV-positive AAMSM were more likely to have either no casual partners at all or main or casual partners who were HIV-positive, thus preventing new HIV transmission by partnering with other HIV-positive men. Attitudinally, HIV-positive men were more accepting of their sexual attractions to men and were more likely to identify as gay than their HIV-negative peers. Although causality cannot be determined, the findings of this study can be used to strengthen HIV prevention efforts by improving the selection of targeted behaviors and prevention messages for HIV-positive and HIV-negative AAMSM. C1 [Robinson, Beatrice 'Bean' E.; Romine, Rebecca E. Swinburne] Univ Minnesota, Sch Med, Dept Family Med & Community Hlth, Program Human Sexual, Minneapolis, MN 55454 USA. [Galbraith, Jennifer S.; Zhang, Qing; Herbst, Jeffrey H.] Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Robinson, BE (reprint author), Univ Minnesota, Sch Med, Dept Family Med & Community Hlth, Program Human Sexual, 1300 S 2nd St,Suite 180, Minneapolis, MN 55454 USA. EM brobinson@umphysicians.umn.edu FU PHS HHS [U65/CCU123910, U65/CCU523908] NR 65 TC 3 Z9 3 U1 3 U2 12 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0004-0002 J9 ARCH SEX BEHAV JI Arch. Sex. Behav. PD FEB PY 2013 VL 42 IS 2 BP 267 EP 278 DI 10.1007/s10508-011-9891-5 PG 12 WC Psychology, Clinical; Social Sciences, Interdisciplinary SC Psychology; Social Sciences - Other Topics GA 068JN UT WOS:000313363100011 PM 22194090 ER PT J AU Brunetti, M Shemilt, I Pregno, S Vale, L Oxman, AD Lord, J Sisk, J Ruiz, F Hill, S Guyatt, GH Jaeschke, R Helfand, M Harbour, R Davoli, M Amato, L Liberati, A Schunemann, HJ AF Brunetti, Massimo Shemilt, Ian Pregno, Silvia Vale, Luke Oxman, Andrew D. Lord, Joanne Sisk, Jane Ruiz, Francis Hill, Suzanne Guyatt, Gordon H. Jaeschke, Roman Helfand, Mark Harbour, Robin Davoli, Marina Amato, Laura Liberati, Alessandro Schuenemann, Holger J. TI GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE GRADE; Economic evaluations; Costs; Quality of evidence; Risk of bias; Health technology assessment ID COST-EFFECTIVENESS; METHADONE-MAINTENANCE; RANDOMIZED-TRIAL; HEALTH-CARE; BUPRENORPHINE; HOME AB Objectives: In this article, we describe how to include considerations about resource utilization when making recommendations according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Study Design and Settings: We focus on challenges with rating the confidence in effect estimates (quality of evidence) and incorporating resource use into evidence profiles and Summary of Findings (SoF) tables. Results: GRADE recommends that important differences in resource use between alternative management strategies should be included along with other important outcomes in the evidence profile and SoF table. Key steps in considering resources in making recommendations with GRADE are the identification of items of resource use that may differ between alternative management strategies and that are potentially important to decision makers, finding evidence for the differences in resource use, making judgments regarding confidence in effect estimates using the same criteria used for health outcomes, and valuing the resource use in terms of costs for the specific setting for which recommendations are being made. Conclusions: With our framework, decision makers will have access to concise summaries of recommendations, including ratings of the quality of economic evidence, and better understand the implications for clinical decision making. (C) 2013 Elsevier Inc. All rights reserved. C1 [Brunetti, Massimo] Azienda USL Modena, Local Hlth Unit, I-41100 Modena, Italy. [Shemilt, Ian] Univ Cambridge, Inst Publ Hlth, Cambridge, England. [Pregno, Silvia] Univ Modena & Reggio Emilia, Modena, Italy. [Vale, Luke] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Oxman, Andrew D.] Norwegian Knowledge Ctr Hlth Serv, Oslo, Norway. [Lord, Joanne] Brunel Univ, Uxbridge UB8 3PH, Middx, England. [Sisk, Jane] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ruiz, Francis] Natl Inst Hlth & Clin Excellence, London, England. [Hill, Suzanne] WHO, CH-1211 Geneva, Switzerland. [Guyatt, Gordon H.; Jaeschke, Roman; Schuenemann, Holger J.] McMaster Univ, Hamilton, ON, Canada. [Helfand, Mark] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Harbour, Robin] Scottish Intercollegiate Guidelines Network, Edinburgh, Midlothian, Scotland. [Davoli, Marina; Amato, Laura] Lazio Reg Hlth Serv, Dept Epidemiol, Rome, Italy. [Liberati, Alessandro] Univ Modena & Reggio Emilia, Bologna, Italy. [Liberati, Alessandro] Agenzia Sanit Reg, Bologna, Italy. RP Brunetti, M (reprint author), Azienda USL Modena, Local Hlth Unit, Via S Giovanni del Cantone 43 Modena, I-41100 Modena, Italy. EM m.brunetti@ausl.mo.it RI Davoli, Marina/K-1975-2016; Amato, Laura/J-9046-2016; OI Davoli, Marina/0000-0003-4521-032X; Amato, Laura/0000-0003-0282-0881; Lord, Joanne/0000-0003-1086-1624 NR 36 TC 63 Z9 67 U1 2 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD FEB PY 2013 VL 66 IS 2 BP 140 EP 150 DI 10.1016/j.jclinepi.2012.04.012 PG 11 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 068PK UT WOS:000313378500005 PM 22863410 ER PT J AU Wyres, KL Lambertsen, LM Croucher, NJ McGee, L von Gottberg, A Linares, J Jacobs, MR Kristinsson, KG Beall, BW Klugman, KP Parkhill, J Hakenbeck, R Bentley, SD Brueggemann, AB AF Wyres, Kelly L. Lambertsen, Lotte M. Croucher, Nicholas J. McGee, Lesley von Gottberg, Anne Linares, Josefina Jacobs, Michael R. Kristinsson, Karl G. Beall, Bernard W. Klugman, Keith P. Parkhill, Julian Hakenbeck, Regine Bentley, Stephen D. Brueggemann, Angela B. TI Pneumococcal Capsular Switching: A Historical Perspective SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Capsule; serotype; switching; pneumococcus ID PNEUMONIAE SEROTYPE 14; STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; EVOLUTIONARY GENETICS; INVASIVE-DISEASE; UNITED-STATES; HEAT-SHOCK; CLONE; CHILDREN; LOCUS AB Background. Changes in serotype prevalence among pneumococcal populations result from both serotype replacement and serotype (capsular) switching. Temporal changes in serotype distributions are well documented, but the contribution of capsular switching to such changes is unknown. Furthermore, it is unclear to what extent vaccine-induced selective pressures drive capsular switching. Methods. Serotype and multilocus sequence typing data for 426 pneumococci dated from 1937 through 2007 were analyzed. Whole-genome sequence data for a subset of isolates were used to investigate capsular switching events. Results. We identified 36 independent capsular switch events, 18 of which were explored in detail with whole-genome sequence data. Recombination fragment lengths were estimated for 11 events and ranged from approximately 19.0 kb to >= 58.2 kb. Two events took place no later than 1960, and the imported DNA included the capsular locus and the nearby penicillin-binding protein genes pbp2x and pbp1a. Conclusions. Capsular switching has been a regular occurrence among pneumococcal populations throughout the past 7 decades. Recombination of large DNA fragments (> 30 kb), sometimes including the capsular locus and penicillin-binding protein genes, predated both vaccine introduction and widespread antibiotic use. This type of recombination has likely been an intrinsic feature throughout the history of pneumococcal evolution. C1 [Wyres, Kelly L.; Brueggemann, Angela B.] Univ Oxford, Dept Zool, Hinxton, S Cambs, England. [Croucher, Nicholas J.; Parkhill, Julian; Bentley, Stephen D.] Wellcome Trust Sanger Inst, Pathogen Genom Team, Hinxton, Cambs, England. [Lambertsen, Lotte M.] Statens Serum Inst, Dept Microbiol Surveillance & Res, DK-2300 Copenhagen, Denmark. [McGee, Lesley; Beall, Bernard W.] Ctr Dis Control & Prevent, Streptococcus Lab, Atlanta, GA USA. [Klugman, Keith P.] Emory Univ, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Jacobs, Michael R.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA. [von Gottberg, Anne; Klugman, Keith P.] Ctr Resp Dis & Meningitis, Natl Inst Communicable Dis, Gauteng, South Africa. [Linares, Josefina] Bellvitge Hosp CIBERes IDIBELL UB, Dept Microbiol, Barcelona, Spain. [Kristinsson, Karl G.] Univ Iceland, Reykjavik, Iceland. [Kristinsson, Karl G.] Landspitali Univ Hosp, Dept Clin Microbiol, Reykjavik, Iceland. [Hakenbeck, Regine] Univ Kaiserslautern, Dept Microbiol, D-67663 Kaiserslautern, Germany. RP Brueggemann, AB (reprint author), Univ Oxford, Dept Zool, Tinbergen Bldg,S Parks Rd, Oxford OX1 3PS, England. EM angela.brueggemann@zoo.ox.ac.uk RI Parkhill, Julian/G-4703-2011; Linares, Josefina/N-9450-2014; OI Parkhill, Julian/0000-0002-7069-5958; Brueggemann, Angela/0000-0002-2329-1934; Lambertsen, Lotte/0000-0001-6409-6337 FU Wellcome Trust [083511/Z/07/Z, 098051]; Stiftung Rheinland Pfalz fur Innovation; Ciber de Enfermedades Respiratorias (Instituto de Salud Carlos III, Madrid Spain); Pfizer Vaccines; GlaxoSmithKline Biologicals FX This work was supported by the Wellcome Trust (grant 083511/Z/07/Z to A. B. B. and grant 098051 to J. P. and S. D. B.), Stiftung Rheinland Pfalz fur Innovation (to R. H.), and Ciber de Enfermedades Respiratorias (Instituto de Salud Carlos III, Madrid Spain [to J. L.]). A. B. B. is a Wellcome Trust Career Development Fellow.; K. P. K. received research funding from and is a consultant for Pfizer Vaccines and is a consultant for GlaxoSmithKline Biologicals and Merck. A. B. B. received research funding from GlaxoSmithKline Biologicals. All other authors report no potential conflicts. NR 47 TC 48 Z9 51 U1 0 U2 26 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2013 VL 207 IS 3 BP 439 EP 449 DI 10.1093/infdis/jis703 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 066JH UT WOS:000313216300011 PM 23175765 ER PT J AU Raczniak, GA Bulkow, LR Bruce, MG Zanis, CL Baum, RL Snowball, MM Byrd, KK Sharapov, UM Hennessy, TW McMahon, BJ AF Raczniak, Gregory A. Bulkow, Lisa R. Bruce, Michael G. Zanis, Carolyn L. Baum, Richard L. Snowball, Mary M. Byrd, Kathy K. Sharapov, Umid M. Hennessy, Thomas W. McMahon, Brian J. TI Long-Term Immunogenicity of Hepatitis A Virus Vaccine in Alaska 17 Years After Initial Childhood Series SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE hepatitis A; inactivated hepatitis A vaccine; enterovirus infections; immunogenicity; infectious hepatitis ID FOLLOW-UP; CHILDREN; POPULATION; INFECTION; PROGRAM; TRENDS; IMPACT AB The Centers for Disease Control and Prevention recommends hepatitis A virus (HAV) vaccination for all children at age 1 year and for high-risk adults. The vaccine is highly effective; however, protection duration is unknown. We report HAV antibody concentrations 17 years after childhood immunization, demonstrating that protective antibody levels remain and have stabilized over the past 7 years. C1 [Raczniak, Gregory A.; Bulkow, Lisa R.; Bruce, Michael G.; Zanis, Carolyn L.; Baum, Richard L.; Hennessy, Thomas W.; McMahon, Brian J.] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. [Snowball, Mary M.; McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Community Hlth Serv, Liver Dis & Hepatitis Program, Anchorage, AK USA. [Raczniak, Gregory A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Publ Hlth Training, Epidemiol Program Off, Atlanta, GA USA. [Byrd, Kathy K.] Ctr Dis Control & Prevent, Prevent Res & Evaluat Team, Atlanta, GA USA. [Sharapov, Umid M.] Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis Sexually Transm, Atlanta, GA USA. RP Raczniak, GA (reprint author), 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM graczniak@cdc.gov FU Centers for Disease Control and Prevention [U50/CCU022279, U01PS001097] FX This work was supported by the Centers for Disease Control and Prevention through a cooperative agreement grant to the Alaska Native Tribal Health Consortium (U50/CCU022279 and U01PS001097). NR 14 TC 13 Z9 13 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2013 VL 207 IS 3 BP 493 EP 496 DI 10.1093/infdis/jis710 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 066JH UT WOS:000313216300017 PM 23204169 ER PT J AU Taylor, AK Cao, WP Vora, KP De La Cruz, J Shieh, WJ Zaki, SR Katz, JM Sambhara, S Gangappa, S AF Taylor, Andrew K. Cao, Weiping Vora, Keyur P. De La Cruz, Juan Shieh, Wun-Ju Zaki, Sherif R. Katz, Jacqueline M. Sambhara, Suryaprakash Gangappa, Shivaprakash TI Protein Energy Malnutrition Decreases Immunity and Increases Susceptibility to Influenza Infection in Mice SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Scientific Meeting of American-Association-of-Immunologists CY MAY, 2011 CL San Francisco, CA SP Amer Assoc Immunologists, APHL DE Nutrition; protein energy; malnutrition; influenza; immunity ID VIRUS-INFECTION; ZINC SUPPLEMENTATION; DEVELOPING-COUNTRIES; VIRAL-INFECTION; CHILDREN; RESPONSES; CELLS; H1N1; DIET; PREVENTION AB Background. Protein energy malnutrition (PEM), a common cause of secondary immune deficiency in children, is associated with an increased risk of infections. Very few studies have addressed the relevance of PEM as a risk factor for influenza. Methods. We investigated the influence of PEM on susceptibility to, and immune responses following, influenza virus infection using isocaloric diets providing either adequate protein (AP; 18%) or very low protein (VLP; 2%) in a mouse model. Results. We found that mice maintained on the VLP diet, when compared to mice fed with the AP diet, exhibited more severe disease following influenza infection based on virus persistence, trafficking of inflammatory cell types to the lung tissue, and virus-induced mortality. Furthermore, groups of mice maintained on the VLP diet showed significantly lower virus-specific antibody response and a reduction in influenza nuclear protein-specific CD8(+) T cells compared with mice fed on the AP diet. Importantly, switching diets for the group maintained on the VLP diet to the AP diet improved virus clearance, as well as protective immunity to viral challenge. Conclusions. Our results highlight the impact of protein energy on immunity to influenza infection and suggest that balanced protein energy replenishment may be one strategy to boost immunity against influenza viral infections. C1 [Gangappa, Shivaprakash] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Shieh, Wun-Ju; Zaki, Sherif R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Gangappa, S (reprint author), Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Bldg 15,Rm SSB611,MS G47, Atlanta, GA 30333 USA. EM sgangappa@cdc.gov NR 47 TC 24 Z9 24 U1 3 U2 16 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2013 VL 207 IS 3 BP 501 EP 510 DI 10.1093/infdis/jis527 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 066JH UT WOS:000313216300019 PM 22949306 ER PT J AU Ward, JW AF Ward, John W. TI The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States SO CLINICS IN LIVER DISEASE LA English DT Article DE Hepatitis C virus; HCV testing; Baby boomers; HCV testing recommendations ID HEALTH-CARE WORKERS; SEXUAL TRANSMISSION; GENOTYPE 1; HEPATOCELLULAR-CARCINOMA; PERINATAL TRANSMISSION; HUMAN-IMMUNODEFICIENCY; INCREASING INCIDENCE; NEEDLESTICK INJURY; COST-EFFECTIVENESS; VIRAL-HEPATITIS AB Hepatitis C virus (HCV) is the most common blood-borne infection in the United States. HCV infection is a leading cause of chronic liver disease, end-stage liver disease, and liver transplantation. Newly available therapies can clear HCV in most infected persons who receive treatment. However, many persons living with HCV infection are unaware of their infection status, including those born during 1945-1965 (a population at increased risk for chronic hepatitis C in the United States). This review highlights the epidemiology of hepatitis C and the importance of HCV testing and linkage to care in an era of more effective antiviral therapies. C1 Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Ward, JW (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jww4@cdc.gov NR 66 TC 27 Z9 27 U1 1 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1089-3261 J9 CLIN LIVER DIS JI Clin. Liver Dis. PD FEB PY 2013 VL 17 IS 1 BP 1 EP + DI 10.1016/j.cld.2012.09.011 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 065FW UT WOS:000313134900002 PM 23177279 ER PT J AU Barbour, K Lui, LY Ensrud, K Hillier, T Hochberg, M Cauley, J AF Barbour, Kamil Lui, Li-Yung Ensrud, Kristine Hillier, Teresa Hochberg, Marc Cauley, Jane TI Inflammatory Markers and Risk of Hip Fracture in Older Women: The Study of Osteoporotic Fractures SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY OCT 04-07, 2013 CL Baltimore, MD SP Amer Soc Bone & Mineral Res C1 [Barbour, Kamil] CDC, Atlanta, GA 30333 USA. [Lui, Li-Yung] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Ensrud, Kristine] Univ Minnesota, Minneapolis, MN 55455 USA. [Ensrud, Kristine] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Hillier, Teresa] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Hochberg, Marc] Univ Maryland, Sch Med, College Pk, MD 20742 USA. [Cauley, Jane] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD FEB PY 2013 VL 28 SU 1 MA 1083 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AB8JI UT WOS:000332035800084 ER PT J AU Akinsanya-Beysolow, I Jenkins, R Meissner, HC AF Akinsanya-Beysolow, Iyabode Jenkins, Renee Meissner, H. Cody CA Acip Childhood Adolescent TI Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedules for Persons Aged 0 Through 18 years and Adults Aged 19 Years and Older - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Akinsanya-Beysolow, Iyabode] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Jenkins, Renee] Howard Univ, Coll Med, Dept Pediat & Child Hlth, Washington, DC USA. [Meissner, H. Cody] Tufts Med Ctr, Boston, MA USA. RP Akinsanya-Beysolow, I (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM iakinsanyabeysolow@cdc.gov NR 3 TC 0 Z9 0 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 1 PY 2013 VL 62 IS 1 SU S BP 1 EP 8 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40JY UT WOS:000209476100001 ER PT J AU Bridges, CB Woods, L Coyne-Beasley, T AF Bridges, Carolyn B. Woods, LaDora Coyne-Beasley, Tamera CA Acip Adult Immunization Work Grp TI Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Adults Aged 19 Years and Older - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Bridges, Carolyn B.; Woods, LaDora] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Coyne-Beasley, Tamera] Univ N Carolina, Div Gen Pediat & Adolescent Med, Chapel Hill, NC USA. RP Bridges, CB (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM cbridges@cdc.gov NR 8 TC 30 Z9 31 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 1 PY 2013 VL 62 IS 1 SU S BP 9 EP 19 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40JY UT WOS:000209476100002 ER PT J AU George, MG Tong, X AF George, Mary G. Tong, Xin TI Statin Use among Patients with Intracerebral Hemorrhage in the Paul Coverdell National Acute Stroke Registry SO STROKE LA English DT Meeting Abstract CT American-Heart-Association/American-Stroke-Association International Stroke Conference / Nursing Symposium CY FEB 06-08, 2013 CL Honolulu, HI SP Amer Heart Assoc, Amer Stroke Assoc DE Stroke; Lipids; Health services research; Cardiovascular disease C1 [George, Mary G.; Tong, Xin] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD FEB PY 2013 VL 44 IS 2 SU S PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 301NY UT WOS:000330540201053 ER PT J AU Jiang, BJ Hamedani, A Cheng, YC Koontz, D Bean, CJ Gallagher, M Hooper, WC Sparks, MJ McArdle, P O'Connell, JR Stine, OC Wozniak, MA Stern, BJ Mitchell, BD Kittner, SJ Cole, JW AF Jiang, Baijia Hamedani, Ali Cheng, Yuching Koontz, Deborah Bean, Christopher J. Gallagher, Margaret Hooper, W. C. Sparks, Mary J. McArdle, Patrick O'Connell, Jeffrey R. Stine, O. C. Wozniak, Marcella A. Stern, Barney J. Mitchell, Braxton D. Kittner, Steven J. Cole, John W. TI Prothrombin G20210A Mutation and Ischemic Stroke Risk in European Ancestry: The Genetics of Early Onset Stroke Study and Meta-Analysis of 2304 Young-Onset Stroke Cases SO STROKE LA English DT Meeting Abstract CT American-Heart-Association/American-Stroke-Association International Stroke Conference / Nursing Symposium CY FEB 06-08, 2013 CL Honolulu, HI SP Amer Heart Assoc, Amer Stroke Assoc DE Genetics; Thrombosis; Blood coagulation; Risk factors; Stroke C1 [Jiang, Baijia; Hamedani, Ali; Cheng, Yuching; Sparks, Mary J.; McArdle, Patrick; O'Connell, Jeffrey R.; Stine, O. C.; Wozniak, Marcella A.; Stern, Barney J.; Mitchell, Braxton D.; Kittner, Steven J.; Cole, John W.] UMD SOM, Baltimore, MD USA. [Koontz, Deborah; Bean, Christopher J.; Gallagher, Margaret; Hooper, W. C.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD FEB PY 2013 VL 44 IS 2 SU S PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 301NY UT WOS:000330540201436 ER PT J AU Tong, X Yang, QH George, MG AF Tong, Xin Yang, Quanhe George, Mary G. TI Predictors of In-hospital Death in Patients with Acute Ischemic Stroke Treated with Thrombolytic Therapy: Paul Coverdell Acute Stroke Registry 2008-2011 SO STROKE LA English DT Meeting Abstract CT American-Heart-Association/American-Stroke-Association International Stroke Conference / Nursing Symposium CY FEB 06-08, 2013 CL Honolulu, HI SP Amer Heart Assoc, Amer Stroke Assoc DE Stroke; Prognosis C1 [Tong, Xin; Yang, Quanhe; George, Mary G.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD FEB PY 2013 VL 44 IS 2 SU S PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 301NY UT WOS:000330540200004 ER PT J AU Tong, X Yang, QH George, MG AF Tong, Xin Yang, Quanhe George, Mary G. TI Thrombolytic Therapy and Survival for Medicare Beneficiaries with Acute Ischemic Stroke SO STROKE LA English DT Meeting Abstract CT American-Heart-Association/American-Stroke-Association International Stroke Conference / Nursing Symposium CY FEB 06-08, 2013 CL Honolulu, HI SP Amer Heart Assoc, Amer Stroke Assoc DE Stroke C1 [Tong, Xin; Yang, Quanhe; George, Mary G.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD FEB PY 2013 VL 44 IS 2 SU S PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 301NY UT WOS:000330540200003 ER PT J AU Hubbs, AF Sargent, LM Porter, DW Sager, TM Chen, BT Frazer, DG Castranova, V Sriram, K Nurkiewicz, TR Reynolds, SH Battelli, LA Schwegler-Berry, D McKinney, W Fluharty, KL Mercer, RR AF Hubbs, Ann F. Sargent, Linda M. Porter, Dale W. Sager, Tina M. Chen, Bean T. Frazer, David G. Castranova, Vincent Sriram, Krishnan Nurkiewicz, Timothy R. Reynolds, Steven H. Battelli, Lori A. Schwegler-Berry, Diane McKinney, Walter Fluharty, Kara L. Mercer, Robert R. TI Nanotechnology: Toxicologic Pathology SO TOXICOLOGIC PATHOLOGY LA English DT Article DE toxicologic pathology; mechanisms of toxicity; microscopy techniques; pharmaceutical development/products; risk identification; safety assessment; other ID WALLED-CARBON-NANOTUBES; BLOOD-BRAIN-BARRIER; NEAR-INFRARED FLUORESCENCE; SCANNING-ELECTRON-MICROSCOPY; IN-VIVO; PARTICLE-SIZE; DRUG-DELIVERY; SURFACE-AREA; OXIDE NANOPARTICLES; ULTRAFINE PARTICLES AB Nanotechnology involves technology, science, and engineering in dimensions less than 100 nm. A virtually infinite number of potential nanoscale products can be produced from many different molecules and their combinations. The exponentially increasing number of nanoscale products will solve critical needs in engineering, science, and medicine. However, the virtually infinite number of potential nanotechnology products is a challenge for toxicologic pathologists. Because of their size, nanoparticulates can have therapeutic and toxic effects distinct from micron-sized particulates of the same composition. In the nanoscale, distinct intercellular and intracellular translocation pathways may provide a different distribution than that obtained by micron-sized particulates. Nanoparticulates interact with subcellular structures including microtubules, actin filaments, centrosomes, and chromatin; interactions that may be facilitated in the nanoscale. Features that distinguish nanoparticulates from fine particulates include increased surface area per unit mass and quantum effects. In addition, some nanotechnology products, including the fullerenes, have a novel and reactive surface. Augmented microscopic procedures including enhanced dark-field imaging, immunofluorescence, field-emission scanning electron microscopy, transmission electron microscopy, and confocal microscopy are useful when evaluating nanoparticulate toxicologic pathology. Thus, the pathology assessment is facilitated by understanding the unique features at the nanoscale and the tools that can assist in evaluating nanotoxicology studies. C1 [Hubbs, Ann F.; Sargent, Linda M.; Porter, Dale W.; Sager, Tina M.; Chen, Bean T.; Frazer, David G.; Castranova, Vincent; Sriram, Krishnan; Reynolds, Steven H.; Battelli, Lori A.; Schwegler-Berry, Diane; McKinney, Walter; Fluharty, Kara L.; Mercer, Robert R.] NIOSH, Hlth Effects Lab Div, Morgantown, WV USA. [Nurkiewicz, Timothy R.] W Virginia Univ, Sch Med, Ctr Cardiovasc & Resp Sci, Morgantown, WV 26506 USA. RP Hubbs, AF (reprint author), NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM ahubbs@cdc.gov RI Geracitano, Laura/E-6926-2013 FU [NIH-R01-ES015022] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The contribution of Timothy R. Nurkiewicz was supported by NIH-R01-ES015022. NR 205 TC 13 Z9 14 U1 2 U2 21 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0192-6233 EI 1533-1601 J9 TOXICOL PATHOL JI Toxicol. Pathol. PD FEB PY 2013 VL 41 IS 2 BP 395 EP 409 DI 10.1177/0192623312467403 PG 15 WC Pathology; Toxicology SC Pathology; Toxicology GA AB0DP UT WOS:000331462300019 PM 23389777 ER PT J AU Salama, C Morris, M Armistead, L Koenig, LJ Demas, P Ferdon, C Bachanas, P AF Salama, Christina Morris, Mary Armistead, Lisa Koenig, Linda J. Demas, Penelope Ferdon, Corinne Bachanas, Pamela TI Depressive and conduct disorder symptoms in youth living with HIV: The independent and interactive roles of coping and neuropsychological functioning SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV; neuropsychological functioning; adolescents; depression; conduct disorder ID HUMAN-IMMUNODEFICIENCY-VIRUS; RISKY SEXUAL-BEHAVIOR; EXECUTIVE FUNCTION; PSYCHOLOGICAL DISTRESS; INFECTION; ASSOCIATIONS; ADOLESCENCE; CHILDHOOD; WOMEN; SCHIZOPHRENIA AB Emerging research suggests the importance of psychosocial characteristics (e.g., coping and social support) for positive adaptation among youth with behaviorally acquired HIV. However, little is known about how these traits interact with cognitive abilities to impact emotional and behavioral adjustment. This study examined whether coping skills and executive functioning interact in their association with psychological adjustment in HIV-positive youth. Data from Project Adolescents Living with HIV/AIDS (ALPHA), a study to examine psychosocial, behavioral and neuropsychological functioning of youth with behaviorally acquired HIV, were used. Fifty-nine participants, aged 1423, diagnosed with HIV prior to age 20 and receiving care in one of two HIV clinics in Atlanta or New York City, were recruited, consented and enrolled. Participants completed measures of depressive symptoms (Beck Depression Inventory), conduct disorder (Adolescent Symptom Index), and use of positive and negative coping strategies (Kidcope). The Wisconsin Card Sorting Test (WCST) assessed abstract reasoning (categories completed) and cognitive inflexibility (perseverative errors). In this sample of HIV-positive youth, depressive symptoms were best predicted by an interactive combination of negative coping skills and poor neuropsychological functioning. Neuropsychological functioning (cognitive inflexibility) and negative coping skills were directly associated with conduct disorder symptoms. Results highlight the importance of including neuropsychological assessment in the evaluation of HIV-positive youth, particularly those with emotional or behavioral problems. C1 [Salama, Christina; Morris, Mary; Armistead, Lisa] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA. [Koenig, Linda J.; Ferdon, Corinne] Ctr Dis Control & Prevent, Atlanta, GA USA. [Demas, Penelope] Jacobi Med Ctr, Bronx, NY USA. [Ferdon, Corinne; Bachanas, Pamela] Emory Univ, Sch Med, Atlanta, GA USA. RP Armistead, L (reprint author), Georgia State Univ, Dept Psychol, Univ Plaza, Atlanta, GA 30303 USA. EM lparmistead@gsu.edu NR 33 TC 3 Z9 4 U1 3 U2 24 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PD FEB 1 PY 2013 VL 25 IS 2 BP 160 EP 168 DI 10.1080/09540121.2012.687815 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 055VG UT WOS:000312445300003 PM 22690655 ER PT J AU El Bcheraoui, C Sutton, MY Hardnett, FP Jones, SB AF El Bcheraoui, Charbel Sutton, Madeline Y. Hardnett, Felicia P. Jones, Sandra B. TI Patterns of condom use among students at historically Black colleges and universities: Implications for HIV prevention efforts among college-age young adults SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV; African-Americans; college students; condoms; HBCUs ID SEXUALLY-TRANSMITTED INFECTIONS; TESTING BELIEF INVENTORY; AFRICAN-AMERICAN MALES; RISK BEHAVIORS; PREDICTORS; KNOWLEDGE; SEX; MEN; INTERVENTIONS; COMMUNICATION AB Over 1.1 million Americans are living with human immunodeficiency virus (HIV), and African-American youth and young adults are disproportionately affected. Condoms are the most effective prevention tool, yet data regarding condom use patterns for African-American college youth are lacking. To inform and strengthen HIV prevention strategies with African-American college-age youth, we surveyed students attending 24 historically Black colleges and universities regarding condom use patterns. Students were administered anonymous questionnaires online to explore knowledge, attitudes, and practices related to condom use during last sexual intercourse (LSI). Among 824 sexually active respondents (51.8% female, median age 20 years, 90.6% heterosexuals), 526 (63.8%) reported condom use during LSI. Students who used condoms for disease prevention, whose mothers completed high school or had some college education or completed college were more likely to have used a condom during LSI. Spontaneity of sexual encounters, not feeling at risk of HIV, and partner-related perceptions were associated with condom non-use during LSI (p<0.05). Over a third of our college youth sample did not use a condom during LSI and may benefit from increased condom education efforts. These efforts should highlight condoms effectiveness in protection from HIV. Future HIV education and prevention strategies with similar groups of young adults should explore the implications of maternal education, clarify perceptions of HIV risk, and consider strategies that increase consistent condom use to interrupt sexual transmission of HIV. C1 [El Bcheraoui, Charbel] Fulton Cty Hlth Serv, Hlth & Wellness, Atlanta, GA 30303 USA. [Sutton, Madeline Y.; Hardnett, Felicia P.] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Jones, Sandra B.] CDC, Div Adolescent & Sch Hlth, Atlanta, GA 30333 USA. RP El Bcheraoui, C (reprint author), Fulton Cty Hlth Serv, Hlth & Wellness, Atlanta, GA 30303 USA. EM igj4@cdc.gov NR 46 TC 7 Z9 7 U1 2 U2 17 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PD FEB 1 PY 2013 VL 25 IS 2 BP 186 EP 193 DI 10.1080/09540121.2012.687864 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 055VG UT WOS:000312445300007 PM 22670599 ER PT J AU McKenna, JJ Bramley, AM Skarbinski, J Fry, AM Finelli, L Jain, S AF McKenna, John J. Bramley, Anna M. Skarbinski, Jacek Fry, Alicia M. Finelli, Lyn Jain, Seema CA 2009 Pandemic Influenza A H1N1 Vir TI Asthma in patients hospitalized with pandemic influenza A( H1N1)pdm09 virus infection-United States, 2009 SO BMC INFECTIOUS DISEASES LA English DT Article DE Asthma; Influenza A virus; Hospitalization; ICU; H1N1pdm09 AB Background: Asthma was the most common co-morbidity among patients hospitalized with pandemic influenza A (H1N1)pdm09 [pH1N1] infection. The objective was to compare characteristics of hospitalized pH1N1 patients with and without asthma and assess factors associated with severity among asthma patients. Methods: Patient data were derived from two 2009 pandemic case-series of U. S. pH1N1 hospitalizations. A case was defined as a person >= 2 years old hospitalized with laboratory-confirmed pH1N1. Asthma status was determined through chart review. Results: Among 473 cases, 29% had asthma. Persons with asthma were more likely to be 2-17 years old (39% vs. 30%, p = 0.04) and black (29% vs. 18%, p < 0.01), and have chronic obstructive pulmonary disease (13% vs. 9%, p = 0.04) but less likely to have pneumonia (37% vs. 47%, p = 0.05), need mechanical ventilation (13% vs. 23%, p = 0.02), and die (4% vs. 10%, p = 0.04) than those without asthma. Among patients with asthma, those admitted to an intensive care unit (ICU) or who died (n = 38) compared with survivors not admitted to an ICU (n = 99) were more likely to have pneumonia on admission (60% vs. 27%, p < 0.01) or acute respiratory distress syndrome (24% vs. 0%, p < 0.01) and less likely to receive influenza antiviral agents <= 2 days of admission (73% vs. 92%, p = 0.02). Conclusions: The majority of persons with asthma had an uncomplicated course; however, severe disease, including ICU admission and death, occurred in asthma patients who presented with pneumonia. Influenza antiviral agents should be started early in hospitalized patients with suspected influenza, including those with asthma. C1 [McKenna, John J.; Bramley, Anna M.; Skarbinski, Jacek; Fry, Alicia M.; Finelli, Lyn; Jain, Seema] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP McKenna, JJ (reprint author), 1929 Huxley St, Madison, WI 53704 USA. EM jjmckenn@wisc.edu FU Influenza Division at the Centers for Disease Control and Prevention (CDC); External Medical Affairs, Pfizer Inc. FX This investigation was supported by the Influenza Division at the Centers for Disease Control and Prevention (CDC). The CDC Experience Applied Epidemiology Fellowship is a one-year fellowship in applied epidemiology at CDC made possible by a public/private partnership supported by a grant to the CDC Foundation from External Medical Affairs, Pfizer Inc. NR 27 TC 8 Z9 8 U1 0 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD JAN 31 PY 2013 VL 13 AR 57 DI 10.1186/1471-2334-13-57 PG 8 WC Infectious Diseases SC Infectious Diseases GA 099NC UT WOS:000315627400001 PM 23369034 ER PT J AU Auffray, C Caulfield, T Khoury, MJ Lupski, JR Schwab, M Veenstra, T AF Auffray, Charles Caulfield, Timothy Khoury, Muin J. Lupski, James R. Schwab, Matthias Veenstra, Timothy TI 2012 highlights in translational 'omics SO GENOME MEDICINE LA English DT Editorial Material ID INTELLECTUAL DISABILITY; PERSONALIZED MEDICINE; DIGENIC INHERITANCE; SYSTEMS BIOLOGY; PUBLIC-HEALTH; MUTATIONS; DISEASE; GENOMICS; ERA C1 [Auffray, Charles] Univ Lyon 1, CNRS, Inst Biol Sci, European Inst Syst Biol & Med, F-69622 Villeurbanne, France. [Caulfield, Timothy] Univ Alberta, Fac Law, Edmonton, AB T6G 2H5, Canada. [Caulfield, Timothy] Univ Alberta, Sch Publ Hlth, Law Ctr 461, Edmonton, AB T6G 2H5, Canada. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. [Lupski, James R.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA. [Lupski, James R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Lupski, James R.] Texas Childrens Hosp, Houston, TX 77030 USA. [Schwab, Matthias] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70367 Stuttgart, Germany. [Schwab, Matthias] Univ Hosp, Dept Clin Pharmacol, Inst Expt & Clin Pharmacol & Toxicol, D-72076 Tubingen, Germany. [Veenstra, Timothy] NCI, Lab Prote & Analyt Technol, Frederick, MD 21702 USA. RP Auffray, C (reprint author), Univ Lyon 1, CNRS, Inst Biol Sci, European Inst Syst Biol & Med, F-69622 Villeurbanne, France. EM auffraycharles@yahoo.fr NR 38 TC 2 Z9 2 U1 1 U2 36 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-994X J9 GENOME MED JI Genome Med. PD JAN 31 PY 2013 VL 5 AR 10 DI 10.1186/gm414 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA 084ZZ UT WOS:000314581700002 PM 23369291 ER PT J AU Scheel, CM Hurst, SF Barreiros, G Akiti, T Nucci, M Balajee, SA AF Scheel, Christina M. Hurst, Steven F. Barreiros, Gloria Akiti, Tiyomi Nucci, Marcio Balajee, S. Arunmozhi TI Molecular analyses of Fusarium isolates recovered from a cluster of invasive mold infections in a Brazilian hospital SO BMC INFECTIOUS DISEASES LA English DT Article DE Fusarium; Invasive fusariosis; Molecular epidemiology; Multi-locus sequence typing; Invasive fungal infection; Bone marrow transplant; Hospital associated infection; Community acquired disease; Brazil ID PHYLOGENETIC DIVERSITY; EPIDEMIOLOGY; MYCOLOGY AB Background: Invasive fusariosis (IF) is a rare but often fatal fungal infection in immunosuppressed patients. In 2007, cases of IF above the expected epidemiologic baseline were detected in the hematology ward of a hospital in Rio de Janeiro, Brazil. Possible sources of infection were investigated by performing environmental sampling and patient isolate collection, followed by molecular typing. Isolates from dermatology patients with superficial fusariosis were included in the study for comparison to molecular types found in the community. Methods: Environmental sampling focused on water-related sources in and around the hematology ward. Initially, we characterized 166 clinical and environmental isolates using the Fusarium translation elongation factor 1 alpha (EF-1 alpha) genetic locus. Isolates included 68 collected from water-related sources in the hospital environment, 55 from 18 hematology patients, and 43 from the skin/nails of 40 outpatients seen at the hospital dermatology clinic. Multi-locus sequence typing was performed on Fusarium solani species complex (FSSC) species 1 and 2 isolates to investigate their relatedness further. Results: Most of the hematology samples were FSSC species 2, with species type FSSC 2-d the most commonly isolated from these patients. Most of the outpatient dermatology samples were also FSSC 2, with type 2-d again predominating. In contrast, environmental isolates from water sources were mostly Fusarium oxysporum species complex (FOSC) and those from air samples mostly Fusarium incarnatum-equiseti species complex (FIESC). A third of the environmental samples were FSSC, with species types FSSC 1-a and FSSC 1-b predominating. Conclusions: Fusarium isolate species types from hematology patient infections were highly similar to those recovered from dermatology patients in the community. Four species types (FSSC 1-a, 1-b, 2-d and 2-f) were shared between hematology patients and the environment. Limitations in environmental sampling do not allow for nosocomial sources of infection to be ruled out. Future studies will focus on environmental factors that may have influenced the prevalence of FSSC fusariosis in this hematology ward. C1 [Scheel, Christina M.; Hurst, Steven F.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA. [Barreiros, Gloria; Akiti, Tiyomi; Nucci, Marcio] Univ Fed Rio de Janeiro, Univ Hosp, Rio De Janeiro, Brazil. [Balajee, S. Arunmozhi] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. RP Scheel, CM (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA. EM zsr3@cdc.gov RI Nucci, Marcio/G-4515-2012 OI Nucci, Marcio/0000-0003-4867-0014 NR 17 TC 16 Z9 16 U1 2 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD JAN 30 PY 2013 VL 13 AR 49 DI 10.1186/1471-2334-13-49 PG 12 WC Infectious Diseases SC Infectious Diseases GA 096KE UT WOS:000315401900001 PM 23363475 ER PT J AU Ford, ES Li, CY Sniderman, A AF Ford, Earl S. Li, Chaoyang Sniderman, Allan TI Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988-1991 to 2005-2008 SO CARDIOVASCULAR DIABETOLOGY LA English DT Article DE Apolipoprotein B; Cholesterol; Diabetes; High-density lipoprotein cholesterol; Lipids; Prediabetes; Triglycerides; Fenofibrate; Gemfibrozil; Niacin ID DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR RISK; MELLITUS; DISEASE; TRENDS; MORTALITY; MICROALBUMINURIA; DYSLIPIDEMIA; METAANALYSIS; ASSOCIATION AB Background: Diabetes is characterized by profound lipid abnormalities. The objective of this study was to examine changes in concentrations of lipids and apolipoprotein B among participants stratified by glycemic status (diabetes, undiagnosed diabetes, prediabetes, and normoglycemia) in the United States from 1988-1991 to 2005-2008. Methods: We used data from 3202 participants aged >= 20 years from the National Health and Nutrition Examination Survey (NHANES) III (1988-1991) and 3949 participants aged >= 20 years from NHANES 2005-2008. Results: Among participants of all four groups, unadjusted and adjusted mean concentrations of total cholesterol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B, but not triglycerides, decreased significantly. Among participants with prediabetes and normoglycemia, unadjusted and adjusted mean concentrations of high-density lipoprotein cholesterol increased significantly. Adjusted mean log-transformed concentrations of triglycerides decreased in adults with undiagnosed diabetes and prediabetes. During 2005-2008, unadjusted concentrations of apolipoprotein B >= 80 mg/dl were observed in 72.8% of participants with diagnosed diabetes, 87.9% of participants with undiagnosed diabetes, 86.6% of participants with prediabetes, and 77.2% of participants with normoglycemia. The unadjusted use of cholesterol-lowering medications rose rapidly, especially among participants with diabetes (from similar to 1% to similar to 49%, P < 0.001). The use of fenofibrate, gemfibrozil, and niacin rose significantly only among adults with diagnosed diabetes (from similar to 2% to similar to 8%, P = 0.011). Conclusion: Lipid profiles of adults with diabetes improved during the approximately 16-year study period. Nevertheless, large percentages of adults continue to have elevated concentrations of apolipoprotein B. C1 [Ford, Earl S.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Li, Chaoyang] Ctr Dis Control & Prevent, Div Behav Surveillance, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. [Sniderman, Allan] McGill Univ, Ctr Hlth, Mike Rosenbloom Lab Cardiovasc Res, Montreal, PQ, Canada. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM eford@cdc.gov NR 42 TC 6 Z9 7 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2840 J9 CARDIOVASC DIABETOL JI Cardiovasc. Diabetol. PD JAN 30 PY 2013 VL 12 AR 26 DI 10.1186/1475-2840-12-26 PG 13 WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism SC Cardiovascular System & Cardiology; Endocrinology & Metabolism GA 095RH UT WOS:000315351700001 PM 23360385 ER PT J AU Freitas, DRC Moura, E Araujo, G Cardoso, A Scheidt, P Ferraz, E Madalosso, G Chen, RT Hatch, DL AF Freitas, Daniel R. C. Moura, Evoide Araujo, Gisele Cardoso, Alessandra Scheidt, Penelope Ferraz, Elizabete Madalosso, Geraldine Chen, Robert T. Hatch, Douglas L. TI Investigation of an outbreak of hypersensitivity-type reactions during the 2004 national measles-mumps-rubella vaccination campaign in Brazil SO VACCINE LA English DT Article DE Measles; MMR vaccine; Measles-containing vaccine; Adverse effects; Hypersensitivity reaction ID MASS VACCINATION; ADVERSE EVENTS; IGG RESPONSE; MMR VACCINE; DEXTRAN; IMMUNIZATION; CHILDREN; RISK; ALLERGY; PROGRAM AB Introduction: During Brazil's national measles, mumps, and rubella (MMR) vaccination campaign in August 2004, an unexpectedly high rate of hypersensitivity-type adverse events (HAEs) was reported. Materials and methods: We reviewed information about children with suspected HAEs reported by clinicians to Brazil's national passive surveillance system for adverse events following immunization (AEFI), compared attack rate of HAE by manufacturer of MMR vaccine used in the campaign, and conducted a case-control study to determine possible risk factors for HAEs. Results: During the 2004 national campaign, the rate of HAEs following MMR vaccination was one log higher for manufacturer A (15.2/100,000 doses administered) compared to the other two manufacturers (1.2 and 0.6/100,000 doses; p < 0.0001); a similar pattern was observed retrospectively in analysis of the 2000-2003 AEFI surveillance (0.95 vs. 0.07 per 100,000 doses administered; p < 0.0001). In the case-control study, among the 49 case-patients with HAEs identified, reported symptoms included conjunctival injection (60%), urticaria (55%), fever (54%), and facial edema (53%); no deaths occurred. The median time interval between vaccination and symptom onset was 42 min (range: 5 min-24 h). We did not identify any differences in the proportion of case-patients and control children with a history of known allergy to food (including egg, egg-containing products or gelatin), drugs, or environmental antigens. Discussion: Our study highlights the importance of a well-functioning routine AEFI surveillance system linked with mass vaccination campaigns. Such a system in Brazil permitted timely detection of HAEs and validation of a safety signal associated with one vaccine manufacturer. Unlike earlier publications, this outbreak linked to a single manufacturer of MMR showed no association with a prior allergic history to eggs or other foods, including gelatin; subsequent studies implicate the dextran stabilizer in MMR from manufacturer A as the likely cause of HAEs. (c) 2012 Elsevier Ltd. All rights reserved. C1 [Freitas, Daniel R. C.; Moura, Evoide; Araujo, Gisele; Cardoso, Alessandra; Hatch, Douglas L.] Minist Hlth MoH, Hlth Surveillance Secretariat SVS, Field Epidemiol Training Program EPISUS, Brasilia, DF, Brazil. [Freitas, Daniel R. C.] MoH, Natl Agcy Hlth Surveillance ANVISA, Brasilia, DF, Brazil. [Freitas, Daniel R. C.] Univ Brasilia, Postgrad Program Trop Med Infect Dis Epidemiol, BR-70910900 Brasilia, DF, Brazil. [Moura, Evoide] MoH, SVS, DEVEP, Natl Immunizat Program PNI, Brasilia, DF, Brazil. [Scheidt, Penelope] Santa Catarina State Hlth Dept SES SC, Florianopolis, SC, Brazil. [Ferraz, Elizabete] Municipal Hlth Dept SMS, Curitiba, Parana, Brazil. [Madalosso, Geraldine] Sao Paulo State Hlth Dept SES SP, Sao Paulo, Brazil. [Chen, Robert T.] Ctr Dis Control & Prevent, Natl Immunizat Program, Immunizat Safety Branch, Atlanta, GA USA. [Hatch, Douglas L.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Freitas, DRC (reprint author), AOS 04 Bloco B,Apto 423, BR-70660042 Brasilia, DF, Brazil. EM danielcoradi@gmail.com NR 27 TC 7 Z9 7 U1 0 U2 17 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JAN 30 PY 2013 VL 31 IS 6 BP 950 EP 954 DI 10.1016/j.vaccine.2012.11.095 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 083AP UT WOS:000314435400014 PM 23246259 ER PT J AU Wakadha, H Chandir, S Were, EV Rubin, A Obor, D Levine, OS Gibson, DG Odhiambo, F Laserson, KF Feikin, DR AF Wakadha, Hotenzia Chandir, Subhash Were, Elijah Victor Rubin, Alan Obor, David Levine, Orin S. Gibson, Dustin G. Odhiambo, Frank Laserson, Kayla F. Feikin, Daniel R. TI The feasibility of using mobile-phone based SMS reminders and conditional cash transfers to improve timely immunization in rural Kenya SO VACCINE LA English DT Article DE Conditional cash transfers; Short message service; DTP-HepB-Hib; Mobile money services; RapidSMS; Reimbursement ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY-HEALTH-CARE; DEVELOPING-COUNTRIES; WESTERN KENYA; DISEASE; INTERVENTIONS; INCENTIVES; ADHERENCE; MALARIA; IMPACT AB Background: Demand-side strategies could contribute to achieving high and timely vaccine coverage in rural Africa, but require platforms to deliver either messages or conditional cash transfers (CCTs). We studied the feasibility of using short message services (SMS) reminders and mobile phone-based conditional cash transfers (CCTs) to reach parents in rural Western Kenya. Methods: In a Health and Demographic Surveillance System (HDSS), mothers with children aged 0-3 weeks old were approached to determine who had access to a mobile phone. SMS reminders were sent three days prior to and on the scheduled day of immunization for 1st (age 6 weeks) and 2nd doses (age 10 weeks) of DTP-HepB-Hib (Pentavalent) vaccine, using open-source Rapid SMS software. Approximately $2.00 USD was sent as cash using mPESA, a mobile money transfer platform (2/3 of mothers), or airtime (1/3 of mothers) via phone if the child was vaccinated within 4 weeks of the scheduled date. Follow-up surveys were done when children reached 14 weeks of age. Results: We approached 77 mothers; 72 were enrolled into the study (26% owned a phone and 74% used someone else's). Of the 63 children with known vaccination status at 14 weeks of age, 57 (90%) received pentavalent1 and 54 (86%) received pentavalent2 within 4 weeks of their scheduled date. Of the 61 mothers with follow-up surveys administered at 14 weeks of age, 55 (90%) reported having received SMS reminders. Of the 54 women who reported having received SMS reminders and answered the CCT questions on the survey, 45 (83%) reported receiving their CCT. Most (89%) of mothers in the mPESA group obtained their cash within 3 days of being sent their credit via mobile phone. All mothers stated they preferred CCTs as cash via mobile phone rather than airtime. Of the 9 participants who did not vaccinate their children at the designated clinic 2(22%) cited refusals by husbands to participate in the study. Conclusion: The data show that in rural Western Kenya mobile phone-based strategies are a potentially useful platform to deliver reminders and cash transfers. Follow-up studies are needed that provide evidence for the effectiveness of these strategies in improving vaccine coverage and timeliness. Published by Elsevier Ltd. C1 [Wakadha, Hotenzia; Were, Elijah Victor; Rubin, Alan; Obor, David; Odhiambo, Frank; Laserson, Kayla F.] Ctr Dis Control & Prevent Publ Hlth & Res Collab, Kenya Med Res Inst, Kisumu, Kenya. [Chandir, Subhash; Levine, Orin S.; Gibson, Dustin G.; Feikin, Daniel R.] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Int Hlth, Baltimore, MD USA. [Feikin, Daniel R.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Feikin, DR (reprint author), 855N Wolfe St,Suite 600, Baltimore, MD 21205 USA. EM dfeikin@jhsph.edu RI Emchi, Karma/Q-1952-2016; OI Gibson, Dustin/0000-0002-9073-3376 FU KEMRI/CDC FX We are grateful to KEMRI/CDC for funding the study and we would like to also acknowledge the HDSS community members who participated in the study. We thank Matt Coles for help with design of Figure 1. This work is published with the approval of the director of KEMRI.; KEMRI/CDC provided the funds for the study. NR 42 TC 26 Z9 26 U1 3 U2 26 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JAN 30 PY 2013 VL 31 IS 6 BP 987 EP 993 DI 10.1016/j.vaccine.2012.11.093 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 083AP UT WOS:000314435400020 PM 23246258 ER PT J AU Poli, F Overeem, S Lammers, GJ Plazzi, G Lecendreux, M Bassetti, CL Dauvilliers, Y Keene, D Khatami, R Li, YL Mayer, G Nohynek, H Pahud, B Paiva, T Partinen, M Scammell, TE Shimabukuro, T Sturkenboom, M van Dinthers, K Wiznitzer, M Bonhoeffer, J AF Poli, Francesca Overeem, Sebastiaan Lammers, Gert Jan Plazzi, Giuseppe Lecendreux, Michel Bassetti, Claudio L. Dauvilliers, Yves Keene, Daniel Khatami, Ramin Li, Yulin Mayer, Geert Nohynek, Hanna Pahud, Barbara Paiva, Teresa Partinen, Markku Scammell, Thomas E. Shimabukuro, Tom Sturkenboom, Miriam van Dinthers, Kristy Wiznitzer, Max Bonhoeffer, Jan TI Narcolepsy as an adverse event following immunization: Case definition and guidelines for data collection, analysis and presentation SO VACCINE LA English DT Article DE Cataplexy; Hypocretin; Classification; Sleep; Autoimmunity; H1N1; Children ID SLEEP LATENCY TEST; EXCESSIVE DAYTIME SLEEPINESS; HYPOCRETIN-1 OREXIN-A; PRADER-WILLI-SYNDROME; ONSET REM PERIODS; LIMP MAN SYNDROME; DISEASE TYPE-C; CHILDHOOD NARCOLEPSY; CEREBROSPINAL-FLUID; CLINICAL-FEATURES C1 [Poli, Francesca; Plazzi, Giuseppe] Ist Sci Neurol, IRCCS, Bologna, Italy. [Overeem, Sebastiaan] Radboud Univ Nijmegen, Med Ctr, Donders Inst Neurosci, Dept Neurol, NL-6500 HB Nijmegen, Netherlands. [Lammers, Gert Jan] Leiden Univ, Med Ctr, Leiden, Netherlands. [Lecendreux, Michel] Univ Paris 07, Robert Debre Hosp, Paris, France. [Bassetti, Claudio L.] Univ Hosp Bern, Dept Neurol, CH-3010 Bern, Switzerland. [Dauvilliers, Yves] Univ Montpellier, Ctr Hosp, F-34059 Montpellier, France. [Keene, Daniel] Hlth Canada, Ottawa, ON K1A 0L2, Canada. [Khatami, Ramin] Klin Barmelweid, Barmelweid, Switzerland. [Li, Yulin; Bonhoeffer, Jan] Univ Children Hosp, Basel, Switzerland. [Li, Yulin; Bonhoeffer, Jan] Brighton Collaborat Fdn, Basel, Switzerland. [Mayer, Geert] Hephata Clin, Schwalmstadt, Germany. [Nohynek, Hanna] Natl Inst Hlth & Welf, Helsinki, Finland. [Pahud, Barbara] Childrens Mercy Hosp & Clin, Kansas City, MO USA. [Paiva, Teresa] Sleep Med Ctr CENC, Med Fac Lisbon, Lisbon, Portugal. [Partinen, Markku] Univ Helsinki, Helsinki, Finland. [Scammell, Thomas E.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Scammell, Thomas E.] Harvard Univ, Sch Med, Boston, MA USA. [Shimabukuro, Tom] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sturkenboom, Miriam] Erasmus MC, Rotterdam, Netherlands. [van Dinthers, Kristy] CSL Biotherapies, Parkville, Vic, Australia. [Wiznitzer, Max] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA. RP Overeem, S (reprint author), Radboud Univ Nijmegen, Med Ctr, Donders Inst Neurosci, Dept Neurol, POB 9101, NL-6500 HB Nijmegen, Netherlands. EM contact@brightoncollaboration.org; S.Overeem@neuro.umcn.nl RI Bonhoeffer, Jan/E-5903-2014; Overeem, Sebastiaan/D-2139-2010; OI Paiva, Maria Teresa Aguiar dos Santos/0000-0002-7937-7841; Plazzi, Giuseppe/0000-0002-1051-0472; Partinen, Markku/0000-0002-8182-9368 FU European Centers of Disease Control (ECDC) in the frame of the VAESCO project [2009/003/SpAg4]; World Health Organization (WHO) in the frame of the Global Vaccine Safety Initiative (GVSI) FX We are grateful for the support by the European Centers of Disease Control (ECDC) in the frame of the VAESCO project (GRANT 2009/003/SpAg4 and the World Health Organization (WHO) in the frame of the Global Vaccine Safety Initiative (GVSI). The authors are grateful for the support and helpful comments provided by Prof. Emmanuel Mignot, Prof. Mehdi Tafti, and Prof. Karel Sonka. The authors are also grateful for the support and helpful comments provided by the members of the Brighton Collaboration Science Board not co-authoring the article (Mike Blum, Jim Buttery, Steve Black, Paul T. Heath, Egeruan Babatunde Imoukhuede, Hector Izurieta, Najwa Khuri-Bulos, Heidi Larson) and participants in the Reference group, Bob Wise, Hudson Michael, Nokleby Hanne, Santuccio Carmela, Schmidt Claudia, Trimis Georgios, Keene Daniel, Nalin David, Falup-Pecurariu Cristian, Huang Wan-Ting, Evans Bradley, Falup-Pecurariu Oana, Wimalaratne Omala, Ramasamy Ranjan, Mandyam Ravi, Holden John, Fedders Charlotte, Korejwo Joanna, Hossain Shah, Lapeyre-Mestre Maryse, Kochhar Sonali, Chatterjee Arani, Tomini Eugena, Toma Valeriu, Varricchio Frederick, Madhava Ram Balakrishnan, Webster Peggy, Thomas Roger, Kawade Anand, Lahariya Chandrakant, Zajdowicz Thaddeus, Birger Trollfors, Hans Rumke, Ingrid Trolin, Kevin Connolly, Emmanuel Grimprel, and Maurizio Zani for the literature search, as well as other experts consulted as part of the process. The authors are also grateful to Simone Casagrande, Sabine Faisst, Norbert Sommerfeld, Daniel Weibel of the Brighton management team for harmonization of the document with other Brighton Collaboration documents. Finally, we thank the members of the WHO/CIOMS Working Group on Vaccine Pharmacovigilance (http://www.cioms.ch/frame_current_programme.htm) for the review of, constructive comments on, and endorsement of this document. NR 175 TC 30 Z9 30 U1 0 U2 14 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JAN 30 PY 2013 VL 31 IS 6 BP 994 EP 1007 DI 10.1016/j.vaccine.2012.12.014 PG 14 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 083AP UT WOS:000314435400021 PM 23246545 ER PT J AU Taylor, SM Antonia, AL Parobek, CM Juliano, JJ Janko, M Emch, M Alam, MT Udhayakumar, V Tshefu, AK Meshnick, SR AF Taylor, Steve M. Antonia, Alejandro L. Parobek, Christian M. Juliano, Jonathan J. Janko, Mark Emch, Michael Alam, Md Tauqeer Udhayakumar, Venkatachalam Tshefu, Antoinette K. Meshnick, Steven R. TI Plasmodium falciparum sulfadoxine resistance is geographically and genetically clustered within the DR Congo SO SCIENTIFIC REPORTS LA English DT Article ID DIHYDROPTEROATE SYNTHASE; MOLECULAR MARKERS; SELECTIVE SWEEPS; PYRIMETHAMINE RESISTANCE; UNCOMPLICATED MALARIA; DRUG-RESISTANCE; DHPS ALLELES; POPULATION; EFFICACY; SPREAD AB Understanding the spatial clustering of Plasmodium falciparum populations can assist efforts to contain drug-resistant parasites and maintain the efficacy of future drugs. We sequenced single nucleotide polymorphisms (SNPs) in the dihydropteroate synthase gene (dhps) associated with sulfadoxine resistance and 5 microsatellite loci flanking dhps in order to investigate the genetic backgrounds, genetic relatedness, and geographic clustering of falciparum parasites in the Democratic Republic of the Congo (DRC). Resistant haplotypes were clustered into subpopulations: one in the northeast DRC, and the other in the balance of the DRC. Network and clonal lineage analyses of the flanking microsatellites indicate that geographically-distinct mutant dhps haplotypes derive from separate lineages. The DRC is therefore a watershed for haplotypes associated with sulfadoxine resistance. Given the importance of central Africa as a corridor for the spread of antimalarial resistance, the identification of the mechanisms of this transit can inform future policies to contain drug-resistant parasite strains. C1 [Taylor, Steve M.; Antonia, Alejandro L.; Meshnick, Steven R.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. [Taylor, Steve M.] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Durham, NC USA. [Parobek, Christian M.] UNC Sch Med, Dept Genet, Chapel Hill, NC USA. [Juliano, Jonathan J.] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC USA. [Janko, Mark; Emch, Michael] Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC USA. [Emch, Michael] Univ N Carolina, Dept Geog, Chapel Hill, NC USA. [Alam, Md Tauqeer; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Alam, Md Tauqeer] Atlanta Res & Educ Fdn, Decatur, GA USA. RP Taylor, SM (reprint author), Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. EM steve.taylor@duke.edu OI Parobek, Christian/0000-0002-4511-3493 FU Gillings Innovation Laboratory award from the UNC Gillings School of Global Public Health; Summer Undergraduate Research Fellowship from the Office for Undergraduate Research at the University of North Carolina at Chapel Hill; CDC Antimicrobial Resistance Network; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [K08AI100924]; NIH [T32GM0088719] FX We thank Dr Augustin Okenge (Programme National de Lutte Contre le SIDA, Kinshasa, DRC), Dr Jeremie Mwonga (Laboratoire National de Reference SIDA et IST, Kinshasa, DRC), and Ann Way, Mohamed Ayad, and Martin Vaessen (all of MeasureDHS, Calverton, MD) for help in obtaining access to the dried blood spots. Stephanie Carrier, Hannah Hoffman, and Jaymin Patel (all of the University of North Carolina, Chapel Hill) assisted in the laboratory. This work would not have been possible without the work of scores of survey administrators. Ultimately, we are indebted to the DHS respondents for their participation. This work was supported by a Gillings Innovation Laboratory award from the UNC Gillings School of Global Public Health (to SRM), a Summer Undergraduate Research Fellowship from the Office for Undergraduate Research at the University of North Carolina at Chapel Hill (to ALA), and the CDC Antimicrobial Resistance Network for the laboratory work performed at CDC (to VU). Dr Taylor is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number K08AI100924, and Mr Parobek was supported in part by NIH training grant T32GM0088719. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 7 Z9 7 U1 0 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD JAN 30 PY 2013 VL 3 AR 1165 DI 10.1038/srep01165 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 082MA UT WOS:000314394800001 PM 23372922 ER PT J AU Liu, Y Croft, JB Wheaton, AG Perry, GS Chapman, DP Strine, TW McKnight-Eily, LR Presley-Cantrell, L AF Liu, Yong Croft, Janet B. Wheaton, Anne G. Perry, Geraldine S. Chapman, Daniel P. Strine, Tara W. McKnight-Eily, Lela R. Presley-Cantrell, Letitia TI Association between perceived insufficient sleep, frequent mental distress, obesity and chronic diseases among US adults, 2009 behavioral risk factor surveillance system SO BMC PUBLIC HEALTH LA English DT Article DE Insufficient sleep; Chronic disease; Population-based study ID CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; DURATION; POPULATION; HYPERTENSION; DEPRIVATION; DEPRESSION; ANXIETY; HEALTH; ASTHMA AB Background: Although evidence suggests that poor sleep is associated with chronic disease, little research has been conducted to assess the relationships between insufficient sleep, frequent mental distress (FMD >= 14 days during the past 30 days), obesity, and chronic disease including diabetes mellitus, coronary heart disease, stroke, high blood pressure, asthma, and arthritis. Methods: Data from 375,653 US adults aged >= 18 years in the 2009 Behavioral Risk Factor Surveillance System were used to assess the relationships between insufficient sleep and chronic disease. The relationships were further examined using a multivariate logistic regression model after controlling for age, sex, race/ethnicity, education, and potential mediators (FMD and obesity). Results: The overall prevalence of insufficient sleep during the past 30 days was 10.4% for all 30 days, 17.0% for 14-29 days, 42.0% for 1-13 days, and 30.6% for zero day. The positive relationships between insufficient sleep and each of the six chronic disease were significant (p < 0.0001) after adjustment for covariates and were modestly attenuated but not fully explained by FMD. The relationships between insufficient sleep and both diabetes and high blood pressure were also modestly attenuated but not fully explained by obesity. Conclusions: Assessment of sleep quantity and quality and additional efforts to encourage optimal sleep and sleep health should be considered in routine medical examinations. Ongoing research designed to test treatments for obesity, mental distress, or various chronic diseases should also consider assessing the impact of these treatments on sleep health. C1 [Liu, Yong; Croft, Janet B.; Wheaton, Anne G.; Perry, Geraldine S.; Chapman, Daniel P.; McKnight-Eily, Lela R.; Presley-Cantrell, Letitia] Ctr Dis Control & Prevent CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Strine, Tara W.] Ctr Dis Control & Prevent CDC, Div Behav Surveillance, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30345 USA. RP Liu, Y (reprint author), Ctr Dis Control & Prevent CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mail Stop K-67, Atlanta, GA 30341 USA. EM ikd8@cdc.gov NR 53 TC 31 Z9 32 U1 0 U2 25 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD JAN 29 PY 2013 VL 13 AR 84 DI 10.1186/1471-2458-13-84 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 082LE UT WOS:000314392500001 PM 23360346 ER PT J AU Freedman, DS Blanck, HM Dietz, WH DasMahapatra, P Srinivasan, SR Berenson, GS AF Freedman, David S. Blanck, Heidi M. Dietz, William H. DasMahapatra, Pronabesh Srinivasan, Sathanur R. Berenson, Gerald S. TI Is the body adiposity index (hip circumference/height(1.5)) more strongly related to skinfold thicknesses and risk factor levels than is BMI? The Bogalusa Heart Study SO BRITISH JOURNAL OF NUTRITION LA English DT Article DE Obesity; BMI; Children; Lipids; Skinfolds; Hip circumference; Waist circumference ID TO-HEIGHT RATIO; MASS INDEX; ANTHROPOMETRIC PREDICTORS; ABDOMINAL ADIPOSITY; WAIST CIRCUMFERENCE; FAT DISTRIBUTION; OBESITY; WEIGHT; MEN; WOMEN AB Because of its strong association (r 0.85) with percentage of body fat determined by dual-energy X-ray absorptiometry, hip circumference divided by height(1.5) (the body adiposity index) has recently been proposed as an index of body fatness among adults. We examined whether this proposed index was more strongly associated with skinfold thicknesses and levels of CVD risk factors (lipids, fasting insulin and glucose, and blood pressure) than was BMI among 2369 18- to 49-year-olds in the Bogalusa Heart Study. All analyses indicated that the body adiposity index was less strongly associated with skinfold thicknesses and CVD risk factors than was either waist circumference or BMI. Correlations with the skinfold sum, for example, were r 0.81 (BMI) v. r 0.75 (body adiposity index) among men, and r 0.87 (BMI) v. r 0.80 among women; P<0.001 for both differences. An overall index of seven CVD risk factors was also more strongly associated with BMI (r 0.58) and waist circumference (r 0.61) than with the body adiposity index (r 0.49). The weaker associations with the body adiposity index were observed in analyses stratified by sex, race, age and year of examination. Multivariable analyses indicated that if either BMI or waist circumference were known, the body adiposity index provided no additional information on skinfold thicknesses or risk factor levels. These findings indicate that the body adiposity index is likely to be an inferior index of adiposity than is either BMI or waist circumference. C1 [Freedman, David S.; Blanck, Heidi M.; Dietz, William H.] Ctr Dis Control & Prevent, Div Nutr & Phys Act & Obes, Atlanta, GA 30341 USA. [DasMahapatra, Pronabesh; Srinivasan, Sathanur R.; Berenson, Gerald S.] Tulane Univ, Sch Publ Hlth & Trop Med, Tulane Ctr Cardiovasc Hlth, New Orleans, LA USA. RP Freedman, DS (reprint author), Ctr Dis Control & Prevent, Div Nutr & Phys Act & Obes, CDC K-26,4770 Buford Highway, Atlanta, GA 30341 USA. EM dxf1@cdc.gov FU National Institutes of Aging [AG-16592] FX This study was supported by the National Institutes of Aging Grant AG-16592. The findings and conclusions in this study are those of the authors and not necessarily those of the Centers for Disease Control (CDC). D. S. F. was responsible for the data analyses, interpretation of the results, and writing of the manuscript. H. M. B. was involved in the interpretation of the results. W. H. D. was involved in the formulation of the study objectives, and in the drafting of the manuscript. P. D., S. R. S. and G. S. B. were involved in data collection, and G. S. B. was the principal investigator. All authors participated in the revision of the paper. None of the authors has a personal or financial conflict of interest. NR 39 TC 9 Z9 10 U1 2 U2 13 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0007-1145 J9 BRIT J NUTR JI Br. J. Nutr. PD JAN 28 PY 2013 VL 109 IS 2 BP 338 EP 345 DI 10.1017/S0007114512000979 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 076RR UT WOS:000313975800016 PM 22716994 ER PT J AU Barclay, L Wikswo, M Gregoricus, N Vinje, J Lopman, B Parashar, U Hall, A Leshem, E AF Barclay, Leslie Wikswo, Mary Gregoricus, Nicole Vinje, Jan Lopman, Ben Parashar, Umesh Hall, Aron Leshem, Eyal TI Emergence of New Norovirus Strain GII.4 Sydney - United States, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID OUTBREAKS C1 [Leshem, Eyal] CDC, Atlanta, GA 30333 USA. RP Leshem, E (reprint author), CDC, Atlanta, GA 30333 USA. EM eleshem@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 25 PY 2013 VL 62 IS 3 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188DV UT WOS:000322173200004 ER PT J AU Cardemil, C Pabst, L Gerlach, K AF Cardemil, Cristina Pabst, Laura Gerlach, Ken TI Progress in Immunization Information Systems - United States, 2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Cardemil, Cristina; Pabst, Laura; Gerlach, Ken] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Cardemil, C (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM ccardemil@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 25 PY 2013 VL 62 IS 3 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188DV UT WOS:000322173200002 ER PT J AU Gould, LH Mungai, EA Johnson, SD Richardson, LC Williams, IT Griffin, PM Cole, DJ Hall, AJ AF Gould, L. Hannah Mungai, Elisabeth A. Johnson, Shacara D. Richardson, LaTonia C. Williams, Ian T. Griffin, Patricia M. Cole, Dana J. Hall, Aron J. TI Surveillance for Foodborne Disease Outbreaks - United States, 2009-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Hall, Aron J.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM lgould@cdc.gov NR 10 TC 0 Z9 0 U1 5 U2 16 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 25 PY 2013 VL 62 IS 3 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188DV UT WOS:000322173200001 ER PT J AU Lovegrove, M Hampton, LM Budnitz, DS Geller, AI AF Lovegrove, Maribeth Hampton, Lee M. Budnitz, Daniel S. Geller, Andrew I. TI Emergency Department Visits and Hospitalizations for Buprenorphine Ingestion by Children - United States, 2010-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Geller, Andrew I.] CDC, Atlanta, GA 30333 USA. RP Geller, AI (reprint author), CDC, Atlanta, GA 30333 USA. EM wia0@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 25 PY 2013 VL 62 IS 3 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188DV UT WOS:000322173200005 ER PT J AU Rubin, L Cohn, A MacNeil, J Messonnier, N AF Rubin, Lorry Cohn, Amanda MacNeil, Jessica Messonnier, Nancy TI Infant Meningococcal Vaccination: Advisory Committee on Immunization Practices (ACIP) Recommendations and Rationale SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID INFLUENZAE TYPE-B; CONJUGATE VACCINE; IMMUNOGENICITY; SAFETY C1 [Rubin, Lorry] Advisory Comm Immunizat Practices, Meningococcal Vaccines Work Grp, Atlanta, GA USA. [Cohn, Amanda; MacNeil, Jessica; Messonnier, Nancy] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Cohn, A (reprint author), CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM acohn@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 25 PY 2013 VL 62 IS 3 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188DV UT WOS:000322173200003 ER PT J AU Abernathy, E Chen, MH Bera, J Shrivastava, S Kirkness, E Zheng, Q Bellini, W Icenogle, J AF Abernathy, Emily Chen, Min-hsin Bera, Jayati Shrivastava, Susmita Kirkness, Ewen Zheng, Qi Bellini, William Icenogle, Joseph TI Analysis of whole genome sequences of 16 strains of rubella virus from the United States, 1961-2009 SO VIROLOGY JOURNAL LA English DT Article DE Rubella virus; Whole genome ID PCR PRIMER DESIGN; CAPSID PROTEIN; DOMAINS; GENOTYPES; PROGRAM AB Rubella virus is the causative agent of rubella, a mild rash illness, and a potent teratogenic agent when contracted by a pregnant woman. Global rubella control programs target the reduction and elimination of congenital rubella syndrome. Phylogenetic analysis of partial sequences of rubella viruses has contributed to virus surveillance efforts and played an important role in demonstrating that indigenous rubella viruses have been eliminated in the United States. Sixteen wild-type rubella viruses were chosen for whole genome sequencing. All 16 viruses were collected in the United States from 1961 to 2009 and are from 8 of the 13 known rubella genotypes. Phylogenetic analysis of 30 whole genome sequences produced a maximum likelihood tree giving high bootstrap values for all genotypes except provisional genotype 1a. Comparison of the 16 new complete sequences and 14 previously sequenced wild-type viruses found regions with clusters of variable amino acids. The 5' 250 nucleotides of the genome are more conserved than any other part of the genome. Genotype specific deletions in the untranslated region between the non-structural and structural open reading frames were observed for genotypes 2B and genotype 1G. No evidence was seen for recombination events among the 30 viruses. The analysis presented here is consistent with previous reports on the genetic characterization of rubella virus genomes. Conserved and variable regions were identified and additional evidence for genotype specific nucleotide deletions in the intergenic region was found. Phylogenetic analysis confirmed genotype groupings originally based on structural protein coding region sequences, which provides support for the WHO nomenclature for genetic characterization of wild-type rubella viruses. C1 [Abernathy, Emily; Chen, Min-hsin; Zheng, Qi; Bellini, William; Icenogle, Joseph] Ctr Dis Control & Prevent, Nat Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. [Bera, Jayati; Shrivastava, Susmita; Kirkness, Ewen] J Craig Venter Inst, Rockville, MD USA. RP Icenogle, J (reprint author), Ctr Dis Control & Prevent, Nat Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. EM jci1@cdc.gov FU National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200900007C] FX The authors would like to thank public health officials in the state health departments that contributed viruses and the MMR epidemiology team at CDC. This project has been funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under contract number HHSN272200900007C. We thank Ludmila Perelygina and Pierre Rivailler for critical reading of the manuscript. NR 27 TC 13 Z9 13 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-422X J9 VIROL J JI Virol. J. PD JAN 25 PY 2013 VL 10 AR 32 DI 10.1186/1743-422X-10-32 PG 9 WC Virology SC Virology GA 092JI UT WOS:000315116200001 PM 23351667 ER PT J AU Stockman, LJ Brooks, WA Streatfield, PK Rahman, M Goswami, D Nahar, K Rahman, MZ Luby, SP Anderson, LJ AF Stockman, Lauren J. Brooks, W. Abdullah Streatfield, Peter K. Rahman, Mustafizur Goswami, Doli Nahar, Kamrun Rahman, Mohammed Z. Luby, Stephen P. Anderson, Larry J. TI Challenges to Evaluating Respiratory Syncytial Virus Mortality in Bangladesh, 2004-2008 SO PLOS ONE LA English DT Article ID CHILDHOOD PNEUMONIA; YOUNG-CHILDREN; ETIOLOGY; INFECTIONS; INFLUENZA; BURDEN; INFANTS; SEASON; URBAN AB Background: Acute lower respiratory illness is the most common cause of death among children, globally. Data are not available to make accurate estimates on the global mortality from respiratory syncytial virus (RSV), specifically. Methods: Respiratory samples collected from children under 5 years of age during 2004 to 2008 as part of population-based respiratory disease surveillance in an urban community in Dhaka, Bangladesh were tested for RSV, human metapneumovirus (HMPV), human parainfluenza virus (PIV) types 1, 2, and 3, influenza and adenovirus by RT-PCR. Verbal autopsy data were used to identify children who died from respiratory illness in a nearby rural community. Significance of the correlation between detections and community respiratory deaths was determined using Spearman's coefficient. Results: RSV activity occurred during defined periods lasting approximately three months but with no clear seasonal pattern. There was no significant correlation between respiratory deaths and detection of any of the respiratory viruses studied. Conclusion: Outbreaks of respiratory viruses may not be associated with deaths in children in the study site; however, the few respiratory deaths observed and community-to-community variation in the timing of outbreaks may have obscured an association. An accurate assessment of respiratory virus-associated deaths will require detections and death data to come from the same location and a larger study population. C1 [Stockman, Lauren J.; Anderson, Larry J.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Brooks, W. Abdullah; Streatfield, Peter K.; Rahman, Mustafizur; Goswami, Doli; Nahar, Kamrun; Rahman, Mohammed Z.; Luby, Stephen P.] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. RP Stockman, LJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM lstockman@cdc.gov RI rahman, mustafizur/E-6918-2010 FU Bill & Melinda Gates Foundation FX This study was funded by a grant from the Bill & Melinda Gates Foundation to the International Center for Diarrheal Diseases Research, Bangladesh. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 26 TC 9 Z9 9 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 24 PY 2013 VL 8 IS 1 AR e53857 DI 10.1371/journal.pone.0053857 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 077JK UT WOS:000314023600023 PM 23365643 ER PT J AU Jha, P Landsman, V Rostron, B Thun, M Anderson, RN McAfee, T Peto, R AF Jha, Prabhat Landsman, Victoria Rostron, Brian Thun, Michael Anderson, Robert N. McAfee, Tim Peto, Richard TI 21st-Century Hazards of Smoking and Benefits of Cessation in the United States SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID CIGARETTE; EPIDEMIC; TOBACCO AB Background Extrapolation from studies in the 1980s suggests that smoking causes 25% of deaths among women and men 35 to 69 years of age in the United States. Nationally representative measurements of the current risks of smoking and the benefits of cessation at various ages are unavailable. Methods We obtained smoking and smoking-cessation histories from 113,752 women and 88,496 men 25 years of age or older who were interviewed between 1997 and 2004 in the U. S. National Health Interview Survey and related these data to the causes of deaths that occurred by December 31, 2006 (8236 deaths in women and 7479 in men). Hazard ratios for death among current smokers, as compared with those who had never smoked, were adjusted for age, educational level, adiposity, and alcohol consumption. Results For participants who were 25 to 79 years of age, the rate of death from any cause among current smokers was about three times that among those who had never smoked (hazard ratio for women, 3.0; 99% confidence interval [CI], 2.7 to 3.3; hazard ratio for men, 2.8; 99% CI, 2.4 to 3.1). Most of the excess mortality among smokers was due to neoplastic, vascular, respiratory, and other diseases that can be caused by smoking. The probability of surviving from 25 to 79 years of age was about twice as great in those who had never smoked as in current smokers (70% vs. 38% among women and 61% vs. 26% among men). Life expectancy was shortened by more than 10 years among the current smokers, as compared with those who had never smoked. Adults who had quit smoking at 25 to 34, 35 to 44, or 45 to 54 years of age gained about 10, 9, and 6 years of life, respectively, as compared with those who continued to smoke. Conclusions Smokers lose at least one decade of life expectancy, as compared with those who have never smoked. Cessation before the age of 40 years reduces the risk of death associated with continued smoking by about 90%. C1 [Jha, Prabhat] Univ Toronto, Ctr Global Hlth Res, St Michaels Hosp, Toronto, ON M5C 1N8, Canada. [Rostron, Brian] US FDA, Rockville, MD 20857 USA. [Anderson, Robert N.] Ctr Dis Control & Prevent, Hyattsville, MD USA. [Thun, Michael] Amer Canc Soc, Atlanta, GA 30329 USA. [McAfee, Tim] Ctr Dis Control & Prevent, Atlanta, GA USA. [Peto, Richard] Univ Oxford, Clin Trial & Epidemiol Serv Unit, Oxford, England. RP Jha, P (reprint author), Univ Toronto, Ctr Global Hlth Res, St Michaels Hosp, Toronto, ON M5C 1N8, Canada. FU Fogarty International Center [TW007939-01]; National Institutes of Health; Canadian Institutes of Health Research [IEG-53506]; Disease Control Priorities Project; Bill and Melinda Gates Foundation FX Supported by a grant (TW007939-01) from the Fogarty International Center, National Institutes of Health; by a grant (IEG-53506) from the Canadian Institutes of Health Research; and by the Disease Control Priorities Project, Bill and Melinda Gates Foundation. Dr. Jha holds an endowed faculty position at the University of Toronto. NR 29 TC 358 Z9 363 U1 3 U2 58 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JAN 24 PY 2013 VL 368 IS 4 BP 341 EP 350 DI 10.1056/NEJMsa1211128 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 075KX UT WOS:000313885900007 PM 23343063 ER PT J AU Rao, AK Jackson, KA Mahon, BE AF Rao, Agam K. Jackson, Kelly A. Mahon, Barbara E. TI The Eyes Have It SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Rao, Agam K.; Jackson, Kelly A.; Mahon, Barbara E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Rao, AK (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM akrao@cdc.gov NR 3 TC 1 Z9 1 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JAN 24 PY 2013 VL 368 IS 4 BP 392 EP 392 DI 10.1056/NEJMc1213034 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 075KX UT WOS:000313885900017 PM 23343073 ER PT J AU Bennett, NM Whitney, CG Moore, M Pilishvili, T Dooling, KL AF Bennett, Nancy M. Whitney, Cynthia G. Moore, Matt Pilishvili, Tamara Dooling, Kathleen L. TI Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) (Reprinted from MMWR vol 40, pg 816, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Bennett, Nancy M.] CDC, Advisory Comm Immunizat Practices Pneumococcal Wo, Atlanta, GA 30333 USA. [Whitney, Cynthia G.; Moore, Matt; Pilishvili, Tamara] CDC, Resp Dis Br, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Dooling, Kathleen L.] CDC, EIS, Atlanta, GA 30333 USA. RP Pilishvili, T (reprint author), CDC, Resp Dis Br, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM tdp4@cdc.gov NR 1 TC 1 Z9 1 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 23 PY 2013 VL 309 IS 4 BP 334 EP 336 DI 10.1001/jama.2012.31377 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 074FT UT WOS:000313799000007 ER PT J AU Caixeta, RB Khoury, RN Sinha, DN Rarick, J Tong, V Dietz, P Hsia, J Blutcher-Nelson, G England, L Shin, M Asma, S AF Caixeta, Roberta B. Khoury, Rula N. Sinha, Dhirendra N. Rarick, James Van Tong Dietz, Patricia Hsia, Jason Blutcher-Nelson, Glenda England, Lucinda Shin, Mikyong Asma, Samira TI Current Tobacco Use and Secondhand Smoke Exposure Among Women of Reproductive Age-14 Countries, 2008-2010 (Reprinted form MMWR vol 43, pg 877, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Van Tong; Dietz, Patricia; Hsia, Jason; Blutcher-Nelson, Glenda; England, Lucinda; Shin, Mikyong; Asma, Samira] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Tong, V (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM vtong@cdc.gov NR 1 TC 0 Z9 0 U1 1 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 23 PY 2013 VL 309 IS 4 BP 336 EP 338 DI 10.1001/jama.2012.91588 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 074FT UT WOS:000313799000008 ER PT J AU Patel, JC Oberstaller, J Xayavong, M Narayanan, J DeBarry, JD Srinivasamoorthy, G Villegas, L Escalante, AA DaSilva, A Peterson, DS Barnwell, JW Kissinger, JC Udhayakumar, V Lucchi, NW AF Patel, Jaymin C. Oberstaller, Jenna Xayavong, Maniphet Narayanan, Jothikumar DeBarry, Jeremy D. Srinivasamoorthy, Ganesh Villegas, Leopoldo Escalante, Ananias A. DaSilva, Alexandre Peterson, David S. Barnwell, John W. Kissinger, Jessica C. Udhayakumar, Venkatachalam Lucchi, Naomi W. TI Real-Time Loop-Mediated Isothermal Amplification (RealAmp) for the Species-Specific Identification of Plasmodium vivax SO PLOS ONE LA English DT Article ID HUMAN MALARIA PARASITE; FALCIPARUM-MALARIA; DIAGNOSIS; INFECTIONS; LAMP; DNA; MICROSCOPY; GENOMICS; TARGETS; TESTS AB Plasmodium vivax infections remain a major source of malaria-related morbidity and mortality. Early and accurate diagnosis is an integral component of effective malaria control programs. Conventional molecular diagnostic methods provide accurate results but are often resource-intensive, expensive, have a long turnaround time and are beyond the capacity of most malaria-endemic countries. Our laboratory has recently developed a new platform called RealAmp, which combines loop-mediated isothermal amplification (LAMP) with a portable tube scanner real-time isothermal instrument for the rapid detection of malaria parasites. Here we describe new primers for the detection of P. vivax using the RealAmp method. Three pairs of amplification primers required for this method were derived from a conserved DNA sequence unique to the P. vivax genome. The amplification was carried out at 64 degrees C using SYBR Green or SYTO-9 intercalating dyes for 90 minutes with the tube scanner set to collect fluorescence signals at 1-minute intervals. Clinical samples of P. vivax and other human-infecting malaria parasite species were used to determine the sensitivity and specificity of the primers by comparing with an 18S ribosomal RNA-based nested PCR as the gold standard. The new set of primers consistently detected laboratory-maintained isolates of P. vivax from different parts of the world. The primers detected P. vivax in the clinical samples with 94.59% sensitivity (95% CI: 87.48-98.26%) and 100% specificity (95% CI: 90.40-100%) compared to the gold standard nested-PCR method. The new primers also proved to be more sensitive than the published species-specific primers specifically developed for the LAMP method in detecting P. vivax. C1 [Patel, Jaymin C.; Xayavong, Maniphet; DaSilva, Alexandre; Barnwell, John W.; Udhayakumar, Venkatachalam; Lucchi, Naomi W.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Oberstaller, Jenna; Peterson, David S.; Kissinger, Jessica C.] Univ Georgia, Dept Genet, Athens, GA 30602 USA. [Oberstaller, Jenna; DeBarry, Jeremy D.; Srinivasamoorthy, Ganesh; Peterson, David S.; Kissinger, Jessica C.] Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA. [Narayanan, Jothikumar; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Villegas, Leopoldo] Asociac Civil Impacto Social, Tumeremo, Venezuela. [Escalante, Ananias A.] Arizona State Univ, Tempe, AZ USA. [Kissinger, Jessica C.] Univ Georgia, Inst Bioinformat, Athens, GA 30602 USA. RP Patel, JC (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. EM jaymin86@gmail.com RI Kissinger, Jessica/E-9610-2010; OI Kissinger, Jessica/0000-0002-6413-1101; DeBarry, Jeremy/0000-0001-5718-2675 FU CDC-UGA (OPHR) [8212] FX This work was supported by a CDC-UGA seed grant (OPHR #8212) awarded to JCK and VU. This study was supported in part by resources and technical expertise from the University of Georgia Research Computing Center, a partnership between the Office of the Vice President for Research and the Office of the Chief Information Officer and CDC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 29 TC 27 Z9 29 U1 4 U2 26 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 22 PY 2013 VL 8 IS 1 AR e54986 DI 10.1371/journal.pone.0054986 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 077HS UT WOS:000314019100115 PM 23349994 ER PT J AU Zhu, XY Yu, WL McBride, R Li, Y Chen, LM Donis, RO Tong, SX Paulson, JC Wilson, IA AF Zhu, Xueyong Yu, Wenli McBride, Ryan Li, Yan Chen, Li-Mei Donis, Ruben O. Tong, Suxiang Paulson, James C. Wilson, Ian A. TI Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE crystal structure; evolution; infection; protease susceptibility; viral entry ID A VIRUS; NEURAMINIDASE; ACID; SITE; PATHOGENICITY; RECOGNITION; DETERMINANT; PROTEINS; CLEAVAGE; ORIGIN AB Bat influenza virus H17N10 represents a distinct lineage of influenza A viruses with gene segments coding for proteins that are homologs of the surface antigens, hemagglutinin (HA) and neuraminidase (NA). Our recent study of the N10 NA homolog revealed an NA-like structure, but with a highly divergent putative active site exhibiting little or no NA activity, and provided strong motivation for performing equivalent structural and functional analyses of the H17 HA protein. The overall structure of the H17 HA homolog from A/little yellow-shouldered bat/Guatemala/060/2010 at 3.18 angstrom resolution is very similar to other influenza HAs, with a putative receptor-binding site containing some conserved aromatic residues that form the base of the sialic acid binding site. However, the rest of the H17 receptor-binding site differs substantially from the other HA subtypes, including substitution of other conserved residues associated with receptor binding. Significantly, electrostatic potential analyses reveal that this putative receptor-binding site is highly acidic, making it unfavorable to bind any negatively charged sialylated receptors, consistent with the recombinant H17 protein exhibiting no detectable binding to sialylated glycans. Furthermore, the fusion mechanism is also distinct; trypsin digestion with recombinant H17 protein, when exposed to pH 4.0, did not degrade the HA1 and HA2, in contrast to other HAs. These distinct structural features and functional differences suggest that the H17 HA behaves very differently compared with other influenza HAs. C1 [Zhu, Xueyong; Yu, Wenli; Paulson, James C.; Wilson, Ian A.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA. [McBride, Ryan; Paulson, James C.] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA. [Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA. [Chen, Li-Mei; Donis, Ruben O.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Li, Yan; Tong, Suxiang] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. RP Wilson, IA (reprint author), Scripps Res Inst, Dept Mol Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA. EM Wilson@scripps.edu FU National Institutes of Health [AI058113]; Centers for Disease Control; Skaggs Institute for Chemical Biology; Natural Sciences and Engineering Research Council of Canada; National Research Council Canada; Canadian Institutes of Health Research; Province of Saskatchewan; Western Economic Diversification Canada; University of Saskatchewan; [U54 GM094586] FX We thank Henry Tien of the Robotics Core at the Joint Center for Structural Genomics (supported by Grant U54 GM094586) for automated crystal screening. X-ray diffraction datasets were collected at the Canadian Light Source (CLS) beamline 08ID-1 with the help of Drs. Jean-Philippe Julien and Minsun Hong. We thank Dr. Rui Xu for helpful discussions. This work was supported in part by National Institutes of Health Grant AI058113 (to J.C.P. and I.A.W.), a contract from the Centers for Disease Control (to J.C.P.), and the Skaggs Institute for Chemical Biology. Portions of this research were carried out at the CLS, which is supported by the Natural Sciences and Engineering Research Council of Canada, the National Research Council Canada, the Canadian Institutes of Health Research, the Province of Saskatchewan, Western Economic Diversification Canada, and the University of Saskatchewan. This is publication 21983 of The Scripps Research Institute. NR 29 TC 65 Z9 72 U1 5 U2 35 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD JAN 22 PY 2013 VL 110 IS 4 BP 1458 EP 1463 DI 10.1073/pnas.1218509110 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 083HK UT WOS:000314453900065 PM 23297216 ER PT J AU Wu, HM Cordeiro, SM Harcourt, BH Carvalho, MDS Azevedo, J Oliveira, TQ Leite, MC Salgado, K Reis, MG Plikaytis, BD Clark, TA Mayer, LW Ko, AI Martin, SW Reis, JN AF Wu, Henry M. Cordeiro, Soraia M. Harcourt, Brian H. Carvalho, Maria da Gloria S. Azevedo, Jailton Oliveira, Tainara Q. Leite, Mariela C. Salgado, Katia Reis, Mitermayer G. Plikaytis, Brian D. Clark, Thomas A. Mayer, Leonard W. Ko, Albert I. Martin, Stacey W. Reis, Joice N. TI Accuracy of real-time PCR, Gram stain and culture for Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae meningitis diagnosis SO BMC INFECTIOUS DISEASES LA English DT Article DE Bacterial meningitis; Diagnostic test evaluation; Real-time PCR; Streptococcus pneumoniae Neisseria meningitidis; Haemophilus influenzae ID POLYMERASE-CHAIN-REACTION; BACTERIAL-MENINGITIS; MENINGOCOCCAL MENINGITIS; CEREBROSPINAL-FLUID; DISEASE; AMPLIFICATION; EPIDEMIOLOGY; CHILDREN; FEATURES; ADULTS AB Background: Although cerebrospinal fluid (CSF) culture is the diagnostic reference standard for bacterial meningitis, its sensitivity is limited, particularly when antibiotics were previously administered. CSF Gram staining and real-time PCR are theoretically less affected by antibiotics; however, it is difficult to evaluate these tests with an imperfect reference standard. Methods and findings: CSF from patients with suspected meningitis from Salvador, Brazil were tested with culture, Gram stain, and real-time PCR using S. pneumoniae, N. meningitidis, and H. influenzae specific primers and probes. An antibiotic detection disk bioassay was used to test for the presence of antibiotic activity in CSF. The diagnostic accuracy of tests were evaluated using multiple methods, including direct evaluation of Gram stain and real-time PCR against CSF culture, evaluation of real-time PCR against a composite reference standard, and latent class analysis modeling to evaluate all three tests simultaneously. Results: Among 451 CSF specimens, 80 (17.7%) had culture isolation of one of the three pathogens (40 S. pneumoniae, 36 N. meningitidis, and 4 H. influenzae), and 113 (25.1%) were real-time PCR positive (51 S. pneumoniae, 57 N. meningitidis, and 5 H. influenzae). Compared to culture, real-time PCR sensitivity and specificity were 95.0% and 90.0%, respectively. In a latent class analysis model, the sensitivity and specificity estimates were: culture, 81.3% and 99.7%; Gram stain, 98.2% and 98.7%; and real-time PCR, 95.7% and 94.3%, respectively. Gram stain and real-time PCR sensitivity did not change significantly when there was antibiotic activity in the CSF. Conclusion: Real-time PCR and Gram stain were highly accurate in diagnosing meningitis caused by S. pneumoniae, N. meningitidis, and H. influenzae, though there were few cases of H. influenzae. Furthermore, real-time PCR and Gram staining were less affected by antibiotic presence and might be useful when antibiotics were previously administered. Gram staining, which is inexpensive and commonly available, should be encouraged in all clinical settings. C1 [Wu, Henry M.; Harcourt, Brian H.; Carvalho, Maria da Gloria S.; Plikaytis, Brian D.; Clark, Thomas A.; Mayer, Leonard W.; Martin, Stacey W.] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Cordeiro, Soraia M.; Azevedo, Jailton; Salgado, Katia; Reis, Mitermayer G.; Ko, Albert I.; Reis, Joice N.] Fundacao Oswaldo Cruz, BR-40296710 Salvador, BA, Brazil. [Oliveira, Tainara Q.; Leite, Mariela C.; Reis, Joice N.] Univ Fed Bahia, Salvador, BA, Brazil. [Ko, Albert I.] Cornell Univ, Weill Med Coll, New York, NY 10065 USA. RP Wu, HM (reprint author), 550 Peachtree St NE,MOT 7, Atlanta, GA 30308 USA. EM hmwu@emory.edu RI Ko, Albert/P-2343-2015; Reis, Joice/H-9227-2013; OI Azevedo, Jailton /0000-0002-0801-8673 NR 29 TC 23 Z9 25 U1 1 U2 39 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD JAN 22 PY 2013 VL 13 AR 26 DI 10.1186/1471-2334-13-26 PG 10 WC Infectious Diseases SC Infectious Diseases GA 080IE UT WOS:000314234200001 PM 23339355 ER PT J AU Auld, AF Mbofana, F Shiraishi, RW Alfredo, C Sanchez, M Ellerbrock, TV Nelson, LJ AF Auld, Andrew F. Mbofana, Francisco Shiraishi, Ray W. Alfredo, Charity Sanchez, Mauro Ellerbrock, Tedd V. Nelson, Lisa J. TI Incidence and Determinants of Tuberculosis among Adults Initiating Antiretroviral Therapy - Mozambique, 2004-2008 SO PLOS ONE LA English DT Article ID ISONIAZID PREVENTIVE THERAPY; HIV-ASSOCIATED TUBERCULOSIS; RESOURCE-LIMITED SETTINGS; RISK-FACTORS; MULTIPLE IMPUTATION; POSITIVE PATIENTS; MISSING VALUES; SOUTH-AFRICA; TERM; ADHERENCE AB Background: In Mozambique, tuberculosis (TB) is thought to be the most common cause of death among antiretroviral therapy (ART) enrollees. Monitoring proportions of enrollees screened for TB, and incidence and determinants of TB during ART can help clinicians and program managers identify program improvement opportunities. Methodology/Principal Findings: We conducted a retrospective cohort study among a nationally representative sample of the 79,500 adults (>14 years old) initiating ART during 2004-2007 to estimate clinician compliance with TB screening guidelines, factors associated with active TB at ART initiation, and incidence and predictors of documented TB during ART follow-up. Of 94 sites enrolling >= 50 adults on ART, 30 were selected using probability-proportional-to-size sampling; 2,596 medical records at these sites were randomly selected for abstraction and analysis. At ART initiation, median age of patients was 34, 62% were female, median baseline CD4(+) T-cell count was 153/mu L, and 11% were taking TB treatment. Proportions of records with TB screening documentation before ART initiation improved from 31% to 66% during 2004-2007 (p<0.001). TB screening compliance varied widely by ART clinic [n = 30, 2%-98% (p<0.001)] and supporting non-Governmental Organization (NGO) [n = 7, 27%-83% (p<0.001)]. Receiving TB treatment at ART enrollment was associated with male sex (p<0.001), weight <45 kg (p<0.001) and CD4<50/mu L (p=0.001). Isoniazid preventive therapy (IPT) was prescribed to <1% of ART enrollees not taking TB treatment. TB incidence during ART was 2.32 cases per 100 person-years. Factors associated with TB incidence included adherence to ART<95% (AHR 2.06; 95% CI, 1.32-3.21). Conclusion: Variations in TB screening by clinic and NGO may reflect differing investments in TB screening activities. Future scale-up should target under-performing clinics. Scale-up of TB screening at ART initiation, IPT, and ART adherence interventions could significantly reduce incident TB during ART. C1 [Auld, Andrew F.; Shiraishi, Ray W.; Ellerbrock, Tedd V.] Ctr Dis Control & Prevent, DGHA, CGH, Atlanta, GA 30333 USA. [Mbofana, Francisco] Minist Hlth, Insituto Nacl Saude, Maputo, Mozambique. [Alfredo, Charity] Ctr Dis Control & Prevent, DGHA, CGH, Maputo, Mozambique. [Sanchez, Mauro] Univ Brasilia, Sch Hlth Sci, Dept Publ Hlth, Brasilia, DF, Brazil. RP Auld, AF (reprint author), Ctr Dis Control & Prevent, DGHA, CGH, Atlanta, GA 30333 USA. EM aauld@cdc.gov OI Auld, Andrew/0000-0001-5089-9163 FU United States (U.S.) President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) FX All parts of the study were funded by the United States (U.S.) President's Emergency Plan for AIDS Relief (PEPFAR) (http://www.pepfar.gov/) through the U.S. Centers for Disease Control and Prevention (CDC) (http://www.cdc.gov/). Authors Auld, Shiraishi, Alfredo, Nelson, and Ellerbrock are employed by the CDC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 42 TC 11 Z9 11 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 22 PY 2013 VL 8 IS 1 AR e54665 DI 10.1371/journal.pone.0054665 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 077HS UT WOS:000314019100089 PM 23349948 ER PT J AU Des Jarlais, DC Feelemyer, JP Modi, SN Abu Abdul-Quader Hagan, H AF Des Jarlais, Don C. Feelemyer, Jonathan P. Modi, Shilpa N. Abu Abdul-Quader Hagan, Holly TI High coverage needle/syringe programs for people who inject drugs in low and middle income countries: a systematic review SO BMC PUBLIC HEALTH LA English DT Review DE HIV; Hepatitis C; Needle and syringe programs; Syringe exchange programs; People who inject drugs; Injecting drug use ID HEPATITIS-C VIRUS; HIV-INFECTION; EXCHANGE PROGRAMS; RISK BEHAVIORS; USERS; NEEDLE; EPIDEMIOLOGY; PREVENTION; PREVALENCE; PROVISION AB Background: Persons who inject drugs (PWID) are at an elevated risk for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. In many high-income countries, needle and syringe exchange programs (NSP) have been associated with reductions in blood-borne infections. However, we do not have a good understanding of the effectiveness of NSP in low/middle-income and transitional-economy countries. Methods: A systematic literature review based on PRISMA guidelines was utilized to collect primary study data on coverage of NSP programs and changes in HIV and HCV infection over time among PWID in low-and middle-income and transitional countries (LMICs). Included studies reported laboratory measures of either HIV or HCV and at least 50% coverage of the local injecting population (through direct use or through secondary exchange). We also included national reports on newly reported HIV cases for countries that had national level data for PWID in conjunction with NSP scale-up and implementation. Results: Studies of 11 NSPs with high-coverage from Bangladesh, Brazil, China, Estonia, Iran, Lithuania, Taiwan, Thailand and Vietnam were included in the review. In five studies HIV prevalence decreased (range -3% to -15%) and in three studies HCV prevalence decreased (range -4.2% to -10.2%). In two studies HIV prevalence increased (range +5.6% to +14.8%). HCV incidence remained stable in one study. Of the four national reports of newly reported HIV cases, three reported decreases during NSP expansion, ranging from -30% to -93.3%, while one national report documented an increase in cases (+37.6%). Estimated incidence among new injectors decreased in three studies, with reductions ranging from -11/100 person years at risk to -16/100 person years at risk. Conclusions: While not fully consistent, the data generally support the effectiveness of NSP in reducing HIV and HCV infection in low/middle-income and transitional-economy countries. If high coverage is achieved, NSP appear to be as effective in LMICs as in high-income countries. Additional monitoring and evaluation research is needed for NSPs where reductions in HIV/HCV infection among PWID are not occurring in order to identify and correct contributing problems. C1 [Des Jarlais, Don C.; Feelemyer, Jonathan P.; Modi, Shilpa N.] Beth Israel Deaconess Med Ctr, Baron Edmond Rothschild Chem Dependency Inst, New York, NY 10003 USA. [Abu Abdul-Quader] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hagan, Holly] NYU, Coll Nursing, New York, NY USA. RP Des Jarlais, DC (reprint author), Beth Israel Deaconess Med Ctr, Baron Edmond Rothschild Chem Dependency Inst, New York, NY 10003 USA. EM ddesjarlais@chpnet.org FU National Institutes of Health [R01 AI 083035-02] FX This study was funded by the National Institutes of Health (R01 AI 083035-02). The review is conducted in parallel with a Cochrane Systematic Review on high income countries utilizing different inclusion criteria, but benefited from joint discussions between the two research teams. The views expressed in this publication do not necessarily represent the position of the National Institutes of Health, Beth Israel Medical Center, the Centers for Disease Control and Prevention, or New York University. NR 41 TC 22 Z9 22 U1 2 U2 18 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD JAN 19 PY 2013 VL 13 AR 53 DI 10.1186/1471-2458-13-53 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 087MK UT WOS:000314765400001 PM 23332005 ER PT J AU Whitney, CG AF Whitney, Cynthia G. TI More evidence for use of pneumococcal conjugate vaccines SO LANCET LA English DT Editorial Material ID ACUTE OTITIS-MEDIA; DOUBLE-BLIND; EFFICACY; CHILDREN; TRIAL; SAFETY C1 Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Whitney, CG (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM cwhitney@cdc.gov NR 15 TC 3 Z9 3 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD JAN 19 PY 2013 VL 381 IS 9862 BP 182 EP 183 DI 10.1016/S0140-6736(12)61957-6 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 075LL UT WOS:000313887600007 PM 23158884 ER PT J AU Seaworth, BJ Field, K Flood, J Saliba, J Mase, SR Cronin, A Shah, N Jereb, J Chorba, T AF Seaworth, Barbara J. Field, Kim Flood, Jennifer Saliba, Jouhayna Mase, Sundari R. Cronin, Ann Shah, Neha Jereb, John Chorba, Terence TI Interruptions in Supplies of Second-Line Antituberculosis Drugs - United States, 2005-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID SHORTAGE C1 [Seaworth, Barbara J.] Univ Texas Hlth Sci Ctr, Houston, TX USA. [Field, Kim] San Diego Cty TB Control Program, San Diego, CA USA. [Saliba, Jouhayna] US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA. [Mase, Sundari R.; Cronin, Ann; Shah, Neha; Jereb, John; Chorba, Terence] CDC, Div TB Eliminat, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Mase, SR (reprint author), CDC, Div TB Eliminat, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. EM smase@cdc.gov NR 9 TC 6 Z9 6 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 18 PY 2013 VL 62 IS 2 BP 23 EP 26 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188DO UT WOS:000322172500002 ER PT J AU Perry, RT Gacic-Dobo, M Dabbagh, A Strebel, PM Okwo-Bele, JM Goodson, JL AF Perry, Robert T. Gacic-Dobo, Marta Dabbagh, Alya Strebel, Peter M. Okwo-Bele, Jean-Marie Goodson, James L. TI Global Control and Regional Elimination of Measles, 2000-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Perry, Robert T.; Gacic-Dobo, Marta; Dabbagh, Alya; Strebel, Peter M.; Okwo-Bele, Jean-Marie] WHO, Dept Immunizat Vaccines & Biologicals, CH-1211 Geneva, Switzerland. [Goodson, James L.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Goodson, JL (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. EM jgoodson@cdc.gov NR 10 TC 17 Z9 17 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 18 PY 2013 VL 62 IS 2 BP 27 EP 31 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188DO UT WOS:000322172500003 ER PT J AU Jackson, L Jackson, ML Phillips, CH Benoit, J Belongia, EA Cole, D Kopitzke, S Koepel, TAK McLean, HQ Meece, JK Strey, SK Sundaram, ME Vandermause, M Gaglani, M Song, J Clipper, L Kjar, D Robertson, A Murthy, K Dunnahoo, M Oliver, S Weir, M Gonzales, H Zayed, M Reis, M Rivera, C Morgan, D Piedra, P Avadhanula, V Monto, AS Ohmit, SE Petrie, JG Johnson, E Cross, RT Martens, C Zervos, M Lamerato, L Eng, H Nowalk, MP Wisniewski, SR Zimmerman, RK Rinaldo, CR Bullotta, A Suyama, J Reis, E Middleton, DB Hess, R Thompson, M Fry, AM Thaker, SN Spencer, S Cheng, PY Shay, DK Berman, L Bresee, J Burns, E Tokars, J Cox, N AF Jackson, Lisa Jackson, Michael L. Phillips, C. Hallie Benoit, Joyce Belongia, Edward A. Cole, Deanna Kopitzke, Sarah Koepel, Tamara A. Kronenwetter McLean, Huong Q. Meece, Jennifer K. Strey, Sandra K. Sundaram, Maria E. Vandermause, Mary Gaglani, Manjusha Song, Juhee Clipper, Lydia Kjar, Dean Robertson, Anne Murthy, Kempapura Dunnahoo, Melinda Oliver, Stephanie Weir, Monica Gonzales, Hope Zayed, Martha Reis, Michael Rivera, Cathleen Morgan, David Piedra, Pedro Avadhanula, Vasanthi Monto, Arnold S. Ohmit, Suzanne E. Petrie, Joshua G. Johnson, Emileigh Cross, Rachel T. Martens, Casey Zervos, Marcus Lamerato, Lois Eng, Heather Nowalk, Mary Patricia Wisniewski, Stephen R. Zimmerman, Richard K. Rinaldo, Charles R., Jr. Bullotta, Arlene Suyama, Joe Reis, Evelyn Middleton, Donald B. Hess, Rachel Thompson, Mark Fry, Alicia M. Thaker, Swathi N. Spencer, Sarah Cheng, Po-Yung Shay, David K. Berman, LaShondra Bresee, Joseph Burns, Erin Tokars, Jerome Cox, Nancy TI Early Estimates of Seasonal Influenza Vaccine Effectiveness - United States, January 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Jackson, Lisa; Jackson, Michael L.; Phillips, C. Hallie; Benoit, Joyce] Grp Hlth Res Inst, Seattle, WA USA. [Belongia, Edward A.; Cole, Deanna; Kopitzke, Sarah; Koepel, Tamara A. Kronenwetter; McLean, Huong Q.; Meece, Jennifer K.; Strey, Sandra K.; Sundaram, Maria E.; Vandermause, Mary] Marshfield Clin Res Fdn, Marshfield, WI USA. [Gaglani, Manjusha; Song, Juhee; Clipper, Lydia; Kjar, Dean; Robertson, Anne; Murthy, Kempapura; Dunnahoo, Melinda; Oliver, Stephanie; Weir, Monica; Gonzales, Hope; Zayed, Martha; Reis, Michael; Rivera, Cathleen; Morgan, David; Piedra, Pedro; Avadhanula, Vasanthi] Scott & White Healthcare, Temple, TX USA. [Gaglani, Manjusha; Song, Juhee; Clipper, Lydia; Kjar, Dean; Robertson, Anne; Murthy, Kempapura; Dunnahoo, Melinda; Oliver, Stephanie; Weir, Monica; Gonzales, Hope; Zayed, Martha; Reis, Michael; Rivera, Cathleen; Morgan, David; Piedra, Pedro; Avadhanula, Vasanthi] Baylor Coll Med, Houston, TX 77030 USA. [Monto, Arnold S.; Ohmit, Suzanne E.; Petrie, Joshua G.; Johnson, Emileigh; Cross, Rachel T.; Martens, Casey; Zervos, Marcus; Lamerato, Lois] Univ Michigan, Ann Arbor, MI 48109 USA. [Monto, Arnold S.; Ohmit, Suzanne E.; Petrie, Joshua G.; Johnson, Emileigh; Cross, Rachel T.; Martens, Casey; Zervos, Marcus; Lamerato, Lois] Henry Ford Hlth Syst, Detroit, MI USA. [Eng, Heather; Nowalk, Mary Patricia; Wisniewski, Stephen R.; Zimmerman, Richard K.; Rinaldo, Charles R., Jr.; Bullotta, Arlene; Suyama, Joe; Reis, Evelyn; Middleton, Donald B.; Hess, Rachel] Univ Pittsburgh, Sch Hlth Sci, Pittsburgh, PA USA. [Eng, Heather; Nowalk, Mary Patricia; Wisniewski, Stephen R.; Zimmerman, Richard K.; Rinaldo, Charles R., Jr.; Bullotta, Arlene; Suyama, Joe; Reis, Evelyn; Middleton, Donald B.; Hess, Rachel] Univ Pittsburgh, Sch UPMC, Pittsburgh, PA USA. [Thompson, Mark; Fry, Alicia M.; Thaker, Swathi N.; Spencer, Sarah; Cheng, Po-Yung; Shay, David K.; Berman, LaShondra; Bresee, Joseph; Burns, Erin; Tokars, Jerome; Cox, Nancy] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Thompson, M (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM isq8@cdc.gov OI Shay, David/0000-0001-9619-4820; Wisniewski, Stephen/0000-0002-3877-9860; Zimmerman, Richard/0000-0001-5941-6092 NR 8 TC 28 Z9 29 U1 0 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 18 PY 2013 VL 62 IS 2 BP 32 EP 35 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188DO UT WOS:000322172500004 ER PT J AU Parekh, AK Galloway, JM Hong, YL Wright, JS AF Parekh, Anand K. Galloway, James M. Hong, Yuling Wright, Janet S. TI Aspirin in the Secondary Prevention of Cardiovascular Disease SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Parekh, Anand K.] US Dept Hlth & Human Serv, Off Assistant Secretary Hlth, Washington, DC USA. [Galloway, James M.] US Dept Hlth & Human Serv, Off Assistant Secretary Hlth, Chicago, IL USA. [Hong, Yuling; Wright, Janet S.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Wright, Janet S.] Ctr Medicare & Medicaid Innovat, Baltimore, MD USA. RP Parekh, AK (reprint author), US Dept Hlth & Human Serv, Off Assistant Secretary Hlth, Washington, DC USA. NR 5 TC 7 Z9 8 U1 0 U2 3 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JAN 17 PY 2013 VL 368 IS 3 BP 204 EP 205 DI 10.1056/NEJMp1213380 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 070YG UT WOS:000313549900004 PM 23323896 ER PT J AU Amer, S Zidan, S Feng, YY Adamu, H Li, N Xiao, LH AF Amer, Said Zidan, Shereif Feng, Yaoyu Adamu, Haileeyesus Li, Na Xiao, Lihua TI Identity and public health potential of Cryptosporidium spp. in water buffalo calves in Egypt SO VETERINARY PARASITOLOGY LA English DT Article DE Cryptosporidium; Genotype; Subtype; Buffalo; Calves; Egypt ID MOLECULAR CHARACTERIZATION; DAIRY CALVES; BUBALUS-BUBALIS; GENETIC CLASSIFICATION; PROTOZOAN PARASITES; NATIONAL-PARK; PREVALENCE; SUBTYPES; CATTLE; TRANSMISSION AB Little is known about the diversity and public health significance of Cryptosporidium species in water buffaloes. In this study, we examined the distribution of Cryptosporidium spp. in water buffalo calves in Egypt. Rectal fecal specimens from 179 calves and 359 adults were screened microscopically for Cryptosporidium oocysts using modified Ziehl-Neelsen stain. Cry ptosporidium spp. in 17 microscopy-positive specimens from calves were genotyped by DNA sequence analysis of the small-subunit rRNA gene, and Cryptosporidium parvum was subtyped by sequence analysis of the 60 kDa glycoprotein gene. Cryptosporidium ryanae was found in 10 specimens and C. parvum in 7 specimens, with the former belonging to the newly identified C. ryanae buffalo variant and the latter belonging to the subtypes IldA20G1 (in 5 specimens) and IlaA15G1R1 (in 2 specimens). The prevailing occurrence of C. ryanae and the subtype family lid of C. parvum and the absence of C. bovis and C. andersoni represent some features of Cryptosporidium transmission in water buffaloes in Egypt. Published by Elsevier B.V. C1 [Amer, Said; Adamu, Haileeyesus; Li, Na; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. [Amer, Said] Kafr El Sheikh Univ, Fac Sci, Dept Zool, Kafe El Sheikh, Egypt. [Zidan, Shereif] Menoufia Univ, Sadat Branch, Dept Anim Hyg & Zoonoses, Fac Vet Med, Al Menofia, Egypt. [Feng, Yaoyu; Li, Na] E China Univ Sci & Technol, Sch Resources & Environm Engn, Shanghai 200237, Peoples R China. [Adamu, Haileeyesus] Univ Addis Ababa, Addis Ababa, Ethiopia. RP Xiao, LH (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM lxiao@cdc.gov RI Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014; OI Xiao, Lihua/0000-0001-8532-2727; Adamu, Haileeyesus/0000-0003-2998-5977 FU Arab Fund for Economic & Social Development "Zamalat Program"; National Natural Science Foundation of China [31110103901, 31229005] FX This study was supported in part by the Arab Fund for Economic & Social Development "Zamalat Program" and the National Natural Science Foundation of China (Project No. 31110103901 and 31229005). We thank the Kafr El Sheikh University and Menofia University for supporting the field work in Egypt, Centers for Disease Control and Prevention for supporting the molecular analysis, and Dawn Roellig and Hongwei Zhang for technical assistance. NR 40 TC 24 Z9 25 U1 2 U2 17 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-4017 J9 VET PARASITOL JI Vet. Parasitol. PD JAN 16 PY 2013 VL 191 IS 1-2 BP 123 EP 127 DI 10.1016/j.vetpar.2012.08.015 PG 5 WC Parasitology; Veterinary Sciences SC Parasitology; Veterinary Sciences GA 054PF UT WOS:000312355000019 PM 22963712 ER PT J AU Kobau, R Luo, YH Zack, MM Helmers, S Thurman, DJ AF Kobau, Rosemarie Luo, Yao-Hua Zack, Matthew M. Helmers, Sandra Thurman, David J. TI Epilepsy in Adults and Access to Care-United States, 2010 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Kobau, Rosemarie; Luo, Yao-Hua; Zack, Matthew M.; Helmers, Sandra; Thurman, David J.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Kobau, R (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM rkobau@cdc.gov NR 0 TC 1 Z9 1 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 16 PY 2013 VL 309 IS 3 BP 224 EP 226 DI 10.1001/jama.2012.147846 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 070XG UT WOS:000313546800007 ER PT J AU Borse, NN Rudd, RA Dellinger, AM Sleet, DA AF Borse, Nagesh N. Rudd, Rose A. Dellinger, Ann M. Sleet, David A. TI Years of Potential Life Lost from Unintentional Injuries Among Persons Aged 0-19 Years-United States, 2000-2009 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Borse, Nagesh N.] CDC, Div Global HIV & AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Rudd, Rose A.; Dellinger, Ann M.; Sleet, David A.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Borse, NN (reprint author), CDC, Div Global HIV & AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. EM nborse@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 16 PY 2013 VL 309 IS 3 BP 226 EP 231 DI 10.1001/jama.2012.64960 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 070XG UT WOS:000313546800008 ER PT J AU Wang, DX Baudys, J Ye, YM Rees, JC Barr, JR Pirkle, JL Kalb, SR AF Wang, Dongxia Baudys, Jakub Ye, Yiming Rees, Jon C. Barr, John R. Pirkle, James L. Kalb, Suzanne R. TI Improved detection of botulinum neurotoxin serotype A by Endopep-MS through peptide substrate modification SO ANALYTICAL BIOCHEMISTRY LA English DT Article DE Botulinum neurotoxin; Detection; Mass spectrometry; Peptide substrate ID LINKED-IMMUNOSORBENT-ASSAY; CLOSTRIDIUM-BOTULINUM; MASS-SPECTROMETRY; MOUSE BIOASSAY; TOXIN; DIFFERENTIATION; SEQUENCE; SNAP-25; SAMPLES; STOOL AB Botulinum neurotoxins (BoNTs) are a family of seven toxin serotypes that are the most toxic substances known to humans. Intoxication with BoNT causes flaccid paralysis and can lead to death if untreated with serotype-specific antibodies. Supportive care, including ventilation, may be necessary. Rapid and sensitive detection of BoNT is necessary for timely clinical confirmation of clinical botulism. Previously, our laboratory developed a fast and sensitive mass spectrometry (MS) method termed the Endopep MS assay. The BoNT serotypes are rapidly detected and differentiated by extracting the toxin with serotype-specific antibodies and detecting the unique and serotype-specific cleavage products of peptide substrates that mimic the sequence of the BoNT native targets. To further improve the sensitivity of the Endopep MS assay, we report here the optimization of the substrate peptide for the detection of BoNT/A. Modifications on the terminal groups of the original peptide substrate with acetylation and amidation significantly improved the detection of BoNT/A cleavage products. The replacement of some internal amino acid residues with single or multiple substitutions led to further improvement. An optimized peptide increased assay sensitivity 5-fold with toxin spiked into buffer solution or different biological matrices. Published by Elsevier Inc. C1 [Wang, Dongxia; Baudys, Jakub; Ye, Yiming; Rees, Jon C.; Barr, John R.; Pirkle, James L.; Kalb, Suzanne R.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Kalb, SR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. EM skalb@cdc.gov OI Kalb, Suzanne/0000-0002-8067-136X FU Intramural CDC HHS [CC999999] NR 38 TC 9 Z9 9 U1 1 U2 10 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0003-2697 J9 ANAL BIOCHEM JI Anal. Biochem. PD JAN 15 PY 2013 VL 432 IS 2 BP 115 EP 123 DI 10.1016/j.ab.2012.09.021 PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 047ZJ UT WOS:000311879700010 PM 23017875 ER PT J AU Agolory, SG Barbot, O Averhoff, F Weiss, D Wilson, E Egger, J Miller, J Ogbuanu, I Walton, S Kahn, E AF Agolory, Simon G. Barbot, Oxiris Averhoff, Francisco Weiss, Don Wilson, Elisha Egger, Joseph Miller, Jeffery Ogbuanu, Ikechukwu Walton, Sabrina Kahn, Emily TI Implementation of Non-Pharmaceutical Interventions by New York City Public Schools to Prevent 2009 Influenza A SO PLOS ONE LA English DT Article ID H1N1 VIRUS-INFECTIONS; PANDEMIC INFLUENZA; ABSENTEEISM; ILLNESS; TRANSMISSION; HOUSEHOLDS; OUTBREAK; CHILDREN AB Introduction: Children are important transmitters of influenza in the community and a number of non-pharmaceutical interventions (NPIs), including hand washing and use of hand sanitizer, have been recommended to mitigate the transmission of influenza, but limited information is available regarding schools' ability to implement these NPIs during an influenza outbreak. We evaluated implementation of NPIs during fall 2009 in response to H1N1 pandemic influenza (pH1N1) by New York City (NYC) public schools. Methods: From January 25 through February 9, 2010, an online survey was sent to all the 1,632 NYC public schools and principals were asked to participate in the survey or to designate a school nurse or other school official with knowledge of school policies and characteristics to do so. Results: Of 1,633 schools, 376(23%) accessed and completed the survey. Nearly all respondents (99%) implemented at least two NPIs. Schools that had a Flu Response Team (FRT) as a part of school emergency preparedness plan were more likely to implement the NPI guidelines recommended by NYC public health officials than schools that did not have a FRT. Designation of a room for isolating ill students, for example, was more common in schools with a FRT (72%) than those without (53%) (p < 0.001). Conclusions: Implementing an NPI program in a large school system to mitigate the effects of an influenza outbreak is feasible, but there is potential need for additional resources in some schools to increase capacity and adherence to all recommendations. Public health influenza-preparedness plans should include school preparedness planning and FRTs. C1 [Agolory, Simon G.; Miller, Jeffery; Ogbuanu, Ikechukwu] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Barbot, Oxiris] Dept Hlth, Baltimore, MD USA. [Averhoff, Francisco; Walton, Sabrina; Kahn, Emily] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Barbot, Oxiris; Weiss, Don; Wilson, Elisha; Egger, Joseph] Dept Hlth & Mental Hyg, New York, NY USA. [Egger, Joseph] SciMetrika LLC, Res Triangle Pk, NC USA. RP Agolory, SG (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM sagolory@cdc.gov OI Kahn, Emily/0000-0001-7812-7958 FU Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention FX This study was funded by the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 4 Z9 4 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 15 PY 2013 VL 8 IS 1 AR e50916 DI 10.1371/journal.pone.0050916 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 086SQ UT WOS:000314707700004 PM 23341877 ER PT J AU Pell, C Menaca, A Were, F Afrah, NA Chatio, S Manda-Taylor, L Hamel, MJ Hodgson, A Tagbor, H Kalilani, L Ouma, P Pool, R AF Pell, Christopher Menaca, Arantza Were, Florence Afrah, Nana A. Chatio, Samuel Manda-Taylor, Lucinda Hamel, Mary J. Hodgson, Abraham Tagbor, Harry Kalilani, Linda Ouma, Peter Pool, Robert TI Factors Affecting Antenatal Care Attendance: Results from Qualitative Studies in Ghana, Kenya and Malawi SO PLOS ONE LA English DT Article ID MATERNAL MORTALITY; PREGNANCY; STRATEGIES; TANZANIA; PERSPECTIVES; COVERAGE; MALARIA; AFRICA; BIRTH; WOMEN AB Background: Antenatal care (ANC) is a key strategy to improve maternal and infant health. However, survey data from sub-Saharan Africa indicate that women often only initiate ANC after the first trimester and do not achieve the recommended number of ANC visits. Drawing on qualitative data, this article comparatively explores the factors that influence ANC attendance across four sub-Saharan African sites in three countries (Ghana, Kenya and Malawi) with varying levels of ANC attendance. Methods: Data were collected as part of a programme of qualitative research investigating the social and cultural context of malaria in pregnancy. A range of methods was employed interviews, focus groups with diverse respondents and observations in local communities and health facilities. Results: Across the sites, women attended ANC at least once. However, their descriptions of ANC were often vague. General ideas about pregnancy care - checking the foetus' position or monitoring its progress - motivated women to attend ANC; as did, especially in Kenya, obtaining the ANC card to avoid reprimands from health workers. Women's timing of ANC initiation was influenced by reproductive concerns and pregnancy uncertainties, particularly during the first trimester, and how ANC services responded to this uncertainty; age, parity and the associated implications for pregnancy disclosure; interactions with healthcare workers, particularly messages about timing of ANC; and the cost of ANC, including charges levied for ANC procedures - in spite of policies of free ANC - combined with ideas about the compulsory nature of follow-up appointments. Conclusion: In these socially and culturally diverse sites, the findings suggest that 'supply' side factors have an important influence on ANC attendance: the design of ANC and particularly how ANC deals with the needs and concerns of women during the first trimester has implications for timing of initiation. C1 [Pell, Christopher; Pool, Robert] Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands. [Pell, Christopher; Menaca, Arantza; Pool, Robert] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain. [Were, Florence; Ouma, Peter] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Afrah, Nana A.; Tagbor, Harry] Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Dept Community Hlth, Kumasi, Ghana. [Chatio, Samuel; Hodgson, Abraham] Navrongo Hlth Res Ctr, Navrongo, Upper East Regi, Ghana. [Manda-Taylor, Lucinda; Kalilani, Linda] Univ Malawi, Coll Med, Blantyre, Malawi. [Tagbor, Harry] London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1, England. [Hamel, Mary J.; Ouma, Peter] Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA USA. RP Pell, C (reprint author), Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands. EM c.l.pell@uva.nl OI Pell, Christopher/0000-0001-9405-5851 FU Malaria in Pregnancy (MiP) Consortium; Bill and Melinda Gates Foundation [OPP46099] FX This research was supported and endorsed by the Malaria in Pregnancy (MiP) Consortium, which is funded by a grant from the Bill and Melinda Gates Foundation (www.gatesfoundation.org), Grant OPP46099. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 38 TC 45 Z9 45 U1 3 U2 25 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 15 PY 2013 VL 8 IS 1 AR e53747 DI 10.1371/journal.pone.0053747 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 086SQ UT WOS:000314707700029 PM 23335973 ER PT J AU Mancuso, JD Bernardo, J Mazurek, GH AF Mancuso, James D. Bernardo, John Mazurek, Gerald H. TI The Elusive "Gold" Standard for Detecting Mycobacterium tuberculosis Infection SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID CONVERSION; TESTS C1 [Mancuso, James D.] Walter Reed Army Inst Res, Silver Spring, MD USA. [Bernardo, John] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA. [Mazurek, Gerald H.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. RP Mancuso, JD (reprint author), Walter Reed Army Inst Res, Silver Spring, MD USA. OI Bernardo, John/0000-0002-3922-0559 NR 12 TC 11 Z9 11 U1 0 U2 3 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JAN 15 PY 2013 VL 187 IS 2 BP 122 EP 124 DI 10.1164/rccm.201211-2033ED PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 075YY UT WOS:000313924600006 PM 23322793 ER PT J AU Nelson, JC Yu, O Dominguez-Islas, CP Cook, AJ Peterson, D Greene, SK Yih, WK Daley, MF Jacobsen, SJ Klein, NP Weintraub, ES Broder, KR Jackson, LA AF Nelson, Jennifer C. Yu, Onchee Dominguez-Islas, Clara P. Cook, Andrea J. Peterson, Do Greene, Sharon K. Yih, W. Katherine Daley, Matthew F. Jacobsen, Steven J. Klein, Nicola P. Weintraub, Eric S. Broder, Karen R. Jackson, Lisa A. TI Adapting Group Sequential Methods to Observational Postlicensure Vaccine Safety Surveillance: Results of a Pentavalent Combination DTaP-IPV-Hib Vaccine Safety Study SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE managed care programs; population surveillance; safety; sequential analysis; vaccines; combined ID B CONJUGATE VACCINE; ADVERSE EVENTS; INACTIVATED POLIOMYELITIS; ACELLULAR PERTUSSIS; ACTIVE SURVEILLANCE; DATALINK PROJECT; CLINICAL-TRIALS; IMMUNOGENICITY; DIPHTHERIA; TETANUS AB To address gaps in traditional postlicensure vaccine safety surveillance and to promote rapid signal identification, new prospective monitoring systems using large health-care database cohorts have been developed. We newly adapted clinical trial group sequential methods to this observational setting in an original safety study of a combination diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP), inactivated poliovirus (IPV), and Haemophilus influenzae type b (Hib) conjugate vaccine (DTaP-IPV-Hib) among children within the Vaccine Safety Datalink population. For each prespecified outcome, we conducted 11 sequential Poisson-based likelihood ratio tests during September 2008January 2011 to compare DTaP-IPV-Hib vaccinees with historical recipients of other DTaP-containing vaccines. No increased risk was detected among 149,337 DTaP-IPV-Hib vaccinees versus historical comparators for any outcome, including medically attended fever, seizure, meningitis/encephalitis/myelitis, nonanaphylactic serious allergic reaction, anaphylaxis, Guillain-Barr syndrome, or invasive Hib disease. In end-of-study prespecified subgroup analyses, risk of medically attended fever was elevated among 1- to 2-year-olds who received DTaP-IPV-Hib vaccine versus historical comparators (relative risk 1.83, 95 confidence interval: 1.34, 2.50) but not among infants under 1 year old (relative risk 0.83, 95 confidence interval: 0.73, 0.94). Findings were similar in analyses with concurrent comparators who received other DTaP-containing vaccines during the study period. Although lack of a controlled experiment presents numerous challenges, implementation of group sequential monitoring methods in observational safety surveillance studies is promising and warrants further investigation. C1 [Nelson, Jennifer C.; Dominguez-Islas, Clara P.; Cook, Andrea J.] Univ Washington, Dept Biostat, Sch Publ Hlth, Seattle, WA 98195 USA. [Greene, Sharon K.; Yih, W. Katherine] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Greene, Sharon K.; Yih, W. Katherine] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Klein, Nicola P.] Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA. [Weintraub, Eric S.; Broder, Karen R.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Hlth Care Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Daley, Matthew F.] Kaiser Permanente Colorado, Inst Hlth Res, Aurora, CO USA. [Daley, Matthew F.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA. [Jacobsen, Steven J.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA. RP Nelson, JC (reprint author), Grp Hlth Res Inst, Biostat Unit, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. EM nelson.jl@ghc.org OI Jacobsen, Steven/0000-0002-8174-8533 FU America's Health Insurance Plans, Centers for Disease Control and Prevention [200-2002-00732]; Sanofi Pasteur; Glaxo-Smith-Kline; Pfizer; Novartis; Merck FX This work was supported by a subcontract with America's Health Insurance Plans under contract 200-2002-00732 from the Centers for Disease Control and Prevention.; Dr. Nelson has served as a statistical consultant to Glaxo-Smith-Kline. Dr. Klein has received research support from Sanofi Pasteur, Glaxo-Smith-Kline, Pfizer, Novartis, and Merck. Dr. Jackson has received research funding from Sanofi Pasteur, Pfizer, and Novartis and has received travel support for meeting attendance from Pfizer. NR 43 TC 14 Z9 16 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JAN 15 PY 2013 VL 177 IS 2 BP 131 EP 141 DI 10.1093/aje/kws317 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 070RP UT WOS:000313528700005 PM 23292957 ER PT J AU Enfield, KB Sharapov, U Hall, KK Leiner, J Berg, CL Xia, GL Thompson, ND Ganova-Raeva, L Sifri, CD AF Enfield, Kyle B. Sharapov, Umid Hall, Keri K. Leiner, John Berg, Carl L. Xia, Guo-liang Thompson, Nicola D. Ganova-Raeva, Lilia Sifri, Costi D. TI Transmission of Hepatitis B Virus From an Orthopedic Surgeon With a High Viral Load SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE hepatitis B virus; reverse exposure; transmission ID HEALTH-CARE WORKERS; UNITED-STATES; INFECTION; RECOMMENDATIONS; MANAGEMENT; PATHOGENS; EXPOSURE AB Background. During the evaluation of a needle-stick injury, an orthopedic surgeon was found to be unknowingly infected with hepatitis B virus (HBV) (viral load >17.9 million IU/mL). He had previously completed two 3-dose series of hepatitis B vaccine without achieving a protective level of surface antibody. We investigated whether any surgical patients had acquired HBV infection while under his care. Methods. A retrospective cohort study of all patients who underwent surgery by the surgeon was conducted. Patients were notified of their potential exposure and need for testing, and samples with positive HBV loads underwent DNA sequencing. Characteristics of the surgical procedures for the cohort were evaluated. Results. A total of 232 (70.7%) of potentially exposed patients consented to testing; 2 were found to have acute infection and 6 had possible transmission (evidence of past exposure without risk factors). Genome sequence analysis of HBV DNA from the infected surgeon and patients with acute infection revealed genetically related virus (>99.9% nucleotide identity). Only age was found to be statistically different between those with confirmed or possible HBV transmission and those who remained susceptible to HBV. Conclusions. We documented HBV transmission during orthopedic surgery to 2 patients from a surgeon with HBV. This investigation highlights the importance of evaluating individuals who do not respond to 2 series of HBV vaccination, the increased risk of HBV transmission from providers with high viral loads, and the need to evaluate the clinical practice of providers with HBV and implement appropriate procedure-based practice restrictions. C1 [Hall, Keri K.; Sifri, Costi D.] Univ Virginia Hlth Syst, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA. [Enfield, Kyle B.; Hall, Keri K.; Sifri, Costi D.] Univ Virginia Hlth Syst, Off Hosp Epidemiol, Charlottesville, VA 22908 USA. [Enfield, Kyle B.] Univ Virginia Hlth Syst, Div Pulm Crit Care Med, Charlottesville, VA 22908 USA. [Sharapov, Umid; Xia, Guo-liang; Thompson, Nicola D.; Ganova-Raeva, Lilia] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Leiner, John] Univ Virginia Hlth Syst, Div Gen Internal Med Geriatr & Palliat Care, Charlottesville, VA 22908 USA. [Berg, Carl L.] Univ Virginia Hlth Syst, Div Gastroenterol & Hepatol, Charlottesville, VA 22908 USA. RP Sifri, CD (reprint author), Univ Virginia Hlth Syst, Div Infect Dis & Int Hlth, POB 800473, Charlottesville, VA 22908 USA. EM csifri@virginia.edu OI Enfield, Kyle/0000-0003-4624-0176 NR 20 TC 6 Z9 6 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2013 VL 56 IS 2 BP 218 EP 224 DI 10.1093/cid/cis869 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 058AJ UT WOS:000312606100012 PM 23074317 ER PT J AU Wilkins, PP Keystone, JS AF Wilkins, Patricia P. Keystone, Jay S. TI Schistosomiasis Serology Is Valuable and Reliable SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID FAST-ELISA; MANSONI C1 [Wilkins, Patricia P.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30329 USA. [Keystone, Jay S.] Univ Toronto, Toronto Gen Hosp, Trop Dis Unit, Toronto, ON M5S 1A1, Canada. RP Wilkins, PP (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Mail Stop D-64,1600 Clifton Rd, Atlanta, GA 30329 USA. EM pwilkins@cdc.gov NR 5 TC 2 Z9 2 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2013 VL 56 IS 2 BP 312 EP 312 DI 10.1093/cid/cis827 PG 1 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 058AJ UT WOS:000312606100030 PM 22997211 ER PT J AU Donis, RO Cox, NJ AF Donis, Ruben O. Cox, Nancy J. TI So Many Questions, So Little Time SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material ID INFLUENZA-VIRUS; HOST; TRANSMISSION; VIRULENCE; FERRETS; PROTEIN; DISEASE C1 [Donis, Ruben O.; Cox, Nancy J.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. RP Cox, NJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, 1600 Clifton Rd,MS A20, Atlanta, GA 30333 USA. EM njc1@cdc.gov NR 25 TC 1 Z9 1 U1 0 U2 16 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD JAN 15 PY 2013 VL 207 IS 2 BP 208 EP 210 DI 10.1093/infdis/jis529 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 061YO UT WOS:000312886400004 PM 23042758 ER PT J AU McNaghten, AD Valverde, EE Blair, JM Johnson, CH Freedman, MS Sullivan, PS AF McNaghten, A. D. Valverde, Eduardo E. Blair, Janet M. Johnson, Christopher H. Freedman, Mark S. Sullivan, Patrick S. TI Routine HIV Testing among Providers of HIV Care in the United States, 2009 SO PLOS ONE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; FOR-DISEASE-CONTROL; ACTIVE ANTIRETROVIRAL THERAPY; COST-EFFECTIVENESS; RECOMMENDATIONS; SETTINGS; HEALTH; INFECTION AB In 2006, CDC recommended HIV screening as part of routine medical care for all persons aged 13-64 years. We examined adherence to the recommendations among a sample of HIV care providers in the US to determine if known providers of HIV care are offering routine HIV testing in outpatient settings. Data were from the CDC's Medical Monitoring Project Provider Survey, administered to physicians, nurse practitioners and physician assistants from June-September 2009. We assessed bivariate associations between testing behaviors and provider and practice characteristics and used multivariate regression to determine factors associated with offering HIV screening to all patients aged 13-64 years. Sixty percent of providers reported offering HIV screening to all patients 13 to 64 years of age. Being a nurse practitioner (aOR = 5.6, 95% CI = 2.6-11.9) compared to physician, age <39 (aOR = 1.9, 95% CI = 1.0-3.5) or 39-49 (aOR = 2.1, 95% CI = 1.4-3.3) compared with >= 50 years, and black race (aOR = 2.6, 95% CI = 1.2-6.0) compared with white race was associated with offering testing to all patients. Providers with low (aOR = 0.2, 95% CI = 0.1-0.3) or medium (aOR = 0.4, 95% CI = 0.2-0.6) HIV-infected patient loads were less likely to offer HIV testing to all patients compared with providers with high patient loads. Many providers of HIV care are still conducting risk-based rather than routine testing. We found that provider profession, age, race, and HIV-infected patient load were associated with offering HIV testing. Health care providers should use patient encounters as an opportunity to offer routine HIV testing to patients as outlined in CDC's revised recommendations for HIV testing in health care settings. C1 [McNaghten, A. D.; Valverde, Eduardo E.; Blair, Janet M.; Johnson, Christopher H.; Freedman, Mark S.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Sullivan, Patrick S.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP McNaghten, AD (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM a.d.mcnaghten@emory.edu OI Sullivan, Patrick/0000-0002-7728-0587 FU Centers for Disease Control and Prevention FX This project was funded exclusively by the Centers for Disease Control and Prevention, which conceived the project, developed project-associated materials including data collection instruments, provided oversight of implementation, conducted analytic procedures, and developed this report. NR 49 TC 4 Z9 4 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 14 PY 2013 VL 8 IS 1 AR e51231 DI 10.1371/journal.pone.0051231 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 087KE UT WOS:000314759400003 PM 23341880 ER PT J AU Zhang, QB Fillmore, TL Schepmoes, AA Clauss, TRW Gritsenko, MA Mueller, PW Rewers, M Atkinson, MA Smith, RD Metz, TO AF Zhang, Qibin Fillmore, Thomas L. Schepmoes, Athena A. Clauss, Therese R. W. Gritsenko, Marina A. Mueller, Patricia W. Rewers, Marian Atkinson, Mark A. Smith, Richard D. Metz, Thomas O. TI Serum proteomics reveals systemic dysregulation of innate immunity in type 1 diabetes SO JOURNAL OF EXPERIMENTAL MEDICINE LA English DT Article ID ANTIBODY STANDARDIZATION PROGRAM; GLUTAMIC-ACID DECARBOXYLASE; GENERAL-POPULATION; MASS-SPECTROMETRY; ISLET ANTIGEN-2; PLASMA-PROTEINS; YOUNG DAISY; PREDICTION; MELLITUS; ASSAYS AB Using global liquid chromatography-mass spectrometry (LC-MS)-based proteomics analyses, we identified 24 serum proteins that were significantly variant between those with type 1 diabetes (T1D) and healthy controls. Functionally, these proteins represent innate immune responses, the activation cascade of complement, inflammatory responses, and blood coagulation. Targeted verification analyses were performed on 52 surrogate peptides representing these proteins, with serum samples from an antibody standardization program cohort of 100 healthy control and 50 type 1 diabetic subjects. 16 peptides were verified as having very good discriminating power, with areas under the receiver operating characteristic curve >= 0.8. Further validation with blinded serum samples from an independent cohort (10 healthy control and 10 type 1 diabetics) demonstrated that peptides from platelet basic protein and C1 inhibitor achieved both 100% sensitivity and 100% specificity for classification of samples. The disease specificity of these proteins was assessed using sera from 50 age-matched type 2 diabetic individuals, and a subset of proteins, C1 inhibitor in particular, were exceptionally good discriminators between these two forms of diabetes. The panel of biomarkers distinguishing those with T1D from healthy controls and those with type 2 diabetes suggests that dysregulated innate immune responses may be associated with the development of this disorder. C1 [Zhang, Qibin; Schepmoes, Athena A.; Clauss, Therese R. W.; Gritsenko, Marina A.; Smith, Richard D.; Metz, Thomas O.] Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99354 USA. [Fillmore, Thomas L.] Pacific NW Natl Lab, Environm Mol Sci Lab, Richland, WA 99354 USA. [Mueller, Patricia W.] Ctr Dis Control & Prevent, Natl Diabet Lab, Atlanta, GA 30333 USA. [Rewers, Marian] Univ Colorado Denver, Barbara Davis Ctr Childhood Diabet, Aurora, CO 80045 USA. [Atkinson, Mark A.] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA. RP Zhang, QB (reprint author), Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99354 USA. EM qibin.zhang@pnnl.gov; thomas.metz@pnnl.gov RI Smith, Richard/J-3664-2012; OI Smith, Richard/0000-0002-2381-2349; Metz, Tom/0000-0001-6049-3968 FU National Institutes of Health [DK070146]; Laboratory Directed Research and Development and Technology Maturation Grants of Pacific Northwest National Laboratory (PNNL); National Center for Research Resources [P41RR018522]; National Institute of General Medical Sciences [P41GM103493]; National Institute of Diabetes and Digestive and Kidney Diseases [DK32083, P30 DK57516]; U. S. Department of Energy (DOE) Office of Biological and Environmental Research; DOE [DE-AC06-76RLO-1830] FX This research was supported by National Institutes of Health grant DK070146, and Laboratory Directed Research and Development and Technology Maturation Grants of Pacific Northwest National Laboratory (PNNL). Portions of this research were supported by the National Center for Research Resources (P41RR018522), the National Institute of General Medical Sciences (P41GM103493), and National Institute of Diabetes and Digestive and Kidney Diseases grants DK32083 and P30 DK57516. Work was performed at the Environmental Molecular Sciences Laboratory, a national scientific user facility located at PNNL and sponsored by the U. S. Department of Energy (DOE) Office of Biological and Environmental Research. PNNL is operated by Battelle for the DOE under contract no. DE-AC06-76RLO-1830. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 58 TC 26 Z9 26 U1 1 U2 20 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA SN 0022-1007 J9 J EXP MED JI J. Exp. Med. PD JAN 14 PY 2013 VL 210 IS 1 BP 191 EP 203 DI 10.1084/jem.20111843 PG 13 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 071BP UT WOS:000313560900016 PM 23277452 ER PT J AU Balaji, AB Bowles, KE Le, BC Paz-Bailey, G Oster, AM AF Balaji, Alexandra B. Bowles, Kristina E. Le, Binh C. Paz-Bailey, Gabriela Oster, Alexandra M. CA NHBS Study Grp TI High HIV incidence and prevalence and associated factors among young MSM, 2008 SO AIDS LA English DT Article DE HIV seroprevalence; MSM; risk factors; sexual behaviors; young adult ID BEHAVIORAL SURVEILLANCE SYSTEM; AFRICAN-AMERICAN MEN; UNITED-STATES; HIGH-RISK; SEXUAL-BEHAVIOR; BISEXUAL MEN; US CITIES; INFECTION; PREVENTION; PARTNERS AB Objective: To estimate HIV prevalence, annual HIV incidence density, and factors associated with HIV infection among young MSM in the United States. Design: The 2008 National HIV Behavioral Surveillance System (NHBS), a cross-sectional survey conducted in 21 US cities. Methods: NHBS respondents included in the analysis were MSM aged 18-24 with a valid HIV test who reported at least one male sex partner in the past year. We calculated HIV prevalence and estimated annual incidence density (number of HIV infections/total number of person-years at risk). Generalized estimating equations were used to determine factors associated with testing positive for HIV. Results: Of 1889 young MSM, 198 (10%) had a positive HIV test; of these, 136 (69%) did not report previously testing HIV positive when interviewed. Estimated annual HIV incidence density was 2.9%; incidence was highest for blacks. Among young MSM who did not report being HIV infected, factors associated with testing HIV positive included black race; less than high school education; using both alcohol and drugs before or during last sex; having an HIV test more than 12 months ago; and reporting a visit to a medical provider in the past year. Conclusion: HIV prevalence and estimated incidence density for young MSM were high. Individual risk behaviors did not fully explain HIV risk, emphasizing the need to address sociodemographic and structural-level factors in public health interventions targeted toward young MSM. (c) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:269-278 C1 [Balaji, Alexandra B.; Bowles, Kristina E.; Le, Binh C.; Paz-Bailey, Gabriela; Oster, Alexandra M.; NHBS Study Grp] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Balaji, AB (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-46, Atlanta, GA 30333 USA. EM dvi7@cdc.gov FU CDC FX Funding for NHBS is provided by CDC. NR 43 TC 37 Z9 40 U1 0 U2 23 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD JAN 14 PY 2013 VL 27 IS 2 BP 269 EP 278 DI 10.1097/QAD.0b013e32835ad489 PG 10 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 057DS UT WOS:000312542900016 PM 23079807 ER PT J AU Marder, E Kirschke, D Robbins, D Dunn, J Jones, TF Racoosin, J Paulozzi, L Chang, A AF Marder, Ellyn Kirschke, David Robbins, Donna Dunn, John Jones, Timothy F. Racoosin, Judy Paulozzi, Leonard Chang, Art TI Thrombotic Thrombocytopenic Purpura (TTP)-Like Illness Associated with Intravenous Opana ER Abuse - Tennessee, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ADAMTS13 C1 [Chang, Art] CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM david.kirschke@tn.gov NR 9 TC 262 Z9 263 U1 0 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 11 PY 2013 VL 62 IS 1 BP 1 EP 4 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188CP UT WOS:000322169800001 ER PT J AU Briggs, M Arguin, PM AF Briggs, Melissa Arguin, Paul M. TI Published Reports of Delayed Hemolytic Anemia After Treatment with Artesunate for Severe Malaria - Worldwide, 2010-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID FALCIPARUM-MALARIA; INTRAVENOUS ARTESUNATE C1 [Briggs, Melissa; Arguin, Paul M.] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Briggs, M (reprint author), CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. EM vka5@cdc.gov NR 10 TC 24 Z9 24 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 11 PY 2013 VL 62 IS 1 BP 5 EP 8 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188CP UT WOS:000322169800002 ER PT J AU Kanny, D Liu, Y Brewer, RD Eke, PI Cox, SN Cheal, NE Green, Y AF Kanny, Dafna Liu, Yong Brewer, Robert D. Eke, Paul I. Cox, Shanna N. Cheal, Nancy E. Green, Yvonne TI Vital Signs: Binge Drinking Among Women and High School Girls - United States, 2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ALCOHOL-CONSUMPTION; PREVALENCE; ADULTS; RISK; FREQUENCY; STUDENTS; EXPOSURE; IMPACT; YOUTH AB Background: Excessive alcohol use accounted for an estimated average of 23,000 deaths and 633,000 years of potential life lost (YPLL) among women and girls in the United States each year during 2001-2005. Binge drinking accounted for more than half of those deaths and YPLL. Binge drinking also is a risk factor for many health and social problems among women and girls, including unintended and alcohol-exposed pregnancy, sexually transmitted diseases, and breast cancer. Methods: To describe the prevalence, frequency, and intensity of binge drinking (four or more drinks on an occasion in the last 30 days) among U. S. women aged >= 18 years, CDC analyzed data from the 2011 Behavioral Risk Factor Surveillance System. Data were also analyzed from the 2011 national Youth Risk Behavior Survey on the prevalence of current alcohol use (one or more drinks during the past 30 days) and binge drinking (five or more drinks in a row during the past 30 days) among U. S. high school girls in grades 9-12. Results: Among adult women, the prevalence of binge drinking was 12.5%, and among those who binge drank, the frequency of binge drinking was 3.2 episodes per month and the intensity was 5.7 drinks on occasion. Binge drinking was most prevalent among women aged 18-24 years (24.2%) and 25-34 years (19.9%), and among those from households with annual incomes of >=$75,000 (16.0%). Among those who binge drank, women aged 18-24 years had the highest frequency (3.6 episodes) and intensity (6.4 drinks) of binge drinking. Among high school girls, the prevalence of current alcohol use was 37.9%, the prevalence of binge drinking was 19.8%, and the prevalence of binge drinking among girls who reported current alcohol use was 54.6%. Conclusions: Binge drinking is reported by one in eight U. S. adult women and one in five high school girls. Women who binge drink tend to do so frequently and with high intensity. Most high school girls who reported current alcohol use also reported binge drinking. Implications for Public Health Practice: More widespread implementation of evidence-based interventions, such as those recommended by the Guide to Community Preventive Services and the U. S. Preventive Services Task Force, would be expected to reduce the frequency and intensity, and ultimately the prevalence of binge drinking among women and girls, and the harms related to it. C1 [Green, Yvonne] CDC, Off Womens Hlth, Atlanta, GA 30333 USA. EM dkanny@cdc.gov NR 21 TC 23 Z9 23 U1 2 U2 10 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 11 PY 2013 VL 62 IS 1 BP 9 EP 13 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188CP UT WOS:000322169800003 ER PT J AU Iriemenam, NC Pandey, JP Williamson, J Blackstock, AJ Yesupriya, A Namboodiri, AM Rocca, KM van Eijk, AM Ayisi, J Oteino, J Lal, RB ter Kuile, FO Steketee, R Nahlen, B Slutsker, L Shi, YP AF Iriemenam, Nnaemeka C. Pandey, Janardan P. Williamson, John Blackstock, Anna J. Yesupriya, Ajay Namboodiri, Aryan M. Rocca, Keith M. van Eijk, Anna Maria Ayisi, John Oteino, Juliana Lal, Renu B. ter Kuile, Feiko O. Steketee, Richard Nahlen, Bernard Slutsker, Laurence Shi, Ya Ping TI Association between Immunoglobulin GM and KM Genotypes and Placental Malaria in HIV-1 Negative and Positive Women in Western Kenya SO PLOS ONE LA English DT Article ID PLASMODIUM-FALCIPARUM MALARIA; HARDY-WEINBERG PROPORTIONS; CHONDROITIN SULFATE-A; INFECTED ERYTHROCYTES; ANTIBODY-RESPONSES; PREGNANT-WOMEN; KM ALLOTYPES; HEAVY-CHAIN; ANTIGEN; FC AB Immunoglobulin (Ig) GM and KM allotypes, genetic markers of gamma and kappa chains, are associated with humoral immune responsiveness. Previous studies have shown the relationships between GM6-carrying haplotypes and susceptibility to malaria infection in children and adults; however, the role of the genetic markers in placental malaria (PM) infection and PM with HIV co-infection during pregnancy has not been investigated. We examined the relationship between the gene polymorphisms of Ig GM6 and KM allotypes and the risk of PM infection in pregnant women with known HIV status. DNA samples from 728 pregnant women were genotyped for GM6 and KM alleles using polymerase chain reaction-restriction fragment length polymorphism method. Individual GM6 and KM genotypes and the combined GM6 and KM genotypes were assessed in relation to PM in HIV-1 negative and positive women, respectively. There was no significant effect of individual GM6 and KM genotypes on the risk of PM infection in HIV-1 negative and positive women. However, the combination of homozygosity for GM6(+) and KM3 was associated with decreased risk of PM (adjusted OR, 0.25; 95% CI, 0.08-0.8; P = 0.019) in HIV-1 negative women while in HIV-1 positive women the combination of GM6(+/-) with either KM1-3 or KM1 was associated with increased risk of PM infection (adjusted OR, 2.10; 95% CI, 1.18-3.73; P = 0.011). Hardy-Weinberg Equilibrium (HWE) tests further showed an overall significant positive F(is) (indication of deficit in heterozygotes) for GM6 while there was no deviation for KM genotype frequency from HWE in the same population. These findings suggest that the combination of homozygous GM6(+) and KM3 may protect against PM in HIV-1 negative women while the HIV-1 positive women with heterozygous GM6(+/-) combined with KM1-3 or KM1 may be more susceptible to PM infection. The deficit in heterozygotes for GM6 further suggests that GM6 could be under selection likely by malaria infection. C1 [Iriemenam, Nnaemeka C.; Williamson, John; Blackstock, Anna J.; Steketee, Richard; Nahlen, Bernard; Slutsker, Laurence; Shi, Ya Ping] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Pandey, Janardan P.; Namboodiri, Aryan M.; Rocca, Keith M.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Blackstock, Anna J.] Vet Affairs Med Ctr, Atlanta Res & Educ Fdn, Decatur, GA 30033 USA. [Yesupriya, Ajay] Ctr Dis Control & Prevent, Natl Off Publ Hlth Genom, Coordinating Ctr Hlth Promot, Atlanta, GA USA. [van Eijk, Anna Maria; Ayisi, John] Kenya Govt Med Res Ctr, Ctr Vector Biol & Control Res, Kisumu, Kenya. [Oteino, Juliana] Minist Hlth, New Nyanza Prov Gen Hosp, Kisumu, Kenya. [Lal, Renu B.] Ctr Dis Control & Prevent, Div AIDS STD TB Lab Res, Natl Ctr HIV STD TB Prevent, Atlanta, GA USA. [ter Kuile, Feiko O.] Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England. RP Pandey, JP (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. EM pandeyj@musc.edu; yps0@cdc.gov OI ter Kuile, Feiko/0000-0003-3663-5617 FU National Office of Public Health Genomics, Centers for Disease Control and Prevention [92129RQ]; American Society for Microbiology (ASM); Centers for Disease Control and Prevention (CDC) (ASM/CDC) FX This study was supported by intramural funding from The National Office of Public Health Genomics, Centers for Disease Control and Prevention (Project ID# 92129RQ). NCI was supported by the American Society for Microbiology (ASM) and Centers for Disease Control and Prevention (CDC) Postdoctoral Fellowship (ASM/CDC Research Fellowship Program). The funders had no role in study design, data collection, and decision to publish, or preparation of the manuscript except for AY, a statistician, from the National Office of Public Health Genomics, CDC assisting in data analysis. NR 47 TC 1 Z9 1 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 11 PY 2013 VL 8 IS 1 AR e53948 DI 10.1371/journal.pone.0053948 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 086RY UT WOS:000314705800092 PM 23326546 ER PT J AU Beck, E Fan, J Hendrickson, K Kumar, S Shively, R Kramp, W Villanueva, J Jernigan, D Klimov, A Chen, LM Donis, R Williams, T Pirkle, J Barr, J AF Beck, Eric Fan, Jiang Hendrickson, Kelly Kumar, Swati Shively, Roxanne Kramp, William Villanueva, Julie Jernigan, Daniel Klimov, Alexander Chen, Li-Mei Donis, Ruben Williams, Tracie Pirkle, James Barr, John TI Evaluation of 11 Commercially Available Rapid Influenza Diagnostic Tests-United States, 2011-2012 (Reprinted from MMWR, vol 43, pg 873-876, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID A VIRUS; INFECTION C1 [Beck, Eric; Fan, Jiang; Hendrickson, Kelly; Kumar, Swati] Med Coll Wisconsin, Dept Pediat, Midwest Resp Virus Program, Milwaukee, WI 53226 USA. [Shively, Roxanne; Kramp, William] CDC, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM roxanne.shively@hhs.gov NR 10 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 9 PY 2013 VL 309 IS 2 BP 127 EP 129 DI 10.1001/jama.2012.91538 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 070NW UT WOS:000313517000007 ER PT J AU Ruiz-Tiben, E Eberhard, ML Roy, SL AF Ruiz-Tiben, Ernesto Eberhard, Mark L. Roy, Sharon L. TI Progress Toward Global Eradication of Dracunculiasis-January 2011-June 2012 (Reprinted from MMWR, vol 42, pg 854-857, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Ruiz-Tiben, Ernesto] Emory Univ, Carter Ctr, Atlanta, GA 30322 USA. [Eberhard, Mark L.] CDC, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Roy, Sharon L.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Roy, Sharon L.] CDC, World Hlth Org Collaborating Ctr Res Training & E, Atlanta, GA 30333 USA. RP Roy, SL (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM slroy@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 9 PY 2013 VL 309 IS 2 BP 129 EP 132 DI 10.1001/jama.2012.64610 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 070NW UT WOS:000313517000008 ER PT J AU Kirkcaldy, RD Bolan, GA Wasserheit, JN AF Kirkcaldy, Robert D. Bolan, Gail A. Wasserheit, Judith N. TI Cephalosporin-Resistant Gonorrhea in North America SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID SEXUALLY-TRANSMITTED-DISEASES; GONOCOCCAL INFECTIONS; TREATMENT-GUIDELINES; NO LONGER; UPDATE; MANAGEMENT; ADULTS C1 [Kirkcaldy, Robert D.; Bolan, Gail A.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Wasserheit, Judith N.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Wasserheit, Judith N.] Univ Washington, Dept Med, Seattle, WA USA. [Wasserheit, Judith N.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Kirkcaldy, RD (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS E-02, Atlanta, GA 30333 USA. EM rkirkcaldy@cdc.gov NR 16 TC 13 Z9 14 U1 0 U2 12 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 9 PY 2013 VL 309 IS 2 BP 185 EP 187 DI 10.1001/jama.2012.205107 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 070NW UT WOS:000313517000029 PM 23299612 ER PT J AU Wheaton, AG Chapman, DP Presley-Cantrell, LR Croft, JB Roehler, DR AF Wheaton, Anne G. Chapman, Daniel P. Presley-Cantrell, Letitia R. Croft, Janet B. Roehler, Douglas R. TI Drowsy Driving-19 States and the District of Columbia, 2009-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CRASHES; DRIVER C1 [Wheaton, Anne G.; Chapman, Daniel P.; Presley-Cantrell, Letitia R.; Croft, Janet B.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA. [Roehler, Douglas R.] CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Wheaton, AG (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA. EM awheaton@cdc.gov NR 10 TC 20 Z9 20 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 4 PY 2013 VL 61 IS 51-52 BP 1033 EP 1037 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 068PW UT WOS:000313379700001 ER PT J AU Saraiya, M King, J Thompson, T Watson, M Ajani, U Li, J Houston, KA AF Saraiya, Mona King, Jessica Thompson, Trevor Watson, Meg Ajani, Umed Li, Jun Houston, Keisha A. TI Cervical Cancer Screening Among Women Aged 18-30 Years - United States, 2000-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HUMAN-PAPILLOMAVIRUS; PREVENTION C1 [Houston, Keisha A.] CDC, EIS, Atlanta, GA 30333 USA. [Saraiya, Mona; King, Jessica; Thompson, Trevor; Watson, Meg; Ajani, Umed; Li, Jun] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Houston, KA (reprint author), CDC, EIS, Atlanta, GA 30333 USA. EM kahouston@cdc.gov NR 10 TC 22 Z9 22 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 4 PY 2013 VL 61 IS 51-52 BP 1038 EP 1042 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 068PW UT WOS:000313379700002 ER PT J AU Watson, M King, J Ajani, U Houston, KA Saraiya, M AF Watson, Meg King, Jessica Ajani, Umed Houston, Keisha A. Saraiya, Mona TI Cervical Cancer Screening Among Women by Hysterectomy Status and Among Women Aged >= 65 Years - United States, 2000-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Watson, Meg; King, Jessica; Ajani, Umed; Houston, Keisha A.; Saraiya, Mona] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Watson, M (reprint author), CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM eze5@cdc.gov NR 10 TC 10 Z9 10 U1 1 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 4 PY 2013 VL 61 IS 51-52 BP 1043 EP 1047 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 068PW UT WOS:000313379700003 ER PT J AU Weiss, D Antwi, M Del Rosso, P Dorsinville, M Lee, L Lin, Y Kornblum, J Varma, JK Ridpath, A AF Weiss, Don Antwi, Mike Del Rosso, Paula Dorsinville, Marie Lee, Lillian Lin, Ying Kornblum, John Varma, Jay K. Ridpath, Alison TI Serogroup C Invasive Meningococcal Disease Among Men Who Have Sex With Men - New York City, 2010-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Ridpath, Alison] CDC, EIS, Atlanta, GA 30333 USA. [Weiss, Don; Antwi, Mike; Del Rosso, Paula; Dorsinville, Marie; Lee, Lillian; Lin, Ying; Kornblum, John; Varma, Jay K.] New York City Dept Hlth & Mental Hyg, New York, NY 11101 USA. RP Ridpath, A (reprint author), CDC, EIS, Atlanta, GA 30333 USA. EM aridpath@cdc.gov NR 4 TC 11 Z9 11 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JAN 4 PY 2013 VL 61 IS 51-52 BP 1048 EP 1048 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 068PW UT WOS:000313379700004 ER PT J AU Chapman, DP Liu, Y Presley-Cantrell, LR Edwards, VJ Wheaton, AG Perry, GS Croft, JB AF Chapman, Daniel P. Liu, Yong Presley-Cantrell, Letitia R. Edwards, Valerie J. Wheaton, Anne G. Perry, Geraldine S. Croft, Janet B. TI Adverse childhood experiences and frequent insufficient sleep in 5 U.S. States, 2009: a retrospective cohort study SO BMC PUBLIC HEALTH LA English DT Article DE Insufficient sleep; Childhood abuse; Childhood neglect ID BODY-MASS INDEX; SEXUAL-ABUSE; HOUSEHOLD DYSFUNCTION; HEALTH-SURVEY; ADULTS; RISK; DISTURBANCE; DEPRESSION; PARALYSIS; SYMPTOMS AB Background: Although adverse childhood experiences (ACEs) have previously been demonstrated to be adversely associated with a variety of health outcomes in adulthood, their specific association with sleep among adults has not been examined. To better address this issue, this study examines the relationship between eight self-reported ACEs and frequent insufficient sleep among community-dwelling adults residing in 5 U.S. states in 2009. Methods: To assess whether ACEs were associated with frequent insufficient sleep (respondent did not get sufficient rest or sleep >= 14 days in past 30 days) in adulthood, we analyzed ACE data collected in the 2009 Behavioral Risk Factor Surveillance System, a random-digit-dialed telephone survey in Arkansas, Louisiana, New Mexico, Tennessee, and Washington. ACEs included physical abuse, sexual abuse, verbal abuse, household mental illness, incarcerated household members, household substance abuse, parental separation/divorce, and witnessing domestic violence before age 18. Smoking status and frequent mental distress (FMD) (>= 14 days in past 30 days when self-perceived mental health was not good) were assessed as potential mediators in multivariate logistic regression analyses of frequent insufficient sleep by ACEs adjusted for race/ethnicity, gender, education, and body mass index. Results: Overall, 28.8% of 25,810 respondents reported frequent insufficient sleep, 18.8% were current smokers, 10.8% reported frequent mental distress, 59.5% percent reported >= 1 ACE, and 8.7% reported >= 5 ACEs. Each ACE was associated with frequent insufficient sleep in multivariate analyses. Odds of frequent insufficient sleep were 2.5 (95% CI, 2.1-3.1) times higher in persons with >= 5 ACEs compared to those with no ACEs. Most relationships were modestly attenuated by smoking and FMD, but remained significant. Conclusions: Childhood exposures to eight indicators of child maltreatment and household dysfunction were significantly associated with frequent insufficient sleep during adulthood in this population. ACEs could be potential indicators promoting further investigation of sleep insufficiency, along with consideration of FMD and smoking. C1 [Chapman, Daniel P.; Liu, Yong; Presley-Cantrell, Letitia R.; Edwards, Valerie J.; Wheaton, Anne G.; Perry, Geraldine S.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30041 USA. RP Chapman, DP (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop K-67, Atlanta, GA 30041 USA. EM dpc2@cdc.gov FU Association for Prevention Teaching and Research [3U50CD300860]; Centers for Disease Control and Prevention [3U50CD300860, U58/CCU324336-05]; National Association of Chronic Disease Directors [U58/CCU324336-05] FX AGW received support from a fellowship through a cooperative agreement (award number 3U50CD300860) between the Association for Prevention Teaching and Research and the Centers for Disease Control and Prevention. This project was supported, in part, by cooperative agreement U58/CCU324336-05 between the National Association of Chronic Disease Directors and the Centers for Disease Control and Prevention. NR 37 TC 19 Z9 19 U1 5 U2 20 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD JAN 3 PY 2013 VL 13 AR 3 DI 10.1186/1471-2458-13-3 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 077PK UT WOS:000314039500001 PM 23286392 ER PT J AU van Beek, J Ambert-Balay, K Botteldoorn, N Eden, JS Fonager, J Hewitt, J Iritani, N Kroneman, A Vennema, H Vinje, J White, PA Koopmans, M AF van Beek, J. Ambert-Balay, K. Botteldoorn, N. Eden, J. S. Fonager, J. Hewitt, J. Iritani, N. Kroneman, A. Vennema, H. Vinje, J. White, P. A. Koopmans, M. CA NoroNet TI Indications for worldwide increased norovirus activity associated with emergence of a new variant of genotype II.4, late 2012 SO EUROSURVEILLANCE LA English DT Article ID OUTBREAKS AB Globally, surveillance systems showed an increase in norovirus activity in late 2012. Molecular data shared through the NoroNet network suggest that this increase is related to the emergence of a new norovirus genotype II.4 variant, termed Sydney 2012. Healthcare institutions are advised to be prepared for a severe norovirus season. C1 [van Beek, J.; Kroneman, A.; Vennema, H.; Koopmans, M.] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. [Ambert-Balay, K.] Natl Reference Ctr Enter Viruses, Dijon, France. [Botteldoorn, N.] Sci Inst Publ Hlth, Brussels, Belgium. [Eden, J. S.; White, P. A.] Univ New S Wales, Sydney, NSW, Australia. [Fonager, J.] Statens Serum Inst, DK-2300 Copenhagen, Denmark. [Hewitt, J.] Inst Environm Sci & Res, Porirua, New Zealand. [Iritani, N.] Osaka City Inst Publ Hlth & Environm Sci, Osaka 543, Japan. [Vinje, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP van Beek, J (reprint author), Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. EM janko.van.beek@rivm.nl RI White, Peter/C-6573-2012; OI White, Peter/0000-0002-6046-9631; Eden, John-Sebastian/0000-0003-1374-3551 NR 15 TC 96 Z9 98 U1 3 U2 22 PU EUR CENTRE DIS PREVENTION & CONTROL PI STOCKHOLM PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN SN 1560-7917 J9 EUROSURVEILLANCE JI Eurosurveillance PD JAN 3 PY 2013 VL 18 IS 1 BP 8 EP 9 AR 20345 PG 2 WC Infectious Diseases SC Infectious Diseases GA 071AU UT WOS:000313558400003 PM 23305715 ER PT J AU Thigpen, MC Rose, CE Paxton, LA AF Thigpen, Michael C. Rose, Charles E. Paxton, Lynn A. TI Antiretroviral Preexposure Prophylaxis for HIV Prevention REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Thigpen, Michael C.; Rose, Charles E.; Paxton, Lynn A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Thigpen, MC (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM mthigpen@cdc.gov NR 4 TC 9 Z9 9 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JAN 3 PY 2013 VL 368 IS 1 BP 82 EP 83 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 062PA UT WOS:000312930600022 PM 23281985 ER PT J AU DeBastiani, SD Strine, TW AF DeBastiani, Summer D. Strine, Tara W. TI Household Preparedness for Public Health Emergencies-14 States, 2006-2010 (Reprinted from MMWR, vol 36, pg 713-719, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [DeBastiani, Summer D.; Strine, Tara W.] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. RP DeBastiani, SD (reprint author), CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. EM sdebastiani@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 2 PY 2013 VL 309 IS 1 BP 21 EP 24 DI 10.1001/jama.2012.13026 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 146TB UT WOS:000319113000008 ER PT J AU Flegal, KM Kit, BK Orpana, H Graubard, BI AF Flegal, Katherine M. Kit, Brian K. Orpana, Heather Graubard, Barry I. TI Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories A Systematic Review and Meta-analysis SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID LONG-TERM MORTALITY; CARDIOVASCULAR-DISEASE MORTALITY; CORONARY-ARTERY-DISEASE; DWELLING OLDER-ADULTS; SELF-REPORTED WEIGHT; MIDDLE-AGED MEN; FOLLOW-UP; RISK-FACTORS; LIFE-STYLE; PROSPECTIVE COHORT AB Importance Estimates of the relative mortality risks associated with normal weight, overweight, and obesity may help to inform decision making in the clinical setting. Objective To perform a systematic review of reported hazard ratios (HRs) of all-cause mortality for overweight and obesity relative to normal weight in the general population. Data Sources PubMed and EMBASE electronic databases were searched through September 30, 2012, without language restrictions. Study Selection Articles that reported HRs for all-cause mortality using standard body mass index (BMI) categories from prospective studies of general populations of adults were selected by consensus among multiple reviewers. Studies were excluded that used nonstandard categories or that were limited to adolescents or to those with specific medical conditions or to those undergoing specific procedures. PubMed searches yielded 7034 articles, of which 141 (2.0%) were eligible. An EMBASE search yielded 2 additional articles. After eliminating overlap, 97 studies were retained for analysis, providing a combined sample size of more than 2.88 million individuals and more than 270 000 deaths. Data Extraction Data were extracted by 1 reviewer and then reviewed by 3 independent reviewers. We selected the most complex model available for the full sample and used a variety of sensitivity analyses to address issues of possible overadjustment (adjusted for factors in causal pathway) or underadjustment (not adjusted for at least age, sex, and smoking). Results Random-effects summary all-cause mortality HRs for overweight (BMI of 25-<30), obesity (BMI of >= 30), grade 1 obesity (BMI of 30-<35), and grades 2 and 3 obesity (BMI of >= 35) were calculated relative to normal weight (BMI of 18.5-<25). The summary HRs were 0.94 (95% CI, 0.91-0.96) for overweight, 1.18 (95% CI, 1.12-1.25) for obesity (all grades combined), 0.95 (95% CI, 0.88-1.01) for grade 1 obesity, and 1.29 (95% CI, 1.18-1.41) for grades 2 and 3 obesity. These findings persisted when limited to studies with measured weight and height that were considered to be adequately adjusted. The HRs tended to be higher when weight and height were self-reported rather than measured. Conclusions and Relevance Relative to normal weight, both obesity (all grades) and grades 2 and 3 obesity were associated with significantly higher all-cause mortality. Grade 1 obesity overall was not associated with higher mortality, and overweight was associated with significantly lower all-cause mortality. The use of predefined standard BMI groupings can facilitate between-study comparisons. C1 [Flegal, Katherine M.; Kit, Brian K.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Orpana, Heather] Univ Ottawa, Sch Psychol, Ottawa, ON K1N 6N5, Canada. [Graubard, Barry I.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. RP Flegal, KM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4336, Hyattsville, MD 20782 USA. EM kmf2@cdc.gov OI Orpana, Heather/0000-0001-9982-981X; Flegal, Katherine/0000-0002-0838-469X FU Intramural CDC HHS [CC999999] NR 138 TC 897 Z9 926 U1 20 U2 230 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 2 PY 2013 VL 309 IS 1 BP 71 EP 82 DI 10.1001/jama.2012.113905 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 146TB UT WOS:000319113000029 PM 23280227 ER PT J AU Hounton, S De Bernis, L Hussein, J Graham, WJ Danel, I Byass, P Mason, EM AF Hounton, Sennen De Bernis, Luc Hussein, Julia Graham, Wendy J. Danel, Isabella Byass, Peter Mason, Elizabeth M. TI Towards elimination of maternal deaths: maternal deaths surveillance and response SO REPRODUCTIVE HEALTH LA English DT Review ID BURKINA-FASO; SEASONAL-VARIATION; MORTALITY; LESSONS; MALARIA; GAMBIA AB Current methods for estimating maternal mortality lack precision, and are not suitable for monitoring progress in the short run. In addition, national maternal mortality ratios (MMRs) alone do not provide useful information on where the greatest burden of mortality is located, who is concerned, what are the causes, and more importantly what sub-national variations occur. This paper discusses a maternal death surveillance and response (MDSR) system. MDSR systems are not yet established in most countries and have potential added value for policy making and accountability and can build on existing efforts to conduct maternal death reviews, verbal autopsies and confidential enquiries. Accountability at national and sub-national levels cannot rely on global, regional and national retrospective estimates periodically generated from academia or United Nations organizations but on routine counting, investigation, sub national data analysis, long term investments in vital registration and national health information systems. Establishing effective maternal death surveillance and response will help achieve MDG 5, improve quality of maternity care and eliminate maternal mortality (MMR <= 30 per 100,000 by 2030). C1 [Hounton, Sennen; De Bernis, Luc] UNFPA Tech Div, New York, NY USA. [Hussein, Julia; Graham, Wendy J.] Univ Aberdeen, Aberdeen, Scotland. [Danel, Isabella] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Byass, Peter] Umea Univ, Umea, Sweden. [Mason, Elizabeth M.] WHO, CH-1211 Geneva, Switzerland. RP Hounton, S (reprint author), UNFPA Tech Div, New York, NY USA. EM hounton@unfpa.org OI Byass, Peter/0000-0001-5474-4361 NR 28 TC 13 Z9 13 U1 1 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4755 J9 REPROD HEALTH JI Reprod. Health PD JAN 2 PY 2013 VL 10 AR 1 DI 10.1186/1742-4755-10-1 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 118ZG UT WOS:000317065500001 PM 23279882 ER PT J AU Shen, AK Bridges, CB Tan, LJ AF Shen, Angela K. Bridges, Carolyn B. Tan, Litjen TI The first national adult immunization summit 2012: Implementing change through action SO VACCINE LA English DT Article DE Adult immunization; Immunization policy; Barriers to Immunization; Policy development; Conference summary; Vaccination policy; Adult vaccination ID UNITED-STATES; COVERAGE AB To address lagging vaccine coverage among adults in the United States, over 150 organizations representing a wide range of immunization partners convened in Atlanta, GA from May 15-16, 2012 for the inaugural National Adult Immunization Summit. The meeting called for solution-oriented discussion toward improving current immunization levels, implementing the 2011 National Vaccine Advisory Committee adult immunization recommendations, and capitalizing on new opportunities to improve coverage. Provisions in the federal health reform law that increase access to preventive services, including immunizations, and the increasing numbers of complementary vaccine providers such as pharmacists, create new opportunities to increase access for immunization services and improve coverage for adults. The Summit organized around five focal areas: empowering providers, quality and performance measures, increasing access and collaboration, educating patients, and informing decision-makers. These focal areas formed the basis of working groups, charged to coordinate efforts by the participating organizations to address gaps in the current immunization system. Summit participants identified priority themes to address as tasks during the coming year, including better communicating the value of immunizations to increase demand for immunizations, creating a central repository of resources for providers, patients, and others interested in improving adult immunization levels, examining performance and quality measures and evaluating means to use such measures to motivate vaccine providers, increasing engagement with employer and employee groups to increase awareness and demand for vaccinations, improving the use of immunization information systems and electronic health reports, decreasing barriers to all vaccine providers including pharmacists and community vaccinators, decreasing the complexity of the adult vaccine schedule where possible, engaging adult immunization champions and leaders in key sectors, including adult healthcare provider groups, and encouraging more integration of immunization services with other preventive services. C1 [Shen, Angela K.] US Dept HHS, Natl Vaccine Program Off, Washington, DC 20201 USA. [Bridges, Carolyn B.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Tan, Litjen] Amer Med Assoc, Chicago, IL 60610 USA. RP Tan, LJ (reprint author), Immunizat Act Coalit, 1573 Selby Ave,Suite 234, St Paul, MN 55104 USA. EM angela.shen@hhs.gov; ctb1@cdc.gov; ljtan63@gmail.com OI Tan, Litjen/0000-0001-9054-6696 NR 17 TC 5 Z9 5 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JAN 2 PY 2013 VL 31 IS 2 BP 279 EP 284 DI 10.1016/j.vaccine.2012.11.033 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 077FE UT WOS:000314012500001 PM 23174197 ER PT J AU Owusu-Edusei, K Roby, T Wright, SS Chesson, HW AF Owusu-Edusei, Kwame, Jr. Roby, TaNisha Wright, Shaunta S. Chesson, Harrell W. TI The consistency of relative incidence rates of nonviral sexually transmissible infections from health insurance claims and surveillance data, 2005-10 SO SEXUAL HEALTH LA English DT Article DE chlamydia; claims data; gonorrhoea; syphilis ID ADMINISTRATIVE DATABASES GARBAGE; PELVIC-INFLAMMATORY-DISEASE; DIRECT MEDICAL COST; UNITED-STATES; TRANSMITTED INFECTIONS; INSURED POPULATION; YOUNG-WOMEN; US WOMEN; DIAGNOSIS; SYPHILIS AB Background: Given the growing popularity of administrative data for health research, information on the differences and similarities between administrative data and customary data sources (e.g. surveillance) will help to inform the use of administrative data in the field of sexually transmissible infections (STIs). The objective of this study was to compare the incidence rates of three nonviral STIs from a large health insurance administrative database (MarketScan) with surveillance data. Methods: We computed and compared STI rates for 2005-10 from MarketScan and national surveillance data for three major nonviral STIs (i.e. chlamydia (Chlamydia trachomatis), gonorrhoea (Neisseria gonorrhoeae) and syphilis (Treponema pallidum)). For administrative data, we assessed the sensitivity of the rates to enrolee inclusion criteria: continuous (>= 320 member-days) versus all enrolees. Relative rates were computed for 5-year age groups and by gender. Results: The administrative database rates were significantly lower (P < 0.01) than those in the national surveillance data, except for syphilis in females. Gonorrhoea and syphilis rates based on administrative data were significantly lower (P < 0.01) for all enrolees versus continuous enrolees only. The relative STI rates by age group from the administrative data were similar to those in the surveillance data. Conclusions: Although absolute STI rates in administrative data were lower than in the surveillance data, relative STI rates from administrative data were consistent with national surveillance data. For gonorrhoea and syphilis, the estimated rates from administrative data were sensitive to the enrolee inclusion criteria. Future studies should examine the potential for administrative data to complement surveillance data. C1 [Owusu-Edusei, Kwame, Jr.; Roby, TaNisha; Wright, Shaunta S.; Chesson, Harrell W.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Owusu-Edusei, K (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd MS E-80, Atlanta, GA 30333 USA. EM Kowusuedusei@cdc.gov NR 34 TC 0 Z9 0 U1 0 U2 0 PU CSIRO PUBLISHING PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIA SN 1448-5028 EI 1449-8987 J9 SEX HEALTH JI Sex Health PY 2013 VL 10 IS 5 BP 400 EP 407 DI 10.1071/SH12191 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AU9GP UT WOS:000345900100002 PM 23849061 ER PT J AU Cecil, M Warner, L Siegler, AJ AF Cecil, Michael Warner, Lee Siegler, Aaron J. TI Online purchases of an expanded range of condom sizes in comparison to current dimensional requirements allowable by US national standards SO SEXUAL HEALTH LA English DT Article DE AIDS; American Society for Testing and Materials; condom fit; safer sex; sexually transmissible infections ID SEXUAL PLEASURE; PENILE LENGTH; ANAL INTERCOURSE; SAFER SEX; MEN; FIT; BREAKAGE; SLIPPAGE; ACCEPTABILITY; RISK AB Background: Across studies, 35-50% of men describe condoms as fitting poorly. Rates of condom use may be inhibited in part due to the inaccessibility of appropriately sized condoms. As regulated medical devices, condom sizes conform to national standards such as those developed by the American Society for Testing and Materials (ASTM) or international standards such as those developed by the International Organisation for Standardisation (ISO). We describe the initial online sales experience of an expanded range of condom sizes and assess uptake in relation to the current required standard dimensions of condoms. Methods: Data regarding the initial 1000 sales of an expanded range of condom sizes in the United Kingdom were collected from late 2011 through to early 2012. Ninety-five condom sizes, comprising 14 lengths (83-238 mm) and 12 widths (41-69 mm), were available. Results: For the first 1000 condom six-pack units that were sold, a total of 83 of the 95 unique sizes were purchased, including all 14 lengths and 12 widths, and both the smallest and largest condoms. Initial condom purchases were made by 572 individuals from 26 countries. Only 13.4% of consumer sales were in the ASTM's allowable range of sizes. Conclusions: These initial sales data suggest consumer interest in an expanded choice of condom sizes that fall outside the range currently allowable by national and international standards organisations. C1 [Cecil, Michael] TheyFit, Covington, GA 30014 USA. [Warner, Lee] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Siegler, Aaron J.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30031 USA. RP Cecil, M (reprint author), TheyFit, Covington, GA 30014 USA. EM drmichael@drmichael.com NR 41 TC 0 Z9 0 U1 0 U2 1 PU CSIRO PUBLISHING PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIA SN 1448-5028 EI 1449-8987 J9 SEX HEALTH JI Sex Health PY 2013 VL 10 IS 5 BP 408 EP 413 DI 10.1071/SH13049 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AU9GP UT WOS:000345900100003 PM 23849142 ER PT J AU Chesson, HW Owusu-Edusei, K Leichliter, JS Aral, SO AF Chesson, Harrell W. Owusu-Edusei, Kwame, Jr. Leichliter, Jami S. Aral, Sevgi O. TI Violent crime rates as a proxy for the social determinants of sexually transmissible infection rates: the consistent state-level correlation between violent crime and reported sexually transmissible infections in the United States, 1981-2010 SO SEXUAL HEALTH LA English DT Article DE epidemiology; gonorrhoea; poverty; syphilis ID TRANSMITTED INFECTIONS; BROKEN WINDOWS; SYPHILIS; GONORRHEA; INCARCERATION; ASSOCIATION; DISPARITIES; PREVALENCE; HIV AB Background: Numerous social determinants of health are associated with violent crime rates and sexually transmissible infection (STI) rates. This report aims to illustrate the potential usefulness of violent crime rates as a proxy for the social determinants of STI rates. Methods: For each year from 1981 to 2010, we assessed the strength of the association between the violent crime rate and the gonorrhoea (Neisseria gonorrhoeae) rate (number of total reported cases per 100 000) at the state level. Specifically, for each year, we calculated Pearson correlation coefficients (and P-values) between two variables (the violent crime rate and the natural log of the gonorrhoea rate) for all 50 states and Washington, DC. For comparison, we also examined the correlation between gonorrhoea rates, and rates of poverty and unemployment. We repeated the analysis using overall syphilis rates instead of overall gonorrhoea rates. Results: The correlation between gonorrhoea and violent crime was significant at the P < 0.001 level for every year from 1981 to 2010. Syphilis rates were also consistently correlated with violent crime rates. In contrast, the P-value for the correlation coefficient exceeded 0.05 in 9 of the 30 years for the association between gonorrhoea and poverty, and in 17 of the 30 years for that between gonorrhoea and unemployment. Conclusions: Because violent crime is associated with many social determinants of STIs and because it is consistently associated with STI rates, violent crime rates can be a useful proxy for the social determinants of health in statistical analyses of STI rates. C1 [Chesson, Harrell W.; Owusu-Edusei, Kwame, Jr.; Leichliter, Jami S.; Aral, Sevgi O.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Atlanta, GA 30333 USA. RP Chesson, HW (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Atlanta, GA 30333 USA. EM hbc7@cdc.gov NR 26 TC 2 Z9 2 U1 1 U2 5 PU CSIRO PUBLISHING PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIA SN 1448-5028 EI 1449-8987 J9 SEX HEALTH JI Sex Health PY 2013 VL 10 IS 5 BP 419 EP 423 DI 10.1071/SH13006 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AU9GP UT WOS:000345900100005 PM 23987728 ER PT J AU Owusu-Edusei, K Roby, TM Chesson, HW Gift, TL AF Owusu-Edusei, Kwame, Jr. Roby, TaNisha M. Chesson, Harrell W. Gift, Thomas L. TI Productivity costs of nonviral sexually transmissible infections among patients who miss work to seek medical care: evidence from claims data SO SEXUAL HEALTH LA English DT Article DE absence from work; chlamydia; gonorrhoea; syphilis; trichomoniasis ID UNITED-STATES; TRANSMITTED INFECTIONS; INSURED POPULATION; STIGMA; INSURANCE; WOMEN; SHAME; PRESENTEEISM; ABSENTEEISM; DISEASES AB Background: Productivity losses can arise when employees miss work to seek care for sexually transmissible infections (STIs). We estimated the average productivity loss per acute case of four nonviral STIs: chlamydia, gonorrhoea, syphilis and trichomoniasis. Methods: We extracted outpatient claims from 2001-2005 MarketScan databases using International Classification Disease ver. 9 (ICD-9) codes. We linked claims with their absence records in the Health and Productivity Management database by matching enrolee identifiers and the service dates from the claims such that our final data included only those who were absent because they were sick and were diagnosed with an STI on the day of their visit. To ensure that the visit was for the STIs being examined, we restricted the criteria to records with the specified ICD-9 codes only, excluding claims with other codes. We estimated the average number of hours absent and multiplied it by the mean hourly wage rate including benefits ($29.72 in 2011 United States dollars) to estimate the average productivity loss per case. Results: The average productivity losses per case were: $262 for chlamydia, $197 for gonorrhoea, $419 for syphilis and $289 for trichomoniasis. There were no significant differences between males and females. Conclusions: Among those who take sick leave to seek care, productivity losses associated with treating nonviral STIs may be higher than their estimated direct medical costs. These productivity cost estimates can help to quantify the overall STI burden, and inform cost-effectiveness analyses of prevention and control efforts. C1 [Owusu-Edusei, Kwame, Jr.; Roby, TaNisha M.; Chesson, Harrell W.; Gift, Thomas L.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Owusu-Edusei, K (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd M-S E-80, Atlanta, GA 30333 USA. EM kowusuedusei@cdc.gov NR 31 TC 2 Z9 2 U1 1 U2 4 PU CSIRO PUBLISHING PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIA SN 1448-5028 EI 1449-8987 J9 SEX HEALTH JI Sex Health PY 2013 VL 10 IS 5 BP 434 EP 437 DI 10.1071/SH13021 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AU9GP UT WOS:000345900100007 PM 23987746 ER PT J AU Raiford, JL Seth, P Braxton, ND DiClemente, RJ AF Raiford, Jerris L. Seth, Puja Braxton, Nikia D. DiClemente, Ralph J. TI Masculinity, condom use self-efficacy and abusive responses to condom negotiation: the case for HIV prevention for heterosexual African-American men SO SEXUAL HEALTH LA English DT Article DE HIV/AIDS; safer sex; partner violence ID SEXUALLY-TRANSMITTED-DISEASES; UNITED-STATES; GENDER; RISK AB Background: This study explored the role of masculinity and perceived condom use skills in African-American men's abusive response to female partners' condom requests. Methods: Eighty African-American men aged 18-29 years completed measures on sexual behaviour, responses to condom requests, condom use self-efficacy and other masculine constructs. Men also were tested for sexually transmissible infections. Results: Men's condom use self-efficacy explained 16.5% of the variance in abusive response to condom requests, beyond demographics and masculine constructs. The full model accounted for 63% of the variance. Conclusions: Many HIV interventions with women encourage condom negotiation. Findings highlight the need to address men's condom use skills and masculine norms. C1 [Raiford, Jerris L.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Seth, Puja; DiClemente, Ralph J.] Emory Univ, Dept Behav Sci & Hlth Educ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Seth, Puja; Braxton, Nikia D.; DiClemente, Ralph J.] Emory Ctr AIDS Res, Atlanta, GA 30322 USA. RP Raiford, JL (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jraiford@cdc.gov FU Emory Center for AIDS Research; Atlanta Clinical & Translational Sciences Institute; Center for Contextual Genetics Prevention FX This research was supported, in part, through the Emory Center for AIDS Research, the Atlanta Clinical & Translational Sciences Institute and the Center for Contextual Genetics & Prevention. The authors acknowledge the contribution of the other members of their research team who helped make this study possible: Phillip D. Williams,, Adannaa Oparanozie, Deja Er, Tamu M. Daniel, Anita C. Conner, Rachel Nash, Tiffany A. Pennick, Gina M. Wingood, Michelle Mott, Tiffaney Renfro, Mary Ukuku and Jamilia LaFleur. The authors also acknowledge Angela M. Caliendo, professor of pathology and laboratory medicine at Emory University, and her molecular diagnostics and microbiology laboratory staff for conducting biological assays of the three STIs collected in this study. A special thank you to Jeffrey Herbst and Ann O'Leary of the Centers for Disease Control and Prevention for providing insightful comments on earlier versions of this manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the USA Centers for Disease Control and Prevention. NR 13 TC 3 Z9 3 U1 0 U2 1 PU CSIRO PUBLISHING PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIA SN 1448-5028 EI 1449-8987 J9 SEX HEALTH JI Sex Health PY 2013 VL 10 IS 5 BP 467 EP 469 DI 10.1071/SH13011 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AU9GP UT WOS:000345900100016 PM 23838050 ER PT J AU Verbeek, J Morata, T Ruotsalainen, J Vainio, H AF Verbeek, Jos Morata, Thais Ruotsalainen, Jani Vainio, Harri TI PREVENTION OF OCCUPATIONAL DISEASES: IMPLEMENTING THE EVIDENCE SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Editorial Material DE Occupational safety & health C1 [Verbeek, Jos; Ruotsalainen, Jani] Finnish Inst Occupat Hlth, Cochrane Occupat Safety & Hlth Review Grp, Kuopio, Finland. [Morata, Thais] NIOSH, Cincinnati, OH 45226 USA. [Vainio, Harri] Finnish Inst Occupat Hlth, Helsinki, Finland. RP Verbeek, J (reprint author), Finnish Inst Occupat Hlth, Cochrane Occupat Safety & Hlth Review Grp, Kuopio, Finland. EM jos.verbeek@ttl.fi; tmorata@cdc.gov; jani.ruotsalainen@ttl.fi; harri.vainio@ttl.fi NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2013 IS 4 AR ED000056 DI 10.1002/14651858.ED000056 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AQ8AR UT WOS:000343043400001 ER PT J AU Decker, JA DeBord, DG Bernard, B Dotson, GS Halpin, J Hines, CJ Kiefer, M Myers, K Page, E Schulte, P Snawder, J AF Decker, John A. DeBord, D. Gayle Bernard, Bruce Dotson, G. Scott Halpin, John Hines, Cynthia J. Kiefer, Max Myers, Kyle Page, Elena Schulte, Paul Snawder, John TI Recommendations for Biomonitoring of Emergency Responders: Focus on Occupational Health Investigations and Occupational Health Research SO MILITARY MEDICINE LA English DT Article ID WORKERS; ISSUES AB The disaster environment frequently presents rapidly evolving and unpredictable hazardous exposures to emergency responders. Improved estimates of exposure and effect from biomonitoring can be used to assess exposure response relationships, potential health consequences, and effectiveness of control measures. Disaster settings, however, pose significant challenges for biomonitoring. A decision process for determining when to conduct biomonitoring during and following disasters was developed. Separate but overlapping decision processes were developed for biomonitoring performed as part of occupational health investigations that directly benefit emergency responders in the short term and for biomonitoring intended to support research studies. Two categories of factors critical to the decision process for biomonitoring were identified: Is biomonitoring appropriate for the intended purpose and is biomonitoring feasible under the circumstances of the emergency response? Factors within these categories include information needs, relevance, interpretability, ethics, methodology, and logistics. Biomonitoring of emergency responders can be a valuable tool for exposure and risk assessment. Information needs, relevance, and interpretability will largely determine if biomonitoring is appropriate; logistical factors will largely determine if biomonitoring is feasible. The decision process should be formalized and may benefit from advance planning. C1 [Decker, John A.; Halpin, John; Myers, Kyle] NIOSH, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [DeBord, D. Gayle; Bernard, Bruce; Dotson, G. Scott; Hines, Cynthia J.; Page, Elena; Schulte, Paul; Snawder, John] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Kiefer, Max] NIOSH, Ctr Dis Control & Prevent, Denver Fed Ctr, Denver, CO 80226 USA. RP Decker, JA (reprint author), NIOSH, Ctr Dis Control & Prevent, 1600 Clifton Rd,Mail Stop E-20, Atlanta, GA 30333 USA. FU Intramural CDC HHS [CC999999] NR 24 TC 2 Z9 2 U1 1 U2 2 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD JAN PY 2013 VL 178 IS 1 BP 68 EP 75 DI 10.7205/MILMED-D-12-00173 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA AN7TV UT WOS:000340804800017 PM 23356122 ER PT J AU Jernigan, DB Cox, NJ AF Jernigan, Daniel B. Cox, Nancy J. BE Webster, RG Monto, AS Braciale, TJ Lamb, RA TI Human influenza: One health, one world SO TEXTBOOK OF INFLUENZA, 2ND EDITION LA English DT Article; Book Chapter ID A H1N1 VIRUS; SEASONAL INFLUENZA; PANDEMIC H1N1; UNITED-STATES; 2009 HAJJ; SURVEILLANCE; SPREAD; CIRCULATION; QUARANTINE; BURDEN C1 [Jernigan, Daniel B.; Cox, Nancy J.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Jernigan, DB (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. NR 62 TC 5 Z9 5 U1 0 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, WEST SUSSEX, ENGLAND BN 978-1-118-63684-8 PY 2013 BP 3 EP 19 D2 10.1002/9781118636817 PG 17 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA BA5CQ UT WOS:000336536600003 ER PT J AU Chambers, TM Dubovi, EJ Donis, RO AF Chambers, Thomas M. Dubovi, Edward J. Donis, Ruben O. BE Webster, RG Monto, AS Braciale, TJ Lamb, RA TI Equine/Canine/Feline/Seal influenza SO TEXTBOOK OF INFLUENZA, 2ND EDITION LA English DT Article; Book Chapter ID EQUINE INFLUENZA; AVIAN INFLUENZA; A VIRUSES; EXPERIMENTAL-INFECTION; GENETIC EVOLUTION; H3N8 VIRUSES; DOGS; HEMAGGLUTININ; TRANSMISSION; RESPONSES C1 [Chambers, Thomas M.] Univ Kentucky, Maxwell H Gluck Equine Res Ctr, Dept Vet Sci, Lexington, KY 40506 USA. [Dubovi, Edward J.] Cornell Univ, Coll Vet Med, Anim Hlth Diagnost Ctr, Ithaca, NY 14853 USA. [Donis, Ruben O.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Chambers, TM (reprint author), Univ Kentucky, Maxwell H Gluck Equine Res Ctr, Dept Vet Sci, Lexington, KY 40506 USA. NR 51 TC 2 Z9 2 U1 2 U2 4 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, WEST SUSSEX, ENGLAND BN 978-1-118-63684-8 PY 2013 BP 203 EP 217 D2 10.1002/9781118636817 PG 15 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA BA5CQ UT WOS:000336536600015 ER PT J AU Widdowson, MA Monto, AS AF Widdowson, Marc-Alain Monto, Arnold S. BE Webster, RG Monto, AS Braciale, TJ Lamb, RA TI Epidemiology of influenza SO TEXTBOOK OF INFLUENZA, 2ND EDITION LA English DT Article; Book Chapter ID CLUSTER RANDOMIZED-TRIAL; UNITED-STATES; PANDEMIC INFLUENZA; HONG-KONG; SEASONAL INFLUENZA; YOUNG-CHILDREN; HAND HYGIENE; MORTALITY; DISEASE; HOSPITALIZATIONS C1 [Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Influenza Div, Epidemiol & Prevent Branch, Int Epidemiol & Res Team, Atlanta, GA 30333 USA. [Monto, Arnold S.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. RP Widdowson, MA (reprint author), Ctr Dis Control & Prevent, Influenza Div, Epidemiol & Prevent Branch, Int Epidemiol & Res Team, Atlanta, GA 30333 USA. NR 53 TC 1 Z9 1 U1 0 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, WEST SUSSEX, ENGLAND BN 978-1-118-63684-8 PY 2013 BP 250 EP 265 D2 10.1002/9781118636817 PG 16 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA BA5CQ UT WOS:000336536600018 ER PT J AU Bridges, CB Peasah, SK Meltzer, MI AF Bridges, Carolyn B. Peasah, Samuel K. Meltzer, Martin I. BE Webster, RG Monto, AS Braciale, TJ Lamb, RA TI The control of influenza and cost-effectiveness of interventions SO TEXTBOOK OF INFLUENZA, 2ND EDITION LA English DT Article; Book Chapter ID HEALTH-CARE WORKERS; RANDOMIZED CONTROLLED-TRIAL; A H3N2 EPIDEMIC; SEASONAL INFLUENZA; PANDEMIC INFLUENZA; PREGNANT-WOMEN; ECONOMIC EVALUATIONS; ABSOLUTE-HUMIDITY; VIRUS-INFECTION; NURSING-HOMES C1 [Bridges, Carolyn B.] Ctr Dis Control & Prevent CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Peasah, Samuel K.] Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, NCIRD, Atlanta, GA USA. [Meltzer, Martin I.] Ctr Dis Control & Prevent CDC, HEMU, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Bridges, CB (reprint author), Ctr Dis Control & Prevent CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. NR 67 TC 1 Z9 1 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, WEST SUSSEX, ENGLAND BN 978-1-118-63684-8 PY 2013 BP 419 EP 433 D2 10.1002/9781118636817 PG 15 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA BA5CQ UT WOS:000336536600028 ER PT J AU Nguyen-Van-Tam, JS Bresee, J AF Nguyen-Van-Tam, Jonathan S. Bresee, Joseph BE Webster, RG Monto, AS Braciale, TJ Lamb, RA TI Pandemic preparedness and response SO TEXTBOOK OF INFLUENZA, 2ND EDITION LA English DT Article; Book Chapter ID INFLUENZA-A; PUBLIC-HEALTH; NONPHARMACEUTICAL INTERVENTIONS; PREVENT TRANSMISSION; ANTIVIRAL DRUGS; HONG-KONG; H1N1 2009; VACCINES; H5N1; VACCINATION C1 [Nguyen-Van-Tam, Jonathan S.] Univ Nottingham, Sch Med, City Hosp, Hlth Protect & Influenza Res Grp, Nottingham, England. [Bresee, Joseph] Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, Atlanta, GA USA. RP Nguyen-Van-Tam, JS (reprint author), Univ Nottingham, Sch Med, City Hosp, Hlth Protect & Influenza Res Grp, Nottingham, England. NR 63 TC 0 Z9 1 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, WEST SUSSEX, ENGLAND BN 978-1-118-63684-8 PY 2013 BP 453 EP 469 D2 10.1002/9781118636817 PG 17 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA BA5CQ UT WOS:000336536600030 ER PT J AU Brodsky, JL Samuel, MC Mohle-Boetani, JC Ng, RC Miller, J Gorman, JM Espain, G Bolan, G AF Brodsky, Jennifer L. Samuel, Michael C. Mohle-Boetani, Janet C. Ng, Rilene Chew Miller, Jamie Gorman, Janelle M. Espain, Guadalupe Bolan, Gail TI Syphilis Outbreak at a California Men's Prison, 2007-2008: Propagation by Lapses in Clinical Management, Case Management, and Public Health Surveillance SO JOURNAL OF CORRECTIONAL HEALTH CARE LA English DT Editorial Material DE syphilis; outbreak; HIV; prison; disparities; correctional health care ID SEXUALLY-TRANSMITTED INFECTIONS; C VIRUS-INFECTION; HEPATITIS-C; CORRECTIONAL FACILITIES; PREVALENCE; HIV; SYSTEM; SEX; POLICY AB This field report describes an investigation to identify cases to control a syphilis outbreak in a prison and determine whether clinical, case management, and surveillance practices influenced the outbreak occurrence, detection, or management. Key performance measures were assessed to evaluate timeliness and quality of clinical and case management activities and surveillance practices. Thirty cases were found. Prior to the investigation, median times for clinical and reporting/surveillance measures were 15 days from primary and secondary (P&S) symptom onset to exam, 7 days from P&S exam to treatment, and 63 days from serologic test to the state's receipt of case. After the investigation, these measures improved to 8, 4.5, and 28 days, respectively. Lack of adherence to surveillance and clinical management protocols likely contributed to this outbreak, which was curtailed by aggressive control measures. C1 [Brodsky, Jennifer L.; Samuel, Michael C.; Ng, Rilene Chew; Miller, Jamie; Bolan, Gail] Calif Dept Publ Hlth, Sexually Transmitted Dis Control Branch, Richmond, CA 94804 USA. [Mohle-Boetani, Janet C.; Gorman, Janelle M.] Calif Prison Hlth Care Serv, Publ Hlth Unit, Sacramento, CA USA. [Miller, Jamie] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Espain, Guadalupe] Calif Dept Publ Hlth, Sexually Transmitted Dis Control Branch, Bakersfield, CA USA. RP Brodsky, JL (reprint author), Calif Dept Publ Hlth, Sexually Transmitted Dis Control Branch, 850 Marina Bay Pkwy,Bldg P,2nd Floor, Richmond, CA 94804 USA. EM Jennifer.Brodsky@gmail.com FU NCHHSTP CDC HHS [5H25/PS904362-17] NR 30 TC 3 Z9 3 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1078-3458 EI 1940-5200 J9 J CORRECT HEALTH CAR JI J. Correct. Health Care PD JAN PY 2013 VL 19 IS 1 BP 54 EP 64 DI 10.1177/1078345812458088 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AK3QO UT WOS:000338340000007 PM 22989493 ER PT S AU Kilinc, FS AF Kilinc, F. Selcen BE Kilinc, FS TI Handbook of fire resistant textiles Introduction SO HANDBOOK OF FIRE RESISTANT TEXTILES SE Woodhead Publishing Series in Textiles LA English DT Editorial Material; Book Chapter C1 NIOSH, NPPTL, Ctr Dis Control & Prevent CDC, Pittsburgh, PA 15236 USA. RP Kilinc, FS (reprint author), NIOSH, NPPTL, Ctr Dis Control & Prevent CDC, 626 Cochrans Mill Rd,Bldg 403,POB 18070, Pittsburgh, PA 15236 USA. EM fselcen@gmail.com NR 0 TC 3 Z9 3 U1 0 U2 0 PU WOODHEAD PUBL LTD PI CAMBRIDGE PA ABINGTON HALL ABINGTON, CAMBRIDGE CB1 6AH, CAMBS, ENGLAND SN 2042-0803 BN 978-0-85709-893-1; 978-0-85709-123-9 J9 WOODHEAD PUBL SER TE PY 2013 IS 140 BP XXVII EP XXX PG 4 WC Materials Science, Textiles SC Materials Science GA BA3TO UT WOS:000334793600001 ER PT S AU Williams, WJ AF Williams, W. J. BE Kilinc, FS TI Physiological impact of flame resistant clothing: managing heat stress SO HANDBOOK OF FIRE RESISTANT TEXTILES SE Woodhead Publishing Series in Textiles LA English DT Article; Book Chapter DE metabolic heat; environmental heat; physiological responses to heat; occupational heat stress; fire-retardant personal protective ensembles ID PROTOTYPE FIREFIGHTER ENSEMBLE; UNCOMPENSABLE HEAT; FLUID REPLACEMENT; STANDARD ENSEMBLE; FORESTRY WORKERS; FIRE FIGHTERS; EXERCISE; HYDRATION; STRAIN; PERFORMANCE AB First responders are required to wear protective ensembles constructed of flame-retardant materials. While these ensembles protect against external hazards, they also impose a physiological burden on the wearer primarily due to the nature of the materials (e. g., low vapor permeability, highly insulated) that create a hot and humid microenvironment inside the ensemble. The normal avenues of heat transfer from the body to the environment are blocked resulting in physiological heat strain. This chapter addresses the physiological responses to wearing flame-retardant materials and some potential solutions to mitigating the physiological strain imposed by the ensemble. C1 NIOSH, NPPTL, Ctr Dis Control & Prevent CDC, Pittsburgh, PA 15236 USA. RP Williams, WJ (reprint author), NIOSH, NPPTL, Ctr Dis Control & Prevent CDC, Pittsburgh, PA 15236 USA. EM WJWilliams@cdc.gov NR 82 TC 0 Z9 0 U1 0 U2 0 PU WOODHEAD PUBL LTD PI CAMBRIDGE PA ABINGTON HALL ABINGTON, CAMBRIDGE CB1 6AH, CAMBS, ENGLAND SN 2042-0803 BN 978-0-85709-893-1; 978-0-85709-123-9 J9 WOODHEAD PUBL SER TE PY 2013 IS 140 BP 434 EP 455 DI 10.1533/9780857098931.3.434 PG 22 WC Materials Science, Textiles SC Materials Science GA BA3TO UT WOS:000334793600017 ER PT J AU Ku, BK Deye, G Turkevich, LA AF Ku, Bon Ki Deye, Gregory Turkevich, Leonid A. TI Characterization of a Vortex Shaking Method for Aerosolizing Fibers SO AEROSOL SCIENCE AND TECHNOLOGY LA English DT Article ID CARBON NANOTUBES; INHALATION; CONVECTION; EXPOSURE C1 [Ku, Bon Ki; Deye, Gregory; Turkevich, Leonid A.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Ku, BK (reprint author), NIOSH, Ctr Dis Control & Prevent CDC, 4676 Columbia Pkwy,MS R3, Cincinnati, OH 45226 USA. EM bik5@cdc.gov FU NORA program at NIOSH FX The authors thank Mariko Ono-Ogasawara (Japan National Institute of Occupational Safety and Health, and Japan Fibrous Material Research Association, JFMRA) for the samples of the GW1 glass fibers used in this study. We thank Elizabeth Ashley (University of Cincinnati), for assisting in the analysis of PCM images of the fibers. We thank Doug Evans and Liming Lo for helpful discussions. This work was funded by the NORA program at NIOSH. NR 22 TC 2 Z9 2 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 520 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0278-6826 EI 1521-7388 J9 AEROSOL SCI TECH JI Aerosol Sci. Technol. PY 2013 VL 47 IS 12 BP 1293 EP 1301 PG 9 WC Engineering, Chemical; Engineering, Mechanical; Environmental Sciences; Meteorology & Atmospheric Sciences SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences GA AF8VM UT WOS:000334993700002 PM 26635428 ER PT J AU Hoffmann, CJ Ledwaba, J Li, JF Johnston, V Hunt, G Fielding, KL Chaisson, RE Churchyard, GJ Grant, AD Johnson, JA Charalambous, S Morris, L AF Hoffmann, Christopher J. Ledwaba, Johanna Li, Jin-Fen Johnston, Victoria Hunt, Gillian Fielding, Katherine L. Chaisson, Richard E. Churchyard, Gavin J. Grant, Alison D. Johnson, Jeffrey A. Charalambous, Salome Morris, Lynn TI Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa SO ANTIVIRAL THERAPY LA English DT Article ID 1ST-LINE ANTIRETROVIRAL THERAPY; TREATMENT-NAIVE PATIENTS; REVERSE-TRANSCRIPTASE; DRUG-RESISTANCE; K65R RESISTANCE; MUTATION; LAMIVUDINE; K70E; DF; EMTRICITABINE AB Background: Tenofovir disoproxil fumarate (TDF) is increasingly available for patients infected with subtype C HIV-1. This subtype is reported to develop the principal TDF resistance mutation in the HIV reverse transcriptase, K65R, with greater propensity than other subtypes. We sought to describe K65R development during TDF use in a cohort of patients infected with subtype C HIV. Methods: Using a prospectively followed cohort with 6 monthly HIV RNA assays, we identified virological failure (defined as an HIV RNA>1,000 copies/ml) during treatment that included TDF. Residual serum, stored at the time of the HIV RNA assay, was used for consensus sequencing and allele-specific PCR. We assessed prevalence of resistance at failure during TDF-containing treatment and associated factors. Results: Among 1,682 patients on a TDF-containing regimen, 270 developed failure of which 40 were assessed for resistance. By sequencing, the K65R was identified in 5 (12%), major non-nucleoside reverse transcriptase inhibitor mutations in 24 (57%) and the M184V/I in 12 (28%) patients. The K65R was associated with lower HIV RNA at failure (HIV RNA 3.3 versus 4.2 log(10) copies/ml) and prior stavudine exposure. An additional five patients had minority K65R populations identified by allele-specific PCR. Conclusions: These data suggest that the K65R prevalence at virological failure is moderately higher in our subtype C population than some non-subtype C HIV cohorts. However, we did not find that the K65R was highly selected in HIV-1 subtype-C-infected patients with up to 6 months of failure of a TDF-containing regimen. C1 [Hoffmann, Christopher J.; Chaisson, Richard E.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA. [Hoffmann, Christopher J.; Churchyard, Gavin J.; Charalambous, Salome] Aurum Inst, Johannesburg, South Africa. [Ledwaba, Johanna; Hunt, Gillian; Morris, Lynn] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Ctr HIV & STIs, Johannesburg, South Africa. [Li, Jin-Fen; Johnson, Jeffrey A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, HIV Drug Resistance & Diagnost Dev Unit, Atlanta, GA USA. [Johnston, Victoria; Fielding, Katherine L.; Churchyard, Gavin J.; Grant, Alison D.] London Sch Hyg & Trop Med, London WC1, England. [Churchyard, Gavin J.] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa. RP Hoffmann, CJ (reprint author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA. EM choffmann@jhmi.edu OI Hoffmann, Christopher/0000-0002-9422-0519 FU National Institutes of Health [AI083099, AI5535901, AI016137]; Wellcome Trust Fellowship; Global Health Trials [G1100689]; Bill and Melinda Gates Foundation [OPP1034523] FX CJH was supported by National Institutes of Health AI083099, VJ by a Wellcome Trust Fellowship, REC by National Institutes of Health AI5535901 and AI016137, and ADG by a Global Health Trials (G1100689) and the Bill and Melinda Gates Foundation (OPP1034523). NR 27 TC 11 Z9 11 U1 0 U2 1 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2013 VL 18 IS 7 BP 915 EP 920 DI 10.3851/IMP2652 PG 6 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA AG2EI UT WOS:000335228500008 PM 23751421 ER PT J AU Battalora, L Buchacz, K Armon, C Overton, ET Hammer, J Patel, P Chmiel, JS Bush, TJ Brooks, JT Young, B AF Battalora, L. Buchacz, K. Armon, C. Overton, E. T. Hammer, J. Patel, P. Chmiel, J. S. Bush, T. J. Brooks, J. T. Young, B. CA HIV Outpatient Study HOPS SUN Study Investigators TI Low bone mineral density is associated with increased risk of incident fracture in HIV-infected adults SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT 15th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV CY OCT 15-17, 2013 CL Brussels, BELGIUM C1 [Battalora, L.] Colorado Sch Mines, Golden, CO 80401 USA. [Buchacz, K.; Patel, P.; Bush, T. J.; Brooks, J. T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Armon, C.] Cerner Corp, Vienna, VA USA. [Overton, E. T.] Univ Alabama Birmingham, Birmingham, AL USA. [Hammer, J.] Denver Infect Dis Consultants, Denver, CO USA. [Chmiel, J. S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Young, B.] APEX Family Med, Denver, CO USA. [Young, B.] Int Assoc Providers AIDS Care, Washington, DC USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2013 VL 18 SU 3 BP A24 EP A24 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA AG2EZ UT WOS:000335230200029 ER PT J AU Lipscomb, JT Heneine, W Johnson, JA AF Lipscomb, J. T. Heneine, W. Johnson, J. A. TI Simplified multiplex mutation-specific PCR screening for HIV drug resistance SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies CY JUN 04-08, 2013 CL Toronto, CANADA C1 [Lipscomb, J. T.; Heneine, W.; Johnson, J. A.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2013 VL 18 SU 1 BP A138 EP A138 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA AG2ES UT WOS:000335229500111 ER PT J AU Lipscomb, JT Li, JF Owen, SM Johnson, JA AF Lipscomb, J. T. Li, J-F Owen, S. M. Johnson, J. A. TI High diversity in reverse transcriptase drug resistance mutations relative to envelope variants in early-acute HIV transmission SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies CY JUN 04-08, 2013 CL Toronto, CANADA C1 [Lipscomb, J. T.; Li, J-F; Owen, S. M.; Johnson, J. A.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2013 VL 18 SU 1 BP A17 EP A17 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA AG2ES UT WOS:000335229500013 ER PT J AU Hubbard, B Gelting, R Portillo, MD Williams, T Torres, R AF Hubbard, Brian Gelting, Richard Portillo, Maria del Carmen Williams, Tom Torres, Ricardo TI Awareness, adoption and implementation of the water safety plan methodology: insights from five Latin American and Caribbean experiences SO JOURNAL OF WATER SANITATION AND HYGIENE FOR DEVELOPMENT LA English DT Article DE drinking-water regulations; Latin America and Caribbean; preventive risk management; public health; water safety plans; water supply operations and management ID HACCP AB Considerable effort has been made worldwide to disseminate information and provide technical assistance to encourage the adoption and implementation of the water safety plan (WSP) methodology. Described since the third edition of the World Health Organization (WHO) Guidelines for Drinking-water Quality, a WSP provides guidance for water utilities to ensure the delivery of safe drinking water and protect health. Attention is now being given to understand the success of efforts to advance adoption of the WSP methodology in the Latin America and Caribbean (LAC) region. More specifically, there is interest in knowing how early adopters developed strategies to implement the WSP methodology and what challenges exist for further implementation. To better understand adoption and implementation trends, key informants from five LAC countries were interviewed and case studies were developed to reveal the diversity of WSP approaches applied in the region. Results indicate that WSP implementation is more widespread than previously reported. Respondents affirmed that the WHO Guidelines for Drinking-water Quality are routinely used as a model for country-level drinking-water regulations, which has led to uptake of the WSP methodology. Interview respondents also revealed innovative national strategic approaches for WSP implementation. C1 [Hubbard, Brian; Gelting, Richard] US Ctr Dis Control & Prevent, Dept Hlth & Human Serv, Environm Hlth Serv Branch, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Portillo, Maria del Carmen] Latin Amer & Caribbean Off, Int Water Assoc, Lima, Peru. [Williams, Tom] Int Water Assoc, Den Haag Off, NL-2595 AA The Hague, Netherlands. [Torres, Ricardo] Pan Amer Hlth Org, La Paz, Bolivia. RP Hubbard, B (reprint author), US Ctr Dis Control & Prevent, Dept Hlth & Human Serv, Environm Hlth Serv Branch, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-60, Atlanta, GA 30341 USA. EM bhubbard@cdc.gov NR 16 TC 1 Z9 2 U1 0 U2 3 PU IWA PUBLISHING PI LONDON PA ALLIANCE HOUSE, 12 CAXTON ST, LONDON SW1H0QS, ENGLAND SN 2043-9083 J9 J WATER SANIT HYG DE JI J. Wate Sanit. Hyg. Dev. PY 2013 VL 3 IS 4 BP 541 EP 548 DI 10.2166/washdev.2013.001 PG 8 WC Water Resources SC Water Resources GA AB2GG UT WOS:000331610600008 ER PT J AU Al-Lami, F Al-Fatlawi, A Bloland, P Nawwar, A Jetheer, A Hantoosh, H Radhi, F Mohan, B Abbas, M Kamil, A Khayatt, I Baqir, H AF Al-Lami, F. Al-Fatlawi, A. Bloland, P. Nawwar, A. Jetheer, A. Hantoosh, H. Radhi, F. Mohan, B. Abbas, M. Kamil, A. Khayatt, I. Baqir, H. TI Pattern of morbidity and mortality in Karbala hospitals during Ashura mass gathering at Karbala, Iraq, 2010 SO EASTERN MEDITERRANEAN HEALTH JOURNAL LA English DT Article ID PROSPECTIVE COHORT; HUMAN STAMPEDES; OLYMPIC GAMES; HAJJ; PILGRIMS AB Religious mass gatherings are increasingly common in Iraq and can harbour considerable public health risks. This study was aimed at determining morbidity and mortality patterns in hospitals in Karbala city, Iraq during the mass gathering for Ashura in 2010. We conducted a cross-sectional study on attendees at the 3 public hospitals in the city. The study period was divided into pre-event, event, and post-event phases. Morbidity and mortality data were obtained from hospital registry books and the coroners office. About 80% of the 18 415 consultations were at emergency rooms. Average daily emergency room attendance was higher during the event compared with pre- and post-event phases, while average daily admissions decreased. Compared with the pre-event phase, a 7-fold increase in febrile disorders and a 2-fold increase in chronic diseases and injuries were noted during the event phase. There was no difference between the 3 phases for average daily death rate,nor for cause of death. C1 [Al-Lami, F.; Al-Fatlawi, A.; Jetheer, A.; Hantoosh, H.; Radhi, F.; Mohan, B.; Abbas, M.; Kamil, A.; Khayatt, I.; Baqir, H.] FETP, Baghdad, Iraq. [Bloland, P.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Nawwar, A.] Minist Hlth, Baghdad, Iraq. RP Al-Lami, F (reprint author), FETP, Baghdad, Iraq. EM farislami@gmail.com NR 26 TC 5 Z9 5 U1 1 U2 2 PU WHO EASTERN MEDITERRANEAN REGIONAL OFFICE PI NASR CITY, CAIRO PA P. O. BOX 7608, NASR CITY, CAIRO, EGYPT SN 1020-3397 EI 1687-1634 J9 E MEDITERR HEALTH J JI East Mediterr. Health J. PY 2013 VL 19 SU 2 BP S13 EP S18 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AB1YT UT WOS:000331590600005 PM 24673093 ER PT J AU AlNsour, M Fleischauer, A AF AlNsour, M. Fleischauer, A. TI Public health considerations for mass gatherings in the Middle East and North Africa (MENA) region SO EASTERN MEDITERRANEAN HEALTH JOURNAL LA English DT Review ID MENINGITIDIS SEROGROUP W135; MUSLIM PILGRIMAGE HAJJ; SAUDI-ARABIA; MENINGOCOCCAL CARRIAGE; PROSPECTIVE COHORT; MECCA PILGRIMAGE; FRENCH PILGRIMS; HEATSTROKE; INFECTION; MAKKAH AB This review describes major mass gatherings in the MENA region and the public health implications of these events, and provides recommendations for public health officials of the host country. Through our search of the literature for peer-reviewed publications, we identified relevant 77 papers; all were related to the annual Hajj. Using the information obtained from the literature review, the Eastern Mediterranean Public Health Network (EMPHNET) and the Centers for Disease Control and Prevention (CDC) developed and conducted 2 workshops on Public Health Surveillance during Mass Gatherings for field epidemiology training programmes and ministry of health focal points from 10 countries. The main potential public health concerns associated with mass gatherings include: infectious diseases (e.g. respiratory disease, gastro-intestinal tract disease, foodborne disease), injuries, traffic accidents, heat-related illnesses, insect stings, non-communicable diseases and terrorism. C1 [AlNsour, M.] Eastern Mediterranean Publ Hlth Network, Amman, Jordan. [Fleischauer, A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP AlNsour, M (reprint author), Eastern Mediterranean Publ Hlth Network, Amman, Jordan. EM mohannadnsour973@yahoo.com NR 77 TC 1 Z9 1 U1 2 U2 3 PU WHO EASTERN MEDITERRANEAN REGIONAL OFFICE PI NASR CITY, CAIRO PA P. O. BOX 7608, NASR CITY, CAIRO, EGYPT SN 1020-3397 EI 1687-1634 J9 E MEDITERR HEALTH J JI East Mediterr. Health J. PY 2013 VL 19 SU 2 BP S42 EP S47 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AB1YT UT WOS:000331590600010 PM 24673098 ER PT J AU Youbi, M Dghoughi, N Akrim, M Essolbi, A Barkia, A Azami, AI Fleischauer, AT Schneider, D Maaroufi, A AF Youbi, M. Dghoughi, N. Akrim, M. Essolbi, A. Barkia, A. Azami, A. I. Fleischauer, A. T. Schneider, D. Maaroufi, A. TI Preparedness and health risks associated with Moulay Abdellah Amgharmoussem, Morocco, 2009-2010 SO EASTERN MEDITERRANEAN HEALTH JOURNAL LA English DT Article AB The objective of this study was to describe the risks and human health outcomes associated with attendance at the Moulay Abdellah Amghar moussem (a pre-planned mass gathering attracting more than 360 000 participants) for the purposes of public health prevention, planning, preparedness and response. We performed an environmental health risk assessment and retrospectively reviewed local health centre records before, during and after the event. In addition, standardized interviews with key stakeholders were performed to qualitatively evaluate local public health preparedness and response capacities. During the event, average daily health centre visits increased 5-fold. The sex ratio of health-care visits changed significantly from an average of 1.8:1 female:male visits per day to 1.2:1. The proportion of injuries varied from an average of 3.7% pre- and post-event to 14.8% (P < 0.01) during the event. A significant increase in digestive diseases was also observed during the event. Recommendations include increasing accessibility to free sanitation and hygiene facilities and improving health communications concerning hand washing and food and water safety. C1 [Youbi, M.; Dghoughi, N.; Akrim, M.; Essolbi, A.; Maaroufi, A.] Natl Inst Hlth Adm, Rabat, Morocco. [Barkia, A.] Minist Hlth, Directorate Epidemiol & Dis Control, Rabat, Morocco. [Azami, A. I.] Reg Observ Hlth, Casablanca, Morocco. [Fleischauer, A. T.] North Carolina Div Publ Hlth, Raleigh, NC USA. [Schneider, D.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Youbi, M (reprint author), Natl Inst Hlth Adm, Rabat, Morocco. EM youbimohammed@yahoo.fr NR 6 TC 2 Z9 2 U1 0 U2 1 PU WHO EASTERN MEDITERRANEAN REGIONAL OFFICE PI NASR CITY, CAIRO PA P. O. BOX 7608, NASR CITY, CAIRO, EGYPT SN 1020-3397 EI 1687-1634 J9 E MEDITERR HEALTH J JI East Mediterr. Health J. PY 2013 VL 19 SU 2 BP S19 EP S23 PG 5 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AB1YT UT WOS:000331590600006 PM 24673094 ER PT J AU Allemani, C Rachet, B Weir, HK Richardson, LC Lepage, C Faivre, J Gatta, G Capocaccia, R Sant, M Baili, P Lombardo, C Aareleid, T Ardanaz, E Bielska-Lasota, M Bolick, S Cress, R Elferink, M Fulton, JP Galceran, J Gozdz, S Hakulinen, T Primic-Zakelj, M Rachtan, J Diba, CS Sanchez, MJ Schymura, MJ Shen, TF Tagliabue, G Tumino, R Vercelli, M Wolf, HJ Wu, XC Coleman, MP AF Allemani, Claudia Rachet, Bernard Weir, Hannah K. Richardson, Lisa C. Lepage, Come Faivre, Jean Gatta, Gemma Capocaccia, Riccardo Sant, Milena Baili, Paolo Lombardo, Claudio Aareleid, Tiiu Ardanaz, Eva Bielska-Lasota, Magdalena Bolick, Susan Cress, Rosemary Elferink, Marloes Fulton, John P. Galceran, Jaume Gozdz, Stanislaw Hakulinen, Timo Primic-Zakelj, Maja Rachtan, Jadwiga Diba, Chakameh Safaei Sanchez, Maria-Jose Schymura, Maria J. Shen, Tiefu Tagliabue, Giovanna Tumino, Rosario Vercelli, Marina Wolf, Holly J. Wu, Xiao-Cheng Coleman, Michel P. TI Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study SO BMJ OPEN LA English DT Article ID TOTAL MESORECTAL EXCISION; FLEXIBLE PARAMETRIC MODELS; EUROCARE HIGH-RESOLUTION; QUALITY-OF-LIFE; RECTAL-CANCER; PREOPERATIVE RADIOTHERAPY; RELATIVE SURVIVAL; ELDERLY-PATIENTS; POPULATION; CHEMOTHERAPY AB Objectives: To assess the extent to which stage at diagnosis and adherence to treatment guidelines may explain the persistent differences in colorectal cancer survival between the USA and Europe. Design: A high-resolution study using detailed clinical data on Dukes' stage, diagnostic procedures, treatment and follow-up, collected directly from medical records by trained abstractors under a single protocol, with standardised quality control and central statistical analysis. Setting and participants: 21 population-based registries in seven US states and nine European countries provided data for random samples comprising 12 523 adults (15-99 years) diagnosed with colorectal cancer during 1996-1998. Outcome measures: Logistic regression models were used to compare adherence to 'standard care' in the USA and Europe. Net survival and excess risk of death were estimated with flexible parametric models. Results: The proportion of Dukes' A and B tumours was similar in the USA and Europe, while that of Dukes' C was more frequent in the USA (38% vs 21%) and of Dukes' D more frequent in Europe (22% vs 10%). Resection with curative intent was more frequent in the USA (85% vs 75%). Elderly patients (75-99 years) were 70-90% less likely to receive radiotherapy and chemotherapy. Age-standardised 5-year net survival was similar in the USA (58%) and Northern and Western Europe (54-56%) and lowest in Eastern Europe (42%). The mean excess hazard up to 5 years after diagnosis was highest in Eastern Europe, especially among elderly patients and those with Dukes' D tumours. Conclusions: The wide differences in colorectal cancer survival between Europe and the USA in the late 1990s are probably attributable to earlier stage and more extensive use of surgery and adjuvant treatment in the USA. C1 [Allemani, Claudia; Rachet, Bernard; Coleman, Michel P.] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, Canc Res UK Canc Survival Grp, London WC1, England. [Weir, Hannah K.; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Lepage, Come; Faivre, Jean] Fac Med, Cote dOr Digest Canc Registry, Dijon, France. [Gatta, Gemma] Fdn IRCCS Ist Nazl Tumori, Dept Prevent & Predict Med, Evaluat Epidemiol Unit, Milan, Italy. [Capocaccia, Riccardo] Natl Inst Hlth, Natl Ctr Epidemiol Surveillance & Promot Hlth, Rome, Italy. [Sant, Milena; Baili, Paolo] Fdn IRCCS Ist Nazl Tumori, Descript Studies & Hlth Planning Unit, Milan, Italy. [Lombardo, Claudio] Alleanza Cancro Cancro, Rome, Italy. [Aareleid, Tiiu] Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, Estonia. [Ardanaz, Eva] Navarra Publ Hlth Inst, Navarra Canc Registry, Navarra, Spain. [Ardanaz, Eva] CIBER Epidemiol & Publ Hlth CIBERESP, Madrid, Spain. [Bielska-Lasota, Magdalena] Natl Inst Hyg, Natl Inst Publ Hlth, PL-00791 Warsaw, Poland. [Bolick, Susan] Off Publ Hlth Stat & Informat Syst, South Carolina Cent Canc Registry, SC Dept Hlth & Environm Control, Columbia, SC USA. [Cress, Rosemary] Canc Registry Greater Calif, Publ Hlth Inst, Sacramento, CA USA. [Elferink, Marloes] Comprehens Canc Ctr Netherlands, Utrecht, Netherlands. [Fulton, John P.] Rhode Isl Canc Registry, Rhode Isl Dept Hlth, Providence, RI USA. [Galceran, Jaume] Pere Virgili Hlth Res Inst, Fdn Soc Canc Res & Prevent, Tarragona Canc Registry, Tarragona, Spain. [Gozdz, Stanislaw] Holycross Canc Ctr, Swietokrzyskie Centrum Onkol, Kielce, Poland. [Gozdz, Stanislaw] Jan Kochanowski Univ Humanities & Sci Kielce, Fac Hlth Sci, Kielce, Poland. [Hakulinen, Timo] Finnish Canc Registry, FIN-00170 Helsinki, Finland. [Primic-Zakelj, Maja] Inst Oncol Ljubljana, Epidemiol & Canc Registry, Ljubljana, Slovenia. [Rachtan, Jadwiga] M Sklodowska Curie Mem Canc Inst, Cracow Canc Registry, Ctr Oncol, Krakow, Poland. [Diba, Chakameh Safaei] Natl Hlth Informat Ctr, Natl Canc Registry Slovakia, Bratislava, Slovakia. [Sanchez, Maria-Jose] Andalusian Sch Publ Hlth, Granada, Spain. [Sanchez, Maria-Jose] CIBERESP, Madrid, Spain. [Schymura, Maria J.] New York State Canc Registry, New York State Dept Hlth, Albany, NY USA. [Shen, Tiefu] Illinois State Canc Registry, Illinois Dept Publ Hlth, Springfield, IL USA. [Tagliabue, Giovanna] Fdn IRCCS Ist Nazl Tumori, Canc Registry, Milan, Italy. [Tagliabue, Giovanna] Fdn IRCCS Ist Nazl Tumori, Environm Epidemiol Div, Milan, Italy. [Tumino, Rosario] ASP Ragusa, Civile MP Arezzo Hosp, Canc Registry, Ragusa, Italy. [Tumino, Rosario] ASP Ragusa, Civile MP Arezzo Hosp, Histopathol Unit, Ragusa, Italy. [Vercelli, Marina] IRCCS Azienda Osped Univ San Martino, USM IST, IST Ist Nazl Ric Cancro, UOS Epidemiol Descritt, Genoa, Italy. [Vercelli, Marina] Univ Genoa, Dipartimento Sci Salute, Sez Epidemiol Descritt, Genoa, Italy. [Wolf, Holly J.] Univ Colorado, Ctr Canc, Colorado Sch Publ Hlth, Canc Prevent & Control Div, Aurora, CO USA. [Wu, Xiao-Cheng] LSU, Hlth Sci Ctr, Sch Publ Hlth, Louisiana Tumor Registry, New Orleans, LA USA. RP Allemani, C (reprint author), London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, Canc Res UK Canc Survival Grp, London WC1, England. EM claudia.allemani@lshtm.ac.uk RI SANCHEZ-PEREZ, MARIA JOSE/D-1087-2011; Baili, Paolo/J-7422-2016; Kielce, SCO/O-6702-2016; Gozdz, Stanislaw/D-3300-2013; Gatta, Gemma/B-8627-2017; Tagliabue, Giovanna /D-4194-2017; Sant, Milena/D-2362-2017; OI Rachet, Bernard/0000-0001-5837-7773; SANCHEZ-PEREZ, MARIA JOSE/0000-0003-4817-0757; Baili, Paolo/0000-0003-0335-2418; Gatta, Gemma/0000-0003-4160-6458; Tagliabue, Giovanna /0000-0001-8165-5524; Sant, Milena/0000-0002-4148-8597; Coleman, Michel/0000-0001-8940-3807; Vercelli, Marina/0000-0002-9757-2616 FU Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Cancer Prevention and Control, Cancer Surveillance Branch, Atlanta, GA; Louisiana Tumor Registry, School of Public Health, Louisiana State University, New Orleans, LA [U58/CCU 62(306)]; CDC/NPCR Atlanta, GA; New York State Cancer Registry, New York State Department of Health, Albany, NY [U58/CCU 220322]; Colorado Central Cancer Registry, Colorado Department of Public Health and Environment, Denver, CO [U58/CCU 820326]; Illinois State Cancer Registry, Illinois Department of Public Health, Springfield, IL [U58/CCU 520378]; South Carolina Central Cancer Registry, Columbia; SC [U58/CCU 420312]; California Cancer Registry, Sacramento, CA [U58/CCU 920352]; Rhode Island Cancer Registry, Rhode Island Department of Health, Providence, RI [U58/CCU 520378]; University of Kentucky, Lexington KY [UKRF 3049024672-12-568]; Health Department of the Navarra Government, Spain [79/2000]; Estonian Ministry of Education and Research [SF0940026s07] FX Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Cancer Prevention and Control, Cancer Surveillance Branch, Atlanta, GA; Louisiana Tumor Registry, School of Public Health, Louisiana State University, New Orleans, LA (cooperative agreement #U58/CCU 62(306); CDC/NPCR contractor. Atlanta, GA; New York State Cancer Registry, New York State Department of Health, Albany, NY (cooperative agreement #U58/CCU 220322); Colorado Central Cancer Registry, Colorado Department of Public Health and Environment, Denver, CO (cooperative agreement #U58/CCU 820326); Illinois State Cancer Registry, Illinois Department of Public Health, Springfield, IL (cooperative agreement #U58/CCU 520378); South Carolina Central Cancer Registry, Columbia; SC (cooperative agreement #U58/CCU 420312); California Cancer Registry, Sacramento, CA (cooperative, agreement #U58/CCU 920352); Rhode Island Cancer Registry, Rhode Island Department of Health, Providence, RI (cooperative agreement #U58/CCU 520378); University of Kentucky, Lexington KY (UKRF 3049024672-12-568). Support was also obtained from the Health Department of the Navarra Government, Spain (research grant 79/2000). The participation of Estonia was partly supported by the Estonian Ministry of Education and Research (SF0940026s07). NR 34 TC 18 Z9 20 U1 1 U2 10 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2013 VL 3 IS 9 AR UNSP e003055 DI 10.1136/bmjopen-2013-003055 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 301ON UT WOS:000330541900006 PM 24022388 ER PT J AU Castro, A Jost, H Cox, D Fakile, Y Kikkert, S Tun, Y Zaidi, A Park, M AF Castro, Arnold Jost, Heather Cox, David Fakile, Yetunde Kikkert, Susan Tun, Ye Zaidi, Akbar Park, Mahin TI A comparison of the analytical level of agreement of nine treponemal assays for syphilis and possible implications for screening algorithms SO BMJ OPEN LA English DT Article AB Objective: The serological diagnosis of syphilis requires the detection of two distinct antibodies, the non-treponemal and trepomenal. Center for Disease Control and Prevention (CDC) recommends screening first with a non-treponemal test such as (Rapid Plasma ReaginNenereal Disease Research Laboratory), and then confirming those results with one of the several treponemal tests (Fluorescent Treponemal AntibodyAbsorption (FTA-ABS), Enzyme Immunoassay, chemiluminescence, treponema pallidum particle agglutination (TP-PA) or Point of Care). Owing to the high volume of samples processed by some laboratories using automated systems, the screening with treponemal assays and confirming with nontreponemal tests is becoming the established norm. The purpose of this study was to evaluate eight treponemal assays using TP-PA as the predicate assay. Methods: 290 stored serum samples were tested qualitatively according to the manufacturer's directions. Results: Concordance with specimens tested as reactive or non-reactive using TP-PA was: FTA-ABS 94.5-100%, Trep-Sure 100-98.9%, BioELISA 100 98.9%, INNO-LIA 99.1-99.4%, BIOLINE 100-98.9%, CAPTIA IgG 100-97.2%, Trep-ID 100-100% and LIAISON 100-99.4%. In order to properly evaluate the performance of these assays, the analytical sensitivity was determined by endpoint titration of serial dilutions of the reactive serum samples in normal sera. The median endpoint titre varied from 1:4 for ETA-ABS to 1:512 for Trep-Sure. Conclusions: The performance of the treponemal serological assays was comparable while using medium and high-titre sera. However, the varying performance on specimen dilutions suggests that there may be differences in sensitivity with low-titre sera that are more prevalent in primary and late syphilis cases. C1 [Castro, Arnold; Jost, Heather; Cox, David; Fakile, Yetunde; Kikkert, Susan; Tun, Ye; Zaidi, Akbar] Ctr Dis Control & Prevent, Lab Reference & Res Branch, Atlanta, GA 30329 USA. [Park, Mahin] Georgia Dept Community Hlth, Cordele, GA 31015 USA. RP Castro, A (reprint author), Ctr Dis Control & Prevent, Lab Reference & Res Branch, Atlanta, GA 30329 USA. EM acastro@cdc.gov NR 8 TC 0 Z9 0 U1 2 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2013 VL 3 IS 9 AR e003347 DI 10.1136/bmjopen-2013-003347 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 301ON UT WOS:000330541900045 ER PT J AU Joffres, M Falaschetti, E Gillespie, C Robitaille, C Loustalot, F Poulter, N McAlister, FA Johansen, H Baclic, O Campbell, N AF Joffres, Michel Falaschetti, Emanuela Gillespie, Cathleen Robitaille, Cynthia Loustalot, Fleetwood Poulter, Neil McAlister, Finlay A. Johansen, Helen Baclic, Oliver Campbell, Norm TI Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study SO BMJ OPEN LA English DT Article ID BLOOD-PRESSURE; EDUCATION-PROGRAM; UNITED-KINGDOM; PREVENTION; MANAGEMENT; HEALTH; METAANALYSIS; PERFORMANCE; TRENDS; STATES AB Objective: Comparison of recent national survey data on prevalence, awareness, treatment and control of hypertension in England, the USA and Canada, and correlation of these parameters with each country stroke and ischaemic heart disease (IHD) mortality. Design: Non-institutionalised population surveys. Setting and participants: England (2006 n=6873), the USA (2007-2010 n=10 003) and Canada (2007-2009 n=3485) aged 20-79 years. Outcomes: Stroke and IHD mortality rates were plotted against countries' specific prevalence data. Results: Mean systolic blood pressure (SBP) was higher in England than in the USA and Canada in all age-gender groups. Mean diastolic blood pressure (DBP) was similar in the three countries before age 50 and then fell more rapidly in the USA, being the lowest in the USA. Only 34% had a BP under 140/90 mm Hg in England, compared with 50% in the USA and 66% in Canada. Prehypertension and stages 1 and 2 hypertension prevalence figures were the highest in England. Hypertension prevalence (>= 140 mm Hg SBP and/or >= 90 mm Hg DBP) was lower in Canada (19.5%) than in the USA (29%) and England (30%). Hypertension awareness was higher in the USA (81%) and Canada (83%) than in England (65%). England also had lower levels of hypertension treatment (51%; USA 74%; Canada 80%) and control (<140/90 mm Hg; 27%; the USA 53%; Canada 66%). Canada had the lowest stroke and IHD mortality rates, England the highest and the rates were inversely related to the mean SBP in each country and strongly related to the blood pressure indicators, the strongest relationship being between low hypertension awareness and stroke mortality. Conclusions: While the current prevention efforts in England should result in future-improved figures, especially at younger ages, these data still show important gaps in the management of hypertension in these countries, with consequences on stroke and IHD mortality. C1 [Joffres, Michel] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada. [Falaschetti, Emanuela] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Imperial Clin Trial Unit, London, England. [Gillespie, Cathleen; Loustalot, Fleetwood] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Robitaille, Cynthia] Publ Hlth Agcy Canada, Ctr Chron Dis Prevent, Ottawa, ON, Canada. [Poulter, Neil] Univ London Imperial Coll Sci Technol & Med, Int Ctr Circulatory Hlth, London, England. [McAlister, Finlay A.] Univ Alberta Hosp, Div Gen Internal Med, Edmonton, AB T6G 2B7, Canada. [Johansen, Helen] Univ Ottawa, Dept Community Med & Epidemiol, Ottawa, ON, Canada. [Baclic, Oliver] Publ Hlth Agcy Canada, Ottawa, ON, Canada. [Campbell, Norm] Univ Calgary, Canada Libin Cardiovasc Inst Alberta, Libin Cardiovasc Inst, Dept Med, Calgary, AB, Canada. [Campbell, Norm] Univ Calgary, Canada Libin Cardiovasc Inst Alberta, Libin Cardiovasc Inst, Dept Community Hlth Sci, Calgary, AB, Canada. [Campbell, Norm] Univ Calgary, Canada Libin Cardiovasc Inst Alberta, Libin Cardiovasc Inst, Dept Physiol & Pharmacol, Calgary, AB, Canada. RP Joffres, M (reprint author), Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada. EM mjoffres@sfu.ca FU NCHS; National Health Centre; Canadian Health Measures Survey FX Funding for NHANES comes from two primary sources: direct funding through the NCHS base budget and reimbursable funding from collaborating agencies; The Health Survey for England was funded by the National Health Centre; Health Canada and the Public Health Agency of Canada supported Statistics Canada in obtaining federal funding for the Canadian Health Measures Survey. Other sources of support: FAM is supported by an Alberta Innovates Health Solutions Senior Health Scholar Award and the University of Alberta/Capital Health Chair in Cardiovascular Outcomes Research. NC holds the Heart and Stroke Foundation of Canada CIHR Chair in Hypertension Prevention and Control. NP is grateful for support from the NIHR Biomedical Research funding scheme and the NIHR Senior Investigator Award. Funding of the original surveys. NR 40 TC 90 Z9 93 U1 2 U2 20 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2013 VL 3 IS 8 AR e003423 DI 10.1136/bmjopen-2013-003423 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 301VX UT WOS:000330561300087 PM 23996822 ER PT J AU Wirth, M Burch, J Violanti, J Burchfiel, C Fekedulegn, D Andrew, M Zhang, HM Miller, DB Youngstedt, SD Hebert, JR Vena, JE AF Wirth, Michael Burch, James Violanti, John Burchfiel, Cecil Fekedulegn, Desta Andrew, Michael Zhang, Hongmei Miller, Diane B. Youngstedt, Shawn D. Hebert, James R. Vena, John E. TI Association of the Period3 clock gene length polymorphism with salivary cortisol secretion among police officers SO NEUROENDOCRINOLOGY LETTERS LA English DT Article DE PER3 VNTR; circadian; cortisol; shiftwork; police ID SLEEP PHASE SYNDROME; CIRCADIAN CLOCK; DIURNAL PREFERENCE; AWAKENING RESPONSE; REPEAT POLYMORPHISM; STRESS-RESPONSE; BREAST-CANCER; PER3; RHYTHM; MORNINGNESS AB OBJECTIVE: This study evaluated whether measures of waking or diurnal cortisol secretion, or self-reported psychological disturbances differed among police officers with a Period3 (PER3) clock gene length polymorphism. METHODS: The cortisol awakening response was characterized via the area under the salivary cortisol curve with respect to the increase (AUC(I)) or total waking cortisol (AUC(G)). Diurnal cortisol measures included the slope of diurnal cortisol and the diurnal AUC(G). Psychological disturbances were characterized using the Center for Epidemiologic Studies Depression Scale, Impact of Events Scale, and Life Events Scale. RESULTS: Officers with a 4/5 or 5/5 genotype had higher awakening AUC(G) and greater diurnal cortisol AUC(G) levels compared to officers with the 4/4 genotype. Among those working more afternoon or night shifts, waking AUC(I) and AUC(G) were greater among officers with a 4/5 or 5/5 genotype compared to the 4/4 referents. CONCLUSION: Cortisol secretion was modified among police officers with different PER3 VNTR clock gene variants. C1 [Wirth, Michael; Burch, James; Hebert, James R.] Univ S Carolina, Canc Prevent & Control Program, Columbia, SC 29208 USA. [Wirth, Michael; Burch, James; Zhang, Hongmei; Hebert, James R.] Univ S Carolina, Dept Epidemiol & Biostat, Columbia, SC 29208 USA. [Youngstedt, Shawn D.] Univ S Carolina, Dept Exercise Sci, Columbia, SC 29208 USA. [Burch, James; Youngstedt, Shawn D.] WJB Dorn VA Med Ctr, Columbia, SC USA. [Violanti, John] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Social & Prevent Med, Buffalo, NY 14260 USA. [Burchfiel, Cecil; Fekedulegn, Desta; Andrew, Michael] Ctr Dis Control & Prevent, Biostat & Epidemiol Branch, NIOSH, Morgantown, WV USA. [Miller, Diane B.] Ctr Dis Control & Prevent, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, NIOSH, Morgantown, WV USA. [Vena, John E.] Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA. RP Wirth, M (reprint author), Univ S Carolina, Canc Prevent & Control Program, 915 Greene St,Suite 200, Columbia, SC 29208 USA. EM wirthm@mailbox.sc.edu RI Miller, Diane/O-2927-2013; Wirth, Michael/C-6330-2013 FU Biostatistics and Epidemiology Branch of the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, West Virginia [212-2008-M-24052]; University of South Carolina's Behavioral-Biomedical Interface Program; National Institute of General Medical Sciences [T32-5R18CE001240]; Established Investigator Award in Cancer Prevention and Control from the Cancer Training Branch of the National Cancer Institute [K05 CA136975] FX This project was supported by Contract No. 212-2008-M-24052 from the Biostatistics and Epidemiology Branch of the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, West Virginia. Michael Wirth's participation in this research was supported by the University of South Carolina's Behavioral-Biomedical Interface Program which is funded in part by training grant T32-5R18CE001240 from the National Institute of General Medical Sciences. Dr. Hebert is supported by an Established Investigator Award in Cancer Prevention and Control from the Cancer Training Branch of the National Cancer Institute (K05 CA136975). The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 81 TC 6 Z9 6 U1 2 U2 7 PU MAGHIRA & MAAS PUBLICATIONS PI STOCKHOLM PA PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN SN 0172-780X J9 NEUROENDOCRINOL LETT JI Neuroendocrinol. Lett. PY 2013 VL 34 IS 1 BP 27 EP 37 PG 11 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA AA2AW UT WOS:000330898500005 PM 23524621 ER PT S AU Rubin, CS AF Rubin, Carol S. BE Mackenzie, JS Jeggo, M Daszak, P Richt, JA TI Operationalizing One Health: Stone Mountain and Beyond SO ONE HEALTH: THE HUMAN-ANIMAL-ENVIRONMENT INTERFACES IN EMERGING INFECTIOUS DISEASES: FOOD SAFETY AND SECURITY, AND INTERNATIONAL AND NATIONAL PLANS FOR IMPLEMENTATION OF ONE HEALTH ACTIVITIES SE Current Topics in Microbiology and Immunology LA English DT Review; Book Chapter AB Although the interconnection of humans, animals, and ecosystems has been recognized historically, increasing specialization of professionals in the twentieth century led to decreased communication and collaboration among sectors. In early 2000, a One Health vision of global interconnectedness began gaining in popularity and a series of meetings were held extolling the One Health vision. However, by 2009, detractors were claiming that the One Health approach was indeed all vision and no action. In response to this, international organizations sponsored a carefully planned and structured meeting to construct a way forward that would lead to tangible outcomes. The Stone Mountain meeting, Operationalizing "One Health'': A Policy Perspective-Taking Stock and Shaping an Implementation Roadmap led to the formation of seven multi-national work groups with defined timelines and outputs. The process has garnered increasing participation and support, and the work groups are on track to demonstrate the value added of a One Health approach. C1 Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Rubin, CS (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM crubin@cdc.gov NR 6 TC 3 Z9 3 U1 0 U2 4 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0070-217X BN 978-3-642-35846-3; 978-3-642-35845-6 J9 CURR TOP MICROBIOL JI Curr.Top.Microbiol.Immunol. PY 2013 VL 366 BP 173 EP 183 DI 10.1007/82_2013_310 D2 10.1007/978-3-642-35846-3 PG 11 WC Immunology; Microbiology SC Immunology; Microbiology GA BJU84 UT WOS:000330613600012 PM 23460115 ER PT J AU Nagle, BJ Holub, CK Barquera, S Sanchez-Romero, LM Eisenberg, CM Rivera-Dommarco, JA Mehta, SM Lobelo, F Arredondo, EM Elder, JP AF Nagle, Brian J. Holub, Christina K. Barquera, Simon Maria Sanchez-Romero, Luz Eisenberg, Christina M. Rivera-Dommarco, Juan A. Mehta, Setoo M. Lobelo, Felipe Arredondo, Elva M. Elder, John P. TI Interventions for the treatment of obesity among children and adolescents in Latin America: A systematic review SO SALUD PUBLICA DE MEXICO LA English DT Review DE overweight; quality of health care; child; adolescents; intervention studies; review ID COMMUNITY-PREVENTIVE-SERVICES; PRESCHOOL-CHILDREN; DEVELOPING-COUNTRIES; OVERWEIGHT AB Objective. The objective of this systematic literature review was to identify evidence-based strategies associated with effective healthcare interventions for prevention or treatment of childhood obesity in Latin America. Materials and methods. A systematic review of peer-reviewed, obesity-related interventions implemented in the healthcare setting was conducted. Inclusion criteria included: implementation in Latin America, aimed at overweight or obese children and evaluation of at least one obesity-related outcome (e.g., body mass index (BMI), z-score, weight, and waist circumference, and body fat). Results. Five interventions in the healthcare setting targeting obese children in Latin America were identified. All five studies showed significant changes in BMI, and the majority produced sufficient to large effect sizes through emphasizing physical activity and health eating. Conclusion. Despite the limited number of intervention studies that treat obesity in the healthcare setting, there is evidence that interventions in this setting can be effective in creating positive anthropometric changes in overweight and obese children. C1 [Nagle, Brian J.; Holub, Christina K.; Eisenberg, Christina M.; Mehta, Setoo M.; Arredondo, Elva M.; Elder, John P.] San Diego State Univ, Inst Behav & Community Hlth, San Diego, CA 92182 USA. [Barquera, Simon; Maria Sanchez-Romero, Luz; Rivera-Dommarco, Juan A.] Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico. [Lobelo, Felipe] Ctr Dis Control & Prevent, Global Hlth Promot Off, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Nagle, BJ (reprint author), Inst Behav & Community Hlth, 9245 Sky Pk Ct,Suite 221, San Diego, CA 92123 USA. EM naglebj@gmail.com NR 21 TC 0 Z9 0 U1 1 U2 7 PU INST NACIONAL SALUD PUBLICA PI CUERNAVACA PA AV UNIVERSIDAD 655, COL SANTA MARIA AHUACATITLAN, CUERNAVACA 62508, MORELOS, MEXICO SN 0036-3634 EI 1606-7916 J9 SALUD PUBLICA MEXICO JI Salud Publica Mexico PY 2013 VL 55 SU 3 BP S434 EP S440 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA0XH UT WOS:000330820200011 ER PT S AU York, I Donis, RO AF York, Ian Donis, Ruben O. BE Richt, JA Webby, RJ TI The 2009 Pandemic Influenza Virus: Where Did It Come from, Where Is It Now, and Where Is It Going? SO SWINE INFLUENZA SE Current Topics in Microbiology and Immunology LA English DT Review; Book Chapter ID SWINE-ORIGIN H1N1; A VIRUS; UNITED-STATES; OSELTAMIVIR-RESISTANT; PREEXISTING IMMUNITY; SEASONAL INFLUENZA; IN-VITRO; INFECTION; TRANSMISSION; A(H1N1) AB Around 2008 or 2009, an influenza A virus that had been circulating undetected in swine entered human population. Unlike most swine influenza infections of humans, this virus established sustained human-to-human transmission, leading to a global pandemic. The virus responsible, 2009 pandemic H1N1 (H1N1pdm), is the result of multiple reassortment events that brought together genomic segments from classical H1N1 swine influenza virus, human seasonal H3N2 influenza virus, North American avian influenza virus, and Eurasian avian-origin swine influenza viruses. Genetically, H1N1pdm possesses a number of unusual features, although the genomic characteristics that permitted sustained human-to-human transmission are yet unclear. Human infection with H1N1pdm has generally resulted in low mortality, although certain subgroups (including pregnant women, people with some chronic medical conditions, morbidly obese individuals, and immunosuppressed people) have significantly higher risk of severe disease. As H1N1pdm has spread throughout the human population it continued to evolve. It has also reentered the swine population as a circulating pathogen, and has been transiently identified in other species such as turkeys, cats, and domestic ferrets. Most genetic changes in H1N1pdm to date have not been clearly linked to changes in antigenicity, disease severity, antiviral drug resistance, or transmission efficiency. However, the rapid evolution rate characteristic of influenza viruses suggests that changes in antigenicity are inevitable in future years. Experience with this first pandemic of twenty-first century reemphasizes the importance of influenza surveillance in animals as well as humans, and offers lessons to develop and enhance our ability to identify potentially pandemic influenza viruses in the future. C1 [York, Ian; Donis, Ruben O.] Ctr Dis Control & Prevent, Mol Virol & Vaccines Branch, Influenza Div, NCIRD,CCID, Atlanta, GA 30333 USA. RP Donis, RO (reprint author), Ctr Dis Control & Prevent, Mol Virol & Vaccines Branch, Influenza Div, NCIRD,CCID, 1600 Clifton Rd,Mail Stop G-16, Atlanta, GA 30333 USA. EM rdonis@cdc.gov OI York, Ian/0000-0002-3478-3344 NR 120 TC 7 Z9 7 U1 0 U2 13 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0070-217X BN 978-3-642-36871-4; 978-3-642-36870-7 J9 CURR TOP MICROBIOL JI Curr.Top.Microbiol.Immunol. PY 2013 VL 370 BP 241 EP 257 DI 10.1007/82_2012_221 D2 10.1007/978-3-642-36871-4 PG 17 WC Public, Environmental & Occupational Health; Infectious Diseases; Virology SC Public, Environmental & Occupational Health; Infectious Diseases; Virology GA BJU59 UT WOS:000330591000014 PM 22638836 ER PT J AU Buchacz, K Baker, RK Palella, FJ Shaw, L Patel, P Lichtenstein, KA Chmiel, JS Vellozzi, C Debes, R Henry, K Overton, ET Bush, TJ Tedaldi, E Carpenter, C Mayer, KH Brooks, JT AF Buchacz, Kate Baker, Rose K. Palella, Frank J., Jr. Shaw, Lauren Patel, Pragna Lichtenstein, Kenneth A. Chmiel, Joan S. Vellozzi, Claudia Debes, Rachel Henry, Keith Overton, E. Turner Bush, Timothy J. Tedaldi, Ellen Carpenter, Charles Mayer, Kenneth H. Brooks, John T. CA HIV Outpatient Study Investigators TI Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US SO ANTIVIRAL THERAPY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; MULTICENTER AIDS COHORT; CORONARY-HEART-DISEASE; CHRONIC KIDNEY-DISEASE; UNITED-STATES; RISK-FACTORS; GENERAL-POPULATION; HIV-1-INFECTED PATIENTS; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME AB Background: Certain sociodemographic subgroups of HIV-infected patients may experience more chronic disease than others due to behavioural risk factors, advanced HIV disease or complications from extended use of combination antiretroviral therapy (cART), but recent comparative data are limited. Methods: We studied HIV-infected adult patients in care during 2006-2010 who had been prescribed >= 6 months of cART. We analysed the prevalence of selected key chronic conditions and polymorbidity (having 2 or more out of 10 key conditions) by gender and race/ethnicity. Results: Of the 3,166 HIV-infected patients (median age 47 years, CD4(+) T-cell count 496 cells/mm(3), duration of cART use 6.8 years), 21% were female, 57% were non-Hispanic White and over half were current or former tobacco smokers. The five most frequent conditions among women (median age 45 years) were dyslipidaemia (67.3%), hypertension (57.4%), obesity (31.7%), viral hepatitis B or C coinfection (29.0%) and low high-density lipoprotein cholesterol (HDLc; 27.3%). The five most frequent conditions in men (median age 47 years) were dyslipidaemia (81.2%), hypertension (54.4%), low HDLc (41.1%), elevated triglycerides (32.3%) and elevated non-HDLc (26.8%). In multivariable analyses, Hispanic patients had higher prevalence of obesity and diabetes than White patients; Black patients had higher prevalence of obesity and hypertension but lower rates of lipid abnormalities. Of all patients, 73.7% of women and 66.8% of men had polymorbidity, with no evidence of disparities by race/ethnicity. Conclusions: Among contemporary cART-treated HIVinfected adults, chronic conditions and polymorbidity were common, underscoring the importance of chronic disease prevention and management among ageing HIVinfected patients. C1 [Buchacz, Kate; Patel, Pragna; Vellozzi, Claudia; Bush, Timothy J.; Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA. [Baker, Rose K.; Debes, Rachel] Cerner Corp, Vienna, VA USA. [Palella, Frank J., Jr.; Chmiel, Joan S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Shaw, Lauren] DB Consulting Grp Inc, Silver Spring, MD USA. [Lichtenstein, Kenneth A.] Natl Jewish Hlth, Denver, CO USA. [Henry, Keith] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Overton, E. Turner] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Tedaldi, Ellen] Temple Univ, Sch Med, Philadelphia, PA 19122 USA. [Carpenter, Charles] Miriam Hosp, Providence, RI 02906 USA. [Mayer, Kenneth H.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. RP Buchacz, K (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA. EM acu7@cdc.gov FU Centers for Disease Control and Prevention [200-2001-00133, 200-2006-18797]; HOPS [200-2002-00610, 200-2002-00611, 200-2002-00612, 200-2002-00613, 200-2007-23633, 200-2007-23634, 200-2007-23635, 200-2007-23636]; SUN Stud FX The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. Financial support was received from Centers for Disease Control and Prevention contracts 200-2001-00133 and 200-2006-18797 (for the HOPS), 200-2002-00610, 200-2002-00611, 200-2002-00612, 200-2002-00613, 200-2007-23633, 200-2007-23634, 200-2007-23635 and 200-2007-23636 (for the SUN Study). The authors declare no competing interests. NR 58 TC 30 Z9 30 U1 0 U2 5 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2013 VL 18 IS 1 BP 65 EP 75 DI 10.3851/IMP2450 PG 11 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 287XP UT WOS:000329575900008 PM 23111762 ER PT J AU Ward, JW AF Ward, John W. TI Testing for HCV: the first step in preventing disease transmission and improving health outcomes for HCV-infected individuals (vol 17, pg 1397, 2012) SO ANTIVIRAL THERAPY LA English DT Correction C1 Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30329 USA. RP Ward, JW (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30329 USA. EM jww4@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 1 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2013 VL 18 IS 1 BP 139 EP 139 DI 10.3851/IMP2541 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 287XP UT WOS:000329575900017 ER PT J AU Yun, YX Wang, YP Wang, P Cui, LH Wang, KJ Zhang, JY Dai, LP AF Yun, Yu-Xia Wang, Yan-Ping Wang, Peng Cui, Li-Hong Wang, Kai-Juan Zhang, Jian-Ying Dai, Li-Ping TI CYP1A1 Genetic Polymorphisms and Risk for Esophageal Cancer: a Case-control Study in Central China SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION LA English DT Article DE Polymorphisms; CYP1A1; esophageal cancer; susceptibility; Central China ID SQUAMOUS-CELL CARCINOMA; HIGH-INCIDENCE AREA; LUNG-CANCER; CYTOCHROME-P450IA1 GENE; METABOLIZING ENZYMES; GSTM1 POLYMORPHISMS; MSPI POLYMORPHISM; NORTH CHINA; SUSCEPTIBILITY; SMOKING AB The purpose of this study was to evaluate the associations of CYP1A1 genetic polymorphisms with the risk of developing esophageal cancer (EC). A case-control study was carried out in a Chinese population in which 157 hospital based EC cases and 157 population based healthy controls with 1: 1 match by age and sex were included. PCR based restriction fragment length polymorphisms (PCR-RFLP) were used to detect genotypes in case and control groups. For the CYP1A1 Ile/Val polymorphism, comparing with wild genotype Ile/Ile, both the heterozygote genotype Ile/Val and the combined variant genotype Ile/Val+Val/Val increased the risk of esophageal cancer (OR: 2.05, 95% CI: 1.19-3.54, OR: 1.86, 95% CI: 1.11-3.12). No significant association was found between the CYP1A1 MspI polymorphism and EC. According to analysis of combined genotypes, the TC/AG combined genotype which contained both variant alleles of these two polymorphisms increased the risk of developing EC (OR: 2.12, 95% CI: 1.16-3.85). Our results suggested that genetic polymorphisms of CYP1A1 may increase the susceptibility to EC. C1 [Yun, Yu-Xia; Wang, Yan-Ping; Wang, Peng; Wang, Kai-Juan; Zhang, Jian-Ying; Dai, Li-Ping] Zhengzhou Univ, Coll Publ Hlth, Dept Biostat & Epidemiol, Beijing, Peoples R China. [Wang, Peng; Wang, Kai-Juan; Zhang, Jian-Ying; Dai, Li-Ping] Zhengzhou Univ, Henan Key Lab Tumor Epidemiol, Beijing, Peoples R China. [Yun, Yu-Xia; Wang, Peng; Wang, Kai-Juan; Zhang, Jian-Ying; Dai, Li-Ping] Zhengzhou Univ, Prote Res Ctr, Beijing, Peoples R China. [Wang, Yan-Ping] Henan Vocat Coll Agr, Dept Food Sci, Zhengzhou, Peoples R China. [Cui, Li-Hong] Ctr Dis Control & Prevent, Immunizat Branch Puyang, Puyallup, WA USA. [Cui, Li-Hong] PLA Navy Gen Hosp, Digest Syst Dept, Beijing, Peoples R China. RP Dai, LP (reprint author), Zhengzhou Univ, Coll Publ Hlth, Dept Biostat & Epidemiol, Beijing, Peoples R China. EM lpdai@hotmail.com RI Zhang, Jianying/F-3798-2010; Dai, Liping/E-6089-2013 FU Excellent Youth Foundation of He'nan Scientific Committee [124100510007]; People's Republic of China (National Natural Science Foundation of China) [30872181, 81072360] FX This research was supported by People's Republic of China (National Natural Science Foundation of China, No. 30872181, 81072360), and Excellent Youth Foundation of He'nan Scientific Committee (No. 124100510007). We acknowledge the blood samples of cases given by the First Affiliated Hospital of Zhengzhou University. We also wish to acknowledge the residents in Xinxiang County and Xin'an County of Henan Province support our epidemiological study on the scene. NR 37 TC 5 Z9 5 U1 1 U2 6 PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION PI GYEONGGI-DO PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO, ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA SN 1513-7368 J9 ASIAN PAC J CANCER P JI Asian Pac. J. Cancer Prev. PY 2013 VL 14 IS 11 BP 6507 EP 6512 DI 10.7314/APJCP.2013.14.11.6507 PG 6 WC Oncology SC Oncology GA 291LC UT WOS:000329829200054 PM 24377558 ER PT J AU Calafat, AM Koch, HM Swan, SH Hauser, R Goldman, LR Lanphear, BP Longnecker, MP Rudel, RA Teitelbaum, SL Whyatt, RM Wolff, MS AF Calafat, Antonia M. Koch, Holger M. Swan, Shanna H. Hauser, Russ Goldman, Lynn R. Lanphear, Bruce P. Longnecker, Matthew P. Rudel, Ruthann A. Teitelbaum, Susan L. Whyatt, Robin M. Wolff, Mary S. TI Misuse of blood serum to assess exposure to bisphenol A and phthalates SO BREAST CANCER RESEARCH LA English DT Letter C1 [Calafat, Antonia M.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Koch, Holger M.] Inst Ruhr Univ Bochum, Inst Prevent & Occupat Med German Social Accid In, D-44789 Bochum, Germany. [Swan, Shanna H.; Teitelbaum, Susan L.; Wolff, Mary S.] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA. [Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Geol, Boston, MA 02115 USA. [Goldman, Lynn R.] George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC 20037 USA. [Lanphear, Bruce P.] British Columbia Childrens Hosp, Vancouver, BC V5Z 3ES, Canada. [Longnecker, Matthew P.] NIEHS, Res Triangle Pk, NC 27709 USA. [Rudel, Ruthann A.] Silent Spring Inst, Durham, MA 02458 USA. [Whyatt, Robin M.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10032 USA. RP Wolff, MS (reprint author), Icahn Sch Med Mt Sinai, Dept Prevent Med, 1 Gustave L Levy Pl,Box 1057, New York, NY 10029 USA. EM mary.wolff@mssm.edu RI Koch, Holger/B-3277-2011; OI Koch, Holger/0000-0002-8328-2837; Longnecker, Matthew/0000-0001-6073-5322 FU NIEHS NIH HHS [U01 ES019454] NR 6 TC 38 Z9 38 U1 3 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-542X EI 1465-5411 J9 BREAST CANCER RES JI Breast Cancer Res. PY 2013 VL 15 IS 5 AR 403 DI 10.1186/bcr3494 PG 2 WC Oncology SC Oncology GA 290NA UT WOS:000329763800041 PM 24083327 ER PT J AU Ma, HY Lu, YN Marchbanks, PA Folger, SG Strom, BL McDonald, JA Simon, MS Weiss, LK Malone, KE Burkman, RT Sullivan-Halley, J Deapen, DM Press, MF Bernstein, L AF Ma, Huiyan Lu, Yani Marchbanks, Polly A. Folger, Suzanne G. Strom, Brian L. McDonald, Jill A. Simon, Michael S. Weiss, Linda K. Malone, Kathleen E. Burkman, Ronald T. Sullivan-Halley, Jane Deapen, Dennis M. Press, Michael F. Bernstein, Leslie TI Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women SO BREAST CANCER RESEARCH LA English DT Article ID PROGESTERONE-RECEPTOR; REPRODUCTIVE EXPERIENCES; PROLIFERATIVE ACTIVITY; ENDOCRINE THERAPY; SURVIVAL; RECURRENCE; TAMOXIFEN; BIOMARKERS; CARCINOMA; PATHOLOGY AB Introduction: The association of breast cancer patients' mortality with estrogen receptor (ER) status (ER + versus ER-) has been well studied. However, little attention has been paid to the relationship between the quantitative measures of ER expression and mortality. Methods: We evaluated the association between semi-quantitative, immunohistochemical staining of ER in formalinfixed paraffin-embedded breast carcinomas and breast cancer-specific mortality risk in an observational cohort of invasive breast cancer in 681 white women and 523 black women ages 35-64 years at first diagnosis of invasive breast cancer, who were followed for a median of 10 years. The quantitative measures of ER examined here included the percentage of tumor cell nuclei positively stained for ER, ER Histo (H)-score, and a score based on an adaptation of an equation presented by Cuzick and colleagues, which combines weighted values of ER H-score, percentage of tumor cell nuclei positively stained for the progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) results. This is referred to as the ER/PR/HER2 score. Results: After controlling for age at diagnosis, race, study site, tumor stage, and histologic grade in multivariable Cox proportional hazards regression models, both percentage of tumor cell nuclei positively stained for ER (Ptrend = 0.0003) and the ER H-score (Ptrend = 0.0004) were inversely associated with breast cancer-specific mortality risk. The ER/PR/HER2 score was positively associated with breast cancer-specific mortality risk in women with ER + tumor (Ptrend = 0.001). Analyses by race revealed that ER positivity was associated with reduced risk of breast cancer-specific mortality in white women and black women. The two quantitative measures for ER alone provided additional discrimination in breast cancer-specific mortality risk only among white women with ER + tumors (both Ptrend = 0.01) while the ER/PR/HER2 score provided additional discrimination for both white women (Ptrend = 0.01) and black women (Ptrend = 0.03) with ER + tumors. Conclusions: Our data support quantitative immunohistochemical measures of ER, especially the ER/PR/HER2 score, as a more precise predictor for breast cancer-specific mortality risk than a simple determination of ER positivity. C1 [Ma, Huiyan; Lu, Yani; Sullivan-Halley, Jane; Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Div Canc Etiol, Duarte, CA 91010 USA. [Marchbanks, Polly A.; Folger, Suzanne G.; McDonald, Jill A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. [Strom, Brian L.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Simon, Michael S.] Wayne State Univ, Dept Oncol, Karmanos Canc Inst, Detroit, MI 48201 USA. [Weiss, Linda K.] NCI, Canc Ctr Branch, Bethesda, MD 20892 USA. [Malone, Kathleen E.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Burkman, Ronald T.] Baystate Med Ctr, Dept Obstet & Gynecol, Springfield, MA 01199 USA. [Deapen, Dennis M.] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90033 USA. [Press, Michael F.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA. RP Ma, HY (reprint author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Div Canc Etiol, Duarte, CA 91010 USA. EM hma@coh.org FU National Institute for Child Health and Human Development [NO1-HD-3-3175]; National Cancer Institute [K05-CA136967]; National Institute of Child Health and Human Development; National Cancer Institute, NIH FX The authors would like to thank Dr Karen Petrosyan, Armine Arakelyan, Hasmik Toumaian, and Judith Udove for technical assistance in the performance of the immunohistochemical assays for this study. They would also like to thank collaborators who contributed to the development and conduct of the Women's CARE Study but who did not directly contribute to the current study. This work was supported by National Institute for Child Health and Human Development grant NO1-HD-3-3175 and National Cancer Institute grant K05-CA136967. Data collection for the Women's CARE Study was supported by the National Institute of Child Health and Human Development and National Cancer Institute, NIH, through contracts with Emory University (N01-HD-3-3168), Fred Hutchinson Cancer Research Center (N01-HD-2-3166), Karmanos Cancer Institute at Wayne State University (N01-HD-3-3174), University of Pennsylvania (NO1-HD-3-3276), and University of Southern California (N01-HD-3-3175) and Interagency Agreement with Centers for Disease Control and Prevention (Y01-HD-7022). Collection of cancer incidence data in LA County by University of Southern California was supported by California Department of Health Services as part of statewide cancer reporting program mandated by California Health and Safety Code, Section 103885. Support for use of SEER cancer registries through contracts N01-CN-65064 (Detroit) and N01-PC-67010 (LA). Biomarker determination and analyses were supported by a contract from the National Institute of Child Health and Human Development (NO1-HD-3-3175) and a grant from the Breast Cancer Research Foundation (MFPress). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 37 TC 4 Z9 4 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-542X EI 1465-5411 J9 BREAST CANCER RES JI Breast Cancer Res. PY 2013 VL 15 IS 5 AR R90 DI 10.1186/bcr3486 PG 12 WC Oncology SC Oncology GA 290NA UT WOS:000329763800018 PM 24070170 ER PT J AU Razzaghi, H Troester, MA Gierach, GL Olshan, AF Yankaskas, BC Millikan, RC AF Razzaghi, Hilda Troester, Melissa A. Gierach, Gretchen L. Olshan, Andrew F. Yankaskas, Bonnie C. Millikan, Robert C. TI Association between mammographic density and basal-like and luminal A breast cancer subtypes SO BREAST CANCER RESEARCH LA English DT Article DE Mammographic density; Breast cancer; Subtypes; Basal-like; Epidemiology ID ESTROGEN-RECEPTOR STATUS; BODY-MASS INDEX; TUMOR CHARACTERISTICS; RISK-FACTORS; MOLECULAR SUBTYPES; PARENCHYMAL PATTERNS; POSTMENOPAUSAL WOMEN; MULTIETHNIC COHORT; RECORD LINKAGE; ETHNIC-GROUPS AB Introduction: Mammographic density is a strong risk factor for breast cancer overall, but few studies have examined the association between mammographic density and specific subtypes of breast cancer, especially aggressive basal-like breast cancers. Because basal-like breast cancers are less frequently screen-detected, it is important to understand how mammographic density relates to risk of basal-like breast cancer. Methods: We estimated associations between mammographic density and breast cancer risk according to breast cancer subtype. Cases and controls were participants in the Carolina Breast Cancer Study (CBCS) who also had mammograms recorded in the Carolina Mammography Registry (CMR). A total of 491 cases had mammograms within five years prior to and one year after diagnosis and 528 controls had screening or diagnostic mammograms close to the dates of selection into CBCS. Mammographic density was reported to the CMR using Breast Imaging Reporting and Data System categories. The expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 1 and 2 (HER1 and HER2), and cytokeratin 5/6 (CK5/6) were assessed by immunohistochemistry and dichotomized as positive or negative, with ER+ and/or PR+, and HER2-tumors classified as luminal A and ER-, PR-, HER2-, HER1+ and/or CK5/6+ tumors classified as basal-like breast cancer. Triple negative tumors were defined as negative for ER, PR and HER2. Of the 491 cases 175 were missing information on subtypes; the remaining cases included 181 luminal A, 17 luminal B, 48 basal-like, 29 ER-/PR-/HER2+, and 41 unclassified subtypes. Odds ratios comparing each subtype to all controls and case-case odds ratios comparing mammographic density distributions in basal-like to luminal A breast cancers were estimated using logistic regression. Results: Mammographic density was associated with increased risk of both luminal A and basal-like breast cancers, although estimates were imprecise. The magnitude of the odds ratio associated with mammographic density was not substantially different between basal-like and luminal A cancers in case-control analyses and case-case analyses (case-case OR = 1.08 (95% confidence interval: 0.30, 3.84)). Conclusions: These results suggest that risk estimates associated with mammographic density are not distinct for separate breast cancer subtypes (basal-like/triple negative vs. luminal A breast cancers). Studies with a larger number of basal-like breast cancers are needed to confirm our findings. C1 [Razzaghi, Hilda; Troester, Melissa A.; Olshan, Andrew F.; Millikan, Robert C.] Univ N Carolina, Dept Epidemiol, Gillings Global Sch Publ Hlth, Chapel Hill, NC 27514 USA. [Troester, Melissa A.; Olshan, Andrew F.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Gierach, Gretchen L.] NCI, Hormonal & Reprod Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA. [Yankaskas, Bonnie C.] Univ N Carolina, Sch Med, Dept Radiol, Chapel Hill, NC 27514 USA. [Razzaghi, Hilda] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30345 USA. RP Razzaghi, H (reprint author), Univ N Carolina, Dept Epidemiol, Gillings Global Sch Publ Hlth, Chapel Hill, NC 27514 USA. EM hrazzaghi@cdc.gov RI Gierach, Gretchen/E-1817-2016 OI Gierach, Gretchen/0000-0002-0165-5522 FU Intramural Research Program of the NIH; National Cancer Institute; National Institute Breast Cancer and the Environment Research Program [5U01ES019472-02]; NCI [5R01CA138255]; SPORE in Breast Cancer [5P50CA058233] FX The authors are grateful to Jessica Tse and Robert Christopher Allis for their assistance with data management and data analysis for this manuscript. This research was supported (in part) by the Intramural Research Program of the NIH and the National Cancer Institute. MAT was supported by the National Institute Breast Cancer and the Environment Research Program 5U01ES019472-02 and NCI grant 5R01CA138255. MAT is also supported by a SPORE in Breast Cancer 5P50CA058233. NR 76 TC 6 Z9 7 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-542X EI 1465-5411 J9 BREAST CANCER RES JI Breast Cancer Res. PY 2013 VL 15 IS 5 AR R76 DI 10.1186/bcr3470 PG 10 WC Oncology SC Oncology GA 290NA UT WOS:000329763800004 PM 24008056 ER PT J AU O'Connor, AC Gallaher, MP Loomis, RJ Casey, SE AF O'Connor, Alan C. Gallaher, Michael P. Loomis, Ross J. Casey, Sara E. BE Link, AN Vonortas, NS TI Estimating avoided environmental emissions and environmental health benefits SO HANDBOOK ON THE THEORY AND PRACTICE OF PROGRAM EVALUATION LA English DT Article; Book Chapter ID PARTICULATE AIR-POLLUTION; RESPIRATORY SYMPTOMS; HOSPITAL ADMISSIONS; FINE PARTICLES; POLLUTANTS; MORBIDITY; CHILDREN; SEATTLE C1 [O'Connor, Alan C.; Gallaher, Michael P.] RTI, Environm Technol & Energy Econ Program, Res Triangle Pk, NC 27709 USA. [O'Connor, Alan C.; Gallaher, Michael P.; Loomis, Ross J.] NIST, Gaithersburg, MD USA. [O'Connor, Alan C.] US DOE, Washington, DC 20585 USA. [O'Connor, Alan C.; Gallaher, Michael P.; Loomis, Ross J.] US EPA, Res Triangle Pk, NC USA. [O'Connor, Alan C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gallaher, Michael P.] NSF, Arlington, VA USA. [Gallaher, Michael P.] NTIA, Washington, DC USA. [Loomis, Ross J.] RTI, Global Climate Change & Environm Sci Div, Res Triangle Pk, NC USA. [Loomis, Ross J.] Natl Pk Serv, Washington, DC USA. [Casey, Sara E.] RTI Int, Environm Technol & Energy Econ Program, Res Triangle Pk, NC USA. RP O'Connor, AC (reprint author), RTI, Environm Technol & Energy Econ Program, Res Triangle Pk, NC 27709 USA. NR 44 TC 0 Z9 0 U1 0 U2 0 PU EDWARD ELGAR PUBLISHING LTD PI CHELTENHAM PA GLENSANDA HOUSE, MONTPELLIER PARADE, CHELTENHAM GL50 1UA, GLOS, ENGLAND BN 978-0-85793-239-6 PY 2013 BP 247 EP 290 PG 44 WC Economics SC Business & Economics GA BJL29 UT WOS:000328820800009 ER PT J AU M'ikanatha, NM Lynfield, R Julian, KG Van Beneden, CA de Valk, H AF M'ikanatha, Nkuchia M. Lynfield, Ruth Julian, Kathleen G. Van Beneden, Chris A. de Valk, Henriette BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Infectious disease surveillance: a cornerstone for prevention and control SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID NEW-YORK-CITY; UNITED-STATES; CRYPTOCOCCUS-GATTII; OUTBREAK C1 [M'ikanatha, Nkuchia M.] Penn Dept Hlth, Div Infect Dis Epidemiol, Harrisburg, PA 17108 USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Julian, Kathleen G.] Penn State Coll Med, Hershey, PA USA. [Van Beneden, Chris A.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. [de Valk, Henriette] Inst Veille Sanit, Infect Dis Dept, St Maurice, France. RP M'ikanatha, NM (reprint author), Penn Dept Hlth, Div Infect Dis Epidemiol, Harrisburg, PA 17108 USA. NR 52 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 3 EP 20 D2 10.1002/9781118543504 PG 18 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500006 ER PT J AU Thacker, SB Coulombier, DM AF Thacker, Stephen B. Coulombier, Denis M. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Infectious Disease Surveillance Second Edition Foreword SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Editorial Material; Book Chapter C1 [Thacker, Stephen B.] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Coulombier, Denis M.] European Ctr Dis Prevent & Control, Surveillance & Response Support Unit, Stockholm, Sweden. RP Thacker, SB (reprint author), Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP XIX EP XX D2 10.1002/9781118543504 PG 2 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500001 ER PT J AU Thacker, SB Stroup, DF AF Thacker, Stephen B. Stroup, Donna F. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Origins and progress in surveillance systems SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID PUBLIC-HEALTH SURVEILLANCE; UNITED-STATES; DISEASE SURVEILLANCE; COMMUNICABLE DISEASES; POLIOMYELITIS; ABERRATIONS C1 [Thacker, Stephen B.] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Stroup, Donna F.] Data Solut Inc, Decatur, GA USA. RP Thacker, SB (reprint author), Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. NR 54 TC 2 Z9 2 U1 0 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 21 EP 31 D2 10.1002/9781118543504 PG 11 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500007 ER PT J AU M'ikanatha, NM Lynfield, R Van Beneden, CA de Valk, H AF M'ikanatha, Nkuchia M. Lynfield, Ruth Van Beneden, Chris A. de Valk, Henriette BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Infectious Disease Surveillance Preface to Second Edition SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Editorial Material; Book Chapter C1 [M'ikanatha, Nkuchia M.] Penn Dept Hlth, Div Infect Dis Epidemiol, Harrisburg, PA 17108 USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Van Beneden, Chris A.] Ctr Dis Control & Prevent, Resp Dis Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [de Valk, Henriette] Inst Veille Sanit, Dept Infect Dis, St Maurice, France. RP M'ikanatha, NM (reprint author), Penn Dept Hlth, Div Infect Dis Epidemiol, Harrisburg, PA 17108 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP XXIII EP XXIV D2 10.1002/9781118543504 PG 2 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500003 ER PT J AU M'ikanatha, NM Lynfield, R Van Beneden, C de Valk, H AF M'ikanatha, Nkuchia M. Lynfield, Ruth Van Beneden, Chris de Valk, Henriette BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Infectious Disease Surveillance Preface to First Edition SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Editorial Material; Book Chapter C1 [M'ikanatha, Nkuchia M.] Penn Dept Hlth, Div Infect Dis Epidemiol, Harrisburg, PA 17108 USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Van Beneden, Chris] Ctr Dis Control & Prevent, Resp Dis Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [de Valk, Henriette] Inst Veille Sanit, Dept Infect Dis, St Maurice, France. RP M'ikanatha, NM (reprint author), Penn Dept Hlth, Div Infect Dis Epidemiol, Harrisburg, PA 17108 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP XXV EP XXVI D2 10.1002/9781118543504 PG 2 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500004 ER PT J AU Potter, P AF Potter, Polyxeni BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Weighing of the Heart SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Editorial Material; Book Chapter C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP XXVIII EP XXX D2 10.1002/9781118543504 PG 3 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500005 ER PT J AU Makoy, S Becknell, SR Jones, AH Waat, G Ruiz-tiben, E Hopkins, DR AF Makoy, Samuel Becknell, Steven R. Jones, Alexander H. Waat, Gabriel Ruiz-tiben, Ernesto Hopkins, Donald R. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Use of surveillance in disease eradication efforts PART 2: Lessons learned in Guinea worm disease (dracunculiasis) eradication SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter C1 [Makoy, Samuel] Minist Health Republ South Sudan, Directorate Publ Hlth, Southern Sudan Guinea Worm Eradicat Program, Juba, Sudan. [Becknell, Steven R.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Publ Hlth Syst & Workforce Dev, Atlanta, GA USA. [Jones, Alexander H.; Waat, Gabriel; Ruiz-tiben, Ernesto; Hopkins, Donald R.] Carter Ctr Hlth Programs, Atlanta, GA USA. RP Makoy, S (reprint author), Minist Health Republ South Sudan, Directorate Publ Hlth, Southern Sudan Guinea Worm Eradicat Program, Juba, Sudan. NR 8 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 41 EP 53 D2 10.1002/9781118543504 PG 13 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500009 ER PT J AU Van Beneden, CA Arvay, M Thamthitiwat, S Lynfield, R AF Van Beneden, Chris A. Arvay, Melissa Thamthitiwat, Somsak Lynfield, Ruth BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Active, population-based surveillance for infectious diseases SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID B STREPTOCOCCAL DISEASE; RURAL THAILAND; PNEUMONIA; INFLUENZA C1 [Van Beneden, Chris A.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30333 USA. [Arvay, Melissa] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, Atlanta, GA USA. [Thamthitiwat, Somsak] Thailand Minist Publ Health US CDC Collaborat, Int Emerging Infect Program, Nonthaburi, Thailand. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. RP Van Beneden, CA (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30333 USA. NR 21 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 95 EP 108 D2 10.1002/9781118543504 PG 14 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500013 ER PT J AU Scallan, E Mahon, B Wong, DL AF Scallan, Elaine Mahon, Barbara Wong, Danilo Lo Fo BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Surveillance for foodborne diseases PART 1: Approaches to surveillance for foodborne diseases SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID PUBLIC-HEALTH; UNITED-STATES; FOOD; SALMONELLA; INFECTIONS; ILLNESS; BURDEN; GASTROENTERITIS; PATHOGENS; OUTBREAKS C1 [Scallan, Elaine] Univ Colorado Denver, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. [Mahon, Barbara] Ctr Dis Control & Prevent, Natl Ctr Emerging Zoonot Infect Dis, Atlanta, GA USA. [Wong, Danilo Lo Fo] World Hlth Org Reg Off Europe, Div Communicable Dis Hlth Secur & Environm, Geneva, Switzerland. RP Scallan, E (reprint author), Univ Colorado Denver, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. NR 22 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 109 EP 119 D2 10.1002/9781118543504 PG 11 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500014 ER PT J AU Whichard, JM Gay, K Tate, H Chiller, TM AF Whichard, Jean M. Gay, Kathryn Tate, Heather Chiller, Tom M. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Surveillance for foodborne diseases PART 3: Surveillance for antimicrobial resistance among foodborne bacteria-the US approach SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID UNITED-STATES; VETERINARY-MEDICINE; ESCHERICHIA-COLI; FOOD ANIMALS; SALMONELLA; INFECTIONS; SUSCEPTIBILITY; CAMPYLOBACTER; HUMANS C1 [Whichard, Jean M.; Chiller, Tom M.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Gay, Kathryn] Philadelphia Anim Welf Soc, Philadelphia, PA USA. [Tate, Heather] US FDA, Ctr Vet Med, Laurel, MD USA. RP Whichard, JM (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. NR 39 TC 0 Z9 0 U1 1 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 129 EP 142 D2 10.1002/9781118543504 PG 14 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500016 ER PT J AU Petersen, LR Hadler, JL AF Petersen, Lyle R. Hadler, James L. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Surveillance for vector-borne diseases SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID WEST-NILE-VIRUS; NEW-YORK-STATE; DEAD BIRD SURVEILLANCE; LYME-DISEASE; PUBLIC-HEALTH; USUTU-VIRUS; INFECTION; CONNECTICUT; CALIFORNIA; MOSQUITOS C1 [Petersen, Lyle R.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Hadler, James L.] Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Progam, New Haven, CT USA. RP Petersen, LR (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. NR 57 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 157 EP 173 D2 10.1002/9781118543504 PG 17 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500018 ER PT J AU Iskander, JK Zheteyeva, Y AF Iskander, John K. Zheteyeva, Yenlik BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Public health surveillance for vaccine adverse events SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID GUILLAIN-BARRE-SYNDROME; REPORTING-SYSTEM VAERS; A H1N1 2009; SAFETY DATALINK PROJECT; UNITED-STATES; ROTAVIRUS VACCINATION; SMALLPOX VACCINATION; MONOVALENT VACCINES; ACTIVE SURVEILLANCE; INFLUENZA VACCINE C1 [Iskander, John K.] Ctr Dis Control & Prevent, Off Associate Director Sci, Atlanta, GA 30333 USA. [Zheteyeva, Yenlik] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Iskander, JK (reprint author), Ctr Dis Control & Prevent, Off Associate Director Sci, Atlanta, GA 30333 USA. NR 87 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 187 EP 199 D2 10.1002/9781118543504 PG 13 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500020 ER PT J AU Brammer, L Budd, AP Finelli, L AF Brammer, Lynnette Budd, Alicia P. Finelli, Lyn BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Seasonal and pandemic influenza surveillance SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID UNITED-STATES; ADAMANTANE RESISTANCE; MORTALITY; CHILDREN; VIRUS; HOSPITALIZATION; TRANSMISSION; EPIDEMICS; ILLNESS; DISEASE C1 [Brammer, Lynnette; Budd, Alicia P.; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. RP Brammer, L (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. NR 24 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 200 EP 210 D2 10.1002/9781118543504 PG 11 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500021 ER PT J AU Danila, RN Fleischauer, AT AF Danila, Richard N. Fleischauer, Aaron T. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Surveillance for agents of bioterrorism in the USA SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID NEW-YORK-CITY; SYNDROMIC SURVEILLANCE; UNITED-STATES; INFECTIOUS-DISEASE; PUBLIC-HEALTH; BIOLOGICAL TERRORISM; PREPAREDNESS; ANTHRAX; OUTBREAK; CONTAMINATION C1 [Danila, Richard N.] Minnesota Dept Hlth, St Paul, MN 55164 USA. [Fleischauer, Aaron T.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. RP Danila, RN (reprint author), Minnesota Dept Hlth, St Paul, MN 55164 USA. NR 44 TC 0 Z9 0 U1 0 U2 2 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 211 EP 222 D2 10.1002/9781118543504 PG 12 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500022 ER PT J AU Lynfield, R Nolte, KB Schmitz, AM Fischer, M AF Lynfield, Ruth Nolte, Kurt B. Schmitz, Ann M. Fischer, Marc BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Surveillance for unexplained infectious disease-related deaths SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID MEDICAL EXAMINER SURVEILLANCE; UNITED-STATES; MED-X; BIOTERRORISM; PATHOLOGY; MODEL C1 [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN 55164 USA. [Nolte, Kurt B.] Univ New Mexico Sch Med, Off Med Investigator, Albuquerque, NM USA. [Schmitz, Ann M.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. [Fischer, Marc] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO USA. RP Lynfield, R (reprint author), Minnesota Dept Hlth, St Paul, MN 55164 USA. NR 18 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 223 EP 233 D2 10.1002/9781118543504 PG 11 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500023 ER PT J AU Gastmeier, P Coignard, B Horan, TC AF Gastmeier, Petra Coignard, Bruno Horan, Teresa C. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Surveillance for healthcare-associated infections SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID NOSOCOMIAL INFECTIONS; HOSPITALS; NETWORK; FRANCE; SYSTEM; SAFETY; UNITS C1 [Gastmeier, Petra] Charite, Inst Hyg & Environm Med, D-13353 Berlin, Germany. [Coignard, Bruno] Inst Veille Sanit, Infect Dis Dept, St Maurice, France. [Horan, Teresa C.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Atlanta, GA USA. RP Gastmeier, P (reprint author), Charite, Inst Hyg & Environm Med, D-13353 Berlin, Germany. NR 37 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 248 EP 260 D2 10.1002/9781118543504 PG 13 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500025 ER PT J AU Kuehnert, MJ Wise, RP Holmberg, JA AF Kuehnert, Matthew J. Wise, Robert P. Holmberg, Jerry A. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Biovigilance: designing and implementing surveillance systems for the safety and quality of blood, organs, and tissues SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID RESISTANT STREPTOCOCCUS-PNEUMONIAE; UNITED-STATES; EUROPEAN COUNTRIES; STAPHYLOCOCCUS-AUREUS; ANTIBIOTIC-RESISTANCE; ANTIBIOGRAMS; PREVALENCE; HOSPITALS C1 [Kuehnert, Matthew J.] Ctr Dis Control & Prevent, Off Blood Organ & Other Tissue Safety, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Wise, Robert P.] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA. [Holmberg, Jerry A.] Dept Hlth & Human Serv, Off Publ Hlth & Sci, Rockville, MD USA. RP Kuehnert, MJ (reprint author), Ctr Dis Control & Prevent, Off Blood Organ & Other Tissue Safety, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. NR 38 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 261 EP 287 D2 10.1002/9781118543504 PG 27 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500026 ER PT J AU Mokotoff, ED Shouse, RL AF Mokotoff, Eve D. Shouse, R. Luke BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Surveillance for human immunodeficiency virus infection in the USA SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID HIV BEHAVIORAL SURVEILLANCE; RISK; AIDS; HIV/AIDS; EPIDEMIC C1 [Mokotoff, Eve D.] Michigan Dept Community Hlth, Detroit, MI USA. [Shouse, R. Luke] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Mokotoff, ED (reprint author), Michigan Dept Community Hlth, Detroit, MI USA. NR 36 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 304 EP 316 D2 10.1002/9781118543504 PG 13 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500028 ER PT J AU Imtiaz, R Garg, R Bhattacharya, M AF Imtiaz, Rubina Garg, Renu Bhattacharya, Madhulekha BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Surveillance for human immunodeficiency virus/acquired immunodeficiency syndrome for countries in transition PART 1: Surveillance for human immunodeficiency virus/acquired immunodeficiency syndrome in India SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID HIV/AIDS EPIDEMIC; PREVENTION; WORLD C1 [Imtiaz, Rubina] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Garg, Renu] WHO SEARO, Dept Communicable Dis, HIV Unit, N Delhi, India. [Bhattacharya, Madhulekha] Natl Inst Hlth & Family Welfare, N Delhi, India. RP Imtiaz, R (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 317 EP 326 D2 10.1002/9781118543504 PG 10 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500029 ER PT J AU Kissin, DM Vitek, CR Voronin, E Hillis, SD AF Kissin, Dmitry M. Vitek, Charles R. Voronin, Evgeny Hillis, Susan D. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Surveillance for human immunodeficiency virus/acquired immunodeficiency syndrome for countries in transition PART 2: Surveillance for human immunodeficiency virus/acquired immunodeficiency syndrome in Russia SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID ST-PETERSBURG; ANTIRETROVIRAL PROPHYLAXIS; HIV C1 [Kissin, Dmitry M.; Hillis, Susan D.] Ctr Dis Control & Prevent, Off Noncommunicable Dis Injury & Environm Hlth, Atlanta, GA 30333 USA. [Vitek, Charles R.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. [Voronin, Evgeny] Res & Clin Ctr HIV Prevent & Treatment Pregnant W, St Petersburg, Russia. RP Kissin, DM (reprint author), Ctr Dis Control & Prevent, Off Noncommunicable Dis Injury & Environm Hlth, Atlanta, GA 30333 USA. NR 16 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 327 EP 333 D2 10.1002/9781118543504 PG 7 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500030 ER PT J AU Groseclose, SL Samuel, MC Chow, JM Weinstock, H AF Groseclose, Samuel L. Samuel, Michael C. Chow, Joan M. Weinstock, Hillard BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Surveillance for sexually transmitted diseases SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID CHLAMYDIA-TRACHOMATIS INFECTIONS; PELVIC-INFLAMMATORY-DISEASE; UNITED-STATES; STD SURVEILLANCE; GONORRHEA RATES; INSURED WOMEN; PREVALENCE; SYPHILIS; TRENDS; CORE C1 [Groseclose, Samuel L.] Ctr Dis Control & Prevent, Off Sci & Publ Hlth Practice, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Samuel, Michael C.; Chow, Joan M.] Calif Dept Publ Hlth, Sexually Transmitted Dis Control Branch, Richmond, CA USA. [Weinstock, Hillard] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Groseclose, SL (reprint author), Ctr Dis Control & Prevent, Off Sci & Publ Hlth Practice, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. NR 57 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 343 EP 360 D2 10.1002/9781118543504 PG 18 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500032 ER PT J AU Kohl, KS Rodriguez-Lainz, A AF Kohl, Katrin S. Rodriguez-Lainz, Alfonso BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Infectious disease surveillance in globally mobile populations SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID ILL RETURNED TRAVELERS; US-BOUND IMMIGRANTS; HARD-TO-REACH; HIDDEN POPULATIONS; HEALTH; TUBERCULOSIS; REFUGEES; MEXICO; CHALLENGES; KNOWLEDGE C1 [Kohl, Katrin S.; Rodriguez-Lainz, Alfonso] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Kohl, KS (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. NR 46 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 376 EP 387 D2 10.1002/9781118543504 PG 12 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500034 ER PT J AU Tolentino, HD Brownstein, JS Massoudi, BL Massoudi, MS AF Tolentino, Herman D. Brownstein, John S. Massoudi, Barbara L. Massoudi, Mehran S. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Mobile technology for infectious disease surveillance SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID PUBLIC-HEALTH SURVEILLANCE; SYSTEM; PHONES C1 [Tolentino, Herman D.; Massoudi, Mehran S.] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Brownstein, John S.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA. [Massoudi, Barbara L.] RTI Int, Ctr Adv Hlth IT, Atlanta, GA USA. RP Tolentino, HD (reprint author), Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. NR 26 TC 0 Z9 0 U1 0 U2 2 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 447 EP 456 D2 10.1002/9781118543504 PG 10 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500040 ER PT J AU Besser, JM AF Besser, John M. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Use of molecular epidemiology in infectious disease surveillance SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID FIELD GEL-ELECTROPHORESIS; RESISTANT STAPHYLOCOCCUS-AUREUS; MICROBIAL PAN-GENOME; UNITED-STATES; PUBLIC-HEALTH; INFLUENZA-VIRUSES; GROUP-A; OUTBREAK; SALMONELLA; STREPTOCOCCUS C1 Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Besser, JM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. NR 61 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 485 EP 501 D2 10.1002/9781118543504 PG 17 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500043 ER PT J AU Perilla, MJ Zell, ER AF Perilla, Mindy J. Zell, Elizabeth R. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Software applications, resources, and introduction to statistical analysis PART 2: Analysis and interpretation of reportable infectious disease data SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter C1 [Perilla, Mindy J.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Zell, Elizabeth R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Perilla, MJ (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. NR 24 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 508 EP 521 D2 10.1002/9781118543504 PG 14 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500045 ER PT J AU Lee, LM Rutherford, GW AF Lee, Lisa M. Rutherford, George W. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Analysis and interpretation of case-based infectious disease surveillance data: human immunodeficiency virus-related morbidity and mortality surveillance in the USA SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID UNITED-STATES; HIV-INFECTION; KAPOSIS-SARCOMA; RISK; AIDS; SYSTEM; REDISTRIBUTION; COMPLETENESS; DIAGNOSES; EPIDEMIC C1 [Lee, Lisa M.] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Rutherford, George W.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Lee, LM (reprint author), Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. NR 40 TC 0 Z9 0 U1 0 U2 2 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 522 EP 534 D2 10.1002/9781118543504 PG 13 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500046 ER PT J AU Mak, S Eisen, RJ AF Mak, Sunny Eisen, Rebecca J. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Geospatial technologies and spatial data analysis PART 2: Use of geographic information systems and spatial analysis in infectious disease surveillance in North America and East Africa SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID SOUTHWESTERN UNITED-STATES; VECTOR-BORNE DISEASES; CRYPTOCOCCUS-GATTII; HUMAN PLAGUE; PACIFIC-NORTHWEST; BRITISH-COLUMBIA; RISK; MODELS; PREVENTION; EXPOSURE C1 [Mak, Sunny] British Columbia Ctr Dis Control, Epidemiol Serv, Vancouver, BC, Canada. [Eisen, Rebecca J.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging Zoonot Infect Dis, Ft Collins, CO USA. RP Mak, S (reprint author), British Columbia Ctr Dis Control, Epidemiol Serv, Vancouver, BC, Canada. NR 30 TC 0 Z9 0 U1 0 U2 2 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 558 EP 564 D2 10.1002/9781118543504 PG 7 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500049 ER PT J AU Groseclose, SL Buckeridge, DL Buehler, JW AF Groseclose, Samuel L. Buckeridge, David L. Buehler, James W. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Evaluation of syndromic surveillance systems that use healthcare data SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID AUTOMATED SURVEILLANCE; DIAGNOSES; OUTBREAK C1 [Groseclose, Samuel L.] Ctr Dis Control & Prevent, Off Sci & Publ Hlth Practice, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Buckeridge, David L.] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada. [Buehler, James W.] Ctr Dis Control & Prevent, Publ Hlth Surveillance & Informat Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. RP Groseclose, SL (reprint author), Ctr Dis Control & Prevent, Off Sci & Publ Hlth Practice, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. NR 38 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 565 EP 579 D2 10.1002/9781118543504 PG 15 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500050 ER PT J AU Hoffman, RE Shaw, FE AF Hoffman, Richard E. Shaw, Frederic E. BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Legal basis for infectious disease surveillance and control in the USA SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID PUBLIC-HEALTH; ACT C1 [Hoffman, Richard E.] Colorado Sch Publ Hlth, Denver, CO 80202 USA. [Shaw, Frederic E.] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. RP Hoffman, RE (reprint author), Colorado Sch Publ Hlth, Denver, CO 80202 USA. NR 27 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 583 EP 595 D2 10.1002/9781118543504 PG 13 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500051 ER PT J AU Southwell, BG Reynolds, BJ Fowlie, K AF Southwell, Brian G. Reynolds, Barbara J. Fowlie, Kate BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Communication in infectious disease surveillance PART 1: Communication, mass media relations, and infectious disease surveillance SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID RISK COMMUNICATION; HEALTH-EDUCATION; TELEVISION; INTERVENTIONS; COVERAGE; VACCINE; THREAT; CRISIS; ATTACK; MODEL C1 [Southwell, Brian G.] RTI Int, Res Triangle Pk, NC USA. [Southwell, Brian G.] Univ North Carolina Chapel Hill, Res Triangle Pk, NC USA. [Reynolds, Barbara J.] Ctr Dis Control & Prevent, Off Associate Director Commun, Atlanta, GA USA. [Fowlie, Kate] Contra Costa Hlth Serv, Martinez, CA USA. RP Southwell, BG (reprint author), RTI Int, Res Triangle Pk, NC USA. NR 28 TC 3 Z9 3 U1 0 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 607 EP 617 D2 10.1002/9781118543504 PG 11 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500053 ER PT J AU Koo, D Hamilton, DH Bosman, A AF Koo, Denise Hamilton, Douglas H. Bosman, Arnold BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Training in infectious disease surveillance: contributions of the Epidemic Intelligence Service and European field epidemiology training programs SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID PUBLIC-HEALTH SURVEILLANCE; EARLY WARNING SYSTEM; CAT-SCRATCH-DISEASE; WEST-NILE-VIRUS; UNITED-STATES; SHIGELLA SURVEILLANCE; CONNECTICUT; TENNESSEE C1 [Koo, Denise; Hamilton, Douglas H.] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Bosman, Arnold] European Ctr Dis Prevent & Control, Publ Hlth Training Sect, Stockholm, Sweden. RP Koo, D (reprint author), Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. RI Bosman, Arnold/G-9107-2016 OI Bosman, Arnold/0000-0002-8662-7773 NR 37 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 623 EP 635 D2 10.1002/9781118543504 PG 13 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500055 ER PT J AU Jhung, MA Brammer, L Finelli, L AF Jhung, Michael A. Brammer, Lynnette Finelli, Lyn BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI 2009 pandemic influenza A (H1N1) surveillance in the USA SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter ID SCHOOL-BASED OUTBREAK; APRIL-MAY 2009; PREGNANT-WOMEN; UNITED-STATES; HOUSEHOLD TRANSMISSION; SERIAL INTERVAL; VIRUS; ILLNESS; HOSPITALIZATIONS; ILLINOIS C1 [Jhung, Michael A.; Brammer, Lynnette; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. RP Jhung, MA (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. NR 48 TC 0 Z9 0 U1 1 U2 3 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 657 EP 667 D2 10.1002/9781118543504 PG 11 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500058 ER PT J AU Lynfield, R M'ikanatha, NM Van Beneden, CA de Valk, H AF Lynfield, Ruth M'ikanatha, Nkuchia M. Van Beneden, Chris A. de Valk, Henriette BE Mikanatha, NM Lynfield, R VanBeneden, CA DeValk, H TI Future directions in infectious disease surveillance SO INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION LA English DT Article; Book Chapter C1 [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [M'ikanatha, Nkuchia M.] Penn Dept Hlth, Div Infect Dis Epidemiol, Harrisburg, PA 17108 USA. [Van Beneden, Chris A.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. [de Valk, Henriette] Inst Veille Sanit, Infect Dis Dept, St Maurice, France. RP Lynfield, R (reprint author), Minnesota Dept Hlth, St Paul, MN USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-470-65467-5 PY 2013 BP 668 EP 670 D2 10.1002/9781118543504 PG 3 WC Infectious Diseases SC Infectious Diseases GA BJK54 UT WOS:000328679500059 ER PT J AU Poirot, E Skarbinski, J Sinclair, D Kachur, SP Slutsker, L Hwang, J AF Poirot, Eugenie Skarbinski, Jacek Sinclair, David Kachur, S. Patrick Slutsker, Laurence Hwang, Jimee TI Mass drug administration for malaria SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID INTERMITTENT PREVENTIVE TREATMENT; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; WEST-AFRICAN SAVANNA; TREATED BED NETS; SUPPLEMENTARY ATTACK MEASURE; TIMELY HOME TREATMENT; SCHOOL-AGED CHILDREN; SULFADOXINE-PYRIMETHAMINE; RURAL AREA AB Background Mass drug administration (MDA), defined as the empiric administration of a therapeutic antimalarial regimen to an entire population at the same time, has been a historic component of many malaria control and elimination programmes, but is not currently recommended. With renewed interest in MDA and its role in malaria elimination, this review aims to summarize the findings from existing research studies and program experiences of MDA strategies for reducing malaria burden and transmission. Objectives To assess the impact of antimalarial MDA on population asexual parasitaemia prevalence, parasitaemia incidence, gametocytaemia prevalence, anaemia prevalence, mortality and MDA-associated adverse events. Search methods We searched the Cochrane Infectious Disease Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE+, EMBASE, to February 2013. We also searched CABS Abstracts, LILACS, reference lists, and recent conference proceedings. Selection criteria Cluster-randomized trials and non-randomized controlled studies comparing therapeutic MDA versus placebo or no MDA, and uncontrolled before-and-after studies comparing post-MDAto baseline data were selected. Studies administering intermittent preventive treatment (IPT) to sub-populations (for example, pregnant women, children or infants) were excluded. Data collection and analysis Two authors independently reviewed studies for inclusion, extracted data and assessed risk of bias. Studies were stratified by study design and then subgrouped by endemicity, by co-administration of 8-aminoquinoline plus schizonticide drugs and by plasmodium species. The quality of evidence was assessed using the GRADE approach. Main results Two cluster-randomized trials, eight non-randomized controlled studies and 22 uncontrolled before-and-after studies are included in this review. Twenty-two studies (29 comparisons) compared MDA to placebo or no intervention of which two comparisons were conducted in areas of low endemicity (<= 5%), 12 in areas of moderate endemicity (6-39%) and 15 in areas of high endemicity (>= 40%). Ten studies evaluated MDA plus other vector control measures. The studies used a wide variety of MDA regimens incorporating different drugs, dosages, timings and numbers of MDA rounds. Many of the studies are now more than 30 years old. Areas of low endemicity (<= 5%) Within the first month post-MDA, a single uncontrolled before-and-after study conducted in 1955 on a small Taiwanese island reported a much lower prevalence of parasitaemia following a single course of chloroquine compared to baseline (1 study, very low quality evidence). This lower parasite prevalence was still present after more than 12 months (one study, very low quality evidence). In addition, one cluster-randomized trial evaluating MDA in a low endemic setting reported zero episodes of parasitaemia at baseline, and throughout five months of follow-up in both the control and intervention arms (one study, very low quality evidence). Areas of moderate endemicity (6-39%) Within the first month post-MDA, the prevalence of parasitaemia was much lower in three non-randomized controlled studies from Kenya and India in the 1950s (RR 0.03, 95% CI 0.01 to 0.08, three studies, moderate quality evidence), and in three uncontrolled before-and-after studies conducted between 1954 and 1961 (RR 0.29, 95% CI 0.17 to 0.48, three studies, low quality evidence). The longest follow-up in these settings was four to six months. At this time point, the prevalence of parasitaemia remained substantially lower than controls in the two non-randomized controlled studies (RR 0.18, 95% CI 0.10 to 0.33, two studies, low quality evidence). In contrast, the two uncontrolled before-and-after studies found mixed results: one found no difference and one found a substantially higher prevalence compared to baseline (not pooled, two studies, very low quality evidence). Areas of high endemicity (>= 40%) Within the first month post-MDA, the single cluster-randomized trial from the Gambia in 1999 found no significant difference in parasite prevalence (one study, low quality evidence). However, prevalence was much lower during the MDA programmes in three non-randomized controlled studies conducted in the 1960s and 1970s (RR 0.17, 95% CI 0.11 to 0.27, three studies, moderate quality evidence), and within one month of MDA in four uncontrolled before-and-after studies (RR 0.37, 95% CI 0.28 to 0.49, four studies, low quality evidence). Four trials reported changes in prevalence beyond three months. In the Gambia, the single cluster-randomized trial found no difference at five months (one trial, moderate quality evidence). The three uncontrolled before-and-after studies had mixed findings with large studies from Palestine and Cambodia showing sustained reductions at four months and 12 months, respectively, and a small study from Malaysia showing no difference after four to six months of follow-up (three studies, low quality evidence). 8-aminoquinolines We found no studies directly comparing MDA regimens that included 8-aminoquinolines with regimens that did not. In a crude subgroup analysis with a limited number of studies, we were unable to detect any evidence of additional benefit of primaquine in moderate-and high-transmission settings. Plasmodium species In studies that reported species-specific outcomes, the same interventions resulted in a larger impact on Plasmodium falciparum compared to P. vivax. Authors' conclusions MDA appears to reduce substantially the initial risk of malaria parasitaemia. However, few studies showed sustained impact beyond six months post-MDA, and those that did were conducted on small islands or in highland settings. To assess whether there is an impact of MDA on malaria transmission in the longer term requires more quasi experimental studies with the intention of elimination, especially in low-and moderate-transmission settings. These studies need to address any long-term outcomes, any potential barriers for community uptake, and contribution to the development of drug resistance. C1 [Poirot, Eugenie; Skarbinski, Jacek; Kachur, S. Patrick; Slutsker, Laurence; Hwang, Jimee] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA 30333 USA. [Poirot, Eugenie; Hwang, Jimee] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA. [Sinclair, David] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England. RP Hwang, J (reprint author), Ctr Dis Control & Prevent, Malaria Branch, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30333 USA. EM gdq1@cdc.gov FU Centers for Disease Control and Prevention, USA; Department for International Development, UK FX Internal sources; Centers for Disease Control and Prevention, USA.; External sources; Department for International Development, UK. NR 259 TC 9 Z9 9 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2013 IS 12 AR CD008846 DI 10.1002/14651858.CD008846.pub2 PG 163 WC Medicine, General & Internal SC General & Internal Medicine GA 282QW UT WOS:000329188500015 PM 24318836 ER PT J AU Barcia, C Curtin, J Zirger, J Larocque, D AF Barcia, Carlos Curtin, James Zirger, Jeffrey Larocque, Daniel TI Immunology and the Central Nervous System SO CLINICAL & DEVELOPMENTAL IMMUNOLOGY LA English DT Editorial Material C1 [Barcia, Carlos] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Inst Neurosci, E-08193 Barcelona, Spain. [Barcia, Carlos] Univ Autonoma Barcelona, Sch Med, E-08193 Barcelona, Spain. [Curtin, James] Dublin Inst Technol, Sch Food Sci & Environm Hlth, Dublin, Ireland. [Zirger, Jeffrey] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Larocque, Daniel] GlaxoSmithKline Vaccines, Immunotherapeut BU, Laval, PQ, Canada. RP Barcia, C (reprint author), Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Inst Neurosci, Campus Bellaterra, E-08193 Barcelona, Spain. EM carlos.barcia@uab.es OI Barcia, Carlos/0000-0003-0976-4245; Curtin, James/0000-0002-9320-9254 NR 7 TC 0 Z9 0 U1 1 U2 4 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1740-2522 EI 1740-2530 J9 CLIN DEV IMMUNOL JI Clin. Dev. Immunol. PY 2013 AR 512684 DI 10.1155/2013/512684 PG 3 WC Immunology SC Immunology GA 286DK UT WOS:000329445200001 ER PT B AU Scallan, E Kirk, M Griffin, PM AF Scallan, Elaine Kirk, Martyn Griffin, Patricia M. BE Morris, JG Potter, ME TI Estimates of Disease Burden Associated with Contaminated Food in the United States and Globally SO FOODBORNE INFECTIONS AND INTOXICATIONS, 4TH EDITION LA English DT Article; Book Chapter ID INFECTIOUS INTESTINAL DISEASE; FOODBORNE ILLNESS; LISTERIA-MONOCYTOGENES; ACUTE GASTROENTERITIS; COMMUNITY INCIDENCE; SOURCE ATTRIBUTION; HUMAN SALMONELLA; GENERAL-PRACTICE; PUBLIC-HEALTH; PATHOGENS C1 [Scallan, Elaine] Colorado Sch Publ Hlth, Aurora, CO USA. [Kirk, Martyn] Australian Natl Univ, Canberra, ACT, Australia. [Griffin, Patricia M.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Scallan, E (reprint author), Colorado Sch Publ Hlth, Aurora, CO USA. NR 50 TC 3 Z9 3 U1 1 U2 2 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-391476-7; 978-0-12-416041-5 PY 2013 BP 3 EP 18 PG 16 WC Food Science & Technology; Public, Environmental & Occupational Health SC Food Science & Technology; Public, Environmental & Occupational Health GA BID68 UT WOS:000327740900003 ER PT B AU Nygren, B Bowen, A AF Nygren, Benjamin Bowen, Anna BE Morris, JG Potter, ME TI Shigella SO FOODBORNE INFECTIONS AND INTOXICATIONS, 4TH EDITION LA English DT Article; Book Chapter ID UNITED-STATES; OUTBREAK; SONNEI; TRANSMISSION; SURVIVAL; FLEXNERI; CHILDREN; SALAD; FOOD C1 [Nygren, Benjamin; Bowen, Anna] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Nygren, B (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. NR 24 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-391476-7; 978-0-12-416041-5 PY 2013 BP 217 EP 222 PG 6 WC Food Science & Technology; Public, Environmental & Occupational Health SC Food Science & Technology; Public, Environmental & Occupational Health GA BID68 UT WOS:000327740900014 ER PT B AU Sharapov, UM AF Sharapov, Umid M. BE Morris, JG Potter, ME TI Hepatitis A SO FOODBORNE INFECTIONS AND INTOXICATIONS, 4TH EDITION LA English DT Article; Book Chapter ID IMMUNIZATION PRACTICES ACIP; UNITED-STATES; MOLECULAR EPIDEMIOLOGY; VIRAL-HEPATITIS; VIRUS-INFECTION; MULTISTATE OUTBREAK; ADVISORY-COMMITTEE; GREEN ONIONS; RISK-FACTORS; VACCINE C1 CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Sharapov, UM (reprint author), CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. NR 52 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-391476-7; 978-0-12-416041-5 PY 2013 BP 279 EP 286 PG 8 WC Food Science & Technology; Public, Environmental & Occupational Health SC Food Science & Technology; Public, Environmental & Occupational Health GA BID68 UT WOS:000327740900020 ER PT B AU Teshale, EH AF Teshale, Eyasu H. BE Morris, JG Potter, ME TI Hepatitis E SO FOODBORNE INFECTIONS AND INTOXICATIONS, 4TH EDITION LA English DT Article; Book Chapter ID E-VIRUS; E VACCINE; BLOOD-DONORS; RISK-FACTORS; E ANTIBODIES; E INFECTION; PIG-LIVER; WILD BOAR; TRANSMISSION; STRAIN C1 Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Teshale, EH (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. NR 40 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-391476-7; 978-0-12-416041-5 PY 2013 BP 287 EP 292 PG 6 WC Food Science & Technology; Public, Environmental & Occupational Health SC Food Science & Technology; Public, Environmental & Occupational Health GA BID68 UT WOS:000327740900021 ER PT B AU Hall, AJ Lopman, BA Vinje, J AF Hall, Aron J. Lopman, Ben A. Vinje, Jan BE Morris, JG Potter, ME TI Sapovirus SO FOODBORNE INFECTIONS AND INTOXICATIONS, 4TH EDITION LA English DT Article; Book Chapter ID SAPPORO-VIRUS GASTROENTERITIS; FOODBORNE-DISEASE OUTBREAKS; UNITED-STATES; GENOTYPE ANALYSIS; YOUNG-CHILDREN; NORWALK-VIRUS; CALICIVIRUS; EPIDEMIOLOGY; NOROVIRUS; RECOMBINATION C1 [Hall, Aron J.; Lopman, Ben A.; Vinje, Jan] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Hall, AJ (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. OI Vinje, Jan/0000-0002-1530-3675 NR 36 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-391476-7; 978-0-12-416041-5 PY 2013 BP 313 EP 319 PG 7 WC Food Science & Technology; Public, Environmental & Occupational Health SC Food Science & Technology; Public, Environmental & Occupational Health GA BID68 UT WOS:000327740900023 ER PT J AU Brady, TJ Murphy, L O'Colmain, BJ Beauchesne, D Daniels, B Greenberg, M House, M Chervin, D AF Brady, Teresa J. Murphy, Louise O'Colmain, Benita J. Beauchesne, Danielle Daniels, Brandy Greenberg, Michael House, Marnie Chervin, Doryn TI A Meta-Analysis of Health Status, Health Behaviors, and Health Care Utilization Outcomes of the Chronic Disease Self-Management Program SO PREVENTING CHRONIC DISEASE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; CHRONIC ILLNESS; RHEUMATOID-ARTHRITIS; OLDER-ADULTS; PEOPLE; EDUCATION; EFFICACY; CHINESE; CDSMP AB Introduction Chronic Disease Self-Management Program (CDSMP) is a community-based self-management education program designed to help participants gain confidence (self-efficacy) and skills to better manage their chronic conditions; it has been implemented worldwide. The objective of this meta-analysis was to quantitatively synthesize the results of CDSMP studies conducted in English-speaking countries to determine the program's effects on health behaviors, physical and psychological health status, and health care utilization at 4 to 6 months and 9 to 12 months after baseline. Methods We searched 8 electronic databases to identify CDSMP-relevant literature published from January 1, 1999, through September 30, 2009; experts identified additional unpublished studies. We combined the results of all eligible studies to calculate pooled effect sizes. We included 23 studies. Eighteen studies presented data on small English-speaking groups; we conducted 1 meta-analysis on these studies and a separate analysis on results by other delivery modes. Results Among health behaviors for small English-speaking groups, aerobic exercise, cognitive symptom management, and communication with physician improved significantly at 4- to 6-month follow-up; aerobic exercise and cognitive symptom management remained significantly improved at 9 to 12 months. Stretching/strengthening exercise improved significantly at 9 to 12 months. All measures of psychological health improved significantly at 4 to 6 months and 9 to 12 months. Energy, fatigue, and self-rated health showed small but significant improvements at 4 to 6 months but not at 9 to 12 months. The only significant change in health care utilization was a small improvement in the number of hospitalization days or nights at 4 to 6 months Conclusion Small to moderate improvements in psychological health and selected health behaviors that remain after 12 months suggest that CDSMP delivered in small English-speaking groups produces health benefits for participants and would be a valuable part of comprehensive chronic disease management strategy. C1 [Brady, Teresa J.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA 30341 USA. [Murphy, Louise] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [O'Colmain, Benita J.; Beauchesne, Danielle; Daniels, Brandy; Greenberg, Michael; House, Marnie; Chervin, Doryn] ICF Int, Atlanta, GA USA. RP Brady, TJ (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, 4770 Buford Hwy NE,Mail Stop K-51, Atlanta, GA 30341 USA. EM tob9@cdc.gov FU Centers for Disease Control and Prevention [200-2007-20003]; Arthritis Foundation FX We thank the members of our Subject Matter Expert and Stakeholder Panel that provided counsel in the development of this project. The panel consisted of Julie Barlow, PhD; Basia Belza, PhD, RN; Joshua Chodosh, MD, MSHS; Kris Ernst, RN, CDE; Victoria Fung, MPH; Lori Gerhard; Jean Goeppinger, PhD, RN,; Kate Lorig, DrPH, RN; Patrick McGowan, PhD; Sarah O'Leary, MPH, MA; Marcia Ory, PhD, MPH; Daniel Solomon, MD; Edward H. Wagner, MD; and Nancy Whitelaw, PhD. ICF International staff work on this research was supported by a contract with the Centers for Disease Control and Prevention (contract no. 200-2007-20003) and a service agreement with the Arthritis Foundation. NR 46 TC 33 Z9 33 U1 3 U2 21 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JAN PY 2013 VL 10 AR UNSP 120112 DI 10.5888/pcd10.120112 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285IY UT WOS:000329388600007 PM 23327828 ER PT J AU Gregg, EW Ali, MK Moore, BA Pavkov, ME Devlin, HM Garfield, S Mangione, CM AF Gregg, Edward W. Ali, Mohammed K. Moore, Bernice A. Pavkov, Meda E. Devlin, Heather M. Garfield, Sanford Mangione, Carol M. TI The Importance of Natural Experiments in Diabetes Prevention and Control and the Need for Better Health Policy Research SO PREVENTING CHRONIC DISEASE LA English DT Editorial Material ID UNITED-STATES; PREVALENCE C1 [Pavkov, Meda E.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Gregg, Edward W.; Ali, Mohammed K.; Moore, Bernice A.; Devlin, Heather M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Garfield, Sanford] NIH, Bethesda, MD 20892 USA. [Mangione, Carol M.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Pavkov, ME (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, 4770 Buford Hwy NE,MS K10, Atlanta, GA USA. EM mpavkov@cdc.gov NR 10 TC 3 Z9 3 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JAN PY 2013 VL 10 AR UNSP 120145 DI 10.5888/pcd10.120145 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285IY UT WOS:000329388600014 ER PT J AU Lichtenstein, KA Armon, C Buchacz, K Chmiel, JS Buckner, K Tedaldi, E Wood, K Holmberg, SD Brooks, JT AF Lichtenstein, Kenneth A. Armon, Carl Buchacz, Kate Chmiel, Joan S. Buckner, Kern Tedaldi, Ellen Wood, Kathleen Holmberg, Scott D. Brooks, John T. CA HOPS Investigators TI Provider Compliance With Guidelines for Management of Cardiovascular Risk in HIV-Infected Patients SO PREVENTING CHRONIC DISEASE LA English DT Article ID RECEIVING ANTIRETROVIRAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; ATAZANAVIR PLUS RITONAVIR; CORONARY-ARTERY-DISEASE; MYOCARDIAL-INFARCTION; PROTEASE INHIBITORS; METABOLIC SYNDROME; INSULIN-RESISTANCE; DIABETES-MELLITUS; NAIVE PATIENTS AB Introduction Compliance with National Cholesterol Education Program Adult Treatment Panel III (NCEP) guidelines has been shown to significantly reduce incident cardiovascular events. We investigated physicians' compliance with NCEP guidelines to reduce cardiovascular disease (CVD) risk in a population infected with HIV. Methods We analyzed HIV Outpatient Study (HOPS) data, following eligible patients from January 1, 2002, or first HOPS visit thereafter to calculate 10-year cardiovascular risk (10yCVR), until September 30, 200 9, death, or last office visit. We categorized participants into four 10yCVR strata, according to guidelines determined by NCEP, the Infectious Disease Society of America, and the Adult AIDS Clinical Trials Group. We calculated percentages of patients treated for dyslipidemia and hypertension, calculated percentages of patients who achieved recommended goals, and categorized them by 10yCVR stratum. Results Of 2,005 patients analyzed, 33.7% had fewer than 2 CVD risk factors. For patients who had 2 or more risk factors, 10yCVR was less than 10% for 28.2%, 10% to 20% for 18.2%, and higher than 20% for 20.0% of patients. Of patients eligible for treatment, 81% to 87% were treated for elevated low-density lipoprotein cholesterol./non-high-density lipoprotein cholesterol (LDL-C./non-HDL-C), 2% to 11% were treated for low HDL-C, 56% to 91% were treated for high triglycerides, and 46% to 69 % were treated for hypertension. Patients in higher 10yCVR categories were less likely to meet treatment goals than patients in lower 10yCVR categories. Conclusion At least one-fifth of contemporary HOPS patients have a 10yCVR higher than 20%, yet a large percentage of at-risk patients who were eligible for pharmacologic treatment did not receive recommended interventions and did not reach recommended treatment goals. Opportunities exist for CVD prevention in the HIV-infected population. C1 [Armon, Carl] Cerner Corp, Boulder, CO 80306 USA. [Lichtenstein, Kenneth A.; Buckner, Kern] Natl Jewish Hlth, Denver, CO USA. [Armon, Carl; Wood, Kathleen] Cerner Corp, Vienna, VA USA. [Buchacz, Kate; Holmberg, Scott D.; Brooks, John T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Chmiel, Joan S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Tedaldi, Ellen] Temple Univ, Sch Med, Philadelphia, PA 19122 USA. RP Armon, C (reprint author), Cerner Corp, POB 1677, Boulder, CO 80306 USA. EM cxa@nedernet.net FU Centers for Disease Control and Prevention (CDC) [200-2001-00133, 200-2006-18797]; ViiV; Abbott; Merck FX These data were presented previously at the 18th International AIDS Conference, Mexico City, Mexico, August 3-8, 2008 (abstract no. THPE0229). This work supported by the Centers for Disease Control and Prevention (CDC) (contract nos. 200-2001-00133 and 200-2006-18797). Dr Lichtenstein receives research support from ViiV and Abbott; he serves on advisory boards for Bristol-Myers Squibb and ViiV. Dr Tedaldi receives research support from Merck. Dr Buckner serves on an advisory board for Genessee BioMedical and has intellectual property with that company; he serves on the board of directors and has intellectual property with Wireless Medical, Inc, and is on the speaker bureau for Boehringer Ingelheim Pharmaceuticals, Inc. NR 42 TC 1 Z9 1 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JAN PY 2013 VL 10 AR UNSP 120083 DI 10.5888/pcd10.120083 PG 16 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285IY UT WOS:000329388600010 ER PT J AU Posner, SF AF Posner, Samuel F. TI Advances at Preventing Chronic Disease: Public Health Research, Practice, and Policy SO PREVENTING CHRONIC DISEASE LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Posner, SF (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,Mail Stop F-68, Atlanta, GA 30341 USA. EM shp5@cdc.gov OI Posner, Samuel/0000-0003-1574-585X NR 1 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JAN PY 2013 VL 10 AR UNSP 120304 DI 10.5888/pcd10.120304 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285IY UT WOS:000329388600002 PM 23286360 ER PT J AU Visser, SN Blumberg, SJ Danielson, ML Bitsko, RH Kogan, MD AF Visser, Susanna N. Blumberg, Stephen J. Danielson, Melissa L. Bitsko, Rebecca H. Kogan, Michael D. TI State-Based and Demographic Variation in Parent-Reported Medication Rates for Attention-Deficit/Hyperactivity Disorder, 2007-2008 SO PREVENTING CHRONIC DISEASE LA English DT Article ID TREATMENT STRATEGIES; CHILDREN AB Medication is the most effective treatment of attention-deficit/hyperactivity disorder (ADHD), a common neurobehavioral disorder of childhood. We used data from the 2007-2008 National Survey of Children's Health to calculate weighted estimates of parent-reported ADHD and medication treatment among US children aged 4 to 17 years, by state and sex-stratified age. State-based rates of ADHD medication treatment ranged from 33% in Nevada to 79% in Mississippi; rates of medicated ADHD were higher among boys than girls at every age. State-based investigations of ADHD medication treatment factors are needed, and our findings may inform these public health efforts. C1 [Visser, Susanna N.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Blumberg, Stephen J.; Danielson, Melissa L.; Bitsko, Rebecca H.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Kogan, Michael D.] Hlth Resources & Serv Adm, Rockville, MD USA. RP Visser, SN (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Mailstop E-88,1600 Clifton Rd, Atlanta, GA 30333 USA. EM svisser@cdc.gov OI Danielson, Melissa/0000-0001-9461-0341 FU Maternal and Child Health Bureau, Health Resources and Services Administration FX Funding for the 2007 NSCH was provided to the Centers for Disease Control and Prevention by the Maternal and Child Health Bureau, Health Resources and Services Administration. NR 9 TC 5 Z9 5 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JAN PY 2013 VL 10 AR UNSP 20073 DI 10.5888/pcd9.120073 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285IY UT WOS:000329388600009 ER PT J AU Stevens, RW Wenger, J Bulkow, L Bruce, MG AF Stevens, Ryan W. Wenger, Jay Bulkow, Lisa Bruce, Michael G. TI Streptococcus pneumoniae non-susceptibility and outpatient antimicrobial prescribing rates at the Alaska Native Medical Center SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article DE Streptococcus pneumoniae; invasive pneumococcal disease; antibiotic resistance; antibiotic prescribing; susceptibility; Alaska Natives; Alaska ID PNEUMOCOCCAL CONJUGATE VACCINE; UNITED-STATES; SEROTYPE DISTRIBUTION; RESISTANCE PATTERNS; ANTIBIOTIC USE; MACROLIDE; CHILDREN; TRENDS; ERYTHROMYCIN; DISEASE AB Background. American Indian/Alaska Native (AI/AN) people suffer substantially higher rates of invasive pneumococcal disease (IPD) than the general US population. We evaluated antimicrobial prescribing data and their association with non-susceptibility in Streptococcus pneumoniae causing IPD in AI/AN people between 1992 and 2009. Methods. Antimicrobial use data were gathered from the electronic patient management system and included all prescriptions dispensed to Alaska Native patients aged 5 years and older from outpatient pharmacies at the Alaska Native Medical Center (ANMC). Antimicrobial susceptibility data were gathered from pneumococcal isolates causing IPD among Anchorage Service Unit AI/AN residents aged 5 years and older. Data were restricted to serotypes not contained in the pneumococcal vaccine (PCV7). Results. Over the study period, overall antimicrobial prescribing increased 59% (285/1,000 persons/year in 1992 to 454/1,000 persons per year in 2009, p < 0.001). Trimethoprim/sulfamethoxazole prescribing increased (43/1,000 persons/year in 1992 to 108/1,000 persons/year in 2009, p < 0.001) and non-susceptibility to trimethoprim/sulfamethoxazole in AI/AN patients >= 5 years of age increased in non-PCV7 serotypes (0-12%, p < 0.05). Similarly, prescribing rates increased for macrolide antibiotics (46/1,000 persons/year in 1992 to 84/1,000 persons/year in 2009, p < 0.05). We observed no statistically significant change over time in erythromycin non-susceptibility among non-PCV7 serotypes in AI/AN patients aged 5 years or greater (0-7%, p = 0.087). Conclusion. Antimicrobial prescribing patterns of some antibiotics in the AI/AN population corresponded to increased antimicrobial resistance in clinical isolates. This study highlights the on-going threat of antimicrobial resistance, the critical importance of judicious prescribing of antibiotics and the potential utility of prescribing data for addressing this issue. C1 [Stevens, Ryan W.] Alaska Native Med Ctr, Anchorage, AK USA. [Wenger, Jay; Bulkow, Lisa; Bruce, Michael G.] Ctr Dis Control & Prevent CDC, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Dis, Anchorage, AK 99508 USA. RP Bruce, MG (reprint author), Ctr Dis Control & Prevent CDC, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM zwa8@cdc.gov NR 22 TC 1 Z9 1 U1 0 U2 1 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 AR 22297 DI 10.3402/ijch.v72i0.22297 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 273WW UT WOS:000328568000001 PM 24358456 ER PT J AU Grimes, TS Hou, SI AF Grimes, Tanisha S. Hou, Su-I. TI "A Breast Ain't Nothing but a Sandwich": Narratives of Ella, an African American Social Worker Breast Cancer Survivor SO SOCIAL WORK IN PUBLIC HEALTH LA English DT Article DE Breast cancer; narratives; African Americans ID HEALTH INFORMATION; WOMEN; MAMMOGRAPHY AB Breast cancer mortality rates continue to increase among African American women making it imperative to develop culturally tailored programs to help reduce these rates. In this study, narratives of Ella an African American breast cancer survivor who is also a social worker were constructed. Prevalent themes were self-identity, perceptions of women living with cancer, and the socialization of African Americans in cancer prevention. Her perspective as a survivor and social worker offers insight on how the intersection of race and gender impacts breast cancer survival and has implications for future research in cancer awareness among African Americans. C1 [Grimes, Tanisha S.; Hou, Su-I.] Georgia State Univ, Dept Hlth Promot & Behav, Atlanta, GA 30303 USA. RP Grimes, TS (reprint author), Ctr Dis Control, 1600 Clifton Rd,NE,Mail Stop E-59, Atlanta, GA 30333 USA. EM imf2@cdc.gov OI Hou, Su-I/0000-0002-4519-0974 NR 32 TC 1 Z9 1 U1 2 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1937-1918 EI 1937-190X J9 SOC WORK PUBLIC HLTH JI Soc. Work Public Health PD JAN 1 PY 2013 VL 28 IS 1 BP 44 EP 53 DI 10.1080/19371918.2010.513667 PG 10 WC Public, Environmental & Occupational Health; Social Work SC Public, Environmental & Occupational Health; Social Work GA 263VP UT WOS:000327836400004 PM 23369021 ER PT J AU Cartwright, EJ Jackson, KA Johnson, SD Graves, LM Silk, BJ Mahon, BE AF Cartwright, Emily J. Jackson, Kelly A. Johnson, Shacara D. Graves, Lewis M. Silk, Benjamin J. Mahon, Barbara E. TI Listeriosis Outbreaks and Associated Food Vehicles, United States, 1998-2008 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID MEXICAN-STYLE CHEESE; TO-EAT FOODS; MULTISTATE OUTBREAK; INVASIVE LISTERIOSIS; PASTEURIZED MILK; EPIDEMIC LISTERIOSIS; FOODBORNE ILLNESS; RAW-MILK; MONOCYTOGENES; SURVEILLANCE AB Listeria monocyto genes, a bacterial foodborne pathogen, can cause meningitis, bacteremia, and complications during pregnancy. This report summarizes listeriosis outbreaks reported to the Foodborne Disease Outbreak Surveillance System of the Centers for Disease Control and Prevention during 1998-2008. The study period includes the advent of PulseNet (a national molecular subtyping network for outbreak detection) in 1998 and the Listeria Initiative (enhanced surveillance for outbreak investigation) in 2004. Twenty-four confirmed listeriosis outbreaks were reported during 1998-2008, resulting in 359 illnesses, 215 hospitalizations, and 38 deaths. Outbreaks earlier in the study period were generally larger and longer. Serotype 4b caused the largest number of outbreaks and outbreak-associated cases. Ready-to-eat meats caused more early outbreaks, and novel vehicles (i.e., sprouts, taco/nacho salad) were associated with outbreaks later in the study period. These changes may reflect the effect of PulseNet and the Listeria Initiative and regulatory initiatives designed to prevent contamination in ready-to-eat meat and poultry products. C1 [Cartwright, Emily J.; Jackson, Kelly A.; Johnson, Shacara D.; Graves, Lewis M.; Silk, Benjamin J.; Mahon, Barbara E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Silk, BJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30333 USA. EM bsilk@cdc.gov NR 40 TC 95 Z9 98 U1 4 U2 49 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JAN PY 2013 VL 19 IS 1 BP 1 EP 9 DI 10.3201/eid1901.120393 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LS UT WOS:000328172800001 PM 23260661 ER PT J AU Younan, M Poh, MK Elassal, E Davis, T Rivailler, P Balish, AL Simpson, N Jones, J Deyde, V Loughlin, R Perry, I Gubareva, L ElBadry, MA Truelove, S Gaynor, AM Mohareb, E Amin, M Cornelius, C Pimentel, G Earhart, K Naguib, A Abdelghani, AS Refaey, S Klimov, AI Donis, RO Kandeel, A AF Younan, Mary Poh, Mee Kian Elassal, Emad Davis, Todd Rivailler, Pierre Balish, Amanda L. Simpson, Natosha Jones, Joyce Deyde, Varough Loughlin, Rosette Perry, Ije Gubareva, Larisa ElBadry, Maha A. Truelove, Shaun Gaynor, Anne M. Mohareb, Emad Amin, Magdy Cornelius, Claire Pimentel, Guillermo Earhart, Kenneth Naguib, Amel Abdelghani, Ahmed S. Refaey, Samir Klimov, Alexander I. Donis, Ruben O. Kandeel, Amr TI Microevolution of Highly Pathogenic Avian Influenza A(H5N1) Viruses Isolated from Humans, Egypt, 2007-2011 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID GENETIC DIVERSITY; HONG-KONG; A-VIRUS; H5N1; POLYMERASE; BINDING; PROTEIN; NOMENCLATURE; HOST AB We analyzed highly pathogenic avian influenza A(H5N1) viruses isolated from humans infected in Egypt during 2007-2011. All analyzed viruses evolved from the lineage of subtype H5N1 viruses introduced into Egypt in 2006; we found minimal evidence of reassortment and no exotic introductions. The hemagglutinin genes of the viruses from 2011 formed a monophyletic group within clade 2.2.1 that also included human viruses from 2009 and 2010 and contemporary viruses from poultry; this finding is consistent with zoonotic transmission. Although molecular markers suggestive of decreased susceptibility to antiviral drugs were detected sporadically in the neuraminidase and matrix 2 proteins, functional neuraminidase inhibition assays did not identify resistant viruses. No other mutations suggesting a change in the threat to public health were detected in the viral proteomes. However, a comparison of representative subtype H5N1 viruses from 2011 with older subtype H5N1 viruses from Egypt revealed substantial antigenic drift. C1 [Younan, Mary] US Naval Med Res Unit 3, Viral & Zoonot Dis Res Program, Cairo, Egypt. [Younan, Mary; Elassal, Emad; ElBadry, Maha A.; Truelove, Shaun; Gaynor, Anne M.; Mohareb, Emad; Cornelius, Claire; Pimentel, Guillermo; Earhart, Kenneth] US Naval Med Res Unit 3, Cairo, Egypt. [Poh, Mee Kian; Davis, Todd; Rivailler, Pierre; Balish, Amanda L.; Simpson, Natosha; Jones, Joyce; Deyde, Varough; Loughlin, Rosette; Perry, Ije; Gubareva, Larisa; Klimov, Alexander I.; Donis, Ruben O.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Amin, Magdy] Cairo Univ, Cairo, Egypt. [Naguib, Amel; Abdelghani, Ahmed S.; Refaey, Samir; Kandeel, Amr] Minist Hlth & Populat, Cairo, Egypt. RP Donis, RO (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G16, Atlanta, GA 30333 USA. EM rvd6@cdc.gov OI Pimentel, Guillermo/0000-0003-2464-1526 NR 31 TC 22 Z9 22 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JAN PY 2013 VL 19 IS 1 BP 43 EP 50 DI 10.3201/eid1901.121080 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LS UT WOS:000328172800006 PM 23260983 ER PT J AU Reed, C Biggerstaff, M Finelli, L Koonin, LM Beauvais, D Uzicanin, A Plummer, A Bresee, J Redd, SC Jernigan, DB AF Reed, Carrie Biggerstaff, Matthew Finelli, Lyn Koonin, Lisa M. Beauvais, Denise Uzicanin, Amra Plummer, Andrew Bresee, Joe Redd, Stephen C. Jernigan, Daniel B. TI Novel Framework for Assessing Epidemiologic Effects of Influenza Epidemics and Pandemics SO EMERGING INFECTIOUS DISEASES LA English DT Article ID A H1N1 VIRUS; UNITED-STATES; HOUSEHOLD TRANSMISSION; WORLDWIDE AB The effects of influenza on a population are attributable to the clinical severity of illness and the number of persons infected, which can vary greatly between seasons or pandemics. To create a systematic framework for assessing the public health effects of an emerging pandemic, we reviewed data from past influenza seasons and pandemics to characterize severity and transmissibility (based on ranges of these measures in the United States) and outlined a formal assessment of the potential effects of a novel virus. The assessment was divided into 2 periods. Because early in a pandemic, measurement of severity and transmissibility is uncertain, we used a broad dichotomous scale in the initial assessment to divide the range of historic values. In the refined assessment, as more data became available, we categorized those values more precisely. By organizing and prioritizing data collection, this approach may inform an evidence-based assessment of pandemic effects and guide decision making. C1 [Reed, Carrie; Biggerstaff, Matthew; Finelli, Lyn; Koonin, Lisa M.; Beauvais, Denise; Uzicanin, Amra; Plummer, Andrew; Bresee, Joe; Redd, Stephen C.; Jernigan, Daniel B.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Reed, C (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop A32, Atlanta, GA 30333 USA. EM creed1@cdc.gov NR 17 TC 24 Z9 24 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JAN PY 2013 VL 19 IS 1 BP 85 EP 91 DI 10.3201/eid1901.120124 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LS UT WOS:000328172800011 PM 23260039 ER PT J AU Alagappan, K Silverman, RA Hancock, K Ward, MF Akerman, M Dawood, FS Branch, A De Cicco, S Steward-Clark, E McCullough, M Tenner, K Katz, JM AF Alagappan, Kumar Silverman, Robert A. Hancock, Kathy Ward, Mary Frances Akerman, Meredith Dawood, Fatimah S. Branch, Alicia De Cicco, Sandra Steward-Clark, Evelene McCullough, Megan Tenner, Karen Katz, Jacqueline M. TI Seropositivity for Influenza A(H1N1) pdm09 Virus among Frontline Health Care Personnel SO EMERGING INFECTIOUS DISEASES LA English DT Article ID H1N1 2009; SEROPREVALENCE AB Seroprevalence of antibodies to influenza A(H1N1) pdm09 virus among 193 emergency department health care personnel was similar among 147 non health care personnel (odds ratio 1.4, 95% Cl 0.8-2.4). Working in an acute care setting did not substantially increase risk for virus infection above risk conferred by community-based exposures. C1 [Alagappan, Kumar; Silverman, Robert A.] North Shore Long Isl Jewish Hlth Syst, Dept Emergency Med, New Hyde Pk, NY 11040 USA. [Ward, Mary Frances; De Cicco, Sandra; McCullough, Megan; Tenner, Karen] North Shore Long Isl Jewish Hlth Syst, New Hyde Pk, NY 11040 USA. [Alagappan, Kumar; Silverman, Robert A.; Ward, Mary Frances] Hofstra North Shore Long Isl Jewish Sch Med, Hempstead, NY USA. [Alagappan, Kumar; Silverman, Robert A.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Alagappan, Kumar; Silverman, Robert A.; Ward, Mary Frances; Akerman, Meredith] Feinstein Inst Med Res, Manhasset, NY USA. [Hancock, Kathy; Dawood, Fatimah S.; Branch, Alicia; Steward-Clark, Evelene; Katz, Jacqueline M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Silverman, RA (reprint author), North Shore Long Isl Jewish Hlth Syst, Dept Emergency Med, 270-05 76th Ave, New Hyde Pk, NY 11040 USA. EM aresilv@aol.com NR 13 TC 5 Z9 5 U1 2 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JAN PY 2013 VL 19 IS 1 BP 140 EP 143 DI 10.3201/eid1901.111640 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LS UT WOS:000328172800023 PM 23260627 ER PT J AU Lomonaco, S Verghese, B Gerner-Smidt, P Tarr, C Gladney, L Joseph, L Katz, L Turnsek, M Frace, M Chen, Y Brown, E Meinersmann, R Berrang, M Knabel, S AF Lomonaco, Sara Verghese, Bindhu Gerner-Smidt, Peter Tarr, Cheryl Gladney, Lori Joseph, Lavin Katz, Lee Turnsek, Maryann Frace, Michael Chen, Yi Brown, Eric Meinersmann, Richard Berrang, Mark Knabel, Stephen TI Novel Epidemic Clones of Listeria monocytogenes, United States, 2011 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID PROCESSING PLANT; OUTBREAK; POULTRY; STRAINS; MEAT AB We identified a novel serotype 1/2a outbreak strain and 2 hovel epidemic clones of Listeria monocytogenes while investigating a foodborne outbreak of listeriosis associated with consumption of cantaloupe during 2011 in the United States. Comparative analyses of strains worldwide are essential to identification of novel outbreak strains and epidemic clones. C1 [Lomonaco, Sara] Univ Turin, Dept Anim Pathol, Turin, Italy. [Verghese, Bindhu] Accugenix, Newark, DE USA. [Verghese, Bindhu; Knabel, Stephen] Penn State Univ, University Pk, PA 16802 USA. [Gerner-Smidt, Peter; Tarr, Cheryl; Gladney, Lori; Joseph, Lavin; Katz, Lee; Turnsek, Maryann; Frace, Michael] Ctr Dis Control & Prevent, Atlanta, GA USA. [Chen, Yi; Brown, Eric] US FDA, College Pk, MD USA. [Meinersmann, Richard; Berrang, Mark] USDA, Athens, GA USA. RP Knabel, S (reprint author), Penn State Univ, Dept Food Sci, 405 Food Sci Bldg, University Pk, PA 16802 USA. EM sjk9@psu.edu OI Lomonaco, Sara/0000-0001-8242-6280 FU USDA FX S.L. conducted this research while she was a visiting scientist at Pennsylvania State University during September 5-October 15, 2011. This study was partially funded by a USDA Special Grant on Milk Safety. NR 15 TC 47 Z9 50 U1 1 U2 14 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JAN PY 2013 VL 19 IS 1 BP 147 EP 150 DI 10.3201/eid1901.121167 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LS UT WOS:000328172800025 PM 23260778 ER PT J AU Hassan-Rios, E Torres, P Munoz, E Matos, C Hall, AJ Gregoricus, N Vinje, J AF Hassan-Rios, Encijar Torres, Pilar Munoz, Elizabeth Matos, Carmen Hall, Aron J. Gregoricus, Nicole Vinje, Jan TI Satpovirus Gastroenteritis in Preschool Center, Puerto Rico, 2011 SO EMERGING INFECTIOUS DISEASES LA English DT Letter C1 [Hassan-Rios, Encijar; Torres, Pilar; Munoz, Elizabeth; Matos, Carmen] Puerto Rico Dept Hlth, San Juan, PR 00936 USA. [Hall, Aron J.; Gregoricus, Nicole; Vinje, Jan] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Hassan-Rios, E (reprint author), Puerto Rico Dept Hlth, Epidemiol Off, POB 70184, San Juan, PR 00936 USA. EM ehassan@salud.gov.pr NR 5 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JAN PY 2013 VL 19 IS 1 BP 174 EP 175 DI 10.3201/eid1901.120690 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LS UT WOS:000328172800038 PM 23260219 ER PT J AU Potter, P AF Potter, Polyxeni TI One Rotten Apple Infects All in the Basket SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Potter, Polyxeni] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, EID Journal, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM pmp1@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JAN PY 2013 VL 19 IS 1 BP 182 EP 183 DI 10.3201/eid1901.AC1901 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LS UT WOS:000328172800042 PM 23260598 ER PT J AU Pavuk, M Dutton, N AF Pavuk, Marian Dutton, Nina BE Carpenter, DO TI Cardiovascular Disease and Hypertension SO EFFECTS OF PERSISTENT AND BIOACTIVE ORGANIC POLLUTANTS ON HUMAN HEALTH LA English DT Article; Book Chapter ID NUTRITION EXAMINATION SURVEY; ENDOTHELIUM-DEPENDENT CONTRACTIONS; PERSISTENT ORGANIC POLLUTANTS; TOXIC EQUIVALENCY FACTORS; CAUSE-SPECIFIC MORTALITY; CHEMICAL CORPS VIETNAM; AGENT-ORANGE EXPOSURE; 15-YEAR FOLLOW-UP; POLYCHLORINATED-BIPHENYLS; CANCER INCIDENCE AB Background: Persistent organic pollutants (POPs) have been implicated in altering a variety of physiological processes related to cardiovascular function. Occupationally and accidentally exposed cohorts have been studied for mortality from cardiovascular disease (CVD) and exposure to dioxins since the 1970s. Recently, relationships between hypertension and low-level exposure to polychlorinated biphenyls (PCBs) and other POPs have been intensely studied. Objectives: This chapter reviews evidence for relationships between dioxin exposure and morbidity from CVD and ischemic heart disease (IHD), focusing on recent cohort updates. Associations between hypertension and exposure to PCBs and other POPs are evaluated in studies of the general U. S. population and populations near contaminated sites. Discussion: Results of CVD mortality studies in dioxin-exposed cohorts using external comparisons found little evidence of association. In internal comparison studies with detailed exposure assessments, more evidence of increased IHD and CVD mortality was reported. Two cohort studies with proper adjustment for major CVD risk factors showed little or no association with CVD mortality. In hypertension studies, effects of dioxin-like or non-dioxin-like PCB congeners could not be separated clearly. Conclusions: Mixed results of studies in dioxin-exposed cohorts do not support a strong association between dioxin exposure and cardiovascular mortality in humans. Suggestive findings on PCBs and other POPs and hypertension require confirmation in follow-up studies. C1 [Pavuk, Marian] CDC Atlanta, ATSDR CDC, Atlanta, GA USA. [Dutton, Nina] Oak Ridge Inst Sci & Educ, Res Participat Program, Atlanta, GA USA. [Dutton, Nina] ATSDR CDC, Atlanta, GA USA. RP Pavuk, M (reprint author), CDC Atlanta, ATSDR CDC, Atlanta, GA USA. NR 90 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-1-118-15926-2 PY 2013 BP 143 EP 173 D2 10.1002/9781118679654 PG 31 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA BID81 UT WOS:000327747000007 ER PT J AU Reutman, SR Meadows, JW AF Reutman, Susan R. Meadows, Juliana W. BE Carpenter, DO TI An Overview of the Effects of Organic Compounds on Women's Reproductive Health and Birth Outcomes SO EFFECTS OF PERSISTENT AND BIOACTIVE ORGANIC POLLUTANTS ON HUMAN HEALTH LA English DT Article; Book Chapter ID MENSTRUAL-CYCLE CHARACTERISTICS; ENDOCRINE-DISRUPTING CHEMICALS; SERUM DIOXIN CONCENTRATIONS; SECONDARY SEX-RATIO; POLYBROMINATED DIPHENYL ETHERS; TESTICULAR DYSGENESIS SYNDROME; POLYCHLORINATED BIPHENYL PCB; IN-UTERO EXPOSURE; FEMALE GREENHOUSE WORKERS; PERSISTENT ORGANOCHLORINE POLLUTANTS AB Background: Female reproductive system perturbations may decrease a woman's likelihood of conceiving and carrying her baby to term, influence the future life course of a viable infant, and may also reflect and have an impact on her own gynecological and general health and well-being. This chapter surveys effects of persistent organic compounds (POCs) and other less persistent but often pervasive bioactive organic compounds (BOCs) on these health outcomes. Objectives: To present an overview that highlights evidence gathered from studies and reviews, and to provide readers with background to interpret results of future studies. Results: This chapter provides an overview of human BOC and POC research methods, issues, and findings pertaining to women's reproductive and offspring's developmental effects of exposure. Research gaps and additional information resources are also highlighted. Discussion: Human evidence is mounting for adverse intrauterine exposure effects of (1) polychlorinated biphenyls (particularly estrogenic congeners) on lowered birth weight; (2) phthalates on testicular dysgenesis syndrome; (3) various solvents on fetal loss; (4) smoking on altered reproductive hormone levels, lowered fertility, fecundity, birth weights, and menopausal age, and increased stillbirths, cleft lip malformations, and maternal (diastolic) hypertension; and (5) pesticides on childhood leukemia. There are strikingly few studies of other BOCs and POCs and reproductive outcomes, considering how many of these compounds are prevalent and that their potential effects and comorbidities may be severe with impacts across the life span. Conclusions: Evidence of adverse female reproductive and developmental effects is mounting for some BOCs and POCs but is sparse for many others. Well-designed longitudinal human studies are needed. C1 [Reutman, Susan R.] NIOSH, Cincinnati, OH 45226 USA. [Meadows, Juliana W.] NIOSH, Div Appl Sci & Technol, Biomonitoring & Hlth Assessment Branch, Cincinnati, OH 45226 USA. RP Reutman, SR (reprint author), NIOSH, Cincinnati, OH 45226 USA. NR 386 TC 2 Z9 2 U1 1 U2 10 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-1-118-15926-2 PY 2013 BP 237 EP 314 D2 10.1002/9781118679654 PG 78 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA BID81 UT WOS:000327747000010 ER PT B AU LeRouge, C Tolentino, H Fuller, S Tuma, A AF LeRouge, Cynthia Tolentino, Herman Fuller, Sherrilynne Tuma, Allison BE Sarnikar, S Bennett, D Gaynor, M TI Doing and Understanding: Use of Case Studies for Health Informatics Education and Training SO CASES ON HEALTHCARE INFORMATION TECHNOLOGY FOR PATIENT CARE MANAGEMENT LA English DT Article; Book Chapter AB This chapter provides an introduction to the pedagogy of using the case method particularly for instruction in the health informatics context. The thoughts and insights shared in this chapter are inspired by basic theories, published methods, and lessons learned from the authors' collective experiences. They illustrate the case teaching experience by engaging the reader in an exercise to highlight the basic phases of the case method process and challenges of the process. The case referenced in this exercise (provided in the Appendix to this chapter) has been used on multiple occasions by authors of this chapter, and they draw on their experiences in using this case to illustrate points throughout the exercise. The authors close the chapter by providing the reader with strategies and considerations in using the case method. C1 [LeRouge, Cynthia; Tuma, Allison] St Louis Univ, Dept Hlth Policy & Management, Sch Publ Hlth, St Louis, MO 63103 USA. [Tuma, Allison] St Louis Univ, St Louis, MO 63103 USA. [Tolentino, Herman] Ctr Dis Control & Prevent, Atlanta, GA USA. [Fuller, Sherrilynne] Univ Washington, Dept Biomed Informat & Med Educ, Sch Med, Seattle, WA 98195 USA. [Fuller, Sherrilynne] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Fuller, Sherrilynne] Univ Washington, Informat Sch, Seattle, WA 98195 USA. RP LeRouge, C (reprint author), St Louis Univ, Dept Hlth Policy & Management, Sch Publ Hlth, St Louis, MO 63103 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU IGI GLOBAL PI HERSEY PA 701 E CHOCOLATE AVE, STE 200, HERSEY, PA 17033-1240 USA BN 978-1-4666-2702-4; 978-1-4666-2671-3 PY 2013 BP 1 EP 34 DI 10.4018/978-1-4666-2671-3.ch001 D2 10.4018/978-1-4666-2671-3 PG 34 WC Health Policy & Services; Nursing SC Health Care Sciences & Services; Nursing GA BHZ65 UT WOS:000327089200002 ER PT J AU Singh, GK Rodriguez-Lainz, A Kogan, MD AF Singh, Gopal K. Rodriguez-Lainz, Alfonso Kogan, Michael D. TI Immigrant Health Inequalities in the United States: Use of Eight Major National Data Systems SO SCIENTIFIC WORLD JOURNAL LA English DT Article ID CAUSE-SPECIFIC MORTALITY; LONGITUDINAL MORTALITY; OVERWEIGHT PREVALENCE; ETHNIC-IMMIGRANT; CANCER INCIDENCE; NATIVE-BORN; SURVEILLANCE; BEHAVIORS; RACE/ETHNICITY; ADOLESCENTS AB Eight major federal data systems, including the National Vital Statistics System (NVSS), National Health Interview Survey (NHIS), National Survey of Children's Health, National Longitudinal Mortality Study, and American Community Survey, were used to examine health differentials between immigrants and the US-born across the life course. Survival and logistic regression, prevalence, and age-adjusted death rates were used to examine differentials. Although these data systems vary considerably in their coverage of health and behavioral characteristics, ethnic-immigrant groups, and time periods, they all serve as important research databases for understanding the health of US immigrants. The NVSS and NHIS, the two most important data systems, include a wide range of health variables and many racial/ethnic and immigrant groups. Immigrants live 3.4 years longer than the US-born, with a life expectancy ranging from 83.0 years for Asian/Pacific Islander immigrants to 69.2 years for US-born blacks. Overall, immigrants have better infant, child, and adult health and lower disability and mortality rates than the US-born, with immigrant health patterns varying across racial/ethnic groups. Immigrant children and adults, however, fare substantially worse than the US-born in health insurance coverage and access to preventive health services. Suggestions and new directions are offered for improvements in health monitoring and for strengthening and developing databases for immigrant health assessment in the USA. C1 [Singh, Gopal K.; Kogan, Michael D.] Maternal & Child Hlth Bur, US Dept HHS, Hlth Resources & Serv Adm, Rockville, MD 20857 USA. [Rodriguez-Lainz, Alfonso] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, San Diego, CA 92110 USA. RP Singh, GK (reprint author), Maternal & Child Hlth Bur, US Dept HHS, Hlth Resources & Serv Adm, 5600 Fishers Lane,Room 18-41, Rockville, MD 20857 USA. EM gsingh@hrsa.gov NR 75 TC 14 Z9 14 U1 2 U2 11 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1537-744X J9 SCI WORLD J JI Sci. World J. PY 2013 AR 512313 DI 10.1155/2013/512313 PG 21 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 250HI UT WOS:000326840900001 ER PT J AU Bentley, M Corneli, A Parker, M Chasela, C Kayira, D Moses, A Tembo, M van der Horst, C Jamieson, D Adair, L AF Bentley, M. Corneli, A. Parker, M. Chasela, C. Kayira, D. Moses, A. Tembo, M. van der Horst, C. Jamieson, D. Adair, L. TI THE BREASTFEEDING, ANTIRETROVIRALS, AND NUTRITION (BAN) STUDY IN MALAWI: USE OF QUALITATIVE METHODS TO GUIDE STUDY DESIGN AND EVALUATION OF A RANDOMIZED CONTROLLED TRIAL SO ANNALS OF NUTRITION AND METABOLISM LA English DT Meeting Abstract DE Antirretrovirals; breastfeeding; infants; nutrition; weaning C1 [Bentley, M.; Adair, L.] Univ N Carolina, Carolina Populat Ctr, Dept Nutr, Chapel Hill, NC USA. [Corneli, A.] FHI3601, Durham, NC USA. [Parker, M.; Chasela, C.; Kayira, D.; Moses, A.; Tembo, M.] PATH, Seattle, WA USA. [Chasela, C.] Univ Witwatersrand, Sch Publ Hlth, Div Epidemiol & Biostat, Parktown, South Africa. [van der Horst, C.] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC USA. [Jamieson, D.] US Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-6807 EI 1421-9697 J9 ANN NUTR METAB JI Ann. Nutr. Metab. PY 2013 VL 63 SU 1 BP 25 EP 26 PG 2 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 219YR UT WOS:000324548201053 ER PT J AU Suchdev, PS Namaste, S Aaron, GJ AF Suchdev, P. S. Namaste, S. Aaron, G. J. TI BIOMARKERS REFLECTING INFLAMMATION AND NUTRITION DETERMINANTS OF ANEMIA (BRINDA): PROJECT OVERVIEW SO ANNALS OF NUTRITION AND METABOLISM LA English DT Meeting Abstract DE Biomarkers; inflammation; micronutrients C1 [Suchdev, P. S.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-6807 EI 1421-9697 J9 ANN NUTR METAB JI Ann. Nutr. Metab. PY 2013 VL 63 SU 1 BP 87 EP 87 PG 1 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 219YR UT WOS:000324548201184 ER PT J AU Vesper, HW Thorpe, SJ Rahmani, YI Pfeiffer, CM AF Vesper, H. W. Thorpe, S. J. Rahmani, Y. I. Pfeiffer, C. M. TI SOLUBLE TRANSFERRIN RECEPTOR (STFR) COMMUTABILITY STUDY SO ANNALS OF NUTRITION AND METABOLISM LA English DT Meeting Abstract DE Soluble transferring receptor; reference material; commutability C1 [Vesper, H. W.; Rahmani, Y. I.; Pfeiffer, C. M.] Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-6807 EI 1421-9697 J9 ANN NUTR METAB JI Ann. Nutr. Metab. PY 2013 VL 63 SU 1 BP 87 EP 87 PG 1 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 219YR UT WOS:000324548201183 ER PT J AU Jefferds, M Flores-Ayala, R AF Jefferds, M. Flores-Ayala, R. TI CONTINUOUS HOUSEHOLD SURVEYS TO PRODUCE HIGH QUALITY, LOW COST, AND TIMELY NUTRITION SURVEILLANCE DATA SO ANNALS OF NUTRITION AND METABOLISM LA English DT Meeting Abstract DE Surveillance; continuous household surveys; indicators C1 [Jefferds, M.; Flores-Ayala, R.] US Ctr Dis Control & Prevent, Int Micronutrient Malnutrit Prevent & Control Pro, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-6807 EI 1421-9697 J9 ANN NUTR METAB JI Ann. Nutr. Metab. PY 2013 VL 63 SU 1 BP 89 EP 89 PG 1 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 219YR UT WOS:000324548201188 ER PT J AU Tripp, K Sullivan, K Duque, T AF Tripp, K. Sullivan, K. Duque, T. TI NUTRITION SURVEY TOOLKIT AND 2ND EDITION OF THE MICRONUTRIENT SURVEY MANUAL TO IMPROVE THE DESIGN AND QUALITY OF MICRONUTRIENT SURVEYS SO ANNALS OF NUTRITION AND METABOLISM LA English DT Meeting Abstract DE Nutrition surveys; micronutrients; minerals; vitamins C1 [Tripp, K.; Sullivan, K.; Duque, T.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-6807 EI 1421-9697 J9 ANN NUTR METAB JI Ann. Nutr. Metab. PY 2013 VL 63 SU 1 BP 89 EP 89 PG 1 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 219YR UT WOS:000324548201187 ER PT J AU Bilukha, O Wilkinson, C Andresen, E Husain, F Jacobson, L AF Bilukha, O. Wilkinson, C. Andresen, E. Husain, F. Jacobson, L. TI EFFECTIVENESS OF HOME FORTIFICATION WITH MULTI-MICRONUTRIENT POWDERS IN BHUTANESE REFUGEE CHILDREN: A FIVE YEAR FOLLOW-UP SO ANNALS OF NUTRITION AND METABOLISM LA English DT Meeting Abstract DE micronutrient powders; anemia; effectiveness C1 [Bilukha, O.; Husain, F.; Jacobson, L.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Wilkinson, C.; Andresen, E.] United Nations High Commissioner Refugees, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-6807 EI 1421-9697 J9 ANN NUTR METAB JI Ann. Nutr. Metab. PY 2013 VL 63 SU 1 BP 275 EP 275 PG 1 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 219YR UT WOS:000324548201566 ER PT J AU Lutter, C Mir, R Pachon, H Cheung, E Sullivan, K de Kanashiro, HC Panjwani, A Escobar, J AF Lutter, C. Mir, R. Pachon, H. Cheung, E. Sullivan, K. Creed de Kanashiro, H. Panjwani, A. Escobar, J. TI PROPAN (PROCESS FOR THE PROMOTION OF CHILD FEEDING): A TOOL FOR INFANT AND YOUNG CHILD FEEDING PROGRAMMING SO ANNALS OF NUTRITION AND METABOLISM LA English DT Meeting Abstract DE breastfeeding; complementary feeding; child nutrition ProPAN C1 [Lutter, C.; Panjwani, A.] WHO, Pan Amer Hlth Org, Washington, DC USA. [Mir, R.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Pachon, H.; Sullivan, K.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Escobar, J.] Univ S Carolina, Columbia, SC 29208 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-6807 EI 1421-9697 J9 ANN NUTR METAB JI Ann. Nutr. Metab. PY 2013 VL 63 SU 1 BP 639 EP 639 PG 1 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 219YR UT WOS:000324548202488 ER PT J AU Makhmudov, A Caldwell, K Jones, R AF Makhmudov, A. Caldwell, K. Jones, R. TI COMPREHENSIVE APPROACH TO ENSURE THE QUALITY OF URINARY IODINE DETERMINATIONS SO ANNALS OF NUTRITION AND METABOLISM LA English DT Meeting Abstract DE Urinary iodine; Iodine Deficiency Disorders; Laboratory Proficiency; Laboratory Methods C1 [Makhmudov, A.; Caldwell, K.; Jones, R.] Ctr Dis Control & Prevent, Inorgan & Radiat Analyt Toxicol Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-6807 EI 1421-9697 J9 ANN NUTR METAB JI Ann. Nutr. Metab. PY 2013 VL 63 SU 1 BP 1544 EP 1544 PG 1 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 219YR UT WOS:000324548204713 ER PT J AU Shahab-Ferdows, S Hampel, D York, E Bently, M Adair, L Flax, V van der Horst, C Jamieson, D Tegha, G Allen, L AF Shahab-Ferdows, S. Hampel, D. York, E. Bently, M. Adair, L. Flax, V. van der Horst, C. Jamieson, D. Tegha, G. Allen, L. TI BREASTMILK B-VITAMINS CONCENTRATIONS IN HIV-INFECTED MALAWIAN WOMEN ARE INCREASED BY LIPID-BASED NUTRIENT SUPPLEMENTS AND REDUCED BY ANTIRETROVIRAL PROPHYLAXIS SO ANNALS OF NUTRITION AND METABOLISM LA English DT Meeting Abstract DE B-vitamins; lipid-based nutrient supplements; HIV C1 [Shahab-Ferdows, S.; Hampel, D.; York, E.; Allen, L.] ARS, WHNRC, USDA, Davis, CA USA. [Bently, M.; Adair, L.; Flax, V.; van der Horst, C.] UNC, Sch Publ Health, Chapel Hill, NC USA. [Jamieson, D.] CDC, Atlanta, GA 30333 USA. [Tegha, G.] UNC Project, Lilongwe, Malawi. RI Hampel, Daniela/K-2047-2014 OI Hampel, Daniela/0000-0003-0288-7680 NR 0 TC 0 Z9 0 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-6807 EI 1421-9697 J9 ANN NUTR METAB JI Ann. Nutr. Metab. PY 2013 VL 63 SU 1 BP 1544 EP 1544 PG 1 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 219YR UT WOS:000324548204712 ER PT J AU Parkinson, AJ AF Parkinson, Alan J. TI The Arctic Human Health Initiative: a legacy of the International Polar Year 2007-2009 SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article DE International Polar Year; Arctic Health; research; education outreach communication; Arctic Council ID HEPATITIS-B-VIRUS; MYCOBACTERIUM-TUBERCULOSIS INFECTION; ALASKA NATIVE YOUTH; SUPPURATIVE OTITIS-MEDIA; CANADIAN INUIT; SEXUAL HEALTH; RISK-FACTORS; MULTIDIMENSIONAL ASSESSMENT; STREPTOCOCCUS-PNEUMONIAE; SUSTAINABLE DEVELOPMENT AB Background. The International Polar Year (IPY) 2007-2008 represented a unique opportunity to further stimulate cooperation and coordination on Arctic health research and increase the awareness and visibility of Arctic regions. The Arctic Human Health Initiative (AHHI) was a US-led Arctic Council IPY coordinating project that aimed to build and expand on existing International Union for Circumpolar Health (IUCH) and Arctic Council human health interests. The project aimed to link researchers with potential international collaborators and to serve as a focal point for human health research, education, outreach and communication activities during the IPY. The progress of projects conducted as part of this initiative up until the end of the Arctic Council Swedish chairmanship in May 2013 is summarized in this report. Design. The overall goals of the AHHI was to increase awareness and visibility of human health concerns of Arctic peoples, foster human health research, and promote health strategies that will improve health and wellbeing of all Arctic residents. Proposed activities to be recognized through the initiative included: expanding research networks that will enhance surveillance and monitoring of health issues of concern to Arctic peoples, and increase collaboration and coordination of human health research; fostering research that will examine the health impact of anthropogenic pollution, rapid modernization and economic development, climate variability, infectious and chronic diseases, intentional and unintentional injuries, promoting education, outreach and communication that will focus public and political attention on Arctic health issues, using a variety of publications, printed and electronic reports from scientific conferences, symposia and workshops targeting researchers, students, communities and policy makers; promoting the translation of research into health policy and community action including implementation of prevention strategies and health promotion; and promoting synergy and strategic direction of Arctic human health research and health promotion. Results. As of 31 March, 2009, the official end of the IPY, AHHI represented a total of 38 proposals, including 21 individual Expressions of Intent (EoI), and 9 full proposals (FP), submitted to the IPY Joint Committee for review and approval from lead investigators from the US, Canada, Greenland, Norway, Finland, Sweden and the Russian Federation. In addition, there were 10 National Initiatives (NI-projects undertaken during IPY beyond the IPY Joint Committee review process). Individual project details can be viewed at www.arctichealth.org. The AHHI currently monitors the progress of 28 individual active human health projects in the following thematic areas: health network expansion (5 projects), infectious disease research (7 projects), environmental health research (7 projects), behavioral and mental health research (4 projects), and outreach education and communication (5 projects). Conclusions. While some projects have been completed, others will continue well beyond the IPY. The IPY 2007-2008 represented a unique opportunity to further stimulate cooperation and coordination on Arctic health research and increase the awareness and visibility of Arctic regions. C1 Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK 99508 USA. RP Parkinson, AJ (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK 99508 USA. EM ajp1@cdc.gov NR 122 TC 3 Z9 3 U1 4 U2 10 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 69 EP 86 AR 21655 DI 10.3402/ijch.v72i0.21655 PG 18 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900011 ER PT J AU Dunne, EF Koch, A AF Dunne, Eileen F. Koch, Anders TI HPV vaccines for circumpolar health: summary of plenary session, "Opportunities for Prevention: Global HPV Vaccine" and "Human Papillomavirus Prevention: The Nordic Experience" SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article DE HPV vaccine; Nordic countries; circumpolar health; HPV ID INFECTION AB In this publication, we provide an overview of the presentations, "Opportunities for Prevention: Global HPV Vaccine" and "Human Papillomavirus Prevention: The Nordic Experience" as a part of the 15th International Congress on Circumpolar Health, held at Anchorage, Alaska, on August 8, 2012. We provide an overview of HPV, HPV vaccines and policy as well as the Nordic experience with HPV vaccine introduction. C1 [Dunne, Eileen F.] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Atlanta, GA USA. [Koch, Anders] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark. RP Dunne, EF (reprint author), 1600 Clifton Rd,MS E-02, Atlanta, GA 30333 USA. EM dde9@cdc.gov RI yan, liu/A-1822-2015 OI yan, liu/0000-0001-8517-1084 NR 16 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 101 EP 105 AR 21070 DI 10.3402/ijch.v72i0.21070 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900016 PM 28156289 ER PT J AU Kelly, JJ Unger, ER Dunne, EF Murphy, NJ Tiesinga, J Koller, KR Swango-Wilson, A Philemonof, D Lounmala, X Markowitz, LE Steinau, M Hennessy, T AF Kelly, Janet J. Unger, Elizabeth R. Dunne, Eileen F. Murphy, Neil J. Tiesinga, James Koller, Kathy R. Swango-Wilson, Amy Philemonof, Dino Lounmala, Xay Markowitz, Lauri E. Steinau, Martin Hennessy, Thomas TI HPV genotypes detected in cervical cancers from Alaska Native women, 1980-2007 SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article DE Alaska Native; HPV; cervical cancer; HPV genotypes ID HUMAN-PAPILLOMAVIRUS TYPES; AGED 16-26 YEARS; PARTICLE VACCINE; INFECTION; PREVALENCE; DISEASE; IMPACT AB Background. Human papillomavirus (HPV) vaccine prevents cervical pre-cancers and cancers caused by HPV types 16 and 18. This study provides information on the HPV types detected in cervical cancers of Alaska Native (AN) women. Methods. Cases of invasive cervical cancer diagnosed in AN women aged 18 and above between 1980 and 2007 were identified from the Alaska Native Tumor Registry. A representative formalin-fixed, paraffin-embedded archived pathology block was retrieved and serially sectioned to allow histologic confirmation of lesion (first and last sections) and PCR testing of intervening sections. Extracted DNA was tested for HPV using Linear Array HPV Genotyping Test (Roche Diagnostics) with additional INNO-LiPA HPV Genotyping Assay (Innogenetics) testing on negative or inadequate specimens. All specimens were tested for a minimum 37 HPV types. Results. Of 62 cervical cancer specimens evaluated, 57 (91.9%) contained one or more HPV types. Thirty-eight (61.2%) cancers contained HPV types 16 or 18, and 18 (29%) contained an oncogenic type other than type 16 or 18. Conclusions. Overall, almost two-thirds (61.2%) of the archived cervical cancers had detectible HPV types 16 or 18, a finding similar to studies of US women. As expected, a proportion of cancers would not be prevented by the current vaccines. HPV vaccination and cervical cancer screening are important prevention strategies for AN women. C1 [Kelly, Janet J.; Murphy, Neil J.; Tiesinga, James; Koller, Kathy R.; Swango-Wilson, Amy; Philemonof, Dino; Lounmala, Xay] Alaska Native Tribal Hlth Consortium, Anchorage, AK 99508 USA. [Unger, Elizabeth R.; Dunne, Eileen F.; Markowitz, Lauri E.; Steinau, Martin] Ctr Dis Control, Atlanta, GA 30333 USA. [Hennessy, Thomas] Ctr Dis Control, Anchorage, AK USA. RP Kelly, JJ (reprint author), Alaska Native Tribal Hlth Consortium, Div Community Hlth Serv, Epidemiol Ctr, 4000 Ambassador Dr, Anchorage, AK 99508 USA. EM jjkelly@anthc.org OI Unger, Elizabeth/0000-0002-2925-5635 NR 12 TC 1 Z9 1 U1 0 U2 3 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 289 EP 292 AR 21115 DI 10.3402/ijch.v72i0.21115 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900070 ER PT J AU Fleischer, N Melstrom, P Yard, E Brubaker, M Tcheripanoff, M Thomas, T AF Fleischer, N. Melstrom, P. Yard, E. Brubaker, M. Tcheripanoff, M. Thomas, T. TI MORBIDITY AND MORTALITY ASSOCIATED WITH UNINTENTIONAL FALLS THROUGH THE ICE IN ALASKA SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Meeting Abstract C1 [Fleischer, N.; Melstrom, P.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. EM nfleischer@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 519 EP 519 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900172 ER PT J AU Hennessy, TW Romain, S AF Hennessy, Thomas W. Romain, Sandra TI Infectious Disease - Introduction SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Editorial Material C1 [Hennessy, Thomas W.] Ctr Dis Control & Prevent CDC, Natl Ctr Zoonot Infect Dis, Div Preparedness & Emerging Infect, Arctic Investigat Program, Anchorage, AK USA. [Romain, Sandra] Univ Toronto, Toronto, ON, Canada. RP Hennessy, TW (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Zoonot Infect Dis, Div Preparedness & Emerging Infect, Arctic Investigat Program, Anchorage, AK USA. EM tbh0@cdc.gov; s.romain@mail.utoronto.ca NR 6 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 609 EP 610 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900218 ER PT J AU Holman, RC Hennessy, TW Haberling, DL Callinan, LS Singleton, RJ Redd, JT Steiner, CA Bruce, MG AF Holman, Robert C. Hennessy, Thomas W. Haberling, Dana L. Callinan, Laura S. Singleton, Rosalyn J. Redd, John T. Steiner, Claudia A. Bruce, Michael G. TI Increasing trend in the rate of infectious disease hospitalisations among Alaska Native people SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article DE Alaska Native; infectious disease; hospitalisations; Alaska; lower respiratory tract infection ID SYNCYTIAL VIRUS-DISEASE; RESPIRATORY-TRACT; GENERAL-POPULATION; CHILDREN YOUNGER; UNITED-STATES; AMERICAN; INFANTS; RISK; WATER; AGE AB Objectives. To examine the epidemiology of infectious disease (ID) hospitalisations among Alaska Native (AN) people. Methods. Hospitalisations with a first-listed ID diagnosis for American Indians and ANs residing in Alaska during 2001-2009 were selected from the Indian Health Service direct and contract health service inpatient data. ID hospitalisations to describe the general US population were selected from the Nationwide Inpatient Sample. Annual and average annual (2007-2009) hospitalization rates were calculated. Results. During 2007-2009, IDs accounted for 20% of hospitalisations among AN people. The 2007-2009 average annual age-adjusted ID hospitalisation rate (2126/100,000 persons) was higher than that for the general US population (1679/100,000; 95% CI 1639-1720). The ID hospitalisation rate for AN people increased from 2001 to 2009 (17%, p<0.001). Although the rate during 2001-2009 declined for AN infants (<1 year of age; p=0.03), they had the highest 2007-2009 average annual rate (15106/100,000), which was 3 times the rate for general US infants (5215/100,000; 95% CI 4783-5647). The annual rates for the age groups 1-4, 5-19, 40-49, 50-59 and 70-79 years increased (p<0.05). The highest 2007-2009 age-adjusted average annual ID hospitalisation rates were in the Yukon-Kuskokwim (YK) (3492/100,000) and Kotzebue (3433/ 100,000) regions; infant rates were 30422/100,000 and 26698/100,000 in these regions, respectively. During 2007-2009, lower respiratory tract infections accounted for 39% of all ID hospitalisations and approximately 50% of ID hospitalisations in YK, Kotzebue and Norton Sound, and 74% of infant ID hospitalisations. Conclusions. The ID hospitalisation rate increased for AN people overall. The rate for AN people remained higher than that for the general US population, particularly in infants and in the YK and Kotzebue regions. Prevention measures to reduce ID morbidity among AN people should be increased in high-risk regions and for diseases with high hospitalisation rates. C1 [Holman, Robert C.; Haberling, Dana L.; Callinan, Laura S.] USDHHS, Ctr Dis Control & Prevent CDC, NCEZID, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Hennessy, Thomas W.; Singleton, Rosalyn J.; Bruce, Michael G.] USDHHS, CDC, NCEZID, Arctic Invest Program, Anchorage, AK USA. [Singleton, Rosalyn J.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Redd, John T.] USDHHS, Indian Hlth Serv, Santa Fe, NM USA. [Steiner, Claudia A.] Ctr Delivery Org & Markets, Agcy Healthcare Res & Qual, Healthcare Cost & Utilizat Project, Rockville, MD USA. RP Holman, RC (reprint author), Ctr Dis Control, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Mailstop A-30, Atlanta, GA 30333 USA. EM RHolman@cdc.gov NR 32 TC 3 Z9 3 U1 1 U2 3 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 624 EP 632 AR 20994 DI 10.3402/ijch.v72i0.20994 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900221 ER PT J AU Raczniak, GA Bulkow, L Bruce, M Zanis, L Baum, R Snowball, M Bird, K Sharapov, U Hennessy, T McMahon, B AF Raczniak, Gregory A. Bulkow, Lisa Bruce, Michael Zanis, Lyn Baum, Richard Snowball, Mary Bird, Katherine Sharapov, Umid Hennessy, Thomas McMahon, Brian TI Inactivated hepatitis A vaccine immunogenicity: 17-year follow-up of an Alaska native prospective cohort SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article ID PROGRAM C1 [Raczniak, Gregory A.; Bulkow, Lisa; Bruce, Michael; Zanis, Lyn; Baum, Richard; Snowball, Mary; Bird, Katherine; Sharapov, Umid; Hennessy, Thomas; McMahon, Brian] Ctr Dis Control & Prevent CDC, Natl Ctr Zoonot Infect Dis, Div Preparedness & Emerging Infect, Arctic Invest Program, Anchorage, AK USA. RP Bruce, M (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Zoonot Infect Dis, Div Preparedness & Emerging Infect, Arctic Invest Program, Anchorage, AK USA. EM zwa8@cdc.gov NR 3 TC 0 Z9 0 U1 0 U2 1 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 686 EP 686 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900230 ER PT J AU Reasonover, A Lovgren, M Lambertsen, L Kristinsson, K Martin, I Lefebvre, B Zulz, T Bruden, D Bruce, M Rudolph, K AF Reasonover, Alisa Lovgren, Marguerite Lambertsen, Lotte Kristinsson, Karl Martin, Irene Lefebvre, Brigitte Zulz, Tammy Bruden, Dana Bruce, Michael Rudolph, Karen TI The International Circumpolar Surveillance interlaboratory quality control program for Streptococcus pneumoniae, 1999-2011 SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article C1 [Reasonover, Alisa; Zulz, Tammy; Bruden, Dana; Bruce, Michael; Rudolph, Karen] CDC, Arctic Invest Program, Anchorage, AK USA. [Lovgren, Marguerite] Prov Lab Publ Hlth, Edmonton, AB, Canada. [Lambertsen, Lotte] Statens Serum Inst, Neisseria & Streptococcus Reference Lab, DK-2300 Copenhagen, Denmark. [Kristinsson, Karl] Landspitali Univ Hosp, Dept Clin Microbiol, Reykjavik, Iceland. [Martin, Irene] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada. [Lefebvre, Brigitte] Inst Natl Sante Publ Quebec, Lab Sante Publ Quebec, Ste Anne De Bellevue, PQ, Canada. RP Reasonover, A (reprint author), CDC, Arctic Invest Program, Anchorage, AK USA. EM adr3@cdc.gov NR 2 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 697 EP 697 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900235 ER PT J AU McMahon, BJ Negus, S Snowball, M Homan, C Bulkow, L Bruce, M Simons, B Livingston, S AF McMahon, Brian J. Negus, Susan Snowball, Mary Homan, Chriss Bulkow, Lisa Bruce, Michael Simons, Brenna Livingston, Stephen TI Clinical management of chronic hepatitis B infection in Alaska Native People: outcome and effectiveness of surveillance for early detection of hepatocellular carcinoma and antiviral therapy to prevent cirrhosis SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article C1 [McMahon, Brian J.; Negus, Susan; Snowball, Mary; Homan, Chriss; Simons, Brenna; Livingston, Stephen] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. [McMahon, Brian J.; Bulkow, Lisa; Bruce, Michael] Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. RP McMahon, BJ (reprint author), Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. EM bdm9@cdc.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 700 EP 701 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900237 ER PT J AU Hedlund, C Bruden, D Bruce, M Hurlburt, D Rudolph, K Parkinson, A Evengard, B Hennessy, T AF Hedlund, Christina Bruden, Dana Bruce, Michael Hurlburt, Debby Rudolph, Karen Parkinson, Alan Evengard, Birgitta Hennessy, Thomas TI Factors affecting antimicrobial resistance among colonising Streptococcus pneumoniae in rural Alaska villages over 10 years SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article C1 [Hedlund, Christina; Evengard, Birgitta] Umea Univ, Dept Publ Hlth & Clin Med, Div Epidemiol & Global Hlth, Umea, Sweden. [Bruden, Dana; Bruce, Michael; Hurlburt, Debby; Rudolph, Karen; Parkinson, Alan; Hennessy, Thomas] Ctr Dis Control & Prevent CDC, Arctic Invest Program, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. RP Hedlund, C (reprint author), Umea Univ, Dept Publ Hlth & Clin Med, Div Epidemiol & Global Hlth, Umea, Sweden. EM christina.hedlund@climi.umu.se NR 3 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 702 EP 703 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900238 ER PT J AU Miernyk, K Keck, J Rudolph, K Bruden, D Morris, J Bulkow, L Sacco, F McMahon, B Parkinson, A Hennessy, T Bruce, M AF Miernyk, Karen Keck, James Rudolph, Karen Bruden, Dana Morris, Julie Bulkow, Lisa Sacco, Frank McMahon, Brian Parkinson, Alan Hennessy, Thomas Bruce, Michael TI Is there a need for a multicentre Arctic study of Helicobacter pylori infection and gastric cancer? SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article C1 [Miernyk, Karen; Sacco, Frank; McMahon, Brian] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Miernyk, Karen; Keck, James; Rudolph, Karen; Bruden, Dana; Morris, Julie; Bulkow, Lisa; McMahon, Brian; Parkinson, Alan; Hennessy, Thomas; Bruce, Michael] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Miernyk, K (reprint author), Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. EM kmiernyk@cdc.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 713 EP 714 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900243 ER PT J AU Rogers, K Roohi, S Illig, P Okyere, F AF Rogers, Kimberly Roohi, Shahrokh Illig, Petra Okyere, Frank TI Port of entry operations in Alaska: examples of travel-related infectious disease prevention and response SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article C1 [Rogers, Kimberly; Roohi, Shahrokh; Illig, Petra; Okyere, Frank] Ctr Dis Control & Prevent CDC, Anchorage Quarantine Stn, Anchorage, AK USA. RP Rogers, K (reprint author), Ctr Dis Control & Prevent CDC, Anchorage Quarantine Stn, Anchorage, AK USA. EM kbrogers@cdc.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 723 EP 724 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900247 ER PT J AU Parkinson, A Evengard, B AF Parkinson, A. Evengard, B. TI CLIMATE CHANGE AND POTENTIAL HEALTH IMPACTS OF INFECTIOUS DISEASES IN THE CIRCUMPOLAR NORTH: FORMATION OF AN INTERNATIONAL CIRCUMPOLAR SURVEILLANCE CLIMATE CHANGE AND INFECTIOUS DISEASE WORKING GROUP SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Meeting Abstract C1 [Parkinson, A.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Evengard, B.] Umea Univ Hosp, Umea, Sweden. EM ajp1@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 745 EP 745 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900257 ER PT J AU Singleton, R Bruden, D Bentley, S Hennessy, T AF Singleton, R. Bruden, D. Bentley, S. Hennessy, T. TI CHANGES IN SEASONALITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) IN A SOUTHWEST REGION OF ALASKA (1994-2010) SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Meeting Abstract C1 [Bruden, D.; Hennessy, T.] CDC, AIP, Atlanta, GA 30333 USA. EM ris2@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 745 EP 745 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900258 ER PT J AU Singleton, R Holman, R Folkema, A Redd, J Steiner, C Hennessy, T AF Singleton, R. Holman, R. Folkema, A. Redd, J. Steiner, C. Hennessy, T. TI LOWER RESPIRATORY TRACT HOSPITALIZATIONS IN ALASKA NATIVE CHILDREN COMPARED WITH OTHER AMERICAN INDIAN/ALASKA NATIVE CHILDREN AND THE GENERAL US CHILD POPULATION SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Meeting Abstract C1 [Holman, R.] CDC, NCEZID, Atlanta, GA 30333 USA. [Hennessy, T.] CDC, Arctic Invest Program, Atlanta, GA 30333 USA. EM ris2@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 746 EP 746 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900260 ER PT J AU Jackson, M Rose, C Cohn, A Clark, T Wenger, J Bulkow, L Bruce, M Messonnier, N Hennessy, T AF Jackson, M. Rose, C. Cohn, A. Clark, T. Wenger, J. Bulkow, L. Bruce, M. Messonnier, N. Hennessy, T. TI MODELING INSIGHTS INTO HAEMOPHILUS INFLUENZAE TYPE B VACCINATION PROGRAMS IN ALASKA NATIVES SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Meeting Abstract C1 [Rose, C.; Cohn, A.; Clark, T.; Wenger, J.; Bulkow, L.; Bruce, M.; Messonnier, N.; Hennessy, T.] Ctr Dis Control & Prevent, Atlanta, GA USA. EM jackson.ml@ghc.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 753 EP 753 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900276 ER PT J AU Bruden, D Bruce, MG Wenger, JD Hurlburt, DA Bulkow, LR Hennessy, TW AF Bruden, Dana Bruce, Michael G. Wenger, Jay D. Hurlburt, Debby A. Bulkow, Lisa R. Hennessy, Thomas W. TI Migration of persons between households in rural Alaska: considerations for study design SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article DE household; migration; intervention; crowding; rural; sample size; exposure; power ID RESPIRATORY-INFECTIONS; HOUSING IMPROVEMENT; CONJUGATE VACCINE; TRACT INFECTIONS; HEALTH; DISEASE; IMPACT; CHILDREN; NATIVES; TRENDS AB Introduction. Recent epidemiologic research studies in rural Alaska have examined risk factors for infectious diseases collected at the household level. Examples include the health effects of in-home piped water and household air quality. Because the exposure is measured at the household level, it is necessary to determine if participants remained in the same house throughout the course of follow-up. Methods. We used data from a pneumococcal nasopharyngeal carriage study in 8 rural Alaska villages >= 3 regions; average number of persons: 642 (min 210, max 720 per village) to quantify changes in household membership and individual movements from 2008 to 2010. We define a household as a group of individuals living in a home together. Because the same households participated in carriage surveys over several years, we could determine changes on an annual basis. We calculated the percentage of households with a >= 1 person change in household members from year to year. Additionally, we present the percentage of individuals that changed households during consecutive years. Results. In 3 regions of Alaska, the average household size was 5 persons. Between 2008 and 2009, 50% (250/497) of households had a change in their membership (>= 1 person in-migrated or out-migrated). Fifty-three percent of households experienced some migration of their members between 2009 and 2010. A total of 27 and 15% of households had a change of >= 2 and >= 3 persons, respectively. The percentage of households with movement was similar among the 3 rural regions and varied from 42 to 63% between villages. At the individual level, an average of 11% of persons changed households between years. The group with the most movement between houses was persons 18-29 years of age (19%), and least movement was in 5-10 and 50-64 years of age (6%). There was no difference in movement by gender. Conclusions. In rural Alaska, 52% of households experienced movement of members between years and 11% of individuals change households. These are important demographic figures to consider when planning and designing studies that measure an epidemiological exposure at the household level. Power and sample size calculations should account for the loss to follow-up associated with in-and out-migration of individuals from households. C1 [Bruden, Dana; Bruce, Michael G.; Wenger, Jay D.; Hurlburt, Debby A.; Bulkow, Lisa R.; Hennessy, Thomas W.] Ctr Dis Control & Prevent CDC, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Infect Dis, Anchorage, AK USA. RP Bruden, D (reprint author), CDC, 4055 Tudor Ctr Dr, Anchorage, AK USA. EM dbruden@cdc.gov NR 29 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 851 EP 856 AR 21229 DI 10.3402/ijch.v72i0.21229 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900313 ER PT J AU Parkinson, A Smith, S AF Parkinson, A. Smith, S. TI THE ALASKA AREA SPECIMEN BANK: A TRIBAL-FEDERAL PARTNERSHIP TO MAINTAIN AND MANAGE A RESOURCE FOR HEALTH RESEARCH SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Meeting Abstract C1 [Parkinson, A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Smith, S.] Bristol Bay Area Hlth Corp, Bristol, Avon, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 1022 EP 1023 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900369 ER PT J AU Thomas, T Ritter, T Bruce, M Bruden, D Bentley, S Hickel, K Hennessy, T AF Thomas, T. Ritter, T. Bruce, M. Bruden, D. Bentley, S. Hickel, K. Hennessy, T. TI VALIDATION OF HOUSEHOLD ILLNESS DIARIES AS TOOLS TO ASSESS IMPACT OF HEALTH-RELATED INTERVENTION SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Meeting Abstract C1 [Bruce, M.; Bruden, D.; Bentley, S.; Hennessy, T.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 SU 1 BP 1023 EP 1024 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235LZ UT WOS:000325721900371 ER PT J AU Carter, M Gallo, M Anderson, C Snead, MC Wiener, J Bailey, A Costenbader, E Legardy-Williams, J Hylton-Kong, T AF Carter, M. Gallo, M. Anderson, C. Snead, M. C. Wiener, J. Bailey, A. Costenbader, E. Legardy-Williams, J. Hylton-Kong, T. TI Intravaginal Cleansing among Women Attending a Sexually Transmitted Infection Clinic in Kingston, Jamaica SO WEST INDIAN MEDICAL JOURNAL LA English DT Article DE Intravaginal cleansing; Jamaica; KAP; sexually transmitted infections ID VAGINAL PRACTICES; PREVALENCE; MICROBICIDE; AFRICA AB Objectives: Although common worldwide, intravaginal cleansing is associated with poor health outcomes. We sought to describe intravaginal cleansing among women attending a sexually transmitted infection (STI) clinic in Jamaica. Methods: We examined intravaginal cleansing ("washing up inside the vagina", douching, and products or materials used) among 293 participants in a randomized trial of counselling messages at an STI clinic in Kingston. We focussed on information on intravaginal cleansing performed in the 30 days and three days preceding their baseline study visit. We describe reported cleansing behaviours and used logistic regression to identify, correlates of intravaginal cleansing. Results: Fifty-eight per cent of participants reported intravaginal cleansing in the previous 30 days, and 46% did so in the three days before baseline. Among those who cleansed in the previous 30 days, 88% reported doing so for hygiene unrelated to sex, and three-fourths reported generally doing so more than once per day. Soap (usually with water) and water alone were the most common products used for washing; commercial douches or detergents were reported infrequently. Intravaginal cleansing in the three days before the baseline visit was positively associated with having more than one sex partner in the previous three months (adjusted odds ratio [AOR], 1.9; 95% CI, 1.1, 3.2), and negatively associated with experiencing itching in the genital area at baseline (AOR, 0.6; 95% CI, 0.4, 1.0). Conclusions: A large proportion of women attending STI clinics in Jamaica engage in frequent intravaginal cleansing, indicating a need for clinicians to discuss this topic with them accordingly. C1 [Carter, M.; Gallo, M.; Snead, M. C.; Wiener, J.; Legardy-Williams, J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Anderson, C.; Hylton-Kong, T.] Comprehens Hlth Ctr Epidemiol Res & Training Unit, Minist Hlth, Kingston, Jamaica. [Bailey, A.] Univ West Indies, Kingston 7, Jamaica. [Costenbader, E.] FH1 360, Durham, NC USA. RP Carter, M (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,MS-K-34, Atlanta, GA 30341 USA. EM mcarter1@cdc.gov FU Intramural CDC HHS [CC999999] NR 33 TC 3 Z9 3 U1 0 U2 1 PU UNIV WEST INDIES FACULTY MEDICAL SCIENCES PI KINGSTON PA MONA CAMPUS, KINGSTON 7, JAMAICA SN 0043-3144 J9 W INDIAN MED J JI West Ind. Med. J. PD JAN PY 2013 VL 62 IS 1 BP 56 EP 61 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 236XW UT WOS:000325833800010 PM 24171329 ER PT J AU Knaack, JS Pittman, CT Wooten, JV Jacob, JT Magnuson, M Silvestri, E Johnson, RC AF Knaack, Jennifer S. Pittman, Christopher T. Wooten, Joe V. Jacob, Justin T. Magnuson, Matthew Silvestri, Erin Johnson, Rudolph C. TI Stability of ricinine, abrine, and alpha-amanitin in finished tap water SO ANALYTICAL METHODS LA English DT Article ID CAPILLARY-ZONE-ELECTROPHORESIS; MASS-SPECTROMETRY; CHROMATOGRAPHIC DETERMINATION; LIQUID-CHROMATOGRAPHY; ALKALOID MARKER; BETA-AMANITIN; URINE SAMPLES; TOXINS; QUANTIFICATION; PERFORMANCE AB Ricinine and abrine are potential indicators of drinking water contamination by ricin and abrin, respectively. Simultaneous detection of ricinine and abrine, along with alpha-amanitin, another potential biotoxin water contaminant, is reportable through the use of automated sample preparation via solid phase extraction and detection using liquid chromatography/tandem-mass spectrometry. Performance of the method was characterized over eight analytical batches with quality control samples analyzed over 10 days. For solutions of analytes prepared with appropriate preservatives, the minimum reporting level (MRL) was 0.50 mu g L-1 for ricinine and abrine and 2.0 mu g L-1 for alpha-amanitin. Among the analytes, the accuracy of the analysis ranged between 93 and 100% at concentrations of 1-2.5x the MRL, with analytical precision ranging from 4 to 8%. Five drinking waters representing a range of water quality parameters and disinfection practices were fortified with the analytes and analyzed over a 28 day period to determine their storage stability in these waters. The analytical signal from ricinine was observed to be stable for 28 days after being spiked into all tap waters investigated. The analytical signal for abrine and alpha-amanitin decreased within 5 h after these analytes were spiked into some drinking waters, but afterwards, remained stable for 28 days. The magnitude of the decrease correlated with common water quality parameters potentially related to sorption of contaminants onto dissolved and colloidal components within the particular water. Even with the decrease, the detectability offered by the method may be 100-1000 times greater than potential toxicological benchmarks, suggesting the utility of the method for all three analytes, with additional quality control precautions for abrine and alpha-amanitin. C1 [Knaack, Jennifer S.; Pittman, Christopher T.; Wooten, Joe V.; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Emergency Response Branch, Atlanta, GA 30341 USA. [Jacob, Justin T.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Magnuson, Matthew; Silvestri, Erin] US EPA, Natl Homeland Secur Res Ctr, Cincinnati, OH 45268 USA. RP Johnson, RC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Emergency Response Branch, 4770 Buford Highway,MS F-44, Atlanta, GA 30341 USA. EM RJohnson6@cdc.gov NR 58 TC 2 Z9 2 U1 1 U2 17 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1759-9660 EI 1759-9679 J9 ANAL METHODS-UK JI Anal. Methods PY 2013 VL 5 IS 20 BP 5804 EP 5811 DI 10.1039/c3ay40304a PG 8 WC Chemistry, Analytical; Food Science & Technology; Spectroscopy SC Chemistry; Food Science & Technology; Spectroscopy GA 224XZ UT WOS:000324927300063 ER PT J AU Parkinson, AJ Hennessy, T Bulkow, L Smith, HS AF Parkinson, Alan J. Hennessy, Thomas Bulkow, Lisa Smith, H. Sally CA Alaska Area Specimen Bank TI The Alaska Area Specimen Bank: a tribal-federal partnership to maintain and manage a resource for health research SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article DE Biobanking; policy and procedures; Tribal and Federal Management ID PRIMARY HEPATOCELLULAR-CARCINOMA; HEPATITIS-B VIRUS; ALPHA-FETOPROTEIN; FOLLOW-UP; ANTIBODY; NATIVES; PROTECTION; INFECTION; OWNERSHIP; PROGRAM AB Banked biospecimens from a defined population are a valuable resource that can be used to assess early markers for illness or to determine the prevalence of a disease to aid the development of intervention strategies to reduce morbidity and mortality. The Alaska Area Specimen Bank (AASB) currently contains 266,353 residual biologic specimens ( serum, plasma, whole blood, tissue, bacterial cultures) from 83,841 persons who participated in research studies, public health investigations and clinical testing conducted by the U. S. Public Health Service and Alaska Native tribal health organisations dating back to 1961. The majority (95.7%) are serum specimens, 77% were collected between 1981 and 1994 and 85% were collected from Alaska Native people. Oversight of the specimen bank is provided by a working group with representation from tribal, state and federal health organisations, the Alaska Area IRB and a specimen bank committee which ensures the specimens are used in accordance with policies and procedures developed by the working group. C1 [Parkinson, Alan J.; Hennessy, Thomas; Bulkow, Lisa] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK USA. [Smith, H. Sally] Bristol Bay Area Hlth Corp, Dillingham, AK USA. RP Parkinson, AJ (reprint author), 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM ajp1@cdc.gov NR 24 TC 2 Z9 2 U1 1 U2 1 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 AR 20607 DI 10.3402/ijch.v72i0.20607 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235MF UT WOS:000325722500001 PM 23599909 ER PT J AU Lehman, EJ AF Lehman, Everett J. TI Epidemiology of neurodegeneration in American-style professional football players SO ALZHEIMERS RESEARCH & THERAPY LA English DT Review ID CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL FOOTBALL; HEAD-INJURY; APOLIPOPROTEIN-E; RECURRENT CONCUSSION; LEAGUE PLAYERS; BRAIN TRAUMA; DISEASE; RISK; IMPACTS AB The purpose of this article is to review the history of head injuries in relation to American-style football play, summarize recent research that has linked football head injuries to neurodegeneration, and provide a discussion of the next steps for refining the examination of neurodegeneration in football players. For most of the history of football, the focus of media reports and scientific studies on football-related head injuries was on the acute or short-term effects of serious, traumatic head injuries. Beginning about 10 years ago, a growing concern developed among neurologists and researchers about the long-term effects that playing professional football has on the neurologic health of the players. Autopsy-based studies identified a pathologically distinct neurodegenerative disorder, chronic traumatic encephalopathy, among athletes who were known to have experienced concussive and subconcussive blows to the head during their playing careers. Football players have been well represented in these autopsy findings. A mortality study of a large cohort of retired professional football players found a significantly increased risk of death from neurodegeneration. Further analysis found that non-line players were at higher risk than line players, possibly because of an increased risk of concussion. Although the results of the studies reviewed do not establish a cause-effect relationship between football-related head injury and neurodegenerative disorders, a growing body of research supports the hypothesis that professional football players are at an increased risk of neurodegeneration. Significant progress has been made in the last few years on detecting and defining the pathology of neurodegenerative diseases. However, less progress has been made on other factors related to the progression of those diseases in football players. This review identifies three areas for further research: (a) quantification of exposure - a consensus is needed on the use of clinically practical measurements of blows to the head among football players; (b) genetic susceptibility factors - a more rigorous set of unbiased epidemiological and clinical studies is needed before any causal relationships can be drawn between suspected genetic factors, head injury, and neurodegeneration; and (c) earlier detection and prevention of neurodegenerative diseases. C1 Natl Inst Occupat Safety & Hlth, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Lehman, EJ (reprint author), Natl Inst Occupat Safety & Hlth, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,R-13, Cincinnati, OH 45226 USA. EM elehman@cdc.gov FU intramural research program of the National Institute for Occupational Safety and Health (NIOSH) FX This study was funded by the intramural research program of the National Institute for Occupational Safety and Health (NIOSH). The sponsor reviewed and approved the final submission but did not have a role in design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation of the manuscript. The author wishes to thank Sherry Baron, Misty Hein, and Christine Gersic of NIOSH for their previous work on the cohort study of NFL players. The author wishes to thank Douglas Trout of NIOSH for his review and valuable comments on the manuscript. The findings and conclusions in this report are those of the author and do not necessarily represent the views of the NIOSH. NR 65 TC 4 Z9 4 U1 1 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1758-9193 J9 ALZHEIMERS RES THER JI Alzheimers Res. Ther. PY 2013 VL 5 IS 4 AR 34 DI 10.1186/alzrt188 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 229WL UT WOS:000325298300004 PM 23876143 ER PT J AU Barajas, J Suaza, JD Torres, C Rua, GL Uribe-Soto, S Porter, CH AF Barajas G, Jovany Suaza, Juan David, V Torres G, Carolina Leon Rua, Guillermo Uribe-Soto, Sandra Porter, Charles H. TI Mosquitoes (Diptera: Culicidae) associated to guadua in municipalities of Anserma, Hispania and Jardin, Colombia SO REVISTA COLOMBIANA DE ENTOMOLOGIA LA Spanish DT Article DE Taxonomy; Culicidae; Larval habitats; Phytotelmata ID FOREST; CLASSIFICATION; PHYTOTELMATA; PHYLOGENY AB The study of culicine mosquitoes (Diptera: Culicidae) in Colombia, has been limited even though this subfamily is important in public health. This study aimed to determine the species of Culicinae breeding in stands of Guadua angustifolia in areas with coffee plantations. Three breeding sites were distinguished: guadua stumps, perforated internodes and containers. Nine mosquito species were identified which two are new records for Colombia (Orthopodomyia albicosta, Wyeomyia oblita), five new records for the departments (Culex secundus, Cx. antunesi, Limatus durhami, Trichoprosopon digitatum and Sabethes undosus). Two others are under current study (Trichoprosopon sp. part of the Pallidiventer complex, and Toxorhynchites sp.). There was a relationship between the species found and the water volume and height above ground, measured for each of the breeding sites. Two of the species, Tr digitatum and Li. durhami, are reported in literature as potential vectors of arboviral agents; Toxorhynchites is grouped with species whose larvae are predators. The results support an important role for guadua as breeding sites for various mosquitoes, including some species of public health importance. C1 [Barajas G, Jovany] Univ Antioquia, PECET, SIU, Bogota, Colombia. [Suaza, Juan David, V] Univ Nacl Colombia, Univ Antioquia, PECET Grp Sistennat Mol GSM, Medellin, Colombia. [Torres G, Carolina] Univ Antioquia, SIU, PECET, Fac Med, Bogota, Colombia. [Leon Rua, Guillermo] Univ Antioquia, Fac Med, Lab Hemoparasitosis & Entomol Med, Bogota, Colombia. [Uribe-Soto, Sandra] Univ Nacl Colombia, Fac Ciencias, Sede Medellin, Colombia. [Porter, Charles H.] CDC, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Barajas, J (reprint author), Univ Antioquia, PECET, SIU, Carrera 53 61-30,Torre 2,Lab 632, Bogota, Colombia. EM j.barajas@pecet-colombia.org; jdsuaza@unal.edu.co; carolina.torres@siu.udea.edu.co; gl_rua@medicina.udea.edu.co; suribe@unal.edu.co; chp1@cdc.gov NR 62 TC 3 Z9 3 U1 0 U2 2 PU SOC COLOMBIANA ENTOMOLOGIA-SOCOLEN PI SANTAFE DE BOGOTA PA APARTADO AEREO 11366, SANTAFE DE BOGOTA, D.C. 00000, COLOMBIA SN 0120-0488 J9 REV COLOMB ENTOMOL JI Rev. Colomb. Entomol. PD JAN-JUN PY 2013 VL 39 IS 1 BP 132 EP 140 PG 9 WC Entomology SC Entomology GA 226MH UT WOS:000325039900022 ER PT B AU El-Saharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM AF El-Saharty, Sameh Ahsan, Karar Zunaid Koehlmoos, Tracey L. P. Engelgau, Michael M. BA ElSaharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM BF ElSaharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM TI Tackling Noncommunicable Diseases in Bangladesh Now Is the Time Overview SO TACKLING NONCOMMUNICABLE DISEASES IN BANGLADESH: NOW IS THE TIME SE Directions in Development LA English DT Editorial Material; Book Chapter ID BURDEN C1 [El-Saharty, Sameh; Koehlmoos, Tracey L. P.; Engelgau, Michael M.] World Bank, Washington, DC 20433 USA. [El-Saharty, Sameh] US Agcy Int Dev, Washington, DC 20523 USA. [El-Saharty, Sameh] Harvard Univ, Cambridge, MA 02138 USA. [El-Saharty, Sameh] Amer Univ Cairo, Cairo, Egypt. [Ahsan, Karar Zunaid] World Bank, South Asia Human Dev Sect, Washington, DC 20433 USA. [Koehlmoos, Tracey L. P.] ICDDR B, Dhaka, Bangladesh. [Koehlmoos, Tracey L. P.] ICDDR B, Ctr Systemat Review, Dhaka, Bangladesh. [Koehlmoos, Tracey L. P.] George Mason Univ, Coll Hlth & Human Serv, Fairfax, VA 22030 USA. [Engelgau, Michael M.] US CDC Off, Beijing, Peoples R China. [Engelgau, Michael M.] CDC, Atlanta, GA 30333 USA. RP El-Saharty, S (reprint author), World Bank, 1818 H St NW, Washington, DC 20433 USA. NR 26 TC 0 Z9 0 U1 1 U2 1 PU WORLD BANK INST PI WASHINGTON PA 1818 H ST NW, WASHINGTON, DC 20433 USA BN 978-0-8213-9920-0; 978-0-8213-9921-7 J9 DIR DEV PY 2013 BP 1 EP 15 D2 10.1596/978-0-8213-9920-0 PG 15 WC Health Policy & Services; Planning & Development SC Health Care Sciences & Services; Public Administration GA BHB61 UT WOS:000324888000002 ER PT J AU El-Saharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM AF El-Saharty, Sameh Ahsan, Karar Zunaid Koehlmoos, Tracey L. P. Engelgau, Michael M. BA ElSaharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM BF ElSaharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM TI Tackling Noncommunicable Diseases in Bangladesh Now Is the Time Preface SO TACKLING NONCOMMUNICABLE DISEASES IN BANGLADESH: NOW IS THE TIME SE Directions in Development LA English DT Editorial Material; Book Chapter C1 [El-Saharty, Sameh; Koehlmoos, Tracey L. P.; Engelgau, Michael M.] World Bank, Washington, DC 20433 USA. [El-Saharty, Sameh] US Agcy Int Dev, Washington, DC 20523 USA. [El-Saharty, Sameh] Harvard Univ, Cambridge, MA 02138 USA. [El-Saharty, Sameh] Amer Univ Cairo, Cairo, Egypt. [Ahsan, Karar Zunaid] World Bank, South Asia Human Dev Sect, Washington, DC 20433 USA. [Koehlmoos, Tracey L. P.] ICDDR B, Dhaka, Bangladesh. [Koehlmoos, Tracey L. P.] ICDDR B, Ctr Systemat Review, Dhaka, Bangladesh. [Koehlmoos, Tracey L. P.] George Mason Univ, Coll Hlth & Human Serv, Fairfax, VA 22030 USA. [Engelgau, Michael M.] US CDC Off, Beijing, Peoples R China. [Engelgau, Michael M.] CDC, Atlanta, GA 30333 USA. RP El-Saharty, S (reprint author), World Bank, 1818 H St NW, Washington, DC 20433 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WORLD BANK INST PI WASHINGTON PA 1818 H ST NW, WASHINGTON, DC 20433 USA BN 978-0-8213-9920-0 J9 DIR DEV PY 2013 BP IX EP X D2 10.1596/978-0-8213-9920-0 PG 2 WC Health Policy & Services; Planning & Development SC Health Care Sciences & Services; Public Administration GA BHB61 UT WOS:000324888000001 ER PT B AU El-Saharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM AF El-Saharty, Sameh Ahsan, Karar Zunaid Koehlmoos, Tracey L. P. Engelgau, Michael M. BA ElSaharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM BF ElSaharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM TI Contexts and Transitions SO TACKLING NONCOMMUNICABLE DISEASES IN BANGLADESH: NOW IS THE TIME SE Directions in Development LA English DT Article; Book Chapter C1 [El-Saharty, Sameh; Koehlmoos, Tracey L. P.; Engelgau, Michael M.] World Bank, Washington, DC 20433 USA. [El-Saharty, Sameh] US Agcy Int Dev, Washington, DC 20523 USA. [El-Saharty, Sameh] Harvard Univ, Cambridge, MA 02138 USA. [El-Saharty, Sameh] Amer Univ Cairo, Cairo, Egypt. [Ahsan, Karar Zunaid] World Bank, South Asia Human Dev Sect, Washington, DC 20433 USA. [Koehlmoos, Tracey L. P.] ICDDR B, Dhaka, Bangladesh. [Koehlmoos, Tracey L. P.] ICDDR B, Ctr Systemat Review, Dhaka, Bangladesh. [Koehlmoos, Tracey L. P.] George Mason Univ, Coll Hlth & Human Serv, Fairfax, VA 22030 USA. [Engelgau, Michael M.] US CDC Off, Beijing, Peoples R China. [Engelgau, Michael M.] CDC, Atlanta, GA 30333 USA. RP El-Saharty, S (reprint author), World Bank, 1818 H St NW, Washington, DC 20433 USA. NR 20 TC 0 Z9 0 U1 1 U2 1 PU WORLD BANK INST PI WASHINGTON PA 1818 H ST NW, WASHINGTON, DC 20433 USA BN 978-0-8213-9920-0; 978-0-8213-9921-7 J9 DIR DEV PY 2013 BP 17 EP 26 D2 10.1596/978-0-8213-9920-0 PG 10 WC Health Policy & Services; Planning & Development SC Health Care Sciences & Services; Public Administration GA BHB61 UT WOS:000324888000003 ER PT J AU El-Saharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM AF El-Saharty, Sameh Ahsan, Karar Zunaid Koehlmoos, Tracey L. P. Engelgau, Michael M. BA ElSaharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM BF ElSaharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM TI Burden of Disease and Risk Factors for NCDs SO TACKLING NONCOMMUNICABLE DISEASES IN BANGLADESH: NOW IS THE TIME SE Directions in Development LA English DT Article; Book Chapter ID RURAL BANGLADESH; DRINKING-WATER; GLOBAL BURDEN; PREVALENCE; POPULATION; TOBACCO; HEALTH; DISABILITY; COMMUNITY; COUNTRIES C1 [El-Saharty, Sameh; Koehlmoos, Tracey L. P.; Engelgau, Michael M.] World Bank, Washington, DC 20433 USA. [El-Saharty, Sameh] US Agcy Int Dev, Washington, DC 20523 USA. [El-Saharty, Sameh] Harvard Univ, Cambridge, MA 02138 USA. [El-Saharty, Sameh] Amer Univ Cairo, Cairo, Egypt. [Ahsan, Karar Zunaid] World Bank, South Asia Human Dev Sect, Washington, DC 20433 USA. [Koehlmoos, Tracey L. P.] ICDDR B, Dhaka, Bangladesh. [Koehlmoos, Tracey L. P.] ICDDR B, Ctr Systemat Review, Dhaka, Bangladesh. [Koehlmoos, Tracey L. P.] George Mason Univ, Coll Hlth & Human Serv, Fairfax, VA 22030 USA. [Engelgau, Michael M.] US CDC Off, Beijing, Peoples R China. [Engelgau, Michael M.] CDC, Atlanta, GA 30333 USA. RP El-Saharty, S (reprint author), World Bank, 1818 H St NW, Washington, DC 20433 USA. NR 104 TC 0 Z9 0 U1 1 U2 1 PU WORLD BANK INST PI WASHINGTON PA 1818 H ST NW, WASHINGTON, DC 20433 USA BN 978-0-8213-9920-0 J9 DIR DEV PY 2013 BP 27 EP 60 D2 10.1596/978-0-8213-9920-0 PG 34 WC Health Policy & Services; Planning & Development SC Health Care Sciences & Services; Public Administration GA BHB61 UT WOS:000324888000004 ER PT J AU El-Saharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM AF El-Saharty, Sameh Ahsan, Karar Zunaid Koehlmoos, Tracey L. P. Engelgau, Michael M. BA ElSaharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM BF ElSaharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM TI Health System and NCD Capacity Assessment SO TACKLING NONCOMMUNICABLE DISEASES IN BANGLADESH: NOW IS THE TIME SE Directions in Development LA English DT Article; Book Chapter C1 [El-Saharty, Sameh; Koehlmoos, Tracey L. P.; Engelgau, Michael M.] World Bank, Washington, DC 20433 USA. [El-Saharty, Sameh] US Agcy Int Dev, Washington, DC 20523 USA. [El-Saharty, Sameh] Harvard Univ, Cambridge, MA 02138 USA. [El-Saharty, Sameh] Amer Univ Cairo, Cairo, Egypt. [Ahsan, Karar Zunaid] World Bank, South Asia Human Dev Sect, Washington, DC 20433 USA. [Koehlmoos, Tracey L. P.] ICDDR B, Dhaka, Bangladesh. [Koehlmoos, Tracey L. P.] ICDDR B, Ctr Systemat Review, Dhaka, Bangladesh. [Koehlmoos, Tracey L. P.] George Mason Univ, Coll Hlth & Human Serv, Fairfax, VA 22030 USA. [Engelgau, Michael M.] US CDC Off, Beijing, Peoples R China. [Engelgau, Michael M.] CDC, Atlanta, GA 30333 USA. RP El-Saharty, S (reprint author), World Bank, 1818 H St NW, Washington, DC 20433 USA. NR 26 TC 0 Z9 0 U1 1 U2 1 PU WORLD BANK INST PI WASHINGTON PA 1818 H ST NW, WASHINGTON, DC 20433 USA BN 978-0-8213-9920-0 J9 DIR DEV PY 2013 BP 61 EP 75 D2 10.1596/978-0-8213-9920-0 PG 15 WC Health Policy & Services; Planning & Development SC Health Care Sciences & Services; Public Administration GA BHB61 UT WOS:000324888000005 ER PT J AU El-Saharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM AF El-Saharty, Sameh Ahsan, Karar Zunaid Koehlmoos, Tracey L. P. Engelgau, Michael M. BA ElSaharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM BF ElSaharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM TI National NCD Activities and Challenges SO TACKLING NONCOMMUNICABLE DISEASES IN BANGLADESH: NOW IS THE TIME SE Directions in Development LA English DT Article; Book Chapter C1 [El-Saharty, Sameh; Koehlmoos, Tracey L. P.; Engelgau, Michael M.] World Bank, Washington, DC 20433 USA. [El-Saharty, Sameh] US Agcy Int Dev, Washington, DC 20523 USA. [El-Saharty, Sameh] Harvard Univ, Cambridge, MA 02138 USA. [El-Saharty, Sameh] Amer Univ Cairo, Cairo, Egypt. [Ahsan, Karar Zunaid] World Bank, South Asia Human Dev Sect, Washington, DC 20433 USA. [Koehlmoos, Tracey L. P.] ICDDR B, Dhaka, Bangladesh. [Koehlmoos, Tracey L. P.] ICDDR B, Ctr Systemat Review, Dhaka, Bangladesh. [Koehlmoos, Tracey L. P.] George Mason Univ, Coll Hlth & Human Serv, Fairfax, VA 22030 USA. [Engelgau, Michael M.] US CDC Off, Beijing, Peoples R China. [Engelgau, Michael M.] CDC, Atlanta, GA 30333 USA. RP El-Saharty, S (reprint author), World Bank, 1818 H St NW, Washington, DC 20433 USA. NR 11 TC 0 Z9 0 U1 1 U2 1 PU WORLD BANK INST PI WASHINGTON PA 1818 H ST NW, WASHINGTON, DC 20433 USA BN 978-0-8213-9920-0 J9 DIR DEV PY 2013 BP 77 EP 85 D2 10.1596/978-0-8213-9920-0 PG 9 WC Health Policy & Services; Planning & Development SC Health Care Sciences & Services; Public Administration GA BHB61 UT WOS:000324888000006 ER PT J AU El-Saharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM AF El-Saharty, Sameh Ahsan, Karar Zunaid Koehlmoos, Tracey L. P. Engelgau, Michael M. BA ElSaharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM BF ElSaharty, S Ahsan, KZ Koehlmoos, TLP Engelgau, MM TI Key Policy Options and Strategic Priorities SO TACKLING NONCOMMUNICABLE DISEASES IN BANGLADESH: NOW IS THE TIME SE Directions in Development LA English DT Article; Book Chapter ID DISEASE; HEALTH C1 [El-Saharty, Sameh; Koehlmoos, Tracey L. P.; Engelgau, Michael M.] World Bank, Washington, DC 20433 USA. [El-Saharty, Sameh] US Agcy Int Dev, Washington, DC 20523 USA. [El-Saharty, Sameh] Harvard Univ, Cambridge, MA 02138 USA. [El-Saharty, Sameh] Amer Univ Cairo, Cairo, Egypt. [Ahsan, Karar Zunaid] World Bank, South Asia Human Dev Sect, Washington, DC 20433 USA. [Koehlmoos, Tracey L. P.] ICDDR B, Dhaka, Bangladesh. [Koehlmoos, Tracey L. P.] ICDDR B, Ctr Systemat Review, Dhaka, Bangladesh. [Koehlmoos, Tracey L. P.] George Mason Univ, Coll Hlth & Human Serv, Fairfax, VA 22030 USA. [Engelgau, Michael M.] US CDC Off, Beijing, Peoples R China. [Engelgau, Michael M.] CDC, Atlanta, GA 30333 USA. RP El-Saharty, S (reprint author), World Bank, 1818 H St NW, Washington, DC 20433 USA. NR 17 TC 0 Z9 0 U1 1 U2 1 PU WORLD BANK INST PI WASHINGTON PA 1818 H ST NW, WASHINGTON, DC 20433 USA BN 978-0-8213-9920-0 J9 DIR DEV PY 2013 BP 87 EP 105 D2 10.1596/978-0-8213-9920-0 PG 19 WC Health Policy & Services; Planning & Development SC Health Care Sciences & Services; Public Administration GA BHB61 UT WOS:000324888000007 ER PT J AU Parenti, L Foreman, A Meade, BJ Wirth, O AF Parenti, Lindsay Foreman, Anne Meade, B. Jean Wirth, Oliver TI A revised taxonomy of assistance animals SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE assistance animal; assistance dog; nomenclature; public access rights; service animal; service dog; support animal; taxonomy; therapy animal; vocabulary ID PET OWNERSHIP; HEALTH; DOGS AB The use of animals in various assistive, therapeutic, and emotional support roles has contributed to the uncoordinated expansion of labels used to distinguish these animals. To address the inconsistent vocabulary and confusion, this article proposes a concise taxonomy for classifying assistance animals. Several factors were identified to differentiate categories, including (1) whether the animal performs work or tasks related to an individual's disability; (2) the typical level of skill required by the animal performing the work or task; (3) whether the animal is used by public service, military, or healthcare professionals; (4) whether training certifications or standards are available; and (5) the existence of legal public access protections for the animal and handler. Acknowledging that some category labels have already been widely accepted or codified, six functional categories were identified: (1) service animal; (2) public service animal; (3) therapy animal; (4) visitation animal; (5) sporting, recreational, or agricultural animal; and (6) support animal. This taxonomy provides a clear vocabulary for use by consumers, professionals working in the field, researchers, policy makers, and regulatory agencies. C1 [Parenti, Lindsay; Foreman, Anne; Wirth, Oliver] NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA. [Meade, B. Jean] NIOSH, Off Director, Morgantown, WV 26505 USA. [Meade, B. Jean] W Virginia Univ, Div Anim & Nutr Sci, Davis Coll, Morgantown, WV 26506 USA. RP Wirth, O (reprint author), NIOSH, CDC, 1095 Willowdale Rd,MS 2027, Morgantown, WV 26505 USA. EM owirth@cdc.gov FU Intramural CDC HHS [CC999999] NR 34 TC 4 Z9 4 U1 2 U2 9 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2013 VL 50 IS 6 BP 745 EP 756 DI 10.1682/JRRD.2012.11.0216 PG 12 WC Rehabilitation SC Rehabilitation GA 217HJ UT WOS:000324350200004 PM 24203538 ER PT J AU Ferrari, FAG Goddard, J Caprio, M Paddock, CD Mixson-Hayden, T Varela-Stokes, AS AF Ferrari, Flavia A. G. Goddard, Jerome Caprio, Michael Paddock, Christopher D. Mixson-Hayden, Tonya Varela-Stokes, Andrea S. TI Population analyses of Amblyomma maculatum ticks and Rickettsia parkeri using single-strand conformation polymorphism SO TICKS AND TICK-BORNE DISEASES LA English DT Article DE Amblyomma maculatum; Genetic variation; Spotted fever group rickettsia; Rickettsia parkeri; Single-strand conformation polymorphism ID GULF-COAST TICK; FEVER GROUP RICKETTSIA; SPOTTED-FEVER; GENETIC-VARIATION; UNITED-STATES; DERMACENTOR-VARIABILIS; BORRELIA-BURGDORFERI; ACARI IXODIDAE; F-STATISTICS; DIVERSITY AB Gulf Coast ticks, Amblyomma maculatum, and the zoonotic agents they transmit, Rickettsia parkeri, are expanding into areas in the United States where they were not previously reported, and are emerging threats for public and veterinary health. The dynamics of this tick-pathogen system and implications for disease transmission are still unclear. To assess genetic variation of tick and rickettsial populations, we collected adult A. maculatum from 10 sites in Mississippi, 4 in the northern, one in the central, and 5 in the southern part of the state. PCR amplicons from tick mitochondrial 16S rRNA and rickettsial ompA genes as well as 5 intergenic spacer regions were evaluated for genetic variation using single-strand conformation polymorphism analysis. Frequencies of the 4 tick 16S haplotypes were not significantly different among regions of Mississippi, but within sites there were differences in distribution that can be explained by high migration rates. Phylogenetically, one lineage of tick haplotypes was a species-poor sister group to remaining haplotypes in the species-rich sister group. No genetic variation was identified in any of the 6 selected gene targets of R. parkeri examined in the infected ticks, suggesting high levels of intermixing. (C) 2013 Elsevier GmbH. All rights reserved. C1 [Ferrari, Flavia A. G.; Varela-Stokes, Andrea S.] Mississippi State Univ, Coll Vet Med, Dept Basic Sci, Mississippi State, MS 39762 USA. [Goddard, Jerome; Caprio, Michael] Mississippi State Univ, Dept Biochem Mol Biol Entomol & Plant Pathol, Mississippi State, MS 39762 USA. [Paddock, Christopher D.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA 30333 USA. [Mixson-Hayden, Tonya] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Varela-Stokes, AS (reprint author), Mississippi State Univ, Coll Vet Med, Dept Basic Sci, 240 Wise Ctr Dr, Mississippi State, MS 39762 USA. EM stokes@cvm.msstate.edu FU SECEBT (Southeastern Center for Emerging Biologic Threats); College of Veterinary Medicine at Mississippi State University FX This work is funded by a SECEBT (Southeastern Center for Emerging Biologic Threats) grant awarded to Dr. Varela-Stokes in 2009 and funding from the College of Veterinary Medicine at Mississippi State University. NR 34 TC 4 Z9 4 U1 0 U2 8 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1877-959X J9 TICKS TICK-BORNE DIS JI Ticks Tick-Borne Dis. PY 2013 VL 4 IS 5 BP 439 EP 444 DI 10.1016/j.ttbdis.2013.04.010 PG 6 WC Infectious Diseases; Microbiology; Parasitology SC Infectious Diseases; Microbiology; Parasitology GA 223XM UT WOS:000324845800014 PM 23856472 ER PT S AU Ma, Q AF Ma, Qiang BE Insel, PA TI Role of Nrf2 in Oxidative Stress and Toxicity SO ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 53, 2013 SE Annual Review of Pharmacology and Toxicology LA English DT Review; Book Chapter DE reactive oxygen species; redox signaling; antioxidant response element; inducer; cytoprotection ID ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; SMOKE-INDUCED EMPHYSEMA; INFLAMMATORY CYTOKINE EXPRESSION; ALCOHOL SPECTRUM DISORDERS; UNFOLDED PROTEIN RESPONSE; CELL-CYCLE PROGRESSION; HEME OXYGENASE-1 GENE; YA-SUBUNIT GENE; PHENOLIC ANTIOXIDANTS AB Organismal life encounters reactive oxidants from internal metabolism and environmental toxicant exposure. Reactive oxygen and nitrogen species cause oxidative stress and are traditionally viewed as being harmful. On the other hand, controlled production of oxidants in normal cells serves useful purposes to regulate signaling pathways. Reactive oxidants are counterbalanced by complex antioxidant defense systems regulated by a web of pathways to ensure that the response to oxidants is adequate for the body's needs. A recurrent theme in oxidant signaling and antioxidant defense is reactive cysteine thiol-based redox signaling. The nuclear factor erythroid 2-related factor 2 (Nrf2) is an emerging regulator of cellular resistance to oxidants. Nrf2 controls the basal and induced expression of an array of antioxidant response element-dependent genes to regulate the physiological and pathophysiological outcomes of oxidant exposure. This review discusses the impact of Nrf2 on oxidative stress and toxicity and how Nrf2 senses oxidants and regulates antioxidant defense. C1 [Ma, Qiang] NIOSH, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,Ctr Dis Control & Prevent, Washington, DC 20201 USA. [Ma, Qiang] W Virginia Univ, Dept Biochem, Robert C Byrd Hlth Sci Ctr, Sch Med, Morgantown, WV 26505 USA. RP Ma, Q (reprint author), NIOSH, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,Ctr Dis Control & Prevent, Washington, DC 20201 USA. EM qam1@cdc.gov FU Intramural CDC HHS [CC999999] NR 197 TC 359 Z9 371 U1 19 U2 102 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0362-1642 BN 978-0-8243-0453-9 J9 ANNU REV PHARMACOL JI Annu. Rev. Pharmacol. Toxicol. PY 2013 VL 53 BP 401 EP + DI 10.1146/annurev-pharmtox-011112-140320 PG 32 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA BGH79 UT WOS:000323040100020 PM 23294312 ER EF